{
  "_metadata": {
    "version": "2.0.0",
    "lastUpdated": "2026-02-06",
    "description": "Central medication database for Neuro Plans - single source of truth for all medication data. Contains 936 medications harvested from 124 plans.",
    "safetyNotice": "This database is for clinical decision support only. Always verify dosing against current prescribing information and institutional protocols.",
    "schema": {
      "medication": {
        "id": "Unique identifier (lowercase, hyphenated)",
        "name": "Display name",
        "genericName": "Generic/INN name",
        "brandNames": [
          "Array of brand names"
        ],
        "drugClass": "Pharmacological class",
        "mechanisms": [
          "Mechanism(s) of action"
        ],
        "routes": [
          "Available routes"
        ],
        "formulations": [
          "Available formulations"
        ],
        "contexts": {
          "[indication-id]": {
            "indication": "Specific use case",
            "doseOptions": [
              {
                "text": "",
                "orderSentence": ""
              }
            ],
            "startingDose": "Recommended starting dose",
            "maxDose": "Maximum dose for this indication",
            "titration": "Titration schedule",
            "notes": "Indication-specific notes"
          }
        },
        "safety": {
          "blackBoxWarnings": [
            "FDA black box warnings"
          ],
          "contraindications": [
            "Absolute contraindications"
          ],
          "precautions": [
            "Warnings and precautions"
          ],
          "drugInteractions": [
            {
              "drug": "",
              "severity": "",
              "effect": ""
            }
          ],
          "pregnancyCategory": "FDA pregnancy category",
          "lactation": "Lactation safety"
        },
        "renalAdjustment": {
          "required": true,
          "tiers": [
            {
              "gfr": "≥60",
              "adjustment": "No adjustment"
            },
            {
              "gfr": "30-59",
              "adjustment": "Specific adjustment"
            },
            {
              "gfr": "15-29",
              "adjustment": "Specific adjustment"
            },
            {
              "gfr": "<15",
              "adjustment": "Specific adjustment"
            },
            {
              "gfr": "HD",
              "adjustment": "Hemodialysis dosing"
            }
          ]
        },
        "hepaticAdjustment": {
          "required": false,
          "notes": "Child-Pugh based adjustments if applicable"
        },
        "monitoring": {
          "baseline": [
            "Required baseline labs/tests"
          ],
          "ongoing": [
            "Ongoing monitoring requirements"
          ],
          "frequency": "Monitoring frequency"
        },
        "patientCounseling": [
          "Key counseling points"
        ]
      }
    }
  },
  "medications": {
    "": {
      "id": "",
      "name": "~~AMX0035 / Relyvrio (sodium phenylbutyrate-taurursodiol)~~",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO",
        "~~PO~~"
      ],
      "formulations": [],
      "contexts": {
        "withdrawn-voluntarily-removed-from-us-market-april-2024-afte": {
          "indication": "**WITHDRAWN** — Voluntarily removed from US market April 2024 after PHOENIX trial failed to confirm benefit",
          "doseOptions": [],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "N/A",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "ftd-als-overlap-neuroprotective": {
          "indication": "~~FTD-ALS overlap; neuroprotective~~",
          "doseOptions": [
            {
              "text": "**WITHDRAWN**",
              "orderSentence": "~~Sodium phenylbutyrate/taurursodiol (Relyvrio)~~ **WITHDRAWN** N/A"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**WITHDRAWN FROM MARKET (April 2024)** - Amylyx withdrew Relyvrio after the Phase III PHOENIX trial failed to demonstrate efficacy. No longer available for prescribing.",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "discontinued-biogen-halted-aduhelm-commercialization-january": {
          "indication": "**DISCONTINUED** — Biogen halted Aduhelm commercialization January 2024; no longer available",
          "doseOptions": [],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "N/A",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "N/A"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "N/A"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "als",
        "alzheimers-disease",
        "frontotemporal-dementia"
      ]
    },
    "3-4-diaminopyridine": {
      "id": "3-4-diaminopyridine",
      "name": "3,4-Diaminopyridine (amifampridine/Firdapse)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-symptomatic-treatment-for-lems-enhances-presynapt": {
          "indication": "First-line symptomatic treatment for LEMS; enhances presynaptic acetylcholine release by blocking potassium channels; improves strength and autonomic symptoms",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "3,4-Diaminopyridine (amifampridine/Firdapse) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; increase by 5 mg per dose every 3-5 days; usual effective dose 15-20 mg TID-QID; max 80 mg/day (max 20 mg per single dose); take with food",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "alternative-to-4-ap-for-downbeat-nystagmus-lower-seizure-ris": {
          "indication": "Alternative to 4-AP for downbeat nystagmus; lower seizure risk than 4-AP",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "**3,4-Diaminopyridine (3,4-DAP, amifampridine)** 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**3,4-Diaminopyridine 10 mg PO TID, titrate to max 20 mg TID (80 mg/day)**; [Kalla et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17664175/)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "Seizure disorder (lower risk than 4-AP but still present)",
          "Seizure history (lowers seizure threshold)",
          "concurrent use of drugs that lower seizure threshold"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG",
          "ECG at baseline and after dose changes",
          "GI upset",
          "QTc monitoring",
          "Seizure monitoring",
          "clinical response",
          "paresthesias (perioral, digital)",
          "seizure precautions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "lambert-eaton-syndrome",
        "nystagmus-evaluation"
      ]
    },
    "3-4-diaminopyridine-phosphate": {
      "id": "3-4-diaminopyridine-phosphate",
      "name": "3,4-Diaminopyridine phosphate (Ruzurgi)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-formulation-of-amifampridine-for-lems-enhances-p": {
          "indication": "Alternative formulation of amifampridine for LEMS; enhances presynaptic acetylcholine release by blocking potassium channels; improves strength and autonomic symptoms",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "3,4-Diaminopyridine phosphate (Ruzurgi) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; increase by 5 mg per dose every 3-5 days; usual effective dose 15-20 mg TID-QID; max 80 mg/day (max 20 mg per single dose); take with food",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "Seizure history (lowers seizure threshold)",
          "concurrent use of drugs that lower seizure threshold"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG at baseline and after dose changes",
          "GI upset",
          "QTc monitoring",
          "paresthesias (perioral, digital)",
          "seizure precautions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "lambert-eaton-syndrome"
      ]
    },
    "4-aminopyridine": {
      "id": "4-aminopyridine",
      "name": "4-Aminopyridine (dalfampridine)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "episodic-ataxia-type-2-downbeat-nystagmus-cerebellar-gait-at": {
          "indication": "Episodic ataxia type 2; downbeat nystagmus; cerebellar gait ataxia; improves Purkinje cell function",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "4-Aminopyridine (dalfampridine) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID; may increase to 10 mg BID; 12 hours apart; max 20 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "first-line-for-symptomatic-downbeat-nystagmus-potassium-chan": {
          "indication": "First-line for symptomatic downbeat nystagmus; potassium channel blocker that improves Purkinje cell function",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**4-Aminopyridine (4-AP, dalfampridine)** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**4-Aminopyridine 5 mg PO BID (compounded)** or **Dalfampridine (Ampyra) 10 mg PO BID** (extended-release); [Strupp et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12874393/); [Claassen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23813743/)",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "upbeat-nystagmus-less-evidence-than-for-downbeat-but-reasona": {
          "indication": "Upbeat nystagmus (less evidence than for downbeat, but reasonable trial); improves oculomotor function",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**4-Aminopyridine (4-AP)** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**4-AP 5 mg PO BID**; trial for 2-4 weeks to assess benefit; [Glasauer et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15716550/)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "second-line-for-pan-if-baclofen-not-tolerated-or-insufficien": {
          "indication": "Second-line for PAN if baclofen not tolerated or insufficient",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**4-Aminopyridine (4-AP)** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**4-AP 5 mg PO BID**; may combine with baclofen; [Strupp et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12874393/)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "gaze-evoked-nystagmus-from-cerebellar-pathology-not-drug-ind": {
          "indication": "Gaze-evoked nystagmus from cerebellar pathology (not drug-induced); improves gaze-holding function",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**4-Aminopyridine** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**4-AP 5 mg PO BID**; helps with cerebellar integrator dysfunction",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "potassium-channel-blocker-to-enhance-neuromuscular-transmiss": {
          "indication": "Potassium channel blocker to enhance neuromuscular transmission; off-label, limited evidence; may improve strength in recovery phase",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "4-Aminopyridine (dalfampridine) 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg PO BID (extended-release); off-label use",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "botulism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**Seizure disorder** (lowers seizure threshold)",
          "Seizure disorder (lowers seizure threshold)",
          "Seizure history (lowers seizure threshold)",
          "Seizure history (lowers threshold), renal impairment (CrCl <50)",
          "cardiac arrhythmia (QT prolongation at supratherapeutic doses)",
          "cardiac arrhythmia (QT prolongation)",
          "cardiac arrhythmia (prolongs QT at supratherapeutic doses)",
          "concurrent use of other forms of 4-AP",
          "hepatic impairment",
          "moderate-severe renal impairment (CrCl <50)",
          "renal impairment (CrCl <50 — dose adjustment)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Clinical response",
          "ECG",
          "ECG at baseline",
          "GI side effects",
          "Seizure monitoring",
          "Seizure risk",
          "Seizures",
          "clinical response",
          "renal function",
          "renal function at baseline and periodically",
          "seizure monitoring",
          "therapeutic response",
          "therapeutic response assessment at 2-4 weeks",
          "visual acuity improvement"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "ataxia-evaluation",
        "botulism",
        "nystagmus-evaluation"
      ]
    },
    "abacavir": {
      "id": "abacavir",
      "name": "Abacavir (Ziagen)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nrti-with-high-cpe-score-cpe-3-use-in-cns-optimized-regimens": {
          "indication": "NRTI with high CPE score (CPE 3); use in CNS-optimized regimens",
          "doseOptions": [
            {
              "text": "600 mg",
              "orderSentence": "Abacavir (Ziagen) 600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600 mg PO daily or 300 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**HLA-B*5701 positive** (fatal hypersensitivity reaction -- must test before prescribing)",
          "cardiovascular risk (controversial)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HLA-B*5701 mandatory before initiation",
          "hypersensitivity reaction monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "abobotulinumtoxina-cervical-dystonia": {
      "id": "abobotulinumtoxina-cervical-dystonia",
      "name": "AbobotulinumtoxinA (Dysport) - Cervical dystonia",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-onabotulinum-different-potency": {
          "indication": "Alternative to onabotulinum; different potency",
          "doseOptions": [
            {
              "text": "500 units",
              "orderSentence": "AbobotulinumtoxinA (Dysport) - Cervical dystonia 500 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 units divided among affected muscles; max 1000 units/session; repeat q12wk",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ALS",
          "Infection at site",
          "myasthenia gravis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dysphagia (especially bilateral SCM)",
          "antibody formation",
          "neck weakness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "dystonia"
      ]
    },
    "acetaminophen": {
      "id": "acetaminophen",
      "name": "Acetaminophen",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO",
        "PO/IV"
      ],
      "formulations": [],
      "contexts": {
        "headache-common-in-moyamoya-due-to-collateral-dilation-safe-": {
          "indication": "Headache (common in moyamoya due to collateral dilation); safe first-line analgesic; avoid NSAIDs (bleeding risk)",
          "doseOptions": [
            {
              "text": "650-1000 mg q6h",
              "orderSentence": "Acetaminophen 650-1000 mg q6h PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h PRN; max 3000 mg/day; AVOID NSAIDs and aspirin combinations (GI bleed)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        },
        "headache-ivig-related-or-general": {
          "indication": "Headache (IVIG-related or general)",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h; max 4g/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis"
          ]
        },
        "headache-from-elevated-icp-avoid-nsaids-peri-operatively-due": {
          "indication": "Headache from elevated ICP; avoid NSAIDs peri-operatively due to bleeding risk",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h PRN headache; max 3 g/day (2 g/day if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "myalgia-and-arthralgia-pain-relief": {
          "indication": "Myalgia and arthralgia pain relief",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h PRN; max 4 g/day (2 g if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "fever-target-normothermia-37-5-c-fever-worsens-ich-outcomes": {
          "indication": "Fever (target normothermia <37.5°C; fever worsens ICH outcomes)",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 4g/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "fever-management-in-icu-central-fever-or-status-epilepticus-": {
          "indication": "Fever management in ICU; central fever or status epilepticus-related hyperthermia",
          "doseOptions": [
            {
              "text": "1g",
              "orderSentence": "Acetaminophen (antipyretic) 1g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1g IV/PO q6h PRN (max 4g/day); use as part of targeted temperature management (36-37C)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "prevents-infusion-related-fever-and-rigors-during-amphoteric": {
          "indication": "Prevents infusion-related fever and rigors during amphotericin B administration",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen (amphotericin premedication) 650-1000 mg PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO or IV 30-60 minutes before each amphotericin B infusion; max 4 g/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "fever-temperature-goal-38-c-headache": {
          "indication": "Fever (temperature goal <38°C); headache",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 4g/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hsv-encephalitis"
          ]
        },
        "headache-and-fever-reduction-first-line-analgesic-and-antipy": {
          "indication": "Headache and fever reduction; first-line analgesic and antipyretic for viral meningitis",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 4 g/day; IV formulation for patients unable to take PO",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "first-line-if-nsaid-contraindicated-mild-moderate-headache": {
          "indication": "First-line if NSAID contraindicated; mild-moderate headache",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO at onset; repeat q6h; max 3000 mg/day (2000 mg if liver disease); limit to <15 days/month",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "first-line-oral-analgesic-in-pregnancy-for-any-headache": {
          "indication": "First-line oral analgesic in pregnancy for any headache",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO q6h; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "headache-and-neck-pain-from-dissection-fever-management-temp": {
          "indication": "Headache and neck pain from dissection; fever management (temperature >38C worsens ischemic outcomes)",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h PRN; max 4g/day (2g if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "prophylaxis-and-treatment-of-jarisch-herxheimer-reaction-fev": {
          "indication": "Prophylaxis and treatment of Jarisch-Herxheimer reaction (fever, rigors, headache, myalgia occurring 2-8h after first penicillin dose; occurs in up to 50% of neurosyphilis patients)",
          "doseOptions": [
            {
              "text": "650-1000 mg q6h",
              "orderSentence": "Acetaminophen (Jarisch-Herxheimer prophylaxis/treatment) 650-1000 mg q6h PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h for first 24-48h of treatment; premedicate before first penicillin dose",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "headache-from-elevated-icp-or-meningeal-irritation-first-lin": {
          "indication": "Headache from elevated ICP or meningeal irritation; first-line analgesic; avoid NSAIDs with concurrent methotrexate",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "**Acetaminophen (headache/pain)** 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Acetaminophen 650-1000 mg PO q6h; max 4 g/day (2 g/day if hepatic impairment); dexamethasone often most effective for LMD headache; avoid NSAIDs if concurrent methotrexate (impairs clearance) or thrombocytopenia",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "pain-with-eye-movement": {
          "indication": "Pain with eye movement",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h as needed for pain; max 3000 mg/day (2000 mg if liver disease)",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "headache-symptom-relief": {
          "indication": "Headache symptom relief",
          "doseOptions": [
            {
              "text": "1000 mg q6h",
              "orderSentence": "Acetaminophen 1000 mg q6h PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO q6h PRN headache; max 3000 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        },
        "headache-in-eclampsia-preeclampsia-safe-in-pregnancy-first-l": {
          "indication": "Headache in eclampsia/preeclampsia; safe in pregnancy; first-line analgesic",
          "doseOptions": [
            {
              "text": "650-1000 mg q6h",
              "orderSentence": "Acetaminophen 650-1000 mg q6h PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 3000 mg/day in pregnancy; avoid in hepatic impairment (HELLP)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "headache-from-elevated-icp-or-mass-effect-avoid-nsaids-peri-": {
          "indication": "Headache from elevated ICP or mass effect; avoid NSAIDs peri-biopsy due to bleeding risk; avoid NSAIDs during methotrexate therapy (impairs renal MTX clearance)",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h PRN headache; max 3 g/day (2 g/day if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "musculoskeletal-pain-and-general-discomfort-from-immobility": {
          "indication": "Musculoskeletal pain and general discomfort from immobility",
          "doseOptions": [
            {
              "text": "650 mg",
              "orderSentence": "Acetaminophen 650 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 4 g/day (2 g/day if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h PRN; max 3000 mg/day",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "bells-palsy",
            "migraine"
          ]
        },
        "headache-and-pain-management-avoid-nsaids-due-to-bleeding-an": {
          "indication": "Headache and pain management; avoid NSAIDs due to bleeding and hepatic risk",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h PRN; max 2000 mg/day in liver disease (3000 mg/day if normal liver)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "mild-moderate-headache-pain-during-workup": {
          "indication": "Mild-moderate headache pain during workup",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO/IV once; may repeat q6h; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "headache-management-headache-is-the-most-common-symptom-of-p": {
          "indication": "Headache management; headache is the most common symptom of PACNS (60-70%)",
          "doseOptions": [
            {
              "text": "650-1000 mg q6h PRN",
              "orderSentence": "Acetaminophen 650-1000 mg q6h PRN PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h PRN; max 3g/day (2g/day if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "mild-moderate-post-traumatic-headache": {
          "indication": "Mild-moderate post-traumatic headache",
          "doseOptions": [
            {
              "text": "500-1000 mg",
              "orderSentence": "Acetaminophen 500-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mg PO q6h PRN; max 3000 mg/day",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "headache-management-avoid-nsaids-while-anticoagulated": {
          "indication": "Headache management (avoid NSAIDs while anticoagulated)",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO/IV q6h PRN; max 3g/day (2g if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "pain-management-for-fall-related-injuries-myalgia-uncommon-i": {
          "indication": "Pain management for fall-related injuries; myalgia (uncommon in IBM but may occur)",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h PRN pain; max 4 g/day (2 g/day if hepatic impairment); IV alternative: 1000 mg IV q6h if NPO",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "analgesic-for-thunderclap-headache-first-line-because-it-doe": {
          "indication": "Analgesic for thunderclap headache — first-line because it does NOT cause vasoconstriction; avoid all triptans and ergotamines",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO q6h PRN headache; max 4000 mg/day (3000 mg/day if hepatic impairment). IV: 1000 mg IV q6h PRN if NPO",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "headache-management-fever-control-avoid-nsaids-if-concern-fo": {
          "indication": "Headache management; fever control; avoid NSAIDs if concern for GI bleed during corticosteroid therapy",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 4 g/day; IV route if unable to take PO",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "pain-control-headache-from-steroids-or-acute-attack": {
          "indication": "Pain control; headache from steroids or acute attack",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO/IV q6h PRN; max 3000 mg/day (2000 mg if liver disease)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "fever-temp-38-c-worsens-outcomes": {
          "indication": "Fever (temp >38°C worsens outcomes)",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/PR q6h; max 4g/day (2g if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "headache-management-scalp-tenderness": {
          "indication": "Headache management; scalp tenderness",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO q6h PRN; max 3g/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "fever-prevention-and-treatment-post-ttm-target-normothermia-": {
          "indication": "Fever prevention and treatment post-TTM; target normothermia (<37.7C) for at least 72h post-ROSC",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV q6h scheduled (not PRN); max 4g/day",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "headache-management-headache-is-common-in-susac-syndrome-oft": {
          "indication": "Headache management; headache is common in Susac syndrome, often severe and diffuse",
          "doseOptions": [
            {
              "text": "650 mg q6h PRN",
              "orderSentence": "Acetaminophen 650 mg q6h PRN PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h PRN; max 3g/day (2g/day if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "mild-attack-nsaid-contraindicated": {
          "indication": "Mild attack; NSAID contraindicated",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO once; max 3000 mg/day; limit to ≤14 days/month",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "mild-moderate-pain-adjunct-avoid-hepatotoxicity": {
          "indication": "Mild-moderate pain (adjunct, avoid hepatotoxicity)",
          "doseOptions": [
            {
              "text": "650 mg",
              "orderSentence": "Acetaminophen 650 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg q6h; max 3000 mg/day (2000 mg/day if liver disease)",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "fever-reduction-headache": {
          "indication": "Fever reduction, headache",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 4g/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "fever-management-headache-temperature-goal-38c-to-reduce-cer": {
          "indication": "Fever management; headache; temperature goal <38C to reduce cerebral metabolic demand",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 4 g/day; IV route if unable to take PO",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "first-line-if-nsaid-contraindicated-mild-moderate-tth": {
          "indication": "First-line if NSAID contraindicated; mild-moderate TTH",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO at onset; may repeat q6h; max 3000 mg/day (2000 mg if liver disease); limit to <10 days/month",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "headache-from-tumor-associated-edema-or-post-operative-avoid": {
          "indication": "Headache from tumor-associated edema or post-operative; avoid NSAIDs peri-operatively due to bleeding risk",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h PRN headache; max 3 g/day (2 g/day if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "pain-management-for-fall-related-injuries-myalgia-headache": {
          "indication": "Pain management for fall-related injuries; myalgia; headache",
          "doseOptions": [
            {
              "text": "650 mg",
              "orderSentence": "Acetaminophen 650 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h PRN pain; max 4 g/day (2 g/day if hepatic impairment -- liver involvement common in DM1)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "musculoskeletal-pain-headache": {
          "indication": "Musculoskeletal pain, headache",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h; max 4g/day (2g hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        },
        "fever-management-target-normothermia-37-5-degrees-c-fever-wo": {
          "indication": "Fever management (target normothermia <37.5 degrees C; fever worsens cerebral edema)",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO or IV q6h; max 4 g/day; use IV if NPO",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        },
        "fever-reduction-and-headache-avoid-nsaids-due-to-hepatotoxic": {
          "indication": "Fever reduction and headache; avoid NSAIDs due to hepatotoxicity risk with RIPE therapy",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 3g/day (reduced from 4g due to concurrent hepatotoxic medications)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        },
        "axial-neck-pain-and-musculoskeletal-pain-first-line-analgesi": {
          "indication": "Axial neck pain and musculoskeletal pain; first-line analgesic",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h PRN pain; max 3000 mg/day (2000 mg/day if hepatic impairment or age >65)",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "pain-headache-fever": {
          "indication": "Pain, headache, fever",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 4g/day (2g if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "botulism"
          ]
        },
        "mild-pain-adjunct-avoid-hepatotoxicity": {
          "indication": "Mild pain (adjunct; avoid hepatotoxicity)",
          "doseOptions": [
            {
              "text": "650 mg",
              "orderSentence": "Acetaminophen 650 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg q6h; max 3000 mg/day (2000 mg/day if liver disease)",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        },
        "pain": {
          "indication": "Pain",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO q6h; max 4g/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-myelopathy"
          ]
        },
        "headache-and-pain-management-fever-reduction-alternative-if-": {
          "indication": "Headache and pain management; fever reduction; alternative if NSAIDs contraindicated",
          "doseOptions": [
            {
              "text": "650-1000 mg q6h",
              "orderSentence": "Acetaminophen 650-1000 mg q6h PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h; max 3 g/day (2 g/day if hepatic impairment)",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        },
        "post-ictal-headache": {
          "indication": "Post-ictal headache",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Acetaminophen 650-1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO/IV q6h PRN; max 3000 mg/day (2000 mg if liver disease)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hepatic disease",
          "Hepatic disease, chronic alcohol use",
          "Hepatic disease, chronic alcohol use (>3 drinks/day)",
          "Hepatic disease, chronic alcohol use >3 drinks/day",
          "Hepatic impairment",
          "Hepatic impairment (max 2 g/day)",
          "Severe hepatic disease",
          "Severe hepatic disease (Child-Pugh C)",
          "Severe hepatic disease (caution with concurrent albendazole hepatotoxicity)",
          "Severe hepatic impairment",
          "Severe hepatic impairment (HELLP with transaminases >5x ULN)",
          "Severe hepatic impairment (reduce max dose)",
          "Severe liver disease",
          "acetaminophen allergy",
          "active liver failure",
          "allergy",
          "avoid if >3 alcoholic drinks/day",
          "chronic alcohol use",
          "chronic alcohol use (reduce max to 2 g/day)",
          "chronic heavy alcohol use",
          "concurrent RIPE therapy warrants reduced max dose (3g/day)",
          "hepatic impairment (reduce dose -- GGT/ALT often elevated in DM1)",
          "hepatic impairment (reduce dose)",
          "hepatic impairment (reduce max dose)",
          "metronidazole concurrent use (monitor LFTs closely)",
          "severe hepatic failure",
          "weight <50 kg (reduce dose)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Hepatic function",
          "Hepatic function if prolonged use",
          "LFTs",
          "LFTs (especially with concurrent albendazole)",
          "LFTs (especially with concurrent metronidazole)",
          "LFTs if HELLP",
          "LFTs if chronic use",
          "LFTs if frequent use",
          "LFTs if prolonged",
          "LFTs if prolonged use",
          "LFTs with prolonged use",
          "Pain scores q4h",
          "Temperature",
          "Temperature q4h",
          "hepatic function",
          "hepatic function if prolonged use",
          "medication days/month",
          "pain assessment",
          "reduce dose in liver disease",
          "temperature response",
          "total daily dose",
          "total daily dose from all sources",
          "total daily dose tracking across all formulations"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 51,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "acute-myelopathy",
        "alcohol-withdrawal-seizure",
        "anoxic-brain-injury",
        "bacterial-meningitis",
        "bells-palsy",
        "botulism",
        "brain-abscess",
        "cerebral-venous-thrombosis",
        "cervical-artery-dissection",
        "cervical-myelopathy",
        "chronic-migraine",
        "cns-vasculitis",
        "critical-illness-myopathy-neuropathy",
        "eclampsia-seizure-pregnancy",
        "fungal-meningitis",
        "giant-cell-arteritis",
        "glioblastoma",
        "guillain-barre-syndrome",
        "hashimotos-encephalopathy",
        "headache-evaluation",
        "headache-unspecified",
        "hsv-encephalitis",
        "inclusion-body-myositis",
        "inflammatory-myopathy",
        "intracerebral-hemorrhage",
        "leptomeningeal-carcinomatosis",
        "low-pressure-headache",
        "lyme-neuroborreliosis",
        "meningioma",
        "migraine",
        "mogad",
        "moyamoya-disease",
        "myasthenia-gravis-crisis",
        "myotonic-dystrophy",
        "neurocysticercosis",
        "neurosyphilis",
        "new-onset-seizure",
        "optic-neuritis",
        "plexopathy",
        "post-concussion-syndrome",
        "pres",
        "primary-cns-lymphoma",
        "radiculopathy",
        "rcvs",
        "susac-syndrome",
        "tb-meningitis",
        "tension-headache",
        "viral-meningitis"
      ]
    },
    "acetaminophen-aspirin-caffeine": {
      "id": "acetaminophen-aspirin-caffeine",
      "name": "Acetaminophen-Aspirin-Caffeine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "mild-moderate-migraine-with-aura-otc-option": {
          "indication": "Mild-moderate migraine with aura (OTC option)",
          "doseOptions": [
            {
              "text": "2 tablets",
              "orderSentence": "Acetaminophen-Aspirin-Caffeine 2 tablets PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 tablets (250/250/65 mg each) at onset; max 2 doses/24hr",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Aspirin allergy",
          "avoid if using other acetaminophen sources",
          "hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Limit total acetaminophen <3 g/day"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine-with-aura"
      ]
    },
    "acetaminophen-iv": {
      "id": "acetaminophen-iv",
      "name": "Acetaminophen IV (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "alternative-if-nsaids-contraindicated-nsaid-allergy-renal-im": {
          "indication": "Alternative if NSAIDs contraindicated; NSAID allergy, renal impairment, GI bleed risk",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen IV (CPT 96374) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV over 15 min; max 3000 mg/day from all sources",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "first-line-parenteral-analgesic-in-pregnancy-when-oral-not-t": {
          "indication": "First-line parenteral analgesic in pregnancy when oral not tolerated",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen IV (CPT 96374) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV over 15 min q6h; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "first-line-pain-control-for-thunderclap-headache-during-eval": {
          "indication": "First-line pain control for thunderclap headache during evaluation; avoid masking exam",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Acetaminophen IV (CPT 96374) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV q6h; max 4g/day. Safe first-line — does not affect coagulation or mask pupillary exam",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "mild-moderate-pain-adjunct-when-nsaids-contraindicated-pregn": {
          "indication": "Mild-moderate pain adjunct when NSAIDs contraindicated; pregnancy-safe option",
          "doseOptions": [
            {
              "text": "1000 mg IV q6h",
              "orderSentence": "Acetaminophen IV 1000 mg IV q6h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV q6h; max 3000 mg/day (2000 mg/day if hepatic risk)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "<50 kg (weight-based dosing)",
          "Hepatic disease",
          "Hepatic impairment (reduce dose)",
          "Severe hepatic disease (Child-Pugh C), chronic alcohol use (>3 drinks/day)",
          "Severe hepatic impairment (ALT >3x ULN)",
          "chronic alcohol use (>3 drinks/day)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs if frequent use",
          "LFTs if repeated dosing",
          "LFTs if repeated use >3 days",
          "Pain score",
          "hepatic function if repeat dosing",
          "total daily dose from all acetaminophen sources"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "headache-unspecified",
        "status-migrainosus",
        "thunderclap-headache-evaluation"
      ]
    },
    "acetazolamide": {
      "id": "acetazolamide",
      "name": "Acetazolamide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "elevated-icp-from-cvt-adjunct-to-anticoagulation-intracrania": {
          "indication": "Elevated ICP from CVT (adjunct to anticoagulation); intracranial hypertension secondary to NBD",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Acetazolamide 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID; increase to 500 mg BID as needed; max 2000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "pulsatile-tinnitus-due-to-iih": {
          "indication": "Pulsatile tinnitus due to IIH",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "**Acetazolamide** (IIH-related pulsatile tinnitus) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Acetazolamide 250-500 mg PO BID, titrate up to 1g BID as tolerated; monitor electrolytes; reduces CSF production; can dramatically improve pulsatile tinnitus in IIH",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        },
        "iih-related-pulsatile-tinnitus": {
          "indication": "IIH-related pulsatile tinnitus",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "**Acetazolamide** (IIH-related pulsatile tinnitus) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Acetazolamide 250-500 mg PO BID, titrate up to 1g BID as tolerated; first-line medical therapy for IIH; weight loss is critical adjunct; reduces CSF production",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        },
        "adjunctive-icp-reduction-in-fungal-meningitis-with-persisten": {
          "indication": "Adjunctive ICP reduction in fungal meningitis with persistent mildly elevated ICP after therapeutic LPs; reduces CSF production",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Acetazolamide 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250 mg PO BID-TID; titrate to 500 mg TID if tolerated; monitor for metabolic acidosis and paresthesias",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "temporizing-measure-while-awaiting-surgery-reduces-csf-produ": {
          "indication": "Temporizing measure while awaiting surgery; reduces CSF production",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Acetazolamide 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID; titrate to 250 mg TID or 500 mg BID; max 2 g/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "normal-pressure-hydrocephalus"
          ]
        },
        "communicating-hydrocephalus-elevated-icp-from-meningeal-sarc": {
          "indication": "Communicating hydrocephalus; elevated ICP from meningeal sarcoidosis (adjunct to steroids)",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Acetazolamide 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID; may increase to 500 mg BID; max 2000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "adjunctive-icp-reduction-mild-communicating-hydrocephalus-he": {
          "indication": "Adjunctive ICP reduction; mild communicating hydrocephalus; headache from elevated CSF pressure when surgical CSF diversion not indicated or not yet available",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "**Acetazolamide** 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg PO BID; may increase to 250 mg TID or 500 mg BID; max 2 g/day; reduces CSF production by 50%",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "elevated-icp-without-indication-for-emergent-surgical-interv": {
          "indication": "Elevated ICP without indication for emergent surgical intervention",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Acetazolamide (elevated ICP) 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg PO BID; titrate to 500 mg BID; max 2000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Acetazolamide (Diamox) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg BID; titrate to 2-4 g/day as tolerated; IIHTT used up to 4 g/day",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "idiopathic-intracranial-hypertension"
          ]
        },
        "episodic-ataxia-type-2-ea2-cacna1a-mutation-first-line-preve": {
          "indication": "Episodic ataxia type 2 (EA2, CACNA1A mutation); first-line preventive therapy; reduces frequency and severity of episodes",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Acetazolamide 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID; titrate to 250-500 mg BID-TID based on response; max 1000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "myotonia-refractory-to-first-line-agents-may-improve-myotoni": {
          "indication": "Myotonia refractory to first-line agents; may improve myotonia through carbonic anhydrase inhibition; limited evidence",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Acetazolamide 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg PO BID; may increase to 250 mg TID; max 1000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "hemiplegic-migraine-prevention-familial-hemiplegic-migraine": {
          "indication": "Hemiplegic migraine prevention; familial hemiplegic migraine",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Acetazolamide 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID; may increase to 500 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic insufficiency",
          "Severe hepatic or renal impairment",
          "Sulfa allergy",
          "Sulfa allergy, severe renal/hepatic disease, hypokalemia",
          "Sulfonamide allergy",
          "acidosis",
          "adrenal insufficiency",
          "hepatic insufficiency",
          "hypokalemia",
          "hyponatremia",
          "metabolic acidosis",
          "renal failure",
          "severe hepatic or renal impairment",
          "severe hepatic/renal disease",
          "severe metabolic acidosis",
          "severe renal/hepatic failure",
          "sulfonamide allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP (K, bicarb) q1-2 weeks initially",
          "BMP (bicarbonate, potassium)",
          "BMP (metabolic acidosis, hypokalemia)",
          "BMP (potassium, bicarbonate)",
          "BMP for potassium, bicarbonate",
          "BMP q3 months (metabolic acidosis, hypokalemia)",
          "CBC",
          "Electrolytes (hypokalemia, metabolic acidosis)",
          "Electrolytes (potassium, bicarbonate) weekly x 4 weeks, then monthly",
          "K+",
          "K+, bicarb, renal function q1-3 months",
          "Paresthesias",
          "[NORDIC Idiopathic Intracranial Hypertension Study Group (2014)](https://pubmed.ncbi.nlm.nih.gov/24687293/): acetazolamide effective for IIH",
          "bicarbonate",
          "fatigue, dysgeusia",
          "kidney stones",
          "kidney stones (hydration)",
          "metabolic acidosis",
          "paresthesias",
          "paresthesias (common, benign)",
          "paresthesias (expected)",
          "renal function",
          "renal stones risk",
          "symptoms of ICP (headache, vision)",
          "symptoms of metabolic acidosis",
          "tingling in extremities (common, benign)",
          "visual fields every 3-6 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 12,
      "_sourcePlans": [
        "ataxia-evaluation",
        "cerebral-venous-thrombosis",
        "fungal-meningitis",
        "idiopathic-intracranial-hypertension",
        "leptomeningeal-carcinomatosis",
        "migraine-with-aura",
        "myotonic-dystrophy",
        "neuro-behcets-disease",
        "neurosarcoidosis",
        "normal-pressure-hydrocephalus",
        "tinnitus-evaluation"
      ]
    },
    "acth-gel": {
      "id": "acth-gel",
      "name": "ACTH gel (Acthar)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "80-120 units",
              "orderSentence": "ACTH gel (Acthar) 80-120 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "80-120 units IM daily × 2-3 weeks; alternative to steroids",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as steroids",
          "Similar to corticosteroids"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose, BP, electrolytes",
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "acute-treatment": {
      "id": "acute-treatment",
      "name": "Acute treatment",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "**Acute treatment** 50-100 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Triptans (sumatriptan 50-100 mg PO, 6 mg SQ); NSAIDs; antiemetics (ondansetron, metoclopramide); vestibular suppressants for vertigo component",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vertigo-dizziness-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Standard migraine abortive therapy",
          "triptans can help vestibular symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "vertigo-dizziness-evaluation"
      ]
    },
    "acyclovir": {
      "id": "acyclovir",
      "name": "Acyclovir (HSV/VZV prophylaxis)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "herpes-prophylaxis-during-immunosuppressive-chemotherapy-rit": {
          "indication": "Herpes prophylaxis during immunosuppressive chemotherapy; rituximab increases reactivation risk",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Acyclovir (HSV/VZV prophylaxis) 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Acyclovir 400 mg PO BID or valacyclovir 500 mg PO daily; continue during chemotherapy and 3-6 months after completion",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Acyclovir (alternative) 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400 mg PO 5× daily × 7-10 days; or 800 mg PO TID × 7 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "bells-palsy"
          ]
        },
        "empiric-hsv-encephalitis-coverage-if-fever-altered-mental-st": {
          "indication": "Empiric HSV encephalitis coverage if fever, altered mental status, temporal lobe abnormalities",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Acyclovir (CPT 96365) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV q8h (based on ideal body weight); adjust for renal function",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment",
          "Renal impairment (dose adjust)",
          "Renal insufficiency (dose adjust)",
          "ensure adequate hydration"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function",
          "Renal function q24h, urine output",
          "signs of viral reactivation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "bells-palsy",
        "headache-evaluation",
        "primary-cns-lymphoma"
      ]
    },
    "acyclovir-iv": {
      "id": "acyclovir-iv",
      "name": "Acyclovir IV (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "encephalopathy-of-unknown-etiology-pending-hsv-pcr": {
          "indication": "Encephalopathy of unknown etiology pending HSV PCR",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Acyclovir IV (empiric until HSV ruled out) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV q8h; continue until HSV PCR negative x2 (48h apart) or alternative diagnosis confirmed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Acyclovir IV (CPT 96365) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV q8h (infuse over 1h). Base on IDEAL body weight (IBW). Duration: minimum 14-21 days. Dose adjust for renal impairment: CrCl 25-50: 10 mg/kg q12h; CrCl 10-25: 10 mg/kg q24h; HD: 10 mg/kg after each dialysis session",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hsv-encephalitis",
            "bells-palsy",
            "bacterial-meningitis"
          ]
        },
        "critical-empiric-hsv-coverage-hsv-encephalitis-is-fatal-if-u": {
          "indication": "CRITICAL: Empiric HSV coverage; HSV encephalitis is fatal if untreated; start on ALL patients with meningitis until HSV PCR returns negative and no encephalitic features present",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Acyclovir IV (empiric — until HSV excluded) (CPT 96365) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV q8h (based on ideal body weight); infuse over 1h; discontinue when HSV PCR negative AND no encephalitic features (confusion, focal deficits, seizures, temporal lobe MRI changes). CrCl 25-50: q12h; CrCl 10-25: q24h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "targeted-therapy-for-vzv-meningitis-with-or-without-rash-imm": {
          "indication": "Targeted therapy for VZV meningitis (with or without rash); immunocompromised patients require IV therapy; immunocompetent may be treated with oral valacyclovir if mild",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Acyclovir IV (for confirmed VZV meningitis) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV q8h (based on ideal body weight) x 10-14 days; transition to oral valacyclovir 1000 mg PO TID when clinically improving",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "empiric-antiviral-if-vzv-vasculopathy-not-yet-excluded-vzv-v": {
          "indication": "Empiric antiviral if VZV vasculopathy not yet excluded; VZV vasculopathy is a treatable and common mimic of PACNS",
          "doseOptions": [
            {
              "text": "10 mg/kg q8h",
              "orderSentence": "Acyclovir IV (empiric, until VZV excluded) 10 mg/kg q8h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV q8h; continue until VZV PCR and VZV CSF IgG negative; infuse over 1 hour; dose adjust for renal impairment",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "empiric-while-awaiting-hsv-pcr-fever-encephalopathy": {
          "indication": "Empiric while awaiting HSV PCR; fever + encephalopathy",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Acyclovir IV (CPT 96365) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV q8h. Continue until HSV PCR confirmed negative",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment",
          "Renal impairment (adjust dose)",
          "Renal impairment (dose adjust",
          "Renal impairment (dose adjust)",
          "True acyclovir allergy (extremely rare). Renal impairment — dose adjust, do NOT withhold",
          "adequate hydration required",
          "do NOT withhold)",
          "ensure adequate hydration"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC (rare neutropenia)",
          "Cr daily",
          "LFTs",
          "Renal function (BUN, Cr) daily",
          "Renal function daily",
          "Renal function, hydration",
          "acyclovir crystal nephropathy (maintain urine output)",
          "acyclovir crystal nephropathy risk",
          "adequate IV hydration (1 mL/kg/h)",
          "adequate hydration",
          "crystal nephropathy prevention",
          "ensure adequate hydration (1 mL/kg/h)",
          "ensure adequate hydration (1-1.5 mL/kg/h IV fluids)",
          "hydration",
          "hydration status",
          "urine output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "bacterial-meningitis",
        "bells-palsy",
        "cns-vasculitis",
        "hashimotos-encephalopathy",
        "hsv-encephalitis",
        "rapidly-progressive-dementia",
        "viral-meningitis"
      ]
    },
    "adalimumab": {
      "id": "adalimumab",
      "name": "Adalimumab",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "refractory-nbd-alternative-to-infliximab-preferred-for-outpa": {
          "indication": "Refractory NBD; alternative to infliximab; preferred for outpatient self-administration; refractory uveitis (FDA-approved for non-infectious uveitis)",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Adalimumab 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "80 mg SC at week 0, then 40 mg SC every other week; increase to 40 mg weekly if inadequate response; Pre-treatment: TB testing (QuantiFERON), Hepatitis B/C screening, CBC, LFTs, chest X-ray, pregnancy test",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "refractory-neurosarcoidosis-alternative-to-infliximab-may-be": {
          "indication": "Refractory neurosarcoidosis; alternative to infliximab; may be preferred for outpatient self-administration",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Adalimumab 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "80 mg SC at week 0, then 40 mg SC every other week; may increase to 40 mg weekly or 80 mg q2wk if inadequate response",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active or latent TB (treat first)",
          "active serious infection",
          "decompensated CHF",
          "demyelinating disease",
          "live vaccines within 4 weeks"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ANA annually",
          "CBC q2-4 months",
          "LFTs q3 months",
          "infection surveillance",
          "injection site reactions",
          "skin cancer screening"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "neuro-behcets-disease",
        "neurosarcoidosis"
      ]
    },
    "aducanumab": {
      "id": "aducanumab",
      "name": "Aducanumab (Aduhelm) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-10 mg/kg",
              "orderSentence": "Aducanumab (Aduhelm) (CPT 96365) 1-10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Titration from 1-10 mg/kg IV q4 weeks; limited use",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "MRI monitoring for ARIA"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "dementia-evaluation"
      ]
    },
    "aggressive-iv-hydration": {
      "id": "aggressive-iv-hydration",
      "name": "Aggressive IV hydration (rhabdomyolysis)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "rhabdomyolysis-prevention-treatment-if-ck-10-000-myoglobinur": {
          "indication": "Rhabdomyolysis prevention/treatment if CK >10,000; myoglobinuria",
          "doseOptions": [
            {
              "text": "200-300 mL/h NS",
              "orderSentence": "Aggressive IV hydration (rhabdomyolysis) 200-300 mL/h NS IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200-300 mL/hr normal saline; target urine output >200 mL/h; consider sodium bicarbonate drip to alkalinize urine (target pH >6.5)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart failure",
          "volume overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Urine output hourly",
          "electrolytes q6h (hyperkalemia risk)",
          "renal function",
          "serum CK q6-12h",
          "urine pH"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "inflammatory-myopathy"
      ]
    },
    "airway-icp-management": {
      "id": "airway-icp-management",
      "name": "Airway/ICP management (obtunded patient)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "**Airway/ICP management (obtunded patient)** 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**GCS ≤8:** Intubation; elevate HOB 30°; **Acute herniation:** Mannitol 1-1.5 g/kg IV bolus OR hypertonic saline (23.4% NaCl 30 mL via central line over 15 min or 3% NaCl 250 mL over 30 min); maintain PaCO2 30-35 mmHg (brief hyperventilation only as bridge to definitive treatment); Emergent neurosurgery consult for decompression",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-metastases"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ICP management as bridge to definitive treatment (surgery/radiation)",
          "osmotherapy reduces cerebral edema",
          "prolonged hyperventilation causes cerebral ischemia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-metastases"
      ]
    },
    "airway-management-intubation": {
      "id": "airway-management-intubation",
      "name": "Airway management / Intubation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.3 mg/kg",
              "orderSentence": "**Airway management / Intubation** 0.3 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**GCS ≤8: Secure airway**; RSI with agents that do NOT raise ICP; preferred: etomidate 0.3 mg/kg OR propofol 1-2 mg/kg + rocuronium 1.2 mg/kg OR succinylcholine 1.5 mg/kg; AVOID ketamine in severe TBI (controversial — emerging data suggest may be safe); lidocaine 1.5 mg/kg IV 2-3 min before laryngoscopy (may blunt ICP spike — controversial benefit); avoid hypotension during RSI",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "elevated-icp-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Airway protection",
          "GCS ≤8 cannot protect airway",
          "avoid hypoxia (PaO2 <60) and hypotension (SBP <90) — both worsen outcomes",
          "ventilation control (PaCO2 management)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "elevated-icp-management"
      ]
    },
    "airway-positioning-management": {
      "id": "airway-positioning-management",
      "name": "Airway positioning/management",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Airway positioning/management N/A PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Head-tilt chin-lift, oral airway, prepare for intubation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "O2 sat, airway patency"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-epilepticus"
      ]
    },
    "albendazole": {
      "id": "albendazole",
      "name": "Albendazole",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-antiparasitic-for-viable-parenchymal-ncc-vesicula": {
          "indication": "**First-line antiparasitic** for viable parenchymal NCC (vesicular and colloidal stages); 1-2 viable cysts: albendazole monotherapy x 7-14 days; >2 viable cysts: combine with praziquantel; subarachnoid/racemose NCC: prolonged courses (months); take with fatty meal (increases absorption 5-fold)",
          "doseOptions": [
            {
              "text": "15 mg/kg/day",
              "orderSentence": "Albendazole 15 mg/kg/day PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15 mg/kg/day PO divided BID (standard max 400 mg BID = 800 mg/day; up to 600 mg BID = 1200 mg/day for subarachnoid NCC or heavy cyst burden per ID specialist guidance); take with fatty meal; duration: 7-14 days for 1-2 parenchymal cysts; 10-14 days for >2 cysts (with praziquantel); weeks to months for subarachnoid NCC",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**Ocular cysticercosis** (ABSOLUTE — causes vision loss)",
          "cysticercal encephalitis with uncontrolled edema (treat edema first)",
          "pregnancy (teratogenic)",
          "severe hepatic disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC q2 weeks (leukopenia, thrombocytopenia)",
          "LFTs at baseline, day 7, day 14, then biweekly",
          "clinical response",
          "repeat imaging at 3-6 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neurocysticercosis"
      ]
    },
    "albumin": {
      "id": "albumin",
      "name": "Albumin (25%)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "ascites-management-hepatorenal-syndrome": {
          "indication": "Ascites management; hepatorenal syndrome",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "Albumin (25%) 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 g/kg/day (max 100 g); for large-volume paracentesis or hepatorenal syndrome",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Volume status, serum albumin"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wilsons-disease"
      ]
    },
    "alemtuzumab": {
      "id": "alemtuzumab",
      "name": "Alemtuzumab (Lemtrada)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "12 mg",
              "orderSentence": "Alemtuzumab (Lemtrada) 12 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Year 1: 12 mg IV daily × 5 days; Year 2: 12 mg IV daily × 3 days; highly active MS, REMS",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "Active infection, HIV, immunocompromised",
          "HIV",
          "ongoing autoimmune disease other than MS"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC monthly Ã— 48 months",
          "CBC, LFTs, creatinine, urinalysis, TSH monthly × 48 months after last dose",
          "REMS program",
          "TSH q3mo Ã— 48 months",
          "creatinine/urinalysis monthly Ã— 48 months",
          "secondary autoimmunity risk (thyroid, ITP, nephropathy)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "alendronate": {
      "id": "alendronate",
      "name": "Alendronate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "osteoporosis-prevention-if-chronic-steroids-anticipated-3-mo": {
          "indication": "Osteoporosis prevention if chronic steroids anticipated >3 months",
          "doseOptions": [
            {
              "text": "70 mg",
              "orderSentence": "Alendronate (bone protection) 70 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "70 mg PO weekly on empty stomach; remain upright 30 min after",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "osteoporosis-prevention-treatment-on-chronic-steroids": {
          "indication": "Osteoporosis prevention/treatment on chronic steroids",
          "doseOptions": [
            {
              "text": "70 mg",
              "orderSentence": "Alendronate 70 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "70 mg PO weekly on empty stomach with full glass of water; remain upright 30 min; consider if steroids >3 months at prednisone >5 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "osteoporosis-prevention-in-older-adults-with-ibm-at-high-fal": {
          "indication": "Osteoporosis prevention in older adults with IBM at high fall risk; bone protection if corticosteroid trial",
          "doseOptions": [
            {
              "text": "70 mg",
              "orderSentence": "Alendronate 70 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "70 mg PO weekly on empty stomach with full glass of water; remain upright 30 min after",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "steroids-anticipated-3-months-t-score-1-0": {
          "indication": "Steroids anticipated >3 months; T-score ≤-1.0",
          "doseOptions": [
            {
              "text": "70 mg weekly",
              "orderSentence": "Alendronate (bisphosphonate for osteoporosis prevention) 70 mg weekly PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "70 mg PO weekly; take on empty stomach with 8 oz water; remain upright 30 min",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "osteoporosis-t-score-2-5-or-osteopenia-with-fracture-risk-in": {
          "indication": "Osteoporosis (T-score ≤-2.5) or osteopenia with fracture risk in chronic epilepsy patients on enzyme-inducing ASMs",
          "doseOptions": [
            {
              "text": "70 mg weekly",
              "orderSentence": "Alendronate 70 mg weekly PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "70 mg PO once weekly; take first thing in morning with full glass water; remain upright 30 min; take on empty stomach",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CrCl <35",
          "Esophageal abnormalities",
          "Esophageal disorders",
          "GFR <30-35",
          "GFR <35",
          "esophageal disorders",
          "hypocalcemia",
          "hypocalcemia (correct first)",
          "inability to remain upright",
          "inability to remain upright 30 min",
          "inability to sit upright 30 min"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "DEXA at baseline and q1-2 years",
          "DEXA at baseline and q2 years",
          "DEXA q1-2 years",
          "DEXA q2 years",
          "calcium",
          "dental exam (ONJ risk)",
          "dental exam (osteonecrosis risk with prolonged use)",
          "dental health (osteonecrosis of jaw)",
          "esophageal symptoms",
          "jaw osteonecrosis rare",
          "renal function",
          "serum calcium"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "epilepsy-chronic-management",
        "giant-cell-arteritis",
        "inclusion-body-myositis",
        "inflammatory-myopathy",
        "myasthenia-gravis"
      ]
    },
    "alpha-lipoic-acid": {
      "id": "alpha-lipoic-acid",
      "name": "Alpha-lipoic acid",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "antioxidant-some-evidence-in-painful-neuropathy-european-gui": {
          "indication": "Antioxidant; some evidence in painful neuropathy; European guidelines",
          "doseOptions": [
            {
              "text": "600 mg",
              "orderSentence": "Alpha-lipoic acid 600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600 mg PO daily; may take 3-6 months for effect; limited evidence",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI upset"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "May enhance hypoglycemia in diabetics"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "small-fiber-neuropathy"
      ]
    },
    "alprazolam": {
      "id": "alprazolam",
      "name": "Alprazolam (Xanax)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.25-0.5 mg",
              "orderSentence": "Alprazolam (Xanax) 0.25-0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.25-0.5 mg TID; max 3 mg/day; use cautiously",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "essential-tremor"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Respiratory depression, addiction potential, elderly falls"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation, dependence, falls"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "essential-tremor"
      ]
    },
    "amantadine": {
      "id": "amantadine",
      "name": "Amantadine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "mild-chorea-may-help-fatigue": {
          "indication": "Mild chorea; may help fatigue",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Amantadine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg daily; titrate to 100 mg TID; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "symptomatic-relief-of-dip-enhances-dopamine-release-and-has-": {
          "indication": "Symptomatic relief of DIP; enhances dopamine release and has anticholinergic properties",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Amantadine (Symmetrel) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg daily; may increase to 100 mg BID after 1 week; max 300 mg/day; reduce dose in renal impairment (CrCl <50: 100 mg daily; CrCl <15: contraindicated)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        },
        "limited-evidence-may-reduce-td-severity-antiglutamatergic": {
          "indication": "Limited evidence; may reduce TD severity; antiglutamatergic",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Amantadine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID; may increase to 300-400 mg/day divided; adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        },
        "cognitive-fatigue-processing-speed-motivation": {
          "indication": "Cognitive fatigue, processing speed, motivation",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Amantadine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO every morning; increase to 100 mg BID after 1 week; max 200 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "parkinsonian-features-suspected-but-not-yet-confirmed-mild-s": {
          "indication": "Parkinsonian features suspected but not yet confirmed; mild symptomatic benefit; avoids levodopa commitment",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Amantadine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg daily; increase to 100 mg BID after 1 week; max 300 mg/day; reduce dose if CrCl <50",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "gait-freezing-akinesia-may-help-some-patients-with-motor-sym": {
          "indication": "Gait freezing, akinesia; may help some patients with motor symptoms",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Amantadine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg daily; increase to 100 mg BID-TID; avoid evening dosing (insomnia); max 300 mg/day; reduce dose in renal impairment (CrCl <50)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "arousal-promotion-in-patients-with-disorders-of-consciousnes": {
          "indication": "Arousal promotion in patients with disorders of consciousness (vegetative state/minimally conscious state); accelerates functional recovery",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Amantadine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID (via NG if needed); increase to 200 mg BID; give before noon to avoid insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "fatigue": {
          "indication": "Fatigue",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Amantadine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg every morning; may add 100 mg early afternoon (before 2 PM); max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "cerebellar-ataxia-various-etiologies-modest-evidence-for-gai": {
          "indication": "Cerebellar ataxia (various etiologies); modest evidence for gait improvement; anti-glutamatergic properties",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Amantadine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg daily; increase to 100 mg BID-TID over 1-2 weeks; max 300 mg/day; avoid afternoon dosing (insomnia)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "mild-parkinsonism-symptom-relief-may-help-gait-freezing": {
          "indication": "Mild parkinsonism symptom relief; may help gait freezing",
          "doseOptions": [
            {
              "text": "100 mg daily",
              "orderSentence": "Amantadine 100 mg daily PO"
            },
            {
              "text": "100 mg BID",
              "orderSentence": "Amantadine 100 mg BID PO"
            },
            {
              "text": "100 mg TID",
              "orderSentence": "Amantadine 100 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg daily; increase to 100 mg BID-TID over 1-2 weeks; max 300 mg/day; avoid evening doses (insomnia); adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "dyskinesia-reduction-mild-motor-benefit": {
          "indication": "Dyskinesia reduction; mild motor benefit",
          "doseOptions": [
            {
              "text": "100 mg BID",
              "orderSentence": "Amantadine 100 mg BID PO"
            },
            {
              "text": "100 mg TID",
              "orderSentence": "Amantadine 100 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg daily; titrate to 100 mg BID-TID; max 400 mg/day; dose-reduce in renal impairment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "End-stage renal disease",
          "Renal impairment (adjust dose)",
          "Renal impairment (adjust dose), seizure history (relative)",
          "Renal impairment (dose adjust)",
          "Renal impairment (reduce dose if CrCl <50), seizure history, severe CHF",
          "Severe renal impairment",
          "Severe renal impairment (CrCl <15)",
          "Severe renal impairment (dose adjust if CrCl <50)",
          "angle-closure glaucoma",
          "livedo reticularis",
          "livedo reticularis (cosmetic)",
          "pregnancy",
          "seizure history",
          "seizure history (relative — lowers threshold)",
          "seizure history (relative)",
          "uncontrolled glaucoma",
          "uncontrolled seizures"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Livedo reticularis",
          "Livedo reticularis, ankle edema, confusion, hallucinations",
          "Livedo reticularis, ankle edema, hallucinations, insomnia",
          "Livedo reticularis, hallucinations, edema",
          "Livedo reticularis, peripheral edema, hallucinations, insomnia, confusion",
          "Livedo reticularis, peripheral edema, hallucinations, insomnia, renal function",
          "Renal function",
          "Renal function, hallucinations, livedo reticularis, peripheral edema, confusion in elderly",
          "ankle edema",
          "confusion (elderly)",
          "edema",
          "hallucinations",
          "hallucinations (especially elderly)",
          "insomnia",
          "insomnia (avoid evening dosing)",
          "livedo reticularis",
          "renal function",
          "seizure activity"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 11,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "ataxia-evaluation",
        "drug-induced-parkinsonism",
        "huntingtons-disease",
        "ms-new-diagnosis",
        "multiple-system-atrophy",
        "parkinsons-disease",
        "post-concussion-syndrome",
        "progressive-supranuclear-palsy",
        "tardive-dyskinesia",
        "tremor-unspecified"
      ]
    },
    "amantadine-er": {
      "id": "amantadine-er",
      "name": "Amantadine ER (Gocovri)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "137-274 mg",
              "orderSentence": "Amantadine ER (Gocovri) 137-274 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "137-274 mg at bedtime; for dyskinesia",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "dyskinesia-extended-release-taken-at-bedtime": {
          "indication": "Dyskinesia; extended-release taken at bedtime",
          "doseOptions": [
            {
              "text": "137 mg qHS",
              "orderSentence": "Amantadine ER (Gocovri) 137 mg qHS PO"
            },
            {
              "text": "274 mg qHS",
              "orderSentence": "Amantadine ER (Gocovri) 274 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 137 mg qHS; increase to 274 mg qHS after 1 week",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same",
          "Same as IR"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same",
          "Same as IR"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "amantadine-ir": {
      "id": "amantadine-ir",
      "name": "Amantadine IR",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Amantadine IR 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg BID-TID; avoid evening dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment (reduce dose), seizures"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Livedo reticularis, edema, hallucinations, insomnia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "amikacin": {
      "id": "amikacin",
      "name": "Amikacin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "drug-resistant-tb-mdr-tb-injectable-agent-for-severe-mdr-tbm": {
          "indication": "Drug-resistant TB (MDR-TB); injectable agent for severe MDR-TBM; second-line injectable",
          "doseOptions": [
            {
              "text": "15 mg/kg daily (max 1000 mg)",
              "orderSentence": "Amikacin 15 mg/kg daily (max 1000 mg) IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15 mg/kg IV/IM daily (max 1000 mg); adjust for renal function; duration typically 2-4 months",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment",
          "hearing impairment",
          "pregnancy (ototoxic to fetus)",
          "vestibular dysfunction"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Audiometry monthly",
          "drug levels",
          "renal function weekly",
          "vestibular function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tb-meningitis"
      ]
    },
    "aminocaproic-acid": {
      "id": "aminocaproic-acid",
      "name": "Aminocaproic acid (antifibrinolytic) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "4g",
              "orderSentence": "Aminocaproic acid (antifibrinolytic) (CPT 96365) 4g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4g IV load then 1g/h IV infusion. ONLY use for short-term (<72h) if aneurysm securing will be delayed. Reduces re-bleeding risk but increases thrombotic risk. Discontinue once aneurysm is secured",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active DIC",
          "DVT/PE",
          "renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Coagulation",
          "discontinue when aneurysm treated",
          "thrombotic events"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "subarachnoid-hemorrhage"
      ]
    },
    "aminoglycosides": {
      "id": "aminoglycosides",
      "name": "Aminoglycosides (gentamicin, tobramycin, amikacin)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/IM"
      ],
      "formulations": [],
      "contexts": {
        "ototoxic-dose-dependent-cochlear-and-vestibular-toxicity-can": {
          "indication": "Ototoxic; dose-dependent cochlear and vestibular toxicity; can worsen tinnitus permanently",
          "doseOptions": [
            {
              "text": "-",
              "orderSentence": "**Aminoglycosides** (gentamicin, tobramycin, amikacin) - IV/IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "AVOID in tinnitus patients unless no alternative exists; if essential, use once-daily dosing to reduce ototoxicity",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        },
        "vestibulotoxic-causes-permanent-bilateral-vestibular-hypofun": {
          "indication": "Vestibulotoxic — causes permanent bilateral vestibular hypofunction with oscillopsia; irreversible",
          "doseOptions": [
            {
              "text": "Avoid if possible",
              "orderSentence": "**Aminoglycosides** (gentamicin, tobramycin, streptomycin) Avoid if possible IV/IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If aminoglycoside absolutely necessary, monitor peak/trough levels strictly; discontinue if vestibular symptoms develop",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pre-existing vestibular dysfunction",
          "Tinnitus or pre-existing hearing loss (relative)",
          "concurrent ototoxic agents",
          "renal impairment increases risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Drug levels (trough <1 for gentamicin)",
          "Peak/trough levels",
          "audiometry if prolonged course",
          "serial audiometry if prolonged course",
          "vestibular symptom assessment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "nystagmus-evaluation",
        "tinnitus-evaluation"
      ]
    },
    "amitriptyline": {
      "id": "amitriptyline",
      "name": "Amitriptyline",
      "genericName": "amitriptyline",
      "brandNames": [
        "Elavil"
      ],
      "drugClass": "Tricyclic Antidepressant (TCA)",
      "mechanisms": [
        "Inhibits reuptake of serotonin and norepinephrine",
        "Anticholinergic effects",
        "Sodium channel blockade"
      ],
      "routes": [
        "PO"
      ],
      "formulations": [
        "10 mg tablet",
        "25 mg tablet",
        "50 mg tablet",
        "75 mg tablet",
        "100 mg tablet",
        "150 mg tablet"
      ],
      "contexts": {
        "neuropathic-pain": {
          "indication": "Neuropathic pain (diabetic neuropathy, post-herpetic neuralgia)",
          "doseOptions": [
            {
              "text": "10 mg QHS",
              "orderSentence": "Amitriptyline 10 mg PO QHS"
            },
            {
              "text": "25 mg QHS",
              "orderSentence": "Amitriptyline 25 mg PO QHS"
            },
            {
              "text": "50 mg QHS",
              "orderSentence": "Amitriptyline 50 mg PO QHS"
            },
            {
              "text": "75 mg QHS",
              "orderSentence": "Amitriptyline 75 mg PO QHS"
            },
            {
              "text": "100 mg QHS",
              "orderSentence": "Amitriptyline 100 mg PO QHS"
            }
          ],
          "startingDose": "10-25 mg QHS",
          "maxDose": "150 mg/day (pain); lower in elderly",
          "titration": "Increase by 10-25 mg every 1-2 weeks as tolerated",
          "notes": "First-line TCA for neuropathic pain; sedation limits titration",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          }
        },
        "migraine-prophylaxis": {
          "indication": "Migraine prophylaxis",
          "doseOptions": [
            {
              "text": "10 mg QHS",
              "orderSentence": "Amitriptyline 10 mg PO QHS"
            },
            {
              "text": "25 mg QHS",
              "orderSentence": "Amitriptyline 25 mg PO QHS"
            },
            {
              "text": "50 mg QHS",
              "orderSentence": "Amitriptyline 50 mg PO QHS"
            },
            {
              "text": "75 mg QHS",
              "orderSentence": "Amitriptyline 75 mg PO QHS"
            }
          ],
          "startingDose": "10 mg QHS",
          "maxDose": "100 mg/day",
          "titration": "Increase by 10 mg every 2 weeks",
          "notes": "First-line for migraine prophylaxis; helps with comorbid insomnia"
        },
        "tension-headache": {
          "indication": "Chronic tension-type headache prophylaxis",
          "doseOptions": [
            {
              "text": "10 mg QHS",
              "orderSentence": "Amitriptyline 10 mg PO QHS"
            },
            {
              "text": "25 mg QHS",
              "orderSentence": "Amitriptyline 25 mg PO QHS"
            },
            {
              "text": "50 mg QHS",
              "orderSentence": "Amitriptyline 50 mg PO QHS"
            },
            {
              "text": "75 mg QHS",
              "orderSentence": "Amitriptyline 75 mg PO QHS"
            }
          ],
          "startingDose": "10 mg QHS",
          "maxDose": "100 mg/day",
          "titration": "Increase by 10-25 mg every 1-2 weeks",
          "notes": "First-line for chronic tension headache"
        },
        "neuropathic-pain-second-line-avoid-in-elderly": {
          "indication": "Neuropathic pain (second-line; avoid in elderly)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "sialorrhea-insomnia-depression": {
          "indication": "Sialorrhea; insomnia; depression",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg PO qHS; increase by 10 mg weekly; max 75-100 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-25 mg",
              "orderSentence": "Amitriptyline (neuropathic pain) 10-25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg QHS; titrate to 50-100 mg QHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cidp",
            "diabetic-neuropathy",
            "medication-overuse-headache",
            "migraine"
          ]
        },
        "neuropathic-pain-second-line-useful-for-concurrent-insomnia": {
          "indication": "Neuropathic pain (second-line); useful for concurrent insomnia",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "tinnitus-with-comorbid-insomnia-depression-or-anxiety": {
          "indication": "Tinnitus with comorbid insomnia, depression, or anxiety",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "**Amitriptyline** 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg QHS, titrate by 10 mg every 1-2 weeks to 50 mg; low-dose TCA; reduces tinnitus perception in subset of patients; stronger evidence for comorbid conditions",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        },
        "chronic-pain-insomnia-migraine-prophylaxis-common-fnd-comorb": {
          "indication": "Chronic pain; insomnia; migraine prophylaxis (common FND comorbidities)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg PO qHS; titrate by 10 mg q1-2wk; max 75 mg qHS for pain/insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "functional-neurological-disorder"
          ]
        },
        "tca-for-neuropathic-pain-helps-insomnia-inexpensive": {
          "indication": "TCA for neuropathic pain; helps insomnia; inexpensive",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS; max 150 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "neuropathic-pain-refractory-to-gabapentin-pregabalin-also-he": {
          "indication": "Neuropathic pain refractory to gabapentin/pregabalin; also helps insomnia",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg PO qHS; titrate by 10-25 mg q1-2 weeks; max 150 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "comorbid-chronic-pain-headache-fibromyalgia-insomnia-migrain": {
          "indication": "Comorbid chronic pain (headache, fibromyalgia); insomnia; migraine prophylaxis in PNES patients",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg PO qHS; titrate by 10 mg q1-2wk; max 75 mg qHS for pain/insomnia; lower doses effective for pain than depression",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        },
        "nocturnal-neuropathic-pain-second-line": {
          "indication": "Nocturnal neuropathic pain (second-line)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg qHS; increase by 10 mg weekly; max 75 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peroneal-neuropathy"
          ]
        },
        "first-line-preventive-for-post-traumatic-headache": {
          "indication": "First-line preventive for post-traumatic headache",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg PO QHS; increase by 10 mg every 1-2 weeks; target 25-75 mg QHS; max 150 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "neuropathic-pain-second-line": {
          "indication": "Neuropathic pain (second-line)",
          "doseOptions": [
            {
              "text": "10-25 mg",
              "orderSentence": "Amitriptyline 10-25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "nocturnal-paresthesias-second-line": {
          "indication": "Nocturnal paresthesias (second-line)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg qHS; increase by 10 mg weekly; max 50 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        },
        "neuropathic-pain-insomnia-from-paraneoplastic-sensory-neurop": {
          "indication": "Neuropathic pain; insomnia from paraneoplastic sensory neuropathy",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg qHS; titrate by 10-25 mg q1-2wk; max 150 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "central-post-stroke-pain-insomnia-alternative-when-gabapenti": {
          "indication": "Central post-stroke pain; insomnia; alternative when gabapentinoids insufficient; TCA class",
          "doseOptions": [
            {
              "text": "10 mg qHS",
              "orderSentence": "Amitriptyline 10 mg qHS PO"
            },
            {
              "text": "25 mg qHS",
              "orderSentence": "Amitriptyline 25 mg qHS PO"
            },
            {
              "text": "50 mg qHS",
              "orderSentence": "Amitriptyline 50 mg qHS PO"
            },
            {
              "text": "75 mg qHS",
              "orderSentence": "Amitriptyline 75 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg qHS; increase by 10-25 mg q1wk; target 25-75 mg qHS; max 150 mg/day; use cautiously in elderly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "first-line-comorbid-insomnia-depression-or-tension-type-feat": {
          "indication": "First-line; comorbid insomnia, depression, or tension-type features",
          "doseOptions": [
            {
              "text": "10-25 mg",
              "orderSentence": "Amitriptyline 10-25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg QHS; increase by 10-25 mg q1-2 weeks; target 50-150 mg QHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "neuropathic-pain-second-line-helps-sleep": {
          "indication": "Neuropathic pain (second-line, helps sleep)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "first-line-prevention-for-chronic-tth-15-days-month": {
          "indication": "First-line prevention for chronic TTH; ≥15 days/month",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg qHS; titrate by 10-25 mg every 1-2 weeks; target 25-75 mg qHS; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "neuropathic-pain-insomnia": {
          "indication": "Neuropathic pain, insomnia",
          "doseOptions": [
            {
              "text": "10-25 mg",
              "orderSentence": "Amitriptyline 10-25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg PO qHS; increase by 10-25 mg q1-2 weeks; max 150 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        },
        "neuropathic-pain-with-insomnia-central-pain-syndrome-from-ce": {
          "indication": "Neuropathic pain with insomnia; central pain syndrome from cervical myelopathy",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg PO qHS; titrate by 10-25 mg q1-2 weeks; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "neuropathic-pain-second-line-helps-with-sleep-disruption-fro": {
          "indication": "Neuropathic pain (second-line; helps with sleep disruption from pain)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        },
        "neuropathic-pain-lyme-radiculopathy-chronic-pain-may-also-he": {
          "indication": "Neuropathic pain (Lyme radiculopathy; chronic pain); may also help with insomnia",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; target 50-75 mg qHS; max 150 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        },
        "prevention-with-comorbid-insomnia-depression-tension-type-he": {
          "indication": "Prevention with comorbid insomnia, depression, tension-type headache",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Amitriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg qHS; titrate by 10-25 mg q1-2wk; target 25-75 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [
          "Suicidal thinking and behavior in children, adolescents, and young adults with MDD"
        ],
        "contraindications": [
          "Use within 14 days of MAOIs",
          "Acute recovery phase after myocardial infarction",
          "Concomitant use with cisapride"
        ],
        "precautions": [
          "Cardiac arrhythmias - ECG before starting in patients with cardiac history",
          "Anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision)",
          "Orthostatic hypotension - fall risk in elderly",
          "Sedation - take at bedtime",
          "Lowered seizure threshold",
          "Angle-closure glaucoma risk",
          "QT prolongation at high doses",
          "AVOID in elderly (Beers Criteria - highly anticholinergic)"
        ],
        "drugInteractions": [
          {
            "drug": "MAOIs",
            "severity": "contraindicated",
            "effect": "Hypertensive crisis, serotonin syndrome"
          },
          {
            "drug": "Anticholinergics",
            "severity": "high",
            "effect": "Additive anticholinergic toxicity"
          },
          {
            "drug": "QT-prolonging drugs",
            "severity": "high",
            "effect": "Additive QT prolongation"
          },
          {
            "drug": "Alcohol",
            "severity": "moderate",
            "effect": "Additive CNS depression"
          },
          {
            "drug": "CYP2D6 inhibitors",
            "severity": "moderate",
            "effect": "Increased amitriptyline levels"
          }
        ],
        "pregnancyCategory": "C",
        "lactation": "Caution - excreted in breast milk"
      },
      "renalAdjustment": {
        "required": false,
        "tiers": [
          {
            "gfr": "≥15",
            "adjustment": "No adjustment typically needed"
          },
          {
            "gfr": "<15",
            "adjustment": "Use with caution; active metabolites may accumulate"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": true,
        "notes": "Use lower doses; hepatically metabolized. Avoid in severe impairment."
      },
      "monitoring": {
        "baseline": [
          "ECG if cardiac history or age >50",
          "Consider baseline cognitive assessment in elderly"
        ],
        "ongoing": [
          "Anticholinergic side effects",
          "Orthostatic hypotension",
          "Suicidal ideation"
        ],
        "frequency": "Clinical assessment at each visit"
      },
      "patientCounseling": [
        "Take at bedtime due to sedation",
        "Do not stop abruptly - taper over 2+ weeks",
        "Avoid alcohol",
        "May cause dry mouth - sip water, sugar-free gum",
        "Rise slowly to prevent dizziness",
        "Full effect may take 4-6 weeks",
        "Avoid in very hot weather (impaired sweating)"
      ]
    },
    "amlodipine": {
      "id": "amlodipine",
      "name": "Amlodipine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "bp-control-add-on-or-alternative-antihypertensive": {
          "indication": "BP control; add-on or alternative antihypertensive",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Amlodipine 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; may increase to 10 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "hypertension-especially-if-ace-i-intolerant": {
          "indication": "Hypertension; especially if ACE-I intolerant",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Amlodipine 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5-5 mg daily; increase q2wk; max 10 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "alternative-or-adjunctive-antihypertensive-for-secondary-str": {
          "indication": "Alternative or adjunctive antihypertensive for secondary stroke prevention",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Amlodipine 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily; max 10 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "steroid-induced-hypertension-management-avoid-abrupt-blood-p": {
          "indication": "Steroid-induced hypertension management; avoid abrupt blood pressure changes that may worsen cerebral ischemia",
          "doseOptions": [
            {
              "text": "5 mg daily",
              "orderSentence": "Amlodipine 5 mg daily PO"
            },
            {
              "text": "10 mg daily",
              "orderSentence": "Amlodipine 10 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily; increase to 10 mg daily if needed; target BP <140/90",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "long-acting-ccb-for-patients-transitioning-from-verapamil-or": {
          "indication": "Long-acting CCB for patients transitioning from verapamil or nimodipine; easier compliance for outpatient management; also provides BP control",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Amlodipine (transition to long-acting CCB) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily; increase to 10 mg daily as needed; may use as transition from verapamil/nimodipine for longer-term management",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Amlodipine 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily; max 10 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "calcium-channel-blocker-for-post-stroke-bp-management-add-on": {
          "indication": "Calcium channel blocker for post-stroke BP management; add-on to ACEi/ARB; good in elderly; evidence from ASCOT",
          "doseOptions": [
            {
              "text": "2.5 mg daily",
              "orderSentence": "Amlodipine 2.5 mg daily PO"
            },
            {
              "text": "5 mg daily",
              "orderSentence": "Amlodipine 5 mg daily PO"
            },
            {
              "text": "10 mg daily",
              "orderSentence": "Amlodipine 10 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5-5 mg daily; increase by 2.5-5 mg q1-2wk; max 10 mg; well tolerated in elderly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "calcium-channel-blocker-for-bp-management-add-on-to-acei-arb": {
          "indication": "Calcium channel blocker for BP management; add-on to ACEi/ARB; well tolerated in elderly; evidence from ASCOT trial",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Amlodipine 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5-5 mg daily; increase by 2.5-5 mg q1-2wk; max 10 mg; well tolerated in elderly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "BP, peripheral edema",
          "Severe aortic stenosis",
          "Severe aortic stenosis (relative)",
          "Severe hypotension",
          "aortic stenosis",
          "cardiogenic shock",
          "hypotension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Blood pressure",
          "HR",
          "Peripheral edema",
          "Peripheral edema, BP",
          "heart rate",
          "pedal edema",
          "peripheral edema",
          "peripheral edema (common)",
          "repeat CTA/MRA at 8-12 weeks"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "carotid-stenosis",
        "cervical-artery-dissection",
        "cns-vasculitis",
        "mild-cognitive-impairment",
        "post-stroke-management",
        "rcvs",
        "vascular-dementia"
      ]
    },
    "amphetamine-dextroamphetamine": {
      "id": "amphetamine-dextroamphetamine",
      "name": "Amphetamine/dextroamphetamine (Adderall)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "adhd-comorbidity-alternative-stimulant": {
          "indication": "ADHD comorbidity; alternative stimulant",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Amphetamine/dextroamphetamine (Adderall) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily (IR) or 10 mg daily (XR); increase by 5-10 mg/wk; target 10-30 mg/day; max 40 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAO-I use",
          "glaucoma",
          "pheochromocytoma",
          "severe cardiac disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HR, BP",
          "appetite/weight",
          "cardiac screening if risk factors",
          "sleep",
          "tic severity"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tics-tourette-syndrome"
      ]
    },
    "amphotericin-b": {
      "id": "amphotericin-b",
      "name": "Amphotericin B (liposomal)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "mucormycosis-brain-abscess-severe-refractory-fungal-abscess-": {
          "indication": "Mucormycosis brain abscess; severe/refractory fungal abscess; amphotericin-sensitive fungi when azoles inadequate",
          "doseOptions": [
            {
              "text": "5 mg/kg",
              "orderSentence": "Amphotericin B (liposomal) 5 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/kg IV daily; infuse over 2h; duration based on clinical response (typically 4-6 weeks IV then transition to oral azole); pre-medicate with acetaminophen and diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment (liposomal less nephrotoxic than conventional)",
          "infusion reactions"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "Renal function daily",
          "electrolytes daily (K, Mg -- wasting common)",
          "infusion reactions",
          "pre-medicate"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-abscess"
      ]
    },
    "amphotericin-b-conventional": {
      "id": "amphotericin-b-conventional",
      "name": "Amphotericin B conventional (deoxycholate)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "alternative-induction-if-liposomal-formulation-unavailable-h": {
          "indication": "Alternative induction if liposomal formulation unavailable; higher nephrotoxicity but more widely available globally (WHO preferred in resource-limited settings)",
          "doseOptions": [
            {
              "text": "0.7-1.0 mg/kg/day",
              "orderSentence": "Amphotericin B conventional (deoxycholate) 0.7-1.0 mg/kg/day IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.7-1.0 mg/kg IV daily for minimum 2 weeks; infuse over 4-6 hours; aggressive normal saline pre-hydration (1L before each dose)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe renal impairment",
          "concomitant nephrotoxins"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC twice weekly",
          "Renal function daily",
          "potassium and magnesium twice daily",
          "rigors, fever during infusion"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "amphotericin-b-liposomal": {
      "id": "amphotericin-b-liposomal",
      "name": "Amphotericin B liposomal (AmBisome)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "first-line-induction-therapy-for-cryptococcal-meningitis-fun": {
          "indication": "First-line induction therapy for cryptococcal meningitis; fungicidal; liposomal formulation preferred over conventional due to reduced nephrotoxicity",
          "doseOptions": [
            {
              "text": "3-4 mg/kg/day",
              "orderSentence": "Amphotericin B liposomal (AmBisome) 3-4 mg/kg/day IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-4 mg/kg IV daily for minimum 2 weeks (induction); infuse over 2 hours; premedicate with acetaminophen, diphenhydramine, and normal saline 500 mL before each dose to reduce infusion reactions and nephrotoxicity",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe renal impairment (dose adjust or switch formulation)",
          "anaphylaxis to amphotericin",
          "concurrent nephrotoxic agents (minimize)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC twice weekly",
          "LFTs weekly",
          "Renal function (BMP daily)",
          "infusion reaction monitoring",
          "potassium and magnesium twice daily during induction"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "ampicillin": {
      "id": "ampicillin",
      "name": "Ampicillin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "l-monocytogenes": {
          "indication": "L. monocytogenes",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ampicillin 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q4h (+ gentamicin 5 mg/kg/day IV for synergy in first 7-10 days, if renal function allows)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function (especially with gentamicin)",
          "gentamicin levels"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "bacterial-meningitis"
      ]
    },
    "ampicillin-iv": {
      "id": "ampicillin-iv",
      "name": "Ampicillin IV (add if age >50, immunocompromised, or alcoholism) (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "covers-listeria-monocytogenes-resistant-to-cephalosporins-ad": {
          "indication": "Covers Listeria monocytogenes (resistant to cephalosporins); add to vancomycin + ceftriaxone if risk factors present: age >50, immunocompromised, alcoholism, pregnancy",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ampicillin IV (add if age >50, immunocompromised, or alcoholism) (CPT 96374) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q4h; discontinue when bacterial meningitis excluded and Listeria not identified",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ampicillin IV (add if Listeria risk) (CPT 96374) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q4h. ADD to vancomycin + ceftriaxone if: age >50, immunocompromised, alcoholism, pregnancy. Covers Listeria monocytogenes (resistant to cephalosporins)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Penicillin anaphylaxis (use TMP-SMX as Listeria alternative)",
          "Penicillin anaphylaxis (use TMP-SMX as alternative for Listeria)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Rash",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "bacterial-meningitis",
        "viral-meningitis"
      ]
    },
    "anakinra": {
      "id": "anakinra",
      "name": "Anakinra",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Anakinra 100 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg SC daily (may increase; used in FIRES)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Injection site reactions, infection"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-epilepticus"
      ]
    },
    "anti-emetics": {
      "id": "anti-emetics",
      "name": "Anti-emetics (for radiation/chemotherapy)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "4-8 mg",
              "orderSentence": "**Anti-emetics (for radiation/chemotherapy)** 4-8 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ondansetron 4-8 mg IV/PO q8h PRN; Dexamethasone itself is anti-emetic; Avoid metoclopramide in brain metastases patients (extrapyramidal effects)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "brain-metastases"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Nausea common with elevated ICP and with radiation therapy"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-metastases"
      ]
    },
    "antibiotics": {
      "id": "antibiotics",
      "name": "Antibiotics (if abscess suspected)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-30 mg/kg",
              "orderSentence": "**Antibiotics (if abscess suspected)** 25-30 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Epidural abscess causing CES:** Empiric: Vancomycin 25-30 mg/kg IV load + ceftriaxone 2g IV q12h (or cefepime 2g IV q8h); adjust to culture/sensitivity; MRSA coverage essential; **Duration:** Typically 6-8 weeks IV antibiotics for epidural abscess; **Timing:** Start AFTER blood cultures drawn but do NOT delay if patient is deteriorating",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cauda-equina-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "S. aureus (including MRSA) is most common organism in epidural abscess (60-70%)",
          "gram-negative coverage for UTI/abdominal source",
          "streptococci, anaerobes less common"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cauda-equina-syndrome"
      ]
    },
    "anticoagulation": {
      "id": "anticoagulation",
      "name": "Anticoagulation (if atrial fibrillation detected)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Anticoagulation (if atrial fibrillation detected) 5 mg -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start DOAC within 1-3 days for TIA (can start earlier than stroke). Preferred: Apixaban 5 mg BID (2.5 mg BID if criteria met). Alternative: Rivaroxaban 20 mg daily; Dabigatran 150 mg BID. Discontinue antiplatelet when anticoagulant started (do NOT combine long-term unless specific indication)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "transient-ischemic-attack"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "mechanical valve (use warfarin)",
          "severe renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function q6-12 months",
          "bleeding signs"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "transient-ischemic-attack"
      ]
    },
    "anticoagulation-restart": {
      "id": "anticoagulation-restart",
      "name": "Anticoagulation restart (if AF or mechanical valve)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "most-controversial-decision-aha-2022-may-restart-anticoagula": {
          "indication": "Most controversial decision. AHA 2022: may restart anticoagulation at 4-8 weeks for patients with strong indication (AF with high CHA2DS2-VASc). Avoid in CAA-related lobar ICH if possible",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Anticoagulation restart (if AF or mechanical valve) N/A PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apixaban preferred (APACHE-AF trial: lowest ICH recurrence). Timing: 4-8 weeks; individualized risk-benefit",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CHA2DS2-VASc vs HAS-BLED",
          "Imaging stability",
          "bleeding risk"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "antiemetics": {
      "id": "antiemetics",
      "name": "Antiemetics",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "4-8 mg",
              "orderSentence": "**Antiemetics** 4-8 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ondansetron 4-8 mg IV/PO; metoclopramide 10 mg IV (avoid in elderly — EPS); prochlorperazine 5-10 mg IV/IM",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "vertigo-dizziness-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Nausea is often the most debilitating symptom"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "vertigo-dizziness-evaluation"
      ]
    },
    "antiemetics-prn": {
      "id": "antiemetics-prn",
      "name": "Antiemetics PRN",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Antiemetics PRN 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Metoclopramide 10 mg q8h PRN or ondansetron 4-8 mg q8h PRN",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per agent"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "For nausea during withdrawal"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "medication-overuse-headache"
      ]
    },
    "antifungals": {
      "id": "antifungals",
      "name": "Antifungals (amphotericin B + flucytosine) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.7-1 mg/kg",
              "orderSentence": "Antifungals (amphotericin B + flucytosine) (CPT 96365) 0.7-1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Amphotericin B 0.7-1 mg/kg/day IV + flucytosine 100 mg/kg/day x 2 weeks (induction)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs",
          "Renal function",
          "electrolytes"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "rapidly-progressive-dementia"
      ]
    },
    "antihypertensive-therapy": {
      "id": "antihypertensive-therapy",
      "name": "Antihypertensive therapy (long-term)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "all-ich-patients-bp-is-most-important-modifiable-risk-factor": {
          "indication": "ALL ICH patients; BP is most important modifiable risk factor",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Antihypertensive therapy (long-term) N/A PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Target SBP <130 mmHg (SPS3 trial, PROGRESS trial); agent choice per comorbidities (ACE-I, ARB, CCB, thiazide)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Antihypertensive therapy (chronic) 10-20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Target BP <130/80 mmHg. Start/restart 24-48h after TIA once stable. Agent choice per comorbidities: ACE-I/ARB first-line. Consider: Lisinopril 10-20 mg daily, Amlodipine 5-10 mg, Losartan 50-100 mg, Chlorthalidone 12.5-25 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "transient-ischemic-attack"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bilateral renal artery stenosis (ACE-I/ARB)",
          "pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cr and K+ at 1-2 weeks",
          "Home BP monitoring",
          "clinic BP"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "intracerebral-hemorrhage",
        "transient-ischemic-attack"
      ]
    },
    "antiplatelet-restart": {
      "id": "antiplatelet-restart",
      "name": "Antiplatelet restart",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "restart-trial-restarting-antiplatelet-after-ich-is-associate": {
          "indication": "RESTART trial: restarting antiplatelet after ICH is associated with LOWER risk of recurrent ICH; may restart at 2-4 weeks for patients with cardiovascular indication",
          "doseOptions": [
            {
              "text": "81 mg",
              "orderSentence": "Antiplatelet restart 81 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Aspirin 81 mg or clopidogrel 75 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bleeding signs"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "antiretroviral-therapy-for-hiv-associated-fungal-meningitis": {
      "id": "antiretroviral-therapy-for-hiv-associated-fungal-meningitis",
      "name": "Antiretroviral therapy (ART) — for HIV-associated fungal meningitis",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "delayed-initiation-in-cryptococcal-meningitis-starting-art-t": {
          "indication": "DELAYED initiation in cryptococcal meningitis; starting ART too early increases IRIS risk and mortality; initiate 4-6 weeks after antifungal induction therapy",
          "doseOptions": [
            {
              "text": "Per HIV specialist",
              "orderSentence": "Antiretroviral therapy (ART) — for HIV-associated fungal meningitis Per HIV specialist PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Initiate ART 4-6 WEEKS after starting antifungal therapy (NOT immediately); per COAT trial — early ART (within 1-2 weeks) increased mortality compared to delayed ART (4-6 weeks)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Do NOT start within 2 weeks of antifungal initiation (IRIS risk)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CD4 count and viral load q3 months",
          "IRIS symptoms (worsening headache, fever, meningismus, new focal deficits 2-8 weeks after ART initiation)",
          "LFTs",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "antivirals": {
      "id": "antivirals",
      "name": "Antivirals (controversial)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "**Antivirals (controversial)** 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Valacyclovir 1000 mg TID x 7 days; evidence is WEAK; some use empirically if early presentation; thought to be HSV reactivation (like Bell's palsy)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vertigo-dizziness-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cochrane review: No clear benefit",
          "some clinicians still use empirically, especially if labyrinthitis with hearing loss"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "vertigo-dizziness-evaluation"
      ]
    },
    "apixaban": {
      "id": "apixaban",
      "name": "Apixaban",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "atrial-fibrillation-related-vascular-dementia": {
          "indication": "Atrial fibrillation-related vascular dementia",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Apixaban 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg BID (2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "dissection-with-concurrent-atrial-fibrillation-alternative-a": {
          "indication": "Dissection with concurrent atrial fibrillation; alternative anticoagulant if warfarin not preferred",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Apixaban 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg PO BID standard dose; 2.5 mg BID if >=2 of: age >=80, weight <=60 kg, Cr >=1.5; for concurrent AF or physician preference for anticoagulation strategy",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "alternative-doac-for-cvt-limited-data": {
          "indication": "Alternative DOAC for CVT (limited data)",
          "doseOptions": [
            {
              "text": "5 mg BID",
              "orderSentence": "Apixaban 5 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg PO BID; reduce to 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Apixaban 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg PO BID (2.5 mg BID if ≥2 of: age ≥80, weight ≤60kg, Cr ≥1.5); start 4-14 days post-stroke for AF (timing based on infarct size). Preferred DOAC per guidelines",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "anticoagulation-for-stroke-with-af-preferred-doac-for-most-p": {
          "indication": "Anticoagulation for stroke with AF; preferred DOAC for most patients; superior to warfarin (ARISTOTLE trial)",
          "doseOptions": [
            {
              "text": "5 mg BID",
              "orderSentence": "Apixaban 5 mg BID PO"
            },
            {
              "text": "2.5 mg BID",
              "orderSentence": "Apixaban 2.5 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg BID standard; reduce to 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5; start 2-14 days after stroke depending on infarct size (1-3-6-12 day rule)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "Active major bleeding",
          "Active pathologic bleeding",
          "CBC",
          "Renal function",
          "bleeding signs",
          "hepatic impairment",
          "mechanical heart valve",
          "mechanical valve",
          "pregnancy",
          "prosthetic heart valve",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "CBC annually",
          "CrCl",
          "LFTs",
          "Renal function q6 months",
          "Renal function q6-12 months",
          "Xa level if needed (not routine)",
          "bleeding signs",
          "signs of bleeding"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "cerebral-venous-thrombosis",
        "cervical-artery-dissection",
        "post-stroke-management",
        "vascular-dementia"
      ]
    },
    "apomorphine-continuous-infusion": {
      "id": "apomorphine-continuous-infusion",
      "name": "Apomorphine continuous infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "severe-motor-fluctuations-not-dbs-candidate": {
          "indication": "Severe motor fluctuations; not DBS candidate",
          "doseOptions": [
            {
              "text": "3-8 mg/hr continuous",
              "orderSentence": "Apomorphine continuous infusion 3-8 mg/hr continuous SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Via subcutaneous pump; typical 3-8 mg/hr during waking hours",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as SC apomorphine"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same as SC apomorphine"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease"
      ]
    },
    "apomorphine-sc": {
      "id": "apomorphine-sc",
      "name": "Apomorphine SC (Apokyn)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO",
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.2 mL",
              "orderSentence": "Apomorphine SC (Apokyn) 0.2 mL PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Rescue for off episodes; start 0.2 mL (2 mg) test dose; max 0.6 mL (6 mg)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "off-episode-in-clinic-ed-npo-patient": {
          "indication": "Off episode in clinic/ED; NPO patient",
          "doseOptions": [
            {
              "text": "2 mg SC",
              "orderSentence": "Apomorphine SC 2 mg SC SC"
            },
            {
              "text": "3 mg SC",
              "orderSentence": "Apomorphine SC 3 mg SC SC"
            },
            {
              "text": "4 mg SC",
              "orderSentence": "Apomorphine SC 4 mg SC SC"
            },
            {
              "text": "5 mg SC",
              "orderSentence": "Apomorphine SC 5 mg SC SC"
            },
            {
              "text": "6 mg SC",
              "orderSentence": "Apomorphine SC 6 mg SC SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Test dose 2 mg; titrate by 1 mg to effect; max 6 mg; pretreat with trimethobenzamide",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent 5-HT3 antagonists (ondansetron)",
          "Severe hypotension, 5-HT3 antagonist use",
          "severe hypotension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP, nausea",
          "BP, nausea (pretreat with trimethobenzamide)",
          "may cause severe hypotension"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "apremilast": {
      "id": "apremilast",
      "name": "Apremilast",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "oral-ulcers-of-behcet-s-disease-fda-approved-for-this-indica": {
          "indication": "Oral ulcers of Behcet's disease (FDA-approved for this indication); adjunct to systemic immunotherapy",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Apremilast 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Titrate over 6 days to 30 mg PO BID; start 10 mg daily day 1, increase per schedule",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe renal impairment (CrCl <30: reduce dose to 30 mg daily)",
          "depression/suicidal ideation"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI side effects (nausea, diarrhea)",
          "Weight",
          "depression screening"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neuro-behcets-disease"
      ]
    },
    "aripiprazole": {
      "id": "aripiprazole",
      "name": "Aripiprazole (Abilify)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "psychosis-irritability-weight-neutral": {
          "indication": "Psychosis; irritability; weight-neutral",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Aripiprazole 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2-5 mg daily; titrate by 5 mg q1wk; max 30 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "partial-d2-agonist-with-lower-eps-risk-as-antipsychotic-subs": {
          "indication": "Partial D2 agonist with lower EPS risk as antipsychotic substitute",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Aripiprazole (Abilify) 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2-5 mg daily; titrate based on response; usual range 10-15 mg/day; max 30 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        },
        "second-line-atypical-antipsychotic-favorable-metabolic-profi": {
          "indication": "Second-line; atypical antipsychotic; favorable metabolic profile; AAN Level B",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Aripiprazole (Abilify) 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg daily; increase by 2.5-5 mg q1-2wk; target 2.5-15 mg/day; max 20 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity",
          "None significant",
          "caution in elderly with dementia",
          "caution with strong CYP2D6/CYP3A4 inhibitors"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Akathisia, EPS",
          "EPS/akathisia",
          "Metabolic panel, weight, akathisia (can paradoxically worsen), EPS monitoring",
          "Weight, BMI, waist circumference q3mo",
          "fasting glucose, lipids q3-6mo",
          "prolactin baseline and PRN"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "drug-induced-parkinsonism",
        "huntingtons-disease",
        "tics-tourette-syndrome"
      ]
    },
    "armodafinil": {
      "id": "armodafinil",
      "name": "Armodafinil",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-wake-promoting-agent-for-eds-longer-duration-than": {
          "indication": "First-line wake-promoting agent for EDS; longer duration than modafinil",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Armodafinil (Nuvigil) 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 150 mg each morning; may increase to 250 mg daily; longer half-life than modafinil; max 250 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        },
        "fatigue": {
          "indication": "Fatigue",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Armodafinil 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 150 mg every morning; max 250 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "excessive-daytime-somnolence-in-dm1-if-modafinil-not-tolerat": {
          "indication": "Excessive daytime somnolence in DM1 if modafinil not tolerated; R-enantiomer with longer half-life",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Armodafinil 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 150 mg PO every morning; may increase to 250 mg daily; avoid afternoon dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity",
          "Same as modafinil",
          "cardiac arrhythmia",
          "may reduce efficacy of hormonal contraceptives",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Blood pressure",
          "Same as modafinil",
          "Schedule IV",
          "cardiac rhythm",
          "contraceptive efficacy",
          "heart rate",
          "hepatic function",
          "insomnia",
          "longer half-life",
          "mood",
          "rash (rare Stevens-Johnson)",
          "sleep quality"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "ms-new-diagnosis",
        "myotonic-dystrophy",
        "narcolepsy"
      ]
    },
    "art-initiation": {
      "id": "art-initiation",
      "name": "ART initiation (HIV-associated PCNSL)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "hiv-positive-patients-art-is-critical-component-of-treatment": {
          "indication": "HIV-positive patients: ART is critical component of treatment; immune reconstitution may independently cause tumor regression; start concurrently with chemotherapy or before if CD4 critically low",
          "doseOptions": [
            {
              "text": "Per HIV guidelines",
              "orderSentence": "ART initiation (HIV-associated PCNSL) Per HIV guidelines PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Preferred: bictegravir/emtricitabine/TAF (Biktarvy) 1 tablet PO daily or dolutegravir-based regimen; check for drug interactions with chemotherapy; avoid protease inhibitors (CYP interactions with chemotherapy); INSTI-based regimens preferred",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CD4 count and HIV viral load at baseline and q3 months",
          "IRIS monitoring (immune reconstitution inflammatory syndrome may cause paradoxical worsening)",
          "drug interaction review with each chemotherapy cycle"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "art-regimen-intensification": {
      "id": "art-regimen-intensification",
      "name": "ART regimen intensification (CNS-optimized)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "csf-viral-escape-detectable-csf-hiv-rna-with-suppressed-plas": {
          "indication": "CSF viral escape (detectable CSF HIV RNA with suppressed plasma viral load); neurologic deterioration despite plasma viral suppression",
          "doseOptions": [
            {
              "text": "Individualized",
              "orderSentence": "ART regimen intensification (CNS-optimized) Individualized PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Switch to regimen with highest total CPE score incorporating dolutegravir + 2 high-CPE NRTIs (e.g., DTG/ABC/3TC or DTG + ZDV/3TC); target total CPE >=7-8; guided by resistance profile",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per individual drug contraindications"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Repeat LP in 4-8 weeks to confirm CSF viral suppression",
          "neuropsychological retesting at 6-12 months",
          "plasma VL q4 weeks"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "artificial-tears": {
      "id": "artificial-tears",
      "name": "Artificial tears",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Ophthalmic",
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "keratoconjunctivitis-sicca-from-lacrimal-gland-sarcoidosis": {
          "indication": "Keratoconjunctivitis sicca from lacrimal gland sarcoidosis",
          "doseOptions": [
            {
              "text": "1-2 drops",
              "orderSentence": "Artificial tears 1-2 drops TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 drops in each eye q2-4h PRN for dryness; preservative-free preferred for frequent use",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "dry-eye-secondary-to-reduced-blink-or-lagophthalmos": {
          "indication": "Dry eye secondary to reduced blink or lagophthalmos",
          "doseOptions": [
            {
              "text": "1-2 drops",
              "orderSentence": "Artificial tears 1-2 drops TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Preservative-free artificial tears 1-2 drops q2-4h as needed",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "dry-eyes-from-impaired-blinking-cn-vii-involvement-reduced-l": {
          "indication": "Dry eyes from impaired blinking (CN VII involvement, reduced lacrimation)",
          "doseOptions": [
            {
              "text": "1-2 drops",
              "orderSentence": "Artificial tears (methylcellulose) 1-2 drops Ophthalmic"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 drops each eye q2-4h while awake; lubricating ointment at night",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "botulism"
          ]
        },
        "eye-protection-for-facial-palsy-incomplete-eye-closure-preve": {
          "indication": "Eye protection for facial palsy (incomplete eye closure); prevents exposure keratopathy and corneal abrasion",
          "doseOptions": [
            {
              "text": "1-2 drops",
              "orderSentence": "Artificial tears (lubricant eye drops) 1-2 drops TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply lubricant drops q1-2h while awake; use lubricant ointment at bedtime; tape eye closed at night if unable to fully close",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None",
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Corneal integrity",
          "None",
          "Symptom relief",
          "ophthalmology follow-up",
          "ophthalmology if corneal exposure",
          "refer ophthalmology if corneal exposure"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "botulism",
        "lyme-neuroborreliosis",
        "neurosarcoidosis",
        "optic-neuritis"
      ]
    },
    "artificial-tears-saliva-substitutes": {
      "id": "artificial-tears-saliva-substitutes",
      "name": "Artificial tears/saliva substitutes",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "dry-eyes-and-dry-mouth-from-autonomic-dysfunction": {
          "indication": "Dry eyes and dry mouth from autonomic dysfunction",
          "doseOptions": [
            {
              "text": "1-2 drops",
              "orderSentence": "Artificial tears/saliva substitutes 1-2 drops TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Artificial tears q2-4h PRN for dry eyes; saliva substitute spray or lozenges PRN for dry mouth",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Symptom relief assessment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "lambert-eaton-syndrome"
      ]
    },
    "aspiration-pneumonia-treatment-ampicillin-sulbactam": {
      "id": "aspiration-pneumonia-treatment-ampicillin-sulbactam",
      "name": "Aspiration pneumonia treatment: Ampicillin-sulbactam",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "aspiration-pneumonia-from-ibm-related-dysphagia": {
          "indication": "Aspiration pneumonia from IBM-related dysphagia",
          "doseOptions": [
            {
              "text": "3 g",
              "orderSentence": "Aspiration pneumonia treatment: Ampicillin-sulbactam 3 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3 g (ampicillin 2 g / sulbactam 1 g) IV q6h; duration 5-7 days; switch to oral amoxicillin-clavulanate when improving",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "aspiration-pneumonia-from-dm1-related-dysphagia-and-orophary": {
          "indication": "Aspiration pneumonia from DM1-related dysphagia and oropharyngeal weakness",
          "doseOptions": [
            {
              "text": "3 g",
              "orderSentence": "Aspiration pneumonia treatment: Ampicillin-sulbactam 3 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3 g (ampicillin 2 g / sulbactam 1 g) IV q6h; duration 5-7 days; transition to oral amoxicillin-clavulanate when clinically improving",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Penicillin allergy",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Temperature",
          "WBC",
          "chest X-ray improvement",
          "renal function",
          "renal function for dose adjustment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "inclusion-body-myositis",
        "myotonic-dystrophy"
      ]
    },
    "aspiration-pneumonia-treatment-clindamycin": {
      "id": "aspiration-pneumonia-treatment-clindamycin",
      "name": "Aspiration pneumonia treatment: Clindamycin (penicillin allergy alternative)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "aspiration-pneumonia-in-penicillin-allergic-patients": {
          "indication": "Aspiration pneumonia in penicillin-allergic patients",
          "doseOptions": [
            {
              "text": "600-900 mg",
              "orderSentence": "Aspiration pneumonia treatment: Clindamycin (penicillin allergy alternative) 600-900 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600-900 mg IV q8h; duration 5-7 days; switch to oral clindamycin 300-450 mg q6h when improving",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "aspiration-pneumonia-in-penicillin-allergic-patients-with-dm": {
          "indication": "Aspiration pneumonia in penicillin-allergic patients with DM-related dysphagia",
          "doseOptions": [
            {
              "text": "600 mg",
              "orderSentence": "Aspiration pneumonia treatment: Clindamycin (penicillin allergy alternative) 600 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600-900 mg IV q8h; duration 5-7 days; transition to oral clindamycin 300-450 mg q6h when improving",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "C. difficile history (relative -- GI dysmotility in DM increases risk)",
          "C. difficile history (relative)",
          "Clindamycin hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "C. difficile monitoring",
          "LFTs",
          "diarrhea",
          "diarrhea (GI dysmotility already present)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "inclusion-body-myositis",
        "myotonic-dystrophy"
      ]
    },
    "aspirin": {
      "id": "aspirin",
      "name": "Aspirin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "immediate-antiplatelet-therapy-for-secondary-stroke-preventi": {
          "indication": "Immediate antiplatelet therapy for secondary stroke prevention",
          "doseOptions": [
            {
              "text": "325 mg",
              "orderSentence": "Aspirin (loading) 325 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "325 mg loading dose if no recent stroke, then 81 mg daily ongoing",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "lifelong-antiplatelet-for-secondary-stroke-prevention": {
          "indication": "Lifelong antiplatelet for secondary stroke prevention",
          "doseOptions": [
            {
              "text": "81 mg",
              "orderSentence": "Aspirin (long-term) 81 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "81 mg daily indefinitely for non-cardioembolic vascular dementia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "antiplatelet-therapy-for-ischemic-moyamoya-reduces-thrombus-": {
          "indication": "Antiplatelet therapy for ischemic moyamoya; reduces thrombus formation in stenotic vessels and fragile collaterals",
          "doseOptions": [
            {
              "text": "81 mg daily",
              "orderSentence": "Aspirin 81 mg daily PO"
            },
            {
              "text": "325 mg daily",
              "orderSentence": "Aspirin 325 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "81-325 mg PO daily; 81 mg preferred for long-term; 325 mg may be used acutely; continue indefinitely unless hemorrhagic presentation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        },
        "long-term-antiplatelet-therapy-for-all-moyamoya-patients-wit": {
          "indication": "Long-term antiplatelet therapy for all moyamoya patients with ischemic presentation; reduces ischemic events; continue post-surgery",
          "doseOptions": [
            {
              "text": "81 mg daily",
              "orderSentence": "Aspirin (long-term antiplatelet) 81 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "81 mg PO daily indefinitely; hold 7 days before surgery then resume 24-48h post-op per neurosurgical guidance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        },
        "secondary-prevention-if-established-cvd-not-for-primary-prev": {
          "indication": "Secondary prevention if established CVD; not for primary prevention in MCI",
          "doseOptions": [
            {
              "text": "81 mg",
              "orderSentence": "Aspirin (low-dose) 81 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "81 mg daily; only if established CVD or high vascular risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "first-line-oral-analgesic-anti-inflammatory-and-anti-platele": {
          "indication": "First-line oral analgesic; anti-inflammatory and anti-platelet",
          "doseOptions": [
            {
              "text": "650-1000 mg",
              "orderSentence": "Aspirin 650-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO at onset; max 4000 mg/day; limit to <15 days/month",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "long-term-secondary-stroke-prevention-post-dissection-first-": {
          "indication": "Long-term secondary stroke prevention post-dissection; first-line per CADISS trial equivalence data",
          "doseOptions": [
            {
              "text": "81 mg",
              "orderSentence": "Aspirin (maintenance) 81 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "81 mg PO daily preferred for long-term use; 325 mg daily acceptable; duration minimum 3-6 months; many neurologists continue indefinitely if vascular risk factors present",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "325 mg",
              "orderSentence": "Aspirin 325 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "325 mg PO/PR load (give within 24-48h of onset); if tPA given, wait 24h and obtain CT before starting. Maintenance: 81-325 mg daily",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke",
            "dementia-evaluation",
            "migraine",
            "transient-ischemic-attack"
          ]
        },
        "antiplatelet-therapy-to-reduce-ischemic-complications-visual": {
          "indication": "Antiplatelet therapy to reduce ischemic complications (visual loss, stroke) in GCA",
          "doseOptions": [
            {
              "text": "81 mg daily",
              "orderSentence": "Aspirin (low-dose) 81 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "81 mg PO daily",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "antiplatelet-therapy-for-microvascular-thrombosis-prevention": {
          "indication": "Antiplatelet therapy for microvascular thrombosis prevention; adjunctive to immunotherapy; targets platelet-endothelial interaction in Susac syndrome",
          "doseOptions": [
            {
              "text": "81 mg daily",
              "orderSentence": "Aspirin (low-dose antiplatelet) 81 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "81 mg PO daily; start at diagnosis; continue long-term as adjunctive antiplatelet therapy",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "first-line-antiplatelet-for-non-cardioembolic-ischemic-strok": {
          "indication": "First-line antiplatelet for non-cardioembolic ischemic stroke; lifelong secondary prevention",
          "doseOptions": [
            {
              "text": "81 mg daily",
              "orderSentence": "Aspirin 81 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "81 mg PO daily (preferred); 325 mg for first 3 weeks with minor stroke/TIA per CHANCE/POINT then reduce to 81 mg; lifelong",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "cervical-artery-dissection-antiplatelet-therapy-equivalent-t": {
          "indication": "Cervical artery dissection — antiplatelet therapy (equivalent to anticoagulation per CADISS trial)",
          "doseOptions": [
            {
              "text": "325 mg",
              "orderSentence": "Aspirin (if cervical artery dissection confirmed) 325 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Aspirin 325 mg PO daily x 3-6 months. Preferred in patients with large infarct or hemorrhagic transformation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "first-line-acute-treatment-anti-inflammatory": {
          "indication": "First-line acute treatment; anti-inflammatory",
          "doseOptions": [
            {
              "text": "650 mg",
              "orderSentence": "Aspirin 650 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "650-1000 mg PO at onset; max 4000 mg/day; limit to <10 days/month",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "first-line-antiplatelet-for-all-carotid-stenosis-patients-sy": {
          "indication": "First-line antiplatelet for all carotid stenosis patients (symptomatic and asymptomatic); lifelong secondary prevention; reduces stroke risk 22% in symptomatic patients",
          "doseOptions": [
            {
              "text": "81 mg",
              "orderSentence": "Aspirin 81 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "81 mg PO daily (preferred long-term); 325 mg for first 3 months if symptomatic or perioperative; lifelong therapy",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active GI bleed",
          "Active GI bleed, true aspirin allergy, within 24h of tPA (wait for post-tPA CT)",
          "Active GI bleeding",
          "Active bleeding",
          "Active hemorrhage",
          "Active hemorrhagic stroke",
          "Bleeding",
          "Bleeding disorder, aspirin allergy",
          "Bleeding disorders",
          "GI ulcer",
          "allergy",
          "aspirin allergy",
          "children/teens (Reye syndrome)",
          "concurrent anticoagulation (relative)",
          "concurrent full-dose anticoagulation (use one or other)",
          "hemorrhagic moyamoya presentation",
          "hemorrhagic moyamoya without ischemic history",
          "high bleeding risk",
          "platelet count <50K",
          "severe bleeding risk",
          "third trimester",
          "thrombocytopenia <50K",
          "true aspirin allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bleeding",
          "GI bleeding",
          "GI prophylaxis with PPI if high-risk",
          "GI symptoms",
          "GI symptoms, bleeding",
          "GI symptoms, bleeding signs",
          "Neuro checks",
          "Signs of bleeding",
          "annual CBC",
          "bleeding",
          "bleeding assessment at follow-up",
          "bleeding signs",
          "platelet count",
          "platelet function",
          "platelet function if concerns"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 17,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "carotid-stenosis",
        "cervical-artery-dissection",
        "dementia-evaluation",
        "giant-cell-arteritis",
        "headache-unspecified",
        "migraine",
        "mild-cognitive-impairment",
        "moyamoya-disease",
        "post-stroke-management",
        "susac-syndrome",
        "tension-headache",
        "thunderclap-headache-evaluation",
        "transient-ischemic-attack",
        "vascular-dementia"
      ]
    },
    "aspirin-clopidogrel": {
      "id": "aspirin-clopidogrel",
      "name": "Aspirin + Clopidogrel (DAPT — short-term)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "high-risk-dissection-with-minor-stroke-nihss-3-or-recurrent-": {
          "indication": "High-risk dissection with minor stroke (NIHSS <=3) or recurrent TIA on single antiplatelet; short-term use (21-90 days)",
          "doseOptions": [
            {
              "text": "81 mg + 75 mg",
              "orderSentence": "Aspirin + Clopidogrel (DAPT) 81 mg + 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Aspirin 81 mg daily + Clopidogrel 75 mg daily x 21-90 days; load clopidogrel 300 mg if not previously on it; then transition to single antiplatelet",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "dual-antiplatelet-x-21-days-for-minor-ischemic-stroke-nihss-": {
          "indication": "Dual antiplatelet x 21 days for minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4) per CHANCE/POINT trials",
          "doseOptions": [
            {
              "text": "81 mg aspirin + 75 mg clopidogrel daily x 21 days",
              "orderSentence": "Aspirin + Clopidogrel (DAPT — short-term) 81 mg aspirin + 75 mg clopidogrel daily x 21 days PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Aspirin 81 mg + clopidogrel 75 mg (with 300 mg clopidogrel load) x 21 days from onset; then monotherapy (aspirin or clopidogrel); DO NOT continue DAPT beyond 21-90 days (increases bleeding without benefit)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "dual-antiplatelet-x-21-days-for-minor-ischemic-stroke-nihss--2": {
          "indication": "Dual antiplatelet x 21 days for minor ischemic stroke (NIHSS <=3) or high-risk TIA (ABCD2 >=4) per CHANCE/POINT trials; periprocedural for CAS (30-day minimum DAPT required)",
          "doseOptions": [
            {
              "text": "81 mg + 75 mg",
              "orderSentence": "Aspirin + Clopidogrel (DAPT — short-term) 81 mg + 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Aspirin 81 mg + clopidogrel 75 mg (with 300 mg clopidogrel load) x 21 days from symptom onset then monotherapy; for CAS: DAPT x 30 days minimum (some continue 3-6 months); DO NOT continue long-term DAPT beyond 90 days for stroke (increases bleeding)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Major bleeding",
          "Major stroke (NIHSS >3)",
          "high bleeding risk",
          "planned CEA within 5-7 days (hold clopidogrel)",
          "planned surgery",
          "thrombocytopenia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bleeding signs",
          "Bleeding signs closely during DAPT period",
          "Bleeding signs closely x 21 days",
          "CBC monthly",
          "GI prophylaxis with PPI if high GI risk",
          "platelet count"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "carotid-stenosis",
        "cervical-artery-dissection",
        "post-stroke-management"
      ]
    },
    "aspirin-loading-dose": {
      "id": "aspirin-loading-dose",
      "name": "Aspirin loading dose",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "acute-dissection-without-stroke-or-with-minor-ischemic-strok": {
          "indication": "Acute dissection without stroke or with minor ischemic stroke; first-line antiplatelet per CADISS trial",
          "doseOptions": [
            {
              "text": "325 mg",
              "orderSentence": "Aspirin loading dose 325 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "325 mg PO/PR loading dose; if tPA was given, wait 24h and obtain CT head before starting. Transition to maintenance 81-325 mg daily",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active GI bleeding",
          "true aspirin allergy",
          "within 24h of tPA (wait for post-tPA CT)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "bleeding signs"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cervical-artery-dissection"
      ]
    },
    "atenolol": {
      "id": "atenolol",
      "name": "Atenolol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Atenolol 50-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg daily; less CNS penetration than propranolol",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "essential-tremor"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as propranolol"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HR, BP"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "essential-tremor"
      ]
    },
    "atogepant": {
      "id": "atogepant",
      "name": "Atogepant (Qulipta)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-60 mg",
              "orderSentence": "Atogepant (Qulipta) 10-60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-60 mg PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "chronic-migraine-prevention-oral-alternative-to-cgrp-mabs-on": {
          "indication": "Chronic migraine prevention; oral alternative to CGRP mAbs; only gepant FDA-approved for chronic migraine prevention",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Atogepant (Qulipta) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg PO daily (approved dose for chronic migraine); reduce to 10 mg daily with strong CYP3A4 inhibitors; avoid with strong CYP3A4 inducers",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment",
          "Severe hepatic impairment (Child-Pugh C)",
          "end-stage renal disease",
          "strong CYP3A4 inducers"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs",
          "LFTs q3-6 months",
          "constipation",
          "weight (may cause weight loss)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine"
      ]
    },
    "atomoxetine": {
      "id": "atomoxetine",
      "name": "Atomoxetine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "eds-with-comorbid-adhd-norepinephrine-reuptake-inhibitor-wit": {
          "indication": "EDS with comorbid ADHD; norepinephrine reuptake inhibitor with mild anticataplectic properties",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Atomoxetine 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 40 mg daily; increase to 80 mg after ≥3 days; max 100 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        },
        "adhd-comorbidity-non-stimulant-improves-both-adhd-and-tics": {
          "indication": "ADHD comorbidity; non-stimulant; improves both ADHD and tics",
          "doseOptions": [
            {
              "text": "0.5 mg/kg",
              "orderSentence": "Atomoxetine (Strattera) 0.5 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg/kg/day; increase to 1.2 mg/kg/day after 3-7 days; max 1.4 mg/kg/day or 100 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        },
        "neurogenic-oh-norepinephrine-reuptake-inhibitor-may-augment-": {
          "indication": "Neurogenic OH — norepinephrine reuptake inhibitor; may augment other agents",
          "doseOptions": [
            {
              "text": "10 mg BID",
              "orderSentence": "Atomoxetine 10 mg BID PO"
            },
            {
              "text": "18 mg BID",
              "orderSentence": "Atomoxetine 18 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg BID; increase to 18 mg BID after 1 week; off-label use for neurogenic OH",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAO-I use",
          "Concurrent MAOIs",
          "MAOIs, narrow-angle glaucoma, pheochromocytoma, severe cardiac arrhythmia",
          "narrow-angle glaucoma",
          "pheochromocytoma",
          "severe cardiac disease",
          "severe cardiovascular disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP (supine and standing), heart rate, mood changes",
          "BP, HR",
          "Blood pressure",
          "appetite/weight",
          "heart rate",
          "hepatic function (rare hepatotoxicity)",
          "hepatotoxicity (rare)",
          "suicidality (Black Box in children)",
          "suicidality in children/adolescents"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "multiple-system-atrophy",
        "narcolepsy",
        "tics-tourette-syndrome"
      ]
    },
    "atorvastatin": {
      "id": "atorvastatin",
      "name": "Atorvastatin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "high-intensity-statin-for-secondary-stroke-prevention-ldl-ta": {
          "indication": "High-intensity statin for secondary stroke prevention; LDL target <70",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Atorvastatin 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 40-80 mg daily; target LDL <70 mg/dL; 80 mg preferred for established vascular disease",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "vascular-risk-factor-optimization-pleiotropic-effects-endoth": {
          "indication": "Vascular risk factor optimization; pleiotropic effects (endothelial function, anti-inflammatory); may benefit even with non-atherosclerotic disease",
          "doseOptions": [
            {
              "text": "20 mg daily",
              "orderSentence": "Atorvastatin 20 mg daily PO"
            },
            {
              "text": "40 mg daily",
              "orderSentence": "Atorvastatin 40 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20-40 mg daily; target LDL <70 given high vascular risk; monitor LFTs",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        },
        "hyperlipidemia-vascular-risk-reduction-may-slow-cognitive-de": {
          "indication": "Hyperlipidemia; vascular risk reduction; may slow cognitive decline",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Atorvastatin 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-20 mg daily; titrate to LDL goal; target LDL <100 (or <70 if established CVD)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "vascular-risk-reduction-secondary-stroke-prevention-in-disse": {
          "indication": "Vascular risk reduction; secondary stroke prevention in dissection patients with atherosclerotic risk factors",
          "doseOptions": [
            {
              "text": "40-80 mg",
              "orderSentence": "Atorvastatin 40-80 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40-80 mg PO daily; high-intensity statin therapy for secondary stroke prevention",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "80 mg",
              "orderSentence": "Atorvastatin 80 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "80 mg PO daily (high-intensity); start within 24-48h regardless of baseline LDL",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "high-intensity-statin-for-all-ischemic-stroke-patients-sparc": {
          "indication": "High-intensity statin for all ischemic stroke patients; SPARCL trial demonstrated 16% stroke risk reduction with LDL <70; TST trial supports LDL <70",
          "doseOptions": [
            {
              "text": "40 mg daily",
              "orderSentence": "Atorvastatin 40 mg daily PO"
            },
            {
              "text": "80 mg daily",
              "orderSentence": "Atorvastatin 80 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 40-80 mg daily; target LDL <70 mg/dL; 80 mg preferred for secondary prevention; take any time of day",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "high-intensity-statin-for-all-carotid-stenosis-patients-rega": {
          "indication": "High-intensity statin for ALL carotid stenosis patients regardless of LDL; reduces cardiovascular events; plaque stabilization and possible regression; SPARCL trial supports LDL <70 for secondary prevention",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Atorvastatin 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 40-80 mg daily; target LDL <70 mg/dL; 80 mg preferred for symptomatic carotid stenosis; plaque regression observed with intensive statin therapy",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active liver disease",
          "Active liver disease, pregnancy, breastfeeding",
          "breastfeeding",
          "concurrent strong CYP3A4 inhibitors at high doses",
          "pregnancy",
          "unexplained persistent transaminase elevation"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CK if myalgia",
          "LFTs at 12 weeks then annually",
          "LFTs at baseline",
          "LFTs at baseline and 3 months",
          "LFTs at baseline, 6-12 weeks, then annually",
          "lipid panel at 4-12 weeks",
          "lipid panel q3-6 months until at goal then annually",
          "lipid panel q3-6mo initially",
          "lipid panel q6 months",
          "myalgias"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "carotid-stenosis",
        "cervical-artery-dissection",
        "mild-cognitive-impairment",
        "moyamoya-disease",
        "post-stroke-management",
        "vascular-dementia"
      ]
    },
    "atropine": {
      "id": "atropine",
      "name": "Atropine (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "bradycardia-from-autonomic-dysfunction-excessive-secretions": {
          "indication": "Bradycardia from autonomic dysfunction; excessive secretions",
          "doseOptions": [
            {
              "text": "0.5-1 mg",
              "orderSentence": "Atropine (CPT 96374) 0.5-1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg IV PRN for symptomatic bradycardia; may repeat q3-5 min; max 3 mg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "botulism"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.5-1 mg",
              "orderSentence": "Atropine (for cholinergic side effects/emergency) 0.5-1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg IV PRN for symptomatic bradycardia from pyridostigmine",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis",
            "autoimmune-encephalitis"
          ]
        },
        "post-cas-bradycardia-from-baroreceptor-stimulation-during-st": {
          "indication": "Post-CAS bradycardia from baroreceptor stimulation during stent deployment; prophylactic or reactive",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Atropine (CPT 96374) 0.5 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg IV push; may repeat q3-5min; max 3 mg; prophylactic 0.5 mg IV before CAS balloon inflation in some protocols",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Glaucoma (relative)",
          "Tachycardia",
          "Tachycardia, angle-closure glaucoma",
          "myocardial ischemia",
          "tachyarrhythmia",
          "thyrotoxicosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "HR",
          "HR monitoring",
          "HR, rhythm",
          "crosses BBB (may cause confusion)",
          "rarely needed beyond procedural period",
          "rhythm",
          "urinary retention"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "botulism",
        "carotid-stenosis",
        "myasthenia-gravis-new-diagnosis"
      ]
    },
    "atropine-1-ophthalmic-drops": {
      "id": "atropine-1-ophthalmic-drops",
      "name": "Atropine 1% ophthalmic drops (sublingual)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SL"
      ],
      "formulations": [],
      "contexts": {
        "sialorrhea-rescue": {
          "indication": "Sialorrhea (rescue)",
          "doseOptions": [
            {
              "text": "1-2 drops",
              "orderSentence": "Atropine 1% ophthalmic drops (sublingual) 1-2 drops SL"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 drops sublingual q4-6h as needed; max 4 doses/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "sialorrhea-alternative-to-systemic-anticholinergics-with-les": {
          "indication": "Sialorrhea; alternative to systemic anticholinergics with less cognitive effect",
          "doseOptions": [
            {
              "text": "1-2 drops",
              "orderSentence": "Atropine 1% ophthalmic drops (sublingual) 1-2 drops SL"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 drops of 1% ophthalmic solution sublingual TID PRN drooling; local effect",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Narrow-angle glaucoma",
          "cardiac arrhythmia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dry mouth, tachycardia",
          "HR, dry mouth, urinary retention",
          "minimal systemic absorption"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "als",
        "progressive-supranuclear-palsy"
      ]
    },
    "azathioprine": {
      "id": "azathioprine",
      "name": "Azathioprine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg every 1-2 weeks to target 2-3 mg/kg/day; onset of effect 6-12 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "cidp",
            "myasthenia-gravis-new-diagnosis",
            "acute-myelopathy",
            "autoimmune-encephalitis"
          ]
        },
        "first-line-steroid-sparing-agent-for-nbd-strongest-evidence-": {
          "indication": "**First-line steroid-sparing agent for NBD** (strongest evidence among conventional immunosuppressants); prevents relapse in parenchymal and non-parenchymal NBD",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg every 2 weeks to target 2.5 mg/kg/day; onset of action 2-3 months; continue minimum 2-3 years",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "steroid-sparing-agent-for-pm-and-dm-maintenance-therapy-onse": {
          "indication": "Steroid-sparing agent for PM and DM; maintenance therapy; onset 6-12 months",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine (Imuran) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg every 1-2 weeks to target 2-3 mg/kg/day (typically 150-250 mg/day)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "steroid-sparing-maintenance-relapsing-he": {
          "indication": "Steroid-sparing maintenance; relapsing HE",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine (Imuran) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg every 2 weeks to target 2-3 mg/kg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "steroid-sparing-maintenance-relapse-prevention": {
          "indication": "Steroid-sparing maintenance; relapse prevention",
          "doseOptions": [
            {
              "text": "2-3 mg/kg",
              "orderSentence": "Azathioprine (maintenance) 2-3 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-3 mg/kg/day (target established during initial titration)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "steroid-sparing-agent-alternative-to-methotrexate-mycophenol": {
          "indication": "Steroid-sparing agent; alternative to methotrexate/mycophenolate",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg every 2 weeks to target 2-3 mg/kg/day; onset of action 3-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "steroid-sparing-first-line-maintenance-immunosuppressant": {
          "indication": "Steroid-sparing; first-line maintenance immunosuppressant",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily x 1-2 weeks; increase by 50 mg every 2-4 weeks to target 2-3 mg/kg/day (usually 150-200 mg/day); takes 6-12 months for full effect",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "steroid-sparing-maintenance-immunotherapy-takes-3-6-months-f": {
          "indication": "Steroid-sparing maintenance immunotherapy; takes 3-6 months for full effect -- bridge with prednisone",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine (Imuran) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg every 2-4 weeks to target 2-3 mg/kg/day; onset of action 3-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "steroid-sparing-maintenance-aqp4-or-aqp4-nmosd": {
          "indication": "Steroid-sparing maintenance; AQP4+ or AQP4- NMOSD",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine (off-label) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg q2wk to target 2-3 mg/kg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "steroid-sparing-for-cidp-vasculitis": {
          "indication": "Steroid-sparing for CIDP, vasculitis",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily; increase to 2-3 mg/kg/day over weeks",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "steroid-sparing-agent-for-a-lems-long-term-immunosuppression": {
          "indication": "Steroid-sparing agent for A-LEMS; long-term immunosuppression to reduce VGCC antibody production; onset 6-18 months",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine (Imuran) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily; increase by 50 mg every 1-2 weeks to target 2-3 mg/kg/day (typically 150-250 mg/day); onset 6-18 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "alternative-steroid-sparing-agent-for-autoimmune-cerebellar-": {
          "indication": "Alternative steroid-sparing agent for autoimmune cerebellar ataxia; TPMT testing required",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Check TPMT before starting; start 50 mg daily; increase by 25 mg q2 weeks to target 2-2.5 mg/kg/day based on TPMT activity",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "alternative-steroid-sparing-maintenance-for-autoimmune-cereb": {
          "indication": "Alternative steroid-sparing maintenance for autoimmune cerebellar ataxia",
          "doseOptions": [
            {
              "text": "2-2.5 mg/kg",
              "orderSentence": "Azathioprine (maintenance) 2-2.5 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Target 2-2.5 mg/kg/day divided daily or BID; dose based on TPMT activity",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "steroid-sparing-agent-adjunctive-immunotherapy-for-sps": {
          "indication": "Steroid-sparing agent; adjunctive immunotherapy for SPS",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg every 2 weeks; target 2-3 mg/kg/day; onset of action 3-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "steroid-sparing-immunosuppression-alternative-to-mycophenola": {
          "indication": "Steroid-sparing immunosuppression; alternative to mycophenolate",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine (Imuran) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg every 2 weeks to target 2-3 mg/kg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "alternative-maintenance-immunosuppression-steroid-sparing-ag": {
          "indication": "Alternative maintenance immunosuppression; steroid-sparing agent; used when mycophenolate not tolerated",
          "doseOptions": [
            {
              "text": "50 mg daily",
              "orderSentence": "Azathioprine (Imuran) 50 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg every 2 weeks to target 2-3 mg/kg/day; minimum 2 years",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "steroid-sparing-agent-for-chronic-relapsing-plexopathy": {
          "indication": "Steroid-sparing agent for chronic relapsing plexopathy",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Azathioprine 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily; titrate to 2-3 mg/kg/day over 4-6 weeks; check TPMT before starting",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CBC q2 weeks x 2 months, then monthly",
          "LFTs",
          "TPMT deficiency",
          "TPMT deficiency (check before starting)",
          "TPMT deficiency (check before starting), pregnancy",
          "TPMT deficiency (check genotype before starting)",
          "TPMT deficiency (homozygous)",
          "TPMT deficiency (intermediate requires 50% dose reduction)",
          "TPMT deficiency (myelosuppression risk)",
          "TPMT deficiency (severe myelosuppression)",
          "TPMT deficiency (test before starting)",
          "TPMT genotype before starting",
          "active infection",
          "concurrent allopurinol (75% dose reduction required)",
          "concurrent allopurinol (dose reduce 75%)",
          "concurrent allopurinol (dose reduce by 75%)",
          "concurrent allopurinol (dose reduction required)",
          "concurrent allopurinol (reduce azathioprine dose by 75%)",
          "concurrent allopurinol (reduce dose 75%)",
          "concurrent allopurinol (reduce dose by 75%)",
          "pancreatitis",
          "pregnancy",
          "pregnancy (Category D -- teratogenic)",
          "pregnancy (relative -- category D but commonly used in Behcet's)",
          "pregnancy (relative -- discuss risk/benefit)",
          "pregnancy (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC monthly",
          "CBC q1-2 weeks during titration then monthly",
          "CBC q1-2 weeks during titration, then monthly",
          "CBC q2 weeks x 2 months then monthly",
          "CBC q2 weeks x 2 months then q3 months",
          "CBC q2 weeks x 2 months, then monthly",
          "CBC q2 weeks x 3 months, then monthly",
          "CBC weekly x 4 weeks, then biweekly x 2 months, then monthly",
          "CBC weekly x 4 weeks, then monthly x 3 months, then q3 months",
          "CBC weekly x 4 weeks, then q2 weeks x 3 months, then monthly",
          "CBC weekly x 4, then biweekly, then monthly",
          "CBC weekly Ãƒâ€” 1 month, then q2-4 weeks",
          "CBC, LFTs, TPMT level",
          "LFTs",
          "LFTs monthly",
          "LFTs monthly x 3 months, then q3 months",
          "LFTs monthly x 3, then q3 months",
          "LFTs q month x 3 months, then q3 months",
          "LFTs q3 months",
          "LFTs q4-8 weeks",
          "MCV (macrocytosis indicates therapeutic effect)",
          "TPMT before starting",
          "TPMT genotype",
          "TPMT genotype before starting",
          "TPMT genotype/activity BEFORE starting",
          "TPMT genotype/activity before starting",
          "TPMT genotype/activity before starting (mandatory)",
          "TPMT genotype/phenotype before starting",
          "amylase if abdominal pain (pancreatitis)",
          "amylase/lipase if abdominal pain",
          "annual skin exam",
          "flu-like symptoms on initiation (hypersensitivity, discontinue)",
          "infection surveillance",
          "infections",
          "lymphocyte count target 600-1000",
          "lymphoma risk (long-term)",
          "pancreatitis",
          "pancreatitis symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 21,
      "_sourcePlans": [
        "acute-myelopathy",
        "ataxia-evaluation",
        "autoimmune-encephalitis",
        "cidp",
        "hashimotos-encephalopathy",
        "inflammatory-myopathy",
        "lambert-eaton-syndrome",
        "mogad",
        "myasthenia-gravis",
        "myasthenia-gravis-crisis",
        "myasthenia-gravis-new-diagnosis",
        "neuro-behcets-disease",
        "neurosarcoidosis",
        "nmosd",
        "paraneoplastic-neurological-syndrome",
        "peripheral-neuropathy",
        "plexopathy",
        "stiff-person-syndrome",
        "susac-syndrome"
      ]
    },
    "azathioprine-maintenance": {
      "id": "azathioprine-maintenance",
      "name": "Azathioprine (Imuran) -- maintenance",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "maintenance-immunosuppression-after-cyclophosphamide-inducti": {
          "indication": "Maintenance immunosuppression after cyclophosphamide induction; steroid-sparing agent; prevents relapse (relapse rate 25-30% in PACNS)",
          "doseOptions": [
            {
              "text": "50 mg daily",
              "orderSentence": "Azathioprine (Imuran) -- maintenance 50 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Azathioprine (Imuran) -- maintenance 100 mg daily PO"
            },
            {
              "text": "150 mg daily",
              "orderSentence": "Azathioprine (Imuran) -- maintenance 150 mg daily PO"
            },
            {
              "text": "2 mg/kg daily",
              "orderSentence": "Azathioprine (Imuran) -- maintenance 2 mg/kg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg every 2 weeks to target 2-3 mg/kg/day; minimum 18-24 months; many patients require indefinite therapy",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CBC q2 weeks x 2 months, then monthly",
          "LFTs monthly x 3 months, then q3 months",
          "TPMT genotype/activity before starting (mandatory)",
          "infection surveillance",
          "pancreatitis symptoms"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cns-vasculitis"
      ]
    },
    "azithromycin": {
      "id": "azithromycin",
      "name": "Azithromycin (third-line alternative)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "third-line-alternative-only-when-both-ceftriaxone-and-doxycy": {
          "indication": "Third-line alternative ONLY when both ceftriaxone and doxycycline are contraindicated; inferior CNS penetration; less well-studied for neuroborreliosis",
          "doseOptions": [
            {
              "text": "500 mg daily",
              "orderSentence": "Azithromycin (third-line alternative) 500 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg PO daily for 14-21 days; limited evidence for CNS disease; use only if no other option",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "concurrent QT-prolonging drugs",
          "hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI tolerance",
          "LFTs",
          "QTc",
          "hearing (rare ototoxicity)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "lyme-neuroborreliosis"
      ]
    },
    "b12-replacement": {
      "id": "b12-replacement",
      "name": "B12 replacement",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "B12 replacement N/A IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Cyanocobalamin 1000 µg IM daily x 7 days, then weekly x 4, then monthly long-term",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 and MMA levels at 3 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "rapidly-progressive-dementia"
      ]
    },
    "b12-supplementation": {
      "id": "b12-supplementation",
      "name": "B12 supplementation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "b12-deficiency-associated-sfn": {
          "indication": "B12 deficiency-associated SFN",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "B12 supplementation 1000 mcg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-2000 mcg PO daily; or 1000 mcg IM weekly x 4, then monthly if poor absorption",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 and MMA levels q3-6mo until stable"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "small-fiber-neuropathy"
      ]
    },
    "babybig": {
      "id": "babybig",
      "name": "BabyBIG (botulism immune globulin intravenous, human) (CPT 96365, 96366)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "infant-botulism-only-age-1-year-fda-approved-for-infant-botu": {
          "indication": "Infant botulism ONLY (age <1 year); FDA-approved for infant botulism types A and B",
          "doseOptions": [
            {
              "text": "50 mg/kg",
              "orderSentence": "BabyBIG (botulism immune globulin intravenous, human) (CPT 96365, 96366) 50 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg/kg (1 mL/kg) IV single dose; infuse at 0.5 mL/kg/h initially, increase to 1.0 mL/kg/h if tolerated; obtain from California Infant Botulism Treatment and Prevention Program (IBTPP) at 510-231-7600 (24/7)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "botulism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "IgA deficiency",
          "prior severe reaction to human immunoglobulin"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Vital signs q15min during infusion",
          "renal function",
          "watch for anaphylaxis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "botulism"
      ]
    },
    "baclofen": {
      "id": "baclofen",
      "name": "Baclofen",
      "genericName": "baclofen",
      "brandNames": [
        "Lioresal",
        "Gablofen",
        "Ozobax"
      ],
      "drugClass": "GABA-B Agonist / Skeletal Muscle Relaxant",
      "mechanisms": [
        "GABA-B receptor agonist",
        "Inhibits spinal cord reflex arcs",
        "Reduces muscle tone and spasms"
      ],
      "routes": [
        "PO",
        "IT"
      ],
      "formulations": [
        "5 mg tablet",
        "10 mg tablet",
        "20 mg tablet",
        "5 mg/5mL oral solution",
        "0.05 mg/mL IT",
        "0.5 mg/mL IT",
        "2 mg/mL IT"
      ],
      "contexts": {
        "spasticity": {
          "indication": "Spasticity (MS, spinal cord injury, cerebral palsy, stroke)",
          "doseOptions": [
            {
              "text": "5 mg TID",
              "orderSentence": "Baclofen 5 mg PO TID"
            },
            {
              "text": "10 mg TID",
              "orderSentence": "Baclofen 10 mg PO TID"
            },
            {
              "text": "20 mg TID",
              "orderSentence": "Baclofen 20 mg PO TID"
            },
            {
              "text": "20 mg QID",
              "orderSentence": "Baclofen 20 mg PO QID"
            }
          ],
          "startingDose": "5 mg TID",
          "maxDose": "80 mg/day (20 mg QID); rarely up to 120 mg in select patients",
          "titration": "Increase by 5 mg TID every 3 days",
          "notes": "First-line for spasticity; gradual titration reduces sedation",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          }
        },
        "trigeminal-neuralgia": {
          "indication": "Trigeminal neuralgia (adjunctive)",
          "doseOptions": [
            {
              "text": "10 mg TID",
              "orderSentence": "Baclofen 10 mg PO TID"
            },
            {
              "text": "20 mg TID",
              "orderSentence": "Baclofen 20 mg PO TID"
            }
          ],
          "startingDose": "5-10 mg TID",
          "maxDose": "60-80 mg/day",
          "titration": "Increase by 5-10 mg every 3 days",
          "notes": "Second-line; may be used with carbamazepine"
        },
        "hiccups": {
          "indication": "Intractable hiccups",
          "doseOptions": [
            {
              "text": "5 mg TID",
              "orderSentence": "Baclofen 5 mg PO TID"
            },
            {
              "text": "10 mg TID",
              "orderSentence": "Baclofen 10 mg PO TID"
            }
          ],
          "startingDose": "5 mg TID",
          "maxDose": "30 mg/day",
          "titration": "Increase as needed",
          "notes": "Off-label; evidence limited but commonly used"
        },
        "muscle-relaxant-useful-adjunct-for-dystonia": {
          "indication": "Muscle relaxant; useful adjunct for dystonia",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; increase by 5 mg/dose q3d; typical 30-80 mg/day divided TID; max 80-120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "spasticity-from-myelopathy-or-brainstem-involvement": {
          "indication": "Spasticity from myelopathy or brainstem involvement",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; increase by 5 mg/dose q3-5d; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg TID; increase by 5 mg q3 days; target 30-80 mg/day divided TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "trigeminal-neuralgia"
          ]
        },
        "spasticity-and-painful-tonic-spasms-from-myelitis": {
          "indication": "Spasticity and painful tonic spasms from myelitis",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; titrate by 5 mg/dose q3d; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "spasticity-from-myelitis": {
          "indication": "Spasticity from myelitis",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; titrate by 5 mg/dose q3d; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "axial-rigidity-limb-spasticity-causing-pain-or-functional-im": {
          "indication": "Axial rigidity, limb spasticity causing pain or functional impairment",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; titrate by 5 mg/dose q3-5 days; max 80 mg/day; do NOT discontinue abruptly (risk of withdrawal seizures)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "spasticity-in-abi-survivors-with-upper-motor-neuron-signs-po": {
          "indication": "Spasticity in ABI survivors with upper motor neuron signs; post-anoxic posturing or hypertonia",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO TID; titrate by 5 mg/dose q3d; max 80 mg/day; do not stop abruptly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "adjunct-for-tic-suppression": {
          "indication": "Adjunct for tic suppression",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; increase by 5 mg/dose q3-5d; target 30-60 mg/day divided TID; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        },
        "adjunctive-to-benzodiazepines-for-rigidity-and-spasms-gaba-b": {
          "indication": "Adjunctive to benzodiazepines for rigidity and spasms; GABA-B agonist",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO TID; increase by 5 mg/dose every 3-5 days; target 40-80 mg/day in divided doses; max 80 mg/day (higher doses off-label with close monitoring)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "stiffness-spasticity-from-paraneoplastic-stiff-person-spectr": {
          "indication": "Stiffness/spasticity from paraneoplastic stiff-person spectrum or myelopathy",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; titrate by 5 mg/dose q3d; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "post-stroke-spasticity-gaba-b-agonist-first-line-for-focal-o": {
          "indication": "Post-stroke spasticity; GABA-B agonist; first-line for focal or generalized spasticity",
          "doseOptions": [
            {
              "text": "5 mg TID",
              "orderSentence": "Baclofen 5 mg TID PO"
            },
            {
              "text": "10 mg TID",
              "orderSentence": "Baclofen 10 mg TID PO"
            },
            {
              "text": "20 mg TID",
              "orderSentence": "Baclofen 20 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; increase by 5 mg/dose q3 days; target 10-20 mg TID; max 80 mg/day; taper slowly (withdrawal seizures)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "third-line-for-downbeat-nystagmus-gabaergic-mechanism": {
          "indication": "Third-line for downbeat nystagmus; GABAergic mechanism",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**Baclofen** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Baclofen 5 mg PO TID, titrate to 10-20 mg TID**; less evidence than 4-AP",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "alternative-for-upbeat-nystagmus-gabaergic-modulation": {
          "indication": "Alternative for upbeat nystagmus; GABAergic modulation",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**Baclofen** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Baclofen 5-10 mg PO TID, titrate to 20 mg TID**",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "first-line-for-periodic-alternating-nystagmus-gaba-b-agonist": {
          "indication": "**First-line for periodic alternating nystagmus**; GABA-B agonist disrupts the oscillatory brainstem velocity storage mechanism",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**Baclofen** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Baclofen 5 mg PO TID, titrate by 5 mg every 3 days to 10-20 mg TID (max 80 mg/day)**; highly effective for PAN; [Halmagyi et al. (1980)](https://pubmed.ncbi.nlm.nih.gov/7212648/); Leigh & Zee (2015)",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "symptomatic-relief-of-oscillopsia-from-see-saw-nystagmus-lim": {
          "indication": "Symptomatic relief of oscillopsia from see-saw nystagmus; limited evidence; trial basis",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "**Baclofen** 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Baclofen 10 mg PO TID, titrate to 20 mg TID**",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "muscle-spasm-if-other-relaxants-fail": {
          "indication": "Muscle spasm (if other relaxants fail)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; increase by 5 mg/dose q3d; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "spasticity-from-upper-motor-neuron-dysfunction-stiff-gait-mu": {
          "indication": "Spasticity from upper motor neuron dysfunction (stiff gait, muscle spasms, clonus)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO TID; increase by 5 mg/dose q3 days; target 30-80 mg/day divided TID; max 80 mg/day; do NOT stop abruptly (withdrawal seizures)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "muscle-spasm-refractory-to-cyclobenzaprine": {
          "indication": "Muscle spasm refractory to cyclobenzaprine",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; increase by 5 mg/dose q3d; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        },
        "dystonia-spasticity": {
          "indication": "Dystonia, spasticity",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Baclofen 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; titrate by 5 mg/dose every 3 days; target 30-80 mg/day divided TID; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [
          "Abrupt discontinuation can cause serious withdrawal (hallucinations, seizures, hyperthermia, death)"
        ],
        "contraindications": [
          "Known hypersensitivity"
        ],
        "precautions": [
          "NEVER stop abruptly - life-threatening withdrawal",
          "Sedation and drowsiness",
          "Lowered seizure threshold",
          "Use caution in renal impairment",
          "May worsen psychiatric disorders",
          "Weakness (may unmask when spasticity reduced)"
        ],
        "drugInteractions": [
          {
            "drug": "CNS depressants",
            "severity": "moderate",
            "effect": "Additive sedation"
          },
          {
            "drug": "Alcohol",
            "severity": "moderate",
            "effect": "Additive CNS depression"
          },
          {
            "drug": "Antihypertensives",
            "severity": "low",
            "effect": "Additive hypotension"
          }
        ],
        "pregnancyCategory": "C",
        "lactation": "Caution - excreted in milk"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {
            "gfr": "≥60",
            "adjustment": "No adjustment needed"
          },
          {
            "gfr": "30-59",
            "adjustment": "Use with caution; may need dose reduction"
          },
          {
            "gfr": "<30",
            "adjustment": "Reduce dose significantly; accumulates"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment needed - renally eliminated"
      },
      "monitoring": {
        "baseline": [
          "Renal function"
        ],
        "ongoing": [
          "Spasticity control",
          "Sedation",
          "Signs of withdrawal if dose changed"
        ],
        "frequency": "Clinical assessment at each visit"
      },
      "patientCounseling": [
        "NEVER stop taking suddenly - can cause seizures and hallucinations",
        "Report increased weakness, sedation, or dizziness",
        "May impair driving - avoid until effects known",
        "Avoid alcohol",
        "Always have a supply - do not run out"
      ]
    },
    "benzodiazepine": {
      "id": "benzodiazepine",
      "name": "Benzodiazepine (if actively seizing) (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.1 mg/kg",
              "orderSentence": "**Benzodiazepine (if actively seizing)** (CPT 96374) 0.1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Lorazepam** 0.1 mg/kg IV (max 4 mg), may repeat x1 in 5 min; **OR Midazolam** 10 mg IM (if no IV access); **OR Diazepam** 0.2 mg/kg IV (max 10 mg); **Intranasal midazolam** 5-10 mg if no IV; **Rectal diazepam** 0.2-0.5 mg/kg (home rescue)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "breakthrough-seizure"
          ]
        },
        "severe-anxiety-distress-from-td-movements-temporary-relief": {
          "indication": "Severe anxiety/distress from TD movements; temporary relief",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Benzodiazepine (severe distress) 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Lorazepam 0.5-1 mg TID PRN for acute distress; short-term only",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Respiratory depression",
          "substance use disorder"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "First-line for acute seizure termination",
          "Sedation, respiratory status",
          "follow status epilepticus protocol if seizure continues >5 min",
          "lorazepam preferred IV (longer CNS duration)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "breakthrough-seizure",
        "tardive-dyskinesia"
      ]
    },
    "benzodiazepines": {
      "id": "benzodiazepines",
      "name": "Benzodiazepines (chronic use)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "temporary-relief-but-dependence-risk-does-not-address-underl": {
          "indication": "Temporary relief but dependence risk; does not address underlying cause; rebound tinnitus on withdrawal",
          "doseOptions": [
            {
              "text": "-",
              "orderSentence": "**Benzodiazepines (chronic use)** - PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Short-term use only if severe acute distress; transition to CBT/SSRI for long-term management; avoid chronic use",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-4 mg",
              "orderSentence": "Benzodiazepines (symptom-triggered or scheduled) 1-4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Lorazepam 1-4 mg IV q15min PRN (CIWA-guided); or scheduled dosing if severe",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wernicke-encephalopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Dependence risk",
          "Respiratory depression",
          "caution with hepatic impairment",
          "elderly (fall risk)",
          "respiratory depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CIWA score",
          "Limit to 2-4 weeks",
          "plan transition to non-benzodiazepine therapy",
          "respiratory status",
          "sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "tinnitus-evaluation",
        "wernicke-encephalopathy"
      ]
    },
    "benztropine": {
      "id": "benztropine",
      "name": "Benztropine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/IM",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "acute-dystonic-reaction-drug-induced": {
          "indication": "Acute dystonic reaction (drug-induced)",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Benztropine 1 mg IV/IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg IV/IM; may repeat in 30 min; follow with oral 1-2 mg BID x 2-3 days to prevent recurrence",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "alternative-anticholinergic-maintenance-after-acute-dystonic": {
          "indication": "Alternative anticholinergic; maintenance after acute dystonic reaction",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Benztropine 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg BID; increase by 0.5 mg q5-7d; typical 1-4 mg/day; max 6 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "anticholinergic-for-dip-particularly-useful-for-tremor-predo": {
          "indication": "Anticholinergic for DIP; particularly useful for tremor-predominant symptoms",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Benztropine (Cogentin) 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg daily; titrate by 0.5 mg q5-7d; usual range 1-4 mg/day in divided doses; max 6 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Benztropine (Cogentin) 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg daily; titrate to 1-2 mg BID; max 6 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "alternative-anticholinergic-for-tremor": {
          "indication": "Alternative anticholinergic for tremor",
          "doseOptions": [
            {
              "text": "0.5 mg BID",
              "orderSentence": "Benztropine 0.5 mg BID PO"
            },
            {
              "text": "1 mg BID",
              "orderSentence": "Benztropine 1 mg BID PO"
            },
            {
              "text": "2 mg BID",
              "orderSentence": "Benztropine 2 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg BID; titrate slowly; max 6 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI obstruction",
          "Narrow-angle glaucoma",
          "Same",
          "Same as trihexyphenidyl",
          "dementia",
          "elderly (relative - prefer amantadine)",
          "myasthenia gravis",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anticholinergic effects (dry mouth, constipation, urinary retention, confusion)",
          "Anticholinergic effects (dry mouth, constipation, urinary retention, confusion, blurred vision), cognitive impairment in elderly, tachycardia",
          "Anticholinergic effects, confusion (elderly)",
          "Same",
          "Same as trihexyphenidyl",
          "cognitive effects in elderly"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "drug-induced-parkinsonism",
        "dystonia",
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "benztropine-acute": {
      "id": "benztropine-acute",
      "name": "Benztropine (Cogentin) - acute",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "acute-anticholinergic-relief-for-severe-dip-or-dystonic-reac": {
          "indication": "Acute anticholinergic relief for severe DIP or dystonic reaction",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Benztropine (Cogentin) - acute 1 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg IM or IV for acute relief; may repeat in 30 min; transition to oral maintenance",
          "settings": {
            "ED": "STAT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI obstruction",
          "Narrow-angle glaucoma",
          "dementia",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anticholinergic effects, sedation, heart rate"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-induced-parkinsonism"
      ]
    },
    "betahistine": {
      "id": "betahistine",
      "name": "Betahistine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "persistent-vestibular-symptoms-off-label-in-us": {
          "indication": "Persistent vestibular symptoms (off-label in US)",
          "doseOptions": [
            {
              "text": "16 mg",
              "orderSentence": "Betahistine 16 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "16 mg PO TID; not FDA-approved but used internationally",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Peptic ulcer disease, pheochromocytoma"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI upset"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "post-concussion-syndrome"
      ]
    },
    "bethanechol": {
      "id": "bethanechol",
      "name": "Bethanechol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "urinary-retention": {
          "indication": "Urinary retention",
          "doseOptions": [
            {
              "text": "10-50 mg",
              "orderSentence": "Bethanechol 10-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-50 mg TID-QID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Asthma",
          "GI/GU obstruction",
          "bradycardia",
          "hypotension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI cramping, bronchospasm"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ms-new-diagnosis"
      ]
    },
    "bevacizumab": {
      "id": "bevacizumab",
      "name": "Bevacizumab (Avastin)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "recurrent-glioblastoma-fda-approved-as-monotherapy-for-recur": {
          "indication": "Recurrent glioblastoma; FDA-approved as monotherapy for recurrent GBM; anti-VEGF monoclonal antibody; reduces edema and may allow steroid taper; does not clearly improve overall survival but improves PFS and quality of life",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Bevacizumab (Avastin) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV every 2 weeks; infuse first dose over 90 min, then 60 min, then 30 min if tolerated; continue until progression or intolerable toxicity",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "recurrent-progressive-meningioma-refractory-to-surgery-and-r": {
          "indication": "Recurrent/progressive meningioma refractory to surgery and radiation; anti-VEGF monoclonal antibody; limited evidence but some case series show stabilization",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Bevacizumab (Avastin) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV every 2 weeks; infuse first dose over 90 min, then 60 min, then 30 min if tolerated; continue until progression or intolerable toxicity",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Uncontrolled hypertension",
          "active hemorrhage",
          "bowel perforation risk",
          "pregnancy",
          "recent (28 days) surgery or wound healing complications",
          "recent surgery (28 days)",
          "severe proteinuria (>3.5 g/24h)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP each visit",
          "CBC",
          "hold 28 days before and after surgery",
          "signs of GI perforation, thromboembolism",
          "urinalysis for proteinuria q2-4 weeks",
          "wound healing assessment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "glioblastoma",
        "meningioma"
      ]
    },
    "bevacizumab-lomustine": {
      "id": "bevacizumab-lomustine",
      "name": "Bevacizumab + Lomustine (combination)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "recurrent-glioblastoma-eortc-26101-trial-showed-pfs-benefit-": {
          "indication": "Recurrent glioblastoma; EORTC 26101 trial showed PFS benefit (not OS) vs. lomustine alone; consider for good performance status patients",
          "doseOptions": [
            {
              "text": "Bevacizumab 10 mg/kg q2wk + Lomustine 90 mg/m2 q6wk",
              "orderSentence": "Bevacizumab + Lomustine (combination) Bevacizumab 10 mg/kg q2wk + Lomustine 90 mg/m2 q6wk IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bevacizumab 10 mg/kg IV q2 weeks + Lomustine 90 mg/m2 PO q6 weeks (reduced dose when combined); monitor for combined toxicity",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per individual agents"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Per individual agents",
          "additional monitoring for combined myelosuppression"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "glioblastoma"
      ]
    },
    "bipap": {
      "id": "bipap",
      "name": "BiPAP (noninvasive ventilation)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "INH"
      ],
      "formulations": [],
      "contexts": {
        "fvc-50-predicted-or-symptoms-of-nocturnal-hypoventilation": {
          "indication": "FVC <50% predicted OR symptoms of nocturnal hypoventilation",
          "doseOptions": [
            {
              "text": "IPAP 8-12 cmH2O",
              "orderSentence": "BiPAP (noninvasive ventilation) IPAP 8-12 cmH2O INH"
            },
            {
              "text": "EPAP 4-6 cmH2O",
              "orderSentence": "BiPAP (noninvasive ventilation) EPAP 4-6 cmH2O INH"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start with nocturnal use; IPAP 8-12, EPAP 4-6; titrate for comfort; increase time as tolerated; extend to daytime as needed",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe bulbar dysfunction with aspiration (relative)",
          "inability to clear secretions"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Comfort, adherence, transcutaneous CO2 or ABG, mask fit"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "bisacodyl": {
      "id": "bisacodyl",
      "name": "Bisacodyl",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "constipation": {
          "indication": "Constipation",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Bisacodyl 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO qHS or 10 mg PR PRN",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Intestinal obstruction",
          "acute abdominal pain"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cramping",
          "electrolyte disturbance with overuse"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ms-new-diagnosis"
      ]
    },
    "bisphosphonate": {
      "id": "bisphosphonate",
      "name": "Bisphosphonate (alendronate)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "osteoporosis-treatment-if-t-score-2-5-or-fragility-fracture": {
          "indication": "Osteoporosis treatment if T-score ≤ -2.5 or fragility fracture",
          "doseOptions": [
            {
              "text": "70 mg",
              "orderSentence": "Bisphosphonate (alendronate) 70 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "70 mg PO weekly; take on empty stomach with full glass water; remain upright 30 min",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "70 mg",
              "orderSentence": "Bisphosphonate (bone protection if chronic steroids) 70 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Alendronate 70 mg PO weekly OR risedronate 35 mg PO weekly; start if steroids expected >3 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Esophageal disorders",
          "GFR <30-35",
          "GFR <35",
          "esophageal disorders",
          "inability to remain upright 30 min",
          "inability to sit upright 30 min"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "DEXA at baseline",
          "DEXA q2 years",
          "dental exam (ONJ risk)",
          "esophageal symptoms",
          "jaw osteonecrosis (rare)",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "myasthenia-gravis-new-diagnosis",
        "progressive-supranuclear-palsy"
      ]
    },
    "blood-pressure-control-clevidipine-iv": {
      "id": "blood-pressure-control-clevidipine-iv",
      "name": "Blood pressure control: Clevidipine IV (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-2 mg/h",
              "orderSentence": "Blood pressure control: Clevidipine IV (CPT 96365) 1-2 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg/h IV; max 32 mg/h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Soy/egg allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP continuous"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "subarachnoid-hemorrhage"
      ]
    },
    "blood-pressure-control-labetalol-iv": {
      "id": "blood-pressure-control-labetalol-iv",
      "name": "Blood pressure control: Labetalol IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "severe-hypertension-sbp-180-when-ccb-alone-insufficient-or-n": {
          "indication": "Severe hypertension (SBP >180) when CCB alone insufficient or not yet started",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Blood pressure control: Labetalol IV 20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV push q10-20min; max 300 mg. Target SBP 120-160 mmHg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Blood pressure control: Labetalol IV (CPT 96374) 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV q10-20min; max 300 mg. Alternative to nicardipine",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart block",
          "asthma",
          "decompensated CHF",
          "severe bradycardia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP continuous",
          "HR"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "rcvs",
        "subarachnoid-hemorrhage"
      ]
    },
    "blood-pressure-control-nicardipine-iv": {
      "id": "blood-pressure-control-nicardipine-iv",
      "name": "Blood pressure control: Nicardipine IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "severe-hypertension-sbp-180-in-acute-rcvs-iv-nicardipine-pro": {
          "indication": "Severe hypertension (SBP >180) in acute RCVS — IV nicardipine provides precise BP control; dual benefit as CCB for vasoconstriction",
          "doseOptions": [
            {
              "text": "5 mg/h",
              "orderSentence": "Blood pressure control: Nicardipine IV 5 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/h IV infusion; titrate by 2.5 mg/h q5-15min; max 15 mg/h. Target SBP 120-160 mmHg; avoid aggressive BP lowering below 120 (risk of watershed ischemia from vasoconstriction)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg/h",
              "orderSentence": "Blood pressure control: Nicardipine IV (CPT 96365) 5 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/h IV; titrate by 2.5 mg/h q5-15min; max 15 mg/h. Target SBP <160 mmHg UNTIL aneurysm is secured (re-bleed risk highest in first 24h with uncontrolled HTN); after securing: target SBP <180 (or higher if vasospasm)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe aortic stenosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous arterial BP",
          "Continuous arterial BP monitoring",
          "neuro checks q1h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "rcvs",
        "subarachnoid-hemorrhage"
      ]
    },
    "blood-pressure-cpp-management": {
      "id": "blood-pressure-cpp-management",
      "name": "Blood pressure / CPP management",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "**Blood pressure / CPP management** N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Target CPP 60-70 mmHg** (CPP = MAP - ICP); avoid CPP <60 (ischemia) and >70 (BTF: avoid aggressive CPP >70 due to ARDS risk); **If hypotensive:** IV fluids (isotonic crystalloid; avoid hypotonic fluids); vasopressors (norepinephrine first-line); **If hypertensive with ICP crisis:** Treat ICP first (osmotherapy, sedation); avoid precipitously lowering BP (reduces CPP)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "elevated-icp-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BTF 2016: target CPP 60-70",
          "CPP is the primary determinant of cerebral perfusion",
          "aggressive CPP >70 increases ARDS risk without outcome benefit",
          "individualized based on autoregulation status",
          "lower threshold 60 mmHg"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "elevated-icp-management"
      ]
    },
    "blood-pressure-management": {
      "id": "blood-pressure-management",
      "name": "Blood pressure management (acute)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Various"
      ],
      "formulations": [],
      "contexts": {
        "acute-delirium-or-new-stroke": {
          "indication": "Acute delirium or new stroke",
          "doseOptions": [
            {
              "text": "Per protocol",
              "orderSentence": "Blood pressure management (acute) Per protocol Various"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Do NOT lower BP aggressively unless >220/120 or end-organ damage; permissive hypertension first 24-48h of stroke",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Symptomatic hypotension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q1h initially"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "vascular-dementia"
      ]
    },
    "blood-pressure-management-avoid-hypotension": {
      "id": "blood-pressure-management-avoid-hypotension",
      "name": "Blood pressure management — AVOID HYPOTENSION",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "critical-permissive-hypertension-in-acute-ischemic-moyamoya-": {
          "indication": "**CRITICAL: Permissive hypertension in acute ischemic moyamoya**; collateral-dependent flow is pressure-sensitive; hypotension → watershed infarction",
          "doseOptions": [
            {
              "text": "Target BP varies",
              "orderSentence": "Blood pressure management — **AVOID HYPOTENSION** Target BP varies IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Acute ischemic: allow SBP up to 180-200 (unless hemorrhage or post-tPA); AVOID aggressive BP lowering; chronic: target ~10-20% above patient's baseline; NO specific BP target — individualize",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**DO NOT use IV nitroglycerin or nitroprusside (steal phenomenon)**",
          "Avoid antihypertensives acutely unless SBP >220 or hemorrhagic"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous BP monitoring",
          "avoid BP fluctuations",
          "neuro checks q1h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "moyamoya-disease"
      ]
    },
    "blood-pressure-management-post-tpa": {
      "id": "blood-pressure-management-post-tpa",
      "name": "Blood pressure management POST-tPA (24h)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Blood pressure management POST-tPA (24h) N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Target BP <180/105 x 24h post-tPA; use nicardipine or labetalol drip as above",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "See individual agents above"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Neuro checks with each BP check",
          "hold if SBP <100"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-ischemic-stroke"
      ]
    },
    "blood-pressure-management-pre-tpa-clevidipine-iv": {
      "id": "blood-pressure-management-pre-tpa-clevidipine-iv",
      "name": "Blood pressure management PRE-tPA: Clevidipine IV (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-2 mg/h",
              "orderSentence": "Blood pressure management PRE-tPA: Clevidipine IV (CPT 96365) 1-2 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg/h IV; titrate by doubling q90sec initially; max 32 mg/h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Soy/egg allergy, severe lipid disorders, defective lipid metabolism"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP continuous monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-ischemic-stroke"
      ]
    },
    "blood-pressure-management-pre-tpa-labetalol-iv": {
      "id": "blood-pressure-management-pre-tpa-labetalol-iv",
      "name": "Blood pressure management PRE-tPA: Labetalol IV (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Blood pressure management PRE-tPA: Labetalol IV (CPT 96374) 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV over 1-2 min; may repeat once; target BP <185/110 before tPA",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart block (2nd/3rd degree), severe bradycardia, decompensated HF, asthma/severe COPD"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Heart rate, BP continuous"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-ischemic-stroke"
      ]
    },
    "blood-pressure-management-pre-tpa-nicardipine-iv": {
      "id": "blood-pressure-management-pre-tpa-nicardipine-iv",
      "name": "Blood pressure management PRE-tPA: Nicardipine IV (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg/h",
              "orderSentence": "Blood pressure management PRE-tPA: Nicardipine IV (CPT 96365) 5 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/h IV infusion; increase by 2.5 mg/h q5-15min; max 15 mg/h; target BP <185/110",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe aortic stenosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP continuous monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-ischemic-stroke"
      ]
    },
    "blood-pressure-reduction-clevidipine-iv": {
      "id": "blood-pressure-reduction-clevidipine-iv",
      "name": "Blood pressure reduction: Clevidipine IV (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-2 mg/h",
              "orderSentence": "Blood pressure reduction: Clevidipine IV (CPT 96365) 1-2 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg/h IV; titrate by doubling q90sec initially; max 32 mg/h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "ultra-short-acting-iv-calcium-channel-blocker-for-rapid-bp-c": {
          "indication": "Ultra-short acting IV calcium channel blocker for rapid BP control; useful when precise titration needed",
          "doseOptions": [
            {
              "text": "1-2 mg/h",
              "orderSentence": "Blood pressure reduction: Clevidipine IV (CPT 96365) 1-2 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg/h IV; titrate by doubling dose every 90 seconds initially; usual maintenance 4-6 mg/h; max 32 mg/h; max 21 mg/h average over 24h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Soy/egg allergy",
          "Soy/egg allergy (lipid emulsion)",
          "acute pancreatitis with hyperlipidemia",
          "lipid disorders",
          "severe lipid metabolism disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP continuous",
          "Blood pressure continuous",
          "lipid load calculation",
          "triglycerides if prolonged use (>72h)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "intracerebral-hemorrhage",
        "pres"
      ]
    },
    "blood-pressure-reduction-hydralazine-iv": {
      "id": "blood-pressure-reduction-hydralazine-iv",
      "name": "Blood pressure reduction: Hydralazine IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "second-line-antihypertensive-commonly-used-in-pregnancy-ecla": {
          "indication": "Second-line antihypertensive; commonly used in pregnancy/eclampsia when nicardipine unavailable",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Blood pressure reduction: Hydralazine IV 5-10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg IV q20-30 min PRN; max 20 mg total; less predictable response than nicardipine",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe coronary artery disease",
          "aortic dissection",
          "tachycardia (reflex)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Heart rate",
          "blood pressure q5min after each dose",
          "reflex tachycardia common"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "blood-pressure-reduction-labetalol-iv": {
      "id": "blood-pressure-reduction-labetalol-iv",
      "name": "Blood pressure reduction: Labetalol IV (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Blood pressure reduction: Labetalol IV (CPT 96374) 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV bolus over 1-2 min; may repeat or double q10min; max 300 mg. Alternative to nicardipine",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "alternative-first-line-iv-antihypertensive-preferred-if-tach": {
          "indication": "Alternative first-line IV antihypertensive; preferred if tachycardia present; safe in pregnancy/eclampsia",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Blood pressure reduction: Labetalol IV (CPT 96374) 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV bolus over 1-2 min; may repeat or double dose q10-20 min; max 300 mg total; can also infuse at 0.5-2 mg/min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart block (2nd/3rd degree)",
          "Second/third-degree heart block",
          "asthma",
          "cardiogenic shock",
          "decompensated HF",
          "decompensated heart failure",
          "severe asthma/COPD",
          "severe bradycardia",
          "severe bradycardia (<50 bpm)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP continuous",
          "HR",
          "Heart rate",
          "blood pressure continuous",
          "bronchospasm"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "intracerebral-hemorrhage",
        "pres"
      ]
    },
    "blood-pressure-reduction-nicardipine-iv": {
      "id": "blood-pressure-reduction-nicardipine-iv",
      "name": "Blood pressure reduction: Nicardipine IV (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg/h",
              "orderSentence": "Blood pressure reduction: Nicardipine IV (CPT 96365) 5 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/h IV; increase by 2.5 mg/h q5-15min; max 15 mg/h. Target SBP 130-150 mmHg (INTERACT2: <140 safe; AHA 2022: <140 reasonable if presenting SBP 150-220)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "first-line-iv-antihypertensive-for-hypertensive-emergency-wi": {
          "indication": "First-line IV antihypertensive for hypertensive emergency with PRES; smooth titratable BP reduction without cerebral vasoconstriction",
          "doseOptions": [
            {
              "text": "5 mg/h",
              "orderSentence": "Blood pressure reduction: Nicardipine IV (CPT 96365) 5 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/h IV infusion; increase by 2.5 mg/h every 5-15 min; max 15 mg/h; target 25% reduction in MAP in first hour then SBP 140-160 over next 2-6h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe aortic stenosis",
          "advanced HF",
          "advanced hepatic failure",
          "decompensated heart failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous arterial line BP",
          "Continuous arterial line BP monitoring",
          "avoid SBP <110 (renal hypoperfusion)",
          "avoid SBP <120 (risk of watershed ischemia)",
          "neuro checks q15min during titration",
          "neuro checks with each change"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "intracerebral-hemorrhage",
        "pres"
      ]
    },
    "bone-modifying-agents": {
      "id": "bone-modifying-agents",
      "name": "Bone-modifying agents",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "**Bone-modifying agents** 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Zoledronic acid 4 mg IV q4 weeks OR denosumab 120 mg SQ q4 weeks; reduces skeletal-related events (SRE); dental clearance before starting (ONJ risk); renal adjustment for zoledronic acid (hold if GFR <35)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "spinal-cord-compression-malignant"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Zoledronic acid: Rosen et al. (2003) — reduced SRE by 48% in bone metastases",
          "denosumab: Fizazi et al. (2011) — superior to zoledronic acid for SRE reduction in bone metastases (prostate trial)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "spinal-cord-compression-malignant"
      ]
    },
    "bortezomib": {
      "id": "bortezomib",
      "name": "Bortezomib (third-line)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1.3 mg/m2",
              "orderSentence": "Bortezomib (third-line) 1.3 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1.3 mg/m2 SC/IV on days 1, 4, 8, 11 of 21-day cycles x 4-6 cycles",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment",
          "peripheral neuropathy grade 2+"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "herpes zoster prophylaxis (acyclovir 400 mg BID)",
          "peripheral neuropathy assessment (dose-reduce or hold if worsens)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "autoimmune-encephalitis"
      ]
    },
    "botulinum-toxin": {
      "id": "botulinum-toxin",
      "name": "Botulinum toxin (onabotulinumtoxinA)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "focal-dystonia-bruxism-sialorrhea": {
          "indication": "Focal dystonia; bruxism; sialorrhea",
          "doseOptions": [
            {
              "text": "Variable per muscle",
              "orderSentence": "Botulinum toxin (onabotulinumtoxinA) Variable per muscle IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Dose depends on target muscles; repeat q12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "focal-tardive-dystonia-e-g-cervical-blepharospasm": {
          "indication": "Focal tardive dystonia (e.g., cervical, blepharospasm)",
          "doseOptions": [
            {
              "text": "Per target",
              "orderSentence": "Botulinum toxin (focal TD) Per target IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Cervical: 100-300 units; blepharospasm: 25-50 units per eye; repeat q3mo",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        },
        "focal-tremor-refractory-to-oral-medications-head-tremor-voic": {
          "indication": "Focal tremor refractory to oral medications; head tremor; voice tremor; dystonic tremor; hand tremor affecting function",
          "doseOptions": [
            {
              "text": "50-100 units",
              "orderSentence": "Botulinum toxin (OnabotulinumtoxinA) (CPT 64642; J0585) 50-100 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 units per affected limb for hand tremor; 40-400 units for head/cervical tremor; individualized by movement disorders specialist; effects onset 1-2 weeks, peak 4-6 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "focal-dystonia-cervical-oromandibular-limb": {
          "indication": "Focal dystonia (cervical, oromandibular, limb)",
          "doseOptions": [
            {
              "text": "Dose per target",
              "orderSentence": "Botulinum toxin (OnabotulinumtoxinA) Dose per target IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Site-specific dosing: cervical dystonia 100-300 units; limb dystonia 50-200 units per muscle; q12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection at site",
          "Infection at injection site",
          "Infection at injection site, myasthenia gravis",
          "Infection at site",
          "myasthenia gravis",
          "pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dysphagia (cervical)",
          "Weakness at injection site (dose-related)",
          "Weakness at injection site, dysphagia (cervical injections)",
          "Weakness, dysphagia",
          "dysphagia with head/voice injections",
          "local weakness",
          "ptosis (periocular)",
          "repeat q3 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "huntingtons-disease",
        "tardive-dyskinesia",
        "tremor-unspecified",
        "wilsons-disease"
      ]
    },
    "botulinum-toxin-a": {
      "id": "botulinum-toxin-a",
      "name": "Botulinum toxin A (onabotulinumtoxinA)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "refractory-sialorrhea": {
          "indication": "Refractory sialorrhea",
          "doseOptions": [
            {
              "text": "30-50 units per parotid",
              "orderSentence": "Botulinum toxin A (salivary gland injection) 30-50 units per parotid IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30-50 units per parotid gland + 10-20 units per submandibular gland (total 80-140 units); effects last 3-4 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "focal-refractory-rigidity-and-spasms-specific-muscle-group-t": {
          "indication": "Focal refractory rigidity and spasms; specific muscle group targeting",
          "doseOptions": [
            {
              "text": "50-200 units",
              "orderSentence": "Botulinum toxin A (onabotulinumtoxinA) 50-200 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Dose varies by muscle group; typical 50-200 units per large muscle (e.g., paraspinal); EMG/ultrasound-guided injection; repeat q12 weeks; onset 3-7 days, peak 2-4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "focal-spasticity-in-specific-muscle-groups-biceps-forearm-fl": {
          "indication": "Focal spasticity in specific muscle groups (biceps, forearm flexors, finger flexors) refractory to oral agents; improves range of motion and function",
          "doseOptions": [
            {
              "text": "Dose varies by muscle",
              "orderSentence": "Botulinum toxin A (onabotulinumtoxinA) Dose varies by muscle IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "EMG or ultrasound-guided injection; biceps 100-200 units, brachioradialis 50-100 units, finger flexors 25-50 units per muscle; total dose per session varies; repeat q12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity",
          "Infection at injection site",
          "Systemic neuromuscular disease (relative)",
          "infection at injection site",
          "known antibodies to botulinum toxin",
          "known hypersensitivity",
          "neuromuscular disease (use cautiously)",
          "neuromuscular junction disorders (myasthenia gravis — relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dysphagia worsening (rare)",
          "Excessive weakness",
          "Weakness at injection site",
          "antibody development with repeated use",
          "antibody formation with repeated use",
          "distant spread effects",
          "dry mouth",
          "dysphagia (if cervical muscles)",
          "dysphagia if injecting cervical muscles"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "als",
        "cervical-myelopathy",
        "stiff-person-syndrome"
      ]
    },
    "botulinum-toxin-injection": {
      "id": "botulinum-toxin-injection",
      "name": "Botulinum toxin injection (cricopharyngeal)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Local injection"
      ],
      "formulations": [],
      "contexts": {
        "cricopharyngeal-dysfunction-causing-dysphagia-refractory-to-": {
          "indication": "Cricopharyngeal dysfunction causing dysphagia refractory to conservative measures; EMG-guided injection",
          "doseOptions": [
            {
              "text": "15-30 units",
              "orderSentence": "Botulinum toxin injection (cricopharyngeal) 15-30 units Local injection"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-30 units onabotulinumtoxinA injected into cricopharyngeus muscle under EMG or fluoroscopic guidance; effect onset 3-7 days; duration 3-6 months; may repeat",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Infection at injection site",
          "known hypersensitivity",
          "myasthenia gravis (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dysphagia response",
          "MBSS 2-4 weeks post-injection",
          "aspiration risk monitoring",
          "transient worsening of swallow possible"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "inclusion-body-myositis"
      ]
    },
    "botulinum-toxin-type-a": {
      "id": "botulinum-toxin-type-a",
      "name": "Botulinum toxin type A (Botox)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "focal-spasticity-in-abi-survivors-upper-or-lower-extremity-n": {
          "indication": "Focal spasticity in ABI survivors (upper or lower extremity) not responding to oral agents",
          "doseOptions": [
            {
              "text": "per muscle group",
              "orderSentence": "Botulinum toxin type A (Botox) per muscle group IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Dose per target muscles; typical total 200-400 units; repeat q12 weeks; onset 3-7 days",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "dystonia-antecollis-limb-dystonia-orofacial-dystonia-sialorr": {
          "indication": "Dystonia (antecollis, limb dystonia, orofacial dystonia); sialorrhea",
          "doseOptions": [
            {
              "text": "Per muscle group",
              "orderSentence": "Botulinum toxin type A (onabotulinumtoxinA) Per muscle group IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Dystonia: individualized dosing by muscle group (e.g., sternocleidomastoid 25-50 units each side for antecollis); sialorrhea: 30 units per parotid, 20 units per submandibular; repeat q3 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Infection at injection site",
          "Myasthenia gravis, Lambert-Eaton, infection at injection site",
          "neuromuscular junction disorder"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dysphagia (especially cervical injections — CRITICAL in MSA), weakness at injection site, bruising",
          "Weakness (focal)",
          "antibody formation",
          "dysphagia (if cervical muscles)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "multiple-system-atrophy"
      ]
    },
    "bowel-management": {
      "id": "bowel-management",
      "name": "Bowel management",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PR"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "**Bowel management** 100 mg PR"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Assess rectal tone (digital rectal exam — absent/reduced in CES); bowel regimen: docusate 100 mg BID + senna 2 tabs HS; bisacodyl suppository daily if no BM in 48h; monitor for fecal incontinence vs. constipation (both occur in CES); opioid-related constipation compounds the issue",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cauda-equina-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bowel dysfunction common in CES",
          "S2-S4 denervation affects external anal sphincter and rectal sensation",
          "proactive management prevents complications"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cauda-equina-syndrome"
      ]
    },
    "brexpiprazole": {
      "id": "brexpiprazole",
      "name": "Brexpiprazole (Rexulti)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "partial-d2-agonist-with-lower-eps-risk-alternative-to-aripip": {
          "indication": "Partial D2 agonist with lower EPS risk; alternative to aripiprazole",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Brexpiprazole (Rexulti) 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg daily; titrate to 1-2 mg daily; max 4 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        },
        "agitation-in-ad-fda-approved-2023": {
          "indication": "Agitation in AD (FDA approved 2023)",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Brexpiprazole (Rexulti) 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg daily x 1 week; increase to 1 mg daily x 1 week; target 2-3 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Black box: increased mortality in dementia (but FDA approved for this use)",
          "Hypersensitivity",
          "caution in elderly with dementia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Metabolic panel, weight, EPS monitoring",
          "Weight, metabolic parameters, EPS, falls"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "alzheimers-disease",
        "drug-induced-parkinsonism"
      ]
    },
    "brivaracetam": {
      "id": "brivaracetam",
      "name": "Brivaracetam",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-adjunctive-therapy-sv2a-ligand-with-higher-affinity-than": {
          "indication": "DRE adjunctive therapy; SV2A ligand with higher affinity than levetiracetam; may work when levetiracetam failed; less psychiatric side effects",
          "doseOptions": [
            {
              "text": "25 mg BID",
              "orderSentence": "Brivaracetam (Briviact) 25 mg BID PO"
            },
            {
              "text": "50 mg BID",
              "orderSentence": "Brivaracetam (Briviact) 50 mg BID PO"
            },
            {
              "text": "100 mg BID",
              "orderSentence": "Brivaracetam (Briviact) 100 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg BID; may increase to 100 mg BID; max 200 mg/day; no titration required; IV available for patients unable to take PO",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "alternative-to-levetiracetam-fewer-behavioral-side-effects": {
          "indication": "Alternative to levetiracetam (fewer behavioral side effects)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Brivaracetam 100 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 100 mg IV; Maintenance: 50-100 mg IV/PO BID (max 200 mg/day)",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "alternative-to-levetiracetam-if-behavioral-side-effects": {
          "indication": "Alternative to levetiracetam if behavioral side effects",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Brivaracetam 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg PO/IV BID (max 200 mg/day)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "focal-epilepsy-sv2a-ligand-may-work-when-levetiracetam-faile": {
          "indication": "Focal epilepsy; SV2A ligand; may work when levetiracetam failed; fewer psychiatric side effects than LEV",
          "doseOptions": [
            {
              "text": "25 mg BID",
              "orderSentence": "Brivaracetam (Briviact) 25 mg BID PO"
            },
            {
              "text": "50 mg BID",
              "orderSentence": "Brivaracetam (Briviact) 50 mg BID PO"
            },
            {
              "text": "100 mg BID",
              "orderSentence": "Brivaracetam (Briviact) 100 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg BID; may increase to 100 mg BID; max 200 mg/day; no titration required",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "alternative-to-levetiracetam": {
          "indication": "Alternative to levetiracetam",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Brivaracetam 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO BID; may increase to 100 mg BID; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Brivaracetam 100 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 100 mg IV; Maintenance: 50-100 mg IV/PO BID (max 200 mg/day)",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hepatic impairment (reduce dose)",
          "Hypersensitivity",
          "Hypersensitivity to brivaracetam"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Behavioral changes",
          "Less behavioral side effects than levetiracetam",
          "Psychiatric symptoms (less common than levetiracetam)",
          "Psychiatric symptoms (less frequent than LEV)",
          "hepatic function",
          "hepatic function with concurrent hepatotoxic drugs",
          "sedation",
          "somnolence"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "drug-resistant-epilepsy",
        "epilepsy-chronic-management",
        "hashimotos-encephalopathy",
        "ncse",
        "new-onset-seizure"
      ]
    },
    "brivaracetam-iv": {
      "id": "brivaracetam-iv",
      "name": "Brivaracetam IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100-200 mg",
              "orderSentence": "Brivaracetam IV 100-200 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-200 mg IV over 2-5 min; no titration needed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hepatic impairment (reduce dose)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Faster onset than levetiracetam",
          "fewer behavioral effects"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-epilepticus"
      ]
    },
    "buprenorphine-naloxone": {
      "id": "buprenorphine-naloxone",
      "name": "Buprenorphine/naloxone (Suboxone)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SL"
      ],
      "formulations": [],
      "contexts": {
        "opioid-use-disorder-comorbid-with-hand-improves-art-adherenc": {
          "indication": "Opioid use disorder comorbid with HAND; improves ART adherence; minimal cognitive impairment vs. continued illicit use",
          "doseOptions": [
            {
              "text": "2/0.5 mg",
              "orderSentence": "Buprenorphine/naloxone (Suboxone) 2/0.5 mg SL"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Induction: 2/0.5 mg SL; increase by 2/0.5-4/1 mg q1-2h to relief; target maintenance 8/2-16/4 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent full agonist opioids (precipitated withdrawal)",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs",
          "check interactions with PIs (buprenorphine levels may increase with ritonavir)",
          "precipitated withdrawal",
          "sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "bupropion": {
      "id": "bupropion",
      "name": "Bupropion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "depression-with-fatigue-avoid-if-seizure-risk": {
          "indication": "Depression with fatigue; avoid if seizure risk",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Bupropion 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID or 150 mg SR daily; increase after 1 week; max 300 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "depression-with-fatigue-psychomotor-slowing-avoid-in-seizure": {
          "indication": "Depression with fatigue, psychomotor slowing; avoid in seizure risk; may assist with stimulant cessation in comorbid methamphetamine use",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Bupropion 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 150 mg XL daily; increase to 300 mg XL daily after 1 week if needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "apathy-predominant-ftd-depression-may-help-with-motivation": {
          "indication": "Apathy-predominant FTD; depression; may help with motivation",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Bupropion (Wellbutrin) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID or 150 mg SR daily; titrate to 150 mg SR BID or 300 mg XL daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Seizure disorder",
          "abrupt alcohol withdrawal",
          "abrupt alcohol/benzo withdrawal",
          "abrupt alcohol/benzodiazepine withdrawal",
          "bulimia/anorexia",
          "concurrent MAOIs",
          "eating disorder",
          "eating disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Seizure risk",
          "Seizure risk (dose-related)",
          "agitation (may worsen some patients)",
          "anxiety",
          "blood pressure",
          "insomnia",
          "may improve alertness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "frontotemporal-dementia",
        "hiv-associated-neurocognitive-disorder",
        "mild-cognitive-impairment"
      ]
    },
    "bupropion-sr-xl": {
      "id": "bupropion-sr-xl",
      "name": "Bupropion SR/XL",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "depression-with-fatigue-and-apathy-no-sexual-side-effects-av": {
          "indication": "Depression with fatigue and apathy; no sexual side effects; avoid if seizure risk",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Bupropion SR/XL 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg SR daily or 150 mg XL daily; may increase after 3 days; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "depression": {
          "indication": "Depression",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Bupropion SR/XL 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 150 mg SR daily; increase to 150 mg SR BID after 3 days (or 300 mg XL daily); max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Seizure disorder",
          "abrupt alcohol/benzo withdrawal",
          "anorexia/bulimia",
          "eating disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Seizure risk",
          "anxiety",
          "insomnia",
          "no sexual side effects"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-new-diagnosis",
        "vascular-dementia"
      ]
    },
    "bupropion-xl": {
      "id": "bupropion-xl",
      "name": "Bupropion XL",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "depression-with-fatigue-low-motivation-avoidance-of-sexual-s": {
          "indication": "Depression with fatigue, low motivation; avoidance of sexual side effects",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Bupropion XL 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 150 mg PO daily; may increase to 300 mg daily after 1-2 weeks; max 450 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Seizure disorder (lowers threshold), bulimia/anorexia, concurrent MAOIs"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Seizure risk (dose-dependent)",
          "agitation",
          "avoid in patients with seizure history",
          "insomnia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "post-concussion-syndrome"
      ]
    },
    "buspirone": {
      "id": "buspirone",
      "name": "Buspirone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "anxiety-without-sedation-adjunct-for-irritability": {
          "indication": "Anxiety without sedation; adjunct for irritability",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Buspirone 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; titrate by 5 mg q2-3d; max 60 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "comorbid-generalized-anxiety-disorder-non-addictive-anxiolyt": {
          "indication": "Comorbid generalized anxiety disorder; non-addictive anxiolytic; avoids benzodiazepine dependence",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Buspirone 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO TID; titrate by 5 mg/day q2-3d; max 60 mg/day; takes 2-4 weeks for full effect (NOT a PRN medication)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        },
        "anxiety-non-benzodiazepine": {
          "indication": "Anxiety (non-benzodiazepine)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Buspirone 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO TID; increase by 5 mg every 2-3 days; target 15-30 mg/day divided BID-TID; max 60 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "generalized-anxiety": {
          "indication": "Generalized anxiety",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Buspirone 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; increase by 5 mg every 2-3 days; max 60 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "adjunctive-anti-shivering-during-ttm-lowers-shivering-thresh": {
          "indication": "Adjunctive anti-shivering during TTM; lowers shivering threshold by 0.7C",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Buspirone 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg PO/NG q8h; lowers shivering threshold by 0.7C",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "cerebellar-ataxia-various-etiologies-serotonergic-mechanism-": {
          "indication": "Cerebellar ataxia (various etiologies); serotonergic mechanism may improve cerebellar function; modest evidence",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Buspirone 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg TID; increase by 5 mg/dose q3-5 days; target 30-60 mg/day divided TID; max 60 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAOIs",
          "MAOIs",
          "severe hepatic or renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dizziness",
          "Dizziness, headache",
          "None significant",
          "Serotonin syndrome if combined with SSRIs/SNRIs",
          "Shivering scale",
          "Takes 2-4 weeks for effect",
          "dizziness",
          "headache",
          "nausea (usually transient)",
          "no abuse potential",
          "no dependence",
          "no dependence risk unlike benzodiazepines",
          "takes 2-4 weeks for full effect"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "ataxia-evaluation",
        "huntingtons-disease",
        "peripheral-neuropathy",
        "pnes",
        "post-concussion-syndrome"
      ]
    },
    "butterbur": {
      "id": "butterbur",
      "name": "Butterbur (Petasites)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "preventive-level-a-evidence-aan-recommendation-withdrawn-due": {
          "indication": "Preventive; Level A evidence (AAN recommendation withdrawn due to hepatotoxicity concerns - use with caution)",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Butterbur (Petasites) 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75 mg PO BID of PA-free extract only; NOT recommended without PA-free verification",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hepatotoxicity risk with non-PA-free products",
          "pregnancy",
          "ragweed allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs if prolonged use",
          "USE WITH CAUTION - AAN withdrew recommendation due to safety concerns"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "chronic-migraine"
      ]
    },
    "caffeine-analgesic-combination": {
      "id": "caffeine-analgesic-combination",
      "name": "Caffeine/Analgesic combination",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "enhanced-efficacy-with-caffeine-adjunct": {
          "indication": "Enhanced efficacy with caffeine adjunct",
          "doseOptions": [
            {
              "text": "2 tablets",
              "orderSentence": "Caffeine/Analgesic combination 2 tablets PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg: 2 tablets at onset; max 2 doses/24hr",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Aspirin or acetaminophen contraindications"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Limit use to prevent caffeine dependence and MOH"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tension-headache"
      ]
    },
    "caffeine-oral": {
      "id": "caffeine-oral",
      "name": "Caffeine oral",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "mild-sih-pdph-cerebral-vasoconstriction": {
          "indication": "Mild SIH/PDPH; cerebral vasoconstriction",
          "doseOptions": [
            {
              "text": "200 mg q6h",
              "orderSentence": "Caffeine oral 200 mg q6h PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200-300 mg PO q6h (coffee ~100 mg/cup); max 900 mg/day; adjunct to other measures",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cardiac arrhythmia, severe anxiety, insomnia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Heart rate, sleep quality, anxiety"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "low-pressure-headache"
      ]
    },
    "caffeine-reduction-or-elimination": {
      "id": "caffeine-reduction-or-elimination",
      "name": "Caffeine reduction or elimination",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Dietary"
      ],
      "formulations": [],
      "contexts": {
        "enhanced-physiologic-tremor-exacerbated-by-caffeine-all-trem": {
          "indication": "Enhanced physiologic tremor exacerbated by caffeine; all tremor types worsened by caffeine",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Caffeine reduction or elimination N/A Dietary"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Reduce caffeine intake gradually to avoid withdrawal headache; target <200 mg/day or elimination; educate on hidden caffeine sources (chocolate, energy drinks, medications)",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Tremor severity with caffeine reduction",
          "withdrawal symptoms (headache, fatigue for 1-2 weeks)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tremor-unspecified"
      ]
    },
    "caffeine-sodium-benzoate-iv": {
      "id": "caffeine-sodium-benzoate-iv",
      "name": "Caffeine sodium benzoate IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-treatment-of-pdph-cerebral-vasoconstriction-to-counter": {
          "indication": "Acute treatment of PDPH; cerebral vasoconstriction to counteract CSF hypotension",
          "doseOptions": [
            {
              "text": "500 mg once",
              "orderSentence": "Caffeine sodium benzoate IV 500 mg once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV infused over 1 hour; may repeat once in 4-6 hours; max 1000 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cardiac arrhythmia, uncontrolled tachycardia, seizure disorder"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Heart rate, blood pressure, arrhythmia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "low-pressure-headache"
      ]
    },
    "calcineurin-inhibitor-tacrolimus": {
      "id": "calcineurin-inhibitor-tacrolimus",
      "name": "Calcineurin inhibitor: Tacrolimus (rescue for anti-MDA5 ILD)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "anti-mda5-rapidly-progressive-ild-combined-with-steroids-and": {
          "indication": "Anti-MDA5 rapidly progressive ILD (combined with steroids and cyclophosphamide as triple therapy)",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Calcineurin inhibitor: Tacrolimus (rescue for anti-MDA5 ILD) 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg PO BID; titrate to trough level 5-10 ng/mL; onset 2-4 weeks; used in Japanese triple-therapy protocol",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Uncontrolled hypertension",
          "renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Trough levels q1-2 weeks during titration",
          "electrolytes (K, Mg)",
          "glucose",
          "nephrotoxicity",
          "renal function",
          "tremor"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "inflammatory-myopathy"
      ]
    },
    "calcium-600-mg-vitamin-d-400-iu": {
      "id": "calcium-600-mg-vitamin-d-400-iu",
      "name": "Calcium 600 mg + Vitamin D 400 IU",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "bone-health-protection-for-chronic-asm-use-enzyme-inducing-a": {
          "indication": "Bone health protection for chronic ASM use; enzyme-inducing ASMs accelerate vitamin D metabolism and increase fracture risk",
          "doseOptions": [
            {
              "text": "600 mg calcium + 400 IU vitamin D BID",
              "orderSentence": "Calcium 600 mg + Vitamin D 400 IU 600 mg calcium + 400 IU vitamin D BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600 mg elemental calcium + 400-800 IU vitamin D3 twice daily with meals",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypercalcemia",
          "kidney stones",
          "sarcoidosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "DEXA every 2 years",
          "Serum calcium and vitamin D annually"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "calcium-600-mg-vitamin-d3-400-800-iu": {
      "id": "calcium-600-mg-vitamin-d3-400-800-iu",
      "name": "Calcium 600 mg + Vitamin D3 400-800 IU",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "bone-health-for-all-chronic-epilepsy-patients-especially-enz": {
          "indication": "Bone health for all chronic epilepsy patients; especially enzyme-inducing ASMs",
          "doseOptions": [
            {
              "text": "600 mg calcium + 400 IU vitamin D3 BID",
              "orderSentence": "Calcium 600 mg + Vitamin D3 400-800 IU 600 mg calcium + 400 IU vitamin D3 BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600 mg elemental calcium + 400-800 IU vitamin D3 twice daily with meals; total daily calcium 1000-1200 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypercalcemia",
          "kidney stones"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "DEXA q2 years",
          "Serum calcium",
          "vitamin D annually"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epilepsy-chronic-management"
      ]
    },
    "calcium-carbonate-vitamin-d": {
      "id": "calcium-carbonate-vitamin-d",
      "name": "Calcium carbonate + Vitamin D",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "osteoporosis-prevention-during-chronic-corticosteroid-therap": {
          "indication": "Osteoporosis prevention during chronic corticosteroid therapy",
          "doseOptions": [
            {
              "text": "1000-1200 mg Ca + 1000-2000 IU D",
              "orderSentence": "Calcium carbonate + Vitamin D (bone protection) 1000-1200 mg Ca + 1000-2000 IU D PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Calcium 1000-1200 mg + Vitamin D 1000-2000 IU PO daily while on chronic steroids",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "bone-protection-during-anticipated-prolonged-corticosteroid-": {
          "indication": "Bone protection during anticipated prolonged corticosteroid course (>3 months expected in PACNS)",
          "doseOptions": [
            {
              "text": "1000-1200 mg/day + 1000-2000 IU/day",
              "orderSentence": "Calcium carbonate + Vitamin D 1000-1200 mg/day + 1000-2000 IU/day PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Calcium 500-600 mg PO BID + Vitamin D 1000-2000 IU PO daily; start with steroids",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "bone-health-and-fall-prevention-in-older-adults-with-ibm-vit": {
          "indication": "Bone health and fall prevention in older adults with IBM; vitamin D deficiency common and worsens muscle weakness",
          "doseOptions": [
            {
              "text": "1000-1200 mg Ca + 1000-2000 IU D",
              "orderSentence": "Calcium carbonate + Vitamin D 1000-1200 mg Ca + 1000-2000 IU D PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Calcium 1000-1200 mg + Vitamin D 1000-2000 IU PO daily; higher vitamin D doses if deficient (50,000 IU weekly x 8 weeks then maintenance)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "bone-protection-during-anticipated-prolonged-corticosteroid--2": {
          "indication": "Bone protection during anticipated prolonged corticosteroid course (treatment duration typically 2+ years)",
          "doseOptions": [
            {
              "text": "1000 mg calcium + 1000 IU vitamin D daily",
              "orderSentence": "Calcium carbonate + Vitamin D 1000 mg calcium + 1000 IU vitamin D daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Calcium 500-600 mg PO BID + Vitamin D 1000-2000 IU PO daily; start with steroids",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "bone-health-in-dm-patients-at-fall-risk-vitamin-d-deficiency": {
          "indication": "Bone health in DM patients at fall risk; vitamin D deficiency common and worsens muscle weakness; osteoporosis prevention",
          "doseOptions": [
            {
              "text": "1000 mg Ca + 1000 IU D",
              "orderSentence": "Calcium carbonate + Vitamin D 1000 mg Ca + 1000 IU D PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Calcium 1000-1200 mg + Vitamin D 1000-2000 IU PO daily; higher vitamin D doses if deficient (50,000 IU weekly x 8 weeks then maintenance)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000-1200 mg",
              "orderSentence": "Calcium carbonate + Vitamin D (bone protection) 1000-1200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Calcium 1000-1200 mg + Vitamin D 1000-2000 IU daily while on chronic steroids",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypercalcemia",
          "hyperparathyroidism",
          "renal stones",
          "renal stones (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "25-OH Vitamin D level",
          "DEXA if steroids >3 months",
          "Serum calcium",
          "calcium",
          "consider DEXA if anticipated steroid course >3 months",
          "then annually",
          "vitamin D level",
          "vitamin D level q3-6 months until replete"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "cns-vasculitis",
        "inclusion-body-myositis",
        "inflammatory-myopathy",
        "myasthenia-gravis-new-diagnosis",
        "myotonic-dystrophy",
        "susac-syndrome"
      ]
    },
    "calcium-gluconate": {
      "id": "calcium-gluconate",
      "name": "Calcium gluconate (MgSO4 antidote)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "magnesium-toxicity-rescue-respiratory-depression-loss-of-ref": {
          "indication": "**MAGNESIUM TOXICITY RESCUE**: Respiratory depression, loss of reflexes, cardiac arrest from Mg toxicity",
          "doseOptions": [
            {
              "text": "1 g IV over 3 min",
              "orderSentence": "Calcium gluconate (MgSO4 antidote) 1 g IV over 3 min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 g (10 mL of 10% solution) IV over 3 min; may repeat; MUST be at bedside whenever MgSO4 infusing",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None in emergency"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cardiac monitoring",
          "repeat Mg level",
          "respiratory status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy"
      ]
    },
    "calcium-gluconate-iv": {
      "id": "calcium-gluconate-iv",
      "name": "Calcium gluconate IV (symptomatic hypocalcemia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "perioral-acral-paresthesia-with-documented-hypocalcemia-and-": {
          "indication": "Perioral/acral paresthesia with documented hypocalcemia and tetany",
          "doseOptions": [
            {
              "text": "1-2 g",
              "orderSentence": "Calcium gluconate IV (symptomatic hypocalcemia) 1-2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 g (10-20 mL of 10% solution) IV over 10-20 min; may repeat; follow with continuous infusion if persistent",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "hypocalcemia-correction-ionized-calcium-low": {
          "indication": "Hypocalcemia correction; ionized calcium low",
          "doseOptions": [
            {
              "text": "1-2 g",
              "orderSentence": "Calcium gluconate IV 1-2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 g calcium gluconate IV over 10-20 min; check Mg (required for calcium homeostasis)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Digoxin use (cardiac arrhythmia risk)",
          "Digoxin use (risk of fatal arrhythmia)",
          "hypercalcemia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cardiac monitor during infusion",
          "ECG",
          "Ionized calcium",
          "cardiac monitor during infusion",
          "repeat calcium level q4-6h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "paresthesia-numbness-tingling"
      ]
    },
    "calcium-vitamin-d": {
      "id": "calcium-vitamin-d",
      "name": "Calcium/Vitamin D",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000-1200 mg",
              "orderSentence": "**Calcium/Vitamin D** 1000-1200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Calcium 1000-1200 mg + Vitamin D 800-1000 IU daily while on prolonged steroids (>2 weeks)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "brain-metastases"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Steroid-induced osteoporosis prevention"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-metastases"
      ]
    },
    "candesartan": {
      "id": "candesartan",
      "name": "Candesartan",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-comorbid-hypertension-level-b-evidence": {
          "indication": "First-line; comorbid hypertension; Level B evidence",
          "doseOptions": [
            {
              "text": "8 mg",
              "orderSentence": "Candesartan 8 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 8 mg daily; increase to 16 mg daily after 4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "prevention-comorbid-htn-beta-blocker-intolerant": {
          "indication": "Prevention; comorbid HTN; beta-blocker intolerant",
          "doseOptions": [
            {
              "text": "8 mg",
              "orderSentence": "Candesartan 8 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 8 mg daily; may increase to 16 mg daily after 4 wk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**Pregnancy**",
          "Pregnancy, bilateral renal artery stenosis, hyperkalemia",
          "bilateral renal artery stenosis",
          "hyperkalemia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP, potassium, renal function",
          "creatinine",
          "potassium"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine-with-aura"
      ]
    },
    "cannabidiol": {
      "id": "cannabidiol",
      "name": "Cannabidiol (Epidiolex)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-due-to-dravet-syndrome-lennox-gastaut-syndrome-or-tubero": {
          "indication": "DRE due to Dravet syndrome, Lennox-Gastaut syndrome, or tuberous sclerosis complex; FDA-approved",
          "doseOptions": [
            {
              "text": "2.5 mg/kg BID",
              "orderSentence": "Cannabidiol (Epidiolex) 2.5 mg/kg BID PO"
            },
            {
              "text": "5 mg/kg BID",
              "orderSentence": "Cannabidiol (Epidiolex) 5 mg/kg BID PO"
            },
            {
              "text": "10 mg/kg BID",
              "orderSentence": "Cannabidiol (Epidiolex) 10 mg/kg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5 mg/kg BID; increase after 1 week to 5 mg/kg BID; max 10 mg/kg BID (20 mg/kg/day); take with high-fat meals for absorption",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment",
          "hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs at baseline, 1, 3, 6 months then periodically (hepatotoxicity risk, especially with valproate)",
          "sedation (potentiated by clobazam — reduce clobazam dose)",
          "valproate interaction (hepatotoxicity)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "capsaicin-8-patch": {
      "id": "capsaicin-8-patch",
      "name": "Capsaicin 8% patch (Qutenza)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP",
        "Topical",
        "Transdermal"
      ],
      "formulations": [],
      "contexts": {
        "localized-neuropathic-pain-refractory": {
          "indication": "Localized neuropathic pain (refractory)",
          "doseOptions": [
            {
              "text": "1 patch",
              "orderSentence": "Capsaicin 8% patch (Qutenza) 1 patch Transdermal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Applied by healthcare provider for 30-60 minutes; repeat every 3 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling",
            "peripheral-neuropathy"
          ]
        },
        "localized-neuropathic-pain-refractory-to-standard-topical-th": {
          "indication": "Localized neuropathic pain refractory to standard topical therapy",
          "doseOptions": [
            {
              "text": "8% patch",
              "orderSentence": "Capsaicin 8% patch (Qutenza) 8% patch TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Applied by healthcare provider for 30-60 minutes; may repeat every 3 months; pretreat area with topical lidocaine",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Capsaicin 8% patch (Qutenza) N/A Transdermal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply to painful area × 30-60 min q3 months; in-office",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "diabetic-neuropathy"
          ]
        },
        "localized-neuropathic-pain-add-on-therapy": {
          "indication": "Localized neuropathic pain; add-on therapy",
          "doseOptions": [
            {
              "text": "1 patch",
              "orderSentence": "Capsaicin 8% patch (Qutenza) 1 patch Topical"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Applied by trained healthcare provider; pre-treat with topical anesthetic; may repeat q3mo",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "localized-neuropathic-pain-in-areas-with-preserved-sensation": {
          "indication": "Localized neuropathic pain in areas with preserved sensation; radicular distribution pain",
          "doseOptions": [
            {
              "text": "1-4 patches",
              "orderSentence": "Capsaicin 8% patch (Qutenza) 1-4 patches TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply to painful area for 60 minutes; may repeat q3 months; pre-treat with topical lidocaine",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Application to face/mucous membranes",
          "Open wounds",
          "Same as above",
          "avoid mucous membranes",
          "broken skin",
          "capsaicin allergy",
          "mucous membranes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Apply in clinic",
          "BP during application",
          "Must be applied in clinic",
          "Pain/burning during application",
          "Transient burning at application",
          "blood pressure during application",
          "must be applied in clinical setting",
          "pain",
          "pain during and after application",
          "pretreat area with topical lidocaine",
          "transient BP increase"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "b12-deficiency-neuropathy",
        "cervical-myelopathy",
        "diabetic-neuropathy",
        "paresthesia-numbness-tingling",
        "peripheral-neuropathy",
        "small-fiber-neuropathy"
      ]
    },
    "capsaicin-cream-0-025-0-075": {
      "id": "capsaicin-cream-0-025-0-075",
      "name": "Capsaicin cream 0.025-0.075%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Topical"
      ],
      "formulations": [],
      "contexts": {
        "localized-paresthesia-pain": {
          "indication": "Localized paresthesia/pain",
          "doseOptions": [
            {
              "text": "Thin layer",
              "orderSentence": "Capsaicin cream 0.025-0.075% Thin layer Topical"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply thin layer TID-QID to affected area; takes 2-4 weeks for effect",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Open wounds",
          "avoid eyes/mucous membranes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Initial burning (decreases with continued use)",
          "wash hands after"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "paresthesia-numbness-tingling"
      ]
    },
    "capsaicin-cream-0-075": {
      "id": "capsaicin-cream-0-075",
      "name": "Capsaicin cream 0.075%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "localized-neuropathic-pain-in-feet-or-hands": {
          "indication": "Localized neuropathic pain in feet or hands",
          "doseOptions": [
            {
              "text": "0.075% cream",
              "orderSentence": "Capsaicin cream 0.075% 0.075% cream TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply thin layer TID-QID to affected area; takes 2-4 weeks for full effect; wash hands thoroughly after application",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "localized-radicular-pain-adjunct": {
          "indication": "Localized radicular pain (adjunct)",
          "doseOptions": [
            {
              "text": "Apply thin layer",
              "orderSentence": "Capsaicin cream 0.075% Apply thin layer TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply TID-QID to affected area; takes 2-4 weeks for effect",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "localized-neuropathic-pain-adjunct": {
          "indication": "Localized neuropathic pain (adjunct)",
          "doseOptions": [
            {
              "text": "Apply thin layer",
              "orderSentence": "Capsaicin cream 0.075% Apply thin layer TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply TID-QID to affected area; takes 2-4 weeks for effect",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Open wounds",
          "avoid eyes and mucous membranes",
          "avoid eyes/mucous membranes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Initial burning (decreases with use)",
          "Initial burning sensation (decreases with continued use)",
          "do not apply to broken skin",
          "wash hands after"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "b12-deficiency-neuropathy",
        "plexopathy",
        "radiculopathy"
      ]
    },
    "carbamazepine": {
      "id": "carbamazepine",
      "name": "Carbamazepine",
      "genericName": "carbamazepine",
      "brandNames": [
        "Tegretol",
        "Tegretol XR",
        "Carbatrol",
        "Epitol"
      ],
      "drugClass": "Anticonvulsant / Sodium Channel Blocker",
      "mechanisms": [
        "Blocks voltage-gated sodium channels",
        "Reduces repetitive neuronal firing"
      ],
      "routes": [
        "PO"
      ],
      "formulations": [
        "100 mg chewable tablet",
        "200 mg tablet",
        "100 mg/5mL suspension",
        "100 mg XR capsule",
        "200 mg XR tablet",
        "300 mg XR capsule",
        "400 mg XR tablet"
      ],
      "contexts": {
        "trigeminal-neuralgia": {
          "indication": "Trigeminal neuralgia (first-line)",
          "doseOptions": [
            {
              "text": "100 mg BID",
              "orderSentence": "Carbamazepine 100 mg PO BID"
            },
            {
              "text": "200 mg BID",
              "orderSentence": "Carbamazepine 200 mg PO BID"
            },
            {
              "text": "400 mg BID",
              "orderSentence": "Carbamazepine 400 mg PO BID"
            },
            {
              "text": "600 mg BID",
              "orderSentence": "Carbamazepine 600 mg PO BID"
            }
          ],
          "startingDose": "100 mg BID",
          "maxDose": "1200 mg/day",
          "titration": "Increase by 100-200 mg every 1-2 weeks",
          "notes": "First-line for trigeminal neuralgia; NNT ~1.7",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          }
        },
        "epilepsy": {
          "indication": "Partial seizures, generalized tonic-clonic seizures",
          "doseOptions": [
            {
              "text": "200 mg BID",
              "orderSentence": "Carbamazepine 200 mg PO BID"
            },
            {
              "text": "400 mg BID",
              "orderSentence": "Carbamazepine 400 mg PO BID"
            },
            {
              "text": "600 mg BID",
              "orderSentence": "Carbamazepine 600 mg PO BID"
            },
            {
              "text": "800 mg BID",
              "orderSentence": "Carbamazepine 800 mg PO BID"
            }
          ],
          "startingDose": "200 mg BID",
          "maxDose": "1600 mg/day (adults); adjust by level",
          "titration": "Increase by 200 mg weekly",
          "notes": "First-line for focal epilepsy; induces own metabolism (autoinduction)"
        },
        "neuropathic-pain": {
          "indication": "Neuropathic pain (second-line)",
          "doseOptions": [
            {
              "text": "100 mg BID",
              "orderSentence": "Carbamazepine 100 mg PO BID"
            },
            {
              "text": "200 mg BID",
              "orderSentence": "Carbamazepine 200 mg PO BID"
            },
            {
              "text": "400 mg BID",
              "orderSentence": "Carbamazepine 400 mg PO BID"
            }
          ],
          "startingDose": "100 mg BID",
          "maxDose": "1200 mg/day",
          "titration": "Increase by 100-200 mg every 1-2 weeks",
          "notes": "Consider for lancinating/shooting pain; many drug interactions"
        },
        "agitation-aggression-refractory-to-other-treatments": {
          "indication": "Agitation/aggression refractory to other treatments",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID; titrate to 200-400 mg BID based on response; monitor levels",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "irritability-aggression-alternative-mood-stabilizer": {
          "indication": "Irritability; aggression; alternative mood stabilizer",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID; titrate by 200 mg/wk; target level 4-12 mcg/mL",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "paroxysmal-kinesigenic-dystonia-dyskinesia": {
          "indication": "Paroxysmal kinesigenic dystonia/dyskinesia",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID; increase by 100-200 mg q1wk; target 400-800 mg/day; check HLA-B*1502 in at-risk populations",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "lancinating-shooting-pain-trigeminal-distribution-paresthesi": {
          "indication": "Lancinating/shooting pain, trigeminal distribution paresthesia",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID; increase by 200 mg/day every 3-7 days; max 1200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "trigeminal-neuralgia-from-cn-v-sarcoidosis": {
          "indication": "Trigeminal neuralgia from CN V sarcoidosis",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID; titrate by 200 mg/day q3-7d; target level 4-12 mcg/mL; max 1200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "lancinating-lightning-pain-of-tabes-dorsalis-particularly-ef": {
          "indication": "Lancinating/lightning pain of tabes dorsalis (particularly effective for paroxysmal neuropathic pain)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID; titrate by 200 mg/day q1wk; target 400-800 mg/day; max 1200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "sodium-channel-blocker-limited-evidence-for-sfn-specifically": {
          "indication": "Sodium channel blocker; limited evidence for SFN specifically",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID; titrate by 200 mg/wk; max 1200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100-200 mg",
              "orderSentence": "Carbamazepine (Tegretol) 100-200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-200 mg BID; increase by 100-200 mg q3-7 days; target 400-1200 mg/day divided BID-TID",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "trigeminal-neuralgia",
            "dementia-evaluation"
          ]
        },
        "trigeminal-neuralgia-lancinating-pain": {
          "indication": "Trigeminal neuralgia, lancinating pain",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID; increase by 200 mg/day every 3-7 days; max 1200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "focal-epilepsy-trigeminal-neuralgia-effective-but-many-drug-": {
          "indication": "Focal epilepsy; trigeminal neuralgia; effective but many drug interactions (enzyme inducer)",
          "doseOptions": [
            {
              "text": "100 mg BID",
              "orderSentence": "Carbamazepine (Tegretol) 100 mg BID PO"
            },
            {
              "text": "200 mg BID",
              "orderSentence": "Carbamazepine (Tegretol) 200 mg BID PO"
            },
            {
              "text": "400 mg BID",
              "orderSentence": "Carbamazepine (Tegretol) 400 mg BID PO"
            },
            {
              "text": "600 mg BID",
              "orderSentence": "Carbamazepine (Tegretol) 600 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100-200 mg BID; increase by 200 mg q1wk; target 400-600 mg BID; max 1600 mg/day; use extended-release",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "gaze-evoked-nystagmus-and-ataxia-at-toxic-levels-dose-depend": {
          "indication": "Gaze-evoked nystagmus and ataxia at toxic levels; dose-dependent",
          "doseOptions": [
            {
              "text": "Monitor levels",
              "orderSentence": "**Carbamazepine (supratherapeutic)** Monitor levels PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Drug level; reduce dose; autoinduction may alter levels unpredictably",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "second-line-for-myotonia-if-mexiletine-not-tolerated-or-cont": {
          "indication": "Second-line for myotonia if mexiletine not tolerated or contraindicated; sodium channel blocker",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO BID; increase by 100-200 mg/week; target 400-600 mg/day divided BID-TID; max 1200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "neuropathic-pain-alternative": {
          "indication": "Neuropathic pain (alternative)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO BID; increase by 100 mg/day q3-7 days; target 400-800 mg/day in divided doses; max 1200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        },
        "lancinating-radicular-pain-paroxysmal-neuropathic-pain-trige": {
          "indication": "Lancinating radicular pain; paroxysmal neuropathic pain; trigeminal component",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO BID; increase by 200 mg/day q1 week; max 1200 mg/day; use extended-release formulation",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "lancinating-paroxysmal-neuropathic-pain-in-lyme-radiculopath": {
          "indication": "Lancinating/paroxysmal neuropathic pain in Lyme radiculopathy (similar mechanism to trigeminal neuralgia pain) refractory to gabapentin/pregabalin",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbamazepine 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID; titrate by 200 mg/day q1wk; target 400-800 mg/day divided BID; max 1200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        },
        "focal-seizures": {
          "indication": "Focal seizures",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Carbamazepine 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 200 mg PO BID; increase by 200 mg/day weekly; target 800-1200 mg/day; max 1600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [
          "Serious dermatologic reactions (SJS/TEN) - HLA-B*1502 screening required in Asian populations",
          "Aplastic anemia and agranulocytosis (rare but serious)"
        ],
        "contraindications": [
          "Known HLA-B*1502 allele",
          "Bone marrow depression",
          "Use within 14 days of MAOIs",
          "Concomitant use with nefazodone"
        ],
        "precautions": [
          "Hyponatremia (SIADH)",
          "Cardiac conduction abnormalities",
          "Hepatotoxicity",
          "Potent CYP3A4 inducer - many drug interactions",
          "Autoinduction - levels decrease over first 2-4 weeks",
          "May worsen absence, myoclonic seizures"
        ],
        "drugInteractions": [
          {
            "drug": "Oral contraceptives",
            "severity": "high",
            "effect": "Reduced contraceptive efficacy - use backup method"
          },
          {
            "drug": "Warfarin",
            "severity": "high",
            "effect": "Reduced warfarin effect - monitor INR"
          },
          {
            "drug": "Valproate",
            "severity": "moderate",
            "effect": "Reduced valproate levels; increased carbamazepine epoxide"
          },
          {
            "drug": "Lamotrigine",
            "severity": "moderate",
            "effect": "Reduced lamotrigine levels by 40%"
          },
          {
            "drug": "CYP3A4 substrates (many)",
            "severity": "high",
            "effect": "Reduced levels of substrate drugs"
          }
        ],
        "pregnancyCategory": "D",
        "lactation": "Compatible but monitor infant for sedation"
      },
      "renalAdjustment": {
        "required": false,
        "tiers": [
          {
            "gfr": "≥10",
            "adjustment": "No adjustment typically needed"
          },
          {
            "gfr": "<10",
            "adjustment": "75% of normal dose; use with caution"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": true,
        "notes": "Reduce dose in hepatic impairment; hepatically metabolized. Avoid in severe impairment."
      },
      "monitoring": {
        "baseline": [
          "CBC with differential",
          "LFTs",
          "BMP (sodium)",
          "HLA-B*1502 in at-risk populations"
        ],
        "ongoing": [
          "Sodium levels",
          "CBC",
          "LFTs",
          "Carbamazepine level (therapeutic: 4-12 mcg/mL)"
        ],
        "frequency": "CBC and sodium monthly x 3 months, then every 3-6 months"
      },
      "patientCounseling": [
        "Take with food to reduce GI upset",
        "Report any rash, fever, sore throat, mouth ulcers immediately (stop drug if rash)",
        "Do not stop abruptly - seizure risk",
        "Many drug interactions - inform all providers",
        "May reduce effectiveness of birth control pills",
        "Avoid grapefruit juice"
      ]
    },
    "carbamazepine-po": {
      "id": "carbamazepine-po",
      "name": "Carbamazepine PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-adjunctive-for-mild-moderate-withdrawal-may-redu": {
          "indication": "Alternative/adjunctive for mild-moderate withdrawal; may reduce withdrawal severity and seizure risk; evidence in European literature",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Carbamazepine PO 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 200 mg TID on day 1; may increase to 400 mg TID; taper over 5-7 days; can be used alone for mild withdrawal or as adjunct",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "AV block",
          "HLA-B*1502 positive (Asian populations)",
          "Hepatic disease",
          "bone marrow suppression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC, LFTs, sodium (hyponatremia risk)",
          "drug interactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure"
      ]
    },
    "carbidopa-levodopa": {
      "id": "carbidopa-levodopa",
      "name": "Carbidopa/Levodopa (Sinemet)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Carbidopa/Levodopa (Sinemet) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25/100 mg TID with meals; titrate by 25/100 mg q1-2 weeks; usual maintenance 300-800 mg levodopa/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "levodopa-responsiveness-trial-required-by-mds-criteria-for-a": {
          "indication": "Levodopa responsiveness trial; required by MDS criteria for akinetic-rigid parkinsonism",
          "doseOptions": [
            {
              "text": "25/100 mg",
              "orderSentence": "Carbidopa/Levodopa (Sinemet) 25/100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25/100 mg TID with meals; titrate by 25/100 mg q1-2 weeks to 25/250 mg TID; adequate trial requires 800-1000 mg levodopa/day for ≥1 month; document response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Narrow-angle glaucoma",
          "caution with MAOIs",
          "concurrent non-selective MAOIs"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dyskinesia, nausea, orthostatic hypotension",
          "Nausea, orthostatic hypotension, dyskinesia (rare in PSP)",
          "document percent improvement"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "parkinsons-disease-new-diagnosis",
        "progressive-supranuclear-palsy"
      ]
    },
    "carbidopa-levodopa-cr": {
      "id": "carbidopa-levodopa-cr",
      "name": "Carbidopa-Levodopa CR (Sinemet CR)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nocturnal-symptoms-wearing-off": {
          "indication": "Nocturnal symptoms; wearing off",
          "doseOptions": [
            {
              "text": "25/100 CR qHS",
              "orderSentence": "Carbidopa-Levodopa CR (Sinemet CR) 25/100 CR qHS PO"
            },
            {
              "text": "50/200 CR BID",
              "orderSentence": "Carbidopa-Levodopa CR (Sinemet CR) 50/200 CR BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25/100 to 50/200 CR at bedtime or BID; 70% bioavailability vs IR",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as IR"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same as IR"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease"
      ]
    },
    "carbidopa-levodopa-er": {
      "id": "carbidopa-levodopa-er",
      "name": "Carbidopa-Levodopa ER (Rytary)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "motor-fluctuations-extend-levodopa-effect": {
          "indication": "Motor fluctuations; extend levodopa effect",
          "doseOptions": [
            {
              "text": "23.75/95 TID",
              "orderSentence": "Carbidopa-Levodopa ER (Rytary) 23.75/95 TID PO"
            },
            {
              "text": "36.25/145 TID",
              "orderSentence": "Carbidopa-Levodopa ER (Rytary) 36.25/145 TID PO"
            },
            {
              "text": "48.75/195 TID",
              "orderSentence": "Carbidopa-Levodopa ER (Rytary) 48.75/195 TID PO"
            },
            {
              "text": "61.25/245 TID",
              "orderSentence": "Carbidopa-Levodopa ER (Rytary) 61.25/245 TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Convert from IR using manufacturer table; typically TID dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as IR"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same as IR"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease"
      ]
    },
    "carbidopa-levodopa-intestinal-gel": {
      "id": "carbidopa-levodopa-intestinal-gel",
      "name": "Carbidopa/Levodopa intestinal gel (Duopa)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Carbidopa/Levodopa intestinal gel (Duopa) N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Continuous infusion via PEG-J; specialist prescribing",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Advanced PD",
          "requires surgical placement"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Device complications"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "carbidopa-levodopa-ir": {
      "id": "carbidopa-levodopa-ir",
      "name": "Carbidopa-Levodopa IR (Sinemet)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "motor-symptoms-first-line-dopaminergic-therapy": {
          "indication": "Motor symptoms; first-line dopaminergic therapy",
          "doseOptions": [
            {
              "text": "25/100 TID",
              "orderSentence": "Carbidopa-Levodopa IR (Sinemet) 25/100 TID PO"
            },
            {
              "text": "25/250 TID",
              "orderSentence": "Carbidopa-Levodopa IR (Sinemet) 25/250 TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25/100 TID; titrate by 1 tablet q1-2wk; typical target 25/100-25/250 TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active psychosis",
          "MAOIs within 14 days"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dyskinesias, nausea, orthostatic hypotension"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease"
      ]
    },
    "carbidopa-levodopa-therapeutic-trial": {
      "id": "carbidopa-levodopa-therapeutic-trial",
      "name": "Carbidopa/Levodopa (Sinemet) — therapeutic trial",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "parkinsonism-in-msa-p-levodopa-trial-required-for-diagnosis-": {
          "indication": "Parkinsonism in MSA-P — levodopa trial required for diagnosis (poor response expected in most)",
          "doseOptions": [
            {
              "text": "25/100 mg TID",
              "orderSentence": "Carbidopa/Levodopa (Sinemet) — therapeutic trial 25/100 mg TID PO"
            },
            {
              "text": "25/250 mg TID",
              "orderSentence": "Carbidopa/Levodopa (Sinemet) — therapeutic trial 25/250 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25/100 mg TID with meals; titrate to 25/250 mg TID over 4-8 weeks; up to 1000-1500 mg levodopa/day to document response; ~30% have partial/transient response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Narrow-angle glaucoma",
          "concurrent non-selective MAOIs"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Orthostatic BP (levodopa may worsen OH), nausea, dyskinesia (especially facial/cervical in MSA), motor response assessment using UPDRS"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "multiple-system-atrophy"
      ]
    },
    "cefepime": {
      "id": "cefepime",
      "name": "Cefepime",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "shunt-infection-empiric-gram-negative-coverage": {
          "indication": "Shunt infection (empiric gram-negative coverage)",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Cefepime 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q8h; adjust for renal function",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "normal-pressure-hydrocephalus"
          ]
        },
        "pseudomonas-nosocomial-immunocompromised": {
          "indication": "Pseudomonas (nosocomial, immunocompromised)",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Cefepime 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q8h",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cephalosporin allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function",
          "neurotoxicity"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "bacterial-meningitis",
        "normal-pressure-hydrocephalus"
      ]
    },
    "cefotaxime": {
      "id": "cefotaxime",
      "name": "Cefotaxime (alternative to ceftriaxone)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "alternative-parenteral-beta-lactam-for-neuroborreliosis-when": {
          "indication": "Alternative parenteral beta-lactam for neuroborreliosis when ceftriaxone is contraindicated (biliary disease) or unavailable; equivalent CNS penetration",
          "doseOptions": [
            {
              "text": "2 g q8h",
              "orderSentence": "Cefotaxime (alternative to ceftriaxone) 2 g q8h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV every 8 hours for 14-28 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cephalosporin anaphylaxis",
          "severe penicillin allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "C. difficile monitoring",
          "CBC",
          "LFTs",
          "Renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "lyme-neuroborreliosis"
      ]
    },
    "ceftriaxone": {
      "id": "ceftriaxone",
      "name": "Ceftriaxone (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "pending-csf-culture-results-empiric-bacterial-meningitis-cov": {
          "indication": "Pending CSF culture results; empiric bacterial meningitis coverage",
          "doseOptions": [
            {
              "text": "2g",
              "orderSentence": "Ceftriaxone (empiric if bacterial meningitis not excluded) 2g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2g IV q12h; continue until CSF cultures negative at 48-72h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "empiric-meningitis-coverage-pending-csf-results-give-before-": {
          "indication": "Empiric meningitis coverage pending CSF results (give BEFORE LP if delay anticipated)",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ceftriaxone (CPT 96374) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q12h (meningitis dosing); give STAT if bacterial meningitis suspected",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "s-pneumoniae-intermediate": {
          "indication": "S. pneumoniae (intermediate)",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ceftriaxone (if intermediate or unknown sensitivity) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q12h; continue vancomycin until sensitivities confirm",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "h-influenzae": {
          "indication": "H. influenzae",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ceftriaxone 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q12h",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "e-coli-gram-negative": {
          "indication": "E. coli / gram-negative",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ceftriaxone 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q12h; adjust per sensitivities",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "empiric-broad-spectrum-coverage-for-streptococci-gram-negati": {
          "indication": "Empiric broad-spectrum coverage for Streptococci, gram-negatives, H. influenzae; penetrates blood-brain barrier well",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ceftriaxone (CPT 96374) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q12h; duration 6-8 weeks total IV therapy; adjust based on culture results",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "febrile-thunderclap-headache-with-meningeal-signs-empiric-gr": {
          "indication": "Febrile thunderclap headache with meningeal signs — empiric gram-negative and pneumococcal coverage",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ceftriaxone (if bacterial meningitis suspected) (CPT 96374) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ceftriaxone 2 g IV q12h. Do NOT delay antibiotics for LP or imaging",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "first-line-treatment-for-neuroborreliosis-with-cns-involveme": {
          "indication": "First-line treatment for neuroborreliosis with CNS involvement (meningitis, encephalomyelitis, encephalopathy) and cranial neuropathy with CSF pleocytosis; also for Lyme radiculopathy with CSF abnormalities",
          "doseOptions": [
            {
              "text": "2 g daily",
              "orderSentence": "Ceftriaxone (CPT 96365) 2 g daily IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV once daily for 14-28 days (most experts recommend 14-21 days); infuse over 30-60 min; standard duration 14 days for most cases, 21-28 days for late neuroborreliosis or encephalomyelitis",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cephalosporin allergy",
          "Cephalosporin allergy (severe)",
          "Cephalosporin allergy (use meropenem or chloramphenicol)",
          "Cephalosporin anaphylaxis",
          "Cephalosporin anaphylaxis (use meropenem as alternative)",
          "adjust if PCN allergy documented",
          "biliary sludge with prolonged use",
          "caution with biliary disease (ceftriaxone can cause biliary sludge/pseudolithiasis)",
          "severe penicillin allergy (cross-reactivity ~1-2%)",
          "severe penicillin allergy (cross-reactivity)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "CBC weekly",
          "CSF culture results",
          "Cultures",
          "IV site assessment",
          "LFTs",
          "LFTs biweekly",
          "Renal function (BUN, Cr) weekly",
          "Renal function, rash, C. difficile",
          "Same as empiric",
          "Standard",
          "biliary symptoms",
          "clinical response",
          "monitor for C. difficile diarrhea",
          "renal function",
          "renal function weekly"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "bacterial-meningitis",
        "brain-abscess",
        "hashimotos-encephalopathy",
        "headache-evaluation",
        "lyme-neuroborreliosis",
        "thunderclap-headache-evaluation"
      ]
    },
    "ceftriaxone-iv": {
      "id": "ceftriaxone-iv",
      "name": "Ceftriaxone IV (empiric — until bacterial meningitis excluded) (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "empiric-bacterial-coverage-covers-s-pneumoniae-n-meningitidi": {
          "indication": "Empiric bacterial coverage; covers S. pneumoniae, N. meningitidis, H. influenzae, gram-negatives; continue until CSF cultures negative at 48-72h and BioFire negative for bacteria",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ceftriaxone IV (empiric — until bacterial meningitis excluded) (CPT 96374) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q12h; start within 30 minutes of presentation; discontinue when bacterial meningitis excluded (negative Gram stain + negative BioFire + CSF consistent with viral + cultures negative at 48-72h)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "alternative-for-neurosyphilis-when-penicillin-desensitizatio": {
          "indication": "Alternative for neurosyphilis when penicillin desensitization is not feasible; CDC-recommended alternative. Evidence supports adequate CSF penetration and treponemicidal activity",
          "doseOptions": [
            {
              "text": "2 g daily",
              "orderSentence": "Ceftriaxone IV (alternative to penicillin G) 2 g daily IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV daily for 10-14 days. Some experts recommend 14 days. Limited clinical trial data but supported by observational studies and CDC guidelines",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Ceftriaxone IV (CPT 96365) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV daily × 14-21 days (if CNS involvement)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bells-palsy",
            "bacterial-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cephalosporin allergy",
          "Cephalosporin allergy (cross-reactivity low with penicillin allergy)",
          "Cephalosporin allergy (true anaphylaxis — use chloramphenicol or meropenem as alternative)",
          "Cephalosporin anaphylaxis",
          "neonatal hyperbilirubinemia",
          "severe penicillin allergy with cephalosporin cross-reactivity (low risk, ~1-2%)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "LFTs",
          "Renal function",
          "Standard",
          "biliary sludge with prolonged use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "bacterial-meningitis",
        "bells-palsy",
        "neurosyphilis",
        "viral-meningitis"
      ]
    },
    "celecoxib": {
      "id": "celecoxib",
      "name": "Celecoxib",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "radicular-pain-gi-sparing-cox-2": {
          "indication": "Radicular pain (GI-sparing COX-2)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Celecoxib 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-200 mg BID; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CAD/CVD (increased CV risk)",
          "CrCl <30",
          "Sulfonamide allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CV events",
          "GI symptoms",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "radiculopathy"
      ]
    },
    "cenobamate": {
      "id": "cenobamate",
      "name": "Cenobamate (Xcopri)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-adjunctive-therapy-novel-mechanism-sodium-channel-gaba-a": {
          "indication": "DRE adjunctive therapy; novel mechanism (sodium channel + GABA-A positive allosteric modulator); demonstrated high responder rates in trials",
          "doseOptions": [
            {
              "text": "12.5 mg daily",
              "orderSentence": "Cenobamate (Xcopri) 12.5 mg daily PO"
            },
            {
              "text": "25 mg daily",
              "orderSentence": "Cenobamate (Xcopri) 25 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Cenobamate (Xcopri) 100 mg daily PO"
            },
            {
              "text": "200 mg daily",
              "orderSentence": "Cenobamate (Xcopri) 200 mg daily PO"
            },
            {
              "text": "400 mg daily",
              "orderSentence": "Cenobamate (Xcopri) 400 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg daily x 2 weeks → 25 mg daily x 2 weeks → 50 mg daily x 2 weeks → 100 mg daily x 2 weeks → 150 mg daily x 2 weeks → 200 mg daily; max 400 mg daily; TITRATE SLOWLY (DRESS risk)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "focal-epilepsy-high-efficacy-in-drug-resistant-cases-dual-me": {
          "indication": "Focal epilepsy; high efficacy in drug-resistant cases; dual mechanism",
          "doseOptions": [
            {
              "text": "12.5 mg daily",
              "orderSentence": "Cenobamate (Xcopri) 12.5 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Cenobamate (Xcopri) 100 mg daily PO"
            },
            {
              "text": "200 mg daily",
              "orderSentence": "Cenobamate (Xcopri) 200 mg daily PO"
            },
            {
              "text": "400 mg daily",
              "orderSentence": "Cenobamate (Xcopri) 400 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg daily; titrate per REMS schedule over 11+ weeks to target 200 mg daily; max 400 mg; SLOW TITRATION MANDATORY",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "adjunctive-for-focal": {
          "indication": "Adjunctive for focal",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Cenobamate 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg daily Ã— 2 weeks; titrate slowly per package insert; target 200-400 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "DRESS risk",
          "DRESS syndrome risk (mandatory slow titration)",
          "Familial short QT syndrome",
          "QT shortening with familial short QT",
          "hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ASM level interactions (reduce clobazam, phenytoin, phenobarbital)",
          "DRESS monitoring (rash, fever, eosinophilia)",
          "ECG",
          "ECG at baseline and after reaching 200 mg",
          "QT shortening",
          "Very slow titration required (DRESS risk)",
          "monitor for DRESS (rash, fever, lymphadenopathy, eosinophilia)",
          "reduce clobazam, phenytoin, phenobarbital doses",
          "titration pack available"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "drug-resistant-epilepsy",
        "epilepsy-chronic-management",
        "new-onset-seizure"
      ]
    },
    "cgrp-monoclonal-antibodies": {
      "id": "cgrp-monoclonal-antibodies",
      "name": "CGRP monoclonal antibodies",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "70-140 mg",
              "orderSentence": "CGRP monoclonal antibodies 70-140 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Erenumab 70-140 mg SC monthly; Fremanezumab 225 mg monthly or 675 mg quarterly; Galcanezumab 240 mg load then 120 mg monthly",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Constipation (erenumab), injection reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "medication-overuse-headache"
      ]
    },
    "chlordiazepoxide-po": {
      "id": "chlordiazepoxide-po",
      "name": "Chlordiazepoxide PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "symptom-triggered-withdrawal-management-ciwa-ar-based-prefer": {
          "indication": "Symptom-triggered withdrawal management (CIWA-Ar based); preferred for mild-moderate withdrawal when oral route available",
          "doseOptions": [
            {
              "text": "25-100 mg",
              "orderSentence": "Chlordiazepoxide PO 25-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "CIWA-Ar >=10: give 25-100 mg PO q1h until CIWA <10; then PRN dosing; typical total day 1: 200-400 mg; taper over 3-5 days; long half-life provides smooth coverage",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment (use lorazepam)",
          "acute intoxication",
          "respiratory depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CIWA-Ar q1h during active treatment, then q4h when stable",
          "RR, sedation level"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure"
      ]
    },
    "chlorpromazine": {
      "id": "chlorpromazine",
      "name": "Chlorpromazine (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "second-line-dopamine-antagonist-effective-for-refractory-acu": {
          "indication": "Second-line dopamine antagonist; effective for refractory acute headache",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Chlorpromazine (CPT 96374) 12.5 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "12.5 mg IV in 500 mL NS over 20 min; repeat 25 mg in 30 min if needed; co-administer diphenhydramine",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CNS depression",
          "Parkinson's disease",
          "QT prolongation",
          "severe hepatic disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP (orthostatic hypotension common), QTc, sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "headache-unspecified"
      ]
    },
    "chlorpromazine-iv": {
      "id": "chlorpromazine-iv",
      "name": "Chlorpromazine IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "alternative-dopamine-antagonist-with-potent-analgesic-and-se": {
          "indication": "Alternative dopamine antagonist with potent analgesic and sedative effect for refractory migraine",
          "doseOptions": [
            {
              "text": "12.5 mg IV once",
              "orderSentence": "Chlorpromazine IV 12.5 mg IV once IV"
            },
            {
              "text": "25 mg IV once",
              "orderSentence": "Chlorpromazine IV 25 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "12.5-25 mg IV over 20 min with 500 mL NS bolus; may repeat x2 q30min; max 75 mg",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation, severe hypotension, Parkinson disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q15min (orthostatic hypotension common), QTc, sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "chlorthalidone": {
      "id": "chlorthalidone",
      "name": "Chlorthalidone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "thiazide-like-diuretic-for-bp-control-effective-for-stroke-p": {
          "indication": "Thiazide-like diuretic for BP control; effective for stroke prevention",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Chlorthalidone 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg daily; may increase to 25 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "thiazide-like-diuretic-for-post-stroke-bp-management-more-po": {
          "indication": "Thiazide-like diuretic for post-stroke BP management; more potent and longer-acting than HCTZ; evidence from ALLHAT",
          "doseOptions": [
            {
              "text": "12.5 mg daily",
              "orderSentence": "Chlorthalidone 12.5 mg daily PO"
            },
            {
              "text": "25 mg daily",
              "orderSentence": "Chlorthalidone 25 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg daily; increase to 25 mg if needed; max 25 mg; take in morning",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hyponatremia",
          "Severe hypokalemia",
          "gout",
          "hypokalemia",
          "hyponatremia",
          "sulfonamide allergy (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP (sodium, potassium, creatinine) at 2 weeks and q3-6 months",
          "K+, Na+, uric acid, glucose",
          "glucose",
          "uric acid"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "post-stroke-management",
        "vascular-dementia"
      ]
    },
    "cholecalciferol": {
      "id": "cholecalciferol",
      "name": "Cholecalciferol (Vitamin D3)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "vitamin-d-deficiency-is-prevalent-in-icu-patients-and-contri": {
          "indication": "Vitamin D deficiency is prevalent in ICU patients and contributes to muscle weakness",
          "doseOptions": [
            {
              "text": "2000 IU",
              "orderSentence": "Cholecalciferol (Vitamin D3) 2000 IU PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2000 IU PO daily for maintenance; 50,000 IU PO weekly x 8 weeks if deficient (<20 ng/mL), then 2000 IU daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypercalcemia",
          "granulomatous disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "25-OH vitamin D level at 8-12 weeks",
          "calcium"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "critical-illness-myopathy-neuropathy"
      ]
    },
    "cilostazol": {
      "id": "cilostazol",
      "name": "Cilostazol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "antiplatelet-with-vasodilatory-properties-may-improve-collat": {
          "indication": "Antiplatelet with vasodilatory properties; may improve collateral development; studied in moyamoya as adjunct to aspirin",
          "doseOptions": [
            {
              "text": "50 mg BID",
              "orderSentence": "Cilostazol 50 mg BID PO"
            },
            {
              "text": "100 mg BID",
              "orderSentence": "Cilostazol 100 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg BID; increase to 100 mg BID if tolerated; take 30 min before or 2h after meals",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart failure (PDE3 inhibitor)",
          "hemorrhagic moyamoya"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HR",
          "Headache (common, usually transient)",
          "bleeding signs"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "moyamoya-disease"
      ]
    },
    "cimetidine": {
      "id": "cimetidine",
      "name": "Cimetidine (praziquantel booster)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "inhibits-cyp3a4-metabolism-of-praziquantel-increases-praziqu": {
          "indication": "Inhibits CYP3A4 metabolism of praziquantel; increases praziquantel bioavailability 2-fold; essential when enzyme-inducing AEDs cannot be avoided",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Cimetidine (praziquantel booster) 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400 mg PO TID; start 1-2 days before praziquantel; continue throughout praziquantel course",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment (dose adjust)",
          "drug interactions (inhibits CYP3A4)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Drug interactions",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neurocysticercosis"
      ]
    },
    "cisatracurium": {
      "id": "cisatracurium",
      "name": "Cisatracurium",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-shivering-despite-first-line-measures-during-ttm-": {
          "indication": "Refractory shivering despite first-line measures during TTM; note: obscures clinical exam and must be discontinued well before prognostication",
          "doseOptions": [
            {
              "text": "0.15 mg/kg",
              "orderSentence": "Cisatracurium 0.15 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.15 mg/kg IV bolus, then 1-3 mcg/kg/min infusion; titrate to train-of-four 1-2/4",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Caution in myasthenia gravis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Train-of-four (TOF) q4h",
          "cEEG mandatory when paralyzed (seizures undetectable clinically)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "anoxic-brain-injury"
      ]
    },
    "cisplatin-and-carboplatin": {
      "id": "cisplatin-and-carboplatin",
      "name": "Cisplatin and carboplatin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "dose-dependent-irreversible-cochlear-toxicity-high-frequency": {
          "indication": "Dose-dependent irreversible cochlear toxicity; high-frequency SNHL and tinnitus",
          "doseOptions": [
            {
              "text": "-",
              "orderSentence": "**Cisplatin and carboplatin** - IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Irreversible ototoxicity; no proven otoprotectant; cisplatin more ototoxic than carboplatin",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pre-existing hearing loss (dose modification)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Baseline and serial audiometry during treatment",
          "monitor cumulative dose"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tinnitus-evaluation"
      ]
    },
    "citalopram": {
      "id": "citalopram",
      "name": "Citalopram",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "depression-agitation-in-dementia": {
          "indication": "Depression; agitation in dementia",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Citalopram (Celexa) 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; max 20 mg in elderly due to QT prolongation risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "depression-anxiety-good-tolerability": {
          "indication": "Depression; anxiety; good tolerability",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Citalopram 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; max 20 mg/day due to QTc risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "depression-contributing-to-cognitive-symptoms-pseudodementia": {
          "indication": "Depression contributing to cognitive symptoms (pseudodementia component)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Citalopram 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; max 20 mg in elderly due to QT risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Citalopram (agitation) 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; max 20 mg (QT risk at higher doses)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "depression-anxiety-compulsive-behaviors": {
          "indication": "Depression; anxiety; compulsive behaviors",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Citalopram 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; max 20 mg in elderly due to QT prolongation risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "depression-mild-moderate-agitation": {
          "indication": "Depression; mild-moderate agitation",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Citalopram 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; max 20 mg in elderly due to QT prolongation risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "QTc >500 ms",
          "concurrent QT-prolonging drugs",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG at baseline if cardiac risk",
          "QTc at baseline and if dose >20 mg",
          "QTc if risk factors",
          "QTc monitoring",
          "QTc monitoring if >20 mg",
          "QTc, hyponatremia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "alzheimers-disease",
        "dementia-evaluation",
        "frontotemporal-dementia",
        "huntingtons-disease",
        "mild-cognitive-impairment",
        "vascular-dementia"
      ]
    },
    "cladribine": {
      "id": "cladribine",
      "name": "Cladribine (Mavenclad)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1.75 mg/kg",
              "orderSentence": "Cladribine (Mavenclad) 1.75 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Year 1: 1.75 mg/kg divided into 2 treatment weeks (week 1 and week 5); Year 2: repeat same dosing; no treatment years 3-4",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "CrCl <30",
          "HIV",
          "active malignancy",
          "pregnancy/breastfeeding"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC at months 2 and 6 of each treatment year",
          "lymphopenia expected and desired",
          "screen for malignancy"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ms-new-diagnosis"
      ]
    },
    "clobazam": {
      "id": "clobazam",
      "name": "Clobazam",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-adjunctive-therapy-benzodiazepine-with-less-sedation-tha": {
          "indication": "DRE adjunctive therapy; benzodiazepine with less sedation than clonazepam; approved for Lennox-Gastaut; effective across seizure types",
          "doseOptions": [
            {
              "text": "5 mg daily",
              "orderSentence": "Clobazam (Onfi) 5 mg daily PO"
            },
            {
              "text": "10 mg BID",
              "orderSentence": "Clobazam (Onfi) 10 mg BID PO"
            },
            {
              "text": "20 mg BID",
              "orderSentence": "Clobazam (Onfi) 20 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase by 5 mg/week; target 20-40 mg/day in 2 divided doses; max 40 mg/day; CYP2C19 poor metabolizers need lower doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "adjunctive-for-refractory-seizures": {
          "indication": "Adjunctive for refractory seizures",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Clobazam 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg BID; titrate to 20-40 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "adjunctive-therapy": {
          "indication": "Adjunctive therapy",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Clobazam 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg daily; increase by 5-10 mg weekly; max 40 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Clobazam 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg BID; titrate to 20-40 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment",
          "myasthenia gravis",
          "sleep apnea (untreated)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CYP2C19 poor metabolizers (reduce dose)",
          "CYP2C19 poor metabolizers need lower dose",
          "CYP2C19 status if excessive sedation",
          "Sedation",
          "dependence",
          "reduce dose if taking cenobamate",
          "respiratory depression",
          "tolerance",
          "tolerance (less than other benzodiazepines)",
          "tolerance may develop"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "drug-resistant-epilepsy",
        "hashimotos-encephalopathy",
        "new-onset-seizure"
      ]
    },
    "clomipramine": {
      "id": "clomipramine",
      "name": "Clomipramine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "potent-anticataplectic-agent-tricyclic-antidepressant-with-s": {
          "indication": "Potent anticataplectic agent; tricyclic antidepressant with strong REM-suppressive properties",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Clomipramine 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg at bedtime; titrate by 25 mg every 1-2 weeks; target 25-75 mg/day; max 150 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Recent MI",
          "cardiac conduction disease",
          "concurrent MAOIs",
          "narrow-angle glaucoma",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG if dose >75 mg/day or age >40",
          "anticholinergic effects",
          "orthostatic hypotension",
          "sexual dysfunction",
          "weight gain"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "narcolepsy"
      ]
    },
    "clonazepam": {
      "id": "clonazepam",
      "name": "Clonazepam",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "adjunct-for-chorea-also-helps-myoclonus-and-anxiety": {
          "indication": "Adjunct for chorea; also helps myoclonus and anxiety",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Clonazepam 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg BID; titrate slowly; max 4 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "adjunct-for-dystonia-myoclonus-dystonia": {
          "indication": "Adjunct for dystonia; myoclonus-dystonia",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Clonazepam 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg BID; increase by 0.25-0.5 mg q3-7d; typical 1-4 mg/day; max 6 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "adjunct-for-td-limited-evidence-reduces-choreiform-movements": {
          "indication": "Adjunct for TD; limited evidence; reduces choreiform movements",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Clonazepam 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg BID; titrate slowly; typical 0.5-4 mg/day divided",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        },
        "rem-sleep-behavior-disorder-second-line": {
          "indication": "REM sleep behavior disorder (second-line)",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Clonazepam 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25-0.5 mg qHS; typical 0.5-1 mg; use with caution due to sedation and fall risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "third-line-for-tremor-useful-when-anxiety-is-a-major-contrib": {
          "indication": "Third-line for tremor; useful when anxiety is a major contributing factor; effective for orthostatic tremor",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Clonazepam (Klonopin) 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg BID; titrate by 0.25 mg q3-5d; target 0.5-4 mg/day divided BID-TID; use lowest effective dose",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Clonazepam (Klonopin) 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5 mg TID; titrate to 2-4 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "essential-tremor"
          ]
        },
        "post-anoxic-myoclonus-both-early-status-myoclonus-and-lance-": {
          "indication": "Post-anoxic myoclonus (both early status myoclonus and Lance-Adams syndrome); first-line for myoclonus suppression",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Clonazepam 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg PO BID; titrate by 0.5 mg q3d to effect; max 6 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "adjunct-for-tic-suppression-also-treats-comorbid-anxiety": {
          "indication": "Adjunct for tic suppression; also treats comorbid anxiety",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Clonazepam 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg qHS; increase by 0.25 mg q3-7d; target 0.5-2 mg/day divided BID; max 4 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        },
        "tremor": {
          "indication": "Tremor",
          "doseOptions": [
            {
              "text": "0.25-0.5 mg",
              "orderSentence": "Clonazepam 0.25-0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25-0.5 mg BID; increase by 0.5 mg every 3 days; max 6 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "cerebellar-tremor-myoclonus-in-progressive-myoclonic-ataxia-": {
          "indication": "Cerebellar tremor; myoclonus in progressive myoclonic ataxia; action tremor refractory to other treatments",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Clonazepam 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg BID; increase by 0.25 mg q3-5 days; target 0.5-2 mg/day; max 4 mg/day; use lowest effective dose",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "adjunctive-benzodiazepine-for-myoclonus-especially-perm-vari": {
          "indication": "Adjunctive benzodiazepine for myoclonus (especially PERM variant); nocturnal spasms",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Clonazepam 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg PO BID; increase by 0.5 mg q3-5d; max 6 mg/day; useful for myoclonus in PERM variant",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "opsoclonus-myoclonus-symptom-relief-myoclonus-management": {
          "indication": "Opsoclonus-myoclonus symptom relief; myoclonus management",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Clonazepam 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg BID; titrate by 0.5 mg q3d; max 6 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "myoclonus-most-effective-treatment-for-cjd-associated-myoclo": {
          "indication": "Myoclonus -- most effective treatment for CJD-associated myoclonus; reduces startle response and involuntary jerking",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Clonazepam (first-line for myoclonus) 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg PO BID; increase by 0.5 mg every 3-5 days as tolerated; target 1-2 mg TID; max 6 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "myoclonus-cjd": {
          "indication": "Myoclonus (CJD)",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Clonazepam 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5 mg PO BID; increase to 1-2 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        },
        "second-line-for-downbeat-nystagmus-gabaergic-effect-on-vesti": {
          "indication": "Second-line for downbeat nystagmus; GABAergic effect on vestibular nuclei",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "**Clonazepam** 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Clonazepam 0.5 mg PO BID, titrate to max 1 mg TID**; improves oscillopsia; [Dieterich et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1654396/)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "symptomatic-relief-of-oscillopsia-from-see-saw-nystagmus-lim": {
          "indication": "Symptomatic relief of oscillopsia from see-saw nystagmus; limited evidence; trial basis",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "**Clonazepam** 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Clonazepam 0.5 mg PO BID, titrate to max 1 mg TID**",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "rem-sleep-behavior-disorder-rbd-second-line-if-melatonin-ins": {
          "indication": "REM sleep behavior disorder (RBD) — second-line if melatonin insufficient; highly effective",
          "doseOptions": [
            {
              "text": "0.25 mg QHS",
              "orderSentence": "Clonazepam 0.25 mg QHS PO"
            },
            {
              "text": "0.5 mg QHS",
              "orderSentence": "Clonazepam 0.5 mg QHS PO"
            },
            {
              "text": "1 mg QHS",
              "orderSentence": "Clonazepam 1 mg QHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg at bedtime; titrate to 0.5-1 mg QHS; max 2 mg; use lowest effective dose",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "rem-sleep-behavior-disorder": {
          "indication": "REM sleep behavior disorder",
          "doseOptions": [
            {
              "text": "0.25 mg qHS",
              "orderSentence": "Clonazepam 0.25 mg qHS PO"
            },
            {
              "text": "0.5 mg qHS",
              "orderSentence": "Clonazepam 0.5 mg qHS PO"
            },
            {
              "text": "1 mg qHS",
              "orderSentence": "Clonazepam 1 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25-0.5 mg qHS; titrate to effect; typical 0.5-1 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        },
        "tremor-dystonia-chorea-sleep-disturbance": {
          "indication": "Tremor, dystonia, chorea, sleep disturbance",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Clonazepam 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg BID; titrate by 0.5 mg q3-5 days; max 4 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Respiratory depression",
          "Respiratory depression, severe hepatic disease, addiction risk",
          "Respiratory insufficiency",
          "Same as alprazolam",
          "Sedation",
          "Severe hepatic impairment",
          "Severe respiratory depression",
          "Severe respiratory depression (non-ventilated)",
          "Severe respiratory disease",
          "Severe sleep apnea",
          "Sleep apnea (may worsen — contraindicated if untreated OSA or stridor), severe hepatic impairment, fall risk",
          "acute narrow-angle glaucoma",
          "avoid abrupt discontinuation",
          "cognitive impairment",
          "dementia (relative)",
          "dependency with long-term use",
          "fall risk",
          "fall risk (elderly)",
          "falls in elderly",
          "falls risk",
          "myasthenia gravis",
          "respiratory compromise",
          "respiratory depression",
          "severe hepatic disease",
          "severe hepatic impairment",
          "substance abuse history",
          "substance use disorder",
          "untreated narrow-angle glaucoma"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Respiratory status (CRITICAL — may worsen stridor/sleep apnea), daytime sedation, falls, cognitive worsening",
          "Same",
          "Sedation",
          "Sedation level",
          "Sedation, dependence, fall risk (especially elderly)",
          "Sedation, dependence, falls",
          "Sedation, falls, cognitive effects",
          "Sedation, falls, cognitive worsening",
          "Sedation, respiratory depression, dependence",
          "adjust dose in hepatic impairment",
          "ataxia",
          "avoid abrupt discontinuation",
          "cognitive impairment",
          "dependence",
          "dependence (limit duration)",
          "dependence risk",
          "do NOT discontinue abruptly",
          "do NOT stop abruptly",
          "fall prevention",
          "fall risk",
          "fall risk assessment",
          "falls",
          "falls risk",
          "limit duration",
          "paradoxical agitation (elderly)",
          "respiratory depression",
          "respiratory status",
          "response assessment",
          "swallowing function",
          "swallowing function (may worsen dysphagia)",
          "taper do not stop abruptly",
          "taper if discontinuing",
          "taper slowly if discontinuing (do not stop abruptly)",
          "tolerance"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 19,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "ataxia-evaluation",
        "creutzfeldt-jakob-disease",
        "dystonia",
        "essential-tremor",
        "huntingtons-disease",
        "lewy-body-dementia",
        "ms-new-diagnosis",
        "multiple-system-atrophy",
        "nystagmus-evaluation",
        "paraneoplastic-neurological-syndrome",
        "parkinsons-disease",
        "rapidly-progressive-dementia",
        "stiff-person-syndrome",
        "tardive-dyskinesia",
        "tics-tourette-syndrome",
        "tremor-unspecified",
        "wilsons-disease"
      ]
    },
    "clonidine": {
      "id": "clonidine",
      "name": "Clonidine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "adjunct-may-help-in-some-patients": {
          "indication": "Adjunct; may help in some patients",
          "doseOptions": [
            {
              "text": "0.1 mg",
              "orderSentence": "Clonidine 0.1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mg BID; increase by 0.1 mg q1wk; max 0.6 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "first-line-medication-alpha-2-agonist-for-tics-also-treats-c": {
          "indication": "First-line medication; alpha-2 agonist for tics; also treats comorbid ADHD and insomnia",
          "doseOptions": [
            {
              "text": "0.05 mg",
              "orderSentence": "Clonidine (Catapres) 0.05 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.05 mg qHS; increase by 0.05 mg q3-7d; target 0.1-0.3 mg/day divided BID-QID; max 0.4 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Second- or third-degree heart block",
          "Severe bradycardia",
          "renal impairment (adjust)",
          "severe hypotension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP, HR at each visit",
          "Hypotension, bradycardia, sedation",
          "rebound hypertension if stopped abruptly",
          "sedation, dry mouth",
          "taper over 1-2 weeks"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "dystonia",
        "tics-tourette-syndrome"
      ]
    },
    "clonidine-transdermal-patch": {
      "id": "clonidine-transdermal-patch",
      "name": "Clonidine transdermal patch (Catapres-TTS)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Transdermal"
      ],
      "formulations": [],
      "contexts": {
        "alternative-delivery-improved-compliance-steady-state-levels": {
          "indication": "Alternative delivery; improved compliance; steady-state levels",
          "doseOptions": [
            {
              "text": "0.1 mg/24hr",
              "orderSentence": "Clonidine transdermal patch (Catapres-TTS) 0.1 mg/24hr Transdermal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mg/24hr patch; increase by 0.1 mg q1-2wk; max 0.3 mg/24hr; change patch weekly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Second- or third-degree heart block",
          "skin sensitivity at application site"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP, HR",
          "rotate placement sites",
          "skin irritation at application site"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tics-tourette-syndrome"
      ]
    },
    "clopidogrel": {
      "id": "clopidogrel",
      "name": "Clopidogrel",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-aspirin-if-aspirin-intolerant-or-after-dapt-p": {
          "indication": "Alternative to aspirin if aspirin-intolerant; or after DAPT period",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Clopidogrel 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75 mg daily; may use instead of aspirin if intolerant",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "alternative-antiplatelet-for-aspirin-intolerant-patients-lon": {
          "indication": "Alternative antiplatelet for aspirin-intolerant patients; long-term secondary prevention post-dissection",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Clopidogrel (maintenance) 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75 mg PO daily; duration minimum 3-6 months; if aspirin intolerant, may use long-term",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "alternative-to-aspirin-if-aspirin-intolerant-dapt-with-aspir": {
          "indication": "Alternative to aspirin if aspirin-intolerant; DAPT with aspirin for 21 days after minor stroke/TIA (CHANCE/POINT protocol)",
          "doseOptions": [
            {
              "text": "75 mg daily",
              "orderSentence": "Clopidogrel 75 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75 mg PO daily; 300 mg loading dose for acute minor stroke; DAPT: aspirin 81 mg + clopidogrel 75 mg x 21 days then clopidogrel monotherapy",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Clopidogrel (loading dose for DAPT) 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300 mg PO loading dose (give with aspirin for DAPT). DAPT is standard for high-risk TIA (ABCD2 ≥4) or minor stroke per CHANCE and POINT trials",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "STAT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "transient-ischemic-attack"
          ]
        },
        "alternative-to-aspirin-if-aspirin-intolerant-component-of-da": {
          "indication": "Alternative to aspirin if aspirin-intolerant; component of DAPT for 21 days after minor stroke/TIA per CHANCE/POINT; perioperative use with CEA",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Clopidogrel 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75 mg PO daily; 300 mg loading dose for acute minor stroke; monotherapy if aspirin-intolerant; lifelong antiplatelet required",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "Active pathologic bleeding",
          "CYP2C19 poor metabolizer (reduced efficacy — consider ticagrelor)",
          "CYP2C19 poor metabolizer (reduced efficacy — use ticagrelor)",
          "concurrent anticoagulation",
          "hypersensitivity to clopidogrel",
          "severe hepatic impairment",
          "thrombocytopenia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bleeding",
          "Bleeding signs",
          "CBC",
          "CYP2C19 genotyping if available",
          "bleeding assessment",
          "bruising",
          "hold 5-7 days before CEA if on DAPT",
          "platelet function testing rarely needed"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "carotid-stenosis",
        "cervical-artery-dissection",
        "post-stroke-management",
        "transient-ischemic-attack",
        "vascular-dementia"
      ]
    },
    "clozapine": {
      "id": "clozapine",
      "name": "Clozapine (Clozaril)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "antipsychotic-with-lowest-eps-risk-for-treatment-refractory-": {
          "indication": "Antipsychotic with lowest EPS risk; for treatment-refractory psychosis requiring continued antipsychotic",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Clozapine (Clozaril) 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg daily; titrate by 25-50 mg/day q1-2wk; usual range 150-450 mg/day; max 900 mg/day; requires Clozapine REMS enrollment",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        },
        "refractory-psychosis-best-evidence-but-monitoring-required": {
          "indication": "Refractory psychosis; best evidence but monitoring required",
          "doseOptions": [
            {
              "text": "6.25 mg qHS",
              "orderSentence": "Clozapine 6.25 mg qHS PO"
            },
            {
              "text": "12.5 mg qHS",
              "orderSentence": "Clozapine 12.5 mg qHS PO"
            },
            {
              "text": "25 mg qHS",
              "orderSentence": "Clozapine 25 mg qHS PO"
            },
            {
              "text": "50 mg qHS",
              "orderSentence": "Clozapine 50 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 6.25-12.5 mg qHS; titrate by 12.5 mg q1-2wk; max 50-100 mg/day in PD",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Prior agranulocytosis",
          "REMS enrollment required",
          "ileus",
          "severe cardiac disease",
          "severe neutropenia (ANC <500)",
          "uncontrolled seizures"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ANC weekly x 6 mo, then q2wk x 6 mo, then monthly",
          "ANC weekly x 6 months, then biweekly x 6 months, then monthly",
          "REMS program required (Clozapine REMS)",
          "agranulocytosis risk",
          "metabolic panel, weight, glucose, lipids",
          "myocarditis (first month)",
          "seizure risk (dose-dependent)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "drug-induced-parkinsonism",
        "parkinsons-disease"
      ]
    },
    "coenzyme-q10": {
      "id": "coenzyme-q10",
      "name": "Coenzyme Q10 (CoQ10)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "mitochondrial-support-investigational-in-psp-negative-phase-": {
          "indication": "Mitochondrial support; investigational in PSP; negative phase III trial but still used by some patients",
          "doseOptions": [
            {
              "text": "600 mg",
              "orderSentence": "Coenzyme Q10 (ubiquinone) 600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600-1200 mg daily in divided doses with fatty food for absorption; no proven efficacy in PSP (QE3 trial negative)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "coq10-deficiency-primary-cerebellar-ataxia-responsive-to-sup": {
          "indication": "CoQ10 deficiency (primary cerebellar ataxia responsive to supplementation); may benefit some mitochondrial ataxias",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Coenzyme Q10 (CoQ10) 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg BID; increase to 600 mg BID if tolerated and deficiency confirmed; take with fatty meal for absorption; may take months for improvement",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "adjunctive-preventive-level-c-evidence-nutraceutical": {
          "indication": "Adjunctive preventive; Level C evidence; nutraceutical",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Coenzyme Q10 (CoQ10) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO TID (300 mg/day total); may take 3 months for full effect",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "supplement-mitochondrial-support": {
          "indication": "Supplement; mitochondrial support",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Coenzyme Q10 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-300 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Caution with warfarin (may reduce INR)",
          "None",
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Clinical ataxia scores",
          "CoQ10 levels if available",
          "GI tolerance",
          "GI upset",
          "None",
          "may reduce warfarin effect",
          "monitor INR if on warfarin",
          "no proven benefit",
          "well-tolerated"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "ataxia-evaluation",
        "chronic-migraine",
        "migraine-with-aura",
        "progressive-supranuclear-palsy"
      ]
    },
    "colchicine": {
      "id": "colchicine",
      "name": "Colchicine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "recurrent-oral-genital-ulcers-mucocutaneous-behcet-s-manifes": {
          "indication": "Recurrent oral/genital ulcers; mucocutaneous Behcet's manifestations (adjunct to CNS treatment)",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Colchicine 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5 mg PO BID; adjust for renal/hepatic impairment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "residual-inflammatory-risk-lodoco2-colcot-trials-support-in-": {
          "indication": "Residual inflammatory risk (LoDoCo2 / COLCOT trials support in ACS — emerging data for stroke prevention)",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Colchicine 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5 mg PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "transient-ischemic-attack"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe renal impairment",
          "bone marrow suppression",
          "concurrent strong CYP3A4 inhibitors"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "GI side effects (diarrhea)",
          "GI symptoms",
          "LFTs",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "neuro-behcets-disease",
        "transient-ischemic-attack"
      ]
    },
    "combination-therapy": {
      "id": "combination-therapy",
      "name": "Combination therapy",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Various"
      ],
      "formulations": [],
      "contexts": {
        "inadequate-response-to-monotherapy": {
          "indication": "Inadequate response to monotherapy",
          "doseOptions": [
            {
              "text": "Per regimen",
              "orderSentence": "Combination therapy Per regimen Various"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Gabapentinoid + SNRI; TCA + gabapentinoid; use lower doses of each",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per individual agents"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Additive side effects",
          "falls in elderly"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "small-fiber-neuropathy"
      ]
    },
    "combination-therapy-for-anti-mda5-ild-methylprednisolone-tacrolimus-cyclophosphamide": {
      "id": "combination-therapy-for-anti-mda5-ild-methylprednisolone-tacrolimus-cyclophosphamide",
      "name": "Combination therapy for anti-MDA5 ILD: Methylprednisolone + Tacrolimus + Cyclophosphamide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "rapidly-progressive-ild-with-anti-mda5-antibody-tsuji-triple": {
          "indication": "Rapidly progressive ILD with anti-MDA5 antibody (Tsuji triple-therapy protocol; high mortality without aggressive treatment)",
          "doseOptions": [
            {
              "text": "Methylpred 1000 mg IV x 3d + tacrolimus 1 mg BID + CYC 500-750 mg/m2",
              "orderSentence": "Combination therapy for anti-MDA5 ILD: Methylprednisolone + Tacrolimus + Cyclophosphamide Methylpred 1000 mg IV x 3d + tacrolimus 1 mg BID + CYC 500-750 mg/m2 IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Pulse methylprednisolone 1000 mg IV x 3 days then prednisone 1 mg/kg + tacrolimus (trough 5-10 ng/mL) + IV cyclophosphamide 500-750 mg/m2 monthly; early combination improves survival",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active untreated infection",
          "bone marrow suppression",
          "hemorrhagic cystitis",
          "pregnancy",
          "renal impairment",
          "uncontrolled diabetes",
          "uncontrolled hypertension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "CBC weekly",
          "Glucose q6h during pulse steroids",
          "combined immunosuppression toxicity",
          "electrolytes",
          "infection prophylaxis critical",
          "renal function",
          "tacrolimus trough q1-2 weeks",
          "urinalysis (hemorrhagic cystitis)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "inflammatory-myopathy"
      ]
    },
    "combined-plex-ivig": {
      "id": "combined-plex-ivig",
      "name": "Combined PLEX + IVIG (sequential)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Extracorporeal/IV"
      ],
      "formulations": [],
      "contexts": {
        "severe-refractory-attack-not-responding-to-steroids-alone-se": {
          "indication": "Severe refractory attack not responding to steroids alone; sequential approach: PLEX first, then IVIG (PLEX removes IVIG, so give IVIG after PLEX completion)",
          "doseOptions": [
            {
              "text": "PLEX x 5-7 exchanges then IVIG 0.4 g/kg x 5 days",
              "orderSentence": "Combined PLEX + IVIG (sequential) PLEX x 5-7 exchanges then IVIG 0.4 g/kg x 5 days Extracorporeal/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "PLEX x 5-7 exchanges, then IVIG 0.4 g/kg/day x 5 days starting at least 24 hours after final PLEX exchange",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "mogad"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hemodynamic instability",
          "IgA deficiency",
          "coagulopathy",
          "renal failure",
          "sepsis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP during PLEX",
          "coagulation",
          "coordinate timing carefully",
          "electrolytes",
          "renal function during IVIG"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "mogad"
      ]
    },
    "comfort-focused-care-palliative-care": {
      "id": "comfort-focused-care-palliative-care",
      "name": "Comfort-focused care / Palliative care",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2-5 mg",
              "orderSentence": "**Comfort-focused care / Palliative care** 2-5 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If patient declines intubation or chronic mechanical ventilation; opioids for dyspnea (morphine 2-5 mg IV/SQ q2-4h PRN — does NOT hasten death and relieves suffering); anxiolytics (lorazepam); comfort measures; hospice referral",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "neuromuscular-respiratory-failure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dyspnea is the most distressing symptom at end of life",
          "do not withhold for fear of \"hastening death\"",
          "opioids are safe and effective"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neuromuscular-respiratory-failure"
      ]
    },
    "comprehensive-behavioral-intervention-for-tics": {
      "id": "comprehensive-behavioral-intervention-for-tics",
      "name": "Comprehensive Behavioral Intervention for Tics (CBIT) (CPT 90834-90837)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "In-person/telehealth"
      ],
      "formulations": [],
      "contexts": {
        "first-line-for-all-tic-disorders-causing-functional-impairme": {
          "indication": "First-line for all tic disorders causing functional impairment; AAN Level A recommendation",
          "doseOptions": [
            {
              "text": "8 sessions",
              "orderSentence": "Comprehensive Behavioral Intervention for Tics (CBIT) (CPT 90834-90837) 8 sessions In-person"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8 sessions over 10 weeks; includes psychoeducation, habit reversal training (awareness training + competing response), relaxation techniques, and function-based assessment",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe cognitive impairment preventing participation",
          "active psychosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "YGTSS score at baseline and after completion",
          "functional improvement",
          "patient engagement"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tics-tourette-syndrome"
      ]
    },
    "continuous-epidural-saline-infusion": {
      "id": "continuous-epidural-saline-infusion",
      "name": "Continuous epidural saline infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Epidural"
      ],
      "formulations": [],
      "contexts": {
        "bridge-therapy-while-awaiting-definitive-treatment-refractor": {
          "indication": "Bridge therapy while awaiting definitive treatment; refractory symptoms",
          "doseOptions": [
            {
              "text": "NS at 20-50 mL/hr",
              "orderSentence": "Continuous epidural saline infusion NS at 20-50 mL/hr Epidural"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Continuous epidural normal saline infusion at 20-50 mL/hr via epidural catheter; temporary measure for severe refractory symptoms",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Epidural infection, coagulopathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Catheter site infection, neurologic exam, headache response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "low-pressure-headache"
      ]
    },
    "copper-iud": {
      "id": "copper-iud",
      "name": "Copper IUD (Paragard)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IUD"
      ],
      "formulations": [],
      "contexts": {
        "non-hormonal-contraception-alternative-when-hormonal-methods": {
          "indication": "Non-hormonal contraception; alternative when hormonal methods not desired; NOT affected by ASMs",
          "doseOptions": [
            {
              "text": "N/A — device placement",
              "orderSentence": "Copper IUD (Paragard) N/A — device placement IUD"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Place copper IUD; completely unaffected by ASM interactions; non-hormonal option",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as hormonal IUD",
          "heavier menses"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epilepsy-chronic-management"
      ]
    },
    "copper-supplementation": {
      "id": "copper-supplementation",
      "name": "Copper supplementation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO/IV"
      ],
      "formulations": [],
      "contexts": {
        "copper-deficiency-myelopathy-and-ataxia-zinc-excess-bariatri": {
          "indication": "Copper deficiency myelopathy and ataxia (zinc excess, bariatric surgery, malabsorption)",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Copper supplementation 2 mg PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Acute: 2 mg IV daily x 5 days; Maintenance: 2 mg PO daily; remove cause (e.g., stop excess zinc)",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Wilson disease (must be excluded before copper supplementation)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC (copper deficiency causes anemia, neutropenia)",
          "Serum copper and ceruloplasmin q3 months",
          "neurologic exam",
          "zinc levels"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ataxia-evaluation"
      ]
    },
    "coq10": {
      "id": "coq10",
      "name": "CoQ10",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "CoQ10 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "None"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine"
      ]
    },
    "correct-electrolyte-abnormalities": {
      "id": "correct-electrolyte-abnormalities",
      "name": "Correct electrolyte abnormalities",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "hyponatremia-hypomagnesemia-hypocalcemia-causing-nystagmus": {
          "indication": "Hyponatremia, hypomagnesemia, hypocalcemia causing nystagmus",
          "doseOptions": [
            {
              "text": "Per specific electrolyte",
              "orderSentence": "**Correct electrolyte abnormalities** Per specific electrolyte IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Hyponatremia:** Correct slowly (max 8-10 mEq/L per 24h to avoid osmotic demyelination); **Hypomagnesemia:** MgSO4 2-4 g IV over 30-60 min then maintenance; **Hypocalcemia:** Calcium gluconate 1-2 g IV",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Overcorrection of sodium — osmotic demyelination syndrome"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Electrolytes q4-6h during correction",
          "neurologic reassessment after correction"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "nystagmus-evaluation"
      ]
    },
    "correction-of-metabolic-derangements": {
      "id": "correction-of-metabolic-derangements",
      "name": "Correction of metabolic derangements",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "exclude-metabolic-confounders-sodium-glucose-ph-calcium-must": {
          "indication": "Exclude metabolic confounders; sodium, glucose, pH, calcium must be within acceptable ranges",
          "doseOptions": [
            {
              "text": "Per derangement",
              "orderSentence": "**Correction of metabolic derangements** Per derangement IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Correct sodium to 115-160 mEq/L range; glucose >54 mg/dL (D50 50 mL if needed); correct severe acidosis (NaHCO3 if pH <7.2); correct severe hypocalcemia (calcium gluconate 1-2 g IV); correct hypothyroidism",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Overly rapid sodium correction (risk of osmotic demyelination — less relevant in brain death but important for organ preservation)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ABG q4h",
          "Serial electrolytes q2-4h",
          "glucose q1-2h",
          "target physiologic ranges"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-death-evaluation"
      ]
    },
    "corticosteroid-minimization": {
      "id": "corticosteroid-minimization",
      "name": "Corticosteroid minimization",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "minimize-corticosteroid-exposure-as-major-risk-factor-for-ci": {
          "indication": "Minimize corticosteroid exposure as major risk factor for CIM; taper to lowest effective dose as rapidly as clinically feasible",
          "doseOptions": [
            {
              "text": "Individualized taper",
              "orderSentence": "Corticosteroid minimization Individualized taper IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Reassess corticosteroid indication daily; taper to lowest effective dose; discontinue if not clearly indicated; avoid concurrent use with NMBAs when possible",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Do not abruptly discontinue if patient has been on >7 days (adrenal suppression risk)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose (steroid-induced hyperglycemia)",
          "adrenal function if tapering after prolonged course",
          "blood pressure"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "critical-illness-myopathy-neuropathy"
      ]
    },
    "corticosteroids": {
      "id": "corticosteroids",
      "name": "Corticosteroids (delayed initiation)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "**Corticosteroids (delayed initiation)** 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**CAUTION: Steroids can cause TRANSIENT WORSENING in MG (up to 50% of patients)**; **In crisis:** Start AFTER IVIG/PLEX initiated and patient stabilizing (days 3-5 or later); do NOT start steroids as initial therapy in crisis; **Protocol:** Prednisone 10-20 mg daily, increase by 10 mg every 3-5 days to 1 mg/kg/day (max 60-80 mg); OR IV methylprednisolone 1g daily x 3-5 days then oral",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "neuromuscular-respiratory-failure",
            "cidp"
          ]
        },
        "adjunctive-anti-inflammatory-therapy-for-ocular-syphilis-uve": {
          "indication": "Adjunctive anti-inflammatory therapy for ocular syphilis (uveitis, optic neuritis, retinal vasculitis) or otic syphilis to prevent permanent vision/hearing loss; used in addition to IV penicillin, not as standalone",
          "doseOptions": [
            {
              "text": "1 mg/kg daily",
              "orderSentence": "Corticosteroids (adjunctive for ocular/otic syphilis) 1 mg/kg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Prednisone 1 mg/kg/day PO (max 60 mg) with IV penicillin; taper over 2-4 weeks based on ophthalmology/ENT guidance; or IV methylprednisolone 250 mg q6h x 3 days then oral taper for severe cases",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Uncontrolled DM, active infection, osteoporosis (relative)",
          "Uncontrolled diabetes",
          "active GI bleed",
          "psychosis (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "GI prophylaxis",
          "Glucose",
          "Glucose, BP, bone density, weight, infection",
          "Steroids are maintenance therapy but can worsen MG acutely (\"steroid dip\")",
          "always start with IVIG or PLEX first in crisis",
          "ophtho/ENT follow-up",
          "steroid-sparing agents (azathioprine, mycophenolate) for long-term"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "cidp",
        "neuromuscular-respiratory-failure",
        "neurosyphilis"
      ]
    },
    "creatine-monohydrate": {
      "id": "creatine-monohydrate",
      "name": "Creatine monohydrate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "modest-improvement-in-muscle-strength-and-endurance-in-ibm-l": {
          "indication": "Modest improvement in muscle strength and endurance in IBM (limited evidence); well-tolerated nutritional supplement",
          "doseOptions": [
            {
              "text": "5 g",
              "orderSentence": "Creatine monohydrate 5 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 g PO daily mixed in water or juice; no loading phase needed; take with meal",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe renal impairment (relative, monitor)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function at baseline and q6 months",
          "serum creatinine (will be mildly elevated from supplement, not nephrotoxicity)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "inclusion-body-myositis"
      ]
    },
    "cyanocobalamin-im": {
      "id": "cyanocobalamin-im",
      "name": "Cyanocobalamin IM",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "confirmed-or-suspected-b12-deficiency-with-neurological-symp": {
          "indication": "Confirmed or suspected B12 deficiency with neurological symptoms; preferred parenteral route",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "Cyanocobalamin IM 1000 mcg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mcg IM daily x 7 days, then 1000 mcg IM weekly x 4 weeks, then 1000 mcg IM monthly indefinitely",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cobalt or cobalamin hypersensitivity (rare)",
          "Leber hereditary optic neuropathy (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 and MMA at 1-2 months",
          "CBC at 1-2 months",
          "Reticulocyte count at day 5-7 (reticulocyte crisis confirms response)",
          "potassium during first 48 hours (hypokalemia from erythropoiesis)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "b12-deficiency-neuropathy"
      ]
    },
    "cyanocobalamin-sc": {
      "id": "cyanocobalamin-sc",
      "name": "Cyanocobalamin SC",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "if-im-injection-contraindicated-anticoagulation-thrombocytop": {
          "indication": "If IM injection contraindicated (anticoagulation, thrombocytopenia) or patient preference",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "Cyanocobalamin SC 1000 mcg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mcg SC daily x 7 days, then 1000 mcg SC weekly x 4 weeks, then 1000 mcg SC monthly indefinitely",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cobalt or cobalamin hypersensitivity (rare)",
          "Leber hereditary optic neuropathy (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 and MMA at 1-2 months",
          "CBC at 1-2 months",
          "Reticulocyte count at day 5-7",
          "potassium during first 48 hours (hypokalemia from erythropoiesis)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "b12-deficiency-neuropathy"
      ]
    },
    "cyclobenzaprine": {
      "id": "cyclobenzaprine",
      "name": "Cyclobenzaprine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "muscle-spasm-short-term": {
          "indication": "Muscle spasm (short-term)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Cyclobenzaprine 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg TID; max 30 mg/day; limit to 2-3 weeks",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "cervical-muscle-spasm-and-neck-pain-short-term-adjunctive-us": {
          "indication": "Cervical muscle spasm and neck pain; short-term adjunctive use for acute exacerbation",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Cyclobenzaprine 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO TID; limit to 2-3 weeks; avoid in elderly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "muscle-spasm-associated-with-plexopathy-short-term": {
          "indication": "Muscle spasm associated with plexopathy (short-term)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Cyclobenzaprine 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg TID; max 30 mg/day; limit to 2-3 weeks",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Arrhythmia",
          "Concurrent MAOIs",
          "MAOIs within 14 days",
          "cardiac arrhythmia",
          "elderly (anticholinergic burden)",
          "heart failure",
          "hyperthyroidism"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation",
          "anticholinergic effects",
          "dry mouth",
          "falls risk in elderly",
          "urinary retention"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "cervical-myelopathy",
        "plexopathy",
        "radiculopathy"
      ]
    },
    "cyclophosphamide": {
      "id": "cyclophosphamide",
      "name": "Cyclophosphamide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "severe-refractory-parenchymal-nbd-with-progressive-neurologi": {
          "indication": "Severe/refractory parenchymal NBD with progressive neurological decline; brainstem syndrome not responding to steroids + azathioprine",
          "doseOptions": [
            {
              "text": "750 mg/m2",
              "orderSentence": "Cyclophosphamide (CPT 96365) 750 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "750 mg/m2 IV monthly for 6 cycles; pre-hydrate with 1L NS; administer with MESNA for uroprotection; follow with azathioprine maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "rapidly-progressive-ild-especially-anti-mda5-severe-refracto": {
          "indication": "Rapidly progressive ILD (especially anti-MDA5); severe refractory myositis; anti-synthetase syndrome with progressive ILD",
          "doseOptions": [
            {
              "text": "500-1000 mg/m2",
              "orderSentence": "Cyclophosphamide (CPT 96365) 500-1000 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "IV pulse: 500-1000 mg/m2 monthly x 6 months; OR low-dose Euro-Lupus protocol: 500 mg IV every 2 weeks x 6 doses; MESNA prophylaxis with each dose",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "EXT",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500-1000 mg",
              "orderSentence": "Cyclophosphamide 500-1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Pulse: 500-1000 mg/m² IV monthly × 6; rarely used due to toxicity",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "cidp",
            "status-epilepticus",
            "rapidly-progressive-dementia",
            "myasthenia-gravis-new-diagnosis",
            "autoimmune-encephalitis"
          ]
        },
        "severe-refractory-he-failing-all-other-agents": {
          "indication": "Severe refractory HE failing all other agents",
          "doseOptions": [
            {
              "text": "750 mg/m2",
              "orderSentence": "Cyclophosphamide (CPT 96365) 750 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "750 mg/m2 IV monthly x 6 cycles; pre-hydrate with 1L NS; administer with MESNA (uroprotection)",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "severe-refractory-neurosarcoidosis-with-progressive-neurolog": {
          "indication": "Severe refractory neurosarcoidosis with progressive neurological decline despite other therapies; last resort",
          "doseOptions": [
            {
              "text": "750 mg/m2",
              "orderSentence": "Cyclophosphamide 750 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "750 mg/m2 IV monthly for 6 cycles; pre-hydrate with 1L NS; administer with MESNA for uroprotection; consider dose reduction for renal impairment",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "severe-refractory-attack-failing-steroids-and-plex": {
          "indication": "Severe refractory attack failing steroids and PLEX",
          "doseOptions": [
            {
              "text": "750 mg/m2",
              "orderSentence": "Cyclophosphamide (refractory acute attack) 750 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "750 mg/m2 IV single pulse; pre-hydrate with 1L NS; administer with MESNA",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "vasculitic-neuropathy-severe": {
          "indication": "Vasculitic neuropathy (severe)",
          "doseOptions": [
            {
              "text": "1-2 mg/kg",
              "orderSentence": "Cyclophosphamide 1-2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg/kg/day PO OR 500-1000 mg/mÃ‚Â² IV monthly Ãƒâ€” 6 months",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "severe-refractory-lems-not-responding-to-other-immunosuppres": {
          "indication": "Severe refractory LEMS not responding to other immunosuppressants; reserved for life-threatening or disabling disease",
          "doseOptions": [
            {
              "text": "500-1000 mg/m2",
              "orderSentence": "Cyclophosphamide 500-1000 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Pulse IV 500-1000 mg/m2 monthly x 6 months; OR oral 1-2 mg/kg/day; reserved for refractory cases; MESNA uroprotection with IV dosing",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "severe-refractory-sps-failing-ivig-rituximab-and-other-agent": {
          "indication": "Severe refractory SPS failing IVIg, rituximab, and other agents; last resort",
          "doseOptions": [
            {
              "text": "750 mg/m2",
              "orderSentence": "Cyclophosphamide 750 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "750 mg/m2 IV monthly for 6 cycles; pre-hydrate with 1L NS; administer with MESNA for uroprotection; adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "second-line-immunotherapy-for-refractory-paraneoplastic-synd": {
          "indication": "Second-line immunotherapy for refractory paraneoplastic syndrome; used for intracellular antibody syndromes unresponsive to first-line",
          "doseOptions": [
            {
              "text": "750 mg/m2",
              "orderSentence": "Cyclophosphamide 750 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "750 mg/m2 IV monthly x 6 cycles; pre-hydrate with 1L NS; administer with MESNA (uroprotection)",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy",
          "Pregnancy (Category D)",
          "Severe cytopenias, active infection",
          "active infection",
          "bladder outlet obstruction",
          "bone marrow failure",
          "bone marrow suppression",
          "hemorrhagic cystitis",
          "hemorrhagic cystitis history"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP",
          "CBC (nadir at 10-14 days)",
          "CBC weekly",
          "CBC weekly during treatment",
          "CBC weekly x 4 weeks (nadir day 10-14)",
          "CBC weekly x 4 weeks after each cycle (nadir day 10-14)",
          "CBC weekly, renal function, hemorrhagic cystitis (hydration + mesna)",
          "CBC, renal function, bladder toxicity",
          "LFTs",
          "MESNA with IV dosing",
          "UA (hemorrhagic cystitis)",
          "aggressive hydration",
          "cumulative dose limit",
          "fertility counseling",
          "fertility preservation discussion",
          "hemorrhagic cystitis prevention",
          "malignancy risk",
          "malignancy risk (bladder cancer)",
          "urinalysis",
          "urinalysis (hemorrhagic cystitis - MESNA with IV dosing)",
          "urinalysis (hemorrhagic cystitis — give MESNA)",
          "urinalysis (hemorrhagic cystitis)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 14,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "cidp",
        "hashimotos-encephalopathy",
        "inflammatory-myopathy",
        "lambert-eaton-syndrome",
        "myasthenia-gravis-new-diagnosis",
        "neuro-behcets-disease",
        "neurosarcoidosis",
        "nmosd",
        "paraneoplastic-neurological-syndrome",
        "peripheral-neuropathy",
        "rapidly-progressive-dementia",
        "status-epilepticus",
        "stiff-person-syndrome"
      ]
    },
    "cyclophosphamide-iv": {
      "id": "cyclophosphamide-iv",
      "name": "Cyclophosphamide IV (induction)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "standard-induction-therapy-for-biopsy-confirmed-pacns-combin": {
          "indication": "Standard induction therapy for biopsy-confirmed PACNS combined with corticosteroids; most evidence-based regimen per Calabrese/Mallek criteria",
          "doseOptions": [
            {
              "text": "750 mg/m2 monthly x 3-6 months",
              "orderSentence": "Cyclophosphamide IV (induction) 750 mg/m2 monthly x 3-6 months IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "750 mg/m2 IV monthly x 3-6 months (typical 6 cycles); pre-hydrate with 1L NS; administer with MESNA for uroprotection; reduce dose for age >65, renal impairment, leukopenia",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "severe-refractory-susac-syndrome-failing-ivig-steroids-and-o": {
          "indication": "Severe refractory Susac syndrome failing IVIG, steroids, and other immunosuppressants; fulminant disease with rapid progression",
          "doseOptions": [
            {
              "text": "750 mg/m2 monthly",
              "orderSentence": "Cyclophosphamide IV (CPT 96365) 750 mg/m2 monthly IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "750 mg/m2 IV monthly x 3-6 months; pre-hydrate with 1L NS; administer with MESNA for uroprotection; used in severe/refractory cases only",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy",
          "active infection",
          "bladder outlet obstruction",
          "bone marrow failure",
          "hemorrhagic cystitis",
          "prior hemorrhagic cystitis",
          "severe leukopenia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP",
          "CBC weekly x 4 weeks after each cycle (nadir day 10-14)",
          "LFTs",
          "MESNA + hydration for uroprotection",
          "cumulative dose tracking (lifetime max ~36g concern for malignancy)",
          "fertility assessment",
          "hemorrhagic cystitis prevention (MESNA + hydration)",
          "urinalysis each cycle"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "cns-vasculitis",
        "susac-syndrome"
      ]
    },
    "cyclophosphamide-po": {
      "id": "cyclophosphamide-po",
      "name": "Cyclophosphamide PO (alternative induction)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-iv-pulse-dosing-some-clinicians-prefer-daily-": {
          "indication": "Alternative to IV pulse dosing; some clinicians prefer daily oral for severe/refractory disease",
          "doseOptions": [
            {
              "text": "2 mg/kg daily",
              "orderSentence": "Cyclophosphamide PO (alternative induction) 2 mg/kg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 mg/kg/day PO (max 200 mg/day); round to nearest 25 mg; duration 3-6 months then transition to maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as IV cyclophosphamide",
          "higher cumulative toxicity risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC with differential weekly x 1 month, then q2 weeks",
          "adjust dose for WBC nadir 3000-4000",
          "higher risk of bladder toxicity than IV pulse",
          "urinalysis monthly"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cns-vasculitis"
      ]
    },
    "cycloserine": {
      "id": "cycloserine",
      "name": "Cycloserine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "drug-resistant-tb-mdr-xdr-tb-cns-penetration-adequate-freque": {
          "indication": "Drug-resistant TB (MDR/XDR-TB); CNS penetration adequate; frequent neuropsychiatric side effects",
          "doseOptions": [
            {
              "text": "250-500 mg",
              "orderSentence": "Cycloserine 250-500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250 mg PO BID initially, increase to 500 mg BID; max 1000 mg/day; take with pyridoxine 50-100 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Seizure disorder (lowers seizure threshold)",
          "psychosis",
          "renal impairment",
          "severe depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Psychiatric symptoms (depression, psychosis, suicidality)",
          "pyridoxine supplementation mandatory",
          "renal function",
          "seizures"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tb-meningitis"
      ]
    },
    "cyclosporine": {
      "id": "cyclosporine",
      "name": "Cyclosporine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2-3 mg/kg",
              "orderSentence": "Cyclosporine 2-3 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2-3 mg/kg/day PO in 2 divided doses; target trough 100-200 ng/mL; onset 3-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "cidp",
            "myasthenia-gravis-new-diagnosis"
          ]
        },
        "refractory-ocular-and-neurological-behcet-s-often-combined-w": {
          "indication": "Refractory ocular and neurological Behcet's; often combined with azathioprine; effective for uveitis; **CAUTION: use with concurrent azathioprine only -- monotherapy worsens CNS disease**",
          "doseOptions": [
            {
              "text": "3 mg/kg",
              "orderSentence": "Cyclosporine 3 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3-5 mg/kg/day in 2 divided doses; adjust per trough level (target 100-200 ng/mL)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "alternative-to-tacrolimus-similar-efficacy": {
          "indication": "Alternative to tacrolimus; similar efficacy",
          "doseOptions": [
            {
              "text": "3 mg/kg",
              "orderSentence": "Cyclosporine 3 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg/kg/day divided BID; adjust to trough 100-200 ng/mL",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "alternative-steroid-sparing-agent-for-a-lems-faster-onset-th": {
          "indication": "Alternative steroid-sparing agent for A-LEMS; faster onset than azathioprine (2-6 months)",
          "doseOptions": [
            {
              "text": "2-3 mg/kg/day",
              "orderSentence": "Cyclosporine (Sandimmune/Neoral) 2-3 mg/kg/day PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2-3 mg/kg/day divided BID; target trough 100-150 ng/mL; onset 2-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal failure, uncontrolled HTN, malignancy",
          "Renal impairment",
          "Renal impairment, uncontrolled HTN",
          "Uncontrolled hypertension",
          "active infection",
          "concurrent nephrotoxic drugs",
          "concurrent nephrotoxins",
          "renal impairment",
          "uncontrolled hypertension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP q visit",
          "Cyclosporine trough levels",
          "Cyclosporine trough monthly",
          "K",
          "Mg",
          "Renal function, BP, drug levels",
          "Trough levels",
          "Trough levels, Cr, BP, Mg, lipids monthly",
          "electrolytes (K, Mg)",
          "gingival hyperplasia",
          "hirsutism",
          "lipids",
          "renal function",
          "renal function (Cr) q2 weeks",
          "renal function monthly",
          "renal function q2 weeks then monthly",
          "uric acid"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "cidp",
        "lambert-eaton-syndrome",
        "myasthenia-gravis",
        "myasthenia-gravis-crisis",
        "myasthenia-gravis-new-diagnosis",
        "neuro-behcets-disease"
      ]
    },
    "cytarabine": {
      "id": "cytarabine",
      "name": "Cytarabine (high-dose, MATRix regimen component)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "component-of-matrix-regimen-mtx-ara-c-thiotepa-rituximab-hig": {
          "indication": "Component of MATRix regimen (MTX, Ara-C, Thiotepa, Rituximab); high-dose achieves therapeutic CSF levels; consolidation in younger patients",
          "doseOptions": [
            {
              "text": "2 g/m2",
              "orderSentence": "Cytarabine (high-dose, MATRix regimen component) 2 g/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g/m2 IV over 3h q12h on Days 2-3 (4 doses total per cycle); corticosteroid eye drops (dexamethasone 0.1% q6h) starting 12h before and continuing 48h after to prevent chemical conjunctivitis; cerebellar function assessment before each dose",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CBC",
          "Cerebellar exam before each dose (finger-to-nose, rapid alternating movements, tandem gait)",
          "LFTs",
          "if ANY cerebellar signs develop, STOP immediately (irreversible)",
          "ophtho eye drops compliance",
          "renal function"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "d-penicillamine": {
      "id": "d-penicillamine",
      "name": "D-penicillamine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "wilson-s-disease-with-neurological-symptoms": {
          "indication": "Wilson's disease with neurological symptoms",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "D-penicillamine 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg daily; increase by 250 mg q4-7d; target 1000-1500 mg/day divided BID (take 1hr before meals); lifelong treatment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "wilson-disease-confirmed-first-line-copper-chelation-therapy": {
          "indication": "Wilson disease confirmed; first-line copper chelation therapy",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "D-Penicillamine 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg daily; increase by 250 mg q4-7d to target 1000-1500 mg/day divided QID; take on empty stomach 1 hour before meals; pyridoxine 25 mg daily supplementation required",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "first-line-chelation-symptomatic-wd-hepatic-or-neurologic-re": {
          "indication": "First-line chelation (symptomatic WD — hepatic or neurologic); removes copper via renal excretion",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "D-Penicillamine (Cuprimine) 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250-500 mg/day; increase by 250 mg every 4-7 days; target 1000-1500 mg/day divided BID-QID; take on empty stomach (1h before or 2h after meals); SLOW titration reduces neurologic worsening risk",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Penicillin allergy (may cross-react)",
          "Penicillin allergy (not absolute but caution)",
          "Penicillin allergy (relative)",
          "blood dyscrasias",
          "lupus-like syndrome",
          "lupus-like syndrome history",
          "nephrotoxicity",
          "pregnancy (teratogenic — switch to zinc)",
          "prior severe adverse reaction",
          "renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "24-hour urine copper",
          "24h urine copper q3-6 months (target 200-500 mcg/24h on treatment)",
          "CBC q2 weeks for first 3 months then monthly",
          "CBC weekly x1 month then monthly x6 months then q3 months",
          "CBC weekly x1mo then monthly x6mo then q3mo",
          "LFTs monthly",
          "UA for proteinuria every 2 weeks x3 months then monthly",
          "hepatologist co-management",
          "neurologic monitoring for initial worsening (up to 50% of patients)",
          "neurologic worsening first 6 months possible",
          "urinalysis (proteinuria)",
          "urinalysis monthly",
          "watch for neurologic WORSENING in first 6-8 weeks (occurs in 10-50%)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "dystonia",
        "tremor-unspecified",
        "wilsons-disease"
      ]
    },
    "dabigatran": {
      "id": "dabigatran",
      "name": "Dabigatran",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-warfarin-for-cvt-re-spect-cvt-trial-no-inr-mo": {
          "indication": "Alternative to warfarin for CVT (RE-SPECT CVT trial); no INR monitoring needed",
          "doseOptions": [
            {
              "text": "150 mg BID",
              "orderSentence": "Dabigatran 150 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150 mg PO BID; reduce to 110 mg BID if age >80, concurrent P-gp inhibitor, or CrCl 30-50",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Dabigatran 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150 mg PO BID (75 mg BID if CrCl 15-30); start 4-14 days post-stroke for AF",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "anticoagulation-for-stroke-with-af-re-ly-trial-reversible-wi": {
          "indication": "Anticoagulation for stroke with AF; RE-LY trial; reversible with idarucizumab",
          "doseOptions": [
            {
              "text": "150 mg BID",
              "orderSentence": "Dabigatran 150 mg BID PO"
            },
            {
              "text": "110 mg BID",
              "orderSentence": "Dabigatran 110 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150 mg BID standard; 110 mg BID if age ≥80 or concurrent P-gp inhibitor; CrCl 30-50: 150 mg BID acceptable; avoid if CrCl <30",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CrCl <30",
          "GI side effects",
          "Renal function q6-12 months",
          "active bleeding",
          "bleeding signs",
          "mechanical heart valve",
          "mechanical valve"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function q6 months (renal elimination)",
          "Renal function q6-12 months",
          "aPTT as qualitative screen",
          "idarucizumab for reversal",
          "signs of bleeding",
          "thrombin time or ecarin clotting time if needed"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "cerebral-venous-thrombosis",
        "post-stroke-management"
      ]
    },
    "dabigatran-reversal-idarucizumab": {
      "id": "dabigatran-reversal-idarucizumab",
      "name": "Dabigatran reversal: Idarucizumab (Praxbind) (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 g",
              "orderSentence": "Dabigatran reversal: Idarucizumab (Praxbind) (CPT 96374) 5 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 g IV (two 2.5g boluses or infusions). Specific reversal agent for dabigatran. Reversal within minutes",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None absolute"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Thrombin time (TT), aPTT",
          "clinical hemostasis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "dantrolene": {
      "id": "dantrolene",
      "name": "Dantrolene",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "refractory-spasms-with-hyperthermia-or-malignant-hyperthermi": {
          "indication": "Refractory spasms with hyperthermia or malignant hyperthermia-like presentation during severe SPS crisis",
          "doseOptions": [
            {
              "text": "1-2.5 mg/kg",
              "orderSentence": "Dantrolene 1-2.5 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2.5 mg/kg IV push; may repeat q5-10 min; max 10 mg/kg; transition to PO 25-100 mg QID when stabilized",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "spasticity-refractory-to-baclofen-and-tizanidine-acts-periph": {
          "indication": "Spasticity refractory to baclofen and tizanidine; acts peripherally on muscle",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Dantrolene 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO daily; increase by 25 mg q4-7 days; max 400 mg/day divided TID-QID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active hepatic disease",
          "Hepatic disease",
          "active hepatitis",
          "severely impaired cardiac or pulmonary function"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CK",
          "LFTs",
          "LFTs at baseline, then monthly for first 6 months",
          "hepatotoxicity",
          "hepatotoxicity (BLACK BOX)",
          "muscle weakness (reduces overall strength)",
          "temperature"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "cervical-myelopathy",
        "stiff-person-syndrome"
      ]
    },
    "dapt-long-term": {
      "id": "dapt-long-term",
      "name": "DAPT long-term (aspirin + clopidogrel)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "intracranial-stenosis-70-99-sammpris-trial-medical-stenting": {
          "indication": "Intracranial stenosis 70-99% (SAMMPRIS trial: medical > stenting)",
          "doseOptions": [
            {
              "text": "325 mg",
              "orderSentence": "DAPT long-term (aspirin + clopidogrel) 325 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Aspirin 325 mg + clopidogrel 75 mg daily x 90 days; then single antiplatelet + aggressive risk factor management",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "transient-ischemic-attack"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bleeding",
          "MRA q6-12 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "transient-ischemic-attack"
      ]
    },
    "darunavir-ritonavir": {
      "id": "darunavir-ritonavir",
      "name": "Darunavir/ritonavir (Prezista/Norvir)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "pi-with-moderate-cpe-boosted-pi-for-resistant-virus-use-when": {
          "indication": "PI with moderate CPE; boosted PI for resistant virus; use when INSTI resistance present",
          "doseOptions": [
            {
              "text": "800/100 mg",
              "orderSentence": "Darunavir/ritonavir (Prezista/Norvir) 800/100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "800 mg darunavir + 100 mg ritonavir PO daily with food; 600/100 mg BID if resistance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Sulfonamide allergy (relative)",
          "concurrent drugs with CYP3A4 interactions"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI tolerance",
          "LFTs",
          "drug interactions (extensive CYP3A4 inhibition)",
          "glucose",
          "lipid panel"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "deep-brain-stimulation-of-anterior-nucleus-of-thalamus": {
      "id": "deep-brain-stimulation-of-anterior-nucleus-of-thalamus",
      "name": "Deep brain stimulation (DBS) of anterior nucleus of thalamus",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Surgical implant"
      ],
      "formulations": [],
      "contexts": {
        "dre-with-focal-epilepsy-when-resection-rns-not-feasible-sant": {
          "indication": "DRE with focal epilepsy when resection/RNS not feasible; SANTE trial showed ~69% seizure reduction at 5 years",
          "doseOptions": [
            {
              "text": "N/A — device implantation",
              "orderSentence": "Deep brain stimulation (DBS) of anterior nucleus of thalamus N/A — device implantation Surgical"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bilateral electrodes in anterior nucleus of thalamus; parameters optimized over months; typically cycling stimulation",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Depression risk (15%)",
          "MRI restrictions post-implant",
          "caution in patients with pre-existing psychiatric disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Device interrogation q3-6 months",
          "battery monitoring",
          "psychiatric monitoring (depression, memory)",
          "stimulation parameter optimization"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "delivery": {
      "id": "delivery",
      "name": "Delivery",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Surgical/vaginal"
      ],
      "formulations": [],
      "contexts": {
        "definitive-treatment-for-eclampsia-delivery-of-fetus-and-pla": {
          "indication": "**DEFINITIVE TREATMENT for eclampsia**: Delivery of fetus and placenta cures eclampsia in most cases",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Delivery N/A Obstetric"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Plan delivery after maternal stabilization (seizure control + BP control); ≥34 weeks: delivery recommended; <34 weeks: consider steroids for fetal lung maturity if maternal condition allows 24-48h delay; emergent C-section if fetal distress",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Maternal instability precluding anesthesia (stabilize first)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous fetal monitoring",
          "maternal hemodynamics",
          "postpartum MgSO4 continuation 24-48h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy"
      ]
    },
    "desipramine": {
      "id": "desipramine",
      "name": "Desipramine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "tca-with-minimal-anticholinergic-effects": {
          "indication": "TCA with minimal anticholinergic effects",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Desipramine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg qHS; titrate by 25 mg q1-2wk; target 50-100 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "neuropathic-pain-second-line": {
          "indication": "Neuropathic pain (second-line)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Desipramine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg qHS; increase by 25 mg weekly; max 150 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as amitriptyline",
          "Same as other TCAs"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG",
          "Same",
          "drug levels available if needed",
          "least anticholinergic TCA"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "peripheral-neuropathy",
        "small-fiber-neuropathy"
      ]
    },
    "desmopressin": {
      "id": "desmopressin",
      "name": "Desmopressin (DDAVP)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "diabetes-insipidus-treatment-common-in-brain-death-due-to-pi": {
          "indication": "Diabetes insipidus treatment (common in brain death due to pituitary failure); maintain hemodynamic stability for valid examination",
          "doseOptions": [
            {
              "text": "1-4 mcg",
              "orderSentence": "**Desmopressin (DDAVP)** 1-4 mcg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-4 mcg IV q6-12h; titrate to urine output <200-300 mL/hr; may also give 10-20 mcg intranasally; onset IV: 15-30 min; adjust based on urine output and sodium",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        },
        "diabetes-insipidus-treatment-maintain-euvolemia-and-sodium-h": {
          "indication": "Diabetes insipidus treatment; maintain euvolemia and sodium homeostasis for organ preservation; most brain-dead patients develop DI",
          "doseOptions": [
            {
              "text": "1-4 mcg",
              "orderSentence": "**Desmopressin (DDAVP) (donor management)** 1-4 mcg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-4 mcg IV q6-12h PRN; titrate to urine output 0.5-3 mL/kg/hr; target sodium 135-155 mEq/L; may also give 10-20 mcg intranasally",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        },
        "central-diabetes-insipidus-from-hypothalamic-posterior-pitui": {
          "indication": "Central diabetes insipidus from hypothalamic/posterior pituitary sarcoidosis",
          "doseOptions": [
            {
              "text": "1-2 mcg",
              "orderSentence": "Desmopressin 1-2 mcg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mcg IV/SC q12h; or 10-20 mcg intranasal BID; titrate to urine output and serum sodium",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "nocturia": {
          "indication": "Nocturia",
          "doseOptions": [
            {
              "text": "0.1-0.4 mg",
              "orderSentence": "Desmopressin 0.1-0.4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1-0.4 mg qHS (oral) or 10-40 mcg intranasal",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "nocturnal-polyuria-contributing-to-morning-oh": {
          "indication": "Nocturnal polyuria contributing to morning OH",
          "doseOptions": [
            {
              "text": "0.1 mg QHS",
              "orderSentence": "Desmopressin (DDAVP) 0.1 mg QHS PO"
            },
            {
              "text": "0.2 mg QHS",
              "orderSentence": "Desmopressin (DDAVP) 0.2 mg QHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1-0.2 mg PO at bedtime; OR 10 mcg intranasal at bedtime; reduces nocturnal urine production",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CHF",
          "Hyponatremia",
          "Hyponatremia (hold if Na <135)",
          "Hyponatremia (relative)",
          "Hyponatremia risk",
          "Hyponatremia, heart failure, polydipsia",
          "age >65 (relative)",
          "polydipsia",
          "type IIb von Willebrand disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Serum sodium (check at 1 week, 1 month, then q3 months), weight, fluid balance",
          "Sodium at baseline, 1 week, 1 month, then periodically",
          "Sodium q4-6h initially",
          "Urine output hourly",
          "fluid restrict evening",
          "goal UOP 0.5-3 mL/kg/hr",
          "serum osmolality",
          "serum sodium q2-4h",
          "urine output",
          "urine specific gravity",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "brain-death-evaluation",
        "ms-new-diagnosis",
        "multiple-system-atrophy",
        "neurosarcoidosis"
      ]
    },
    "deutetrabenazine": {
      "id": "deutetrabenazine",
      "name": "Deutetrabenazine (Austedo)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "fda-approved-for-hd-chorea-better-tolerability-than-tetraben": {
          "indication": "FDA-approved for HD chorea; better tolerability than tetrabenazine",
          "doseOptions": [
            {
              "text": "6 mg",
              "orderSentence": "Deutetrabenazine (Austedo) 6 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 6 mg daily; increase by 6 mg/wk; max 48 mg/day (24 mg per dose)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "longer-half-life-alternative-to-tetrabenazine": {
          "indication": "Longer half-life alternative to tetrabenazine",
          "doseOptions": [
            {
              "text": "6 mg",
              "orderSentence": "Deutetrabenazine (Austedo) 6 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 6 mg BID; increase by 6 mg/day weekly; max 48 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "fda-approved-first-line-for-td-vmat2-inhibitor": {
          "indication": "FDA-approved first-line for TD; VMAT2 inhibitor",
          "doseOptions": [
            {
              "text": "6 mg",
              "orderSentence": "Deutetrabenazine (Austedo) 6 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 6 mg BID (12 mg/day); increase by 6 mg/day weekly; max 48 mg/day; take with food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        },
        "vmat2-inhibitor-better-tolerated-than-tetrabenazine-longer-h": {
          "indication": "VMAT2 inhibitor; better tolerated than tetrabenazine; longer half-life",
          "doseOptions": [
            {
              "text": "6 mg",
              "orderSentence": "Deutetrabenazine (Austedo) 6 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 6 mg daily; increase by 6 mg/day weekly; target 12-48 mg/day divided BID; max 48 mg/day; take with food",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active suicidality",
          "Depression",
          "Depression/suicidality",
          "Depression/suicidality (Black Box)",
          "MAO-I use",
          "Parkinsonism",
          "concurrent MAOIs",
          "hepatic impairment",
          "reserpine use within 20 days",
          "suicidality",
          "untreated depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Black Box: suicidality",
          "Depression (PHQ-9 monthly), akathisia, parkinsonism, QTc",
          "Depression (PHQ-9)",
          "Depression screening (PHQ-9) at each visit",
          "Depression, sedation, parkinsonism, akathisia",
          "QTc",
          "QTc at baseline and dose changes",
          "akathisia",
          "may be better tolerated than tetrabenazine",
          "parkinsonism",
          "suicidality assessment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "dystonia",
        "huntingtons-disease",
        "tardive-dyskinesia",
        "tics-tourette-syndrome"
      ]
    },
    "dexamethasone": {
      "id": "dexamethasone",
      "name": "Dexamethasone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "cerebral-edema-from-parenchymal-mass-like-lesion-acute-eleva": {
          "indication": "Cerebral edema from parenchymal mass-like lesion; acute elevated ICP",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV loading dose, then 4 mg IV q6h; taper over days-weeks as clinically improving",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "vasogenic-edema-from-tumor-symptomatic-mass-effect-reduce-pe": {
          "indication": "Vasogenic edema from tumor; symptomatic mass effect; reduce peritumoral edema to improve neurologic function",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone (vasogenic edema) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV loading dose, then 4 mg IV/PO q6h; moderate symptoms: 4-8 mg/day; severe edema/herniation: 10 mg IV bolus then 4-8 mg q6h (up to 16-24 mg/day); taper as soon as clinically feasible over 2-4 weeks; GI prophylaxis with PPI while on steroids; symptomatic improvement typically within 24-72h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "URGENT",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "transition-from-iv-to-po-taper-as-soon-as-clinically-feasibl": {
          "indication": "Transition from IV to PO; taper as soon as clinically feasible to minimize steroid side effects; taper after surgery and/or after radiation",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Dexamethasone (taper) 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper by 2 mg every 3-5 days (e.g., 16 to 12 to 8 to 6 to 4 to 2 to 1 to off); slower taper if symptoms recur; monitor for adrenal insufficiency if >3 weeks of use",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "adjunctive-with-empiric-antibiotics-for-suspected-bacterial-": {
          "indication": "Adjunctive with empiric antibiotics for suspected bacterial meningitis",
          "doseOptions": [
            {
              "text": "0.15 mg/kg",
              "orderSentence": "Dexamethasone (empiric meningitis dose) 0.15 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.15 mg/kg IV q6h x 4 days; give first dose BEFORE or WITH first antibiotic dose",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "iris-management-in-hiv-patients-who-develop-worsening-sympto": {
          "indication": "IRIS management in HIV patients who develop worsening symptoms after ART initiation; NOT recommended as routine adjunct in cryptococcal meningitis (unlike bacterial meningitis — dexamethasone INCREASED mortality in cryptococcal meningitis per ACTA trial)",
          "doseOptions": [
            {
              "text": "0.3 mg/kg/day",
              "orderSentence": "Dexamethasone 0.3 mg/kg/day IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.3 mg/kg/day IV (or equivalent) for IRIS only; taper over 2-6 weeks based on clinical response; use ONLY for IRIS, NOT for routine cryptococcal meningitis",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.15 mg/kg",
              "orderSentence": "Dexamethasone 0.15 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.15 mg/kg IV q6h x 4 days — give empirically with antibiotics until bacterial meningitis excluded. Discontinue when bacterial excluded. Role in HSV encephalitis itself is CONTROVERSIAL — some evidence for reducing edema but no clear mortality benefit; not standard of care for isolated HSV",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hsv-encephalitis",
            "bells-palsy",
            "elevated-icp-management",
            "medication-overuse-headache",
            "cluster-headache",
            "spinal-cord-compression-malignant",
            "cauda-equina-syndrome",
            "bacterial-meningitis",
            "brain-metastases"
          ]
        },
        "give-empirically-with-antibiotics-greatest-benefit-if-bacter": {
          "indication": "Give empirically with antibiotics; greatest benefit if bacterial meningitis (especially S. pneumoniae); discontinue when bacterial meningitis excluded",
          "doseOptions": [
            {
              "text": "0.15 mg/kg",
              "orderSentence": "Dexamethasone (adjunctive — give BEFORE or WITH first antibiotic dose) 0.15 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.15 mg/kg IV q6h (typically 10 mg IV q6h) x 4 days; MUST be given BEFORE or simultaneously with first antibiotic dose; discontinue when bacterial meningitis excluded; no proven benefit in viral meningitis",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "reduces-24-72h-headache-recurrence-recommended-adjunct-to-ed": {
          "indication": "Reduces 24-72h headache recurrence; recommended adjunct to ED headache cocktail",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV push once (single dose)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "cerebral-edema-from-granulomatous-mass-lesion-acute-elevated": {
          "indication": "Cerebral edema from granulomatous mass lesion; acute elevated ICP",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV loading dose, then 4 mg IV q6h; taper over days-weeks as clinically improving",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "vasogenic-edema-from-leptomeningeal-disease-symptomatic-reli": {
          "indication": "Vasogenic edema from leptomeningeal disease; symptomatic relief of headache, nausea, cranial neuropathies; bridge to definitive treatment",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "**Dexamethasone** 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV loading dose, then 4 mg IV/PO q6h; moderate symptoms 4-8 mg/day; severe symptoms/herniation 10 mg IV then 4-8 mg q6h (up to 16-24 mg/day); begin taper once definitive treatment initiated; GI prophylaxis with PPI while on steroids",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "URGENT",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "vasogenic-edema-with-herniation-risk-or-severe-mass-effect-o": {
          "indication": "Vasogenic edema with herniation risk or severe mass effect ONLY when biopsy cannot be performed within 24-48h; steroids cause rapid tumor regression making biopsy non-diagnostic",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone (ONLY if life-threatening herniation or biopsy not immediately available) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV bolus, then 4 mg IV/PO q6h; use LOWEST effective dose for SHORTEST duration; document that steroids were given and inform neurosurgeon and neuro-oncologist; biopsy should proceed ASAP even after steroids (may need repeat biopsy if non-diagnostic)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "transition-from-iv-to-po-after-biopsy-obtained-taper-as-soon": {
          "indication": "Transition from IV to PO after biopsy obtained; taper as soon as clinically feasible; PCNSL often dramatically steroid-responsive; rapid taper once chemotherapy begins (MTX preferred without steroids)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Dexamethasone (taper - post-biopsy only) 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper by 2 mg every 3-5 days (e.g., 16 to 12 to 8 to 6 to 4 to 2 to 1 to off); PCNSL may regrow during taper; definitive chemotherapy should start before taper is complete if possible",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "reduce-headache-recurrence-anti-inflammatory-effect-for-susp": {
          "indication": "Reduce headache recurrence; anti-inflammatory effect for suspected inflammatory etiology",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV once (reduces 24-72h headache recurrence)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "reduce-inflammation-and-improve-outcomes-in-bacterial-mening": {
          "indication": "Reduce inflammation and improve outcomes in bacterial meningitis (give BEFORE or with first antibiotic dose)",
          "doseOptions": [
            {
              "text": "0.15 mg/kg",
              "orderSentence": "Dexamethasone (for meningitis) (CPT 96374) 0.15 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.15 mg/kg IV q6h x 4 days (typically 10 mg q6h); start before or with first antibiotic dose",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "significant-vasogenic-edema-surrounding-venous-infarction-no": {
          "indication": "Significant vasogenic edema surrounding venous infarction; NOT routine",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone (vasogenic edema) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV loading dose, then 4 mg IV q6h; taper over 5-7 days",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "pre-treatment-corticosteroid-before-antiparasitic-therapy-re": {
          "indication": "Pre-treatment corticosteroid BEFORE antiparasitic therapy; reduces treatment-induced inflammation from cyst degeneration; essential for cysticercal encephalitis; subarachnoid NCC with arachnoiditis",
          "doseOptions": [
            {
              "text": "0.15 mg/kg",
              "orderSentence": "Dexamethasone (CPT 96374) 0.15 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.15 mg/kg IV q6h (typically 4-8 mg q6h); start 1-2 days BEFORE antiparasitic drugs; taper over 2-4 weeks based on clinical response; longer courses for subarachnoid NCC; dexamethasone increases albendazole sulfoxide levels by 50%",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "vasogenic-edema-from-cerebellar-mass-tumor-abscess-not-for-c": {
          "indication": "Vasogenic edema from cerebellar mass (tumor, abscess); NOT for cytotoxic edema (stroke)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV loading dose, then 4 mg IV q6h; for tumor/abscess-related edema only",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "acute-severe-radiculopathy-disc-herniation-with-inflammation": {
          "indication": "Acute severe radiculopathy, disc herniation with inflammation",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV once, then 4 mg IV/PO q6h x 3-5 days; taper over 5-7 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "significant-mass-effect-cerebral-edema-impending-herniation-": {
          "indication": "Significant mass effect, cerebral edema, impending herniation, or declining neurologic status; NOT routine for all brain abscesses; may reduce antibiotic penetration",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV q6h (0.15 mg/kg q6h) for 48-72h then rapid taper over 5-7 days; use ONLY for significant edema/mass effect; taper as soon as clinically feasible",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "reduce-inflammation-and-improve-outcomes-in-bacterial-mening-2": {
          "indication": "Reduce inflammation and improve outcomes in bacterial meningitis (especially pneumococcal)",
          "doseOptions": [
            {
              "text": "0.15 mg/kg",
              "orderSentence": "Dexamethasone (if bacterial meningitis suspected) (CPT 96374) 0.15 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.15 mg/kg IV q6h x 4 days. Give 15-20 min before or with first antibiotic dose",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "vasogenic-edema-from-meningioma-symptomatic-mass-effect-peri": {
          "indication": "Vasogenic edema from meningioma; symptomatic mass effect; perioperative edema reduction; reduce peritumoral swelling to improve neurologic function",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone (vasogenic edema) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV loading dose, then 4 mg IV/PO q6h; moderate symptoms: 4-8 mg/day; severe edema/herniation: 10 mg IV bolus then 4-8 mg q6h (up to 16-24 mg/day); taper as soon as clinically feasible over 1-2 weeks post-surgery; GI prophylaxis with PPI while on steroids",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "URGENT",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "transition-from-iv-to-po-taper-after-surgery-as-soon-as-clin": {
          "indication": "Transition from IV to PO; taper after surgery as soon as clinically feasible to minimize steroid side effects",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Dexamethasone (taper) 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper by 2 mg every 3-5 days (e.g., 16 to 12 to 8 to 6 to 4 to 2 to 1 to off); slower taper if symptoms recur; monitor for adrenal insufficiency if >3 weeks of use",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "adjunctive-corticosteroid-for-all-bmrc-stages-reduces-mortal": {
          "indication": "Adjunctive corticosteroid for ALL BMRC stages — reduces mortality by 30% (NNT ~5 for stage II/III); reduces inflammation, cerebral edema, and vasculitis",
          "doseOptions": [
            {
              "text": "See Appendix A for detailed Thwaites protocol",
              "orderSentence": "Dexamethasone (Thwaites protocol) See Appendix A for detailed Thwaites protocol IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "BMRC Stage I: 0.3 mg/kg/day IV x 4 weeks, then taper PO over 4 weeks. BMRC Stage II-III: 0.4 mg/kg/day IV x 4 weeks, then taper PO over 4 weeks. Total steroid duration: 6-8 weeks. Start simultaneously with anti-TB therapy",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        },
        "acute-neurologic-deterioration-from-cervical-cord-compressio": {
          "indication": "Acute neurologic deterioration from cervical cord compression with progressive deficit; reduces vasogenic edema",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV loading dose, then 4 mg IV q6h; transition to oral taper over 5-7 days once stable",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "acute-plexopathy-with-severe-pain-and-inflammation-peritumor": {
          "indication": "Acute plexopathy with severe pain and inflammation; peritumoral edema",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone (CPT 96374 when IV) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV loading dose, then 4 mg IV/PO q6h; taper over 7-14 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        },
        "empiric-adjunctive-therapy-if-bacterial-meningitis-cannot-ye": {
          "indication": "Empiric adjunctive therapy if bacterial meningitis cannot yet be excluded pending culture results; give BEFORE or WITH first antibiotic dose; discontinue if Lyme meningitis confirmed (no role for steroids in Lyme meningitis)",
          "doseOptions": [
            {
              "text": "0.15 mg/kg q6h x 4 days",
              "orderSentence": "Dexamethasone (if bacterial meningitis not excluded) 0.15 mg/kg q6h x 4 days IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.15 mg/kg IV q6h for 4 days (discontinue if Lyme meningitis confirmed); administer before or with first antibiotic dose",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        },
        "prevent-headache-recurrence-after-acute-treatment": {
          "indication": "Prevent headache recurrence after acute treatment",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV x1 at time of discharge or admission; single dose",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "AVOID BEFORE BIOPSY whenever possible (causes vanishing tumor)",
          "Active GI bleeding",
          "Active GI bleeding (relative)",
          "Active fungal infection",
          "Active infection",
          "Active untreated fungal/bacterial infection",
          "Active untreated infection",
          "Active untreated infection (relative",
          "Active untreated infection (relative)",
          "Active untreated infection, uncontrolled diabetes (relative), psychosis (relative)",
          "GI bleed (relative)",
          "GI bleeding",
          "GI bleeding (relative)",
          "Not beneficial if antibiotics already started >1h prior",
          "Not proven beneficial if antibiotics already started >1h prior",
          "Same",
          "Symptom recurrence (hold taper, reassess)",
          "Symptom recurrence during taper (may need slower taper or earlier chemotherapy)",
          "Uncontrolled infection (relative)",
          "active untreated infection",
          "avoid in stroke",
          "benefit of edema reduction may outweigh risk)",
          "concurrent untreated strongyloides (dissemination risk — screen in endemic areas)",
          "defer if viral meningitis confirmed",
          "immunocompromised (relative)",
          "known hypersensitivity",
          "known viral meningitis",
          "may impair abscess encapsulation",
          "psychosis from prior steroids",
          "psychosis history (relative)",
          "unclear role in CVT",
          "uncontrolled diabetes",
          "uncontrolled diabetes (relative -- still give, monitor glucose)",
          "uncontrolled diabetes (relative — manage glucose aggressively)",
          "uncontrolled diabetes (relative — monitor closely)",
          "uncontrolled diabetes (relative)",
          "uncontrolled infection (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Begin within 6h of diagnosis",
          "Blood glucose",
          "Blood glucose q6h",
          "Blood glucose within 4-6h",
          "CRASH trial: steroids HARMFUL in TBI — avoid",
          "Dexamethasone is preferred corticosteroid (minimal mineralocorticoid effect, long half-life)",
          "GI bleeding",
          "GI prophylaxis",
          "GI prophylaxis (PPI)",
          "GI prophylaxis with PPI",
          "GI symptoms",
          "Glucose",
          "Glucose if diabetic",
          "Glucose q6h",
          "Glucose q6h (steroid hyperglycemia)",
          "Glucose q6h (target <180 mg/dL), BP, document timing relative to biopsy, neurologic exam improvement (may confirm lymphoma diagnosis clinically)",
          "Glucose q6h (target <180 mg/dL), BP, mood/sleep, GI symptoms, signs of infection",
          "Glucose q6h during IV therapy",
          "Glucose q6h while on IV steroids",
          "Glucose, BP, mood, steroid myopathy (proximal weakness may mimic disease progression), immunosuppression, osteoporosis",
          "Glucose, BP, mood, steroid myopathy (proximal weakness), immunosuppression",
          "Glucose, BP, mood, steroid myopathy, immunosuppression, osteoporosis risk",
          "Glucose, blood pressure",
          "High-dose (96 mg) vs. standard (10 mg): Vecht et al. (1989) — higher response rate at 1 week but more side effects",
          "MOST centers now use moderate dose (10 mg load → 16 mg/day)",
          "No RCT evidence supporting steroids for disc-related CES",
          "Reduces vasogenic edema around tumors",
          "Same",
          "Sorensen et al. (1994): Dexamethasone + radiation vs. radiation alone → 81% vs. 63% ambulatory at treatment end",
          "abscess: prioritize antibiotics + surgical drainage",
          "blood pressure",
          "clinical response",
          "discontinue when Lyme confirmed",
          "do NOT use prolonged course",
          "dramatic effect within 24-48h",
          "infection signs",
          "infection surveillance",
          "inhibits VEGF",
          "insomnia",
          "mental status",
          "mental status changes",
          "mood changes",
          "mood/psychiatric effects",
          "neurological status",
          "no benefit in asymptomatic patients without edema (AVOID routine prophylactic use)",
          "no benefit in stroke",
          "psychiatric effects",
          "reduces vasogenic edema via BBB stabilization",
          "signs of infection (immunosuppression)",
          "signs of infection progression",
          "symptomatic improvement in 24-72h",
          "taper schedule",
          "taper slowly (do NOT stop abruptly)",
          "tumor CES: Sorensen et al. (1994) supports steroids"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 35,
      "_sourcePlans": [
        "ataxia-evaluation",
        "bacterial-meningitis",
        "bells-palsy",
        "brain-abscess",
        "brain-metastases",
        "cauda-equina-syndrome",
        "cerebral-venous-thrombosis",
        "cervical-myelopathy",
        "cluster-headache",
        "elevated-icp-management",
        "fungal-meningitis",
        "glioblastoma",
        "hashimotos-encephalopathy",
        "headache-evaluation",
        "headache-unspecified",
        "hsv-encephalitis",
        "leptomeningeal-carcinomatosis",
        "lyme-neuroborreliosis",
        "medication-overuse-headache",
        "meningioma",
        "migraine-with-aura",
        "neuro-behcets-disease",
        "neurocysticercosis",
        "neurosarcoidosis",
        "plexopathy",
        "primary-cns-lymphoma",
        "radiculopathy",
        "spinal-cord-compression-malignant",
        "tb-meningitis",
        "thunderclap-headache-evaluation",
        "viral-meningitis"
      ]
    },
    "dexamethasone-injection": {
      "id": "dexamethasone-injection",
      "name": "Dexamethasone injection",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Local injection"
      ],
      "formulations": [],
      "contexts": {
        "alternative-corticosteroid-shorter-acting": {
          "indication": "Alternative corticosteroid (shorter acting)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Dexamethasone injection 4 mg Local injection"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg injected into carpal tunnel; shorter duration than triamcinolone",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local infection",
          "bleeding disorder"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood glucose (diabetics)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "carpal-tunnel-syndrome"
      ]
    },
    "dexamethasone-iv": {
      "id": "dexamethasone-iv",
      "name": "Dexamethasone IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone IV 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV once (reduces recurrence)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "reduce-headache-recurrence-refractory-migraine": {
          "indication": "Reduce headache recurrence; refractory migraine",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dexamethasone IV 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV once (reduces 72h recurrence by ~25%)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "prevention-of-headache-recurrence-within-72-hours-does-not-t": {
          "indication": "Prevention of headache recurrence within 72 hours; does not treat acute pain",
          "doseOptions": [
            {
              "text": "10 mg IV once",
              "orderSentence": "Dexamethasone IV 10 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV once; single dose (NNT 9 for recurrence prevention)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection, uncontrolled DM",
          "Active infection, uncontrolled diabetes",
          "Active untreated infection, uncontrolled diabetes mellitus"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood glucose (check at 4-6h), mood changes",
          "Glucose",
          "Glucose, insomnia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "status-migrainosus"
      ]
    },
    "dexamethasone-po-taper": {
      "id": "dexamethasone-po-taper",
      "name": "Dexamethasone PO taper",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "prevention-of-headache-recurrence-after-ed-hospital-discharg": {
          "indication": "Prevention of headache recurrence after ED/hospital discharge; bridge to preventive therapy",
          "doseOptions": [
            {
              "text": "4 mg BID x 4 days",
              "orderSentence": "Dexamethasone PO taper 4 mg BID x 4 days PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg PO BID x 4 days; may taper over 1 week",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection, uncontrolled DM, GI ulcer"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood glucose, GI symptoms, mood"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "dexamethasone-taper": {
      "id": "dexamethasone-taper",
      "name": "Dexamethasone taper (short)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "prevent-headache-recurrence-after-ed-discharge-bridging-for-": {
          "indication": "Prevent headache recurrence after ED discharge; bridging for refractory cases",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Dexamethasone taper (short) 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg PO BID x 2 days, then 4 mg daily x 2 days, then stop",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "symptom-management-transition-from-acute-iv-to-oral-taper-as": {
          "indication": "Symptom management transition from acute IV to oral; taper as definitive treatment initiated",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "**Dexamethasone taper** 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper from 16 mg/day: 16 to 12 to 8 to 6 to 4 to 2 to 1 to off, reducing every 3-5 days; slower taper if symptoms recur; minimum effective dose long-term; monitor for adrenal insufficiency if >3 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "Inability to taper due to symptoms (consider radiation to enable taper)",
          "adrenal suppression after prolonged use",
          "uncontrolled DM"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood glucose",
          "Blood glucose (daily on steroids)",
          "bone density if prolonged",
          "cushingoid features",
          "insomnia",
          "mental status (steroid psychosis)",
          "mood changes",
          "proximal weakness (steroid myopathy)",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "headache-unspecified",
        "leptomeningeal-carcinomatosis"
      ]
    },
    "dexmedetomidine": {
      "id": "dexmedetomidine",
      "name": "Dexmedetomidine (agitation in ICU)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "icu-agitation-requiring-sedation": {
          "indication": "ICU agitation requiring sedation",
          "doseOptions": [
            {
              "text": "1 mcg/kg",
              "orderSentence": "Dexmedetomidine (agitation in ICU) 1 mcg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 1 mcg/kg IV over 10 min (optional); Infusion: 0.2-0.7 mcg/kg/hr (max 1.5 mcg/kg/hr)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "sedation-possible-antiseizure": {
          "indication": "Sedation, possible antiseizure",
          "doseOptions": [
            {
              "text": "0.2-1.5 mcg/kg",
              "orderSentence": "Dexmedetomidine 0.2-1.5 mcg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.2-1.5 mcg/kg/hr",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1 mcg/kg",
              "orderSentence": "Dexmedetomidine (agitation in ICU) 1 mcg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 1 mcg/kg IV over 10 min (optional); Infusion: 0.2-0.7 mcg/kg/hr (max 1.5 mcg/kg/hr)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bradycardia, heart block",
          "Severe bradycardia",
          "advanced heart block"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP (hypotension)",
          "HR (bradycardia)",
          "HR, BP",
          "sedation level (RASS)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "hashimotos-encephalopathy",
        "status-epilepticus"
      ]
    },
    "dexmedetomidine-infusion": {
      "id": "dexmedetomidine-infusion",
      "name": "Dexmedetomidine infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "adjunctive-sedation-for-withdrawal-reduces-benzodiazepine-re": {
          "indication": "Adjunctive sedation for withdrawal; reduces benzodiazepine requirement; treats sympathetic hyperactivity",
          "doseOptions": [
            {
              "text": "0.2 mcg/kg/hr",
              "orderSentence": "Dexmedetomidine infusion 0.2 mcg/kg/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.2 mcg/kg/hr; titrate to effect (max 1.5 mcg/kg/hr); no loading dose in hemodynamically unstable patients; reduces BZD requirements by 30-50%",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "2nd/3rd degree heart block",
          "Severe bradycardia",
          "hypotension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HR, BP (bradycardia and hypotension)",
          "does NOT prevent seizures - must continue benzodiazepines"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure"
      ]
    },
    "dextroamphetamine": {
      "id": "dextroamphetamine",
      "name": "Dextroamphetamine (Dexedrine)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "eds-refractory-to-modafinil-solriamfetol-potent-wake-promoti": {
          "indication": "EDS refractory to modafinil/solriamfetol; potent wake-promoting agent",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Dextroamphetamine (Dexedrine) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg once or twice daily; titrate by 5 mg/week; max 60 mg/day; avoid evening dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAOIs",
          "advanced atherosclerosis",
          "agitated states",
          "glaucoma",
          "history of drug abuse",
          "moderate-severe hypertension",
          "symptomatic cardiovascular disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood pressure",
          "abuse potential (Schedule II)",
          "appetite",
          "heart rate",
          "psychiatric symptoms",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "narcolepsy"
      ]
    },
    "dextromethorphan-quinidine": {
      "id": "dextromethorphan-quinidine",
      "name": "Dextromethorphan/Quinidine (Nuedexta)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "pseudobulbar-affect-involuntary-laughing-crying-fda-approved": {
          "indication": "Pseudobulbar affect (involuntary laughing/crying); FDA-approved for PBA",
          "doseOptions": [
            {
              "text": "20/10 mg",
              "orderSentence": "Dextromethorphan/Quinidine (Nuedexta) 20/10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20/10 mg daily x 7 days, then increase to 20/10 mg BID; take at least q12 hours",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "pseudobulbar-affect-emotional-lability-pathological-laughing": {
          "indication": "Pseudobulbar affect; emotional lability; pathological laughing/crying",
          "doseOptions": [
            {
              "text": "20/10 mg",
              "orderSentence": "Dextromethorphan/quinidine (Nuedexta) 20/10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20/10 mg daily x 7 days; then 20/10 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "pseudobulbar-affect-pathological-laughing-crying": {
          "indication": "Pseudobulbar affect (pathological laughing/crying)",
          "doseOptions": [
            {
              "text": "20/10 mg daily",
              "orderSentence": "Dextromethorphan/Quinidine (Nuedexta) 20/10 mg daily PO"
            },
            {
              "text": "20/10 mg BID",
              "orderSentence": "Dextromethorphan/Quinidine (Nuedexta) 20/10 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20/10 mg daily x7 days, then 20/10 mg BID; space 12 hours apart",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CYP2D6 poor metabolizers on quinidine",
          "Concurrent quinidine/quinine/mefloquine, MAOIs, CYP2D6 substrates with narrow TI, prolonged QT, complete AV block",
          "QT prolongation",
          "complete AV block",
          "concurrent MAOIs",
          "quinidine hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "QTc",
          "QTc at baseline and after dose increase",
          "QTc on ECG (baseline and at steady state), hepatic function, concomitant medications",
          "avoid in hepatic/renal impairment",
          "drug interactions (CYP2D6 substrates)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "frontotemporal-dementia",
        "multiple-system-atrophy",
        "progressive-supranuclear-palsy"
      ]
    },
    "dextrose": {
      "id": "dextrose",
      "name": "Dextrose (if hypoglycemic)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-50 mL",
              "orderSentence": "Dextrose (if hypoglycemic) 25-50 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "D50 25-50 mL IV or D10 infusion; AFTER thiamine",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wernicke-encephalopathy"
          ]
        },
        "hypoglycemia-induced-tremor-with-blood-glucose-70-mg-dl": {
          "indication": "Hypoglycemia-induced tremor with blood glucose <70 mg/dL",
          "doseOptions": [
            {
              "text": "25 g",
              "orderSentence": "Dextrose (for hypoglycemia) (CPT 96374) 25 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Administer 50 mL of D50W IV push; recheck glucose in 15 minutes; repeat if glucose remains <70 mg/dL; transition to oral carbohydrates once able",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Give thiamine first",
          "None in emergent hypoglycemia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood glucose q15 min until >100 mg/dL",
          "Glucose levels",
          "identify and treat underlying cause of hypoglycemia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "tremor-unspecified",
        "wernicke-encephalopathy"
      ]
    },
    "dextrose-50": {
      "id": "dextrose-50",
      "name": "Dextrose 50% (hypoglycemia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "glucose-60-mg-dl": {
          "indication": "Glucose <60 mg/dL",
          "doseOptions": [
            {
              "text": "25-50 mL",
              "orderSentence": "Dextrose 50% (hypoglycemia) 25-50 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mL D50W IV push; recheck glucose in 15 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose",
          "IV access"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ncse"
      ]
    },
    "dextrose-50-iv": {
      "id": "dextrose-50-iv",
      "name": "Dextrose 50% IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "hypoglycemia-correction-give-after-thiamine": {
          "indication": "Hypoglycemia correction; give AFTER thiamine",
          "doseOptions": [
            {
              "text": "25 g (50 mL)",
              "orderSentence": "Dextrose 50% IV 25 g (50 mL) IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mL IV push (25 g) if glucose <70 or unknown; ALWAYS give thiamine first or simultaneously",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50 mL",
              "orderSentence": "Dextrose 50% IV 50 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mL IV push (25g) if glucose <70 or unknown",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus",
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Document hyperglycemia",
          "Hyperglycemia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose",
          "Glucose recheck in 15-30 min"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "new-onset-seizure",
        "status-epilepticus"
      ]
    },
    "dhe-nasal": {
      "id": "dhe-nasal",
      "name": "DHE nasal",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IN"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "DHE nasal 0.5 mg -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5 mg per nostril (1 mg total); may repeat once in 15 min; max 3 mg/24h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as IV"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine"
      ]
    },
    "dhe-nasal-spray": {
      "id": "dhe-nasal-spray",
      "name": "DHE nasal spray",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IN"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-iv-dhe-for-patients-who-decline-iv-protocol-o": {
          "indication": "Alternative to IV DHE for patients who decline IV protocol or as bridge to outpatient",
          "doseOptions": [
            {
              "text": "0.5 mg per nostril once",
              "orderSentence": "DHE nasal spray 0.5 mg per nostril once IN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5 mg per nostril (1 mg total); may repeat once in 15 min; max 3 mg/24h; max 4 mg/week",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy, CAD, CVA, PVD, uncontrolled HTN (>180/110), triptan within 24h, ergot allergy, basilar/hemiplegic migraine, severe hepatic or renal disease, concurrent CYP3A4 inhibitors"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Nausea, nasal congestion, BP, chest pain"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "dhe-protocol": {
      "id": "dhe-protocol",
      "name": "DHE protocol (inpatient) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.5-1 mg",
              "orderSentence": "DHE protocol (inpatient) (CPT 96365) 0.5-1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "DHE 0.5-1 mg IV q8h × 3-5 days (with antiemetic pretreatment)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CAD, CVA, uncontrolled HTN, triptans <24h"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP, nausea, peripheral vasoconstriction"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cluster-headache"
      ]
    },
    "diabetes-management": {
      "id": "diabetes-management",
      "name": "Diabetes management (optimize)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO/SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "7%",
              "orderSentence": "Diabetes management (optimize) 7% -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Target HbA1c <7% (individualized); GLP-1 agonists and SGLT2 inhibitors have cardiovascular benefit",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "transient-ischemic-attack"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per agent"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HbA1c q3 months",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "transient-ischemic-attack"
      ]
    },
    "diabetes-optimization": {
      "id": "diabetes-optimization",
      "name": "Diabetes optimization",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "180 mg",
              "orderSentence": "**Diabetes optimization** 180 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Endocrinology consult if poorly controlled; insulin titration; goal HbA1c <7.5% (individualized); glucose <180 mg/dL during acute illness",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "epidural-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Diabetes is major risk factor",
          "uncontrolled diabetes impairs healing and immune response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epidural-abscess"
      ]
    },
    "diaphragm-pacing": {
      "id": "diaphragm-pacing",
      "name": "Diaphragm pacing (NeuRx)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "—"
      ],
      "formulations": [],
      "contexts": {
        "diaphragm-weakness": {
          "indication": "Diaphragm weakness",
          "doseOptions": [
            {
              "text": "Surgical implantation",
              "orderSentence": "Diaphragm pacing (NeuRx) Surgical implantation —"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Laparoscopic implantation of intramuscular diaphragm electrodes; controversial efficacy; FDA approved but limited evidence",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe diaphragm atrophy",
          "unable to tolerate surgery"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Diaphragm function, surgical complications"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "diazepam": {
      "id": "diazepam",
      "name": "Diazepam",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/PO",
        "PO",
        "PO/IV"
      ],
      "formulations": [],
      "contexts": {
        "status-dystonicus-muscle-spasm-relief": {
          "indication": "Status dystonicus; muscle spasm relief",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Diazepam 5 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg IV slow push (2 mg/min) or PO; may repeat q4h PRN",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "alternative-benzodiazepine-muscle-relaxant-properties": {
          "indication": "Alternative benzodiazepine; muscle relaxant properties",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Diazepam 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg TID; increase by 2-5 mg/day q3-7d; typical 10-40 mg/day divided",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "acute-severe-spasms-status-spasticus-first-line-benzodiazepi": {
          "indication": "Acute severe spasms; status spasticus; first-line benzodiazepine for SPS",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Diazepam 5-10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg IV push over 2-5 minutes; may repeat q5-10 min PRN; max 30 mg in first hour; then transition to scheduled dosing; typical maintenance 10-30 mg PO TID-QID",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "first-line-symptomatic-therapy-for-rigidity-and-spasms-in-sp": {
          "indication": "First-line symptomatic therapy for rigidity and spasms in SPS; GABAergic mechanism addresses pathophysiology",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Diazepam 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO TID; titrate by 5 mg/dose every 3-5 days as tolerated; typical effective dose 20-60 mg/day in divided doses; some patients require up to 100+ mg/day; max limited by sedation",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "stiff-person-spectrum-muscle-spasms-paraneoplastic-rigidity": {
          "indication": "Stiff-person spectrum; muscle spasms; paraneoplastic rigidity",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Diazepam 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg BID; titrate to effect; max 40 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "acute-vestibular-nystagmus-with-severe-vertigo-potent-vestib": {
          "indication": "Acute vestibular nystagmus with severe vertigo; potent vestibular suppressant; **SHORT-TERM ONLY (24-72h)**",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "**Diazepam** 2 mg PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Diazepam 2-5 mg PO or IV q8h PRN**; limit to 48-72h maximum; taper rapidly",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "acute-muscle-spasm": {
          "indication": "Acute muscle spasm",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Diazepam 5 mg PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO/IV q6-8h PRN for muscle spasm; short course (1-2 weeks)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "severe-acute-spasticity-and-muscle-spasm-with-anxiety-compon": {
          "indication": "Severe acute spasticity and muscle spasm with anxiety component; short-term use only",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Diazepam 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg PO BID; max 10 mg TID; short-term use only (2-4 weeks); taper to discontinue",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Acute narrow-angle glaucoma",
          "CNS depression",
          "Respiratory depression",
          "Respiratory depression without ventilator support",
          "Severe respiratory depression",
          "Severe respiratory insufficiency",
          "acute narrow-angle glaucoma",
          "avoid in elderly",
          "avoid in hepatic impairment",
          "dependency risk",
          "myasthenia gravis",
          "severe OSA without CPAP",
          "severe hepatic impairment",
          "severe hepatic insufficiency",
          "severe respiratory depression",
          "substance abuse history"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Respiratory depression, sedation",
          "Respiratory rate",
          "Respiratory status",
          "Sedation",
          "Sedation, dependence, falls",
          "SpO2",
          "airway patency",
          "avoid in suspected central cause until stroke excluded",
          "cognitive function",
          "cognitive impairment",
          "dependence",
          "dependence (do NOT abruptly discontinue)",
          "fall risk",
          "falls",
          "falls (especially in myelopathy patients)",
          "have flumazenil available",
          "limit to 72h",
          "respiratory depression",
          "respiratory status",
          "sedation level",
          "taper if discontinuing",
          "tolerance"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "cervical-myelopathy",
        "dystonia",
        "nystagmus-evaluation",
        "paraneoplastic-neurological-syndrome",
        "radiculopathy",
        "stiff-person-syndrome"
      ]
    },
    "diazepam-iv": {
      "id": "diazepam-iv",
      "name": "Diazepam IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-seizure-cessation-preferred-for-smooth-withdrawal-prop": {
          "indication": "Acute seizure cessation; preferred for smooth withdrawal prophylaxis due to long-acting metabolites",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Diazepam IV 5-10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg IV push over 2-5 min; may repeat q5-10min; max 30 mg in first hour; long-acting active metabolite (desmethyldiazepam) provides smoother withdrawal coverage",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.15 mg/kg",
              "orderSentence": "Diazepam IV 0.15 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.15 mg/kg IV (max 10 mg); may repeat x1 in 5 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Acute narrow-angle glaucoma",
          "Severe hepatic impairment (use lorazepam instead)",
          "severe respiratory depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RR, O2 sat",
          "RR, O2 sat, BP, sedation level",
          "active metabolites accumulate in liver disease",
          "short duration - requires follow-up ASM"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "status-epilepticus"
      ]
    },
    "diazepam-nasal": {
      "id": "diazepam-nasal",
      "name": "Diazepam nasal (Valtoco)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IN"
      ],
      "formulations": [],
      "contexts": {
        "acute-seizure-clusters-rescue-nasal-alternative-to-rectal": {
          "indication": "Acute seizure clusters/rescue; nasal alternative to rectal",
          "doseOptions": [
            {
              "text": "5-20 mg based on weight",
              "orderSentence": "Diazepam nasal (Valtoco) 5-20 mg based on weight IN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg, 10 mg, 15 mg, or 20 mg intranasal based on weight; may repeat x1 in 4-12h; max 2 doses per episode",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "seizure-cluster-rescue-nasal-alternative": {
          "indication": "Seizure cluster rescue; nasal alternative",
          "doseOptions": [
            {
              "text": "5-20 mg based on weight",
              "orderSentence": "Diazepam nasal (Valtoco) 5-20 mg based on weight IN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5, 10, 15, or 20 mg intranasal based on weight; may repeat x1 in 4-12h; max 2 doses/episode",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Acute narrow-angle glaucoma"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Respiratory status",
          "sedation",
          "sedation level"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "drug-resistant-epilepsy",
        "epilepsy-chronic-management"
      ]
    },
    "diazepam-po": {
      "id": "diazepam-po",
      "name": "Diazepam PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "symptom-triggered-withdrawal-management-alternative-to-chlor": {
          "indication": "Symptom-triggered withdrawal management; alternative to chlordiazepoxide",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Diazepam PO 10-20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "CIWA-Ar >=10: give 10-20 mg PO q1-2h until CIWA <10; then PRN dosing; taper over 3-5 days; long-acting metabolites",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment (use lorazepam)",
          "respiratory depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CIWA-Ar q1h during active treatment, then q4h",
          "RR, sedation level"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure"
      ]
    },
    "diazepam-rectal": {
      "id": "diazepam-rectal",
      "name": "Diazepam rectal (Diastat)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PR"
      ],
      "formulations": [],
      "contexts": {
        "acute-seizure-clusters-rescue-alternative-outpatient-rescue": {
          "indication": "Acute seizure clusters/rescue; alternative outpatient rescue",
          "doseOptions": [
            {
              "text": "10-20 mg based on weight",
              "orderSentence": "Diazepam rectal (Diastat) 10-20 mg based on weight PR"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.2 mg/kg PR rounded to available dose (10, 12.5, 15, 17.5, 20 mg); may repeat x1 in 4-12h; max 2 doses per episode; max 5 episodes/month",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.2-0.5 mg/kg",
              "orderSentence": "Diazepam rectal 0.2-0.5 mg/kg PR"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.2-0.5 mg/kg PR (max 20 mg); use rectal gel formulation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "seizure-cluster-rescue-alternative-to-intranasal-midazolam": {
          "indication": "Seizure cluster rescue; alternative to intranasal midazolam",
          "doseOptions": [
            {
              "text": "10-20 mg based on weight",
              "orderSentence": "Diazepam rectal (Diastat) 10-20 mg based on weight PR"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.2 mg/kg PR; may repeat x1 in 4-12h; max 2 doses/episode; max 5 episodes/month",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Acute narrow-angle glaucoma",
          "Rectal pathology",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RR, O2 sat",
          "Respiratory status",
          "sedation",
          "sedation level"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "drug-resistant-epilepsy",
        "epilepsy-chronic-management",
        "status-epilepticus"
      ]
    },
    "dihydroergotamine": {
      "id": "dihydroergotamine",
      "name": "Dihydroergotamine (DHE)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Dihydroergotamine (DHE) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Premedicate: metoclopramide 10 mg IV + diphenhydramine 25 mg IV; Test dose: 0.5 mg IV over 1 min; If tolerated: 0.5-1 mg IV q8h",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "refractory-migraine-status-migrainosus-not-for-hemiplegic": {
          "indication": "Refractory migraine; status migrainosus; **NOT for hemiplegic**",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Dihydroergotamine (DHE) 0.5 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "IV: 0.5-1 mg q8h for up to 3 days (pretreat with antiemetic); SC: 1 mg, may repeat in 1 hr; Nasal: 1 spray each nostril, repeat in 15 min",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**HEMIPLEGIC MIGRAINE**",
          "CAD",
          "Pregnancy",
          "Pregnancy, CAD, CVA, uncontrolled HTN, triptan <24h, ergot allergy",
          "peripheral vascular disease",
          "severe hepatic/renal impairment",
          "triptan use within 24hr",
          "uncontrolled HTN"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP, chest pain, nausea",
          "chest pain",
          "continuous cardiac monitoring for IV",
          "nausea"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "migraine",
        "migraine-with-aura"
      ]
    },
    "dihydroergotamine-iv": {
      "id": "dihydroergotamine-iv",
      "name": "Dihydroergotamine (DHE) IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-status-migrainosus-prolonged-migraine": {
          "indication": "Refractory status migrainosus; prolonged migraine",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Dihydroergotamine (DHE) IV 1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Premedicate: metoclopramide 10 mg IV + diphenhydramine 25 mg IV 30 min prior; Test dose: 0.5 mg IV over 1 min; If tolerated: 0.5-1 mg IV q8h x 3-5 days",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CAD, CVA, uncontrolled HTN, peripheral vascular disease, pregnancy, triptan within 24h, ergot allergy, CYP3A4 inhibitors"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q4h, chest pain, nausea, extremity perfusion"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "chronic-migraine"
      ]
    },
    "dihydroergotamine-iv-repetitive-protocol": {
      "id": "dihydroergotamine-iv-repetitive-protocol",
      "name": "Dihydroergotamine (DHE) IV - repetitive protocol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "repetitive-iv-dhe-for-sustained-break-of-status-migrainosus-": {
          "indication": "Repetitive IV DHE for sustained break of status migrainosus (Raskin protocol)",
          "doseOptions": [
            {
              "text": "0.5 mg IV q8h",
              "orderSentence": "Dihydroergotamine (DHE) IV - repetitive protocol 0.5 mg IV q8h IV"
            },
            {
              "text": "1 mg IV q8h",
              "orderSentence": "Dihydroergotamine (DHE) IV - repetitive protocol 1 mg IV q8h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If test dose tolerated: 0.5-1 mg IV q8h for up to 3-5 days; premedicate each dose with antiemetic; may titrate to 1 mg if 0.5 mg tolerated",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy, CAD, CVA, PVD, uncontrolled HTN (>180/110), triptan within 24h, ergot allergy, basilar/hemiplegic migraine, severe hepatic or renal disease, concurrent CYP3A4 inhibitors"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q15min during infusion, chest pain, limb ischemia, nausea",
          "daily ECG during protocol"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "dihydroergotamine-iv-test-dose": {
      "id": "dihydroergotamine-iv-test-dose",
      "name": "Dihydroergotamine (DHE) IV - test dose",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "first-dose-to-assess-tolerability-before-initiating-repetiti": {
          "indication": "First dose to assess tolerability before initiating repetitive DHE protocol",
          "doseOptions": [
            {
              "text": "0.5 mg IV once",
              "orderSentence": "Dihydroergotamine (DHE) IV - test dose 0.5 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Premedicate: metoclopramide 10 mg IV + diphenhydramine 25 mg IV 30 min prior; then DHE 0.5 mg IV over 3-5 min as test dose",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy, CAD, CVA, PVD, uncontrolled HTN (>180/110), triptan within 24h, ergot allergy, basilar/hemiplegic migraine, severe hepatic or renal disease, concurrent CYP3A4 inhibitors"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q15min during infusion, chest pain, limb ischemia, nausea"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "dimenhydrinate": {
      "id": "dimenhydrinate",
      "name": "Dimenhydrinate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO",
        "PO/IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-vestibular-symptoms-short-term-only": {
          "indication": "Acute vestibular symptoms (short-term only)",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Dimenhydrinate 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg PO q6h PRN; short-term only (<1-2 weeks)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "acute-peripheral-vestibular-nystagmus-with-nausea-and-vertig": {
          "indication": "Acute peripheral vestibular nystagmus with nausea and vertigo; **SHORT-TERM ONLY (24-72h)**; avoid in central nystagmus until etiology established",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "**Dimenhydrinate** 50 mg PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Dimenhydrinate 50 mg PO or IV q6h PRN**; limit to 48-72h maximum",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Avoid in central nystagmus until etiology established",
          "Same as meclizine",
          "anticholinergic effects in elderly",
          "prolonged use delays vestibular compensation",
          "sedation"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Limit to 72h",
          "Sedation",
          "anticholinergic side effects",
          "avoid chronic use",
          "sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "nystagmus-evaluation",
        "post-concussion-syndrome"
      ]
    },
    "dimethyl-fumarate": {
      "id": "dimethyl-fumarate",
      "name": "Dimethyl fumarate (Tecfidera)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "120 mg",
              "orderSentence": "Dimethyl fumarate (Tecfidera) 120 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "120 mg BID × 7 days, then 240 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Lymphopenia (<500), PML risk",
          "Lymphopenia <500 (discontinue)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC q6 months",
          "CBC q6mo (lymphocytes)",
          "GI side effects (take with food)",
          "GI symptoms, flushing",
          "LFTs",
          "flushing (aspirin 30 min prior)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "diphenhydramine": {
      "id": "diphenhydramine",
      "name": "Diphenhydramine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/IM"
      ],
      "formulations": [],
      "contexts": {
        "acute-dystonic-reaction-drug-induced": {
          "indication": "Acute dystonic reaction (drug-induced)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Diphenhydramine 25 mg IV/IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV/IM over 2-5 min; may repeat in 30 min if needed; max 100 mg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "ivig-premedication": {
          "indication": "IVIG premedication",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Diphenhydramine 25-50 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV/PO 30 min before IVIG infusion",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis"
          ]
        },
        "prevents-infusion-related-allergic-reactions-during-amphoter": {
          "indication": "Prevents infusion-related allergic reactions during amphotericin B",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Diphenhydramine (amphotericin premedication) 25-50 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV 30-60 minutes before each amphotericin B infusion",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "prevents-akathisia-from-dopamine-antagonists-mild-analgesic-": {
          "indication": "Prevents akathisia from dopamine antagonists; mild analgesic adjunct",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Diphenhydramine (CPT 96374) 25 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg IV push prior to or with metoclopramide",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "prevention-of-akathisia-dystonia-from-dopamine-antagonist-an": {
          "indication": "Prevention of akathisia/dystonia from dopamine antagonist antiemetics",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Diphenhydramine (CPT 96374) 25-50 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV push (co-administer with prochlorperazine or metoclopramide)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "adjunct-to-prevent-akathisia-from-dopamine-antagonists": {
          "indication": "Adjunct to prevent akathisia from dopamine antagonists",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Diphenhydramine 25 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg IV prior to metoclopramide",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "prevent-akathisia-from-dopamine-antagonists-sedation": {
          "indication": "Prevent akathisia from dopamine antagonists; sedation",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Diphenhydramine 25 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV given concurrently with dopamine antagonist",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Angle-closure glaucoma",
          "Glaucoma, urinary retention, elderly (increased sedation risk)",
          "Narrow-angle glaucoma",
          "avoid in elderly (anticholinergic)",
          "severe prostatic hypertrophy",
          "severe sedation risk (elderly)",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation",
          "Sedation level",
          "Sedation, dry mouth",
          "Sedation, hypotension",
          "anticholinergic effects"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "dystonia",
        "fungal-meningitis",
        "headache-evaluation",
        "headache-unspecified",
        "migraine-with-aura",
        "myasthenia-gravis-crisis",
        "tension-headache"
      ]
    },
    "diphenhydramine-iv": {
      "id": "diphenhydramine-iv",
      "name": "Diphenhydramine IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Diphenhydramine IV 25-50 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV to prevent akathisia (give with antiemetic)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "akathisia-prophylaxis-with-dopamine-antagonists": {
          "indication": "Akathisia prophylaxis with dopamine antagonists",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Diphenhydramine IV 25-50 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV push (give with prochlorperazine or metoclopramide)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "prevention-of-akathisia-and-dystonic-reactions-from-dopamine": {
          "indication": "Prevention of akathisia and dystonic reactions from dopamine antagonist antiemetics",
          "doseOptions": [
            {
              "text": "25 mg IV once",
              "orderSentence": "Diphenhydramine IV 25 mg IV once IV"
            },
            {
              "text": "50 mg IV once",
              "orderSentence": "Diphenhydramine IV 50 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV push with each antiemetic dose",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Glaucoma, urinary retention",
          "Narrow-angle glaucoma, urinary retention",
          "Narrow-angle glaucoma, urinary retention, severe drowsiness risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation",
          "Sedation level"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "status-migrainosus"
      ]
    },
    "diphenhydramine-iv-im": {
      "id": "diphenhydramine-iv-im",
      "name": "Diphenhydramine (Benadryl) IV/IM",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-symptomatic-relief-of-dip-in-ed-inpatient-mild-anticho": {
          "indication": "Acute symptomatic relief of DIP in ED/inpatient; mild anticholinergic properties",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Diphenhydramine (Benadryl) IV/IM 25 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV/IM for acute relief; may repeat q6-8h; max 300 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Narrow-angle glaucoma",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation, anticholinergic effects, falls in elderly"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-induced-parkinsonism"
      ]
    },
    "diphenhydramine-po": {
      "id": "diphenhydramine-po",
      "name": "Diphenhydramine (Benadryl) PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "mild-symptomatic-relief-of-dip-oral-maintenance": {
          "indication": "Mild symptomatic relief of DIP; oral maintenance",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Diphenhydramine (Benadryl) PO 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg PO q6-8h for ongoing symptoms; max 300 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Narrow-angle glaucoma",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation, anticholinergic effects, falls in elderly"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-induced-parkinsonism"
      ]
    },
    "diroximel-fumarate": {
      "id": "diroximel-fumarate",
      "name": "Diroximel fumarate (Vumerity)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "231 mg",
              "orderSentence": "Diroximel fumarate (Vumerity) 231 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "231 mg BID × 7 days, then 462 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same",
          "Same as Tecfidera"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same",
          "less GI effects",
          "less GI side effects than Tecfidera"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "discontinuation-of-non-essential-medications": {
      "id": "discontinuation-of-non-essential-medications",
      "name": "Discontinuation of non-essential medications",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "medication-reconciliation-stop-statins-antihypertensives-dia": {
          "indication": "Medication reconciliation -- stop statins, antihypertensives, diabetes medications, preventive therapies that no longer serve goals of care",
          "doseOptions": [
            {
              "text": "-",
              "orderSentence": "Discontinuation of non-essential medications - -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Gradual taper or discontinuation per clinical judgment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Do not abruptly stop benzodiazepines, opioids, or anticonvulsants (taper if discontinuing)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Comfort",
          "symptom control after medication changes"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "creutzfeldt-jakob-disease"
      ]
    },
    "discontinue-or-reduce-suspected-causative-medication": {
      "id": "discontinue-or-reduce-suspected-causative-medication",
      "name": "Discontinue or reduce suspected causative medication",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "drug-induced-tremor-temporal-relationship-between-medication": {
          "indication": "Drug-induced tremor; temporal relationship between medication initiation and tremor onset",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Discontinue or reduce suspected causative medication N/A PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Identify and discontinue offending agent if safe; taper if abrupt withdrawal is dangerous (benzodiazepines, antiepileptics, antipsychotics); coordinate with prescribing physician",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active psychosis, seizure disorder, or condition requiring the medication without safe alternative"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Symptom resolution timeline",
          "rebound of treated condition",
          "withdrawal symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tremor-unspecified"
      ]
    },
    "dobutamine": {
      "id": "dobutamine",
      "name": "Dobutamine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "post-arrest-cardiogenic-shock-with-reduced-ef-30-augment-car": {
          "indication": "Post-arrest cardiogenic shock with reduced EF (<30%); augment cardiac output when vasopressors alone insufficient",
          "doseOptions": [
            {
              "text": "2.5-20 mcg/kg/min",
              "orderSentence": "Dobutamine 2.5-20 mcg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5 mcg/kg/min; titrate to cardiac output and MAP; consider with echo guidance",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "LVOT obstruction",
          "severe tachyarrhythmia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "HR",
          "arrhythmia",
          "cardiac output (echo or PA catheter)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "anoxic-brain-injury"
      ]
    },
    "docusate": {
      "id": "docusate",
      "name": "Docusate (stool softener)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "avoid-valsalva-straining-may-increase-icp-re-bleed-risk-in-s": {
          "indication": "Avoid Valsalva/straining (may increase ICP; re-bleed risk in SAH)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate (stool softener) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bowel obstruction"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bowel movements"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "thunderclap-headache-evaluation"
      ]
    },
    "docusate-senna": {
      "id": "docusate-senna",
      "name": "Docusate + senna (constipation prophylaxis)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "constipation-prevention-universal-need-with-immobility-and-o": {
          "indication": "Constipation prevention -- universal need with immobility and opioid use",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate + senna (constipation prophylaxis) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Docusate 100 mg PO BID + senna 8.6 mg PO BID; titrate senna to effect",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bowel obstruction"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bowel frequency",
          "abdominal distension"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "creutzfeldt-jakob-disease"
      ]
    },
    "docusate-sodium": {
      "id": "docusate-sodium",
      "name": "Docusate sodium",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "constipation-immobility-opioid-use": {
          "indication": "Constipation (immobility + opioid use)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate sodium 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "prevent-straining-during-bed-rest-which-can-worsen-csf-leak": {
          "indication": "Prevent straining during bed rest which can worsen CSF leak",
          "doseOptions": [
            {
              "text": "100 mg BID",
              "orderSentence": "Docusate sodium 100 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID; continue throughout bed rest period and until regular activity resumes",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        },
        "constipation-from-immobility-and-opioid-use": {
          "indication": "Constipation from immobility and opioid use",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate sodium 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "constipation-prevention-immobility-reduced-activity": {
          "indication": "Constipation prevention (immobility, reduced activity)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate sodium 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "stool-softener-to-prevent-straining-valsalva-which-may-trigg": {
          "indication": "Stool softener to prevent straining/Valsalva which may trigger thunderclap headache recurrence",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate sodium 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID while symptomatic; Valsalva is a common trigger for RCVS thunderclap headaches",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "constipation-prevention-during-opioid-use-or-immobility-from": {
          "indication": "Constipation prevention during opioid use or immobility from myelitis",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate sodium 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "constipation": {
          "indication": "Constipation",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate sodium 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg BID; max 500 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy",
            "ms-new-diagnosis"
          ]
        },
        "constipation-prevention-gi-dysmotility-common-in-dm1-reduced": {
          "indication": "Constipation prevention (GI dysmotility common in DM1; reduced activity; smooth muscle involvement)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate sodium 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "constipation-immobility-opioids": {
          "indication": "Constipation (immobility + opioids)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate sodium 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        },
        "constipation-prevention-in-neurogenic-bowel-maintain-regular": {
          "indication": "Constipation prevention in neurogenic bowel; maintain regular bowel program",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate sodium 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID; take with adequate fluids",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "constipation-immobility-autonomic-dysfunction": {
          "indication": "Constipation (immobility + autonomic dysfunction)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Docusate sodium 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "botulism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bowel obstruction",
          "GI obstruction",
          "Intestinal obstruction",
          "concurrent mineral oil"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bowel frequency",
          "Bowel function",
          "Bowel function daily",
          "Minimal efficacy alone",
          "Minimal efficacy as monotherapy",
          "abdominal distension",
          "best for stool softening"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 12,
      "_sourcePlans": [
        "botulism",
        "cervical-myelopathy",
        "critical-illness-myopathy-neuropathy",
        "guillain-barre-syndrome",
        "inclusion-body-myositis",
        "inflammatory-myopathy",
        "low-pressure-headache",
        "mogad",
        "ms-new-diagnosis",
        "myotonic-dystrophy",
        "peripheral-neuropathy",
        "rcvs"
      ]
    },
    "dolutegravir": {
      "id": "dolutegravir",
      "name": "Dolutegravir (Tivicay)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-insti-with-high-cpe-score-cpe-4-excellent-cns-pen": {
          "indication": "First-line INSTI with high CPE score (CPE 4); excellent CNS penetration; backbone of CNS-optimized ART regimen",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Dolutegravir (Tivicay) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg PO daily; increase to 50 mg BID if INSTI resistance suspected or with rifampin",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity",
          "concurrent dofetilide"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CD4 q3-6 months",
          "CMP",
          "Viral load q4-8 weeks until undetectable, then q3-6 months",
          "weight gain monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "domperidone": {
      "id": "domperidone",
      "name": "Domperidone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "peripheral-dopamine-antagonist-for-gastroparesis-does-not-cr": {
          "indication": "Peripheral dopamine antagonist for gastroparesis; does not cross BBB significantly; substitute for metoclopramide",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Domperidone (Motilium) 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg TID before meals; max 30 mg/day; not FDA-approved in US (available via compassionate use/international pharmacy)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        },
        "gastroparesis-prokinetic-with-less-cns-effects": {
          "indication": "Gastroparesis; prokinetic with less CNS effects",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Domperidone 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg TID before meals; not FDA-approved (requires IND or international pharmacy)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "gastroparesis-if-metoclopramide-contraindicated": {
          "indication": "Gastroparesis (if metoclopramide contraindicated)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Domperidone 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg TID before meals; max 30 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI bleeding or obstruction",
          "QT prolongation",
          "concurrent QT-prolonging drugs",
          "hepatic impairment",
          "prolactinoma",
          "ventricular arrhythmia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG at baseline",
          "ECG before initiation and periodically",
          "ECG for QT",
          "QTc must be <450 ms",
          "arrhythmia",
          "electrolytes",
          "not FDA-approved (requires special access)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "drug-induced-parkinsonism",
        "peripheral-neuropathy",
        "small-fiber-neuropathy"
      ]
    },
    "donanemab": {
      "id": "donanemab",
      "name": "Donanemab (Kisunla)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "mci-due-to-ad-with-confirmed-amyloid-and-intermediate-high-t": {
          "indication": "MCI due to AD with confirmed amyloid and intermediate/high tau pathology",
          "doseOptions": [
            {
              "text": "700 mg",
              "orderSentence": "Donanemab (Kisunla) 700 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "700 mg q4wk x 3 doses, then 1400 mg q4wk until amyloid cleared (PET-guided discontinuation)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "700 mg",
              "orderSentence": "Donanemab (Kisunla) (CPT 96365) 700 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "700 mg IV q4 weeks × 3, then 1400 mg q4 weeks until amyloid clearance; discontinue when cleared",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "early-ad-mci-or-mild-dementia-with-confirmed-amyloid-and-int": {
          "indication": "Early AD (MCI or mild dementia) with confirmed amyloid AND intermediate/high tau pathology",
          "doseOptions": [
            {
              "text": "700 mg IV q4wk x 3",
              "orderSentence": "Donanemab (Kisunla) 700 mg IV q4wk x 3 IV"
            },
            {
              "text": "then 1400 mg IV q4wk",
              "orderSentence": "Donanemab (Kisunla) then 1400 mg IV q4wk IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "700 mg IV every 4 weeks x 3 doses, then 1400 mg IV every 4 weeks until amyloid clearance (by PET); discontinue when PET negative",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          ">4 microbleeds",
          "APOE4 homozygotes have higher ARIA risk",
          "Same",
          "Same as lecanemab",
          "anticoagulation",
          "higher ARIA risk in APOE ε4 homozygotes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "MRI at baseline, weeks 16, 24, 52, 76",
          "MRI: baseline, weeks 12, 24, 52, 76 (ARIA monitoring)",
          "Same",
          "amyloid PET to guide discontinuation",
          "discontinue at clearance",
          "repeat amyloid PET to assess clearance"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "alzheimers-disease",
        "dementia-evaluation",
        "mild-cognitive-impairment"
      ]
    },
    "donepezil": {
      "id": "donepezil",
      "name": "Donepezil",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "vascular-dementia-cognitive-symptoms-modest-but-measurable-b": {
          "indication": "Vascular dementia cognitive symptoms; modest but measurable benefit",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Donepezil (Aricept) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg qHS x 4-6 weeks; if tolerated, increase to 10 mg qHS; benefit smaller than in AD",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "cognitive-impairment-limited-evidence-in-hd": {
          "indication": "Cognitive impairment; limited evidence in HD",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Donepezil 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg qHS; may increase to 10 mg after 4-6 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "mci-with-high-likelihood-of-ad-pathology-amnestic-mci-positi": {
          "indication": "MCI with high likelihood of AD pathology (amnestic MCI, positive biomarkers); modest symptomatic benefit",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Donepezil 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg qHS x 4-6 weeks; may increase to 10 mg qHS; limited evidence in MCI but may offer modest benefit",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "cognitive-symptoms-if-ad-component-suspected": {
          "indication": "Cognitive symptoms if AD component suspected",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Donepezil 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg qHS x 4-6 weeks; increase to 10 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "normal-pressure-hydrocephalus"
          ]
        },
        "cognitive-impairment-alternative-to-rivastigmine": {
          "indication": "Cognitive impairment; alternative to rivastigmine",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Donepezil 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg qHS x 4-6 weeks; may increase to 10 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "cognitive-impairment-in-psp-cholinergic-deficit-in-psp": {
          "indication": "Cognitive impairment in PSP; cholinergic deficit in PSP",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Donepezil 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg QHS x 4-6 weeks; may increase to 10 mg QHS; limited evidence in PSP but reasonable trial",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Donepezil (Aricept) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg QHS × 4-6 weeks, then increase to 10 mg QHS; 23 mg available for moderate-severe",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "avoid-may-worsen-behavioral-symptoms-in-ftd": {
          "indication": "AVOID - May worsen behavioral symptoms in FTD",
          "doseOptions": [
            {
              "text": "AVOID",
              "orderSentence": "Donepezil (Aricept) AVOID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Do NOT use; cholinesterase inhibitors can worsen disinhibition, agitation, and behavioral symptoms in FTD",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "mild-moderate-or-severe-ad-first-line": {
          "indication": "Mild, moderate, or severe AD (first-line)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Donepezil (Aricept) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg qHS x 4-6 weeks; if tolerated, increase to 10 mg qHS; 23 mg available for moderate-severe AD after stable on 10 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        },
        "parkinson-s-disease-dementia-once-daily-option": {
          "indication": "Parkinson's disease dementia; once daily option",
          "doseOptions": [
            {
              "text": "5 mg qHS",
              "orderSentence": "Donepezil 5 mg qHS PO"
            },
            {
              "text": "10 mg qHS",
              "orderSentence": "Donepezil 10 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg qHS; increase to 10 mg after 4-6 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bradycardia",
          "Bradycardia, sick sinus, GI bleeding",
          "COPD",
          "COPD exacerbation",
          "FTD diagnosis",
          "GI bleeding",
          "Sick sinus syndrome",
          "active GI bleeding",
          "peptic ulcer",
          "second/third degree heart block without pacemaker",
          "severe COPD",
          "sick sinus syndrome"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bradycardia, GI side effects (nausea, diarrhea), nightmares",
          "Bradycardia, GI symptoms",
          "Bradycardia, GI symptoms, vivid dreams",
          "Bradycardia, GI upset, nightmares",
          "Bradycardia, vivid dreams (may worsen RBD), GI",
          "GI symptoms (nausea, diarrhea)",
          "Heart rate",
          "Nausea, bradycardia, diarrhea",
          "Nausea, bradycardia, vivid dreams",
          "Worsening behavior if inadvertently started",
          "heart rate",
          "limited efficacy data in MCI",
          "muscle cramps",
          "vivid dreams"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "alzheimers-disease",
        "dementia-evaluation",
        "frontotemporal-dementia",
        "huntingtons-disease",
        "lewy-body-dementia",
        "mild-cognitive-impairment",
        "normal-pressure-hydrocephalus",
        "parkinsons-disease",
        "progressive-supranuclear-palsy",
        "vascular-dementia"
      ]
    },
    "doxycycline": {
      "id": "doxycycline",
      "name": "Doxycycline",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "third-line-alternative-only-when-both-iv-penicillin-and-ceft": {
          "indication": "Third-line alternative ONLY when both IV penicillin and ceftriaxone are contraindicated; limited evidence for neurosyphilis; better studied for early syphilis",
          "doseOptions": [
            {
              "text": "200 mg BID",
              "orderSentence": "Doxycycline (third-line alternative) 200 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg PO BID for 28 days. Some experts recommend 30 days. LOWER confidence in CNS penetration; use only if no other option. Close CSF monitoring mandatory",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Doxycycline 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID × 14-21 days (isolated facial palsy)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "bells-palsy"
          ]
        },
        "first-line-for-isolated-facial-palsy-without-csf-pleocytosis": {
          "indication": "First-line for isolated facial palsy WITHOUT CSF pleocytosis or other evidence of CNS involvement; also acceptable for Lyme radiculopathy without meningitis in European practice; IDSA/AAN guidelines support oral doxycycline for cranial neuropathy without meningitis",
          "doseOptions": [
            {
              "text": "100 mg BID",
              "orderSentence": "Doxycycline 100 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID for 14-21 days; take with full glass of water; remain upright 30 min after dosing to prevent esophageal ulceration",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        },
        "late-neuroborreliosis-with-encephalopathy-or-peripheral-neur": {
          "indication": "Late neuroborreliosis with encephalopathy or peripheral neuropathy; some European guidelines support oral doxycycline for all neuroborreliosis (including meningitis); may be used as step-down therapy after initial IV ceftriaxone",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Doxycycline (extended course for late neuroborreliosis) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO BID for 21-28 days (some European protocols use 200 mg BID); IDSA 2020 guidelines suggest oral doxycycline may be equivalent to IV ceftriaxone for neuroborreliosis",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy",
          "Pregnancy, children <8",
          "children <8 years",
          "concurrent retinoids",
          "esophageal stricture",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI tolerance",
          "GI upset",
          "LFTs",
          "LFTs if prolonged course",
          "photosensitivity",
          "photosensitivity counseling",
          "sun protection counseling"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "bells-palsy",
        "lyme-neuroborreliosis",
        "neurosyphilis"
      ]
    },
    "droperidol-iv": {
      "id": "droperidol-iv",
      "name": "Droperidol IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "alternative-dopamine-antagonist-with-strong-antiemetic-and-a": {
          "indication": "Alternative dopamine antagonist with strong antiemetic and analgesic effect; FDA black box for QT prolongation requires ECG",
          "doseOptions": [
            {
              "text": "2.5 mg IV once",
              "orderSentence": "Droperidol IV 2.5 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2.5 mg IV over 2-5 min; may repeat x1 in 30 min; max 5 mg",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation (QTc >440 ms), hypokalemia, hypomagnesemia, Parkinson disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG before and after (FDA black box), QTc, BP, akathisia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "droxidopa": {
      "id": "droxidopa",
      "name": "Droxidopa (Northera)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "neurogenic-orthostatic-hypotension-fda-approved-for-autonomi": {
          "indication": "Neurogenic orthostatic hypotension; FDA-approved for autonomic failure",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Droxidopa (Northera) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg TID; titrate by 100 mg/day q24-48h; max 600 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "neurogenic-orthostatic-hypotension": {
          "indication": "Neurogenic orthostatic hypotension",
          "doseOptions": [
            {
              "text": "100 mg TID",
              "orderSentence": "Droxidopa (Northera) 100 mg TID PO"
            },
            {
              "text": "200 mg TID",
              "orderSentence": "Droxidopa (Northera) 200 mg TID PO"
            },
            {
              "text": "300 mg TID",
              "orderSentence": "Droxidopa (Northera) 300 mg TID PO"
            },
            {
              "text": "600 mg TID",
              "orderSentence": "Droxidopa (Northera) 600 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg TID; titrate by 100 mg/dose q24-48h; max 600 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia",
            "peripheral-neuropathy",
            "parkinsons-disease"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Droxidopa (orthostatic hypotension) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg TID; max 600 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "neurogenic-orthostatic-hypotension-not-responsive-to-midodri": {
          "indication": "Neurogenic orthostatic hypotension not responsive to midodrine/fludrocortisone",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Droxidopa (Northera) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg TID; titrate by 100 mg/dose q24-48h; max 600 mg TID; last dose 5+ hours before bedtime",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "neurogenic-oh-norepinephrine-precursor-fda-approved-for-neur": {
          "indication": "Neurogenic OH — norepinephrine precursor; FDA-approved for neurogenic OH",
          "doseOptions": [
            {
              "text": "100 mg TID",
              "orderSentence": "Droxidopa (Northera) 100 mg TID PO"
            },
            {
              "text": "200 mg TID",
              "orderSentence": "Droxidopa (Northera) 200 mg TID PO"
            },
            {
              "text": "300 mg TID",
              "orderSentence": "Droxidopa (Northera) 300 mg TID PO"
            },
            {
              "text": "600 mg TID",
              "orderSentence": "Droxidopa (Northera) 600 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg TID; titrate by 100 mg TID q24-48h; max 600 mg TID; take upon awakening, midday, late afternoon",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent ergot alkaloids",
          "Supine HTN",
          "Supine hypertension",
          "Supine hypertension (SBP >180 at baseline), closed-angle glaucoma",
          "Supine hypertension (severe)",
          "hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP supine and standing",
          "Supine BP",
          "Supine BP, headache",
          "Supine and standing BP (initial dose and titration)",
          "Supine blood pressure",
          "Supine hypertension (do not take within 3 hours of bedtime)",
          "avoid lying flat for 2h after dose",
          "falls",
          "headache",
          "supine hypertension (measure BP supine before bedtime)",
          "use caution with MAOIs and triptans (hypertensive risk)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "lewy-body-dementia",
        "multiple-system-atrophy",
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis",
        "peripheral-neuropathy",
        "progressive-supranuclear-palsy",
        "small-fiber-neuropathy"
      ]
    },
    "dual-antiplatelet-therapy-aspirin-ticagrelor": {
      "id": "dual-antiplatelet-therapy-aspirin-ticagrelor",
      "name": "Dual antiplatelet therapy (alternative): Aspirin + Ticagrelor",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "81 mg",
              "orderSentence": "Dual antiplatelet therapy (alternative): Aspirin + Ticagrelor 81 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Aspirin 81 mg daily + Ticagrelor 90 mg BID x 30 days (THALES trial; for minor stroke NIHSS ≤5). Then single antiplatelet",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "STAT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "transient-ischemic-attack"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Intracranial hemorrhage history",
          "hepatic impairment",
          "high bleeding risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bleeding",
          "avoid strong CYP3A4 inhibitors",
          "dyspnea (common side effect)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "transient-ischemic-attack"
      ]
    },
    "duloxetine": {
      "id": "duloxetine",
      "name": "Duloxetine",
      "genericName": "duloxetine",
      "brandNames": [
        "Cymbalta",
        "Drizalma"
      ],
      "drugClass": "SNRI (Serotonin-Norepinephrine Reuptake Inhibitor)",
      "mechanisms": [
        "Inhibits reuptake of serotonin and norepinephrine",
        "Descending pain inhibition pathway modulation"
      ],
      "routes": [
        "PO"
      ],
      "formulations": [
        "20 mg capsule",
        "30 mg capsule",
        "40 mg capsule",
        "60 mg capsule"
      ],
      "contexts": {
        "neuropathic-pain": {
          "indication": "Diabetic peripheral neuropathy, neuropathic pain",
          "doseOptions": [
            {
              "text": "30 mg daily",
              "orderSentence": "Duloxetine 30 mg PO daily"
            },
            {
              "text": "60 mg daily",
              "orderSentence": "Duloxetine 60 mg PO daily"
            },
            {
              "text": "90 mg daily",
              "orderSentence": "Duloxetine 90 mg PO daily"
            },
            {
              "text": "120 mg daily",
              "orderSentence": "Duloxetine 120 mg PO daily"
            }
          ],
          "startingDose": "30 mg daily (to minimize nausea)",
          "maxDose": "120 mg/day",
          "titration": "Start 30 mg daily x 1-2 weeks, then increase to 60 mg daily",
          "notes": "FDA-approved for DPNP; first-line option",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          }
        },
        "fibromyalgia": {
          "indication": "Fibromyalgia",
          "doseOptions": [
            {
              "text": "30 mg daily",
              "orderSentence": "Duloxetine 30 mg PO daily"
            },
            {
              "text": "60 mg daily",
              "orderSentence": "Duloxetine 60 mg PO daily"
            }
          ],
          "startingDose": "30 mg daily",
          "maxDose": "60 mg/day",
          "titration": "Start 30 mg daily x 1 week, then increase to 60 mg daily",
          "notes": "FDA-approved; doses above 60 mg show no additional benefit for fibromyalgia"
        },
        "depression-anxiety": {
          "indication": "Major depressive disorder, generalized anxiety disorder",
          "doseOptions": [
            {
              "text": "30 mg daily",
              "orderSentence": "Duloxetine 30 mg PO daily"
            },
            {
              "text": "60 mg daily",
              "orderSentence": "Duloxetine 60 mg PO daily"
            },
            {
              "text": "90 mg daily",
              "orderSentence": "Duloxetine 90 mg PO daily"
            },
            {
              "text": "120 mg daily",
              "orderSentence": "Duloxetine 120 mg PO daily"
            }
          ],
          "startingDose": "30-60 mg daily",
          "maxDose": "120 mg/day",
          "titration": "May increase by 30 mg increments",
          "notes": "Dual benefit when comorbid depression/anxiety with chronic pain"
        },
        "neuropathic-pain-first-line-especially-diabetic-neuropathy": {
          "indication": "Neuropathic pain (first-line, especially diabetic neuropathy)",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "neuropathic-pain-comorbid-depression": {
          "indication": "Neuropathic pain; comorbid depression",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 week, then increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease",
            "neurosarcoidosis",
            "nmosd"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine (neuropathic pain) 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily; increase to 60 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cidp",
            "diabetic-neuropathy"
          ]
        },
        "neuropathic-pain-first-line-especially-effective-for-painful": {
          "indication": "Neuropathic pain (first-line); especially effective for painful neuropathy with comorbid depression",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "comorbid-depression-chronic-pain-dual-benefit": {
          "indication": "Comorbid depression + chronic pain (dual benefit)",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "functional-neurological-disorder"
          ]
        },
        "neuropathic-pain-tabes-dorsalis-concurrent-depression": {
          "indication": "Neuropathic pain (tabes dorsalis); concurrent depression",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 wk; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "first-line-for-neuropathic-pain-also-treats-depression-anxie": {
          "indication": "First-line for neuropathic pain; also treats depression/anxiety common in SFN",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "neuropathic-pain-and-concurrent-depression-dual-benefit-in-i": {
          "indication": "Neuropathic pain and concurrent depression; dual benefit in ICUAW recovery",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg PO daily x 1 week, then increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "comorbid-depression-with-chronic-pain-common-in-pnes-fibromy": {
          "indication": "Comorbid depression with chronic pain (common in PNES); fibromyalgia comorbidity",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        },
        "neuropathic-pain-with-comorbid-depression-anxiety": {
          "indication": "Neuropathic pain with comorbid depression/anxiety",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily; increase to 60 mg after 1 week; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peroneal-neuropathy"
          ]
        },
        "depression-with-comorbid-pain-headache-musculoskeletal": {
          "indication": "Depression with comorbid pain (headache, musculoskeletal)",
          "doseOptions": [
            {
              "text": "20-30 mg",
              "orderSentence": "Duloxetine 20-30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20-30 mg PO daily; increase to 60 mg daily after 1-2 weeks; max 120 mg",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "neuropathic-pain-first-line-especially-diabetic": {
          "indication": "Neuropathic pain (first-line, especially diabetic)",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily Ãƒâ€” 1 week; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "comorbid-neuropathic-pain-depression-and-anxiety-common-in-s": {
          "indication": "Comorbid neuropathic pain; depression and anxiety (common in SPS)",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg PO daily x 1 week; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "neuropathic-pain-with-comorbid-anxiety-depression": {
          "indication": "Neuropathic pain with comorbid anxiety/depression",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily; increase to 60 mg after 1 week",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        },
        "neuropathic-pain-concurrent-depression-management": {
          "indication": "Neuropathic pain; concurrent depression management",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "neuropathic-radicular-pain-with-depression-anxiety": {
          "indication": "Neuropathic/radicular pain with depression/anxiety",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "neuropathic-pain-with-comorbid-depression-or-anxiety-mixed-p": {
          "indication": "Neuropathic pain with comorbid depression or anxiety; mixed pain syndrome",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg PO daily x 1 week, then increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "neuropathic-pain-with-depression-anxiety-diabetic-amyotrophy": {
          "indication": "Neuropathic pain with depression/anxiety; diabetic amyotrophy pain",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        },
        "neuropathic-pain-late-lyme-peripheral-neuropathy-concurrent-": {
          "indication": "Neuropathic pain (late Lyme peripheral neuropathy); concurrent depression",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Duloxetine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily x 1 wk; increase to 60 mg daily; max 120 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [
          "Suicidal thinking and behavior in children, adolescents, and young adults with MDD and other psychiatric disorders"
        ],
        "contraindications": [
          "Use within 14 days of MAOIs",
          "Concomitant use with linezolid or IV methylene blue",
          "Uncontrolled narrow-angle glaucoma",
          "Severe hepatic impairment"
        ],
        "precautions": [
          "Serotonin syndrome risk with serotonergic drugs",
          "Hepatotoxicity - monitor LFTs",
          "Increased bleeding risk especially with anticoagulants/NSAIDs",
          "Hyponatremia (SIADH) especially in elderly",
          "Discontinuation syndrome - taper slowly",
          "May elevate blood pressure - monitor"
        ],
        "drugInteractions": [
          {
            "drug": "MAOIs",
            "severity": "contraindicated",
            "effect": "Risk of serotonin syndrome"
          },
          {
            "drug": "Triptans",
            "severity": "high",
            "effect": "Serotonin syndrome risk"
          },
          {
            "drug": "Tramadol",
            "severity": "high",
            "effect": "Serotonin syndrome risk, seizure threshold lowered"
          },
          {
            "drug": "Warfarin",
            "severity": "moderate",
            "effect": "Increased bleeding risk"
          },
          {
            "drug": "NSAIDs",
            "severity": "moderate",
            "effect": "Increased bleeding risk"
          },
          {
            "drug": "CYP1A2 inhibitors (fluvoxamine, ciprofloxacin)",
            "severity": "high",
            "effect": "Increased duloxetine levels"
          },
          {
            "drug": "CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine)",
            "severity": "moderate",
            "effect": "Increased duloxetine levels"
          }
        ],
        "pregnancyCategory": "C",
        "lactation": "Caution - present in breast milk"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {
            "gfr": "≥30",
            "adjustment": "No adjustment needed"
          },
          {
            "gfr": "<30",
            "adjustment": "Not recommended (AUC increased 2-fold)"
          },
          {
            "gfr": "HD",
            "adjustment": "Not recommended"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": true,
        "notes": "Avoid in severe hepatic impairment (Child-Pugh C). Use caution in moderate impairment. Monitor LFTs."
      },
      "monitoring": {
        "baseline": [
          "LFTs",
          "Renal function",
          "Blood pressure"
        ],
        "ongoing": [
          "Blood pressure",
          "LFTs if symptoms",
          "Suicidal ideation",
          "Signs of bleeding"
        ],
        "frequency": "Blood pressure at each visit initially; LFTs PRN"
      },
      "patientCounseling": [
        "Do not stop abruptly - taper over 2+ weeks to avoid discontinuation syndrome",
        "May take 2-4 weeks for full pain relief; 4-6 weeks for antidepressant effect",
        "Take with food to minimize nausea",
        "Avoid alcohol",
        "Report unusual bleeding, mood changes, or allergic reactions",
        "Swallow capsule whole - do not crush or chew"
      ]
    },
    "duration-of-antibiotics": {
      "id": "duration-of-antibiotics",
      "name": "Duration of antibiotics",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "**Duration of antibiotics** N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**SEA without osteomyelitis:** 4-6 weeks IV; **SEA with vertebral osteomyelitis (most cases):** 6-8 weeks IV; **SEA with endocarditis:** 6 weeks minimum from first negative blood culture; duration guided by clinical response, inflammatory markers (ESR, CRP), repeat imaging; may extend if slow response",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "epidural-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "4-6 weeks for epidural abscess alone",
          "IDSA guidelines: 6 weeks for vertebral osteomyelitis",
          "endocarditis requires 6-week minimum",
          "individualized based on response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epidural-abscess"
      ]
    },
    "dvt-prophylaxis": {
      "id": "dvt-prophylaxis",
      "name": "DVT prophylaxis",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "**DVT prophylaxis** 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "SCDs immediately; pharmacologic prophylaxis (enoxaparin 40 mg SQ daily) once stable; immobile patients at very high VTE risk",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuromuscular-respiratory-failure",
            "epidural-abscess",
            "spinal-cord-compression-malignant",
            "cauda-equina-syndrome",
            "brain-metastases",
            "autoimmune-encephalitis"
          ]
        },
        "immobilized-patients": {
          "indication": "Immobilized patients",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "DVT prophylaxis (enoxaparin) 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily (adjust for renal function: 30 mg SC daily if CrCl <30)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "HIT",
          "severe thrombocytopenia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "AVERT trial)",
          "Brain tumor patients have 20-30% VTE risk",
          "Cancer + immobility + spinal cord injury = extremely high VTE risk",
          "High VTE risk in paralyzed/weak patients",
          "Immobile + infection + inflammatory state = very high DVT risk",
          "Immobility + lower extremity weakness = high DVT risk",
          "Platelet count",
          "anti-Xa if renal impairment",
          "balance with IVIG timing (hold anticoagulation during IVIG infusion in some protocols)",
          "bleeding signs",
          "early pharmacologic prophylaxis post-operatively",
          "mechanical prophylaxis alone insufficient",
          "mechanical prophylaxis pre-operatively",
          "mechanical prophylaxis universal",
          "pharmacologic prophylaxis as soon as surgically safe",
          "pharmacologic prophylaxis does NOT significantly increase intracranial hemorrhage risk (Perry et al., 2009"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "brain-metastases",
        "cauda-equina-syndrome",
        "epidural-abscess",
        "hashimotos-encephalopathy",
        "neuromuscular-respiratory-failure",
        "spinal-cord-compression-malignant"
      ]
    },
    "dvt-prophylaxis-enoxaparin": {
      "id": "dvt-prophylaxis-enoxaparin",
      "name": "DVT prophylaxis: Enoxaparin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "vte-prevention-in-immobilized-patients-with-myositis": {
          "indication": "VTE prevention in immobilized patients with myositis",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "DVT prophylaxis: Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start on admission",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "immobilized-icu-patients-at-high-risk-for-vte-icuaw-patients": {
          "indication": "Immobilized ICU patients at high risk for VTE; ICUAW patients are bedbound",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "DVT prophylaxis: Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; adjust for renal function (CrCl <30: 30 mg SC daily or use UFH)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "vte-prevention-in-immobilized-patients-admitted-with-fall-re": {
          "indication": "VTE prevention in immobilized patients admitted with fall-related injuries or acute deconditioning",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "DVT prophylaxis: Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start on admission if immobile",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "inclusion-body-myositis",
            "myotonic-dystrophy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "DVT prophylaxis: Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start on admission",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome",
            "acute-myelopathy"
          ]
        },
        "immobilized-myelopathy-patients-at-high-risk-for-venous-thro": {
          "indication": "Immobilized myelopathy patients at high risk for venous thromboembolism",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "DVT prophylaxis: Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start within 24-48h of admission if no active bleeding and no imminent surgery",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "immobilized-patients-at-high-risk-of-vte": {
          "indication": "Immobilized patients at high risk of VTE",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "DVT prophylaxis: Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start on admission",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "botulism"
          ]
        },
        "immobilized-hospitalized-patients": {
          "indication": "Immobilized hospitalized patients",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "DVT prophylaxis: Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; hold if INR >1.5 or platelets <50K or active bleeding",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "Active bleeding, platelets <50K, CrCl <30 (use UFH)",
          "Active bleeding, severe coagulopathy, CrCl <30 (use UFH)",
          "CrCl <30 (use UFH)",
          "CrCl <30 (use heparin instead)",
          "coagulopathy",
          "planned surgery within 12h",
          "platelets <50K",
          "post-surgical (timing per surgeon)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Platelets q3 days",
          "Platelets, signs of bleeding",
          "anti-Xa if renal impairment",
          "renal function (dose adjust CrCl <30)",
          "signs of bleeding"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 9,
      "_sourcePlans": [
        "acute-myelopathy",
        "botulism",
        "cervical-myelopathy",
        "critical-illness-myopathy-neuropathy",
        "guillain-barre-syndrome",
        "inclusion-body-myositis",
        "inflammatory-myopathy",
        "myotonic-dystrophy",
        "wilsons-disease"
      ]
    },
    "dvt-prophylaxis-heparin": {
      "id": "dvt-prophylaxis-heparin",
      "name": "DVT prophylaxis: Heparin (unfractionated)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "alternative-dvt-prophylaxis-if-crcl-30-ml-min-or-high-bleedi": {
          "indication": "Alternative DVT prophylaxis if CrCl <30 mL/min or high bleeding risk",
          "doseOptions": [
            {
              "text": "5000 units",
              "orderSentence": "DVT prophylaxis: Heparin (unfractionated) 5000 units SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5000 units SC q8h; preferred over enoxaparin in renal impairment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "HIT history"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Platelets q3 days",
          "signs of bleeding"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cervical-myelopathy"
      ]
    },
    "dvt-prophylaxis-heparin-sc": {
      "id": "dvt-prophylaxis-heparin-sc",
      "name": "DVT prophylaxis: Heparin SC (alternative)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "vte-prevention-if-enoxaparin-contraindicated": {
          "indication": "VTE prevention if enoxaparin contraindicated",
          "doseOptions": [
            {
              "text": "5000 units",
              "orderSentence": "DVT prophylaxis: Heparin SC (alternative) 5000 units SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5000 units SC q8-12h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "vte-prophylaxis-when-enoxaparin-contraindicated-due-to-renal": {
          "indication": "VTE prophylaxis when enoxaparin contraindicated due to renal impairment",
          "doseOptions": [
            {
              "text": "5000 units",
              "orderSentence": "DVT prophylaxis: Heparin SC (renal alternative) 5000 units SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5000 units SC q8h; use when CrCl <30 mL/min",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "vte-prevention-if-enoxaparin-contraindicated-crcl-30": {
          "indication": "VTE prevention if enoxaparin contraindicated (CrCl <30)",
          "doseOptions": [
            {
              "text": "5000 units",
              "orderSentence": "DVT prophylaxis: Heparin SC (alternative) 5000 units SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5000 units SC q8-12h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "inclusion-body-myositis",
            "myotonic-dystrophy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5000 units",
              "orderSentence": "DVT prophylaxis: Heparin SC (after aneurysm secured) 5000 units SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5000 units SC q8h; start 24h after aneurysm is secured (clipping or coiling); some centers start earlier",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage",
            "guillain-barre-syndrome"
          ]
        },
        "vte-prophylaxis-if-enoxaparin-contraindicated": {
          "indication": "VTE prophylaxis if enoxaparin contraindicated",
          "doseOptions": [
            {
              "text": "5000 units",
              "orderSentence": "DVT prophylaxis: Heparin SC (alternative) 5000 units SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5000 units SC q8-12h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "botulism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "Active bleeding, HIT",
          "HIT history",
          "within 24h of craniotomy (per surgeon)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Platelets q3 days",
          "Platelets q3 days for HIT surveillance"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "botulism",
        "critical-illness-myopathy-neuropathy",
        "guillain-barre-syndrome",
        "inclusion-body-myositis",
        "inflammatory-myopathy",
        "myotonic-dystrophy",
        "subarachnoid-hemorrhage"
      ]
    },
    "eclampsia-magnesium-sulfate": {
      "id": "eclampsia-magnesium-sulfate",
      "name": "Eclampsia: Magnesium sulfate (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "first-line-for-eclampsia-associated-pres-prevents-recurrent-": {
          "indication": "FIRST-LINE for eclampsia-associated PRES; prevents recurrent seizures; superior to phenytoin and diazepam for eclampsia seizures (Magpie Trial, Eclampsia Trial Collaborative Group)",
          "doseOptions": [
            {
              "text": "4-6 g IV load over 15-20 min",
              "orderSentence": "Eclampsia: Magnesium sulfate (CPT 96365) 4-6 g IV load over 15-20 min IV"
            },
            {
              "text": "1-2 g/h maintenance",
              "orderSentence": "Eclampsia: Magnesium sulfate (CPT 96365) 1-2 g/h maintenance IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-6 g IV loading dose over 15-20 min, then 1-2 g/h continuous infusion; maintain serum Mg 4-7 mEq/L; continue 24-48h postpartum; reduce dose if Cr >1.0",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Myasthenia gravis",
          "heart block",
          "renal failure (dose adjust)",
          "respiratory depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Serum Mg q4-6h (target 4-7 mEq/L)",
          "calcium gluconate at bedside as antidote",
          "deep tendon reflexes q1h (loss of patellar reflex = toxicity)",
          "respiratory rate (hold if <12)",
          "urine output (>25 mL/h)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "eculizumab": {
      "id": "eculizumab",
      "name": "Eculizumab (Soliris)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "900 mg",
              "orderSentence": "Eculizumab 900 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "900 mg IV q1 week x 4 weeks, then 1200 mg IV q2 weeks; for AChR-positive refractory generalized MG",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "myasthenia-gravis-new-diagnosis",
            "acute-myelopathy"
          ]
        },
        "nmosd-aqp4-igg-positive-fda-approved": {
          "indication": "NMOSD (AQP4-IgG positive) - FDA approved",
          "doseOptions": [
            {
              "text": "900 mg",
              "orderSentence": "Eculizumab (Soliris) 900 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "900 mg weekly x 4; then 1200 mg at week 5; then 1200 mg q2 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "achr-refractory-generalized-mg-fda-approved": {
          "indication": "AChR+ refractory generalized MG; FDA approved",
          "doseOptions": [
            {
              "text": "900 mg",
              "orderSentence": "Eculizumab (Soliris) 900 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "900 mg IV weekly x 4 weeks (induction), then 1200 mg IV every 2 weeks (maintenance); infuse over 35 min",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "fda-approved-for-aqp4-nmosd-complement-c5-inhibitor": {
          "indication": "FDA-approved for AQP4+ NMOSD; complement C5 inhibitor",
          "doseOptions": [
            {
              "text": "900 mg",
              "orderSentence": "**Eculizumab (Soliris)** 900 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Induction: 900 mg IV weekly x 4 weeks; then 1200 mg IV at week 5; maintenance: 1200 mg IV every 2 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Unresolved Neisseria infection",
          "Unresolved Neisseria meningitidis infection",
          "must vaccinate ≥2 weeks before starting",
          "not current with meningococcal vaccines",
          "not vaccinated against meningococcal disease",
          "unvaccinated against meningococcus"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "LDH/reticulocyte (hemolysis on discontinuation)",
          "LFTs",
          "Meningococcal infection",
          "Meningococcal infection risk (BLACK BOX)",
          "Meningococcal vaccination (≥2 weeks before)",
          "Meningococcal vaccine ≥2 weeks before",
          "REMS program",
          "REMS program enrollment required",
          "URI",
          "ciprofloxacin prophylaxis recommended",
          "complement levels",
          "complement levels (CH50)",
          "headache",
          "infection",
          "infusion reactions",
          "meningococcal infection surveillance",
          "signs of meningococcal infection"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "acute-myelopathy",
        "myasthenia-gravis",
        "myasthenia-gravis-crisis",
        "myasthenia-gravis-new-diagnosis",
        "nmosd",
        "optic-neuritis"
      ]
    },
    "edaravone": {
      "id": "edaravone",
      "name": "Edaravone (Radicava)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "**Edaravone (Radicava)** N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "IV infusion or oral formulation; may slow functional decline; expensive; used in early ALS",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuromuscular-respiratory-failure"
          ]
        },
        "ftd-als-if-early-in-disease-course": {
          "indication": "FTD-ALS if early in disease course",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Edaravone (Radicava) 60 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Initial: 60 mg IV daily x 14 days; maintenance: 60 mg IV daily x 10 days of 14-day cycles; oral formulation available",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity",
          "sulfite allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Infusion reactions",
          "Recent approval",
          "hypersensitivity",
          "modest benefit in selected patients",
          "often continued if started"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "frontotemporal-dementia",
        "neuromuscular-respiratory-failure"
      ]
    },
    "edaravone-iv-formulation": {
      "id": "edaravone-iv-formulation",
      "name": "Edaravone (Radicava) - IV formulation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "antioxidant-slows-functional-decline-in-selected-patients": {
          "indication": "Antioxidant; slows functional decline in selected patients",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Edaravone (Radicava) - IV formulation 60 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Initial cycle: 60 mg IV daily x 14 days, then 14 days off; subsequent cycles: 60 mg IV daily x 10 of 14 days, then 14 days off",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity to edaravone or sodium bisulfite"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Infusion reactions",
          "gait (sulfite sensitivity)",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "edaravone-oral-suspension": {
      "id": "edaravone-oral-suspension",
      "name": "Edaravone oral suspension (Radicava ORS)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "oral-alternative-to-iv-edaravone": {
          "indication": "Oral alternative to IV edaravone",
          "doseOptions": [
            {
              "text": "105 mg",
              "orderSentence": "Edaravone oral suspension (Radicava ORS) 105 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Initial cycle: 105 mg PO daily x 14 days, then 14 days off; subsequent cycles: 105 mg PO daily x 10 of 14 days, then 14 days off",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity to edaravone or sodium bisulfite"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Infusion reactions",
          "gait (sulfite sensitivity)",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "efavirenz": {
      "id": "efavirenz",
      "name": "Efavirenz (Sustiva)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nnrti-with-high-cpe-score-cpe-3-historical-use-in-hand-cns-s": {
          "indication": "NNRTI with high CPE score (CPE 3); historical use in HAND; CNS side effects limit utility due to neuropsychiatric toxicity",
          "doseOptions": [
            {
              "text": "600 mg",
              "orderSentence": "Efavirenz (Sustiva) 600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600 mg PO at bedtime on empty stomach",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy (first trimester -- teratogenic)",
          "concurrent CYP interactions",
          "severe psychiatric disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "**Neuropsychiatric monitoring** (vivid dreams, depression, suicidality, psychosis -- especially first 2-4 weeks)",
          "LFTs",
          "lipid panel"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "efgartigimod": {
      "id": "efgartigimod",
      "name": "Efgartigimod (Vyvgart)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Efgartigimod (Vyvgart) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV weekly x 4 weeks per cycle; repeat cycles based on clinical response; for AChR-positive generalized MG",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "myasthenia-gravis-new-diagnosis"
          ]
        },
        "achr-generalized-mg-fcrn-inhibitor-lowers-igg": {
          "indication": "AChR+ generalized MG; FcRn inhibitor; lowers IgG",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Efgartigimod (Vyvgart) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV infusion over 1 hour weekly x 4 weeks per treatment cycle; repeat cycles as needed based on clinical response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "Active infection, IgG <2 g/L",
          "Active serious infection",
          "IgG <2 g/L (relative)",
          "concurrent IgG-dependent therapies"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "IgG levels",
          "IgG levels (expect ~70% reduction)",
          "IgG levels (target reduction)",
          "headache",
          "infection",
          "infection monitoring",
          "infection signs",
          "infusion reactions",
          "no meningococcal vaccine required"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "myasthenia-gravis",
        "myasthenia-gravis-crisis",
        "myasthenia-gravis-new-diagnosis"
      ]
    },
    "efgartigimod-fvhp-hyaluronidase": {
      "id": "efgartigimod-fvhp-hyaluronidase",
      "name": "Efgartigimod-fvhp + hyaluronidase (Vyvgart Hytrulo)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "achr-generalized-mg-subcutaneous-administration": {
          "indication": "AChR+ generalized MG; subcutaneous administration",
          "doseOptions": [
            {
              "text": "1008 mg",
              "orderSentence": "Efgartigimod-fvhp + hyaluronidase (Vyvgart Hytrulo) 1008 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1008 mg SC injection weekly x 4 weeks per treatment cycle; self-administered at home after training",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active serious infection",
          "IgG <2 g/L (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "IgG levels",
          "headache",
          "infection",
          "injection site reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "myasthenia-gravis"
      ]
    },
    "efgartigimod-hyaluronidase-sc": {
      "id": "efgartigimod-hyaluronidase-sc",
      "name": "Efgartigimod/hyaluronidase SC (Vyvgart Hytrulo)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1008 mg",
              "orderSentence": "Efgartigimod/hyaluronidase SC (Vyvgart Hytrulo) 1008 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1008 mg efgartigimod + 11,200 units hyaluronidase SC weekly × 4 weeks per cycle",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as IV efgartigimod"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same",
          "injection site reactions",
          "self-administered option"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "myasthenia-gravis-new-diagnosis"
      ]
    },
    "electrolyte-correction": {
      "id": "electrolyte-correction",
      "name": "Electrolyte correction (Na, Ca, Mg, PO4)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "electrolyte-derangement-contributing-to-seizures": {
          "indication": "Electrolyte derangement contributing to seizures",
          "doseOptions": [
            {
              "text": "Per specific electrolyte protocol",
              "orderSentence": "Electrolyte correction (Na, Ca, Mg, PO4) Per specific electrolyte protocol IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Correct to normal; sodium: avoid >8 mEq/L/24h correction; hypomagnesemia: 2g MgSO4 IV over 20 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "enhanced-physiologic-tremor-from-hyponatremia": {
          "indication": "Enhanced physiologic tremor from hyponatremia",
          "doseOptions": [
            {
              "text": "0.9% NaCl",
              "orderSentence": "Electrolyte correction (hyponatremia) (CPT 96365) 0.9% NaCl IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Normal saline or hypertonic saline per sodium deficit calculation; correct sodium no faster than 8-10 mEq/L per 24 hours to prevent osmotic demyelination",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypervolemic hyponatremia (use fluid restriction instead)",
          "Per specific electrolyte (ODS risk with rapid Na correction)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Repeat electrolytes q2-4h during correction",
          "Serum sodium q4-6h during correction",
          "strict I/O monitoring",
          "tremor resolution with correction"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ncse",
        "tremor-unspecified"
      ]
    },
    "eletriptan": {
      "id": "eletriptan",
      "name": "Eletriptan",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Eletriptan 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg PO; may repeat in 2h; max 80 mg/24h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "moderate-severe-migraine-high-efficacy": {
          "indication": "Moderate-severe migraine; high efficacy",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Eletriptan 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg PO once; may repeat in 2h; max 80 mg/24h; limit ≤9 days/month",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "acute-typical-migraine-with-aura-good-for-recurrence": {
          "indication": "Acute typical migraine with aura; good for recurrence",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Eletriptan 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg PO; may repeat 40 mg after 2 hr if partial response; max 80 mg/24hr",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**HEMIPLEGIC MIGRAINE (motor aura)**",
          "CAD",
          "CAD, stroke/TIA, uncontrolled HTN, hemiplegic migraine, MAOIs, pregnancy",
          "MAOIs within 14 days",
          "Same",
          "ergots within 24 hr",
          "potent CYP3A4 inhibitors (ketoconazole, clarithromycin)",
          "prior stroke/TIA",
          "severe hepatic impairment",
          "uncontrolled HTN"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Chest tightness, BP",
          "Same",
          "Triptan sensation",
          "medication days/month",
          "serotonin syndrome signs if on SNRI/SSRI"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "migraine-with-aura"
      ]
    },
    "eletriptan-po": {
      "id": "eletriptan-po",
      "name": "Eletriptan PO (post-discharge rescue)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "outpatient-rescue-for-breakthrough-migraine-high-efficacy-or": {
          "indication": "Outpatient rescue for breakthrough migraine; high efficacy oral triptan option",
          "doseOptions": [
            {
              "text": "40 mg PO once",
              "orderSentence": "Eletriptan PO (post-discharge rescue) 40 mg PO once PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg PO at onset; may repeat in 2h; max 80 mg/24h; limit to ≤9 days/month",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CAD, prior stroke/TIA, uncontrolled HTN (>140/90), hemiplegic or basilar migraine, pregnancy, concurrent ergot/DHE within 24h, severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Chest tightness, blood pressure, coronary symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "empagliflozin": {
      "id": "empagliflozin",
      "name": "Empagliflozin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "sglt2-inhibitor-for-diabetes-with-cardiovascular-benefit": {
          "indication": "SGLT2 inhibitor for diabetes with cardiovascular benefit",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Empagliflozin 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; may increase to 25 mg; cardiovascular mortality benefit",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "sglt2-inhibitor-for-diabetes-with-cardiovascular-benefit-red": {
          "indication": "SGLT2 inhibitor for diabetes with cardiovascular benefit; reduces MACE and heart failure; renoprotective",
          "doseOptions": [
            {
              "text": "10 mg daily",
              "orderSentence": "Empagliflozin 10 mg daily PO"
            },
            {
              "text": "25 mg daily",
              "orderSentence": "Empagliflozin 25 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; may increase to 25 mg; take in morning; cardiovascular and renal benefit independent of HbA1c",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "DKA history",
          "Type 1 DM",
          "eGFR <20",
          "eGFR <20 (for glucose lowering)",
          "recurrent UTI/genital infections",
          "type 1 DM"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP",
          "eGFR",
          "genital infections",
          "ketoacidosis risk (rare)",
          "volume status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "post-stroke-management",
        "vascular-dementia"
      ]
    },
    "empiric-acyclovir": {
      "id": "empiric-acyclovir",
      "name": "Empiric acyclovir (HSV encephalitis not excluded)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "febrile-ncse-temporal-lobe-focus-encephalopathy-until-hsv-pc": {
          "indication": "Febrile NCSE; temporal lobe focus; encephalopathy; until HSV PCR results",
          "doseOptions": [
            {
              "text": "10 mg/kg q8h",
              "orderSentence": "Empiric acyclovir (HSV encephalitis not excluded) 10 mg/kg q8h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV q8h; continue until HSV PCR negative (×2 if high suspicion)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment (adjust dose)",
          "adequate hydration required"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function daily",
          "hydration"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ncse"
      ]
    },
    "empiric-acyclovir-iv": {
      "id": "empiric-acyclovir-iv",
      "name": "Empiric acyclovir IV (until HSV ruled out)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Empiric acyclovir IV (until HSV ruled out) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV q8h; continue until HSV PCR negative x2 (48h apart) or alternative diagnosis confirmed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment (adjust dose)",
          "adequate hydration required"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function daily",
          "crystal nephropathy prevention",
          "hydration status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "autoimmune-encephalitis"
      ]
    },
    "empiric-antibiotics": {
      "id": "empiric-antibiotics",
      "name": "Empiric antibiotics (aspiration pneumonia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "suspected-aspiration-pneumonia": {
          "indication": "Suspected aspiration pneumonia",
          "doseOptions": [
            {
              "text": "Ampicillin-sulbactam 3g IV q6h",
              "orderSentence": "Empiric antibiotics (aspiration pneumonia) Ampicillin-sulbactam 3g IV q6h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3g IV q6h; alternative: piperacillin-tazobactam 4.5g q6h; cover oral flora and anaerobes",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "febrile-ncse-with-meningismus-or-csf-pleocytosis": {
          "indication": "Febrile NCSE with meningismus or CSF pleocytosis",
          "doseOptions": [
            {
              "text": "Per protocol",
              "orderSentence": "Empiric antibiotics (bacterial meningitis not excluded) Per protocol IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ceftriaxone 2g IV q12h + vancomycin 15-20 mg/kg IV q8-12h + dexamethasone",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2g",
              "orderSentence": "Empiric antibiotics (if bacterial meningitis not excluded) 2g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ceftriaxone 2g IV q12h + vancomycin 15-20 mg/kg IV q8-12h + dexamethasone 0.15 mg/kg q6h x 4 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Allergies",
          "Per individual drug allergies"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cultures",
          "WBC, fever curve, respiratory status",
          "clinical response",
          "renal function",
          "vancomycin troughs"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "als",
        "autoimmune-encephalitis",
        "ncse"
      ]
    },
    "empiric-iv-antibiotics": {
      "id": "empiric-iv-antibiotics",
      "name": "Empiric IV antibiotics (STAT) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-30 mg/kg",
              "orderSentence": "**Empiric IV antibiotics (STAT)** (CPT 96365) 25-30 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Start IMMEDIATELY after blood cultures drawn — do NOT delay for MRI or organism identification**; **First-line empiric:** Vancomycin 25-30 mg/kg IV load (max 2g), then 15-20 mg/kg IV q8-12h (target trough 15-20 mcg/mL) PLUS Ceftriaxone 2g IV q12h OR Cefepime 2g IV q8h; **Alternative for β-lactam allergy:** Vancomycin + aztreonam 2g IV q8h OR Vancomycin + fluoroquinolone (levofloxacin 750 mg daily); **If Pseudomonas risk (IVDU, immunocompromised):** Add anti-pseudomonal coverage with cefepime or piperacillin-tazobactam 4.5g IV q6h; **Adjust to culture results when available**",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "epidural-abscess",
            "acute-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "See individual agents"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cultures",
          "Vancomycin covers MRSA (most important cause)",
          "ceftriaxone/cefepime covers MSSA, streptococci, gram-negatives",
          "early antibiotics are associated with better outcomes",
          "every hour of delay increases mortality in sepsis",
          "renal function",
          "vancomycin trough"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "acute-myelopathy",
        "epidural-abscess"
      ]
    },
    "enfuvirtide-salvage-therapy": {
      "id": "enfuvirtide-salvage-therapy",
      "name": "Enfuvirtide (Fuzeon) — salvage therapy",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "multidrug-resistant-csf-viral-escape-refractory-to-oral-opti": {
          "indication": "Multidrug-resistant CSF viral escape refractory to oral optimization; extensive NRTI/NNRTI/PI/INSTI resistance",
          "doseOptions": [
            {
              "text": "90 mg",
              "orderSentence": "Enfuvirtide (Fuzeon) — salvage therapy 90 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "90 mg SC BID (injection site rotation)",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity",
          "injection site reactions (nearly universal)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CSF VL follow-up",
          "Injection site reactions",
          "eosinophilia",
          "pneumonia risk"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "enoxaparin": {
      "id": "enoxaparin",
      "name": "Enoxaparin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "dvt-prophylaxis": {
          "indication": "DVT prophylaxis",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "hsv-encephalitis",
            "status-epilepticus",
            "acute-ischemic-stroke",
            "bacterial-meningitis"
          ]
        },
        "cvt-alternative-to-ufh-stable-non-parenchymal-nbd": {
          "indication": "CVT (alternative to UFH); stable non-parenchymal NBD",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Enoxaparin (LMWH) 1 mg/kg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg SC every 12 hours; renally adjust if CrCl <30",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "brain-tumor-patients-have-20-30-vte-risk-sequential-compress": {
          "indication": "Brain tumor patients have 20-30% VTE risk; sequential compression devices immediately; pharmacologic prophylaxis within 24-48h post-operatively",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin (DVT prophylaxis) 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Enoxaparin 40 mg SC daily or heparin 5000 units SC q8h; start within 24-48h unless hemorrhagic or planned surgery within 24h; post-craniotomy restart per neurosurgery (typically 24-48h)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "dvt-prophylaxis-start-24-48h-after-hemorrhage-stabilizes-aft": {
          "indication": "DVT prophylaxis (start 24-48h after hemorrhage stabilizes; after repeat CT shows stability)",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily. AHA 2022: intermittent pneumatic compression devices on admission; pharmacologic prophylaxis after hemorrhage stable on repeat imaging",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "dvt-prophylaxis-in-hospitalized-patients-with-prolonged-immo": {
          "indication": "DVT prophylaxis in hospitalized patients with prolonged immobility",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start when no active coagulopathy",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "dvt-prophylaxis-if-not-on-therapeutic-anticoagulation-and-li": {
          "indication": "DVT prophylaxis if not on therapeutic anticoagulation and limited mobility",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin (prophylactic) 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start within 24-48h; hold if on therapeutic anticoagulation",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "bridge-from-iv-heparin-to-oral-anticoagulation-alternative-t": {
          "indication": "Bridge from IV heparin to oral anticoagulation; alternative to IV heparin in stable dissection with embolic risk",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Enoxaparin (therapeutic) 1 mg/kg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg SC q12h; adjust for renal function (1 mg/kg daily if CrCl 15-30); bridge to warfarin if needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "cns-malignancy-with-high-vte-risk-20-30-immobility-from-neur": {
          "indication": "CNS malignancy with high VTE risk (20-30%); immobility from neurologic deficits",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "**Enoxaparin (DVT prophylaxis)** 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Enoxaparin 40 mg SC daily starting within 24-48h unless contraindicated; SCDs immediately on admission; hold 24h before and after LP or IT chemo",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "dvt-prophylaxis-during-prolonged-bed-rest-in-hospitalized-si": {
          "indication": "DVT prophylaxis during prolonged bed rest in hospitalized SIH patients",
          "doseOptions": [
            {
              "text": "40 mg daily",
              "orderSentence": "Enoxaparin 40 mg daily SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; begin within 24 hours of admission if on bed rest >48 hours; hold 12 hours before and after epidural blood patch",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        },
        "lymphoma-patients-have-elevated-vte-risk-scds-immediately-ph": {
          "indication": "Lymphoma patients have elevated VTE risk; SCDs immediately; pharmacologic prophylaxis within 24-48h post-biopsy",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin (DVT prophylaxis) 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Enoxaparin 40 mg SC daily or heparin 5000 units SC q8h; start within 24-48h post-biopsy per neurosurgery; SCDs until ambulatory",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "acute-cvt-without-large-hemorrhagic-infarction-preferred-ini": {
          "indication": "Acute CVT without large hemorrhagic infarction; preferred initial therapy per guidelines",
          "doseOptions": [
            {
              "text": "1 mg/kg BID",
              "orderSentence": "Enoxaparin (LMWH) 1 mg/kg BID SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg SC every 12 hours; adjust for CrCl <30 (1 mg/kg daily) or obesity",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "dvt-prophylaxis-prolonged-hospitalization-and-immobilization": {
          "indication": "DVT prophylaxis; prolonged hospitalization and immobilization; steroid use increases VTE risk",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin (CPT 96372) 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start 24h post-surgery if no active bleeding; hold if upcoming surgery",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "dvt-prophylaxis-immobilized-comatose-patients-at-high-vte-ri": {
          "indication": "DVT prophylaxis; immobilized comatose patients at high VTE risk; start after active hemorrhage excluded and hemostasis adequate",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start 24-48h post-ROSC if no active bleeding",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "dvt-prophylaxis-prolonged-immobilization-and-hospitalization": {
          "indication": "DVT prophylaxis; prolonged immobilization and hospitalization are significant VTE risk factors",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start 24-48h post-surgery if no active bleeding; hold if upcoming surgery",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "dvt-prophylaxis-for-surgical-patients-meningioma-surgery-car": {
          "indication": "DVT prophylaxis for surgical patients; meningioma surgery carries VTE risk especially with prolonged procedures",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin (DVT prophylaxis) 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Enoxaparin 40 mg SC daily; start 24h post-operatively per neurosurgery; mechanical prophylaxis (SCDs) from admission until ambulatory",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "dvt-prophylaxis-start-when-seizures-controlled-and-no-hemorr": {
          "indication": "DVT prophylaxis (start when seizures controlled and no hemorrhagic PRES)",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; adjust for renal function (CrCl <30: 30 mg daily); hold if hemorrhagic PRES",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "pres"
          ]
        },
        "dvt-prophylaxis-prolonged-hospitalization-and-immobility": {
          "indication": "DVT prophylaxis (prolonged hospitalization and immobility)",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Enoxaparin 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC daily; start when no active hemorrhagic complications and platelet count adequate",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "Active bleeding, CrCl <30 (use UFH)",
          "Active bleeding, DIC, coagulopathy",
          "Active bleeding, HIT, severe renal impairment (CrCl <30: reduce to 30 mg daily), coagulopathy, within 12 hours of EBP",
          "Active bleeding, hemorrhagic transformation, coagulopathy, platelets <50K",
          "Active bleeding, platelets <50K, CrCl <30 (use UFH 5000u SC q8-12h)",
          "Active bleeding, recent LP",
          "Active hemorrhage",
          "Active hemorrhagic PRES",
          "Active hemorrhagic expansion",
          "Active intracranial bleeding",
          "Active intracranial hemorrhage",
          "Active uncontrolled bleeding",
          "CrCl <15",
          "CrCl <30 (use UFH 5000 units SC q8-12h instead)",
          "CrCl <30 (use heparin instead)",
          "DIC",
          "HIT",
          "Severe renal impairment (CrCl <30)",
          "active major hemorrhage",
          "coagulopathy",
          "hemorrhagic transformation on imaging",
          "large hemorrhagic infarct",
          "planned LP within 12h",
          "planned Ommaya surgery",
          "planned biopsy within 24h",
          "planned surgery within 24h",
          "platelet count <50,000",
          "platelets <50K",
          "pre-surgical",
          "recent LP (wait 12h)",
          "recent craniotomy (<24h)",
          "severe renal failure (dose adjust)",
          "thrombocytopenia (<50K)",
          "thrombocytopenia (platelets <50K)",
          "within 24h of ICH onset"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anti-Xa level (target 0.5-1.0 IU/mL)",
          "Anti-Xa levels (target 0.5-1.0 IU/mL)",
          "Anti-Xa levels (target 0.5-1.0 IU/mL) if extremes of weight or renal impairment",
          "CBC",
          "Platelet count",
          "Platelet count q2-3 days",
          "Platelets",
          "Platelets q3 days",
          "Platelets q3 days (HIT monitoring)",
          "Platelets, bleeding",
          "anti-Xa level if renal impairment",
          "anti-Xa levels if renal impairment",
          "bleeding signs",
          "clinical DVT signs",
          "coags",
          "coagulation panel",
          "coagulation studies",
          "platelet count",
          "platelet count q2d",
          "platelets q3 days",
          "renal function",
          "repeat CT before starting",
          "signs of bleeding",
          "signs of hemorrhage"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 21,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "anoxic-brain-injury",
        "bacterial-meningitis",
        "brain-abscess",
        "cerebral-venous-thrombosis",
        "cervical-artery-dissection",
        "fungal-meningitis",
        "glioblastoma",
        "hsv-encephalitis",
        "intracerebral-hemorrhage",
        "leptomeningeal-carcinomatosis",
        "low-pressure-headache",
        "meningioma",
        "myasthenia-gravis-crisis",
        "neuro-behcets-disease",
        "neurocysticercosis",
        "pres",
        "primary-cns-lymphoma",
        "status-epilepticus",
        "tb-meningitis"
      ]
    },
    "entacapone": {
      "id": "entacapone",
      "name": "Entacapone (Comtan)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Entacapone (Comtan) 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg with each levodopa dose; max 8 doses/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "comt-inhibitor-extends-levodopa-effect-wearing-off": {
          "indication": "COMT inhibitor; extends levodopa effect; wearing off",
          "doseOptions": [
            {
              "text": "200 mg with each levodopa dose",
              "orderSentence": "Entacapone 200 mg with each levodopa dose PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg with each levodopa dose; max 8 doses (1600 mg)/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hepatic impairment",
          "None absolute",
          "concurrent MAOIs"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Diarrhea, orange urine, dyskinesias",
          "Orange urine, diarrhea, dyskinesia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "enteral-nutrition": {
      "id": "enteral-nutrition",
      "name": "Enteral nutrition (high-protein)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "EN"
      ],
      "formulations": [],
      "contexts": {
        "protein-supplementation-to-support-muscle-preservation-and-r": {
          "indication": "Protein supplementation to support muscle preservation and recovery; protein catabolism is accelerated in ICUAW",
          "doseOptions": [
            {
              "text": "1.2-2.0 g/kg/day protein",
              "orderSentence": "Enteral nutrition (high-protein) 1.2-2.0 g/kg/day protein EN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Target protein 1.2-2.0 g/kg/day (adjusted body weight if obese); initiate enteral nutrition within 24-48h of ICU admission; caloric target 25-30 kcal/kg/day; avoid overfeeding",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI obstruction",
          "bowel ischemia",
          "uncontrolled shock (delay until resuscitated)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Prealbumin weekly",
          "feeding tolerance (residuals)",
          "glucose",
          "nitrogen balance"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "critical-illness-myopathy-neuropathy"
      ]
    },
    "enzyme-inducing-aeds": {
      "id": "enzyme-inducing-aeds",
      "name": "Enzyme-inducing AEDs (phenytoin, carbamazepine, phenobarbital)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "cyp-enzyme-induction-reduces-efficacy-of-many-chemotherapy-a": {
          "indication": "CYP enzyme induction reduces efficacy of many chemotherapy agents, targeted therapies, and dexamethasone",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Enzyme-inducing AEDs (phenytoin, carbamazepine, phenobarbital) N/A PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Use levetiracetam, lacosamide, or valproic acid instead (non-enzyme-inducing); if already on phenytoin, transition to levetiracetam",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent use with temozolomide, irinotecan, many targeted agents",
          "reduce dexamethasone efficacy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "AED levels",
          "Seizure control during transition"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "enzyme-replacement-therapy-fabry-disease": {
      "id": "enzyme-replacement-therapy-fabry-disease",
      "name": "Enzyme replacement therapy — Fabry disease",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "fabry-disease-associated-sfn": {
          "indication": "Fabry disease-associated SFN",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Enzyme replacement therapy — Fabry disease 1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Agalsidase beta (Fabrazyme) 1 mg/kg IV q2wk; lifelong therapy; infusion reactions common early",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None absolute"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Infusion reactions",
          "anti-drug antibodies"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "small-fiber-neuropathy"
      ]
    },
    "epidural-blood-patch": {
      "id": "epidural-blood-patch",
      "name": "Epidural blood patch (treat underlying cause)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Epidural"
      ],
      "formulations": [],
      "contexts": {
        "subdural-collections-secondary-to-sih-treating-the-leak-ofte": {
          "indication": "Subdural collections secondary to SIH; treating the leak often resolves the subdural",
          "doseOptions": [
            {
              "text": "15-30 mL autologous blood",
              "orderSentence": "Epidural blood patch (treat underlying cause) 15-30 mL autologous blood Epidural"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "EBP should be performed BEFORE considering surgical evacuation; inject 15-30 mL autologous blood into epidural space under fluoroscopy; SDH from SIH often recurs after drainage if leak not addressed",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active systemic infection/bacteremia, local skin infection, coagulopathy (INR >1.5, platelets <50K), patient refusal"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Vital signs during and 1h post-procedure",
          "neurologic exam",
          "serial CT for SDH"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "low-pressure-headache"
      ]
    },
    "epidural-blood-patch-blind-non-targeted": {
      "id": "epidural-blood-patch-blind-non-targeted",
      "name": "Epidural blood patch - blind/non-targeted (CPT 62273)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Epidural"
      ],
      "formulations": [],
      "contexts": {
        "first-line-definitive-treatment-for-pdph-and-sih-seals-dural": {
          "indication": "First-line definitive treatment for PDPH and SIH; seals dural defect with autologous blood clot",
          "doseOptions": [
            {
              "text": "15-30 mL autologous blood",
              "orderSentence": "Epidural blood patch - blind/non-targeted (CPT 62273) 15-30 mL autologous blood Epidural"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Inject 15-30 mL autologous blood into lumbar or thoracolumbar epidural space under fluoroscopy; patient lies flat 1-2 hours post-procedure; ~70-90% PDPH success rate; ~30-50% SIH success rate on first attempt",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active systemic infection/bacteremia, local skin infection, coagulopathy (INR >1.5, platelets <50K), patient refusal"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Vital signs during and 1h post-procedure",
          "neurologic exam",
          "pain at injection site",
          "radicular symptoms (transient acceptable)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "low-pressure-headache"
      ]
    },
    "epidural-blood-patch-targeted": {
      "id": "epidural-blood-patch-targeted",
      "name": "Epidural blood patch - targeted (CPT 62273)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Epidural"
      ],
      "formulations": [],
      "contexts": {
        "sih-after-leak-localization-by-ct-myelography-or-mri-spine-t": {
          "indication": "SIH after leak localization by CT myelography or MRI spine; targeted to level of leak",
          "doseOptions": [
            {
              "text": "15-30 mL autologous blood",
              "orderSentence": "Epidural blood patch - targeted (CPT 62273) 15-30 mL autologous blood Epidural"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Inject 15-30 mL autologous blood at or near identified leak level under fluoroscopic or CT guidance; higher success rate for SIH when targeted; may require multi-level injection",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active systemic infection/bacteremia, local skin infection, coagulopathy (INR >1.5, platelets <50K), patient refusal"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Vital signs during and 1h post-procedure",
          "headache improvement within 24-72 hours",
          "neurologic exam",
          "radicular symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "low-pressure-headache"
      ]
    },
    "epidural-fibrin-glue-patch": {
      "id": "epidural-fibrin-glue-patch",
      "name": "Epidural fibrin glue patch",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Epidural"
      ],
      "formulations": [],
      "contexts": {
        "refractory-sih-after-failed-ebp-2-3-attempts-seals-dural-def": {
          "indication": "Refractory SIH after failed EBP (2-3 attempts); seals dural defect with fibrin sealant",
          "doseOptions": [
            {
              "text": "Fibrin sealant at leak site",
              "orderSentence": "Epidural fibrin glue patch Fibrin sealant at leak site Epidural"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Inject fibrin glue (e.g., Tisseel) at identified leak site under fluoroscopic or CT guidance; may combine with blood patch; performed by anesthesia or interventional radiology",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection, known allergy to fibrin/bovine components, coagulopathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Post-procedure neuro exam, headache assessment, vital signs",
          "observe 2-4 hours post"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "low-pressure-headache"
      ]
    },
    "eptinezumab": {
      "id": "eptinezumab",
      "name": "Eptinezumab (Vyepti)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100-300 mg",
              "orderSentence": "Eptinezumab (Vyepti) 100-300 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-300 mg IV q3 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "chronic-migraine-prevention-rapid-onset-may-work-within-days": {
          "indication": "Chronic migraine prevention; rapid onset (may work within days); IV formulation for clinic/infusion center",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Eptinezumab (Vyepti) 100 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg IV q3 months; may increase to 300 mg IV q3 months if inadequate response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Infusion reactions",
          "Infusion reactions (nasopharyngitis, hypersensitivity)",
          "reassess efficacy at 3-6 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine"
      ]
    },
    "erenumab": {
      "id": "erenumab",
      "name": "Erenumab (Aimovig)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "70-140 mg",
              "orderSentence": "Erenumab (Aimovig) 70-140 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "70-140 mg SC monthly",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "chronic-migraine-prevention-may-use-as-first-line-or-after-o": {
          "indication": "Chronic migraine prevention; may use as first-line or after oral failure; only CGRP receptor antibody",
          "doseOptions": [
            {
              "text": "70 mg",
              "orderSentence": "Erenumab (Aimovig) 70 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "70 mg SC monthly; may increase to 140 mg SC monthly if inadequate response after 3 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "cgrp-mab-failed-2-oral-preventives-or-intolerance": {
          "indication": "CGRP mAb; failed 2+ oral preventives or intolerance",
          "doseOptions": [
            {
              "text": "70 mg",
              "orderSentence": "Erenumab (Aimovig) 70 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "70 mg SC monthly; may increase to 140 mg monthly after 3 months if suboptimal response",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity",
          "Hypersensitivity to erenumab",
          "caution with constipation, HTN",
          "caution with severe constipation (can cause serious constipation), uncontrolled HTN"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP (may increase), constipation (can be severe), injection site reactions",
          "BP, constipation",
          "Constipation (can be severe - may need laxatives)",
          "HTN monitoring",
          "injection site reactions",
          "reassess efficacy at 3 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "migraine-with-aura"
      ]
    },
    "ergotamine": {
      "id": "ergotamine",
      "name": "Ergotamine (prophylactic)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-2 mg",
              "orderSentence": "Ergotamine (prophylactic) 1-2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg at bedtime if nocturnal attacks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as DHE"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Limited to <2 weeks to avoid overuse"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cluster-headache"
      ]
    },
    "erythromycin": {
      "id": "erythromycin",
      "name": "Erythromycin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "gastroparesis-motilin-receptor-agonist": {
          "indication": "Gastroparesis; motilin receptor agonist",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Erythromycin 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250 mg PO TID before meals; short-term use due to tachyphylaxis",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "drug interactions"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG",
          "GI upset",
          "tachyphylaxis limits long-term use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "small-fiber-neuropathy"
      ]
    },
    "erythropoietin": {
      "id": "erythropoietin",
      "name": "Erythropoietin (EPO)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "refractory-neurogenic-oh-with-anemia-hgb-11-increases-red-ce": {
          "indication": "Refractory neurogenic OH with anemia (Hgb <11) — increases red cell mass and BP",
          "doseOptions": [
            {
              "text": "25-50 units/kg",
              "orderSentence": "Erythropoietin (EPO) 25-50 units/kg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 units/kg SC three times weekly; target Hgb 11-12 g/dL; used when other agents fail; off-label for OH",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Uncontrolled hypertension, history of VTE, pure red cell aplasia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC with reticulocytes q2 weeks until stable, iron studies, BP, VTE surveillance"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "multiple-system-atrophy"
      ]
    },
    "escitalopram": {
      "id": "escitalopram",
      "name": "Escitalopram",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "post-stroke-depression-well-tolerated-in-elderly": {
          "indication": "Post-stroke depression; well-tolerated in elderly",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Escitalopram (Lexapro) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily in elderly; increase to 10 mg after 1 week; max 20 mg (10 mg if >65y)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "depression-anxiety-similar-to-citalopram": {
          "indication": "Depression; anxiety; similar to citalopram",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Escitalopram 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg daily; max 20 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "depression-anxiety-comorbidity-well-tolerated-in-epilepsy-do": {
          "indication": "Depression/anxiety comorbidity; well-tolerated in epilepsy; does NOT lower seizure threshold",
          "doseOptions": [
            {
              "text": "5 mg daily",
              "orderSentence": "Escitalopram 5 mg daily PO"
            },
            {
              "text": "10 mg daily",
              "orderSentence": "Escitalopram 10 mg daily PO"
            },
            {
              "text": "20 mg daily",
              "orderSentence": "Escitalopram 20 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg daily; increase to 20 mg after 1 week if needed; max 20 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "depression-anxiety-with-cognitive-symptoms": {
          "indication": "Depression; anxiety with cognitive symptoms",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Escitalopram 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase to 10 mg after 1 week; max 10 mg in elderly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "depression-anxiety": {
          "indication": "Depression; anxiety",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Escitalopram 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; may increase to 10 mg; max 10 mg in elderly (QT)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "comorbid-generalized-anxiety-disorder-depression-alternative": {
          "indication": "Comorbid generalized anxiety disorder; depression; alternative to sertraline",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Escitalopram 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; may increase to 20 mg after 4 weeks; max 20 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        },
        "depression-anxiety-post-tbi": {
          "indication": "Depression, anxiety post-TBI",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Escitalopram 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily; increase to 10 mg after 1 week; max 20 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "depression-and-anxiety-in-ibm-patients-alternative-to-sertra": {
          "indication": "Depression and anxiety in IBM patients; alternative to sertraline",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Escitalopram 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily in elderly; increase to 10 mg after 1 week; max 20 mg/day (10 mg in age >65 per FDA)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "depression-anxiety-comorbid-with-hand-well-tolerated-minimal": {
          "indication": "Depression/anxiety comorbid with HAND; well tolerated; minimal CYP interactions",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Escitalopram 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg daily; max 20 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "depression-as-alternative-ssri-well-tolerated": {
          "indication": "Depression as alternative SSRI; well-tolerated",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Escitalopram 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase to 10-20 mg daily; max 20 mg (QTc risk at higher doses)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "depression": {
          "indication": "Depression",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Escitalopram 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; may increase to 20 mg after 1 week; max 20 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "depression-anxiety-comorbidity-well-tolerated-in-epilepsy-do-2": {
          "indication": "Depression/anxiety comorbidity; well tolerated in epilepsy; does NOT lower seizure threshold",
          "doseOptions": [
            {
              "text": "5 mg daily",
              "orderSentence": "Escitalopram 5 mg daily PO"
            },
            {
              "text": "10 mg daily",
              "orderSentence": "Escitalopram 10 mg daily PO"
            },
            {
              "text": "20 mg daily",
              "orderSentence": "Escitalopram 20 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg daily; increase to 20 mg after 1 week if needed; max 20 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "post-stroke-depression-well-tolerated-alternative-ssri": {
          "indication": "Post-stroke depression; well tolerated; alternative SSRI",
          "doseOptions": [
            {
              "text": "5 mg daily",
              "orderSentence": "Escitalopram 5 mg daily PO"
            },
            {
              "text": "10 mg daily",
              "orderSentence": "Escitalopram 10 mg daily PO"
            },
            {
              "text": "20 mg daily",
              "orderSentence": "Escitalopram 20 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg daily; max 20 mg; well tolerated in elderly stroke patients",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "depression-anxiety-better-tolerated-than-citalopram": {
          "indication": "Depression; anxiety; better tolerated than citalopram",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Escitalopram (Lexapro) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase to 10 mg after 1 week; max 10 mg in elderly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "depression-and-anxiety-in-dm-patients-alternative-to-sertral": {
          "indication": "Depression and anxiety in DM patients; alternative to sertraline",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Escitalopram 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily; increase to 10 mg after 1 week; max 20 mg/day (10 mg in age >65 per FDA)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "depression-anxiety-chronic": {
          "indication": "Depression/anxiety (chronic)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Escitalopram 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; max 20 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAOIs",
          "Concurrent MAOIs, QT prolongation",
          "MAOIs",
          "QT prolongation",
          "QTc >500 ms",
          "QTc prolongation",
          "QTc prolongation (particularly relevant given cardiac conduction risk in DM1)",
          "concurrent MAOIs",
          "concurrent QT-prolonging drugs",
          "concurrent pimozide",
          "congenital long QT syndrome",
          "max 10 mg in elderly per FDA",
          "pimozide"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI bleeding",
          "GI symptoms",
          "GI upset",
          "QTc",
          "QTc if cardiac risk",
          "QTc if cardiac risk factors",
          "QTc if elderly or QT risk",
          "QTc if risk factors",
          "QTc if risk factors or dose >10 mg",
          "QTc monitoring",
          "QTc monitoring (essential in DM1)",
          "QTc monitoring if risk factors",
          "Suicidality monitoring",
          "check interactions with PIs",
          "hyponatremia",
          "hyponatremia (SIADH, especially elderly)",
          "hyponatremia in elderly",
          "serotonin syndrome",
          "sexual dysfunction",
          "suicidality",
          "suicidality monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 16,
      "_sourcePlans": [
        "drug-resistant-epilepsy",
        "epilepsy-chronic-management",
        "frontotemporal-dementia",
        "hiv-associated-neurocognitive-disorder",
        "huntingtons-disease",
        "inclusion-body-myositis",
        "lewy-body-dementia",
        "mild-cognitive-impairment",
        "ms-new-diagnosis",
        "myotonic-dystrophy",
        "new-onset-seizure",
        "pnes",
        "post-concussion-syndrome",
        "post-stroke-management",
        "progressive-supranuclear-palsy",
        "vascular-dementia"
      ]
    },
    "eslicarbazepine": {
      "id": "eslicarbazepine",
      "name": "Eslicarbazepine (Aptiom)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-adjunctive-therapy-voltage-gated-sodium-channel-blocker-": {
          "indication": "DRE adjunctive therapy; voltage-gated sodium channel blocker; once-daily dosing; may work when carbamazepine/oxcarbazepine failed",
          "doseOptions": [
            {
              "text": "400 mg daily",
              "orderSentence": "Eslicarbazepine (Aptiom) 400 mg daily PO"
            },
            {
              "text": "800 mg daily",
              "orderSentence": "Eslicarbazepine (Aptiom) 800 mg daily PO"
            },
            {
              "text": "1200 mg daily",
              "orderSentence": "Eslicarbazepine (Aptiom) 1200 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 400 mg daily x 1 week → 800 mg daily; may increase to 1200 mg daily after 1 week; max 1200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Third-degree AV block",
          "known HLA-B*15:02 positive",
          "oxcarbazepine hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG",
          "LFTs",
          "Sodium (hyponatremia)",
          "skin rash (cross-reactivity with carbamazepine/oxcarbazepine in ~25%)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "esmolol-iv": {
      "id": "esmolol-iv",
      "name": "Esmolol IV (autonomic tachycardia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500 mcg/kg",
              "orderSentence": "Esmolol IV (autonomic tachycardia) 500 mcg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bolus: 500 mcg/kg over 1 min; Infusion: 50-200 mcg/kg/min",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe bradycardia",
          "cardiogenic shock",
          "decompensated CHF"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous HR/BP",
          "ECG"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "autoimmune-encephalitis"
      ]
    },
    "ethambutol": {
      "id": "ethambutol",
      "name": "Ethambutol (EMB)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-anti-tb-therapy-bacteriostatic-included-to-preven": {
          "indication": "First-line anti-TB therapy; bacteriostatic; included to prevent emergence of drug resistance during intensive phase; POOR CNS penetration",
          "doseOptions": [
            {
              "text": "15-20 mg/kg daily (max 1600 mg)",
              "orderSentence": "Ethambutol (EMB) 15-20 mg/kg daily (max 1600 mg) PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg PO daily (max 1600 mg/day); duration: 2 months (intensive phase); some experts substitute ethionamide (better CNS penetration) for TBM",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Optic neuritis (pre-existing)",
          "renal impairment (dose adjust, renally cleared)",
          "visual impairment that prevents acuity monitoring"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Visual acuity and color vision (Ishihara plates) at baseline, then monthly",
          "discontinue IMMEDIATELY if visual symptoms develop (optic neuritis)",
          "renal function for dose adjustment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tb-meningitis"
      ]
    },
    "ethionamide": {
      "id": "ethionamide",
      "name": "Ethionamide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-ethambutol-for-cns-tb-better-cns-penetration-": {
          "indication": "Alternative to ethambutol for CNS TB (BETTER CNS penetration than EMB); used when drug resistance suspected or EMB toxicity",
          "doseOptions": [
            {
              "text": "15-20 mg/kg daily (max 1000 mg)",
              "orderSentence": "Ethionamide 15-20 mg/kg daily (max 1000 mg) PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg PO daily (max 1000 mg); often in divided BID dosing to reduce GI side effects; frequently used in place of EMB for TBM due to superior CNS penetration",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic disease (hepatotoxic — additive with INH/RIF)",
          "pregnancy (teratogenic)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI tolerance",
          "LFTs monthly",
          "TSH q3 months (causes hypothyroidism in up to 30%)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tb-meningitis"
      ]
    },
    "evolocumab": {
      "id": "evolocumab",
      "name": "Evolocumab (PCSK9 inhibitor)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "add-on-if-ldl-not-at-goal-70-mg-dl-despite-maximum-tolerated": {
          "indication": "Add-on if LDL not at goal (<70 mg/dL) despite maximum tolerated statin + ezetimibe; FOURIER trial showed cardiovascular event reduction; indicated for high-risk atherosclerotic disease including carotid stenosis",
          "doseOptions": [
            {
              "text": "140 mg",
              "orderSentence": "Evolocumab (PCSK9 inhibitor) 140 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "140 mg SC every 2 weeks or 420 mg SC monthly; significant additional LDL lowering (50-60%); use if LDL remains above 70 mg/dL on max statin + ezetimibe",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity to evolocumab"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Lipid panel q4-12 weeks",
          "cost and insurance authorization",
          "injection site reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "carotid-stenosis"
      ]
    },
    "excedrin": {
      "id": "excedrin",
      "name": "Excedrin (ASA/APAP/caffeine)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2 tab",
              "orderSentence": "Excedrin (ASA/APAP/caffeine) 2 tab PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 tablets PO once",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per components"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Risk of MOH"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine"
      ]
    },
    "excessive-iv-fluids": {
      "id": "excessive-iv-fluids",
      "name": "Excessive IV fluids (post-operatively)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "-",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cauda-equina-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cauda-equina-syndrome"
      ]
    },
    "exposure-and-response-prevention": {
      "id": "exposure-and-response-prevention",
      "name": "Exposure and Response Prevention (ERP) (CPT 90834-90837)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "In-person/telehealth"
      ],
      "formulations": [],
      "contexts": {
        "alternative-behavioral-approach-for-patients-who-tolerate-pr": {
          "indication": "Alternative behavioral approach for patients who tolerate premonitory urges poorly",
          "doseOptions": [
            {
              "text": "8-12 sessions",
              "orderSentence": "Exposure and Response Prevention (ERP) (CPT 90834-90837) 8-12 sessions In-person"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Graduated exposure to premonitory urge sensations with response prevention; habituation-based",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active psychosis",
          "severe cognitive impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "YGTSS score",
          "premonitory urge rating (PUTS)",
          "tolerance of urges"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tics-tourette-syndrome"
      ]
    },
    "extended-iv-steroids": {
      "id": "extended-iv-steroids",
      "name": "Extended IV steroids",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "incomplete-response-to-3-day-course": {
          "indication": "Incomplete response to 3-day course",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Extended IV steroids 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Extend to 5-7 total days if inadequate response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Extended IV steroids N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Additional 2-5 days methylprednisolone (total 5-10 days)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "As above",
          "Same as initial course"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "As above",
          "Same as initial course"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-new-diagnosis",
        "optic-neuritis"
      ]
    },
    "extended-release-oxycodone": {
      "id": "extended-release-oxycodone",
      "name": "Extended-release oxycodone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Extended-release oxycodone 10-20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg QHS; for severe refractory RLS",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "restless-legs-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "restless-legs-syndrome"
      ]
    },
    "eye-patch-or-moisture-chamber": {
      "id": "eye-patch-or-moisture-chamber",
      "name": "Eye patch or moisture chamber",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Transdermal"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Eye patch or moisture chamber N/A Transdermal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "At night and in dusty/windy environments",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "bells-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Corneal status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "bells-palsy"
      ]
    },
    "ezetimibe": {
      "id": "ezetimibe",
      "name": "Ezetimibe",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "add-on-for-ldl-not-at-goal-on-statin": {
          "indication": "Add-on for LDL not at goal on statin",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Ezetimibe 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg daily with or without food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Ezetimibe 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg PO daily; add if LDL not at goal on max statin",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke",
            "transient-ischemic-attack"
          ]
        },
        "add-on-to-statin-if-ldl-not-at-goal-on-maximum-statin-improv": {
          "indication": "Add-on to statin if LDL not at goal on maximum statin; IMPROVE-IT trial showed benefit",
          "doseOptions": [
            {
              "text": "10 mg daily",
              "orderSentence": "Ezetimibe 10 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg PO daily; can add to any statin; no dose adjustment needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "add-on-to-statin-if-ldl-not-at-goal-on-maximum-tolerated-sta": {
          "indication": "Add-on to statin if LDL not at goal on maximum tolerated statin; IMPROVE-IT trial showed benefit in secondary prevention; contributes to plaque regression when combined with statin",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Ezetimibe 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg PO daily; add to any statin; no dose adjustment needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "LFTs",
          "LFTs, lipid panel",
          "Severe hepatic impairment",
          "Severe hepatic impairment (when combined with statin)",
          "hypersensitivity",
          "lipid panel"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LDL",
          "LFTs",
          "LFTs with statin combination",
          "Lipid panel q3 months after starting until at goal"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "carotid-stenosis",
        "post-stroke-management",
        "transient-ischemic-attack",
        "vascular-dementia"
      ]
    },
    "factor-xa-inhibitor-reversal-4-factor-pcc": {
      "id": "factor-xa-inhibitor-reversal-4-factor-pcc",
      "name": "Factor Xa inhibitor reversal: 4-factor PCC (if andexanet unavailable)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50 units/kg",
              "orderSentence": "Factor Xa inhibitor reversal: 4-factor PCC (if andexanet unavailable) 50 units/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 units/kg IV. Off-label but supported by guidelines if andexanet not available",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as PCC"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anti-Xa levels",
          "clinical hemostasis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "factor-xa-inhibitor-reversal-andexanet-alfa": {
      "id": "factor-xa-inhibitor-reversal-andexanet-alfa",
      "name": "Factor Xa inhibitor reversal: Andexanet alfa (Andexxa) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Factor Xa inhibitor reversal: Andexanet alfa (Andexxa) (CPT 96365) 400 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "For rivaroxaban/apixaban. Low-dose: 400 mg IV bolus then 4 mg/min x 2h (last dose >8h ago). High-dose: 800 mg IV bolus then 8 mg/min x 2h (last dose <8h ago or unknown, or rivaroxaban)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Thrombotic risk (10-15% VTE in trials)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anti-Xa levels",
          "arterial line",
          "thrombosis monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "famotidine": {
      "id": "famotidine",
      "name": "Famotidine (stress ulcer prophylaxis)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "icu-admission-with-steroid-use": {
          "indication": "ICU admission with steroid use",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Famotidine (stress ulcer prophylaxis) 20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg IV q12h",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "gi-prophylaxis-during-corticosteroid-therapy-to-prevent-stre": {
          "indication": "GI prophylaxis during corticosteroid therapy to prevent stress ulcer",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Famotidine 20 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg IV or PO daily while on corticosteroids",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GFR <50 (reduce dose)",
          "Severe renal impairment (dose adjust)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI bleeding signs",
          "GI symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "cervical-myelopathy",
        "hashimotos-encephalopathy"
      ]
    },
    "felbamate": {
      "id": "felbamate",
      "name": "Felbamate (Felbatol)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-refractory-to-all-other-options-lennox-gastaut-syndrome-": {
          "indication": "DRE refractory to all other options; Lennox-Gastaut syndrome; last-resort due to serious risks",
          "doseOptions": [
            {
              "text": "400 mg TID",
              "orderSentence": "Felbamate (Felbatol) 400 mg TID PO"
            },
            {
              "text": "600 mg TID",
              "orderSentence": "Felbamate (Felbatol) 600 mg TID PO"
            },
            {
              "text": "800 mg TID",
              "orderSentence": "Felbamate (Felbatol) 800 mg TID PO"
            },
            {
              "text": "1200 mg TID",
              "orderSentence": "Felbamate (Felbatol) 1200 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 400 mg TID (1200 mg/day); increase by 600 mg every 2 weeks; target 2400-3600 mg/day; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**BLACK BOX: Aplastic anemia (1:3000-5000) and hepatic failure (1:18,500-25,000)**",
          "prior hematologic or hepatic disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "**CBC with differential q2wk for first year",
          "LFTs q1-2wk for first year**",
          "informed consent REQUIRED documenting risk discussion",
          "reticulocyte count"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "fenfluramine": {
      "id": "fenfluramine",
      "name": "Fenfluramine (Fintepla)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-due-to-dravet-syndrome-or-lennox-gastaut-syndrome-seroto": {
          "indication": "DRE due to Dravet syndrome or Lennox-Gastaut syndrome; serotonin-releasing agent",
          "doseOptions": [
            {
              "text": "0.1 mg/kg BID",
              "orderSentence": "Fenfluramine (Fintepla) 0.1 mg/kg BID PO"
            },
            {
              "text": "0.2 mg/kg BID",
              "orderSentence": "Fenfluramine (Fintepla) 0.2 mg/kg BID PO"
            },
            {
              "text": "0.35 mg/kg BID",
              "orderSentence": "Fenfluramine (Fintepla) 0.35 mg/kg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mg/kg BID (0.2 mg/kg/day); increase after 7 days to 0.2 mg/kg BID; max 0.35 mg/kg BID (26 mg/day) without stiripentol; max 0.2 mg/kg BID with stiripentol",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pulmonary arterial hypertension",
          "aortic/mitral valve disease",
          "concurrent MAOIs or serotonergic drugs",
          "valvular heart disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "**REMS PROGRAM REQUIRED**: Echocardiogram at baseline, 6 months, then annually",
          "cardiac monitoring mandatory",
          "serotonin syndrome risk"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "fentanyl": {
      "id": "fentanyl",
      "name": "Fentanyl",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "analgesia-and-sedation-during-ttm-preferred-analgesic-during": {
          "indication": "Analgesia and sedation during TTM; preferred analgesic during hypothermia (hepatic metabolism reduced)",
          "doseOptions": [
            {
              "text": "25-200 mcg/h",
              "orderSentence": "Fentanyl 25-200 mcg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-100 mcg/h continuous infusion; titrate to RASS target; bolus 25-50 mcg PRN",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Respiratory depression (ventilated patients)",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RASS",
          "bowel function",
          "respiratory rate (if not ventilated)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "anoxic-brain-injury"
      ]
    },
    "fentanyl-infusion": {
      "id": "fentanyl-infusion",
      "name": "Fentanyl infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "analgesia-sedation-adjunct": {
          "indication": "Analgesia/sedation adjunct",
          "doseOptions": [
            {
              "text": "25-100 mcg/hr",
              "orderSentence": "Fentanyl infusion 25-100 mcg/hr PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-100 mcg/hr; titrate to comfort",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hemodynamic instability"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Pain scale, respiratory status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-epilepticus"
      ]
    },
    "ferrous-gluconate": {
      "id": "ferrous-gluconate",
      "name": "Ferrous gluconate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "324 mg",
              "orderSentence": "Ferrous gluconate 324 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "324 mg (36 mg elemental iron) daily; better tolerated",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "restless-legs-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "restless-legs-syndrome"
      ]
    },
    "filgrastim": {
      "id": "filgrastim",
      "name": "Filgrastim (G-CSF)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "chemotherapy-induced-neutropenia-prevention-or-treatment-use": {
          "indication": "Chemotherapy-induced neutropenia prevention or treatment; used with dose-dense methotrexate regimens to maintain treatment intensity",
          "doseOptions": [
            {
              "text": "5 mcg/kg",
              "orderSentence": "Filgrastim (G-CSF) 5 mcg/kg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mcg/kg SC daily starting 24-48h after chemotherapy until ANC >1500; pegfilgrastim 6 mg SC x1 dose alternative (not with MTX due to timing)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity",
          "concurrent with chemotherapy (start 24h after)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC daily during neutropenic phase",
          "bone pain (common)",
          "spleen size if prolonged use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "fingolimod": {
      "id": "fingolimod",
      "name": "Fingolimod (Gilenya)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Fingolimod (Gilenya) 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5 mg daily; first dose observation 6h",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "2nd/3rd degree AV block",
          "Bradycardia <55",
          "QTc >500 ms",
          "Recent MI, unstable angina, heart block, bradycardia",
          "recent MI/stroke/TIA (within 6 months)",
          "sick sinus syndrome"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "First-dose cardiac monitoring (6h)",
          "First-dose observation 6 hours (HR, BP q1h, ECG at 6h)",
          "LFTs",
          "lymphocyte count",
          "lymphocytes",
          "macular edema screen at 3-4 months",
          "ophtho exam (macular edema)",
          "varicella status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "fluconazole": {
      "id": "fluconazole",
      "name": "Fluconazole",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO",
        "PO/IV"
      ],
      "formulations": [],
      "contexts": {
        "alternative-induction-when-amphotericin-b-or-flucytosine-una": {
          "indication": "Alternative induction when amphotericin B or flucytosine unavailable (WHO alternative regimen); inferior to amphotericin-based regimens but used in resource-limited settings",
          "doseOptions": [
            {
              "text": "1200 mg",
              "orderSentence": "Fluconazole (high-dose induction alternative) 1200 mg PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1200 mg PO or IV daily for 2 weeks (induction); used with flucytosine if amphotericin B unavailable",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "consolidation-therapy-after-successful-2-week-induction-cryp": {
          "indication": "Consolidation therapy after successful 2-week induction (Cryptococcus); transition from IV amphotericin B when CSF is sterilizing; 8 weeks consolidation",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Fluconazole (consolidation phase) 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400 mg PO daily for 8 weeks (consolidation); begin after minimum 2-week induction and clinical improvement",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "long-term-maintenance-after-consolidation-cryptococcus-preve": {
          "indication": "Long-term maintenance after consolidation (Cryptococcus); prevents relapse; continue until immune reconstitution (CD4 >100 for >3 months on ART with suppressed viral load)",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Fluconazole (maintenance/secondary prophylaxis) 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg PO daily; continue for minimum 1 year; in HIV patients, continue until CD4 >100 for >3 months with suppressed viral load; in non-HIV, continue for 6-12 months minimum",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "lifelong-therapy-for-coccidioidal-meningitis-relapse-rate-ne": {
          "indication": "LIFELONG therapy for coccidioidal meningitis; relapse rate near 80% if azole discontinued; never discontinue without ID specialist involvement",
          "doseOptions": [
            {
              "text": "400-800 mg",
              "orderSentence": "Fluconazole (coccidioidal meningitis — lifelong) 400-800 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400 mg PO daily (standard); 800-1000 mg daily for refractory cases; LIFELONG treatment required — do NOT discontinue",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "secondary-prophylaxis-if-prior-cryptococcal-meningitis-maint": {
          "indication": "Secondary prophylaxis if prior cryptococcal meningitis; maintenance until immune reconstitution (CD4 >200 x 6 months)",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Fluconazole 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg PO daily until CD4 >200 for >=6 months on suppressive ART",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "candida-brain-abscess-uncommon-cryptococcus-consolidation-th": {
          "indication": "Candida brain abscess (uncommon); Cryptococcus consolidation therapy after amphotericin induction",
          "doseOptions": [
            {
              "text": "800 mg",
              "orderSentence": "Fluconazole 800 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "800 mg IV/PO daily x 2 weeks induction (with amphotericin for Crypto), then 400 mg PO daily consolidation x 8 weeks; maintenance 200 mg PO daily for Crypto in HIV",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hepatic disease",
          "Hepatic impairment",
          "QT prolongation",
          "Severe hepatic impairment",
          "concurrent QT-prolonging medications",
          "concurrent terfenadine/cisapride",
          "drug interactions (azoles + PIs)",
          "pregnancy",
          "pregnancy (teratogenic in first trimester at high doses)",
          "pregnancy (teratogenic)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CD4 count and viral load q3 months (HIV)",
          "Coccidioides CF titers q3-6 months (declining indicates response)",
          "LFTs",
          "LFTs at 2 weeks then monthly",
          "LFTs biweekly",
          "LFTs q3 months",
          "LFTs weekly",
          "QTc",
          "QTc at baseline and weekly",
          "QTc if risk factors",
          "bone density (long-term azole use)",
          "clinical assessment",
          "clinical assessment for relapse symptoms",
          "clinical response",
          "drug interactions (CYP2C9, CYP3A4 inhibitor)",
          "drug interactions (CYP2C9/3A4 inhibitor)",
          "drug interactions with ART (especially ritonavir)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "brain-abscess",
        "fungal-meningitis",
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "flucytosine": {
      "id": "flucytosine",
      "name": "Flucytosine (5-FC, Ancobon)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "combination-with-amphotericin-b-for-induction-improves-funga": {
          "indication": "Combination with amphotericin B for induction; improves fungal clearance and reduces relapse; synergistic with amphotericin B",
          "doseOptions": [
            {
              "text": "25 mg/kg",
              "orderSentence": "Flucytosine (5-FC, Ancobon) 25 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg/kg PO q6h (100 mg/kg/day in 4 divided doses) for 2 weeks; adjust for renal function (GFR-based dosing); take with food to reduce GI side effects",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment",
          "bone marrow suppression",
          "pregnancy (teratogenic, Category C)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC with differential twice weekly (myelosuppression — leukopenia, thrombocytopenia)",
          "LFTs weekly",
          "flucytosine drug levels if available (target peak 30-80 mcg/mL",
          "renal function daily (adjust dose with declining GFR)",
          "toxic >100)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "fludrocortisone": {
      "id": "fludrocortisone",
      "name": "Fludrocortisone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.1-0.2 mg",
              "orderSentence": "Fludrocortisone 0.1-0.2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1-0.2 mg daily (refractory cases)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "syncope",
            "parkinsons-disease-new-diagnosis",
            "autoimmune-encephalitis"
          ]
        },
        "orthostatic-hypotension-volume-expansion": {
          "indication": "Orthostatic hypotension; volume expansion",
          "doseOptions": [
            {
              "text": "0.1 mg",
              "orderSentence": "Fludrocortisone 0.1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mg daily; may increase to 0.2 mg daily; max 0.3 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "orthostatic-hypotension-adjunct": {
          "indication": "Orthostatic hypotension adjunct",
          "doseOptions": [
            {
              "text": "0.1 mg daily",
              "orderSentence": "Fludrocortisone 0.1 mg daily PO"
            },
            {
              "text": "0.2 mg daily",
              "orderSentence": "Fludrocortisone 0.2 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mg daily; may increase to 0.2 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia",
            "parkinsons-disease"
          ]
        },
        "orthostatic-intolerance-post-concussion-autonomic-dysfunctio": {
          "indication": "Orthostatic intolerance, post-concussion autonomic dysfunction",
          "doseOptions": [
            {
              "text": "0.1 mg",
              "orderSentence": "Fludrocortisone 0.1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mg PO daily; max 0.2 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "orthostatic-hypotension-as-adjunct-to-midodrine-or-if-midodr": {
          "indication": "Orthostatic hypotension as adjunct to midodrine or if midodrine insufficient",
          "doseOptions": [
            {
              "text": "0.1 mg",
              "orderSentence": "Fludrocortisone 0.1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mg daily; may increase to 0.2 mg daily; max 0.3 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "orthostatic-hypotension": {
          "indication": "Orthostatic hypotension",
          "doseOptions": [
            {
              "text": "0.1 mg",
              "orderSentence": "Fludrocortisone 0.1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mg daily; increase by 0.1 mg every 1-2 weeks; max 0.3 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "orthostatic-hypotension-refractory-to-midodrine-volume-expan": {
          "indication": "Orthostatic hypotension refractory to midodrine; volume expansion",
          "doseOptions": [
            {
              "text": "0.1 mg",
              "orderSentence": "Fludrocortisone 0.1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mg daily; may increase to 0.2 mg daily; max 0.3 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "cerebral-salt-wasting-volume-depletion-hyponatremia": {
          "indication": "Cerebral salt wasting (volume depletion + hyponatremia)",
          "doseOptions": [
            {
              "text": "0.1-0.2 mg",
              "orderSentence": "Fludrocortisone 0.1-0.2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1-0.2 mg PO BID",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        },
        "neurogenic-oh-volume-expansion-adjunct-to-midodrine": {
          "indication": "Neurogenic OH — volume expansion; adjunct to midodrine",
          "doseOptions": [
            {
              "text": "0.1 mg daily",
              "orderSentence": "Fludrocortisone 0.1 mg daily PO"
            },
            {
              "text": "0.2 mg daily",
              "orderSentence": "Fludrocortisone 0.2 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mg daily; may increase to 0.2 mg daily after 1-2 weeks; max 0.3 mg/day; take with food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CHF",
          "CHF, hypertension, renal failure",
          "HTN, HF",
          "HTN, HF, hypokalemia",
          "Heart failure",
          "Heart failure, HTN",
          "Heart failure, severe edema, severe supine hypertension, hypokalemia",
          "edema",
          "hypertension",
          "hypokalemia",
          "renal failure",
          "severe hypertension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP, potassium, edema",
          "Electrolytes (hypokalemia)",
          "K+ (hypokalemia)",
          "K+, BP",
          "K+, BP, edema",
          "K+, edema, supine BP",
          "K+, edema, supine BP, weight",
          "Na",
          "Potassium (weekly x4, then monthly), supine BP, weight, edema, BMP",
          "Potassium, BP, edema",
          "Potassium, edema, supine blood pressure, weight",
          "Sodium",
          "Weight, BP supine and standing, potassium, edema",
          "edema",
          "hypokalemia",
          "potassium",
          "supine hypertension",
          "volume status",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 13,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "lambert-eaton-syndrome",
        "lewy-body-dementia",
        "multiple-system-atrophy",
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis",
        "peripheral-neuropathy",
        "post-concussion-syndrome",
        "progressive-supranuclear-palsy",
        "small-fiber-neuropathy",
        "subarachnoid-hemorrhage",
        "syncope"
      ]
    },
    "flumazenil": {
      "id": "flumazenil",
      "name": "Flumazenil (rescue only)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.2 mg",
              "orderSentence": "Flumazenil (rescue only) 0.2 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.2 mg IV over 30 sec; may repeat 0.2 mg q1min to max 1 mg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Chronic benzodiazepine use",
          "seizure history",
          "tricyclic overdose"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "**CAUTION:** May lower seizure threshold and precipitate seizures",
          "use only if severe respiratory depression unresponsive to supportive care"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "new-onset-seizure"
      ]
    },
    "flunarizine": {
      "id": "flunarizine",
      "name": "Flunarizine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "calcium-channel-blocker-for-prevention-especially-hemiplegic": {
          "indication": "Calcium channel blocker for prevention; especially hemiplegic migraine",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Flunarizine 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg qHS; may increase to 10 mg qHS; especially useful for hemiplegic migraine (not available in US)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Depression",
          "Parkinson's disease",
          "extrapyramidal disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Weight gain",
          "depression",
          "parkinsonism with prolonged use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine-with-aura"
      ]
    },
    "fluoxetine": {
      "id": "fluoxetine",
      "name": "Fluoxetine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "anticataplectic-agent-also-treats-comorbid-depression": {
          "indication": "Anticataplectic agent; also treats comorbid depression",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Fluoxetine 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-20 mg daily; increase by 10-20 mg every 2-4 weeks; target 20-60 mg/day; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        },
        "ocd-comorbidity-first-line-ssri-for-ocd-in-tourette": {
          "indication": "OCD comorbidity (first-line SSRI for OCD in Tourette)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Fluoxetine (Prozac) 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; increase by 10 mg q2-4wk; target 20-60 mg/day for OCD; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        },
        "depression": {
          "indication": "Depression",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Fluoxetine 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20 mg daily; may increase after several weeks; max 80 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "depression-pseudobulbar-affect-ssri-with-mild-activating-eff": {
          "indication": "Depression; pseudobulbar affect — SSRI with mild activating effect",
          "doseOptions": [
            {
              "text": "10 mg daily",
              "orderSentence": "Fluoxetine 10 mg daily PO"
            },
            {
              "text": "20 mg daily",
              "orderSentence": "Fluoxetine 20 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; increase to 20 mg after 2-4 weeks if needed; max 60 mg/day; take in morning",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAO-I use",
          "Concurrent MAOIs",
          "MAOIs (within 14 days), concurrent thioridazine/pimozide",
          "concurrent pimozide (QTc)",
          "concurrent pimozide or thioridazine",
          "concurrent thioridazine",
          "pimozide",
          "thioridazine"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Long half-life (washout important)",
          "Mood, suicidality (first 4 weeks), serotonin syndrome, hyponatremia",
          "OCD severity (Y-BOCS)",
          "QTc at higher doses",
          "Serotonin syndrome",
          "Suicidality (Black Box in children)",
          "activation/insomnia",
          "activation/mania",
          "serotonin syndrome",
          "suicidality in young adults",
          "suicidality monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "ms-new-diagnosis",
        "multiple-system-atrophy",
        "narcolepsy",
        "tics-tourette-syndrome"
      ]
    },
    "fluphenazine": {
      "id": "fluphenazine",
      "name": "Fluphenazine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "second-line-typical-antipsychotic-with-evidence-for-tic-supp": {
          "indication": "Second-line; typical antipsychotic with evidence for tic suppression",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Fluphenazine 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg daily; increase by 0.5 mg q1wk; target 1.5-5 mg/day; max 10 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CNS depression",
          "Parkinsonism",
          "blood dyscrasias",
          "comatose states"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "EPS/tardive dyskinesia (AIMS q6mo)",
          "QTc",
          "Sedation",
          "prolactin",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tics-tourette-syndrome"
      ]
    },
    "fluvoxamine": {
      "id": "fluvoxamine",
      "name": "Fluvoxamine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "compulsive-behaviors-repetitive-behaviors-may-have-specific-": {
          "indication": "Compulsive behaviors; repetitive behaviors; may have specific benefit in FTD",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Fluvoxamine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg qHS; titrate by 25-50 mg weekly; typical 100-200 mg/day; max 300 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "MAOIs",
          "alosetron, tizanidine (drug interactions)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "Multiple drug interactions (CYP1A2, 2C19, 3A4 inhibitor)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "frontotemporal-dementia"
      ]
    },
    "folate": {
      "id": "folate",
      "name": "Folate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "folate-deficiency": {
          "indication": "Folate deficiency",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Folate 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg PO daily; ensure B12 adequate before treating to avoid masking deficiency",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Folate 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wernicke-encephalopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Folate level at 3 months",
          "None"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "mild-cognitive-impairment",
        "wernicke-encephalopathy"
      ]
    },
    "folic-acid": {
      "id": "folic-acid",
      "name": "Folic acid",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "folate-depletion-by-enzyme-inducing-asms-critical-for-women-": {
          "indication": "Folate depletion by enzyme-inducing ASMs; critical for women of childbearing potential (neural tube defect prevention)",
          "doseOptions": [
            {
              "text": "1 mg daily",
              "orderSentence": "Folic acid 1 mg daily PO"
            },
            {
              "text": "4 mg daily",
              "orderSentence": "Folic acid 4 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg daily for all DRE patients on enzyme-inducing ASMs; 4 mg daily for women planning pregnancy",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "correct-concurrent-folate-deficiency-must-give-with-b12-to-a": {
          "indication": "Correct concurrent folate deficiency; MUST give with B12 to avoid masking B12 deficiency",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Folic acid 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg PO daily; NEVER give folate without B12 in suspected B12 deficiency (may worsen neurological damage)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "neural-tube-defect-prevention-in-women-with-epilepsy-all-wom": {
          "indication": "Neural tube defect prevention in women with epilepsy; ALL women on ASMs planning pregnancy",
          "doseOptions": [
            {
              "text": "4 mg daily",
              "orderSentence": "Folic acid (high-dose preconception) 4 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg daily starting ≥3 months before conception; continue through first trimester; 1 mg daily maintenance after",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "reduce-methotrexate-side-effects-stomatitis-cytopenias": {
          "indication": "Reduce methotrexate side effects (stomatitis, cytopenias)",
          "doseOptions": [
            {
              "text": "1 mg daily",
              "orderSentence": "Folic acid (with methotrexate) 1 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg PO daily (skip day of MTX)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "all-women-of-childbearing-potential-on-asms-neural-tube-defe": {
          "indication": "All women of childbearing potential on ASMs; neural tube defect prevention; folate depletion by enzyme-inducing ASMs",
          "doseOptions": [
            {
              "text": "1 mg daily",
              "orderSentence": "Folic acid 1 mg daily PO"
            },
            {
              "text": "4 mg daily",
              "orderSentence": "Folic acid 4 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg daily for all women on ASMs; increase to 4 mg daily at least 3 months before planned conception; continue through first trimester",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "neural-tube-defect-prevention-for-all-women-of-childbearing-": {
          "indication": "Neural tube defect prevention for ALL women of childbearing potential on ASMs; start before conception",
          "doseOptions": [
            {
              "text": "4 mg daily",
              "orderSentence": "Folic acid (preconception) 4 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg daily starting at least 3 months before planned conception; continue through first trimester; 1 mg daily maintenance otherwise",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Few",
          "Few contraindications",
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ensure B12 is being co-administered",
          "None routine",
          "Serum folate",
          "Serum folate annually",
          "neural tube screening ultrasound",
          "reticulocyte count"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "b12-deficiency-neuropathy",
        "drug-resistant-epilepsy",
        "eclampsia-seizure-pregnancy",
        "epilepsy-chronic-management",
        "giant-cell-arteritis"
      ]
    },
    "folic-acid-po": {
      "id": "folic-acid-po",
      "name": "Folic acid PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "folate-deficiency-correction-common-in-chronic-alcohol-use": {
          "indication": "Folate deficiency correction; common in chronic alcohol use",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Folic acid PO 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg PO daily; continue long-term if alcohol use disorder",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Folate levels"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure"
      ]
    },
    "foscarnet-iv": {
      "id": "foscarnet-iv",
      "name": "Foscarnet IV (acyclovir-resistant HSV)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "60 mg/kg",
              "orderSentence": "Foscarnet IV (acyclovir-resistant HSV) 60 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg/kg IV q8h or 90 mg/kg IV q12h; infuse over 1-2h with aggressive hydration. For proven or suspected acyclovir resistance (immunocompromised, HIV)",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "hsv-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal failure (major nephrotoxin)",
          "electrolyte abnormalities"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ca, Mg, K, PO4 BID (causes severe electrolyte wasting)",
          "Cr daily",
          "hydration 1-2 L NS before each dose"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hsv-encephalitis"
      ]
    },
    "fosphenytoin": {
      "id": "fosphenytoin",
      "name": "Fosphenytoin (severe exacerbation) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "15-20 mg",
              "orderSentence": "Fosphenytoin (severe exacerbation) (CPT 96365) 15-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg PE/kg IV at 100-150 mg/min; then phenytoin 100 mg TID",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "trigeminal-neuralgia"
          ]
        },
        "refractory-seizure-not-responding-to-levetiracetam-status-ep": {
          "indication": "Refractory seizure not responding to levetiracetam; status epilepticus; **NOTE: phenytoin/fosphenytoin is enzyme-inducing and reduces praziquantel levels by 50%**",
          "doseOptions": [
            {
              "text": "20 mg PE/kg",
              "orderSentence": "Fosphenytoin (seizure rescue second-line) (CPT 96374) 20 mg PE/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg PE/kg IV at 150 mg PE/min; maintenance 100 mg PE q8h; target free phenytoin level 1-2 mcg/mL",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "refractory-seizure-not-responding-to-levetiracetam-status-ep-2": {
          "indication": "Refractory seizure not responding to levetiracetam; status epilepticus protocol",
          "doseOptions": [
            {
              "text": "20 mg PE/kg",
              "orderSentence": "Fosphenytoin (seizure rescue second-line) 20 mg PE/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Fosphenytoin 20 mg PE/kg IV at 150 mg PE/min; maintenance 100 mg PE q8h; target free phenytoin level 1-2 ug/mL (total 10-20 ug/mL)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bradycardia",
          "Sinus bradycardia, heart block, Adams-Stokes syndrome",
          "hypotension",
          "reduces praziquantel levels",
          "second/third-degree heart block"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "Continuous telemetry during load",
          "ECG, BP during infusion",
          "LFTs",
          "drug interactions with antiparasitic agents",
          "free phenytoin level",
          "phenytoin levels"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "brain-abscess",
        "neurocysticercosis",
        "trigeminal-neuralgia"
      ]
    },
    "fosphenytoin-iv": {
      "id": "fosphenytoin-iv",
      "name": "Fosphenytoin IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Fosphenytoin IV 20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg PE/kg IV at 150 mg PE/min; may give additional 5-10 mg PE/kg if needed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "second-line-preferred-if-cardiac-monitoring-available": {
          "indication": "Second-line; preferred if cardiac monitoring available",
          "doseOptions": [
            {
              "text": "20 mg PE/kg",
              "orderSentence": "Fosphenytoin IV 20 mg PE/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg PE/kg IV (max rate 150 mg PE/min); then maintenance 5-7 mg/kg/day divided BID-TID (target level 10-20 mcg/mL)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "alternative-first-line": {
          "indication": "Alternative first-line",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Fosphenytoin IV 20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg PE/kg IV at 150 mg PE/min (max rate)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "2nd/3rd degree AV block, sinus bradycardia, allergy",
          "AV block",
          "AV block, sinus bradycardia, pregnancy (relative)",
          "bradycardia",
          "concurrent delavirdine"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous cardiac monitor, BP q5min during infusion",
          "Continuous cardiac monitoring during load",
          "Continuous cardiac monitoring, BP",
          "ECG",
          "phenytoin level",
          "purple glove syndrome (peripheral IV)",
          "purple glove syndrome rare with fosphenytoin"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "ncse",
        "new-onset-seizure",
        "status-epilepticus"
      ]
    },
    "fremanezumab": {
      "id": "fremanezumab",
      "name": "Fremanezumab (Ajovy)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "225 mg",
              "orderSentence": "Fremanezumab (Ajovy) 225 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "225 mg SC monthly OR 675 mg SC quarterly",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "chronic-migraine-prevention-monthly-or-quarterly-dosing-opti": {
          "indication": "Chronic migraine prevention; monthly or quarterly dosing option",
          "doseOptions": [
            {
              "text": "225 mg",
              "orderSentence": "Fremanezumab (Ajovy) 225 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "225 mg SC monthly OR 675 mg SC quarterly (three 225 mg injections)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "cgrp-mab-flexible-dosing-options": {
          "indication": "CGRP mAb; flexible dosing options",
          "doseOptions": [
            {
              "text": "225 mg",
              "orderSentence": "Fremanezumab (Ajovy) 225 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "225 mg SC monthly OR 675 mg SC quarterly (three 225 mg injections)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Injection site reactions",
          "reassess efficacy at 3 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "migraine-with-aura"
      ]
    },
    "fresh-frozen-plasma": {
      "id": "fresh-frozen-plasma",
      "name": "Fresh frozen plasma (FFP)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "coagulopathy-in-fulminant-hepatic-failure": {
          "indication": "Coagulopathy in fulminant hepatic failure",
          "doseOptions": [
            {
              "text": "10-15 mL/kg",
              "orderSentence": "Fresh frozen plasma (FFP) 10-15 mL/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-15 mL/kg IV; target INR <1.5 for procedures; use as bridge to transplant",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "IgA deficiency",
          "Volume overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "INR, fibrinogen, volume status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wilsons-disease"
      ]
    },
    "furosemide": {
      "id": "furosemide",
      "name": "Furosemide (add-on)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20-40 mg",
              "orderSentence": "Furosemide (add-on) 20-40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mg daily; if acetazolamide insufficient alone",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "idiopathic-intracranial-hypertension"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Sulfa allergy (cross-reactivity uncommon), severe dehydration"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "K+, renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "idiopathic-intracranial-hypertension"
      ]
    },
    "gabapentin": {
      "id": "gabapentin",
      "name": "Gabapentin",
      "genericName": "gabapentin",
      "brandNames": [
        "Neurontin",
        "Gralise",
        "Horizant"
      ],
      "drugClass": "Gabapentinoid / Anticonvulsant",
      "mechanisms": [
        "Binds alpha-2-delta subunit of voltage-gated calcium channels",
        "Reduces excitatory neurotransmitter release"
      ],
      "routes": [
        "PO"
      ],
      "formulations": [
        "100 mg capsule",
        "300 mg capsule",
        "400 mg capsule",
        "600 mg tablet",
        "800 mg tablet",
        "250 mg/5mL solution"
      ],
      "contexts": {
        "neuropathic-pain": {
          "indication": "Neuropathic pain (diabetic neuropathy, post-herpetic neuralgia, small fiber neuropathy)",
          "doseOptions": [
            {
              "text": "100 mg TID",
              "orderSentence": "Gabapentin 100 mg PO TID"
            },
            {
              "text": "300 mg TID",
              "orderSentence": "Gabapentin 300 mg PO TID"
            },
            {
              "text": "600 mg TID",
              "orderSentence": "Gabapentin 600 mg PO TID"
            },
            {
              "text": "900 mg TID",
              "orderSentence": "Gabapentin 900 mg PO TID"
            },
            {
              "text": "1200 mg TID",
              "orderSentence": "Gabapentin 1200 mg PO TID"
            }
          ],
          "startingDose": "300 mg QHS or 100-300 mg TID",
          "maxDose": "3600 mg/day",
          "titration": "Increase by 300 mg every 1-3 days as tolerated",
          "notes": "First-line for neuropathic pain; full effect may take 2-4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          }
        },
        "epilepsy": {
          "indication": "Adjunctive therapy for partial seizures",
          "doseOptions": [
            {
              "text": "300 mg TID",
              "orderSentence": "Gabapentin 300 mg PO TID"
            },
            {
              "text": "400 mg TID",
              "orderSentence": "Gabapentin 400 mg PO TID"
            },
            {
              "text": "600 mg TID",
              "orderSentence": "Gabapentin 600 mg PO TID"
            },
            {
              "text": "800 mg TID",
              "orderSentence": "Gabapentin 800 mg PO TID"
            },
            {
              "text": "1200 mg TID",
              "orderSentence": "Gabapentin 1200 mg PO TID"
            }
          ],
          "startingDose": "300 mg TID",
          "maxDose": "3600 mg/day",
          "titration": "Increase by 300 mg every 1-3 days",
          "notes": "Adjunctive only; monotherapy not FDA-approved for epilepsy"
        },
        "tremor": {
          "indication": "Essential tremor",
          "doseOptions": [
            {
              "text": "300 mg TID",
              "orderSentence": "Gabapentin 300 mg PO TID"
            },
            {
              "text": "400 mg TID",
              "orderSentence": "Gabapentin 400 mg PO TID"
            },
            {
              "text": "600 mg TID",
              "orderSentence": "Gabapentin 600 mg PO TID"
            }
          ],
          "startingDose": "300 mg TID",
          "maxDose": "1800 mg/day",
          "titration": "Increase weekly as tolerated",
          "notes": "Second-line after propranolol/primidone; limited evidence"
        },
        "migraine-prophylaxis": {
          "indication": "Migraine prophylaxis",
          "doseOptions": [
            {
              "text": "300 mg QHS",
              "orderSentence": "Gabapentin 300 mg PO QHS"
            },
            {
              "text": "300 mg BID",
              "orderSentence": "Gabapentin 300 mg PO BID"
            },
            {
              "text": "400 mg TID",
              "orderSentence": "Gabapentin 400 mg PO TID"
            },
            {
              "text": "600 mg TID",
              "orderSentence": "Gabapentin 600 mg PO TID"
            }
          ],
          "startingDose": "300 mg QHS",
          "maxDose": "2400 mg/day",
          "titration": "Increase every 1-2 weeks",
          "notes": "Off-label; moderate evidence; may help with sleep"
        },
        "neuropathic-pain-painful-paresthesia-first-line": {
          "indication": "Neuropathic pain, painful paresthesia (first-line)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; increase by 300 mg every 1-3 days; target 900-1800 mg TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "neuropathic-pain-central-pain-from-brainstem-spinal-cord-les": {
          "indication": "Neuropathic pain; central pain from brainstem/spinal cord lesions",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q1-3d; target 900-1800 mg TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "neuropathic-pain-or-myalgia-not-responsive-to-simple-analges": {
          "indication": "Neuropathic pain or myalgia not responsive to simple analgesics",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg PO qHS; increase by 300 mg/day every 1-3 days; target 900-1800 mg TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "muscle-cramps-neuropathic-pain": {
          "indication": "Muscle cramps; neuropathic pain",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg/day q1-3 days; max 3600 mg/day divided TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100-300 mg",
              "orderSentence": "Gabapentin (neuropathic pain) 100-300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100-300 mg TID; titrate to 900-3600 mg/day",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cidp",
            "diabetic-neuropathy",
            "bells-palsy",
            "cluster-headache",
            "essential-tremor",
            "restless-legs-syndrome"
          ]
        },
        "neuropathic-pain-first-line-burning-tingling-shooting-pain": {
          "indication": "Neuropathic pain (first-line); burning, tingling, shooting pain",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg every 1-3 days to TID dosing; target 900-1800 mg/day divided TID; max 3600 mg/day; adjust for renal function (CrCl 30-59: max 1400 mg/day; CrCl 15-29: max 700 mg/day; CrCl <15: max 300 mg/day)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "tinnitus-associated-with-acoustic-trauma-or-comorbid-neuropa": {
          "indication": "Tinnitus associated with acoustic trauma or comorbid neuropathic pain",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "**Gabapentin** 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg QHS, titrate by 300 mg every 3-5 days to 300-600 mg TID; limited evidence for tinnitus alone; helps subset with noise-induced tinnitus",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        },
        "neuropathic-pain-horner-syndrome-associated-pain-persistent-": {
          "indication": "Neuropathic pain (Horner syndrome-associated pain, persistent neck/face pain)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg PO qHS; titrate by 300 mg q1-3 days; target 900-1800 mg/day divided TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "neuropathic-pain-from-peripheral-neuropathy-or-radiculopathy": {
          "indication": "Neuropathic pain from peripheral neuropathy or radiculopathy",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q1-3d; target 900-1800 mg TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "neuropathic-pain-lightning-pains-of-tabes-dorsalis-lancinati": {
          "indication": "Neuropathic pain (lightning pains of tabes dorsalis; lancinating pain)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q1-3d to 300-900 mg TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "radicular-pain-from-nerve-root-involvement-cauda-equina-neur": {
          "indication": "Radicular pain from nerve root involvement (cauda equina); neuropathic pain from cranial neuropathies",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "**Gabapentin (neuropathic/radicular pain)** 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg PO at bedtime; titrate by 300 mg/day every 3 days to 300-900 mg TID; max 3600 mg/day; renal dose adjustment if CrCl <60",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "persistent-periorbital-pain-neuropathic-symptoms": {
          "indication": "Persistent periorbital pain/neuropathic symptoms",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; increase by 300 mg every 1-3 days; target 900-1800 mg/day divided TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "neuropathic-headache-component-adjunctive-pain-management-in": {
          "indication": "Neuropathic headache component; adjunctive pain management in SIH",
          "doseOptions": [
            {
              "text": "300 mg qHS",
              "orderSentence": "Gabapentin 300 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg PO qHS; titrate by 300 mg q3-5d; target 900-1800 mg/day divided TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        },
        "first-line-less-expensive-alternative-to-pregabalin": {
          "indication": "First-line; less expensive alternative to pregabalin",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q3-7d; target 1800-3600 mg/day divided TID; reduce if CrCl <60",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "neuropathic-pain-from-cip-burning-tingling-allodynia-common-": {
          "indication": "Neuropathic pain from CIP (burning, tingling, allodynia); common in recovery phase",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg PO qHS; titrate by 300 mg/day q1-3 days; target 900-1800 mg/day divided TID; max 3600 mg/day; dose adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "neuropathic-pain-dysesthesia-along-lateral-leg-or-dorsal-foo": {
          "indication": "Neuropathic pain/dysesthesia along lateral leg or dorsal foot",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; increase by 300 mg q3-7d as tolerated; target 900-1800 mg/day divided TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peroneal-neuropathy"
          ]
        },
        "post-traumatic-headache-with-neuropathic-component": {
          "indication": "Post-traumatic headache with neuropathic component",
          "doseOptions": [
            {
              "text": "100-300 mg",
              "orderSentence": "Gabapentin 100-300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100-300 mg PO TID; increase by 300 mg/day every 3-5 days; target 900-2400 mg/day divided TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "insomnia-with-comorbid-headache-or-pain": {
          "indication": "Insomnia with comorbid headache or pain",
          "doseOptions": [
            {
              "text": "100-300 mg",
              "orderSentence": "Gabapentin (for sleep) 100-300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100-300 mg PO QHS; may titrate to 600 mg QHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "neuropathic-pain-or-painful-cramps-associated-with-ibm-concu": {
          "indication": "Neuropathic pain or painful cramps associated with IBM; concurrent peripheral neuropathy common in older adults",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg PO qHS; increase by 300 mg/day every 3-5 days; target 900-1800 mg/day divided TID; max 3600 mg/day; reduce dose if CrCl <60",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "neuropathic-pain-from-transverse-myelitis-painful-tonic-spas": {
          "indication": "Neuropathic pain from transverse myelitis; painful tonic spasms",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q1-3d; target 300-900 mg TID; max 3600 mg/day divided TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "neuropathic-pain-from-myelitis": {
          "indication": "Neuropathic pain from myelitis",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q3-5d; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "second-line-for-tremor-when-beta-blockers-and-primidone-not-": {
          "indication": "Second-line for tremor when beta-blockers and primidone not tolerated or contraindicated",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin (Neurontin) 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg QHS; titrate by 300 mg q3-5d; target 900-1800 mg/day divided TID; max 3600 mg/day; adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "neuropathic-pain-first-line": {
          "indication": "Neuropathic pain (first-line)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; increase by 300 mg every 1-3 days; target 900-1800 mg TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "neuropathic-pain-in-sensory-ataxia-proprioceptive-neuropathy": {
          "indication": "Neuropathic pain in sensory ataxia; proprioceptive neuropathy symptoms; cerebellar tremor",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q3d; target 900-1800 mg/day divided TID; max 3600 mg/day; adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "adjunctive-therapy-for-rigidity-spasms-and-neuropathic-pain-": {
          "indication": "Adjunctive therapy for rigidity, spasms, and neuropathic pain; anticonvulsant with GABA-modulating properties",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q1-3d; target 900-1800 mg TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "neuropathic-pain-paresthesias-adjunctive": {
          "indication": "Neuropathic pain/paresthesias (adjunctive)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; increase by 300 mg q3-7d; max 1800 mg/day for CTS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        },
        "neuropathic-pain-from-paraneoplastic-sensory-neuropathy": {
          "indication": "Neuropathic pain from paraneoplastic sensory neuropathy",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q1-3d; max 3600 mg/day divided TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "central-post-stroke-pain-thalamic-pain-syndrome-neuropathic-": {
          "indication": "Central post-stroke pain (thalamic pain syndrome); neuropathic pain; also helps insomnia",
          "doseOptions": [
            {
              "text": "100 mg TID",
              "orderSentence": "Gabapentin 100 mg TID PO"
            },
            {
              "text": "300 mg TID",
              "orderSentence": "Gabapentin 300 mg TID PO"
            },
            {
              "text": "600 mg TID",
              "orderSentence": "Gabapentin 600 mg TID PO"
            },
            {
              "text": "900 mg TID",
              "orderSentence": "Gabapentin 900 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100-300 mg qHS; increase by 300 mg q3-7 days; target 300-900 mg TID; max 3600 mg/day; renal dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "first-line-for-acquired-pendular-nystagmus-ms-associated-red": {
          "indication": "First-line for acquired pendular nystagmus (MS-associated); reduces oscillopsia; [Starck et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9007739/)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "**Gabapentin** 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Gabapentin 300 mg PO TID; titrate by 300 mg/day every 3-5 days to 900-1200 mg TID (max 3600 mg/day)**",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "neuropathic-radicular-pain-first-line-for-radiculopathy": {
          "indication": "Neuropathic/radicular pain (first-line for radiculopathy)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; increase by 300 mg q1-3d; target 900-1800 mg TID; max 3600 mg/day",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "prevention-comorbid-neuropathic-pain-or-anxiety": {
          "indication": "Prevention; comorbid neuropathic pain or anxiety",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg every 3-5 days; target 900-1800 mg/day in 3 divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "neuropathic-pain-or-painful-cramps-concurrent-peripheral-neu": {
          "indication": "Neuropathic pain or painful cramps; concurrent peripheral neuropathy in older DM patients",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg PO qHS; increase by 300 mg/day every 3-5 days; target 900-1800 mg/day divided TID; max 3600 mg/day; reduce dose if CrCl <60",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "neuropathic-pain-very-common-in-gbs-55-89": {
          "indication": "Neuropathic pain (very common in GBS — 55-89%)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg PO qHS; increase by 300 mg/day every 1-3 days; target 900-1800 mg TID; max 3600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        },
        "neuropathic-pain-radicular-pain-burning-dysesthesias-central": {
          "indication": "Neuropathic pain (radicular pain, burning dysesthesias, central neuropathic pain from cord compression)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q3-5d; target 900-1800 mg/day divided TID; max 3600 mg/day; adjust for renal function (CrCl <60)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "neuropathic-pain-from-plexopathy-first-line": {
          "indication": "Neuropathic pain from plexopathy (first-line)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; increase by 300 mg q1-3 days; target 900-1800 mg TID; max 3600 mg/day",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        },
        "neuropathic-pain-spasticity": {
          "indication": "Neuropathic pain, spasticity",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300 mg PO qHS → titrate to 900-1800 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "acute-myelopathy"
          ]
        },
        "neuropathic-pain-lyme-radiculopathy-painful-radiculoneuritis": {
          "indication": "Neuropathic pain (Lyme radiculopathy; painful radiculoneuritis/Bannwarth syndrome; peripheral neuropathy)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg qHS; titrate by 300 mg q1-3d to 300 mg TID; target 900-1800 mg/day divided TID; max 3600 mg/day; dose adjust for CrCl <60",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        },
        "neuropathic-pain-tremor-adjunctive": {
          "indication": "Neuropathic pain, tremor (adjunctive)",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Gabapentin 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg QHS; increase by 300 mg/day every 3 days; target 900-1800 mg/day TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Known hypersensitivity to gabapentin"
        ],
        "precautions": [
          "Respiratory depression risk when combined with CNS depressants or opioids",
          "Suicidal ideation (class warning for antiepileptics)",
          "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)",
          "Dizziness and somnolence - fall risk in elderly",
          "Abuse potential (Schedule V in some states)"
        ],
        "drugInteractions": [
          {
            "drug": "Opioids",
            "severity": "high",
            "effect": "Increased respiratory depression risk"
          },
          {
            "drug": "CNS depressants",
            "severity": "moderate",
            "effect": "Additive sedation"
          },
          {
            "drug": "Antacids",
            "severity": "low",
            "effect": "Reduced gabapentin absorption - separate by 2 hours"
          }
        ],
        "pregnancyCategory": "C",
        "lactation": "Compatible with breastfeeding (low levels in milk)"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {
            "gfr": "≥60",
            "adjustment": "No adjustment needed (max 3600 mg/day)"
          },
          {
            "gfr": "30-59",
            "adjustment": "Max 900-1400 mg/day in divided doses"
          },
          {
            "gfr": "15-29",
            "adjustment": "Max 300-600 mg/day"
          },
          {
            "gfr": "<15",
            "adjustment": "Max 100-300 mg/day"
          },
          {
            "gfr": "HD",
            "adjustment": "125-350 mg after each dialysis session"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment needed - not hepatically metabolized"
      },
      "monitoring": {
        "baseline": [
          "Renal function (BMP/CrCl)"
        ],
        "ongoing": [
          "Renal function periodically",
          "Suicidal ideation",
          "Sedation/dizziness"
        ],
        "frequency": "Renal function annually or more often if changing"
      },
      "patientCounseling": [
        "Do not stop abruptly - taper over 1 week minimum to avoid withdrawal/seizures",
        "May cause drowsiness - avoid driving until effects known",
        "Takes 2-4 weeks to reach full effect for pain",
        "Take with or without food",
        "Report mood changes, suicidal thoughts, or rash immediately"
      ]
    },
    "gabapentin-enacarbil": {
      "id": "gabapentin-enacarbil",
      "name": "Gabapentin enacarbil (Horizant)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "600 mg",
              "orderSentence": "Gabapentin enacarbil (Horizant) 600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600 mg daily at ~5 PM; FDA approved for RLS",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "restless-legs-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment (adjust)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation, dizziness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "restless-legs-syndrome"
      ]
    },
    "gabapentin-po": {
      "id": "gabapentin-po",
      "name": "Gabapentin PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "adjunctive-for-mild-moderate-withdrawal-symptoms-may-reduce-": {
          "indication": "Adjunctive for mild-moderate withdrawal symptoms; may reduce benzodiazepine requirements; limited evidence for seizure prevention",
          "doseOptions": [
            {
              "text": "300-600 mg",
              "orderSentence": "Gabapentin PO 300-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300-600 mg TID; may increase to 900 mg TID; taper over 5-7 days; limited evidence for seizure prevention; better evidence for anxiety/insomnia symptoms",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment (adjust dose)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "NOT a substitute for benzodiazepines in moderate-severe withdrawal",
          "Sedation",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure"
      ]
    },
    "galantamine": {
      "id": "galantamine",
      "name": "Galantamine (Razadyne)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "vascular-dementia-dual-mechanism-may-benefit-executive-funct": {
          "indication": "Vascular dementia; dual mechanism may benefit executive function",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Galantamine (Razadyne) 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4 mg BID with meals x 4 weeks; increase to 8 mg BID x 4 weeks; target 8-12 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "cognitive-impairment-alternative-cholinesterase-inhibitor": {
          "indication": "Cognitive impairment; alternative cholinesterase inhibitor",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Galantamine 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4 mg BID x 4wk; increase to 8 mg BID; target 8-12 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Galantamine (Razadyne) 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4 mg BID with food × 4 weeks; titrate to 8-12 mg BID; ER: 8 mg daily to 24 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "avoid-may-worsen-behavioral-symptoms-in-ftd": {
          "indication": "AVOID - May worsen behavioral symptoms in FTD",
          "doseOptions": [
            {
              "text": "AVOID",
              "orderSentence": "Galantamine (Razadyne) AVOID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Do NOT use; cholinesterase inhibitors contraindicated in FTD",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "mild-moderate-ad-dual-mechanism-ache-inhibitor-nicotinic-mod": {
          "indication": "Mild-moderate AD; dual mechanism (AChE inhibitor + nicotinic modulator)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Galantamine (Razadyne) 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4 mg BID with meals x 4 weeks; increase to 8 mg BID x 4 weeks; target 8-12 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "COPD exacerbation",
          "FTD diagnosis",
          "GI bleeding",
          "Same",
          "Sick sinus",
          "Sick sinus syndrome",
          "second/third degree heart block",
          "severe hepatic impairment",
          "severe renal impairment (CrCl <9)",
          "severe renal/hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "GI symptoms, bradycardia",
          "Same",
          "Worsening behavior if inadvertently started",
          "bradycardia",
          "weight loss"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "alzheimers-disease",
        "dementia-evaluation",
        "frontotemporal-dementia",
        "lewy-body-dementia",
        "vascular-dementia"
      ]
    },
    "galantamine-er": {
      "id": "galantamine-er",
      "name": "Galantamine ER (Razadyne ER)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "once-daily-alternative-for-adherence": {
          "indication": "Once-daily alternative for adherence",
          "doseOptions": [
            {
              "text": "8 mg",
              "orderSentence": "Galantamine ER (Razadyne ER) 8 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 8 mg daily with breakfast x 4 weeks; increase by 8 mg every 4 weeks; target 16-24 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Sick sinus syndrome",
          "second/third degree heart block",
          "severe hepatic impairment",
          "severe renal impairment (CrCl <9)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "bradycardia",
          "weight loss"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alzheimers-disease"
      ]
    },
    "galcanezumab": {
      "id": "galcanezumab",
      "name": "Galcanezumab (Emgality)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Galcanezumab (CGRP mAb) 300 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300 mg SC monthly (FDA approved for episodic CH)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache",
            "migraine"
          ]
        },
        "chronic-migraine-prevention-also-approved-for-episodic-clust": {
          "indication": "Chronic migraine prevention; also approved for episodic cluster headache",
          "doseOptions": [
            {
              "text": "240 mg",
              "orderSentence": "Galcanezumab (Emgality) 240 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "240 mg SC loading dose (two 120 mg injections), then 120 mg SC monthly",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "cgrp-mab-requires-loading-dose": {
          "indication": "CGRP mAb; requires loading dose",
          "doseOptions": [
            {
              "text": "240 mg",
              "orderSentence": "Galcanezumab (Emgality) 240 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "240 mg SC loading dose (2 x 120 mg injections), then 120 mg SC monthly",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Injection site reactions",
          "reassess efficacy at 3 months",
          "vertigo"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "chronic-migraine",
        "cluster-headache",
        "migraine",
        "migraine-with-aura"
      ]
    },
    "gepants": {
      "id": "gepants",
      "name": "Gepants (preferred rescue)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Gepants (preferred rescue) 50-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ubrogepant 50-100 mg or Rimegepant 75 mg; may have lower MOH risk",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per agent"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "May be safer for frequent use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "medication-overuse-headache"
      ]
    },
    "ginkgo-biloba": {
      "id": "ginkgo-biloba",
      "name": "Ginkgo biloba",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "limited-evidence-antioxidant-mechanism-modest-benefit-in-tri": {
          "indication": "Limited evidence; antioxidant mechanism; modest benefit in trials",
          "doseOptions": [
            {
              "text": "120 mg",
              "orderSentence": "Ginkgo biloba 120 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "240 mg/day divided; EGb 761 extract standardized",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bleeding disorders",
          "anticoagulant use"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bleeding risk"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tardive-dyskinesia"
      ]
    },
    "glatiramer-acetate": {
      "id": "glatiramer-acetate",
      "name": "Glatiramer acetate (Copaxone)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO",
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Glatiramer acetate (Copaxone) 20 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg SC daily or 40 mg SC 3×/week",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Injection site reactions",
          "Preferred in pregnancy (no evidence of harm)",
          "Same (generic)",
          "lipoatrophy"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "glatiramer-acetate-20mg": {
      "id": "glatiramer-acetate-20mg",
      "name": "Glatiramer acetate (Copaxone) 20mg",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Glatiramer acetate (Copaxone) 20mg 20 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg SC daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Injection site reactions",
          "post-injection systemic reaction (rare, self-limited)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ms-new-diagnosis"
      ]
    },
    "glatiramer-acetate-40mg": {
      "id": "glatiramer-acetate-40mg",
      "name": "Glatiramer acetate (Copaxone) 40mg",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Glatiramer acetate (Copaxone) 40mg 40 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg SC three times weekly (â‰¥48 hours apart)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ms-new-diagnosis"
      ]
    },
    "glucose-control": {
      "id": "glucose-control",
      "name": "Glucose control",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "180 mg",
              "orderSentence": "**Glucose control** 180 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Target glucose <180 mg/dL; insulin infusion if critically ill; sliding scale or basal-bolus for non-ICU patients; diabetes is major risk factor — optimize control",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "epidural-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Hyperglycemia impairs immune function and wound healing",
          "tight glucose control improves infection outcomes"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epidural-abscess"
      ]
    },
    "glucose-control-optimization": {
      "id": "glucose-control-optimization",
      "name": "Glucose control optimization",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO/IV"
      ],
      "formulations": [],
      "contexts": {
        "diabetic-or-prediabetic-neuropathy-identified": {
          "indication": "Diabetic or prediabetic neuropathy identified",
          "doseOptions": [
            {
              "text": "Per protocol",
              "orderSentence": "Glucose control optimization Per protocol PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Initiate or intensify glycemic management per diabetes protocol; target HbA1c <7% (individualize); insulin infusion if inpatient with acute hyperglycemia",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypoglycemia risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose monitoring",
          "HbA1c at 3 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "paresthesia-numbness-tingling"
      ]
    },
    "glucose-management": {
      "id": "glucose-management",
      "name": "Glucose management",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Various"
      ],
      "formulations": [],
      "contexts": {
        "acute-presentation-with-new-diabetes-diagnosis": {
          "indication": "Acute presentation with new diabetes diagnosis",
          "doseOptions": [
            {
              "text": "Per protocol",
              "orderSentence": "Glucose management Per protocol Various"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Initiate diabetes management; hypoglycemia causes SFN flare",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per specific agent"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "small-fiber-neuropathy"
      ]
    },
    "gluten-free-diet": {
      "id": "gluten-free-diet",
      "name": "Gluten-free diet",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Dietary"
      ],
      "formulations": [],
      "contexts": {
        "gluten-ataxia-positive-anti-gliadin-antibodies-strict-adhere": {
          "indication": "Gluten ataxia (positive anti-gliadin antibodies); strict adherence required for benefit; improvement may take 6-12 months",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Gluten-free diet N/A Dietary"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Complete elimination of wheat, barley, rye, and cross-contaminated oats; dietitian referral essential; compliance monitoring with repeat anti-gliadin antibodies",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anti-gliadin antibody levels q6 months (should decrease with compliance)",
          "B12 and iron",
          "clinical ataxia scores (SARA, ICARS)",
          "nutritional status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ataxia-evaluation"
      ]
    },
    "glycemic-control-optimization": {
      "id": "glycemic-control-optimization",
      "name": "Glycemic control optimization",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Various"
      ],
      "formulations": [],
      "contexts": {
        "diabetes-prediabetes-associated-sfn": {
          "indication": "Diabetes/prediabetes-associated SFN",
          "doseOptions": [
            {
              "text": "Per guidelines",
              "orderSentence": "Glycemic control optimization Per guidelines Various"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Lifestyle first for prediabetes; HbA1c <7% target; tighter control slows progression",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypoglycemia risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HbA1c q3-6mo",
          "glucose monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "small-fiber-neuropathy"
      ]
    },
    "glycemic-optimization": {
      "id": "glycemic-optimization",
      "name": "Glycemic optimization (insulin/OHAs)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Variable"
      ],
      "formulations": [],
      "contexts": {
        "diabetic-amyotrophy-tight-glucose-control-is-cornerstone-of-": {
          "indication": "Diabetic amyotrophy - tight glucose control is cornerstone of management",
          "doseOptions": [
            {
              "text": "Per protocol",
              "orderSentence": "Glycemic optimization (insulin/OHAs) Per protocol Variable"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Target HbA1c <7%; avoid rapid glucose reduction (risk of treatment-induced neuropathy if HbA1c drops >2% in 3 months)",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypoglycemia",
          "individualize targets in elderly"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HbA1c q3 months",
          "daily glucose monitoring",
          "hypoglycemic events"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "plexopathy"
      ]
    },
    "glycopyrrolate": {
      "id": "glycopyrrolate",
      "name": "Glycopyrrolate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "sialorrhea-drooling": {
          "indication": "Sialorrhea (drooling)",
          "doseOptions": [
            {
              "text": "1 mg TID",
              "orderSentence": "Glycopyrrolate 1 mg TID PO"
            },
            {
              "text": "2 mg TID",
              "orderSentence": "Glycopyrrolate 2 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg BID; titrate to effect; max 2 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease",
            "parkinsons-disease"
          ]
        },
        "cholinergic-side-effects-of-pyridostigmine": {
          "indication": "Cholinergic side effects of pyridostigmine",
          "doseOptions": [
            {
              "text": "1-2 mg",
              "orderSentence": "Glycopyrrolate 1-2 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg PO BID-TID; or 0.2 mg IV PRN for excessive secretions",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis"
          ]
        },
        "sialorrhea-excess-saliva": {
          "indication": "Sialorrhea (excess saliva)",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Glycopyrrolate 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg PO TID; may increase to 2 mg TID; max 8 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "cholinergic-side-effects-from-pyridostigmine": {
          "indication": "Cholinergic side effects from pyridostigmine",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Glycopyrrolate 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg PO BID-TID for secretions, diarrhea, or cramping from pyridostigmine; does not cross BBB",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "sialorrhea-drooling-causing-skin-breakdown-or-aspiration-ris": {
          "indication": "Sialorrhea (drooling) causing skin breakdown or aspiration risk",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Glycopyrrolate 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg BID; titrate to 1-2 mg TID; max 8 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "excessive-drooling-sialorrhea-common-in-advanced-cjd-with-bu": {
          "indication": "Excessive drooling/sialorrhea -- common in advanced CJD with bulbar dysfunction",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Glycopyrrolate (sialorrhea) 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg PO TID; increase to 2 mg TID as needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "sialorrhea-anticholinergic-with-minimal-cns-penetration": {
          "indication": "Sialorrhea — anticholinergic with minimal CNS penetration",
          "doseOptions": [
            {
              "text": "1 mg BID",
              "orderSentence": "Glycopyrrolate 1 mg BID PO"
            },
            {
              "text": "2 mg BID",
              "orderSentence": "Glycopyrrolate 2 mg BID PO"
            },
            {
              "text": "1 mg TID",
              "orderSentence": "Glycopyrrolate 1 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg BID; titrate to 1-2 mg BID-TID; max 8 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "excessive-oral-secretions-antisialagogue-preferred-over-atro": {
          "indication": "Excessive oral secretions (antisialagogue); preferred over atropine for secretion management",
          "doseOptions": [
            {
              "text": "0.2 mg",
              "orderSentence": "Glycopyrrolate (CPT 96374) 0.2 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.2 mg IV q4-6h PRN; or 1-2 mg PO TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "botulism"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-2 mg",
              "orderSentence": "Glycopyrrolate (for cholinergic side effects) 1-2 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg PO BID-TID or 0.1-0.2 mg IV PRN",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Angle-closure glaucoma, urinary retention, tachycardia",
          "GI obstruction",
          "Glaucoma",
          "Ileus, urinary retention, angle-closure glaucoma",
          "Narrow-angle glaucoma",
          "Narrow-angle glaucoma, GI obstruction, urinary retention, myasthenia gravis",
          "bowel obstruction",
          "obstructive uropathy",
          "severe cardiac disease",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anticholinergic effects",
          "Does NOT cross BBB (preferred over atropine for peripheral muscarinic side effects)",
          "Dry mouth",
          "Dry mouth (desired), urinary retention, constipation, tachycardia, cognitive worsening",
          "Dry mouth (paradoxical thick secretions), constipation, urinary retention",
          "Dry mouth (therapeutic), urinary retention, constipation, tachycardia",
          "Dry mouth, constipation, urinary retention",
          "HR",
          "Heart rate",
          "Secretion volume",
          "bowel function",
          "constipation",
          "dry mouth",
          "tachycardia",
          "urinary retention"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "als",
        "botulism",
        "creutzfeldt-jakob-disease",
        "huntingtons-disease",
        "multiple-system-atrophy",
        "myasthenia-gravis",
        "myasthenia-gravis-crisis",
        "myasthenia-gravis-new-diagnosis",
        "parkinsons-disease",
        "progressive-supranuclear-palsy"
      ]
    },
    "goal-directed-fluid-therapy": {
      "id": "goal-directed-fluid-therapy",
      "name": "Goal-directed fluid therapy",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "euvolemia-maintenance-organ-perfusion-replace-insensible-and": {
          "indication": "Euvolemia maintenance; organ perfusion; replace insensible and DI losses without fluid overload (damages lungs)",
          "doseOptions": [
            {
              "text": "100-250 mL/hr",
              "orderSentence": "**Goal-directed fluid therapy** 100-250 mL/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.9% NaCl or LR; titrate to CVP 4-12 mmHg (or PCWP 8-12 mmHg if PA catheter); avoid hypovolemia (organ ischemia) and hypervolemia (pulmonary edema); use balanced crystalloid; transfuse PRN (Hgb >7 g/dL)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pulmonary edema (restrict fluids, add diuretics if lung preservation critical)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CVP",
          "ECHO if available",
          "daily CXR",
          "hemodynamics",
          "lactate",
          "urine output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-death-evaluation"
      ]
    },
    "gradual-asm-taper": {
      "id": "gradual-asm-taper",
      "name": "Gradual ASM taper (levetiracetam, lamotrigine, valproic acid, etc.)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "confirmed-functional-seizures-pnes-on-unnecessary-asms-taper": {
          "indication": "Confirmed functional seizures (PNES) on unnecessary ASMs; taper AFTER definitive vEEG diagnosis",
          "doseOptions": [
            {
              "text": "Per drug-specific taper",
              "orderSentence": "Gradual ASM taper (levetiracetam, lamotrigine, valproic acid, etc.) Per drug-specific taper PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper each ASM by 25% every 2 weeks; single-drug taper at a time; monitor for breakthrough if comorbid epilepsy not excluded; complete taper over 2-3 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "functional-neurological-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Comorbid epilepsy (dual diagnosis: ~10-20% of PNES patients also have epilepsy -- do NOT taper in these patients without epilepsy specialist input)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Event frequency",
          "anxiety (taper anxiety is common)",
          "confirm no epileptic events"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "functional-neurological-disorder"
      ]
    },
    "gradual-asm-taper-carbamazepine-oxcarbazepine": {
      "id": "gradual-asm-taper-carbamazepine-oxcarbazepine",
      "name": "Gradual ASM taper -- carbamazepine/oxcarbazepine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "confirmed-pnes-on-carbamazepine-or-oxcarbazepine-without-com": {
          "indication": "Confirmed PNES on carbamazepine or oxcarbazepine without comorbid epilepsy",
          "doseOptions": [
            {
              "text": "100-200 mg reduction",
              "orderSentence": "Gradual ASM taper -- carbamazepine/oxcarbazepine 100-200 mg reduction PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper by 100-200 mg every 2 weeks; carbamazepine induces its own metabolism (levels may shift during taper); complete taper over 8-12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Comorbid epilepsy",
          "trigeminal neuralgia (carbamazepine may be treating pain)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "Event frequency",
          "mood",
          "sodium level (hyponatremia more common with oxcarbazepine -- may resolve with taper)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pnes"
      ]
    },
    "gradual-asm-taper-lamotrigine": {
      "id": "gradual-asm-taper-lamotrigine",
      "name": "Gradual ASM taper -- lamotrigine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "confirmed-pnes-on-lamotrigine-without-comorbid-epilepsy": {
          "indication": "Confirmed PNES on lamotrigine without comorbid epilepsy",
          "doseOptions": [
            {
              "text": "25-50 mg reduction",
              "orderSentence": "Gradual ASM taper -- lamotrigine 25-50 mg reduction PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper by 25-50 mg every 2 weeks; slower taper than other ASMs (lamotrigine has mood-stabilizing properties -- monitor for mood destabilization)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Comorbid epilepsy",
          "bipolar disorder (lamotrigine may be serving as mood stabilizer)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Event frequency",
          "mood stability (PHQ-9, mood diary)",
          "rash (rare during taper but document)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pnes"
      ]
    },
    "gradual-asm-taper-levetiracetam": {
      "id": "gradual-asm-taper-levetiracetam",
      "name": "Gradual ASM taper -- levetiracetam",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "confirmed-pnes-on-levetiracetam-without-comorbid-epilepsy-ta": {
          "indication": "Confirmed PNES on levetiracetam without comorbid epilepsy; taper AFTER definitive vEEG diagnosis",
          "doseOptions": [
            {
              "text": "250-500 mg reduction",
              "orderSentence": "Gradual ASM taper -- levetiracetam 250-500 mg reduction PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper by 250-500 mg every 2 weeks; typical taper from 1000 mg BID over 8-12 weeks; monitor for anxiety/mood changes (levetiracetam withdrawal can worsen mood)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Comorbid epilepsy confirmed or suspected (~10% dual diagnosis)",
          "do NOT taper without epileptologist input in dual-diagnosis patients"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Event frequency diary",
          "mood (levetiracetam withdrawal may improve mood or cause rebound anxiety)",
          "verify no epileptiform events during taper"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pnes"
      ]
    },
    "gradual-asm-taper-phenobarbital": {
      "id": "gradual-asm-taper-phenobarbital",
      "name": "Gradual ASM taper -- phenobarbital",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "confirmed-pnes-on-phenobarbital-without-comorbid-epilepsy-re": {
          "indication": "Confirmed PNES on phenobarbital without comorbid epilepsy; REQUIRES SLOW TAPER (barbiturate withdrawal risk)",
          "doseOptions": [
            {
              "text": "15-30 mg reduction",
              "orderSentence": "Gradual ASM taper -- phenobarbital 15-30 mg reduction PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper by 15-30 mg every 2-4 weeks; VERY SLOW taper over 3-6 months; barbiturate withdrawal can cause TRUE seizures even in non-epileptic patients; inpatient monitoring may be needed for high doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Comorbid epilepsy",
          "barbiturate dependence (consider inpatient taper for high doses >120 mg/day)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Event frequency",
          "may need phenobarbital levels",
          "vital signs during taper",
          "withdrawal symptoms (anxiety, insomnia, tremor, TRUE seizures)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pnes"
      ]
    },
    "gradual-asm-taper-topiramate": {
      "id": "gradual-asm-taper-topiramate",
      "name": "Gradual ASM taper -- topiramate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "confirmed-pnes-on-topiramate-without-comorbid-epilepsy": {
          "indication": "Confirmed PNES on topiramate without comorbid epilepsy",
          "doseOptions": [
            {
              "text": "25-50 mg reduction",
              "orderSentence": "Gradual ASM taper -- topiramate 25-50 mg reduction PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper by 25-50 mg every 1-2 weeks; cognitive side effects may improve with taper; monitor for weight changes",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Comorbid epilepsy",
          "migraine prophylaxis (topiramate may be treating migraines -- assess before taper)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Event frequency",
          "cognitive function (may improve)",
          "migraine frequency if history of headache",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pnes"
      ]
    },
    "gradual-asm-taper-valproic-acid": {
      "id": "gradual-asm-taper-valproic-acid",
      "name": "Gradual ASM taper -- valproic acid",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "confirmed-pnes-on-valproic-acid-without-comorbid-epilepsy": {
          "indication": "Confirmed PNES on valproic acid without comorbid epilepsy",
          "doseOptions": [
            {
              "text": "250 mg reduction",
              "orderSentence": "Gradual ASM taper -- valproic acid 250 mg reduction PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Taper by 250 mg every 2 weeks; monitor for mood changes (valproate has mood-stabilizing properties); check levels during taper if comorbid epilepsy cannot be fully excluded",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Comorbid epilepsy",
          "bipolar disorder (valproate may be serving as mood stabilizer)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Event frequency",
          "LFTs",
          "mood",
          "tremor (may improve with taper)",
          "weight (may lose weight with taper)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pnes"
      ]
    },
    "greater-occipital-nerve-block": {
      "id": "greater-occipital-nerve-block",
      "name": "Greater occipital nerve block",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Local",
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "adjunctive-bridging-therapy-acute-relief-during-preventive-i": {
          "indication": "Adjunctive; bridging therapy; acute relief during preventive initiation",
          "doseOptions": [
            {
              "text": "2-3 mL",
              "orderSentence": "Greater occipital nerve block (CPT 64405) 2-3 mL SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Lidocaine 2% or bupivacaine 0.25% (2-3 mL per side) with optional dexamethasone 4 mg or methylprednisolone 40 mg; bilateral GON block",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "occipital-predominant-pain-refractory-cases": {
          "indication": "Occipital-predominant pain; refractory cases",
          "doseOptions": [
            {
              "text": "2-3 mL",
              "orderSentence": "Greater occipital nerve block 2-3 mL SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-3 mL 2% lidocaine with or without 40 mg triamcinolone at greater occipital nerve bilaterally",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "acute-pain-relief-and-potential-sustained-benefit-3-4-weeks-": {
          "indication": "Acute pain relief and potential sustained benefit (3-4 weeks); safe in pregnancy",
          "doseOptions": [
            {
              "text": "2-3 mL per side",
              "orderSentence": "Greater occipital nerve block 2-3 mL per side Local"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bupivacaine 0.5% 2-3 mL per side (bilateral) at greater occipital nerve; may add triamcinolone 20 mg per side",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local anesthetic allergy",
          "Local anesthetic allergy, infection at injection site, anticoagulation (relative)",
          "Local anesthetic allergy, infection at injection site, concurrent anticoagulation (relative)",
          "infection at site"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Immediate pain relief",
          "Local pain, transient numbness",
          "Local reaction, vasovagal response",
          "assess response in 30-60 min",
          "may repeat q4-12 weeks",
          "monitor for vasovagal"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "status-migrainosus",
        "tension-headache"
      ]
    },
    "guanfacine": {
      "id": "guanfacine",
      "name": "Guanfacine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "refractory-dry-mouth-from-autonomic-dysfunction-not-responsi": {
          "indication": "Refractory dry mouth from autonomic dysfunction not responsive to 3,4-DAP; off-label use",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Guanfacine 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg daily; may increase to 2 mg daily; used off-label for autonomic dry mouth",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "first-line-medication-preferred-alpha-2-agonist-for-tics-als": {
          "indication": "First-line medication; preferred alpha-2 agonist for tics; also treats comorbid ADHD",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Guanfacine (Intuniv) 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg qHS; increase by 1 mg q1wk; target 1-4 mg/day (divided BID for IR, daily for ER); max 4 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypotension",
          "Second- or third-degree heart block",
          "bradycardia",
          "concurrent use of strong CYP3A4 inhibitors",
          "hypotension",
          "renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP, HR at each visit",
          "HR",
          "rebound hypertension if stopped abruptly",
          "sedation",
          "taper over 1 week to discontinue"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "lambert-eaton-syndrome",
        "tics-tourette-syndrome"
      ]
    },
    "guanidine-hydrochloride": {
      "id": "guanidine-hydrochloride",
      "name": "Guanidine hydrochloride",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "historical-agent-to-enhance-acetylcholine-release-at-nmj-lim": {
          "indication": "Historical agent to enhance acetylcholine release at NMJ; limited efficacy; NOT standard of care; may provide modest improvement in chronic phase",
          "doseOptions": [
            {
              "text": "15-35 mg/kg",
              "orderSentence": "Guanidine hydrochloride 15-35 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-35 mg/kg/day divided TID-QID; start low and titrate; limited evidence for benefit",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "botulism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bone marrow suppression, renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC, BMP weekly",
          "bone marrow toxicity (aplastic anemia reported)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "botulism"
      ]
    },
    "habit-reversal-training": {
      "id": "habit-reversal-training",
      "name": "Habit Reversal Training (HRT) (CPT 90834-90837)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "In-person/telehealth"
      ],
      "formulations": [],
      "contexts": {
        "core-component-of-cbit-delivered-alone-if-full-cbit-unavaila": {
          "indication": "Core component of CBIT; delivered alone if full CBIT unavailable",
          "doseOptions": [
            {
              "text": "8-12 sessions",
              "orderSentence": "Habit Reversal Training (HRT) (CPT 90834-90837) 8-12 sessions In-person"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Awareness training for premonitory urge recognition; competing response training; social support",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe cognitive impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "YGTSS score",
          "competing response use",
          "tic frequency"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tics-tourette-syndrome"
      ]
    },
    "haloperidol": {
      "id": "haloperidol",
      "name": "Haloperidol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM",
        "IM/IV",
        "IV",
        "IV/IM",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "acute-severe-agitation-in-delirium-crisis-only-avoid-chronic": {
          "indication": "Acute severe agitation in delirium-crisis only (avoid chronic use)",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Haloperidol 0.5 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-2 mg IM/IV q4-6h PRN; short-term acute use only; avoid chronic use in dementia",
          "settings": {
            "ED": "STAT",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "severe-psychosis-with-agitation-acute-behavioral-emergency": {
          "indication": "Severe psychosis with agitation; acute behavioral emergency",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Haloperidol 2 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-5 mg IM; may repeat q4-6h; max 20 mg/day; transition to oral",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "acute-psychosis-or-severe-agitation-psychiatric-symptoms-in-": {
          "indication": "Acute psychosis or severe agitation (psychiatric symptoms in ~35-45% of HE)",
          "doseOptions": [
            {
              "text": "0.5-2 mg",
              "orderSentence": "Haloperidol (acute agitation/psychosis) 0.5-2 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-2 mg IV/IM q4-6h PRN (lowest effective dose); max 20 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "acute-agitation-with-psychosis-general-paresis-with-severe-a": {
          "indication": "Acute agitation with psychosis (general paresis with severe agitation)",
          "doseOptions": [
            {
              "text": "2-5 mg q4-6h PRN",
              "orderSentence": "Haloperidol 2-5 mg q4-6h PRN IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-5 mg IV/IM q4-6h PRN; max 20 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "acute-agitation-or-psychosis-in-ed-inpatient-setting-with-ha": {
          "indication": "Acute agitation or psychosis in ED/inpatient setting with HAD; short-term use only",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Haloperidol 2 mg IV/IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-5 mg IV/IM PRN; may repeat q30min; max 20 mg/24h; switch to oral atypical ASAP",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "fda-approved-for-tourette-syndrome-potent-d2-antagonist-high": {
          "indication": "FDA-approved for Tourette syndrome; potent D2 antagonist; high EPS risk limits use",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Haloperidol (Haldol) 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg qHS; increase by 0.25-0.5 mg q1wk; target 1-4 mg/day; max 10 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        },
        "acute-severe-agitation-or-psychosis-not-responsive-to-reorie": {
          "indication": "Acute severe agitation or psychosis not responsive to reorientation and non-pharmacologic measures",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Haloperidol (acute severe agitation) 0.5 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-2 mg IV/IM q4-6h PRN agitation; use lowest effective dose; max 10 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "severe-aggression-psychosis-when-benzodiazepines-insufficien": {
          "indication": "Severe aggression/psychosis when benzodiazepines insufficient",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Haloperidol 0.5 mg IM/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-2 mg IM q4-6h PRN; lowest effective dose; short-term crisis only",
          "settings": {
            "ED": "STAT",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "acute-severe-agitation-in-delirium-crisis-only-not-chronic-u": {
          "indication": "Acute severe agitation in delirium-crisis only (not chronic use)",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Haloperidol 0.5 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-2 mg IM/IV q4-6h PRN; short-term acute use only; avoid chronic use",
          "settings": {
            "ED": "STAT",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.5-2 mg",
              "orderSentence": "Haloperidol (acute agitation) 0.5-2 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-2 mg IV/IM q4-6h PRN (lowest effective dose); max 20 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CNS depression",
          "DLB (avoid)",
          "FTD-parkinsonism overlap (avoid if possible)",
          "NMS risk",
          "Parkinson disease",
          "Parkinson's disease",
          "Parkinsonism",
          "QT prolongation",
          "QTc >500 ms",
          "QTc prolongation",
          "comatose states",
          "dementia (black box)",
          "history of NMS",
          "neuroleptic malignant syndrome history",
          "prior NMS",
          "worsens dystonia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CPK if NMS suspected",
          "ECG (QTc before and after)",
          "ECG (QTc)",
          "ECG at baseline and after dose changes",
          "ECG, EPS, sedation",
          "EPS",
          "EPS/TD (AIMS q3-6mo)",
          "NMS monitoring",
          "NMS surveillance",
          "NMS surveillance (temperature, rigidity, CPK)",
          "QTc",
          "QTc (must be <500 msec)",
          "QTc before and during use",
          "QTc monitoring",
          "akathisia",
          "avoid in DLB (not typical in HAND)",
          "sedation",
          "temperature",
          "vital signs",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "alzheimers-disease",
        "autoimmune-encephalitis",
        "creutzfeldt-jakob-disease",
        "frontotemporal-dementia",
        "hashimotos-encephalopathy",
        "hiv-associated-neurocognitive-disorder",
        "huntingtons-disease",
        "neurosyphilis",
        "tics-tourette-syndrome",
        "vascular-dementia"
      ]
    },
    "heparin": {
      "id": "heparin",
      "name": "Heparin (DVT prophylaxis)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "cvt-non-parenchymal-nbd-therapeutic-anticoagulation-for-cere": {
          "indication": "CVT (non-parenchymal NBD); therapeutic anticoagulation for cerebral venous thrombosis -- initiate even with hemorrhagic infarct",
          "doseOptions": [
            {
              "text": "80 units/kg",
              "orderSentence": "Heparin (unfractionated) 80 units/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "80 units/kg IV bolus, then 18 units/kg/hr continuous infusion; target aPTT 60-80 seconds (1.5-2.5x control)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "vte-prophylaxis-when-enoxaparin-contraindicated-renal-impair": {
          "indication": "VTE prophylaxis when enoxaparin contraindicated (renal impairment CrCl <30)",
          "doseOptions": [
            {
              "text": "5000 units",
              "orderSentence": "**Heparin (DVT prophylaxis alternative)** 5000 units SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Heparin 5000 units SC q8h; hold 4h before and after LP or IT chemo; SCDs as adjunct",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "vte-prophylaxis-during-hospitalization-with-immobility-and-c": {
          "indication": "VTE prophylaxis during hospitalization with immobility and CNS inflammation",
          "doseOptions": [
            {
              "text": "5000 units q8h",
              "orderSentence": "Heparin (DVT prophylaxis) 5000 units q8h SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5000 units SC q8h; use enoxaparin 40 mg SC daily if no contraindication",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "vte-prophylaxis-during-hospitalization-with-immobility-and-a": {
          "indication": "VTE prophylaxis during hospitalization with immobility and active CNS disease",
          "doseOptions": [
            {
              "text": "5000 units q8h",
              "orderSentence": "Heparin (DVT prophylaxis) 5000 units q8h SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5000 units SC q8h; use enoxaparin 40 mg SC daily if no contraindication",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "intraoperative-anticoagulation-during-cea-prevent-clamp-thro": {
          "indication": "Intraoperative anticoagulation during CEA (prevent clamp thrombosis) and CAS (prevent catheter/stent thrombosis); standard of care",
          "doseOptions": [
            {
              "text": "5000 units",
              "orderSentence": "Heparin (intraprocedural) (CPT 96374) 5000 units IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5000-10000 units IV bolus before carotid clamping (CEA) or before catheter advancement (CAS); target ACT >250; protamine reversal at surgeon discretion post-CEA",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active hemorrhage",
          "Active intracranial hemorrhage",
          "Active major hemorrhage",
          "Active major hemorrhage (relative in CVT with hemorrhagic infarction -- anticoagulation still indicated per guidelines)",
          "HIT",
          "HIT (use bivalirudin alternative)",
          "HIT history",
          "hemorrhagic infarction",
          "hemorrhagic transformation",
          "planned LP within 4h",
          "planned Ommaya surgery",
          "recent brain biopsy (hold 24-48h)",
          "severe uncontrolled hypertension",
          "thrombocytopenia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ACT intraoperatively",
          "CBC",
          "Platelet count",
          "Platelet count (HIT surveillance)",
          "aPTT q6h until therapeutic x 2, then q12-24h",
          "bleeding from access site (CAS)",
          "neurological status",
          "platelet count (HIT screen)",
          "post-op drain output (CEA)",
          "signs of bleeding",
          "signs of hemorrhage"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "carotid-stenosis",
        "cns-vasculitis",
        "leptomeningeal-carcinomatosis",
        "neuro-behcets-disease",
        "susac-syndrome"
      ]
    },
    "heparin-drip": {
      "id": "heparin-drip",
      "name": "Heparin drip (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "confirmed-cerebral-venous-thrombosis-cvt": {
          "indication": "Confirmed cerebral venous thrombosis (CVT)",
          "doseOptions": [
            {
              "text": "80 units/kg",
              "orderSentence": "Heparin drip (CPT 96365) 80 units/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "80 units/kg bolus, then 18 units/kg/hr; target PTT 60-80 sec",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active hemorrhagic infarction (relative",
          "still often treated), uncontrolled bleeding"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "PTT q6h until stable, then q12h",
          "platelet count"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "headache-evaluation"
      ]
    },
    "heparin-iv": {
      "id": "heparin-iv",
      "name": "Heparin IV (if CVT confirmed) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "cerebral-venous-thrombosis-anticoagulation-is-standard-even-": {
          "indication": "Cerebral venous thrombosis — anticoagulation is standard even with hemorrhagic venous infarct",
          "doseOptions": [
            {
              "text": "80 units/kg",
              "orderSentence": "Heparin IV (if CVT confirmed) (CPT 96365) 80 units/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "80 units/kg IV bolus; then 18 units/kg/h infusion. Target aPTT 1.5-2.5x control. Transition to LMWH or warfarin",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active major hemorrhage (ICH from CVT is NOT a contraindication per guidelines)",
          "HIT"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "aPTT q6h until therapeutic",
          "neuro checks",
          "platelets q3 days"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "thunderclap-headache-evaluation"
      ]
    },
    "heparin-iv-drip": {
      "id": "heparin-iv-drip",
      "name": "Heparin IV drip (therapeutic)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "60-80 units/kg",
              "orderSentence": "Heparin IV drip (therapeutic) 60-80 units/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bolus 60-80 units/kg (max 5000u); infusion 12-18 units/kg/h; target aPTT 1.5-2.5x control. Use for: cardiac source with high re-embolization risk, arterial dissection, crescendo TIA, free-floating thrombus",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Large infarct (hemorrhagic transformation risk), uncontrolled BP, within 24h of tPA"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "aPTT q6h until stable, then q12-24h",
          "neuro checks",
          "platelets q3 days"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-ischemic-stroke"
      ]
    },
    "heparin-iv-infusion": {
      "id": "heparin-iv-infusion",
      "name": "Heparin IV infusion (therapeutic)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-dissection-with-high-embolic-risk-free-floating-thromb": {
          "indication": "Acute dissection with high embolic risk: free-floating thrombus, crescendo TIA, recurrent embolic events despite antiplatelet, critical flow-limiting stenosis",
          "doseOptions": [
            {
              "text": "60-80 units/kg",
              "orderSentence": "Heparin IV infusion (therapeutic) 60-80 units/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bolus 60-80 units/kg (max 5000 units); then infusion 12-18 units/kg/h; target aPTT 1.5-2.5x control (typically 60-80 sec)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active hemorrhagic infarct",
          "active bleeding",
          "intracranial dissection with SAH",
          "large completed infarct (hemorrhagic transformation risk)",
          "uncontrolled BP"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "aPTT q6h until stable, then q12-24h",
          "daily neuro checks",
          "platelets q3 days (HIT surveillance)",
          "signs of bleeding"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cervical-artery-dissection"
      ]
    },
    "heparin-reversal-protamine-sulfate": {
      "id": "heparin-reversal-protamine-sulfate",
      "name": "Heparin reversal: Protamine sulfate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Heparin reversal: Protamine sulfate 1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg per 100 units of heparin given in last 2-3h; max 50 mg; give slow IV over 10 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Fish/protamine allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP (hypotension with rapid infusion)",
          "aPTT",
          "anaphylaxis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "heparin-sc": {
      "id": "heparin-sc",
      "name": "Heparin (unfractionated) SC",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "dvt-prophylaxis-alternative": {
          "indication": "DVT prophylaxis (alternative)",
          "doseOptions": [
            {
              "text": "5000 units",
              "orderSentence": "Heparin (unfractionated) SC 5000 units SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5000 units SC q8-12h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding, HIT"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Platelets q3 days"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-ischemic-stroke"
      ]
    },
    "heparin-then-warfarin": {
      "id": "heparin-then-warfarin",
      "name": "Heparin then warfarin (if cervical artery dissection confirmed — anticoagulation option) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "cervical-artery-dissection-anticoagulation-alternative-equiv": {
          "indication": "Cervical artery dissection — anticoagulation alternative (equivalent to antiplatelet per CADISS trial)",
          "doseOptions": [
            {
              "text": "80 units/kg",
              "orderSentence": "Heparin then warfarin (if cervical artery dissection confirmed — anticoagulation option) (CPT 96365) 80 units/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "80 units/kg IV bolus; then 18 units/kg/h infusion; transition to warfarin (INR 2-3) x 3-6 months. Preferred if recurrent ischemic events on antiplatelet",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active hemorrhagic stroke",
          "HIT",
          "massive infarct"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "INR",
          "aPTT q6h until therapeutic",
          "neuro checks"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "thunderclap-headache-evaluation"
      ]
    },
    "heptavalent-botulinum-antitoxin-obtained-from-cdc": {
      "id": "heptavalent-botulinum-antitoxin-obtained-from-cdc",
      "name": "Heptavalent botulinum antitoxin (HBAT) (equine-derived, serotypes A-G) — obtained from CDC (CPT 96365, 96366)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "all-forms-of-botulism-foodborne-wound-adult-intestinal-colon": {
          "indication": "All forms of botulism (foodborne, wound, adult intestinal colonization, inhalational); administer as early as possible — antitoxin neutralizes circulating toxin but does NOT reverse already-bound toxin",
          "doseOptions": [
            {
              "text": "1 vial",
              "orderSentence": "Heptavalent botulinum antitoxin (HBAT) (equine-derived, serotypes A-G) — obtained from CDC (CPT 96365, 96366) 1 vial IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 vial (containing equine-derived antibodies to types A-G) IV; dilute 1:10 in 0.9% NS; infuse slowly over 15-30 min initially, increase rate per CDC protocol; contact CDC Emergency Operations Center 770-488-7100 (24/7) to obtain antitoxin; administer as soon as clinical suspicion is high — do NOT wait for lab confirmation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "botulism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "History of equine protein hypersensitivity (perform skin test first per CDC protocol)",
          "serum sickness risk 5-10% (monitor for 10-21 days post-infusion)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Skin test before infusion if history of atopy or equine exposure",
          "delayed serum sickness (fever, rash, arthralgias at 10-21 days)",
          "monitor VS q5min during infusion and q15min x 4h post",
          "observe for anaphylaxis (epinephrine at bedside)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "botulism"
      ]
    },
    "high-calorie-nutritional-supplements": {
      "id": "high-calorie-nutritional-supplements",
      "name": "High-calorie nutritional supplements",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "weight-loss-increased-metabolic-demands": {
          "indication": "Weight loss; increased metabolic demands",
          "doseOptions": [
            {
              "text": "1 can",
              "orderSentence": "High-calorie nutritional supplements 1 can PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-3 cans (Ensure Plus, Boost Plus) daily between meals",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Weight, nutritional markers"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "huntingtons-disease"
      ]
    },
    "high-dose-aspirin": {
      "id": "high-dose-aspirin",
      "name": "High-dose aspirin (>2 g/day)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dose-dependent-tinnitus-reversible-with-dose-reduction-salic": {
          "indication": "Dose-dependent tinnitus; reversible with dose reduction; salicylate toxicity",
          "doseOptions": [
            {
              "text": "-",
              "orderSentence": "**High-dose aspirin** (>2 g/day) - PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "AVOID doses >2 g/day; tinnitus usually resolves within 24-48h of dose reduction; low-dose aspirin (81-325 mg) is safe",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pre-existing tinnitus at high doses"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Salicylate level if toxicity suspected",
          "reduce dose if tinnitus develops"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tinnitus-evaluation"
      ]
    },
    "high-dose-chemotherapy-with-autologous-stem-cell-transplant": {
      "id": "high-dose-chemotherapy-with-autologous-stem-cell-transplant",
      "name": "High-dose chemotherapy with autologous stem cell transplant (HDC-ASCT)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "consolidation-alternative-to-wbrt-preferred-in-younger-patie": {
          "indication": "Consolidation alternative to WBRT; preferred in younger patients (age <65-70) to avoid radiation neurotoxicity; thiotepa-based conditioning regimen most common for PCNSL",
          "doseOptions": [
            {
              "text": "Thiotepa-based conditioning",
              "orderSentence": "High-dose chemotherapy with autologous stem cell transplant (HDC-ASCT) Thiotepa-based conditioning IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Stem cell mobilization after induction CR; conditioning: thiotepa 5 mg/kg IV x2 days + carmustine (BCNU) 400 mg/m2 IV x1 day (or other institutional protocol); autologous stem cell infusion Day 0; requires transplant-capable center",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "STAT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Engraftment monitoring (ANC, platelets)",
          "MRI q3 months post-transplant",
          "hepatic VOD screening",
          "infection prophylaxis",
          "mucositis",
          "pulmonary function",
          "renal function"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "high-dose-hypertonic-saline": {
      "id": "high-dose-hypertonic-saline",
      "name": "High-dose hypertonic saline (23.4%)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "**High-dose hypertonic saline (23.4%)** 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**For refractory ICP crisis**; 30 mL IV bolus via central line; can repeat; target sodium up to 155-160 mEq/L in refractory cases (with close monitoring); **Risk:** Central pontine myelinolysis if rapid sodium changes (maintain stable elevated sodium; do not rapidly correct back to normal)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "elevated-icp-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Potent osmotherapy",
          "can achieve higher sodium targets than 3% NaCl",
          "requires central line access",
          "reserved for refractory cases"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "elevated-icp-management"
      ]
    },
    "high-dose-iv-acetazolamide": {
      "id": "high-dose-iv-acetazolamide",
      "name": "High-dose IV acetazolamide (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "High-dose IV acetazolamide (CPT 96374) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV q6h initially",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "idiopathic-intracranial-hypertension"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per above"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "K+, bicarb"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "idiopathic-intracranial-hypertension"
      ]
    },
    "high-dose-methotrexate": {
      "id": "high-dose-methotrexate",
      "name": "High-dose methotrexate (hematologic malignancies)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "lymphomatous-or-leukemic-meningitis-high-dose-systemic-metho": {
          "indication": "Lymphomatous or leukemic meningitis; high-dose systemic methotrexate achieves therapeutic CSF levels",
          "doseOptions": [
            {
              "text": "3.5 g/m2",
              "orderSentence": "**High-dose methotrexate (hematologic malignancies)** 3.5 g/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "High-dose methotrexate 3.5 g/m2 IV over 4h with leucovorin rescue; alternatively, high-dose cytarabine 3 g/m2 IV q12h x 4-6 doses; ibrutinib (for CLL/mantle cell) or lenalidomide (for DLBCL) may have CNS activity; coordinate with hematology/oncology",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment (creatinine clearance <60)",
          "concurrent NSAIDs or PPIs (impair MTX clearance)",
          "mucositis",
          "third-space fluid collections"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "MTX levels q6h until <0.05 mcM",
          "aggressive IV hydration (3 L/m2/day)",
          "mucositis",
          "renal function",
          "urine alkalinization (pH >7)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "high-dose-methotrexate-induction": {
      "id": "high-dose-methotrexate-induction",
      "name": "High-dose Methotrexate (HD-MTX) - Induction",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "cornerstone-of-pcnsl-treatment-first-line-induction-achieves": {
          "indication": "CORNERSTONE of PCNSL treatment; first-line induction; achieves therapeutic CNS concentrations; administered as part of multi-agent regimen (R-MPV, MATRix, DeAngelis protocol); 60-80% overall response rate",
          "doseOptions": [
            {
              "text": "3.5 g/m2",
              "orderSentence": "High-dose Methotrexate (HD-MTX) - Induction 3.5 g/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3.5 g/m2 IV over 4 hours; aggressive IV hydration (2-3 L/m2) starting 12h before and continuing 48h after; urine alkalinization with sodium bicarbonate (target pH >7.0); leucovorin rescue starting 24h after MTX completion (25 mg IV/PO q6h until MTX level <0.05 micromol/L); q2 week cycles x 5-7 based on response; hold TMP-SMX during MTX weeks",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CrCl <50 mL/min",
          "active infection",
          "concurrent nephrotoxic drugs including NSAIDs",
          "pregnancy",
          "severe hepatic impairment",
          "third-space fluid (ascites, large pleural effusion)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC with differential",
          "LFTs",
          "Serum MTX levels at 24h, 48h, 72h (and until <0.05 micromol/L)",
          "creatinine q12h during infusion and for 72h after",
          "mucositis assessment",
          "neurologic exam",
          "urine output (target >100 mL/h)",
          "urine pH q6h (maintain >7.0)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "high-dose-oral-b12": {
      "id": "high-dose-oral-b12",
      "name": "High-dose oral B12 (if parenteral not tolerated)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "b12-replacement-when-injections-refused-or-contraindicated-c": {
          "indication": "B12 replacement when injections refused or contraindicated; compliance concerns",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "High-dose oral B12 (if parenteral not tolerated) 1000 mcg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-2000 mcg PO daily; ~1% absorbed passively independent of intrinsic factor; may be adequate for mild deficiency; monitor closely",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 and MMA levels at 2-3 months to confirm adequate absorption",
          "if MMA remains elevated, switch to parenteral"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "b12-deficiency-neuropathy"
      ]
    },
    "high-dose-systemic-methotrexate-concurrent-with-it-methotrexate": {
      "id": "high-dose-systemic-methotrexate-concurrent-with-it-methotrexate",
      "name": "High-dose systemic methotrexate concurrent with IT methotrexate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/IT"
      ],
      "formulations": [],
      "contexts": {
        "combined-systemic-and-intrathecal-methotrexate-increases-ris": {
          "indication": "Combined systemic and intrathecal methotrexate increases risk of severe leukoencephalopathy and myelosuppression",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "High-dose systemic methotrexate concurrent with IT methotrexate N/A IV/IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Coordinate timing with oncology; do not give IT MTX within 24-48h of systemic MTX without methotrexate level clearance",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent elevated serum methotrexate levels"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "MRI for leukoencephalopathy",
          "Serum MTX levels",
          "neurologic exam"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "high-flow-oxygen": {
      "id": "high-flow-oxygen",
      "name": "High-flow oxygen",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "INH"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100%",
              "orderSentence": "High-flow oxygen 100% INH"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100% O2 at 12-15 L/min via non-rebreather mask × 15-20 min; can repeat",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None",
          "safe in COPD for acute use"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "O2 sat",
          "usually aborts attack in 15 min"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cluster-headache"
      ]
    },
    "high-intensity-statin": {
      "id": "high-intensity-statin",
      "name": "High-intensity statin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "80 mg",
              "orderSentence": "High-intensity statin 80 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Atorvastatin 80 mg PO daily (or Rosuvastatin 20-40 mg). Start immediately regardless of baseline LDL",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "STAT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "transient-ischemic-attack"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active liver disease",
          "pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CK if myalgia",
          "LFTs at 12 weeks",
          "lipid panel at 4-12 weeks"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "transient-ischemic-attack"
      ]
    },
    "hydralazine": {
      "id": "hydralazine",
      "name": "Hydralazine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "second-line-antihypertensive-for-acute-severe-hypertension-i": {
          "indication": "Second-line antihypertensive for acute severe hypertension in pregnancy; alternative when labetalol contraindicated",
          "doseOptions": [
            {
              "text": "5 mg IV",
              "orderSentence": "Hydralazine 5 mg IV IV"
            },
            {
              "text": "10 mg IV",
              "orderSentence": "Hydralazine 10 mg IV IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg IV over 1-2 min; if BP not controlled in 20 min → repeat 5-10 mg; max 20 mg total; then reassess",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Coronary artery disease",
          "mitral stenosis",
          "tachycardia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q5 min",
          "fetal monitoring",
          "heart rate (reflex tachycardia common)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy"
      ]
    },
    "hydrocortisone": {
      "id": "hydrocortisone",
      "name": "Hydrocortisone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "central-adrenal-insufficiency-from-hpa-axis-sarcoidosis": {
          "indication": "Central adrenal insufficiency from HPA axis sarcoidosis",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Hydrocortisone (physiologic replacement) 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg on waking + 5 mg in early afternoon; stress dosing: double or triple during illness/surgery",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "refractory-sih-not-responding-to-ebp-anti-inflammatory-effec": {
          "indication": "Refractory SIH not responding to EBP; anti-inflammatory effect on meninges; may increase CSF production",
          "doseOptions": [
            {
              "text": "200 mg daily",
              "orderSentence": "Hydrocortisone 200 mg daily IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg IV on day 1 then taper: 200 mg IV daily x 2d, 150 mg x 2d, 100 mg x 2d, then convert to oral; total course 7-14 days",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        },
        "refractory-hyponatremia-cerebral-salt-wasting-adrenal-insuff": {
          "indication": "Refractory hyponatremia; cerebral salt wasting; adrenal insufficiency",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Hydrocortisone 50-100 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg IV q8h",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        },
        "acute-adrenal-crisis-in-pituitary-apoplexy": {
          "indication": "Acute adrenal crisis in pituitary apoplexy",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Hydrocortisone (if pituitary apoplexy with hemodynamic instability) (CPT 96374) 100 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg IV bolus; then 50 mg IV q8h until endocrine evaluation complete. Life-saving — do not wait for cortisol results if clinical suspicion high",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection (relative)",
          "Active untreated infection, uncontrolled diabetes",
          "None in acute crisis",
          "peptic ulcer"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ACTH stimulation test",
          "AM cortisol (before dose)",
          "BP",
          "Blood glucose q6h, blood pressure, electrolytes",
          "Na",
          "cortisol",
          "cortisol levels",
          "electrolytes",
          "glucose",
          "stress dose education"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "low-pressure-headache",
        "neurosarcoidosis",
        "subarachnoid-hemorrhage",
        "thunderclap-headache-evaluation"
      ]
    },
    "hydromorphone": {
      "id": "hydromorphone",
      "name": "Hydromorphone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "severe-acute-radicular-pain-alternative-to-morphine": {
          "indication": "Severe acute radicular pain (alternative to morphine)",
          "doseOptions": [
            {
              "text": "0.5-1 mg",
              "orderSentence": "Hydromorphone 0.5-1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg IV q2-4h PRN; titrate to effect",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "severe-acute-plexopathy-pain-alternative-to-morphine": {
          "indication": "Severe acute plexopathy pain (alternative to morphine)",
          "doseOptions": [
            {
              "text": "0.5-1 mg",
              "orderSentence": "Hydromorphone (CPT 96374) 0.5-1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg IV q2-4h PRN; titrate to effect",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Respiratory depression",
          "paralytic ileus",
          "severe asthma"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Respiratory status",
          "pain scores",
          "sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "plexopathy",
        "radiculopathy"
      ]
    },
    "hydroxocobalamin-im": {
      "id": "hydroxocobalamin-im",
      "name": "Hydroxocobalamin IM",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-cyanocobalamin-longer-acting-preferred-in-som": {
          "indication": "Alternative to cyanocobalamin; longer-acting; preferred in some countries; better for cyanide toxicity",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "Hydroxocobalamin IM 1000 mcg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mcg IM daily x 7 days, then 1000 mcg IM every other day x 2 weeks, then 1000 mcg IM monthly indefinitely",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cobalt or cobalamin hypersensitivity (rare)",
          "Leber hereditary optic neuropathy (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 and MMA at 1-2 months",
          "CBC at 1-2 months",
          "Reticulocyte count at day 5-7",
          "potassium during first 48 hours (hypokalemia from erythropoiesis)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "b12-deficiency-neuropathy"
      ]
    },
    "hydroxychloroquine": {
      "id": "hydroxychloroquine",
      "name": "Hydroxychloroquine (Plaquenil)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dm-skin-disease-rash-photosensitivity-anti-synthetase-syndro": {
          "indication": "DM skin disease (rash, photosensitivity); anti-synthetase syndrome arthritis; adjunctive immunomodulation",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Hydroxychloroquine (Plaquenil) 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg PO BID (max 5 mg/kg/day based on actual body weight); onset 2-3 months for skin benefit",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "mild-neurosarcoidosis-cutaneous-sarcoidosis-with-mild-cns-in": {
          "indication": "Mild neurosarcoidosis; cutaneous sarcoidosis with mild CNS involvement; adjunctive therapy",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Hydroxychloroquine 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg PO BID (max 5 mg/kg/day based on actual body weight); onset 2-3 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "G6PD deficiency",
          "QTc prolongation",
          "Retinal disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Baseline and annual ophthalmologic exam (OCT + visual fields) after 5 years (or earlier if risk factors)",
          "Baseline ophthalmologic exam",
          "CBC",
          "ECG",
          "ECG baseline",
          "LFTs",
          "annual retinal screening after 5 years (or 1 year if high risk)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "inflammatory-myopathy",
        "neurosarcoidosis"
      ]
    },
    "hydroxyzine": {
      "id": "hydroxyzine",
      "name": "Hydroxyzine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "acute-anxiety-agitation-in-ed-inpatient": {
          "indication": "Acute anxiety; agitation in ED/inpatient",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Hydroxyzine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg PO q6-8h PRN; max 100 mg/dose",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "functional-neurological-disorder"
          ]
        },
        "acute-anxiety-situational-anxiety-in-pnes-patients-avoids-be": {
          "indication": "Acute anxiety; situational anxiety in PNES patients; avoids benzodiazepine use",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Hydroxyzine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg PO q6-8h PRN anxiety; max 100 mg/dose; non-addictive alternative to benzodiazepines",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        },
        "insomnia-with-anxiety": {
          "indication": "Insomnia with anxiety",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Hydroxyzine 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg PO QHS PRN",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "anxiety-pruritus": {
          "indication": "Anxiety, pruritus",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Hydroxyzine 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg TID-QID PRN; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation (high doses)",
          "QT prolongation, elderly (fall risk)",
          "QTc prolongation",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "QTc",
          "Sedation",
          "anticholinergic effects",
          "sedation",
          "sedation level"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "functional-neurological-disorder",
        "peripheral-neuropathy",
        "pnes",
        "post-concussion-syndrome"
      ]
    },
    "hyoscine-patch": {
      "id": "hyoscine-patch",
      "name": "Hyoscine (scopolamine) patch (sialorrhea)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "alternative-for-sialorrhea-management-when-oral-medications-": {
          "indication": "Alternative for sialorrhea management when oral medications difficult due to dysphagia",
          "doseOptions": [
            {
              "text": "1.5 mg",
              "orderSentence": "Hyoscine (scopolamine) patch (sialorrhea) 1.5 mg TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply 1 transdermal patch behind ear every 72 hours; rotate ears",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Narrow-angle glaucoma",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Confusion (may worsen)",
          "dry mouth",
          "urinary retention"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "creutzfeldt-jakob-disease"
      ]
    },
    "hypertonic-saline": {
      "id": "hypertonic-saline",
      "name": "Hypertonic saline (elevated ICP)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-elevated-icp-alternative-to-mannitol-may-be-preferred-": {
          "indication": "Acute elevated ICP; alternative to mannitol; may be preferred in hypotensive patients",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline (elevated ICP) 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "23.4% NaCl 30 mL via central line over 15 min OR 3% NaCl 250 mL IV over 30 min; target Na 145-155 mEq/L",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma",
            "primary-cns-lymphoma"
          ]
        },
        "emergent-icp-reduction-alternative-to-mannitol": {
          "indication": "Emergent ICP reduction; alternative to mannitol",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline (23.4%) (CPT 96374) 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL of 23.4% NaCl IV over 15-20 min via central line",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "acute-icp-crisis-from-posterior-fossa-mass-effect-when-rapid": {
          "indication": "Acute ICP crisis from posterior fossa mass effect when rapid osmotic effect needed",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline (23.4%) 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL of 23.4% NaCl IV over 10-15 min via central line; may repeat if needed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "acute-elevated-icp-from-large-meningioma-alternative-to-mann": {
          "indication": "Acute elevated ICP from large meningioma; alternative to mannitol; may be preferred in hypotensive patients",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline (elevated ICP) 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "23.4% NaCl 30 mL via central line over 15 min OR 3% NaCl 250 mL IV over 30 min; target Na 145-155 mEq/L",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CHF",
          "Hypernatremia (Na >160)",
          "Severe hypernatremia (Na >160)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Serum sodium q4-6h (target 145-155)",
          "Sodium q2-4h (target 145-155), osmolality",
          "Sodium q4-6h, serum osmolality, I/O, central line required for 23.4%",
          "central line required for 23.4%",
          "serum osmolality"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "ataxia-evaluation",
        "glioblastoma",
        "headache-evaluation",
        "meningioma",
        "primary-cns-lymphoma"
      ]
    },
    "hypertonic-saline-23-4": {
      "id": "hypertonic-saline-23-4",
      "name": "Hypertonic saline 23.4%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-herniation": {
          "indication": "Acute herniation",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline 23.4% 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL IV via central line over 10-20 min",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hsv-encephalitis"
          ]
        },
        "acute-herniation-from-massive-stroke-due-to-dissection-relat": {
          "indication": "Acute herniation from massive stroke due to dissection-related occlusion",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline 23.4% 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL IV bolus via central line over 10-20 min for acute herniation",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "acute-herniation-from-obstructive-hydrocephalus-due-to-lmd-w": {
          "indication": "Acute herniation from obstructive hydrocephalus due to LMD when mannitol contraindicated or insufficient",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "**Hypertonic saline 23.4% (acute herniation)** 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "23.4% NaCl 30 mL via central line over 15 min (MUST be central line); alternative: 3% NaCl 250 mL over 30 min (can be peripheral); bridge to emergent CSF diversion",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "acute-herniation-from-massive-cerebral-edema-in-cysticercal-": {
          "indication": "Acute herniation from massive cerebral edema in cysticercal encephalitis; more sustained ICP reduction than mannitol",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline 23.4% (CPT 96365) 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL via central line over 10-20 min; target Na 145-155 mEq/L; repeat PRN",
          "settings": {
            "ED": "STAT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "acute-herniation-from-post-anoxic-cerebral-edema-requires-ce": {
          "indication": "Acute herniation from post-anoxic cerebral edema; requires central venous access",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline 23.4% 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL IV via central line over 10-20 min for acute herniation",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "elevated-icp-acute-herniation": {
          "indication": "Elevated ICP (acute herniation)",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline 23.4% 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL IV via central line over 10-20 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "acute-herniation-syndrome-more-sustained-icp-reduction-than-": {
          "indication": "Acute herniation syndrome; more sustained ICP reduction than mannitol",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline 23.4% 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL via central line over 10-20 min; target Na 145-155 mEq/L; may repeat PRN",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "acute-herniation-from-hydrocephalus-or-cerebral-edema": {
          "indication": "Acute herniation from hydrocephalus or cerebral edema",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Hypertonic saline 23.4% 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL IV via central line over 10-20 min for acute herniation",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "23.4% requires central line",
          "Hypernatremia (Na >160)",
          "No central access",
          "No central access (causes tissue necrosis peripherally)",
          "No central access (peripheral administration causes tissue necrosis)",
          "No central access for 23.4%",
          "central pontine myelinolysis risk",
          "hypernatremia (Na >160)",
          "hypernatremia >160",
          "hypokalemia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Na (target 145-155)",
          "Na q4-6h",
          "Serum Na (target 145-155)",
          "Serum Na q4-6h",
          "Serum sodium (target 145-155 mEq/L)",
          "Sodium q2-4h",
          "central line access confirmed",
          "central line integrity",
          "neurologic exam",
          "osmolality",
          "serum osmolality",
          "target Na 145-155 mEq/L"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "bacterial-meningitis",
        "brain-abscess",
        "cervical-artery-dissection",
        "hsv-encephalitis",
        "leptomeningeal-carcinomatosis",
        "neurocysticercosis",
        "tb-meningitis"
      ]
    },
    "hypertonic-saline-3": {
      "id": "hypertonic-saline-3",
      "name": "Hypertonic saline 3%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-elevated-icp-from-cvt-or-mass-like-parenchymal-lesion": {
          "indication": "Acute elevated ICP from CVT or mass-like parenchymal lesion",
          "doseOptions": [
            {
              "text": "250 mL",
              "orderSentence": "Hypertonic saline 3% 250 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250 mL 3% NaCl IV over 15-30 minutes; repeat as needed; target sodium 145-155 mEq/L",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "acute-elevated-icp-from-obstructive-hydrocephalus-or-mass-ef": {
          "indication": "Acute elevated ICP from obstructive hydrocephalus or mass effect",
          "doseOptions": [
            {
              "text": "250 mL",
              "orderSentence": "Hypertonic saline 3% 250 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250 mL 3% NaCl IV over 15-30 minutes; may repeat; target sodium 145-155 mEq/L",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "alternative-to-mannitol-for-acute-icp-crisis": {
          "indication": "Alternative to mannitol for acute ICP crisis",
          "doseOptions": [
            {
              "text": "250 mL bolus",
              "orderSentence": "Hypertonic saline 3% (acute elevated ICP) 250 mL bolus IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250 mL IV over 15-20 min via central line preferred; target Na 145-155 mEq/L",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "icp-management-less-emergent-than-23-4-can-give-via-peripher": {
          "indication": "ICP management; less emergent than 23.4%; can give via peripheral line",
          "doseOptions": [
            {
              "text": "150-500 mL",
              "orderSentence": "Hypertonic saline 3% 150-500 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150-500 mL bolus or 0.5-1 mL/kg/h continuous infusion; target Na 145-155",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypernatremia (Na >155)",
          "Hypernatremia >155 mEq/L",
          "Hypernatremia >160",
          "severe CHF"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Na q4-6h",
          "Sodium q2-4h",
          "central line preferred for concentrations >3%",
          "osmolality",
          "serum osmolality"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "cerebral-venous-thrombosis",
        "neuro-behcets-disease",
        "neurosarcoidosis"
      ]
    },
    "hypertonic-saline-3-infusion": {
      "id": "hypertonic-saline-3-infusion",
      "name": "Hypertonic saline 3% infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "150-500 mL",
              "orderSentence": "Hypertonic saline 3% infusion 150-500 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150-500 mL IV bolus or continuous infusion 0.5-1 mL/kg/h; target Na 145-155",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypernatremia, volume overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Serum sodium q4-6h, osmolality"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-ischemic-stroke"
      ]
    },
    "hyponatremia-management-differentiate-csw-vs-siadh": {
      "id": "hyponatremia-management-differentiate-csw-vs-siadh",
      "name": "Hyponatremia management: Differentiate CSW vs SIADH",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "na-135-csw-volume-depleted-treat-with-ns-hypertonic-saline-f": {
          "indication": "Na <135: CSW = volume depleted (treat with NS/hypertonic saline + fludrocortisone). SIADH = euvolemic (treat with fluid restriction ± hypertonic saline)",
          "doseOptions": [
            {
              "text": "0.1-0.2 mg",
              "orderSentence": "Hyponatremia management: Differentiate CSW vs SIADH 0.1-0.2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "CSW: NS or 3% saline; fludrocortisone 0.1-0.2 mg PO BID. SIADH: fluid restriction 1-1.2 L/day; 3% saline if <120",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Na q6h during correction",
          "avoid >8-10 mEq/L rise in 24h (central pontine myelinolysis risk)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "subarachnoid-hemorrhage"
      ]
    },
    "ibrutinib": {
      "id": "ibrutinib",
      "name": "Ibrutinib (BTK inhibitor)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "relapsed-refractory-pcnsl-excellent-cns-penetration-especial": {
          "indication": "Relapsed/refractory PCNSL; excellent CNS penetration; especially effective if MYD88 L265P mutation present; single agent or with MTX-based regimen",
          "doseOptions": [
            {
              "text": "560 mg",
              "orderSentence": "Ibrutinib (BTK inhibitor) 560 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "560 mg PO daily continuously until progression or intolerable toxicity; take at same time daily; avoid strong CYP3A4 inhibitors/inducers",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "atrial fibrillation risk",
          "requires dose modification with CYP3A4 inhibitors",
          "warfarin contraindicated (use DOACs)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC weekly x4 then monthly",
          "ECG for atrial fibrillation",
          "LFTs monthly",
          "bleeding assessment",
          "hold 3-7 days before/after procedures",
          "infection monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "ibuprofen": {
      "id": "ibuprofen",
      "name": "Ibuprofen",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "mild-radicular-pain-musculoskeletal-pain-contributing-to-sym": {
          "indication": "Mild radicular pain, musculoskeletal pain contributing to symptoms",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Ibuprofen 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg q6-8h PRN; max 2400 mg/day; limit duration",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "arthralgia-anti-synthetase-syndrome-mild-myalgia": {
          "indication": "Arthralgia (anti-synthetase syndrome); mild myalgia",
          "doseOptions": [
            {
              "text": "400-600 mg",
              "orderSentence": "Ibuprofen 400-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6-8h PRN with food; max 2400 mg/day; use lowest effective dose for shortest duration",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "headache-and-fever-anti-inflammatory-for-meningeal-inflammat": {
          "indication": "Headache and fever; anti-inflammatory for meningeal inflammation; may be more effective than acetaminophen alone for meningitis headache",
          "doseOptions": [
            {
              "text": "400-600 mg",
              "orderSentence": "Ibuprofen 400-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6h with food; max 2400 mg/day; use in combination with acetaminophen for refractory headache",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "first-line-oral-analgesic-for-mild-moderate-headache": {
          "indication": "First-line oral analgesic for mild-moderate headache",
          "doseOptions": [
            {
              "text": "400-800 mg",
              "orderSentence": "Ibuprofen 400-800 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-800 mg PO at onset; repeat q6-8h; max 2400 mg/day; limit to <15 days/month",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "headache-and-neck-pain-from-dissection-if-not-on-anticoagula": {
          "indication": "Headache and neck pain from dissection if not on anticoagulation; short-term use only",
          "doseOptions": [
            {
              "text": "400-600 mg",
              "orderSentence": "Ibuprofen 400-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6-8h PRN with food; max 2400 mg/day; limit to <7 days",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "pain-with-eye-movement": {
          "indication": "Pain with eye movement",
          "doseOptions": [
            {
              "text": "400-800 mg",
              "orderSentence": "Ibuprofen 400-800 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-800 mg PO q8h as needed for pain; max 2400 mg/day; take with food",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "headache-and-meningeal-inflammation-relief": {
          "indication": "Headache and meningeal inflammation relief",
          "doseOptions": [
            {
              "text": "400 mg q6h",
              "orderSentence": "Ibuprofen 400 mg q6h PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6h PRN; max 2400 mg/day; take with food",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "400-600 mg",
              "orderSentence": "Ibuprofen 400-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6h PRN with food",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "bells-palsy",
            "migraine"
          ]
        },
        "mild-moderate-headache-pain-during-workup": {
          "indication": "Mild-moderate headache pain during workup",
          "doseOptions": [
            {
              "text": "400-800 mg",
              "orderSentence": "Ibuprofen 400-800 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-800 mg PO once; may repeat q6h; max 2400 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "acute-pain-inflammation-at-injury-site": {
          "indication": "Acute pain/inflammation at injury site",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Ibuprofen 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ibuprofen 400 mg TID with food; short course 7-14 days; not for chronic neuropathic pain",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peroneal-neuropathy"
          ]
        },
        "mild-moderate-post-traumatic-headache": {
          "indication": "Mild-moderate post-traumatic headache",
          "doseOptions": [
            {
              "text": "400-600 mg",
              "orderSentence": "Ibuprofen 400-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6-8h PRN with food; max 2400 mg/day; limit to <15 days/month",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "nsaid-for-outpatient-headache-management-after-discharge-avo": {
          "indication": "NSAID for outpatient headache management after discharge; avoid in patients with SAH complication",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Ibuprofen 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6-8h PRN; max 2400 mg/day; take with food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "mild-moderate-migraine-attack": {
          "indication": "Mild-moderate migraine attack",
          "doseOptions": [
            {
              "text": "400-800 mg",
              "orderSentence": "Ibuprofen 400-800 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-800 mg PO once; limit to ≤14 days/month; max 2400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "radicular-pain-inflammation-first-line-otc": {
          "indication": "Radicular pain, inflammation (first-line OTC)",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Ibuprofen 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-800 mg TID with food; max 3200 mg/day; short-term use preferred",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "headache-once-stable": {
          "indication": "Headache (once stable)",
          "doseOptions": [
            {
              "text": "400-600 mg",
              "orderSentence": "Ibuprofen 400-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6h with food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "first-line-acute-treatment-for-episodic-tth": {
          "indication": "First-line acute treatment for episodic TTH",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Ibuprofen 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-800 mg PO at onset; may repeat q6-8h; max 2400 mg/day; limit to <10 days/month",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "axial-neck-pain-alternative-nsaid-for-musculoskeletal-pain": {
          "indication": "Axial neck pain; alternative NSAID for musculoskeletal pain",
          "doseOptions": [
            {
              "text": "400-600 mg",
              "orderSentence": "Ibuprofen 400-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6-8h PRN with food; max 2400 mg/day; limit to 2 weeks when possible",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "mild-moderate-plexopathy-pain-anti-inflammatory-adjunct": {
          "indication": "Mild-moderate plexopathy pain; anti-inflammatory (adjunct)",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Ibuprofen 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-800 mg TID with food; max 3200 mg/day; short-term use preferred",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        },
        "headache-and-pain-management-in-lyme-meningitis-radicular-pa": {
          "indication": "Headache and pain management in Lyme meningitis; radicular pain",
          "doseOptions": [
            {
              "text": "400-600 mg q6-8h",
              "orderSentence": "Ibuprofen 400-600 mg q6-8h PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6-8h as needed; max 2400 mg/day; take with food",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        },
        "post-ictal-headache": {
          "indication": "Post-ictal headache",
          "doseOptions": [
            {
              "text": "400-600 mg",
              "orderSentence": "Ibuprofen 400-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO q6-8h PRN; max 2400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        },
        "mild-moderate-aura-migraine": {
          "indication": "Mild-moderate aura migraine",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Ibuprofen 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-800 mg PO at onset; max 2400 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active GI bleeding",
          "CKD stage 4-5",
          "Concurrent anticoagulation (increased bleeding risk)",
          "CrCl <30",
          "GI bleed",
          "GI bleed history",
          "GI bleed risk",
          "GI bleeding",
          "GI bleeding history",
          "GI bleeding, renal impairment, concurrent anticoagulation, cardiovascular disease",
          "Renal disease, GI bleeding",
          "Renal disease, GI bleeding history, aspirin allergy, third trimester pregnancy",
          "Renal disease, GI bleeding, anticoagulation, aspirin allergy",
          "Renal disease, GI bleeding, aspirin allergy",
          "Renal disease, GI bleeding, aspirin-exacerbated respiratory disease",
          "Renal impairment",
          "Renal impairment, GI bleed risk, coagulopathy",
          "active GI bleed",
          "allergy",
          "aspirin allergy",
          "aspirin-exacerbated respiratory disease",
          "aspirin-sensitive asthma",
          "aspirin/NSAID allergy",
          "cardiovascular disease",
          "coagulopathy",
          "concurrent anticoagulation",
          "concurrent aspirin (may reduce antiplatelet efficacy)",
          "dehydration",
          "known intracranial hemorrhage",
          "post-CABG",
          "renal impairment",
          "third trimester",
          "third trimester pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "Renal function",
          "Renal function if prolonged",
          "Renal function if prolonged use",
          "Renal function, GI symptoms",
          "avoid if not adequately hydrated",
          "bleeding signs",
          "blood pressure",
          "concurrent anticoagulant use",
          "medication days/month",
          "renal function",
          "renal function if prolonged",
          "renal function if prolonged use",
          "renal function with prolonged use",
          "risk of MOH"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 22,
      "_sourcePlans": [
        "bacterial-meningitis",
        "bells-palsy",
        "cervical-artery-dissection",
        "cervical-myelopathy",
        "chronic-migraine",
        "headache-evaluation",
        "headache-unspecified",
        "inflammatory-myopathy",
        "low-pressure-headache",
        "lyme-neuroborreliosis",
        "migraine",
        "migraine-with-aura",
        "new-onset-seizure",
        "optic-neuritis",
        "paresthesia-numbness-tingling",
        "peroneal-neuropathy",
        "plexopathy",
        "post-concussion-syndrome",
        "radiculopathy",
        "rcvs",
        "tension-headache",
        "viral-meningitis"
      ]
    },
    "icp-management-hypertonic-saline-23-4": {
      "id": "icp-management-hypertonic-saline-23-4",
      "name": "ICP management: Hypertonic saline 23.4%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "ICP management: Hypertonic saline 23.4% 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL IV bolus via central line over 10-20 min for acute herniation",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "No central access"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Na (target 145-155)",
          "osmolality"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "icp-management-hypertonic-saline-3": {
      "id": "icp-management-hypertonic-saline-3",
      "name": "ICP management: Hypertonic saline 3%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "150-500 mL",
              "orderSentence": "ICP management: Hypertonic saline 3% 150-500 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150-500 mL bolus or 0.5-1 mL/kg/h infusion; target Na 145-155",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "alternative-to-mannitol-for-elevated-icp-preferred-if-hypote": {
          "indication": "Alternative to mannitol for elevated ICP; preferred if hypotensive or hypovolemic",
          "doseOptions": [
            {
              "text": "150-500 mL",
              "orderSentence": "ICP management: Hypertonic saline 3% 150-500 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150-500 mL bolus or continuous infusion 0.5-1 mL/kg/h; target Na 145-155 mEq/L",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypernatremia >160",
          "congestive heart failure (volume overload)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Na q4-6h",
          "Serum Na q4-6h",
          "osmolality",
          "volume status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "intracerebral-hemorrhage",
        "pres"
      ]
    },
    "icp-management-mannitol-20": {
      "id": "icp-management-mannitol-20",
      "name": "ICP management: Mannitol 20%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "ICP management: Mannitol 20% 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus for acute herniation; 0.25-0.5 g/kg q4-6h maintenance",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "elevated-icp-or-impending-herniation-in-hemorrhagic-pres-or-": {
          "indication": "Elevated ICP or impending herniation in hemorrhagic PRES or massive edema",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "ICP management: Mannitol 20% 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus over 20 min for acute herniation; then 0.25-0.5 g/kg q4-6h maintenance; hold if serum osm >320",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Anuria",
          "serum osm >320",
          "serum osmolality >320 mOsm/kg",
          "severe dehydration"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cr",
          "I&O",
          "I/O",
          "Na",
          "Serum osm q4-6h",
          "Serum osmolality q4-6h",
          "neurological status",
          "osmolar gap"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "intracerebral-hemorrhage",
        "pres"
      ]
    },
    "idebenone": {
      "id": "idebenone",
      "name": "Idebenone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "friedreich-ataxia-may-reduce-cardiac-hypertrophy-limited-evi": {
          "indication": "Friedreich ataxia — may reduce cardiac hypertrophy; limited evidence for neurological benefit; investigational",
          "doseOptions": [
            {
              "text": "5 mg/kg",
              "orderSentence": "Idebenone 5 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/kg TID (typically 150-300 mg TID); take with food; not FDA-approved but used off-label",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cardiac function (echocardiogram)",
          "LFTs",
          "clinical ataxia scores",
          "well-tolerated"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ataxia-evaluation"
      ]
    },
    "immune-checkpoint-inhibitors": {
      "id": "immune-checkpoint-inhibitors",
      "name": "Immune checkpoint inhibitors (with extreme caution)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "sclc-maintenance-atezolizumab-durvalumab-critical-warning-ma": {
          "indication": "SCLC maintenance (atezolizumab, durvalumab); CRITICAL WARNING: may worsen LEMS or trigger myasthenic crisis; only under joint neuro-oncology management",
          "doseOptions": [
            {
              "text": "Per oncology protocol",
              "orderSentence": "Immune checkpoint inhibitors (with extreme caution) Per oncology protocol IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Per oncology; MUST be administered with close neuromuscular monitoring; have IVIg/PLEX available",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pre-existing myasthenic crisis",
          "uncontrolled LEMS",
          "use only with neuromuscular specialist co-management"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "FVC before each cycle",
          "MG-ADL equivalent assessment",
          "creatine kinase",
          "monitor for rapid neurological deterioration",
          "troponin (myocarditis)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "lambert-eaton-syndrome"
      ]
    },
    "immunosuppressant-switch": {
      "id": "immunosuppressant-switch",
      "name": "Immunosuppressant switch (transplant patients)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "switch-to-non-calcineurin-inhibitor-immunosuppression-to-pre": {
          "indication": "Switch to non-calcineurin inhibitor immunosuppression to prevent PRES recurrence; coordinate with transplant team",
          "doseOptions": [
            {
              "text": "Per transplant team",
              "orderSentence": "Immunosuppressant switch (transplant patients) Per transplant team PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Common switches: mycophenolate mofetil 500-1000 mg PO BID or sirolimus 2-5 mg PO daily; agent and dose per transplant team recommendation based on organ type and rejection risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Agent-specific",
          "varies by alternative chosen"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "Graft function",
          "LFTs",
          "drug levels",
          "rejection surveillance",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "immunosuppression": {
      "id": "immunosuppression",
      "name": "Immunosuppression (MOGAD)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Variable",
        "Various"
      ],
      "formulations": [],
      "contexts": {
        "mogad-mog-igg-positive-with-relapsing-course": {
          "indication": "MOGAD (MOG-IgG positive) with relapsing course",
          "doseOptions": [
            {
              "text": "Per agent",
              "orderSentence": "Immunosuppression (MOGAD) Per agent Variable"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Rituximab, azathioprine, or mycophenolate per specialist",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "sjogren-s-associated-sfn-with-systemic-disease-activity": {
          "indication": "Sjogren's-associated SFN with systemic disease activity",
          "doseOptions": [
            {
              "text": "Per rheumatology",
              "orderSentence": "Immunosuppression (Sjogren's) Per rheumatology Various"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Hydroxychloroquine, methotrexate, rituximab; coordinate with rheumatology",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per specific agent"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Per specific agent"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "optic-neuritis",
        "small-fiber-neuropathy"
      ]
    },
    "immunotherapy": {
      "id": "immunotherapy",
      "name": "Immunotherapy (autoimmune NCSE/NORSE)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "autoimmune-etiology-confirmed-or-highly-suspected-norse-fire": {
          "indication": "Autoimmune etiology confirmed or highly suspected (NORSE/FIRES)",
          "doseOptions": [
            {
              "text": "Per autoimmune encephalitis protocol",
              "orderSentence": "Immunotherapy (autoimmune NCSE/NORSE) Per autoimmune encephalitis protocol IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "IV methylprednisolone 1000 mg daily x 5 days + IVIG 0.4 g/kg daily x 5 days; escalate to rituximab/PLEX if refractory",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Per autoimmune encephalitis protocol"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ncse"
      ]
    },
    "immunotherapy-for-post-hsv-autoimmune-encephalitis": {
      "id": "immunotherapy-for-post-hsv-autoimmune-encephalitis",
      "name": "Immunotherapy for post-HSV autoimmune encephalitis",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1g/day",
              "orderSentence": "Immunotherapy for post-HSV autoimmune encephalitis 1g/day IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If relapse at 2-6 weeks with new anti-NMDAR antibodies: IV methylprednisolone 1g/day x 5 days + IVIG 0.4 g/kg/day x 5 days; second-line: rituximab",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "hsv-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active HSV infection (ensure viral replication controlled)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "NMDAR antibody titers",
          "clinical response",
          "viral PCR to confirm HSV not reactivated"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hsv-encephalitis"
      ]
    },
    "incobotulinumtoxina-cervical-dystonia": {
      "id": "incobotulinumtoxina-cervical-dystonia",
      "name": "IncobotulinumtoxinA (Xeomin) - Cervical dystonia",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "alternative-no-complexing-proteins": {
          "indication": "Alternative; no complexing proteins",
          "doseOptions": [
            {
              "text": "120 units",
              "orderSentence": "IncobotulinumtoxinA (Xeomin) - Cervical dystonia 120 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 120-200 units divided; max 300 units/session; repeat q12wk; may have lower immunogenicity",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ALS",
          "Infection at site",
          "myasthenia gravis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dysphagia (especially bilateral SCM)",
          "antibody formation",
          "neck weakness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "dystonia"
      ]
    },
    "increased-fluid-salt-intake": {
      "id": "increased-fluid-salt-intake",
      "name": "Increased fluid/salt intake",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "6-9 g",
              "orderSentence": "Increased fluid/salt intake 6-9 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-3 L fluid/day; 6-9 g salt/day (if no HTN/HF)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "syncope"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "HTN, heart failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "syncope"
      ]
    },
    "induced-hypertension": {
      "id": "induced-hypertension",
      "name": "Induced hypertension",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Induced hypertension N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If clinical vasospasm (new deficit days 4-14, aneurysm MUST be secured first): raise SBP to 180-220 mmHg using vasopressors. Phenylephrine 0.5-5 µg/kg/min or norepinephrine 0.05-0.3 µg/kg/min IV",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Unsecured aneurysm (NEVER induce hypertension before securing)",
          "cardiac failure",
          "pulmonary edema"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Arterial line",
          "CT perfusion",
          "TCD",
          "neuro checks q1h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "subarachnoid-hemorrhage"
      ]
    },
    "inebilizumab": {
      "id": "inebilizumab",
      "name": "Inebilizumab (Uplizna)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "fda-approved-for-aqp4-nmosd-anti-cd19-b-cell-depletion": {
          "indication": "FDA-approved for AQP4+ NMOSD; anti-CD19 B-cell depletion",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "**Inebilizumab (Uplizna)** 300 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Induction: 300 mg IV day 1 and day 15; maintenance: 300 mg IV every 6 months; premedicate with methylprednisolone 100 mg IV + diphenhydramine + acetaminophen",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Inebilizumab 300 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300 mg IV x 2 (14 days apart); then 300 mg q6 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active hepatitis B",
          "active infection",
          "severe immunodeficiency"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC q3 months",
          "CD19",
          "hepatitis B surveillance",
          "immunoglobulin levels q6 months",
          "infection",
          "infection monitoring",
          "infusion reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "acute-myelopathy",
        "nmosd"
      ]
    },
    "infliximab": {
      "id": "infliximab",
      "name": "Infliximab (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-parenchymal-or-non-parenchymal-nbd-failing-azathi": {
          "indication": "Refractory parenchymal or non-parenchymal NBD failing azathioprine/cyclophosphamide; progressive brainstem disease; severe myelopathy; refractory uveitis with CNS involvement",
          "doseOptions": [
            {
              "text": "5 mg/kg",
              "orderSentence": "Infliximab (CPT 96365) 5 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/kg IV at weeks 0, 2, and 6 (induction), then every 6-8 weeks (maintenance); increase to 10 mg/kg if inadequate response; infuse over 2 hours minimum; Pre-treatment: TB testing (QuantiFERON), Hepatitis B/C screening, CBC, LFTs, CMP, chest X-ray, age-appropriate cancer screening, heart failure assessment (NYHA class), pregnancy test",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "refractory-neurosarcoidosis-failing-methotrexate-mycophenola": {
          "indication": "Refractory neurosarcoidosis failing methotrexate/mycophenolate; severe/progressive disease; CNS mass lesions; optic neuropathy not responding to steroids",
          "doseOptions": [
            {
              "text": "5 mg/kg",
              "orderSentence": "Infliximab 5 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg/kg IV at weeks 0, 2, and 6 (induction), then every 4-8 weeks (maintenance); may increase to 7-10 mg/kg if inadequate response; infuse over 2 hours minimum",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "refractory-susac-syndrome-tnf-alpha-inhibitor-targeting-endo": {
          "indication": "Refractory Susac syndrome; TNF-alpha inhibitor targeting endothelial inflammation; limited case reports showing benefit",
          "doseOptions": [
            {
              "text": "5 mg/kg at weeks 0, 2, 6",
              "orderSentence": "Infliximab (CPT 96365) 5 mg/kg at weeks 0, 2, 6 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/kg IV at weeks 0, 2, 6; then every 8 weeks; premedicate",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active TB",
          "Active or latent TB (treat first)",
          "active infection",
          "active serious infection",
          "decompensated CHF (NYHA III-IV)",
          "decompensated heart failure (NYHA III/IV)",
          "demyelinating disease",
          "live vaccines within 4 weeks"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ANA/anti-dsDNA annually (drug-induced lupus)",
          "CBC",
          "CBC with differential q2-4 months",
          "LFTs",
          "LFTs q3 months",
          "TB screening before and annually",
          "heart failure symptoms",
          "hepatitis B",
          "infection surveillance",
          "infusion reactions",
          "skin cancer screening annually"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "neuro-behcets-disease",
        "neurosarcoidosis",
        "susac-syndrome"
      ]
    },
    "inotersen": {
      "id": "inotersen",
      "name": "Inotersen (Tegsedi)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "hattr-amyloidosis-with-polyneuropathy": {
          "indication": "hATTR amyloidosis with polyneuropathy",
          "doseOptions": [
            {
              "text": "284 mg",
              "orderSentence": "Inotersen (Tegsedi) 284 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "284 mg SC once weekly",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Platelet count <100,000",
          "prior glomerulonephritis from inotersen"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Platelet count weekly throughout treatment (more frequent if <75 Ãƒâ€” 10Ã¢ÂÂ¹/L)",
          "REMS program required",
          "continue monitoring 8 weeks post-discontinuation",
          "renal function q2 weeks"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "peripheral-neuropathy"
      ]
    },
    "inotersen-patisiran": {
      "id": "inotersen-patisiran",
      "name": "Inotersen/Patisiran",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC/IV"
      ],
      "formulations": [],
      "contexts": {
        "hereditary-ttr-amyloidosis-with-polyneuropathy": {
          "indication": "Hereditary TTR amyloidosis with polyneuropathy",
          "doseOptions": [
            {
              "text": "Per protocol",
              "orderSentence": "Inotersen/Patisiran Per protocol SC/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Inotersen 284 mg SC weekly; Patisiran 0.3 mg/kg IV q3wk",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Thrombocytopenia (inotersen)",
          "infusion reactions"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Platelets (inotersen)",
          "hepatic function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "small-fiber-neuropathy"
      ]
    },
    "insulin": {
      "id": "insulin",
      "name": "Insulin (steroid-induced hyperglycemia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/SC",
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "glucose-management-while-on-dexamethasone-50-60-of-patients-": {
          "indication": "Glucose management while on dexamethasone; 50-60% of patients on dexamethasone develop hyperglycemia",
          "doseOptions": [
            {
              "text": "Variable",
              "orderSentence": "Insulin (steroid-induced hyperglycemia) Variable SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Fingerstick glucose q6h; sliding scale insulin initially; basal-bolus if persistently >180 mg/dL; may need 2-3x baseline insulin on dexamethasone; anticipate glucose elevation 4-8h after steroid dose",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "hyperglycemia-target-140-180-mg-dl": {
          "indication": "Hyperglycemia (target 140-180 mg/dL)",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Insulin (regular) N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Sliding scale or insulin drip",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "hyperglycemia-management-in-patients-on-high-dose-dexamethas": {
          "indication": "Hyperglycemia management in patients on high-dose dexamethasone; occurs in 50-60% of steroid-treated patients",
          "doseOptions": [
            {
              "text": "Per sliding scale",
              "orderSentence": "**Insulin (steroid-induced hyperglycemia)** Per sliding scale SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Fingerstick glucose q6h; sliding scale insulin initially; transition to basal-bolus if persistent >180 mg/dL (typically need 2-3x baseline insulin requirements); glucose peaks 4-8 hours after steroid dose; anticipate insulin needs decrease as steroids taper",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "glucose-management-while-on-dexamethasone": {
          "indication": "Glucose management while on dexamethasone",
          "doseOptions": [
            {
              "text": "Variable",
              "orderSentence": "Insulin (steroid-induced hyperglycemia) Variable SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Fingerstick glucose q6h; sliding scale insulin initially; basal-bolus if persistently >180 mg/dL; may need 2-3x baseline insulin on dexamethasone",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "hyperglycemia-glucose-180-worsens-outcomes": {
          "indication": "Hyperglycemia (glucose >180 worsens outcomes)",
          "doseOptions": [
            {
              "text": "140-180 mg",
              "orderSentence": "Insulin (regular) 140-180 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Sliding scale or insulin drip for persistent hyperglycemia; target glucose 140-180 mg/dL; avoid hypoglycemia (<60 mg/dL)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "steroid-induced-hyperglycemia-not-controlled-with-oral-agent": {
          "indication": "Steroid-induced hyperglycemia not controlled with oral agents",
          "doseOptions": [
            {
              "text": "Per protocol",
              "orderSentence": "Insulin (steroid-induced diabetes) Per protocol SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Per endocrine protocol; anticipate afternoon/evening hyperglycemia pattern with morning steroid dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "glucose-management-while-on-dexamethasone-hyperglycemia-comm": {
          "indication": "Glucose management while on dexamethasone; hyperglycemia common with steroid use",
          "doseOptions": [
            {
              "text": "Variable",
              "orderSentence": "Insulin (steroid-induced hyperglycemia) Variable SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Fingerstick glucose q6h; sliding scale insulin initially; basal-bolus if persistently >180 mg/dL; may need 2-3x baseline insulin on dexamethasone; anticipate glucose improvement as steroids taper",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "hyperglycemia-management-target-140-180-mg-dl-hyperglycemia-": {
          "indication": "Hyperglycemia management (target 140-180 mg/dL; hyperglycemia worsens cerebral edema)",
          "doseOptions": [
            {
              "text": "Per institutional protocol",
              "orderSentence": "Insulin (regular) Per institutional protocol IV/SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Insulin drip 0.5-1 unit/h IV for persistent BG >180; titrate to target 140-180 mg/dL; transition to SC sliding scale when stable and tolerating PO",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypoglycemia",
          "Hypoglycemia risk",
          "Hypoglycemia risk (especially as steroids taper — adjust insulin promptly)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BG q1h if drip",
          "Blood glucose q1h if drip",
          "Fingerstick glucose q6h (q1h if insulin drip)",
          "Glucose QID",
          "Glucose q6h (q1h if insulin drip)",
          "HbA1c monthly if prolonged steroids",
          "HbA1c q3 months",
          "adjust insulin as steroid dose changes",
          "hypoglycemia symptoms",
          "q6h if sliding scale"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "giant-cell-arteritis",
        "glioblastoma",
        "intracerebral-hemorrhage",
        "leptomeningeal-carcinomatosis",
        "meningioma",
        "pres",
        "primary-cns-lymphoma"
      ]
    },
    "insulin-infusion": {
      "id": "insulin-infusion",
      "name": "Insulin infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "glycemic-control-during-donor-management-methylprednisolone-": {
          "indication": "Glycemic control during donor management; methylprednisolone and stress response cause hyperglycemia; tight glucose control improves organ preservation",
          "doseOptions": [
            {
              "text": "1-10 units/hr",
              "orderSentence": "**Insulin infusion** 1-10 units/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Regular insulin infusion; target blood glucose 120-180 mg/dL; start if BG >150 mg/dL; titrate per institutional insulin drip protocol; avoid hypoglycemia (<70 mg/dL)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        },
        "glycemic-control-to-reduce-icuaw-risk-and-severity-hyperglyc": {
          "indication": "Glycemic control to reduce ICUAW risk and severity; hyperglycemia is major modifiable risk factor",
          "doseOptions": [
            {
              "text": "Variable rate",
              "orderSentence": "Insulin (regular) infusion Variable rate IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Insulin infusion per ICU protocol; target glucose 140-180 mg/dL (NICE-SUGAR target); avoid hypoglycemia <70 mg/dL; transition to subcutaneous when tolerating enteral nutrition",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypoglycemia",
          "Hypoglycemia risk",
          "hypokalemia",
          "requires frequent glucose monitoring"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood glucose q1-2h",
          "Glucose q1-2h during infusion",
          "avoid hypoglycemia",
          "potassium q4h",
          "q4-6h when stable",
          "watch for hypokalemia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "brain-death-evaluation",
        "critical-illness-myopathy-neuropathy"
      ]
    },
    "insulin-sliding-scale": {
      "id": "insulin-sliding-scale",
      "name": "Insulin sliding scale",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "steroid-induced-hyperglycemia-management": {
          "indication": "Steroid-induced hyperglycemia management",
          "doseOptions": [
            {
              "text": "Per protocol",
              "orderSentence": "Insulin sliding scale Per protocol SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Per sliding scale if glucose >180 mg/dL; adjust per glucose trends",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease",
            "neurosarcoidosis",
            "mogad",
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "glucose-management-during-high-dose-steroids": {
          "indication": "Glucose management during high-dose steroids",
          "doseOptions": [
            {
              "text": "Per protocol",
              "orderSentence": "Insulin sliding scale (steroid-induced hyperglycemia) Per protocol SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Per institutional sliding scale protocol if glucose >180 mg/dL",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "steroid-induced-hyperglycemia": {
          "indication": "Steroid-induced hyperglycemia",
          "doseOptions": [
            {
              "text": "Per protocol",
              "orderSentence": "Insulin sliding scale Per protocol SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Per protocol if glucose >180 mg/dL",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy",
            "optic-neuritis",
            "nmosd"
          ]
        },
        "steroid-induced-hyperglycemia-management-high-dose-methylpre": {
          "indication": "Steroid-induced hyperglycemia management; high-dose methylprednisolone frequently causes glucose >200 mg/dL",
          "doseOptions": [
            {
              "text": "Per institutional protocol",
              "orderSentence": "Insulin sliding scale Per institutional protocol SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Per protocol if glucose >180 mg/dL; anticipate need on days 2-5 of pulse steroids",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cns-vasculitis",
            "susac-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypoglycemia risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose q6h",
          "Glucose q6h minimum during pulse steroids",
          "adjust per response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "cns-vasculitis",
        "hashimotos-encephalopathy",
        "inflammatory-myopathy",
        "mogad",
        "neuro-behcets-disease",
        "neurosarcoidosis",
        "nmosd",
        "optic-neuritis",
        "paraneoplastic-neurological-syndrome",
        "susac-syndrome"
      ]
    },
    "intensive-medical-therapy-alone": {
      "id": "intensive-medical-therapy-alone",
      "name": "Intensive medical therapy alone (for asymptomatic stenosis)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "preferred-initial-management-for-most-asymptomatic-carotid-s": {
          "indication": "Preferred initial management for most asymptomatic carotid stenosis given contemporary medical therapy effectiveness; annual stroke risk <1% with optimal medical therapy in modern era (vs 2%/year in ACAS era); CREST-2 comparing revascularization + medical vs medical alone",
          "doseOptions": [
            {
              "text": "Aspirin 81 mg + statin + antihypertensive",
              "orderSentence": "Intensive medical therapy alone (for asymptomatic stenosis) Aspirin 81 mg + statin + antihypertensive PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Aspirin 81 mg daily + high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) + BP target <140/90; add clopidogrel if high-risk features; aggressive risk factor modification; annual surveillance imaging",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None (this is baseline management for all patients)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP monitoring",
          "Carotid duplex q6-12 months",
          "lipid panel q3-6 months",
          "progression of stenosis warrants reassessment for intervention"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "carotid-stenosis"
      ]
    },
    "interferon-alpha-2a": {
      "id": "interferon-alpha-2a",
      "name": "Interferon-alpha 2a",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "refractory-ocular-and-neurological-behcet-s-particularly-eff": {
          "indication": "Refractory ocular and neurological Behcet's; particularly effective for refractory uveitis with CNS involvement",
          "doseOptions": [
            {
              "text": "3 MIU",
              "orderSentence": "Interferon-alpha 2a 3 MIU SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3-6 million IU (MIU) SC three times weekly; increase to 6-9 MIU TIW as needed; taper to lowest effective dose once remission achieved; typically combined with azathioprine; Pre-treatment: CBC, LFTs, TSH, depression screening, ANA",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Depression/suicidal ideation",
          "autoimmune hepatitis",
          "decompensated liver disease",
          "severe cytopenia",
          "uncontrolled thyroid disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ANA",
          "CBC q2 weeks initially, then monthly",
          "LFTs",
          "TSH q3 months",
          "depression screening",
          "flu-like symptoms",
          "injection site reactions",
          "triglycerides"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neuro-behcets-disease"
      ]
    },
    "interferon-beta-1a": {
      "id": "interferon-beta-1a",
      "name": "Interferon beta-1a (Avonex)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM",
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "30 mcg",
              "orderSentence": "Interferon beta-1a (Avonex) 30 mcg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mcg IM weekly",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Depression (relative)",
          "Depression, hepatic disease",
          "Same",
          "Same as Avonex",
          "decompensated liver disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC, LFTs q3-6mo",
          "CBC, LFTs q6 months",
          "Same",
          "TSH annually",
          "flu-like symptoms",
          "flu-like symptoms common (pretreat with NSAIDs/acetaminophen)",
          "injection site reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "interferon-beta-1b": {
      "id": "interferon-beta-1b",
      "name": "Interferon beta-1b (Betaseron, Extavia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "250 mcg",
              "orderSentence": "Interferon beta-1b (Betaseron, Extavia) 250 mcg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250 mcg SC every other day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same",
          "Same as Avonex"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "intra-arterial-nicardipine": {
      "id": "intra-arterial-nicardipine",
      "name": "Intra-arterial nicardipine (endovascular rescue)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IA"
      ],
      "formulations": [],
      "contexts": {
        "severe-progressive-vasoconstriction-with-ischemic-deficit-re": {
          "indication": "Severe, progressive vasoconstriction with ischemic deficit refractory to oral/IV therapy — alternative to IA verapamil",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Intra-arterial nicardipine (endovascular rescue) 5 mg IA"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Nicardipine 5-10 mg intra-arterial per vessel during cerebral angiography",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hemodynamic instability"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Angiographic response",
          "BP",
          "clinical improvement"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "rcvs"
      ]
    },
    "intra-arterial-vasodilator-therapy": {
      "id": "intra-arterial-vasodilator-therapy",
      "name": "Intra-arterial vasodilator therapy (endovascular rescue)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Intra-arterial vasodilator therapy (endovascular rescue) 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Verapamil 5-10 mg intra-arterial or nicardipine 5-10 mg intra-arterial; via catheter into spastic vessel during angiography. For medically refractory vasospasm",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hemodynamic instability during procedure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Angiographic improvement",
          "BP",
          "clinical response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "subarachnoid-hemorrhage"
      ]
    },
    "intra-arterial-verapamil": {
      "id": "intra-arterial-verapamil",
      "name": "Intra-arterial verapamil (endovascular rescue)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IA"
      ],
      "formulations": [],
      "contexts": {
        "severe-progressive-vasoconstriction-with-ischemic-deficit-re": {
          "indication": "Severe, progressive vasoconstriction with ischemic deficit refractory to oral/IV therapy — endovascular rescue",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Intra-arterial verapamil (endovascular rescue) 5 mg IA"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Verapamil 5-10 mg intra-arterial per vessel during cerebral angiography; may repeat in multiple territories; performed by neurointerventionalist",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hemodynamic instability",
          "inaccessible distal vessels"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Angiographic response",
          "BP during procedure",
          "clinical improvement"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "rcvs"
      ]
    },
    "intranasal-lidocaine": {
      "id": "intranasal-lidocaine",
      "name": "Intranasal lidocaine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Intranasal"
      ],
      "formulations": [],
      "contexts": {
        "acute-migraine-with-aura-rapid-onset-option": {
          "indication": "Acute migraine with aura; rapid onset option",
          "doseOptions": [
            {
              "text": "0.5 mL",
              "orderSentence": "Intranasal lidocaine 0.5 mL Intranasal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4% lidocaine 0.5 mL per nostril directed at sphenopalatine fossa; may repeat x1 in 15 min",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local anesthetic allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Local numbness",
          "cardiac arrhythmia (rare with low dose)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine-with-aura"
      ]
    },
    "intrathecal-amphotericin-b": {
      "id": "intrathecal-amphotericin-b",
      "name": "Intrathecal amphotericin B",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IT"
      ],
      "formulations": [],
      "contexts": {
        "refractory-coccidioidal-meningitis-not-responding-to-systemi": {
          "indication": "Refractory coccidioidal meningitis not responding to systemic azoles; rarely used due to toxicity; specialist administration only",
          "doseOptions": [
            {
              "text": "0.01-0.5 mg",
              "orderSentence": "Intrathecal amphotericin B 0.01-0.5 mg IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.01 mg IT; titrate slowly to 0.5 mg as tolerated over weeks; administered via LP or Ommaya reservoir; mix with CSF and inject slowly",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Coagulopathy",
          "infection at injection site"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CSF analysis",
          "Chemical arachnoiditis symptoms (headache, nausea, radiculopathy)",
          "neurological exam after each dose"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "intrathecal-baclofen": {
      "id": "intrathecal-baclofen",
      "name": "Intrathecal baclofen (ITB pump)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IT"
      ],
      "formulations": [],
      "contexts": {
        "refractory-rigidity-and-spasms-not-controlled-by-maximal-ora": {
          "indication": "Refractory rigidity and spasms not controlled by maximal oral medications; severe functional impairment",
          "doseOptions": [
            {
              "text": "50-100 mcg",
              "orderSentence": "Intrathecal baclofen (ITB pump) 50-100 mcg IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Trial: 50-100 mcg intrathecal bolus; if positive response, implant programmable pump; typical maintenance 100-800 mcg/day continuous infusion; titrate over weeks",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "CSF obstruction",
          "coagulopathy",
          "patient unable to return for pump refills"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CSF leak",
          "Pump function and refill schedule",
          "catheter complications",
          "infection",
          "withdrawal symptoms if pump malfunction (medical emergency -- similar to status spasticus)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "stiff-person-syndrome"
      ]
    },
    "intrathecal-baclofen-pump": {
      "id": "intrathecal-baclofen-pump",
      "name": "Intrathecal baclofen pump",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IT"
      ],
      "formulations": [],
      "contexts": {
        "severe-generalized-dystonia-with-spasticity-component-cp-rel": {
          "indication": "Severe generalized dystonia with spasticity component; CP-related",
          "doseOptions": [
            {
              "text": "25 mcg",
              "orderSentence": "Intrathecal baclofen pump 25 mcg IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Test dose 25-100 mcg; maintenance typically 100-1000 mcg/day; titrate over months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "severe-spasticity-refractory-to-maximum-oral-medications-int": {
          "indication": "Severe spasticity refractory to maximum oral medications; intolerable side effects from oral antispasticity agents",
          "doseOptions": [
            {
              "text": "50-100 mcg",
              "orderSentence": "Intrathecal baclofen pump 50-100 mcg IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Trial with intrathecal bolus 50-100 mcg; if >50% spasticity reduction, proceed to pump implantation; maintenance 100-900 mcg/day",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CSF leak history",
          "CSF obstruction",
          "Infection",
          "Infection at insertion site",
          "baclofen hypersensitivity",
          "inability to follow up for pump refills"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "MRI conditional pumps",
          "Pump refill schedule (q1-3 months)",
          "Pump refills q1-3mo",
          "catheter complications",
          "withdrawal syndrome if interruption",
          "withdrawal syndrome if pump malfunction (fever, seizures, rhabdomyolysis — EMERGENCY)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "cervical-myelopathy",
        "dystonia"
      ]
    },
    "intrathecal-chemotherapy": {
      "id": "intrathecal-chemotherapy",
      "name": "Intrathecal chemotherapy (with spinal block)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IT"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "-",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "spinal-cord-compression-malignant"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "spinal-cord-compression-malignant"
      ]
    },
    "intrathecal-cytarabine": {
      "id": "intrathecal-cytarabine",
      "name": "Intrathecal cytarabine (liposomal, DepoCyt)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IT"
      ],
      "formulations": [],
      "contexts": {
        "alternative-or-second-line-it-agent-sustained-release-formul": {
          "indication": "Alternative or second-line IT agent; sustained-release formulation allows less frequent dosing; solid tumors and hematologic malignancies",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "**Intrathecal cytarabine (liposomal, DepoCyt)** 50 mg IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg liposomal cytarabine (DepoCyt) IT via Ommaya or LP q2 weeks for 5 doses (induction), then q4 weeks (maintenance); co-administer dexamethasone 4 mg PO BID for 5 days starting day of injection (prevents chemical arachnoiditis); NOTE: DepoCyt supply has been intermittent — verify availability",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Known hypersensitivity",
          "active meningeal infection",
          "blocked CSF flow"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC before each dose",
          "MRI q6-8 weeks",
          "fever",
          "lumbar symptoms",
          "neurologic exam (chemical arachnoiditis occurs in 20-40% without dex prophylaxis)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "intrathecal-methotrexate": {
      "id": "intrathecal-methotrexate",
      "name": "Intrathecal methotrexate (via Ommaya)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IT"
      ],
      "formulations": [],
      "contexts": {
        "first-line-it-chemotherapy-for-lmd-from-solid-tumors-breast-": {
          "indication": "First-line IT chemotherapy for LMD from solid tumors (breast, lung); best evidence base among IT agents",
          "doseOptions": [
            {
              "text": "12 mg",
              "orderSentence": "**Intrathecal methotrexate (via Ommaya)** 12 mg IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "12 mg in 3-5 mL preservative-free normal saline via Ommaya reservoir; twice weekly for 4 weeks (induction), then weekly for 4 weeks (consolidation), then monthly (maintenance); co-administer leucovorin 10 mg PO q6h x 4 doses starting 24h after each IT dose to prevent systemic toxicity",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "it-chemotherapy-when-ommaya-reservoir-not-yet-placed-initial": {
          "indication": "IT chemotherapy when Ommaya reservoir not yet placed; initial treatment while awaiting surgery",
          "doseOptions": [
            {
              "text": "12 mg",
              "orderSentence": "**Intrathecal methotrexate (via LP)** 12 mg IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "12 mg in 3-5 mL preservative-free normal saline injected slowly via LP; patient lies flat for 1 hour post-injection; same schedule as Ommaya administration; Ommaya preferred for repeated dosing (avoids repeat LPs, more reliable CSF distribution)",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "positive-csf-cytology-flow-cytometry-leptomeningeal-involvem": {
          "indication": "Positive CSF cytology/flow cytometry; leptomeningeal involvement documented; administered via lumbar puncture or Ommaya reservoir; role diminished with HD-MTX (which achieves therapeutic CSF levels)",
          "doseOptions": [
            {
              "text": "12 mg",
              "orderSentence": "Intrathecal Methotrexate 12 mg IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "12 mg IT (preservative-free) via LP or Ommaya reservoir; 2x/week for 4 weeks, then weekly x4-8 weeks, then monthly; reconstitute in preservative-free normal saline; give with leucovorin 10 mg PO q6h x 4 doses starting 24h after IT MTX",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent high-dose systemic methotrexate",
          "Concurrent high-dose systemic methotrexate (combined toxicity)",
          "MTX neurotoxicity symptoms",
          "Opening pressure before each IT injection",
          "active CNS infection",
          "blocked CSF flow",
          "blocked CSF flow (perform flow study first — blocked flow increases neurotoxicity)",
          "coagulopathy",
          "concurrent systemic MTX timing (avoid within 48h)",
          "mass effect",
          "neurologic exam (arachnoiditis, myelopathy)",
          "pre-existing severe leukoencephalopathy",
          "skin infection at LP site"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC before each dose",
          "CSF leak at puncture site",
          "MRI q6-8 weeks for response and leukoencephalopathy surveillance",
          "monitor for post-LP headache",
          "neurologic exam",
          "neurologic exam (chemical meningitis, leukoencephalopathy)",
          "renal function",
          "renal function (methotrexate clearance)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis",
        "primary-cns-lymphoma"
      ]
    },
    "intrathecal-saline-infusion": {
      "id": "intrathecal-saline-infusion",
      "name": "Intrathecal saline infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Intrathecal"
      ],
      "formulations": [],
      "contexts": {
        "severe-refractory-sih-as-bridge-to-definitive-repair-restore": {
          "indication": "Severe refractory SIH as bridge to definitive repair; restores CSF volume temporarily",
          "doseOptions": [
            {
              "text": "NS at 15-30 mL/hr",
              "orderSentence": "Intrathecal saline infusion NS at 15-30 mL/hr Intrathecal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Intrathecal normal saline via lumbar drain at 15-30 mL/hr; temporary measure only; risk of infection increases with duration",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection, coagulopathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Infection surveillance, neurologic exam, ICP monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "low-pressure-headache"
      ]
    },
    "intrathecal-thiotepa": {
      "id": "intrathecal-thiotepa",
      "name": "Intrathecal thiotepa",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IT"
      ],
      "formulations": [],
      "contexts": {
        "third-line-it-agent-used-when-methotrexate-and-cytarabine-no": {
          "indication": "Third-line IT agent; used when methotrexate and cytarabine not tolerated or disease refractory; breast cancer LMD",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "**Intrathecal thiotepa** 10 mg IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg in 3-5 mL preservative-free normal saline via Ommaya reservoir; twice weekly during induction; taper to weekly then monthly per response",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "blocked CSF flow",
          "severe myelosuppression (ANC <500)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC (myelosuppression more common than with MTX)",
          "neurologic exam",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "intubation-and-mechanical-ventilation": {
      "id": "intubation-and-mechanical-ventilation",
      "name": "Intubation and mechanical ventilation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "—"
      ],
      "formulations": [],
      "contexts": {
        "respiratory-failure-not-responding-to-niv": {
          "indication": "Respiratory failure not responding to NIV",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Intubation and mechanical ventilation N/A —"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Discuss advance directives; many ALS patients decline invasive ventilation; if desired, standard intubation and ventilation",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "DNI documented",
          "Patient declines"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ventilator parameters, sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "ipilimumab-nivolumab": {
      "id": "ipilimumab-nivolumab",
      "name": "Ipilimumab + nivolumab (melanoma)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "melanoma-with-leptomeningeal-disease-immunotherapy-combinati": {
          "indication": "Melanoma with leptomeningeal disease; immunotherapy combination has best intracranial activity",
          "doseOptions": [
            {
              "text": "3 mg/kg + 1 mg/kg",
              "orderSentence": "**Ipilimumab + nivolumab (melanoma)** 3 mg/kg + 1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ipilimumab 3 mg/kg + nivolumab 1 mg/kg IV q3 weeks for 4 cycles, then nivolumab 480 mg IV q4 weeks maintenance; BRAF+ melanoma: dabrafenib 150 mg BID + trametinib 2 mg daily is alternative (faster response); response rate for LMD is lower than parenchymal disease",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active autoimmune disease requiring systemic immunosuppression (relative)",
          "concurrent high-dose steroids (>10 mg prednisone equivalent — reduces immunotherapy efficacy)",
          "solid organ transplant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs and TSH before each cycle",
          "glucose",
          "irAE monitoring (hepatic, thyroid, adrenal, colitis, pneumonitis, dermatitis)",
          "lipase",
          "neurologic exam for immune-related neurotoxicity"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "iron-supplementation": {
      "id": "iron-supplementation",
      "name": "Iron supplementation (if deficient)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "iron-deficiency-anemia-correction-anemia-worsens-cerebral-is": {
          "indication": "Iron deficiency anemia correction; anemia worsens cerebral ischemia in moyamoya; optimize before surgery",
          "doseOptions": [
            {
              "text": "325 mg ferrous sulfate daily",
              "orderSentence": "Iron supplementation (if deficient) 325 mg ferrous sulfate daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "325 mg (65 mg elemental iron) PO daily on empty stomach; may increase to BID if tolerated; target ferritin >50",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hemochromatosis",
          "iron overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ferritin, iron studies q3 months until replete"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "moyamoya-disease"
      ]
    },
    "isavuconazole": {
      "id": "isavuconazole",
      "name": "Isavuconazole (Cresemba)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-voriconazole-for-cns-aspergillosis-better-tol": {
          "indication": "Alternative to voriconazole for CNS aspergillosis; better tolerated; fewer drug interactions; does NOT require cyclodextrin (safe in renal impairment)",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Isavuconazole (Cresemba) 200 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Loading: 200 mg IV or PO q8h for 6 doses (48 hours); Maintenance: 200 mg IV or PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment",
          "concurrent strong CYP3A4 inducers",
          "familial short QT syndrome"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs weekly",
          "drug interactions (CYP3A4)",
          "hepatotoxicity monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "isoniazid": {
      "id": "isoniazid",
      "name": "Isoniazid (INH)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-anti-tb-therapy-excellent-cns-penetration-csf-lev": {
          "indication": "First-line anti-TB therapy; excellent CNS penetration (CSF levels 80-90% of serum); bactericidal against M. tuberculosis",
          "doseOptions": [
            {
              "text": "5 mg/kg daily (max 300 mg)",
              "orderSentence": "Isoniazid (INH) 5 mg/kg daily (max 300 mg) PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/kg PO/IV daily (max 300 mg/day); some experts use 10 mg/kg for first 2 months for enhanced CNS penetration; duration 12 months",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        },
        "continuation-phase-anti-tb-therapy-months-3-12-of-treatment": {
          "indication": "Continuation phase anti-TB therapy; months 3-12 of treatment",
          "doseOptions": [
            {
              "text": "5 mg/kg daily (max 300 mg)",
              "orderSentence": "Isoniazid (continuation phase) 5 mg/kg daily (max 300 mg) PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/kg PO daily (max 300 mg/day); continue for total duration 12 months; some experts recommend 18 months for severe disease or slow responders",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Acute hepatic disease",
          "Severe hepatic disease",
          "caution with alcohol use",
          "prior INH hepatotoxicity",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs (ALT/AST) at baseline, 2 weeks, then monthly",
          "LFTs monthly",
          "ensure pyridoxine co-administration",
          "hold if ALT >5x ULN (asymptomatic) or >3x ULN with symptoms",
          "peripheral neuropathy assessment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "tb-meningitis"
      ]
    },
    "isoproterenol-drip": {
      "id": "isoproterenol-drip",
      "name": "Isoproterenol drip (severe autonomic bradycardia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2-10 mcg",
              "orderSentence": "Isoproterenol drip (severe autonomic bradycardia) 2-10 mcg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-10 mcg/min IV infusion; titrate to HR >60",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Tachyarrhythmia",
          "digoxin toxicity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Continuous ECG",
          "HR"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "autoimmune-encephalitis"
      ]
    },
    "isotonic-crystalloid": {
      "id": "isotonic-crystalloid",
      "name": "Isotonic crystalloid (0.9% NaCl or LR)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "volume-resuscitation-for-hemodynamic-stability-replace-massi": {
          "indication": "Volume resuscitation for hemodynamic stability; replace massive urine losses from DI; maintain adequate perfusion for valid examination",
          "doseOptions": [
            {
              "text": "0.9% NaCl",
              "orderSentence": "**Isotonic crystalloid (0.9% NaCl or LR)** 0.9% NaCl IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bolus 500-1000 mL for hypotension; maintenance 100-250 mL/hr; replace urine output mL-for-mL if DI present; avoid hypotonic fluids",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Fluid overload",
          "pulmonary edema (balance with organ preservation goals)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CVP if available",
          "blood pressure",
          "lung auscultation",
          "serum sodium",
          "urine output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-death-evaluation"
      ]
    },
    "istradefylline": {
      "id": "istradefylline",
      "name": "Istradefylline",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "adenosine-a2a-antagonist-adjunct-for-off-time": {
          "indication": "Adenosine A2A antagonist; adjunct for OFF time",
          "doseOptions": [
            {
              "text": "20 mg daily",
              "orderSentence": "Istradefylline 20 mg daily PO"
            },
            {
              "text": "40 mg daily",
              "orderSentence": "Istradefylline 40 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20 mg daily; may increase to 40 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Strong CYP3A4 inducers"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dyskinesias, dizziness, constipation, hallucinations"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease"
      ]
    },
    "it-chemotherapy-with-blocked-csf-flow": {
      "id": "it-chemotherapy-with-blocked-csf-flow",
      "name": "IT chemotherapy with blocked CSF flow",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IT"
      ],
      "formulations": [],
      "contexts": {
        "blocked-csf-flow-verified-by-radionuclide-flow-study-leads-t": {
          "indication": "Blocked CSF flow (verified by radionuclide flow study) leads to poor drug distribution and markedly increased neurotoxicity from drug accumulation",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "IT chemotherapy with blocked CSF flow N/A IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Do NOT administer IT chemotherapy until CSF flow study confirms normal flow or radiation clears obstruction",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Blocked CSF flow",
          "administer focal radiation to site of block first, then repeat flow study before starting IT chemo"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Chemical meningitis",
          "leukoencephalopathy",
          "myelopathy if drug pools at block site"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "itraconazole": {
      "id": "itraconazole",
      "name": "Itraconazole",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-for-histoplasma-meningitis-after-amphotericin-b-": {
          "indication": "Alternative for Histoplasma meningitis (after amphotericin B induction); second-line for Coccidioides meningitis; requires acidic gastric pH for absorption",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Itraconazole 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg PO BID-TID (solution preferred over capsules for better absorption); target trough >1.0 mcg/mL; take solution on empty stomach, capsules with food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "maintenance-therapy-after-amphotericin-b-induction-for-histo": {
          "indication": "Maintenance therapy after amphotericin B induction for Histoplasma meningitis; minimum 12 months; longer if immunosuppressed",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Itraconazole (Histoplasma maintenance) 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg PO BID-TID for minimum 12 months; itraconazole solution preferred (better absorption); take on empty stomach",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment",
          "Ventricular dysfunction",
          "concurrent CYP3A4 substrates",
          "severe hepatic impairment",
          "ventricular dysfunction (negative inotrope)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Histoplasma antigen q3 months (declining indicates response)",
          "Itraconazole trough levels (target >1.0 mcg/mL)",
          "LFTs monthly",
          "LFTs weekly initially then monthly",
          "Trough levels (target >1.0 mcg/mL)",
          "cardiac function",
          "drug interactions",
          "monitor for heart failure symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "iv-access": {
      "id": "iv-access",
      "name": "IV access",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "IV access N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Establish if unstable",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "syncope",
            "status-epilepticus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Access",
          "IV patency"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "status-epilepticus",
        "syncope"
      ]
    },
    "iv-alteplase": {
      "id": "iv-alteplase",
      "name": "IV alteplase (tPA)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-ischemic-stroke-within-4-5h-of-last-known-well-due-to-": {
          "indication": "Acute ischemic stroke within 4.5h of last known well due to dissection-related embolism",
          "doseOptions": [
            {
              "text": "0.9 mg/kg",
              "orderSentence": "IV alteplase (tPA) 0.9 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.9 mg/kg IV (max 90 mg); 10% as bolus over 1 min, remaining 90% infused over 60 min. Dissection is NOT a contraindication to IV tPA if within window",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.9 mg/kg",
              "orderSentence": "IV alteplase (tPA) (CPT 96365) 0.9 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.9 mg/kg IV (max 90 mg); 10% as bolus over 1 min, remaining 90% infused over 60 min. Door-to-needle target <45 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "acute-posterior-circulation-ischemic-stroke-causing-cerebell": {
          "indication": "Acute posterior circulation ischemic stroke causing cerebellar infarction within treatment window",
          "doseOptions": [
            {
              "text": "0.9 mg/kg",
              "orderSentence": "IV alteplase (tPA) 0.9 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.9 mg/kg IV (max 90 mg); 10% bolus over 1 min, remainder over 60 min; within 4.5 hours of symptom onset",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          ">4.5h from last known well (relative 3-4.5h window with additional exclusions)",
          "Active hemorrhage",
          "BP >185/110",
          "BP >185/110 despite treatment",
          "INR >1.7",
          "Standard tPA exclusions: >4.5h from last known well",
          "active bleeding",
          "intracranial dissection with SAH",
          "intracranial hemorrhage",
          "intracranial hemorrhage history",
          "platelets <100,000",
          "platelets <100K",
          "recent stroke <3 months",
          "recent surgery",
          "recent surgery <14 days",
          "see full stroke exclusion criteria"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q15min x 2h, q30min x 6h",
          "BP q15min x 2h, q30min x 6h, then q1h",
          "BP q15min x 2h, then q30min x 6h, then q1h x 16h",
          "NIHSS",
          "Neuro checks q15min during infusion, q30min x 6h, then q1h x 18h",
          "hold anticoagulants/antiplatelets 24h",
          "hold anticoagulants/antiplatelets 24h post-tPA",
          "neuro checks q15min during infusion",
          "signs of hemorrhage"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "ataxia-evaluation",
        "cervical-artery-dissection"
      ]
    },
    "iv-crystalloid": {
      "id": "iv-crystalloid",
      "name": "IV crystalloid (normal saline or lactated Ringer)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "rhabdomyolysis-prevention-and-treatment-during-severe-spasms": {
          "indication": "Rhabdomyolysis prevention and treatment during severe spasms",
          "doseOptions": [
            {
              "text": "250 mL/hr",
              "orderSentence": "IV crystalloid (normal saline or lactated Ringer) 250 mL/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 L bolus then 150-250 mL/hr; target urine output >200 mL/hr if CK >5000; add sodium bicarbonate 150 mEq/L NS if myoglobinuria",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart failure",
          "volume overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP q6-12h",
          "CK q6h",
          "I/O",
          "urine myoglobin",
          "urine output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "stiff-person-syndrome"
      ]
    },
    "iv-dexamethasone": {
      "id": "iv-dexamethasone",
      "name": "IV dexamethasone (sudden SNHL with tinnitus)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "sudden-sensorineural-hearing-loss-with-tinnitus": {
          "indication": "Sudden sensorineural hearing loss with tinnitus",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "**IV dexamethasone** (sudden SNHL with tinnitus) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Sudden SNHL is otologic emergency**: Dexamethasone 10 mg IV then transition to oral prednisone 1 mg/kg/day (max 60 mg) x 14 days with taper; OR methylprednisolone 48 mg daily x 14 days; start within 72 hours for best outcomes; ENT urgent referral",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "URGENT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection (relative)",
          "GI bleed",
          "uncontrolled diabetes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood glucose monitoring every 6 hours while on steroids",
          "[Chandrasekhar et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/33082670/): AAO-HNS guideline recommends steroids within 2 weeks of sudden SNHL onset",
          "earlier is better"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tinnitus-evaluation"
      ]
    },
    "iv-dhe-protocol": {
      "id": "iv-dhe-protocol",
      "name": "IV DHE protocol (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.5-1 mg",
              "orderSentence": "IV DHE protocol (CPT 96365) 0.5-1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "DHE 0.5-1 mg IV q8h × 3-5 days (with metoclopramide 10 mg IV pretreatment)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CAD, CVA, uncontrolled HTN, pregnancy, triptans <24h"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP, nausea, EKG"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "medication-overuse-headache"
      ]
    },
    "iv-diphenhydramine": {
      "id": "iv-diphenhydramine",
      "name": "IV diphenhydramine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "IV diphenhydramine 25-50 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV q6h with antiemetics",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Glaucoma"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "medication-overuse-headache"
      ]
    },
    "iv-fluid-bolus": {
      "id": "iv-fluid-bolus",
      "name": "IV fluid bolus (euvolemia maintenance)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500-1000 mL",
              "orderSentence": "IV fluid bolus (euvolemia maintenance) 500-1000 mL -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS bolus 500-1000 mL if hypovolemic; maintain euvolemia. Avoid prophylactic hypervolemia (no benefit per current evidence — Robertson et al.)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Volume overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CVP",
          "I/O",
          "daily weights"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "subarachnoid-hemorrhage"
      ]
    },
    "iv-fluid-resuscitation": {
      "id": "iv-fluid-resuscitation",
      "name": "IV fluid resuscitation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500-1000 mL",
              "orderSentence": "IV fluid resuscitation 500-1000 mL -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS 500-1000 mL bolus if hypovolemic/dehydrated",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "syncope"
          ]
        },
        "dehydration-from-gi-prodrome-foodborne-botulism-nausea-vomit": {
          "indication": "Dehydration from GI prodrome (foodborne botulism — nausea, vomiting, diarrhea)",
          "doseOptions": [
            {
              "text": "20 mL/kg",
              "orderSentence": "IV fluid resuscitation (0.9% NS) (CPT 96360, 96361) 20 mL/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mL/kg IV bolus, then maintenance; target euvolemia",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "botulism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Fluid overload, CHF",
          "Heart failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "I/O, BMP, volume status",
          "Volume status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "botulism",
        "syncope"
      ]
    },
    "iv-fluids": {
      "id": "iv-fluids",
      "name": "IV fluids",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "dehydration-from-dysphagia-or-decreased-oral-intake": {
          "indication": "Dehydration from dysphagia or decreased oral intake",
          "doseOptions": [
            {
              "text": "NS at 75 mL/hr",
              "orderSentence": "IV fluids NS at 75 mL/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS at 75-125 mL/hr; correct dehydration; transition to oral when safe",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "IV fluids (isotonic) N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS maintenance; hydration for IVIG renal protection",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "migraine",
            "vertigo-dizziness-evaluation",
            "new-onset-seizure"
          ]
        },
        "dehydration": {
          "indication": "Dehydration",
          "doseOptions": [
            {
              "text": "1000-2000 mL NS or LR daily",
              "orderSentence": "IV fluids 1000-2000 mL NS or LR daily IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 L IV daily; adjust for cardiac status",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "maintain-hydration-during-period-of-poor-oral-intake-support": {
          "indication": "Maintain hydration during period of poor oral intake; support acyclovir clearance; replace insensible losses from fever",
          "doseOptions": [
            {
              "text": "75-125 mL/h",
              "orderSentence": "IV fluids (maintenance) 75-125 mL/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75-125 mL/h 0.9% normal saline or LR; adjust based on I/O and clinical status",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "acute-orthostatic-hypotension-with-symptoms": {
          "indication": "Acute orthostatic hypotension with symptoms",
          "doseOptions": [
            {
              "text": "500-1000 mL",
              "orderSentence": "IV fluids 500-1000 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mL NS bolus for symptomatic orthostatic hypotension; avoid in heart failure",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "volume-resuscitation-chronic-alcohol-users-are-often-dehydra": {
          "indication": "Volume resuscitation; chronic alcohol users are often dehydrated",
          "doseOptions": [
            {
              "text": "500-1000 mL",
              "orderSentence": "IV fluids (isotonic) 500-1000 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS or LR bolus 500-1000 mL, then 150-250 mL/hr maintenance; add dextrose (D5NS) once thiamine given; correct dehydration",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "dehydration-and-fall-related-injury-in-patients-presenting-t": {
          "indication": "Dehydration and fall-related injury in patients presenting to ED with IBM-related falls; rhabdomyolysis if CK significantly elevated",
          "doseOptions": [
            {
              "text": "125-250 mL/h",
              "orderSentence": "IV fluids (normal saline) 125-250 mL/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "125-250 mL/h NS for hydration; increase to 200-300 mL/h if CK >5000 (rare in IBM but possible with falls/crush)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "dehydration-volume-repletion": {
          "indication": "Dehydration; volume repletion",
          "doseOptions": [
            {
              "text": "1000 mL",
              "orderSentence": "IV fluids (NS or LR) 1000 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS or LR 1L bolus then 75-125 mL/hr maintenance",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "dehydration-fall-related-injury-rhabdomyolysis-rare-aspirati": {
          "indication": "Dehydration; fall-related injury; rhabdomyolysis (rare); aspiration pneumonia hydration support",
          "doseOptions": [
            {
              "text": "125 mL/h",
              "orderSentence": "IV fluids (normal saline) 125 mL/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "125-250 mL/h NS for hydration; increase rate if CK significantly elevated; monitor for heart failure given cardiac involvement in DM",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Fluid overload",
          "Fluid overload, severe hyponatremia",
          "Heart failure",
          "Heart failure, volume overload",
          "SIADH (restrict if Na <130)",
          "Volume overload",
          "severe hyponatremia (use caution with rate)",
          "volume overload",
          "volume overload (common cardiac comorbidity in DM1)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP response",
          "Electrolytes q12-24h",
          "I/O",
          "I/O, BP, Na",
          "I/O, electrolytes",
          "I/O, electrolytes, edema",
          "Supportive care",
          "Urine output",
          "Volume status",
          "avoid rapid correction of hyponatremia (max 8-10 mEq/L per 24h)",
          "cardiac status",
          "correct volume depletion",
          "daily weight",
          "electrolytes",
          "fluid balance",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 12,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "als",
        "chronic-migraine",
        "huntingtons-disease",
        "inclusion-body-myositis",
        "migraine",
        "myasthenia-gravis-crisis",
        "myotonic-dystrophy",
        "new-onset-seizure",
        "small-fiber-neuropathy",
        "vertigo-dizziness-evaluation",
        "viral-meningitis"
      ]
    },
    "iv-immunoglobulin": {
      "id": "iv-immunoglobulin",
      "name": "IV immunoglobulin (IVIG) (for severe Bannwarth syndrome -- rare)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "severe-refractory-painful-radiculoneuritis-bannwarth-syndrom": {
          "indication": "Severe, refractory painful radiculoneuritis (Bannwarth syndrome) not responding to antibiotics and analgesics; limited evidence; case reports only",
          "doseOptions": [
            {
              "text": "0.4 g/kg/day x 5 days",
              "orderSentence": "IV immunoglobulin (IVIG) (for severe Bannwarth syndrome -- rare) 0.4 g/kg/day x 5 days IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV for 5 days; infuse slowly starting at 0.5 mL/kg/h; premedicate with acetaminophen and diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "IgA deficiency (anaphylaxis risk)",
          "hypercoagulability",
          "renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "Renal function",
          "consider IgA level before first dose",
          "infusion reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "lyme-neuroborreliosis"
      ]
    },
    "iv-iron": {
      "id": "iv-iron",
      "name": "IV iron (ferric carboxymaltose) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "IV iron (ferric carboxymaltose) (CPT 96365) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV once (if oral intolerant or severe deficiency); may repeat",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "restless-legs-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Iron overload, infection"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ferritin in 8 weeks",
          "Helpful during transition",
          "faster response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "restless-legs-syndrome"
      ]
    },
    "iv-iron-sucrose": {
      "id": "iv-iron-sucrose",
      "name": "IV iron sucrose (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "IV iron sucrose (CPT 96365) 200 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg IV × 5 doses over 2 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "restless-legs-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "restless-legs-syndrome"
      ]
    },
    "iv-isotonic-fluids": {
      "id": "iv-isotonic-fluids",
      "name": "IV isotonic fluids (euvolemia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "maintain-euvolemia-to-prevent-worsening-of-vasoconstriction-": {
          "indication": "Maintain euvolemia to prevent worsening of vasoconstriction-related ischemia; dehydration may exacerbate vasospasm",
          "doseOptions": [
            {
              "text": "100 mL/h",
              "orderSentence": "IV isotonic fluids (euvolemia) 100 mL/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS at 75-125 mL/h; titrate to maintain euvolemia; avoid both hypovolemia and fluid overload",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-1.5 mL/kg",
              "orderSentence": "IV isotonic fluids (euvolemia) 1-1.5 mL/kg -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS at 1-1.5 mL/kg/h (80-125 mL/h); goal euvolemia. Avoid hypovolemia (worsens vasospasm) and avoid aggressive hypervolemia (no proven benefit; risk of pulmonary edema). Target CVP 5-8 or clinical euvolemia",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        },
        "volume-resuscitation-and-hydration-dehydration-worsens-heada": {
          "indication": "Volume resuscitation and hydration; dehydration worsens headache and may worsen CVT",
          "doseOptions": [
            {
              "text": "1-1.5 mL/kg/h",
              "orderSentence": "IV isotonic fluids (CPT 96360) 1-1.5 mL/kg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS at 1-1.5 mL/kg/h; goal euvolemia. Essential for pre-contrast hydration (CTA) and general resuscitation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CHF",
          "Volume overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CVP if central line",
          "I/O",
          "daily weights",
          "serum Na",
          "serum Na q6-8h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "rcvs",
        "subarachnoid-hemorrhage",
        "thunderclap-headache-evaluation"
      ]
    },
    "iv-ketorolac": {
      "id": "iv-ketorolac",
      "name": "IV ketorolac (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "15-30 mg",
              "orderSentence": "IV ketorolac (CPT 96374) 15-30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-30 mg IV q6h × 2-3 days (max 5 days)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal disease, GI bleeding"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "medication-overuse-headache"
      ]
    },
    "iv-lidocaine": {
      "id": "iv-lidocaine",
      "name": "IV lidocaine (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-3 mg/kg",
              "orderSentence": "IV lidocaine (CPT 96365) 1-3 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-3 mg/kg IV over 20-30 min (monitored setting); for severe refractory pain",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "trigeminal-neuralgia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cardiac conduction abnormalities"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous cardiac monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "trigeminal-neuralgia"
      ]
    },
    "iv-magnesium": {
      "id": "iv-magnesium",
      "name": "IV magnesium",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-2 g",
              "orderSentence": "IV magnesium 1-2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 g IV daily × 3-5 days",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Mg levels"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "medication-overuse-headache"
      ]
    },
    "iv-methylprednisolone": {
      "id": "iv-methylprednisolone",
      "name": "IV methylprednisolone (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "IV methylprednisolone (CPT 96365) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily x 3-5 days. CAUTION: steroids can transiently worsen MG in first 5-10 days — only initiate in monitored setting with respiratory support available. Some centers use slow oral prednisone uptitration instead",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "guillain-barre-syndrome",
            "acute-myelopathy"
          ]
        },
        "autoimmune-cerebellar-ataxia-anti-gad-paraneoplastic-ms-cere": {
          "indication": "Autoimmune cerebellar ataxia (anti-GAD, paraneoplastic); MS cerebellar relapse; acute inflammatory cerebellitis",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "IV methylprednisolone 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 3-5 days; infuse over 1 hour; may follow with oral prednisone taper",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "empiric-immunotherapy-trial-only-if-autoimmune-encephalitis-": {
          "indication": "Empiric immunotherapy trial ONLY if autoimmune encephalitis remains in differential; do NOT continue if CJD confirmed (steroids do not help CJD)",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "IV methylprednisolone (empiric trial) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily x 3-5 days; infuse over 1-2 hours; DISCONTINUE if CJD confirmed",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "suspected-autoimmune-encephalitis-hashimoto-encephalopathy-s": {
          "indication": "Suspected autoimmune encephalitis, Hashimoto encephalopathy (SREAT), neurosarcoidosis, CNS vasculitis",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "IV methylprednisolone (CPT 96365) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily x 3-5 days. Consider when autoimmune etiology suspected and workup pending. Document pre-treatment baseline exam.",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "Active infection (rule out first)",
          "Active infection, uncontrolled diabetes",
          "Active untreated infection",
          "Active untreated infection (relative — treat infection concurrently if needed)",
          "CJD confirmed (no benefit)",
          "GI bleeding",
          "Uncontrolled diabetes (relative), active infection (relative)",
          "psychosis",
          "uncertain prion disease (steroids do not help CJD and may mask diagnosis)",
          "uncontrolled diabetes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Blood glucose q6h",
          "FVC/NIF closely",
          "GI prophylaxis",
          "GI prophylaxis (PPI)",
          "Glucose q6h",
          "Glucose, BP, GI prophylaxis",
          "blood pressure",
          "clinical response assessment",
          "glucose q6h",
          "insomnia",
          "mood/sleep",
          "potassium",
          "psychosis (rare)",
          "response assessment",
          "taper plan",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "acute-myelopathy",
        "ataxia-evaluation",
        "creutzfeldt-jakob-disease",
        "guillain-barre-syndrome",
        "myasthenia-gravis-crisis",
        "rapidly-progressive-dementia"
      ]
    },
    "iv-methylprednisolone-oral-prednisone-taper": {
      "id": "iv-methylprednisolone-oral-prednisone-taper",
      "name": "IV methylprednisolone (CPT 96365) → oral prednisone taper",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1g",
              "orderSentence": "IV methylprednisolone (CPT 96365) → oral prednisone taper 1g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1g IV x 5d → prednisone 1 mg/kg/day with slow taper over 3-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose, BP, bone density, weight, mood"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "rapidly-progressive-dementia"
      ]
    },
    "iv-normal-saline": {
      "id": "iv-normal-saline",
      "name": "IV normal saline",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-1.5 mL/kg",
              "orderSentence": "IV normal saline (aggressive hydration) 1-1.5 mL/kg -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 mL/kg/h continuous to prevent acyclovir nephrotoxicity; bolus 500-1000 mL if dehydrated",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hsv-encephalitis",
            "acute-ischemic-stroke",
            "bacterial-meningitis"
          ]
        },
        "volume-resuscitation-maintain-hydration-for-acyclovir-cleara": {
          "indication": "Volume resuscitation; maintain hydration for acyclovir clearance (prevent crystal nephropathy); correct dehydration from poor oral intake, vomiting",
          "doseOptions": [
            {
              "text": "1-1.5 mL/kg/h",
              "orderSentence": "IV normal saline 1-1.5 mL/kg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 mL/kg/h continuous maintenance; bolus 500-1000 mL if dehydrated or hypotensive",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "isotonic-fluid-resuscitation-and-maintenance-in-acute-dissec": {
          "indication": "Isotonic fluid resuscitation and maintenance in acute dissection",
          "doseOptions": [
            {
              "text": "125-150 mL/h",
              "orderSentence": "IV normal saline 125-150 mL/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Isotonic fluids; avoid hypotonic solutions (cerebral edema risk); avoid dextrose-containing fluids (hyperglycemia worsens ischemic outcomes)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "maintain-hydration-during-iv-penicillin-therapy-prevent-volu": {
          "indication": "Maintain hydration during IV penicillin therapy; prevent volume depletion",
          "doseOptions": [
            {
              "text": "75-125 mL/h",
              "orderSentence": "IV normal saline (hydration) 75-125 mL/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75-125 mL/h IV maintenance; bolus 500-1000 mL if dehydrated",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "volume-resuscitation-and-symptom-relief-in-acute-sih-pdph": {
          "indication": "Volume resuscitation and symptom relief in acute SIH/PDPH",
          "doseOptions": [
            {
              "text": "75-150 mL/hr",
              "orderSentence": "IV normal saline 75-150 mL/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS at 75-150 mL/hr; bolus 1L if dehydrated; maintain euvolemia",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        },
        "dehydration-contributing-to-headache-pre-procedure-hydration": {
          "indication": "Dehydration contributing to headache; pre-procedure hydration (LP); NPO status",
          "doseOptions": [
            {
              "text": "1000 mL",
              "orderSentence": "IV normal saline (CPT 96360) 1000 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS 1L bolus over 1h, then 75-125 mL/hr maintenance",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "maintenance-fluids-avoid-hypotonic-solutions-which-worsen-ce": {
          "indication": "Maintenance fluids; avoid hypotonic solutions which worsen cerebral edema; euvolemia during corticosteroid therapy",
          "doseOptions": [
            {
              "text": "0.9% NaCl",
              "orderSentence": "IV normal saline (CPT 96360) 0.9% NaCl IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Isotonic fluids only; avoid D5W and half-normal saline; maintain euvolemia",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "maintenance-fluids-avoid-hypotonic-solutions-which-worsen-ce-2": {
          "indication": "Maintenance fluids; avoid hypotonic solutions which worsen cerebral edema",
          "doseOptions": [
            {
              "text": "0.9% NaCl",
              "orderSentence": "IV normal saline 0.9% NaCl IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Isotonic fluids only; avoid D5W and half-normal saline; maintain euvolemia",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "acute-symptomatic-orthostatic-hypotension-with-syncope-or-pr": {
          "indication": "Acute symptomatic orthostatic hypotension with syncope or presyncope; volume resuscitation",
          "doseOptions": [
            {
              "text": "500-1000 mL",
              "orderSentence": "IV normal saline (0.9% NaCl) 500-1000 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mL IV bolus over 1-2 hours; repeat as needed for symptomatic OH; avoid overhydration if supine hypertension",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CHF",
          "Decompensated heart failure, severe volume overload",
          "Heart failure, severe supine hypertension",
          "Heart failure, volume overload, renal failure",
          "Volume overload",
          "Volume overload, CHF"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP supine and standing, urine output, signs of volume overload",
          "Cr daily",
          "I/O",
          "I/O, daily weights, electrolytes",
          "I/O, electrolytes",
          "Intake/output, daily weights if admitted",
          "electrolytes",
          "electrolytes daily",
          "electrolytes q6-12h",
          "serum Na",
          "urine output >0.5 mL/kg/h",
          "watch for SIADH",
          "watch for SIADH (fluid restrict if Na <130)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 11,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "bacterial-meningitis",
        "brain-abscess",
        "cervical-artery-dissection",
        "headache-evaluation",
        "hsv-encephalitis",
        "low-pressure-headache",
        "multiple-system-atrophy",
        "neurocysticercosis",
        "neurosyphilis",
        "viral-meningitis"
      ]
    },
    "iv-normal-saline-bolus": {
      "id": "iv-normal-saline-bolus",
      "name": "IV normal saline bolus (CPT 96360)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "dehydration-commonly-accompanies-headache-empiric-rehydratio": {
          "indication": "Dehydration commonly accompanies headache; empiric rehydration",
          "doseOptions": [
            {
              "text": "500-1000 mL",
              "orderSentence": "IV normal saline bolus (CPT 96360) 500-1000 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS or LR 500-1000 mL IV bolus over 30-60 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart failure, volume overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "I/O, signs of fluid overload"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "headache-unspecified"
      ]
    },
    "iv-penicillin-g": {
      "id": "iv-penicillin-g",
      "name": "IV penicillin G",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "18-24 million units",
              "orderSentence": "IV penicillin G 18-24 million units IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "18-24 MU/day IV x 14 days",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RPR q3-6 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-myelopathy"
      ]
    },
    "iv-steroids": {
      "id": "iv-steroids",
      "name": "IV steroids (controversial) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "IV steroids (controversial) (CPT 96365) 250 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Methylprednisolone 250 mg IV q6h; short-term bridge only; can worsen IIH long-term",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "idiopathic-intracranial-hypertension"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Contraindicated for maintenance"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose",
          "short-term only"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "idiopathic-intracranial-hypertension"
      ]
    },
    "iv-valproate": {
      "id": "iv-valproate",
      "name": "IV valproate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500-1000 mg",
              "orderSentence": "IV valproate 500-1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mg IV BID × 3-5 days",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy, hepatic disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ammonia, LFTs"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "medication-overuse-headache"
      ]
    },
    "ivig": {
      "id": "ivig",
      "name": "IVIG (intravenous immunoglobulin) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2 g/kg",
              "orderSentence": "**IVIG (Intravenous Immunoglobulin)** (CPT 96365) 2 g/kg -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**First-line for MG crisis (with PLEX):** 2 g/kg total divided over 2-5 days (400 mg/kg/day x 5 days OR 1 g/kg/day x 2 days); **Onset:** 2-5 days; **Duration:** 3-6 weeks; **Pre-treatment:** Check IgA (IgA deficiency = anaphylaxis risk); renal function; volume status",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuromuscular-respiratory-failure",
            "myasthenia-gravis-crisis",
            "cidp",
            "diabetic-neuropathy",
            "status-epilepticus",
            "ms-new-diagnosis",
            "rapidly-progressive-dementia",
            "guillain-barre-syndrome",
            "myasthenia-gravis-new-diagnosis",
            "autoimmune-encephalitis"
          ]
        },
        "gbs-cidp-or-other-autoimmune-neuropathy-causing-paresthesia-": {
          "indication": "GBS, CIDP, or other autoimmune neuropathy causing paresthesia/weakness",
          "doseOptions": [
            {
              "text": "2 g/kg",
              "orderSentence": "IVIG (CPT 96365, 96366) 2 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g/kg divided over 2-5 days (induction); maintenance 0.4-1 g/kg every 2-4 weeks for CIDP",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "moderate-severe-dm-proderm-trial-dysphagia-steroid-refractor": {
          "indication": "Moderate-severe DM (ProDERM trial); dysphagia; steroid-refractory myositis; bridge therapy during steroid-sparing agent onset",
          "doseOptions": [
            {
              "text": "2 g/kg",
              "orderSentence": "IVIG (intravenous immunoglobulin) (CPT 96365) 2 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g/kg total divided over 2-5 days (e.g., 0.4 g/kg/day x 5 days); then 2 g/kg every 4 weeks as maintenance; start infusion slow and increase per protocol",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "maintenance-immunomodulation-for-dm-fda-evidence-from-proder": {
          "indication": "Maintenance immunomodulation for DM (FDA evidence from ProDERM); steroid-sparing; refractory disease",
          "doseOptions": [
            {
              "text": "2 g/kg",
              "orderSentence": "IVIG (maintenance) 2 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g/kg IV divided over 2-5 days every 4 weeks; may reduce frequency to q6-8 weeks if stable",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "steroid-refractory-he-relapsing-disease-steroid-contraindica": {
          "indication": "Steroid-refractory HE; relapsing disease; steroid contraindications",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIG (intravenous immunoglobulin) (CPT 96365) 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV x 5 days (total 2 g/kg); infuse per weight-based protocol; premedicate with acetaminophen, diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "multiply-relapsing-he-steroid-dependent": {
          "indication": "Multiply-relapsing HE; steroid-dependent",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIG (maintenance) 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg IV every 4 weeks (adjust per response)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "steroid-refractory-alternative-to-plex": {
          "indication": "Steroid-refractory (alternative to PLEX)",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIG 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day for 5 days (total 2 g/kg); infuse slowly day 1",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "autoimmune-sfn-sjogren-associated-anti-fgfr3-idiopathic-with": {
          "indication": "Autoimmune SFN (Sjogren-associated; anti-FGFR3+; idiopathic with evidence of inflammation)",
          "doseOptions": [
            {
              "text": "2 g/kg",
              "orderSentence": "IVIG 2 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g/kg divided over 2-5 days monthly; limited evidence; consider trial",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "adjunctive-therapy-in-refractory-cases-may-benefit-pacns-wit": {
          "indication": "Adjunctive therapy in refractory cases; may benefit PACNS with evidence of antibody-mediated component",
          "doseOptions": [
            {
              "text": "0.4 g/kg daily x 5 days",
              "orderSentence": "IVIG (intravenous immunoglobulin) 0.4 g/kg daily x 5 days IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV x 5 days (total 2 g/kg); infuse per weight-based protocol",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "ibm-related-dysphagia-unresponsive-to-conservative-measures-": {
          "indication": "IBM-related dysphagia unresponsive to conservative measures; NOT proven for limb weakness in IBM; limited evidence of transient swallowing improvement; time-limited trial (3-6 months) with objective assessment",
          "doseOptions": [
            {
              "text": "2 g/kg",
              "orderSentence": "IVIG (intravenous immunoglobulin) (CPT 96365) 2 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g/kg total divided over 2-5 days (e.g., 0.4 g/kg/day x 5 days) every 4 weeks; assess dysphagia response objectively at 3 and 6 months; discontinue if no improvement",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "alternative-first-line-acute-treatment-especially-useful-if-": {
          "indication": "Alternative first-line acute treatment; especially useful if steroids contraindicated or if steroid-refractory; strong evidence in MOGAD",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIG (intravenous immunoglobulin) (CPT 96365) 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV x 5 days (total 2 g/kg); infuse per weight-based protocol; premedicate with acetaminophen 650 mg and diphenhydramine 25 mg",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "steroid-refractory-attack-second-line-acute-treatment-after-": {
          "indication": "Steroid-refractory attack; second-line acute treatment after IV steroids",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIG (if not used as first-line) 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV x 5 days (total 2 g/kg); premedicate with acetaminophen and diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "alternative-rescue-therapy-when-plex-unavailable": {
          "indication": "Alternative rescue therapy when PLEX unavailable",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIG (if PLEX unavailable or contraindicated) 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV x 5 days (total 2 g/kg); infuse per weight-based protocol",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "cidp-mmn-gbs": {
          "indication": "CIDP, MMN, GBS",
          "doseOptions": [
            {
              "text": "2 g/kg",
              "orderSentence": "IVIG 2 g/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g/kg divided over 2-5 days (induction); maintenance 0.4-1 g/kg every 2-4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "acute-lems-exacerbation-with-significant-functional-impairme": {
          "indication": "Acute LEMS exacerbation with significant functional impairment; rapid symptom control; pre-treatment or perioperative optimization",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIg (intravenous immunoglobulin) (CPT 96365) 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV x 5 days (total 2 g/kg) OR 1 g/kg/day x 2 days; infuse over 4-6 hours; slow initial rate per protocol",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "chronic-immunomodulation-for-lems-with-ongoing-functional-im": {
          "indication": "Chronic immunomodulation for LEMS with ongoing functional impairment despite 3,4-DAP and oral immunotherapy",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "IVIg (maintenance) 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 g/kg IV every 4 weeks (may adjust to 0.4-1 g/kg based on response); infuse over 4-6 hours",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "autoimmune-cerebellar-ataxia-anti-gad-paraneoplastic-cerebel": {
          "indication": "Autoimmune cerebellar ataxia (anti-GAD); paraneoplastic cerebellar degeneration; Miller Fisher syndrome (GBS variant with ataxia); post-infectious cerebellitis",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIG (intravenous immunoglobulin) 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV for 5 days (total 2 g/kg); infuse slowly — start 0.5 mL/kg/h, increase to max 4 mL/kg/h; premedicate with acetaminophen and diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "first-line-immunotherapy-for-sps-class-i-evidence-dalakas-20": {
          "indication": "First-line immunotherapy for SPS; Class I evidence (Dalakas 2001 NEJM RCT); reduces stiffness and improves function",
          "doseOptions": [
            {
              "text": "0.4 g/kg/day",
              "orderSentence": "IVIg (intravenous immunoglobulin) 0.4 g/kg/day IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV for 5 days (total 2 g/kg); infuse initial rate 0.5 mL/kg/hr, increase q30min by 0.5 mL/kg/hr to max 4 mL/kg/hr; premedicate with acetaminophen and diphenhydramine; repeat every 4-6 weeks for maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "first-line-immunotherapy-antibody-mediated-mechanism-given-c": {
          "indication": "First-line immunotherapy; antibody-mediated mechanism; given concurrently or sequentially with IV steroids",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIG (intravenous immunoglobulin) 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV x 5 days (total 2 g/kg); infuse per weight-based protocol; premedicate with acetaminophen, diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "maintenance-immunotherapy-for-partially-responsive-paraneopl": {
          "indication": "Maintenance immunotherapy for partially responsive paraneoplastic syndrome; especially cell-surface antibody syndromes",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIG (maintenance) 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg IV every 4 weeks OR 1 g/kg IV every 4-6 weeks; adjust per response",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "first-line-therapy-in-susac-syndrome-along-with-corticostero": {
          "indication": "FIRST-LINE therapy in Susac syndrome (along with corticosteroids); anti-endothelial cell antibody neutralization; immunomodulation; start early and aggressively",
          "doseOptions": [
            {
              "text": "0.4 g/kg daily",
              "orderSentence": "IVIG (intravenous immunoglobulin) (CPT 96365) 0.4 g/kg daily IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV x 5 days (total 2 g/kg) for induction; infuse per weight-based protocol; premedicate with acetaminophen 650 mg PO and diphenhydramine 25-50 mg IV/PO; followed by maintenance IVIG (see Section 3D)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "severe-refractory-neuralgic-amyotrophy-diabetic-amyotrophy-d": {
          "indication": "Severe/refractory neuralgic amyotrophy; diabetic amyotrophy (DLRPN) with vasculitic features; atypical inflammatory plexopathy",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "IVIg (intravenous immunoglobulin) (CPT 96365, 96366) 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day IV x 5 days (total 2 g/kg); repeat q4 weeks x 3-6 months if responsive",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "IgA deficiency",
          "IgA deficiency (anaphylaxis risk -- check IgA level before first dose)",
          "IgA deficiency (anaphylaxis risk -- check IgA level)",
          "IgA deficiency (anaphylaxis risk — check IgA level)",
          "IgA deficiency (anaphylaxis risk — use IgA-depleted product)",
          "IgA deficiency (anaphylaxis risk)",
          "IgA deficiency (check IgA level first)",
          "IgA deficiency (use IgA-depleted product)",
          "IgA deficiency (use IgA-depleted product), renal failure, thrombosis history",
          "IgA deficiency (use IgA-depleted product), renal failure, thrombosis risk",
          "IgA deficiency (use IgA-depleted)",
          "IgA deficiency, renal failure, thrombosis risk",
          "acute renal failure",
          "anaphylaxis to immunoglobulin",
          "hypercoagulable state",
          "hypercoagulable states (thrombosis risk)",
          "recent thromboembolic event",
          "recent thrombotic event",
          "renal failure",
          "renal failure (adjust infusion rate)",
          "renal failure (use sucrose-free formulation)",
          "renal impairment",
          "renal insufficiency",
          "renal insufficiency (use sucrose-free)",
          "severe renal impairment",
          "thromboembolic history",
          "thrombosis risk",
          "thrombotic risk",
          "volume overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "DVT/PE risk",
          "Efficacy equivalent to PLEX (RCTs)",
          "IgA level",
          "IgA level before first dose",
          "IgA level before first infusion",
          "IgG levels",
          "IgG trough levels",
          "MBSS at 3 and 6 months to assess dysphagia response",
          "Pre-infusion IgA level",
          "Pre-infusion renal function",
          "Pre-infusion: IgA level, renal function, CBC",
          "Renal function",
          "Renal function (BMP before and after)",
          "Renal function (BUN/Cr before each cycle)",
          "Renal function daily",
          "Renal function, headache, aseptic meningitis, thrombosis",
          "Renal function, headache, thrombosis",
          "Renal function, headache, thrombosis, infusion reactions",
          "Renal function, signs of aseptic meningitis, thrombosis",
          "Vital signs q15min during first infusion",
          "Vital signs q15min during first infusion, then q30min",
          "Vital signs q15min first infusion",
          "aseptic meningitis",
          "check IgA before first dose",
          "check IgA level before first dose",
          "during: vital signs q15 min first hour",
          "during: vital signs q15 min first hour then q1h",
          "easier logistics than PLEX",
          "headache",
          "headache (aseptic meningitis in 5-10%)",
          "headache (aseptic meningitis)",
          "hemolysis (DAT, LDH, haptoglobin)",
          "hemolysis (haptoglobin, LDH, direct Coombs if symptoms)",
          "hemolysis (haptoglobin, LDH, direct Coombs)",
          "infusion reaction vitals q15 min",
          "infusion reactions",
          "renal function",
          "renal function (BUN, Cr)",
          "renal function (BUN, Cr) before and after",
          "renal function (BUN, Cr) before and during",
          "renal function daily",
          "renal function post-infusion",
          "renal function trending",
          "serum IgA level before initiation",
          "side effects: headache (aseptic meningitis), renal failure (sucrose-containing products), thrombosis, hemolysis",
          "slower onset than PLEX",
          "thrombosis",
          "thrombosis risk",
          "thrombosis surveillance",
          "thrombotic events",
          "thrombotic risk",
          "vital signs",
          "vital signs during infusion",
          "vital signs q15min during first infusion then q30-60min",
          "volume overload"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 33,
      "_sourcePlans": [
        "ataxia-evaluation",
        "autoimmune-encephalitis",
        "cidp",
        "cns-vasculitis",
        "diabetic-neuropathy",
        "guillain-barre-syndrome",
        "hashimotos-encephalopathy",
        "inclusion-body-myositis",
        "inflammatory-myopathy",
        "lambert-eaton-syndrome",
        "mogad",
        "ms-new-diagnosis",
        "myasthenia-gravis-crisis",
        "myasthenia-gravis-new-diagnosis",
        "neuromuscular-respiratory-failure",
        "nmosd",
        "optic-neuritis",
        "paraneoplastic-neurological-syndrome",
        "paresthesia-numbness-tingling",
        "peripheral-neuropathy",
        "plexopathy",
        "rapidly-progressive-dementia",
        "small-fiber-neuropathy",
        "status-epilepticus",
        "stiff-person-syndrome",
        "susac-syndrome"
      ]
    },
    "ivig-maintenance": {
      "id": "ivig-maintenance",
      "name": "IVIG maintenance (most evidence in MOGAD)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "first-line-maintenance-immunotherapy-for-relapsing-mogad-str": {
          "indication": "First-line maintenance immunotherapy for relapsing MOGAD; strongest evidence base among maintenance options; reduces relapse rate and steroid dependence",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "IVIG maintenance (most evidence in MOGAD) 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4-2 g/kg IV every 4-6 weeks; typical starting dose 1 g/kg monthly; adjust dose/interval based on relapse frequency and trough IgG levels",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "maintenance-immunomodulation-following-acute-induction-backb": {
          "indication": "Maintenance immunomodulation following acute induction; backbone of long-term Susac management; prevents relapse and further end-organ damage",
          "doseOptions": [
            {
              "text": "0.4 g/kg monthly",
              "orderSentence": "IVIG maintenance (CPT 96365) 0.4 g/kg monthly IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Maintenance: 0.4 g/kg IV monthly OR 2 g/kg IV divided over 2-5 days every 4 weeks; taper to q6-8 weeks after 12-24 months of stability; minimum 2 years of treatment recommended",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "IgA deficiency",
          "IgA deficiency (anaphylaxis risk)",
          "acute renal failure",
          "hyperviscosity syndrome",
          "recent thromboembolic event",
          "recent thromboembolism",
          "uncontrolled renal disease",
          "volume overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "IgG trough levels (target >800 mg/dL)",
          "IgG trough levels q3 months (target >800 mg/dL)",
          "Renal function before each infusion",
          "anaphylaxis monitoring",
          "headache (aseptic meningitis)",
          "hemolysis (DAT if anemia)",
          "renal function",
          "skin reactions",
          "thrombosis risk",
          "thrombosis surveillance"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "mogad",
        "susac-syndrome"
      ]
    },
    "ketamine": {
      "id": "ketamine",
      "name": "Ketamine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "adjunctive-for-refractory-post-anoxic-seizures-nmda-antagoni": {
          "indication": "Adjunctive for refractory post-anoxic seizures; NMDA antagonism addresses late-stage glutamate excitotoxicity",
          "doseOptions": [
            {
              "text": "1-2 mg/kg",
              "orderSentence": "Ketamine 1-2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg/kg IV bolus; then 1-5 mg/kg/h infusion; titrate to cEEG",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "status-migrainosus-refractory-to-dhe": {
          "indication": "Status migrainosus refractory to DHE",
          "doseOptions": [
            {
              "text": "0.1 mg/kg/hr",
              "orderSentence": "Ketamine 0.1 mg/kg/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1-0.3 mg/kg/hr continuous infusion for 24-48 hr; subanesthetic dosing only",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Elevated ICP (relative — disputed)",
          "Uncontrolled HTN",
          "elevated ICP",
          "pregnancy",
          "psychosis history",
          "severe hypertension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP (may increase)",
          "Dissociation",
          "HR",
          "cEEG",
          "oral secretions",
          "requires continuous cardiac monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "migraine-with-aura"
      ]
    },
    "ketamine-infusion": {
      "id": "ketamine-infusion",
      "name": "Ketamine infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-2 mg/kg",
              "orderSentence": "Ketamine infusion 1-2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 1-2 mg/kg IV bolus; Infusion: start 1 mg/kg/hr, titrate by 0.5 mg/kg/hr q15-30min; max 5 mg/kg/hr",
          "settings": {
            "ED": "URGENT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus",
            "autoimmune-encephalitis"
          ]
        },
        "super-refractory-ncse-nmda-receptor-antagonist-different-mec": {
          "indication": "Super-refractory NCSE; NMDA receptor antagonist (different mechanism); may add to midazolam/propofol",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Ketamine infusion 1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bolus: 1-3 mg/kg IV; Infusion: 0.5-5 mg/kg/hr; does not require intubation at lower doses",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Uncontrolled hypertension",
          "Uncontrolled hypertension, elevated ICP (relative - actually may be neuroprotective)",
          "acute psychosis",
          "raised ICP (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Continuous EEG",
          "HR",
          "cEEG, BP (may increase), HR",
          "emergence phenomena",
          "hepatic function",
          "laryngospasm risk",
          "less hypotension than other anesthetics"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "ncse",
        "status-epilepticus"
      ]
    },
    "ketamine-iv-sub-anesthetic": {
      "id": "ketamine-iv-sub-anesthetic",
      "name": "Ketamine IV sub-anesthetic",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-status-migrainosus-not-responding-to-standard-the": {
          "indication": "Refractory status migrainosus not responding to standard therapies; NMDA receptor antagonism disrupts central sensitization",
          "doseOptions": [
            {
              "text": "0.1 mg/kg bolus",
              "orderSentence": "Ketamine IV sub-anesthetic 0.1 mg/kg bolus IV"
            },
            {
              "text": "0.1-0.5 mg/kg/hr",
              "orderSentence": "Ketamine IV sub-anesthetic 0.1-0.5 mg/kg/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV bolus, then 0.1-0.5 mg/kg/hr infusion; titrate by 0.1 mg/kg/hr q30min; max 1 mg/kg/hr; typical duration 24-48h",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Uncontrolled hypertension, active psychosis, elevated ICP (relative), age <18"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP, HR (may increase), dissociative symptoms, nystagmus, sedation level, psychiatric effects"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "ketamine-midazolam": {
      "id": "ketamine-midazolam",
      "name": "Ketamine + Midazolam (combination)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Ketamine + Midazolam (combination) 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ketamine load 1 mg/kg + Midazolam load 0.2 mg/kg; then dual infusions per above",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per individual agents"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "2024 data: combination may reduce SE duration faster than midazolam alone"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-epilepticus"
      ]
    },
    "ketogenic-diet": {
      "id": "ketogenic-diet",
      "name": "Ketogenic diet (classic 4:1)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Dietary"
      ],
      "formulations": [],
      "contexts": {
        "dre-especially-glut1-deficiency-and-pdc-deficiency-first-lin": {
          "indication": "DRE, especially GLUT1 deficiency and PDC deficiency (first-line); 50% seizure reduction in ~50% of adults; mechanism involves ketone bodies as alternative fuel",
          "doseOptions": [
            {
              "text": "4:1 fat-to-carbohydrate+protein ratio",
              "orderSentence": "Ketogenic diet (classic 4:1) 4:1 fat-to-carbohydrate+protein ratio Dietary"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Initiate under dietitian supervision; 4:1 ratio (4g fat per 1g carb+protein); caloric restriction not required in adults; monitor ketosis with urine/serum ketones; 3-month trial minimum",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pyruvate carboxylase deficiency",
          "fatty acid oxidation disorders",
          "porphyria",
          "severe liver disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Serum ketones, lipids, CMP q3 months",
          "cardiac monitoring if prolonged",
          "growth parameters",
          "kidney stones (supplement citrate)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "ketorolac": {
      "id": "ketorolac",
      "name": "Ketorolac",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM",
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "severe-headache-refractory-to-oral-analgesics-potent-anti-in": {
          "indication": "Severe headache refractory to oral analgesics; potent anti-inflammatory; short-term use only",
          "doseOptions": [
            {
              "text": "15-30 mg",
              "orderSentence": "Ketorolac 15-30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-30 mg IV q6h (15 mg if age >65, renal impairment, or weight <50 kg); max 5 days; transition to oral NSAID",
          "settings": {
            "ED": "STAT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "first-line-nsaid-for-acute-headache-in-ed-effective-regardle": {
          "indication": "First-line NSAID for acute headache in ED; effective regardless of headache subtype",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Ketorolac (CPT 96374) 30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg IV push (15 mg if age >65, CrCl <50, or weight <50 kg); max 5 days total NSAID use",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "first-line-nsaid-for-acute-headache-when-iv-access-unavailab": {
          "indication": "First-line NSAID for acute headache when IV access unavailable",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Ketorolac (CPT 96372) 60 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg IM once (30 mg if age >65, CrCl <50, or weight <50 kg); max 5 days total NSAID use",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "moderate-severe-headache-pain-during-workup": {
          "indication": "Moderate-severe headache pain during workup",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Ketorolac (CPT 96374) 30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg IV once (15 mg if >65y, CrCl <50, or weight <50 kg); max 2 doses in 24h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "nsaid-for-severe-thunderclap-headache-refractory-to-acetamin": {
          "indication": "NSAID for severe thunderclap headache refractory to acetaminophen; short-course only",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Ketorolac 30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg IV x1, then 15-30 mg IV q6h PRN; max 5 days total; reduce to 15 mg in elderly or renal impairment",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "acute-pain-anti-inflammatory": {
          "indication": "Acute pain, anti-inflammatory",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Ketorolac 30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg IV/IM q6h; max 5 days; reduce to 15 mg if elderly/renal impairment",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "severe-acute-tth-in-ed-nsaid-responsive-headache": {
          "indication": "Severe acute TTH in ED; NSAID-responsive headache",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Ketorolac 30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg IV x1 (15 mg if >65y, renal impairment, or <50 kg); do not exceed 5 days total NSAIDs",
          "settings": {
            "ED": "STAT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "acute-severe-plexopathy-pain-short-term": {
          "indication": "Acute severe plexopathy pain (short-term)",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Ketorolac (CPT 96374 when IV) 30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg IV/IM q6h; max 5 days; reduce to 15 mg if elderly or renal impairment",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        },
        "first-line-acute-migraine-with-aura-in-ed": {
          "indication": "First-line acute migraine with aura in ED",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Ketorolac 30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg IV (15 mg if >65y, renal impairment, or <50 kg); max 5 days NSAIDs",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active GI bleeding",
          "CrCl <30",
          "GI bleed",
          "GI bleed history",
          "Renal disease (CrCl <30), active GI bleeding, anticoagulation, third trimester pregnancy",
          "Renal impairment",
          "Renal impairment (CrCl <30)",
          "active GI bleed",
          "age >65 (dose reduce)",
          "anticoagulation with high bleed risk",
          "aspirin allergy",
          "aspirin/NSAID allergy",
          "coagulopathy",
          "concurrent anticoagulants",
          "concurrent anticoagulation",
          "known SAH with active bleeding risk",
          "post-CABG",
          "renal impairment (CrCl <30)",
          "third trimester",
          "third trimester pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI bleeding",
          "GI symptoms",
          "Renal function",
          "Renal function daily",
          "Renal function if repeated dosing",
          "Renal function, bleeding",
          "bleeding",
          "limit to 5 days maximum"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 9,
      "_sourcePlans": [
        "headache-evaluation",
        "headache-unspecified",
        "migraine-with-aura",
        "plexopathy",
        "radiculopathy",
        "rcvs",
        "tension-headache",
        "viral-meningitis"
      ]
    },
    "ketorolac-iv": {
      "id": "ketorolac-iv",
      "name": "Ketorolac IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Ketorolac IV 30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg IV (15 mg if >65y or CrCl <50); max 2 doses",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "adjunctive-analgesic-anti-inflammatory": {
          "indication": "Adjunctive analgesic; anti-inflammatory",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Ketorolac IV 30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg IV once (15 mg if age >65 or CrCl <50); max 5 days total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "moderate-severe-headache-pain-use-only-after-sah-excluded-or": {
          "indication": "Moderate-severe headache pain; use ONLY after SAH excluded or deemed unlikely (affects platelet function)",
          "doseOptions": [
            {
              "text": "15-30 mg",
              "orderSentence": "Ketorolac IV (CPT 96374) 15-30 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-30 mg IV once; max 120 mg/day. Do NOT use if SAH suspected (platelet inhibition increases re-bleed risk); do NOT use if LP planned within 24h (relative)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "potent-parenteral-nsaid-for-acute-pain-relief-synergistic-wi": {
          "indication": "Potent parenteral NSAID for acute pain relief; synergistic with antiemetics",
          "doseOptions": [
            {
              "text": "30 mg IV once",
              "orderSentence": "Ketorolac IV 30 mg IV once IV"
            },
            {
              "text": "15 mg IV once",
              "orderSentence": "Ketorolac IV 15 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg IV push (15 mg if age >65, CrCl <50, or weight <50 kg); max 2 doses in 24h; max 5 days total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active GI bleeding, renal insufficiency (CrCl <30), coagulopathy, concurrent anticoagulation, third trimester pregnancy",
          "GI bleed",
          "Renal disease, GI bleeding, anticoagulation",
          "Renal disease, GI bleeding, anticoagulation, recent bypass surgery",
          "SAH suspected",
          "active bleeding",
          "coagulopathy",
          "renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "Renal function",
          "Renal function, GI symptoms",
          "Renal function, GI symptoms, bleeding"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "status-migrainosus",
        "thunderclap-headache-evaluation"
      ]
    },
    "l-carnitine": {
      "id": "l-carnitine",
      "name": "L-carnitine (VPA-induced hyperammonemia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "elevated-ammonia-on-valproic-acid": {
          "indication": "Elevated ammonia on valproic acid",
          "doseOptions": [
            {
              "text": "100 mg/kg",
              "orderSentence": "L-carnitine (VPA-induced hyperammonemia) 100 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg/kg IV (max 6g) loading, then 50 mg/kg/day divided q6h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ammonia level",
          "clinical response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ncse"
      ]
    },
    "labetalol": {
      "id": "labetalol",
      "name": "Labetalol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-antihypertensive-for-acute-severe-hypertension-in": {
          "indication": "First-line antihypertensive for acute severe hypertension in pregnancy (SBP ≥160 or DBP ≥110); prevents stroke",
          "doseOptions": [
            {
              "text": "20 mg IV",
              "orderSentence": "Labetalol 20 mg IV IV"
            },
            {
              "text": "40 mg IV",
              "orderSentence": "Labetalol 40 mg IV IV"
            },
            {
              "text": "80 mg IV",
              "orderSentence": "Labetalol 80 mg IV IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg IV push over 2 min; if BP not controlled in 10 min → 40 mg; then 80 mg; max 300 mg total; then start infusion 1-2 mg/min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "transition-from-iv-to-oral-bp-control-in-preeclampsia-mainte": {
          "indication": "Transition from IV to oral BP control in preeclampsia; maintenance antihypertensive",
          "doseOptions": [
            {
              "text": "100 mg BID",
              "orderSentence": "Labetalol (oral maintenance) 100 mg BID PO"
            },
            {
              "text": "200 mg BID",
              "orderSentence": "Labetalol (oral maintenance) 200 mg BID PO"
            },
            {
              "text": "300 mg TID",
              "orderSentence": "Labetalol (oral maintenance) 300 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO BID; increase by 100 mg q12h as needed; target BP <150/100 antepartum; max 2400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "alternative-perioperative-bp-control-combined-alpha-beta-blo": {
          "indication": "Alternative perioperative BP control; combined alpha/beta blocker; useful when HR also elevated",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Labetalol (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV push q10-15min; or infusion 1-2 mg/min; max 300 mg total; target SBP 100-150 post-CEA",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Asthma",
          "Severe bradycardia",
          "bradycardia",
          "cardiogenic shock",
          "decompensated CHF",
          "decompensated HF",
          "decompensated heart failure",
          "heart rate <60",
          "second/third degree heart block",
          "second/third-degree heart block",
          "severe asthma/COPD"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP q5 min during IV bolus",
          "HR",
          "bronchospasm",
          "fetal monitoring",
          "fetal monitoring (labetalol safe in pregnancy)",
          "heart block",
          "heart rate"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "carotid-stenosis",
        "eclampsia-seizure-pregnancy"
      ]
    },
    "labetalol-iv": {
      "id": "labetalol-iv",
      "name": "Labetalol IV (hypertensive emergency in encephalopathy)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "hypertensive-crisis-associated-with-encephalopathy": {
          "indication": "Hypertensive crisis associated with encephalopathy",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Labetalol IV (hypertensive emergency in encephalopathy) 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV q10-15min PRN; or infusion 0.5-2 mg/min; target SBP <180",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "bp-control-in-acute-dissection-with-stroke-target-bp-185-110": {
          "indication": "BP control in acute dissection with stroke; target BP <185/110 if tPA candidate; permissive hypertension if no tPA",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Labetalol IV 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV over 1-2 min; may repeat q10-20min; max 300 mg. Target: <185/110 pre-tPA; <180/105 post-tPA; <220/120 if no tPA",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "alternative-to-nicardipine-for-bp-control": {
          "indication": "Alternative to nicardipine for BP control",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Labetalol IV (CPT 96374) 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV q10-20min; max 300 mg. Alternative first-line for hypertensive emergency",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Labetalol IV (autonomic hypertensive crisis) 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV q10-15min PRN; or infusion 0.5-2 mg/min; target SBP <180",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "AV block",
          "Heart block",
          "Heart block (2nd/3rd degree)",
          "Severe bradycardia",
          "asthma",
          "asthma/severe COPD",
          "cocaine use (relative — unopposed alpha)",
          "decompensated CHF",
          "decompensated HF",
          "severe bradycardia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP continuous",
          "BP continuous monitoring",
          "Continuous BP",
          "HR",
          "Heart rate",
          "I/O"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "cervical-artery-dissection",
        "hashimotos-encephalopathy",
        "thunderclap-headache-evaluation"
      ]
    },
    "lacosamide": {
      "id": "lacosamide",
      "name": "Lacosamide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/PO",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "seizures-second-line-asm-or-adjunctive-therapy": {
          "indication": "Seizures; second-line ASM or adjunctive therapy",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Lacosamide 100 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg BID (IV or PO); increase by 50 mg/dose q1wk; max 400 mg/day; transition to PO",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease",
            "neurosarcoidosis"
          ]
        },
        "alternative-or-adjunct-aed-for-seizures-minimal-drug-interac": {
          "indication": "Alternative or adjunct AED for seizures; minimal drug interactions with chemotherapy",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Lacosamide 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg BID; titrate by 50 mg/dose weekly; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma",
            "primary-cns-lymphoma"
          ]
        },
        "dre-adjunctive-therapy-sodium-channel-slow-inactivation-well": {
          "indication": "DRE adjunctive therapy; sodium channel (slow inactivation); well tolerated; IV formulation for acute use",
          "doseOptions": [
            {
              "text": "50 mg BID",
              "orderSentence": "Lacosamide (Vimpat) 50 mg BID PO"
            },
            {
              "text": "100 mg BID",
              "orderSentence": "Lacosamide (Vimpat) 100 mg BID PO"
            },
            {
              "text": "150 mg BID",
              "orderSentence": "Lacosamide (Vimpat) 150 mg BID PO"
            },
            {
              "text": "200 mg BID",
              "orderSentence": "Lacosamide (Vimpat) 200 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg BID; increase by 50 mg/dose weekly; target 100-200 mg BID; max 400 mg/day; IV loading 200 mg over 15-60 min if needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "second-line-or-adjunctive-for-focal-seizures": {
          "indication": "Second-line or adjunctive for focal seizures",
          "doseOptions": [
            {
              "text": "200-400 mg",
              "orderSentence": "Lacosamide (second-line ASM) 200-400 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 200-400 mg IV; Maintenance: 100-200 mg IV/PO BID (max 400 mg/day)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "seizure-management-adjunctive": {
          "indication": "Seizure management (adjunctive)",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Lacosamide 200 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg IV/PO load; then 100-200 mg BID; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "hsv-encephalitis"
          ]
        },
        "sodium-channel-blocker-well-tolerated": {
          "indication": "Sodium channel blocker; well-tolerated",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Lacosamide 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg BID; increase by 50 mg/day weekly; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Lacosamide (if not tried) 400 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400 mg IV, then 200-400 mg BID",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-epilepticus",
            "autoimmune-encephalitis"
          ]
        },
        "seizures-refractory-to-levetiracetam": {
          "indication": "Seizures refractory to levetiracetam",
          "doseOptions": [
            {
              "text": "200 mg BID",
              "orderSentence": "Lacosamide (second-line ASM) 200 mg BID IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 200-400 mg IV; Maintenance: 100-200 mg IV/PO BID (max 400 mg/day)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "second-line-aed-for-ncc-related-seizures-no-enzyme-induction": {
          "indication": "Second-line AED for NCC-related seizures; no enzyme induction (preferred over carbamazepine/phenytoin which reduce praziquantel levels)",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Lacosamide (CPT 96374) 200 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg IV load, then 100-200 mg PO BID; max 400 mg/day; no significant drug interactions with antiparasitic agents",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "continue-after-loading-favorable-interaction-profile": {
          "indication": "Continue after loading; favorable interaction profile",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Lacosamide (maintenance) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-200 mg PO/IV BID (max 400 mg/day)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "post-anoxic-refractory-seizures-not-controlled-by-levetirace": {
          "indication": "Post-anoxic refractory seizures not controlled by levetiracetam and valproic acid",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Lacosamide 200 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg IV load over 15 min; then 100-200 mg IV BID; target level 10-20 ug/mL",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "second-line-asm-for-seizures-favorable-drug-interaction-prof": {
          "indication": "Second-line ASM for seizures; favorable drug interaction profile with immunotherapy",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Lacosamide 100 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 200-400 mg IV; Maintenance: 100 mg BID, titrate to 200 mg BID; max 400 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "focal-epilepsy-adjunctive-or-monotherapy-well-tolerated-sodi": {
          "indication": "Focal epilepsy adjunctive or monotherapy; well tolerated; sodium channel slow inactivation",
          "doseOptions": [
            {
              "text": "50 mg BID",
              "orderSentence": "Lacosamide (Vimpat) 50 mg BID PO"
            },
            {
              "text": "100 mg BID",
              "orderSentence": "Lacosamide (Vimpat) 100 mg BID PO"
            },
            {
              "text": "150 mg BID",
              "orderSentence": "Lacosamide (Vimpat) 150 mg BID PO"
            },
            {
              "text": "200 mg BID",
              "orderSentence": "Lacosamide (Vimpat) 200 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg BID; increase by 50 mg/dose weekly; target 100-200 mg BID; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "alternative-or-adjunct-aed-for-seizures-from-meningioma-mini": {
          "indication": "Alternative or adjunct AED for seizures from meningioma; minimal drug interactions",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Lacosamide 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg BID; titrate by 50 mg/dose weekly; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "first-line-alternative": {
          "indication": "First-line alternative",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Lacosamide 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO BID; increase by 100 mg/day weekly; target 200-400 mg BID; max 400 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "2nd/3rd degree AV block",
          "AV block",
          "PR interval >200 ms",
          "PR prolongation",
          "PR prolongation >200 ms",
          "PR prolongation, 2nd/3rd degree AV block, severe hepatic impairment",
          "PR prolongation, AV block",
          "Second or third degree AV block (without pacemaker)",
          "Second/third degree AV block",
          "Second/third-degree AV block without pacemaker",
          "hepatic impairment",
          "known cardiac conduction disorders",
          "second/third-degree AV block",
          "second/third-degree heart block",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG",
          "ECG (PR interval)",
          "ECG (PR prolongation)",
          "ECG at baseline and dose changes",
          "ECG at baseline and with dose changes",
          "ECG for PR prolongation",
          "LFTs",
          "PR interval",
          "PR interval (prolongation dose-related)",
          "PR interval monitoring",
          "ataxia",
          "cardiac monitoring during IV load",
          "cardiac monitoring during load",
          "cardiac rhythm",
          "dizziness",
          "dizziness, diplopia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 18,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "autoimmune-encephalitis",
        "cerebral-venous-thrombosis",
        "drug-resistant-epilepsy",
        "epilepsy-chronic-management",
        "glioblastoma",
        "hashimotos-encephalopathy",
        "hsv-encephalitis",
        "meningioma",
        "ncse",
        "neuro-behcets-disease",
        "neurocysticercosis",
        "neurosarcoidosis",
        "new-onset-seizure",
        "paraneoplastic-neurological-syndrome",
        "primary-cns-lymphoma",
        "small-fiber-neuropathy",
        "status-epilepticus"
      ]
    },
    "lacosamide-iv": {
      "id": "lacosamide-iv",
      "name": "Lacosamide IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Lacosamide IV 400 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400 mg IV over 15 min (can give 200 mg over 5 min if urgent)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "second-line-favorable-hemodynamic-profile-fewer-drug-interac": {
          "indication": "Second-line; favorable hemodynamic profile; fewer drug interactions",
          "doseOptions": [
            {
              "text": "200-400 mg",
              "orderSentence": "Lacosamide IV 200-400 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 200-400 mg IV over 15 min; maintenance: 100-200 mg IV/PO BID (max 400 mg/day)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "alternative-first-line": {
          "indication": "Alternative first-line",
          "doseOptions": [
            {
              "text": "200-400 mg",
              "orderSentence": "Lacosamide IV 200-400 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200-400 mg IV over 15-30 min",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "PR >200 ms, 2nd/3rd degree AV block, severe hepatic impairment",
          "PR prolongation >200 ms, 2nd/3rd degree AV block",
          "Second/third degree AV block",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG (PR interval prolongation)",
          "ECG for PR interval",
          "cardiac monitoring during load",
          "dizziness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "ncse",
        "new-onset-seizure",
        "status-epilepticus"
      ]
    },
    "lactated-ringer-s-iv": {
      "id": "lactated-ringer-s-iv",
      "name": "Lactated Ringer's IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "alternative-iv-fluid-for-rehydration-with-electrolyte-replac": {
          "indication": "Alternative IV fluid for rehydration with electrolyte replacement",
          "doseOptions": [
            {
              "text": "1000 mL bolus",
              "orderSentence": "Lactated Ringer's IV 1000 mL bolus IV"
            },
            {
              "text": "75-125 mL/hr",
              "orderSentence": "Lactated Ringer's IV 75-125 mL/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "LR 1L bolus over 1-2h, then 75-125 mL/hr maintenance",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart failure, hyperkalemia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "I/O, electrolytes"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "lactulose": {
      "id": "lactulose",
      "name": "Lactulose",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "hepatic-encephalopathy": {
          "indication": "Hepatic encephalopathy",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Lactulose 30 mL PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL PO TID; titrate to 3-4 bowel movements/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bowel obstruction"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Mental status, ammonia, stool output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wilsons-disease"
      ]
    },
    "lamotrigine": {
      "id": "lamotrigine",
      "name": "Lamotrigine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "mood-stabilization-irritability": {
          "indication": "Mood stabilization; irritability",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Lamotrigine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily x 2wk; then 50 mg daily x 2wk; titrate by 50 mg q2wk; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "sodium-channel-blocker-some-evidence-in-sfn": {
          "indication": "Sodium channel blocker; some evidence in SFN",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Lamotrigine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily x 2wk; then 50 mg daily x 2wk; increase by 50 mg q2wk; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "preferred-asm-in-pregnancy-for-known-epilepsy-lowest-teratog": {
          "indication": "Preferred ASM in pregnancy for known epilepsy; lowest teratogenicity risk among effective broad-spectrum ASMs; requires dose monitoring",
          "doseOptions": [
            {
              "text": "Individualized per levels",
              "orderSentence": "Lamotrigine Individualized per levels PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Monitor levels monthly during pregnancy (drops 50-70%); increase dose to maintain pre-pregnancy level; reduce dose by 25% within first 2 weeks postpartum then rapidly taper to pre-pregnancy dose over next 2 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Lamotrigine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg daily × 2 weeks, then 50 mg daily × 2 weeks, then increase by 50 mg q2 weeks; target 200-400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "trigeminal-neuralgia"
          ]
        },
        "broad-spectrum-asm-first-line-for-focal-and-generalized-epil": {
          "indication": "Broad-spectrum ASM; first-line for focal and generalized epilepsy; favorable cognitive and teratogenicity profile; preferred in women of childbearing potential",
          "doseOptions": [
            {
              "text": "25 mg daily",
              "orderSentence": "Lamotrigine (Lamictal) 25 mg daily PO"
            },
            {
              "text": "50 mg daily",
              "orderSentence": "Lamotrigine (Lamictal) 50 mg daily PO"
            },
            {
              "text": "100 mg BID",
              "orderSentence": "Lamotrigine (Lamictal) 100 mg BID PO"
            },
            {
              "text": "150 mg BID",
              "orderSentence": "Lamotrigine (Lamictal) 150 mg BID PO"
            },
            {
              "text": "200 mg BID",
              "orderSentence": "Lamotrigine (Lamictal) 200 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "WITHOUT valproate: Start 25 mg daily x 2wk → 50 mg daily x 2wk → increase by 50 mg/day q1-2wk; target 100-200 mg BID; WITH valproate: Start 25 mg QOD x 2wk → 25 mg daily x 2wk → slow titration (VPA doubles LTG level); max 400 mg/day (200 mg with VPA)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "alternative-for-myotonia-refractory-to-mexiletine-limited-ev": {
          "indication": "Alternative for myotonia refractory to mexiletine; limited evidence but sodium channel blocking mechanism",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Lamotrigine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO daily x 2 weeks; then 50 mg daily x 2 weeks; then 100 mg daily; max 200-400 mg/day divided BID; SLOW titration to avoid SJS/TEN",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "first-line-especially-women-of-childbearing-potential": {
          "indication": "First-line (especially women of childbearing potential)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Lamotrigine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily Ã— 2 weeks; then 50 mg daily Ã— 2 weeks; then 100 mg daily; target 200-400 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        },
        "may-reduce-aura-frequency-specifically-hemiplegic-migraine": {
          "indication": "May reduce aura frequency specifically; hemiplegic migraine",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Lamotrigine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25 mg q2wk to 50-100 mg BID; SLOW titration to prevent rash",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "History of lamotrigine-related rash",
          "History of rash with AEDs",
          "History of severe rash with lamotrigine",
          "Hypersensitivity",
          "MUST titrate slowly (SJS/TEN risk with rapid titration)",
          "SJS/TEN history",
          "SJS/TEN with rapid dose changes",
          "Slow titration required (SJS/TEN risk)",
          "concurrent valproate (halve dose due to interaction)",
          "do not increase faster than 50 mg q2wk",
          "interacting drugs (valproate halves dose)",
          "rash history with AEDs",
          "valproate use (reduce dose by 50%)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "**RASH (stop immediately if rash develops - SJS risk)**",
          "**SJS/TEN risk**: rash in first 8 weeks → stop immediately and do not rechallenge",
          "LFTs",
          "Monthly lamotrigine levels",
          "RASH (especially first 8 weeks) - stop immediately if rash",
          "Rash (SJS risk with rapid titration)",
          "Rash (SJS risk)",
          "Rash (Stevens-Johnson/TEN risk -- educate patient to stop immediately if rash develops)",
          "Rash (stop if any rash",
          "SJS/TEN risk higher with fast titration or valproate co-therapy)",
          "drug interactions",
          "lamotrigine levels (especially in pregnancy)",
          "monitor closely during titration",
          "postpartum level within 1 week of delivery",
          "renal function",
          "slow titration mandatory",
          "suicidality monitoring",
          "toxicity symptoms (diplopia, ataxia) as levels rebound postpartum"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy",
        "epilepsy-chronic-management",
        "huntingtons-disease",
        "migraine-with-aura",
        "myotonic-dystrophy",
        "new-onset-seizure",
        "small-fiber-neuropathy",
        "trigeminal-neuralgia"
      ]
    },
    "lamotrigine-dose-adjustment": {
      "id": "lamotrigine-dose-adjustment",
      "name": "Lamotrigine dose adjustment (pregnancy)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "lamotrigine-levels-drop-50-70-during-pregnancy-due-to-increa": {
          "indication": "Lamotrigine levels drop 50-70% during pregnancy due to increased glucuronidation; dose increases typically needed to maintain seizure control",
          "doseOptions": [
            {
              "text": "Individualized per levels",
              "orderSentence": "Lamotrigine dose adjustment (pregnancy) Individualized per levels PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Check lamotrigine level monthly during pregnancy; increase dose to maintain pre-pregnancy level; reduce dose over 2-3 weeks postpartum (levels rebound rapidly)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Stevens-Johnson syndrome risk with rapid dose increases"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Monthly lamotrigine levels during pregnancy",
          "postpartum level within 2 weeks of delivery"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epilepsy-chronic-management"
      ]
    },
    "lasmiditan": {
      "id": "lasmiditan",
      "name": "Lasmiditan",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "5-ht1f-agonist-safe-in-cardiovascular-disease-ditan-class": {
          "indication": "5-HT1F agonist; safe in cardiovascular disease; ditan class",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Lasmiditan 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-200 mg PO x1; max 200 mg/24hr; DO NOT DRIVE for 8 hours after dose",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CYP3A4 substrates with narrow TI",
          "Concurrent alcohol"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CNS depression",
          "NO driving for 8 hr",
          "dizziness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine-with-aura"
      ]
    },
    "lecanemab": {
      "id": "lecanemab",
      "name": "Lecanemab (Leqembi)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "mci-due-to-ad-with-confirmed-amyloid-pathology-positive-amyl": {
          "indication": "MCI due to AD with confirmed amyloid pathology (positive amyloid PET or CSF biomarkers)",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Lecanemab (Leqembi) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV every 2 weeks; infuse over 1 hour; continue as long as benefit maintained",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg/kg",
              "orderSentence": "Lecanemab (Leqembi) (CPT 96365) 10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV q2 weeks; confirm amyloid-positive before starting",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "early-ad-mci-or-mild-dementia-with-confirmed-amyloid-patholo": {
          "indication": "Early AD (MCI or mild dementia) with confirmed amyloid pathology",
          "doseOptions": [
            {
              "text": "10 mg/kg IV q2wk",
              "orderSentence": "Lecanemab (Leqembi) 10 mg/kg IV q2wk IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg IV every 2 weeks; infuse over approximately 1 hour",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          ">4 cerebral microbleeds",
          ">4 microbleeds on MRI",
          "APOE ε4/ε4 (higher ARIA risk - not absolute CI)",
          "Anticoagulation (relative), ARIA risk factors",
          "anticoagulation (increased ARIA risk)",
          "concurrent anticoagulation (relative)",
          "recent macrohemorrhage",
          "recent stroke/TIA",
          "superficial siderosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ARIA monitoring",
          "MRI at baseline, week 6, 12",
          "MRI at baseline, weeks 14, 52, 78",
          "MRI: baseline, weeks 7, 14, 52, 78 (ARIA monitoring)",
          "clinical assessment for ARIA symptoms (headache, confusion, visual changes)",
          "monitor for ARIA-E/H symptoms (headache, confusion, vision changes)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "alzheimers-disease",
        "dementia-evaluation",
        "mild-cognitive-impairment"
      ]
    },
    "leflunomide": {
      "id": "leflunomide",
      "name": "Leflunomide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "steroid-sparing-agent-alternative-to-methotrexate-similar-me": {
          "indication": "Steroid-sparing agent; alternative to methotrexate (similar mechanism)",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Leflunomide 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Loading dose: 100 mg PO daily x 3 days (optional); then 20 mg PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "alternative-steroid-sparing-if-mtx-intolerant-limited-eviden": {
          "indication": "Alternative steroid-sparing if MTX intolerant (limited evidence)",
          "doseOptions": [
            {
              "text": "10-20 mg daily",
              "orderSentence": "Leflunomide 10-20 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy (Category X)",
          "hepatic disease",
          "immunodeficiency",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "CBC",
          "LFTs monthly x 6 months, then q1-3 months",
          "LFTs monthly x 6 months, then q2 months",
          "cholestyramine washout if pregnancy desired (11g TID x 11 days)",
          "diarrhea"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "giant-cell-arteritis",
        "neurosarcoidosis"
      ]
    },
    "lenalidomide": {
      "id": "lenalidomide",
      "name": "Lenalidomide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "relapsed-refractory-pcnsl-immunomodulatory-agent-may-combine": {
          "indication": "Relapsed/refractory PCNSL; immunomodulatory agent; may combine with rituximab (R2 regimen)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Lenalidomide 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg PO days 1-21 of 28-day cycle (21 days on, 7 days off); requires REMS enrollment (Revlimid REMS); thromboprophylaxis required",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "DVT/PE history (requires prophylaxis)",
          "Pregnancy (teratogenic, Category X)",
          "neutropenia (ANC <1000)",
          "renal impairment (dose reduce)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC weekly x8 then monthly",
          "LFTs",
          "REMS compliance",
          "TSH q3 months",
          "VTE monitoring",
          "pregnancy testing monthly (female patients)",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "leucovorin": {
      "id": "leucovorin",
      "name": "Leucovorin (folinic acid)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "prevent-pyrimethamine-induced-bone-marrow-suppression-must-c": {
          "indication": "Prevent pyrimethamine-induced bone marrow suppression; MUST co-administer with pyrimethamine",
          "doseOptions": [
            {
              "text": "10-25 mg",
              "orderSentence": "Leucovorin (folinic acid) 10-25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-25 mg PO daily; continue throughout pyrimethamine therapy and 1 week after discontinuation",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "signs of myelosuppression"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-abscess"
      ]
    },
    "leucovorin-rescue": {
      "id": "leucovorin-rescue",
      "name": "Leucovorin rescue (with IT methotrexate)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "prevents-systemic-methotrexate-toxicity-from-it-methotrexate": {
          "indication": "Prevents systemic methotrexate toxicity from IT methotrexate absorbed systemically; mandatory with each IT MTX dose",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "**Leucovorin rescue (with IT methotrexate)** 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Leucovorin 10 mg PO q6h for 4 doses starting 24 hours after each IT methotrexate administration; increase to 25 mg q6h if elevated serum MTX levels; continue until serum MTX level <0.05 microM",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Known hypersensitivity (rare)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "Serum methotrexate level at 24h and 48h if concurrent systemic MTX",
          "diarrhea",
          "mucositis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "levetiracetam": {
      "id": "levetiracetam",
      "name": "Levetiracetam",
      "genericName": "levetiracetam",
      "brandNames": [
        "Keppra",
        "Keppra XR",
        "Spritam",
        "Elepsia XR"
      ],
      "drugClass": "Anticonvulsant",
      "mechanisms": [
        "Binds synaptic vesicle protein SV2A",
        "Modulates neurotransmitter release"
      ],
      "routes": [
        "PO",
        "IV"
      ],
      "formulations": [
        "250 mg tablet",
        "500 mg tablet",
        "750 mg tablet",
        "1000 mg tablet",
        "500 mg XR tablet",
        "750 mg XR tablet",
        "100 mg/mL oral solution",
        "100 mg/mL IV solution"
      ],
      "contexts": {
        "epilepsy-partial": {
          "indication": "Partial onset seizures (focal epilepsy)",
          "doseOptions": [
            {
              "text": "250 mg BID",
              "orderSentence": "Levetiracetam 250 mg PO BID"
            },
            {
              "text": "500 mg BID",
              "orderSentence": "Levetiracetam 500 mg PO BID"
            },
            {
              "text": "750 mg BID",
              "orderSentence": "Levetiracetam 750 mg PO BID"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Levetiracetam 1000 mg PO BID"
            },
            {
              "text": "1500 mg BID",
              "orderSentence": "Levetiracetam 1500 mg PO BID"
            }
          ],
          "startingDose": "500 mg BID",
          "maxDose": "3000 mg/day",
          "titration": "May increase by 500 mg BID every 2 weeks",
          "notes": "First-line for focal epilepsy; no titration required but may help tolerability"
        },
        "epilepsy-generalized": {
          "indication": "Generalized tonic-clonic seizures, myoclonic seizures",
          "doseOptions": [
            {
              "text": "500 mg BID",
              "orderSentence": "Levetiracetam 500 mg PO BID"
            },
            {
              "text": "750 mg BID",
              "orderSentence": "Levetiracetam 750 mg PO BID"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Levetiracetam 1000 mg PO BID"
            },
            {
              "text": "1500 mg BID",
              "orderSentence": "Levetiracetam 1500 mg PO BID"
            }
          ],
          "startingDose": "500 mg BID",
          "maxDose": "3000 mg/day",
          "titration": "Increase by 500 mg BID every 2 weeks",
          "notes": "Effective for JME; good for mixed seizure types"
        },
        "seizure-prophylaxis-acute": {
          "indication": "Seizure prophylaxis (post-TBI, post-craniotomy, ICH)",
          "doseOptions": [
            {
              "text": "500 mg IV q12h",
              "orderSentence": "Levetiracetam 500 mg IV q12h"
            },
            {
              "text": "1000 mg IV q12h",
              "orderSentence": "Levetiracetam 1000 mg IV q12h"
            },
            {
              "text": "1500 mg IV load then 1000 mg IV q12h",
              "orderSentence": "Levetiracetam 1500 mg IV load then 1000 mg IV q12h"
            }
          ],
          "startingDose": "1000 mg IV q12h (or 20 mg/kg load)",
          "maxDose": "3000 mg/day",
          "titration": "N/A for acute prophylaxis",
          "notes": "Duration typically 7 days post-TBI; IV=PO bioequivalent"
        },
        "seizure-treatment-prophylaxis-seizures-occur-in-20-30-of-moy": {
          "indication": "Seizure treatment/prophylaxis; seizures occur in 20-30% of moyamoya patients; broad-spectrum; no hepatic metabolism",
          "doseOptions": [
            {
              "text": "500 mg BID",
              "orderSentence": "Levetiracetam 500 mg BID PO"
            },
            {
              "text": "750 mg BID",
              "orderSentence": "Levetiracetam 750 mg BID PO"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Levetiracetam 1000 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; increase by 500 mg/day q1-2wk; max 3000 mg/day; IV loading 1000 mg over 15 min if needed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        },
        "seizures-secondary-to-cortical-parenchymal-nbd": {
          "indication": "Seizures secondary to cortical/parenchymal NBD",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam 500 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID (IV or PO); increase by 500 mg/day q1-2wk; max 3000 mg/day; transition to PO when tolerated",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "anti-seizure-medication-loading-for-new-seizures-preferred-i": {
          "indication": "Anti-seizure medication loading for new seizures; preferred in brain tumor patients due to no CYP enzyme induction (does not reduce efficacy of steroids, chemotherapy, or targeted agents)",
          "doseOptions": [
            {
              "text": "1500 mg",
              "orderSentence": "Levetiracetam (seizure - loading) 1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV load, then 500-1500 mg PO/IV BID; renal dosing if GFR <50",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "seizure-prevention-after-first-seizure-no-prophylactic-aeds-": {
          "indication": "Seizure prevention after first seizure; NO prophylactic AEDs in patients without seizures (AAN guideline)",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam (maintenance) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; titrate by 500 mg/day q1-2 weeks to seizure control; max 3000 mg/day; renal dosing if GFR <50",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "seizure-treatment-not-routine-prophylaxis-aha-2022-recommend": {
          "indication": "Seizure treatment (NOT routine prophylaxis — AHA 2022 recommends against routine prophylaxis). Treat if clinical or electrographic seizures",
          "doseOptions": [
            {
              "text": "1000-1500 mg",
              "orderSentence": "Levetiracetam 1000-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV load; then 500-1000 mg IV/PO BID",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "seizures-associated-with-he-occur-in-60-70-of-cases": {
          "indication": "Seizures associated with HE (occur in ~60-70% of cases)",
          "doseOptions": [
            {
              "text": "1000-1500 mg",
              "orderSentence": "Levetiracetam (first-line ASM) 1000-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 1000-1500 mg IV; Maintenance: 500-1500 mg IV/PO BID (max 3000 mg/day)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "seizure-management-if-seizures-occur-not-routine-prophylaxis": {
          "indication": "Seizure management if seizures occur; NOT routine prophylaxis; lower drug interaction profile than phenytoin (important with azoles)",
          "doseOptions": [
            {
              "text": "1000-1500 mg",
              "orderSentence": "Levetiracetam 1000-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV or PO BID; load 1000-1500 mg if acute seizure; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000-1500 mg",
              "orderSentence": "Levetiracetam (if seizures) 1000-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV load; then 500-1000 mg IV/PO BID; max 3000 mg/day. Seizures occur in 40-60% of HSV encephalitis",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hsv-encephalitis",
            "brain-metastases",
            "autoimmune-encephalitis"
          ]
        },
        "seizure-management-if-seizures-develop-uncommon-in-uncomplic": {
          "indication": "Seizure management if seizures develop (uncommon in uncomplicated viral meningitis; suggests encephalitis component); NOT routine prophylaxis",
          "doseOptions": [
            {
              "text": "1000-1500 mg",
              "orderSentence": "Levetiracetam (if seizures occur) 1000-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV load then 500-1000 mg IV/PO BID; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "seizures-secondary-to-cortical-or-meningeal-neurosarcoidosis": {
          "indication": "Seizures secondary to cortical or meningeal neurosarcoidosis",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID (IV or PO); increase by 500 mg/day q1-2wk; max 3000 mg/day; transition to PO when tolerated",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "seizures-neurosyphilis-related-seizures-meningovascular-with": {
          "indication": "Seizures (neurosyphilis-related seizures; meningovascular with cortical involvement)",
          "doseOptions": [
            {
              "text": "1000-1500 mg BID",
              "orderSentence": "Levetiracetam 1000-1500 mg BID IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV load; then 500-1000 mg IV/PO BID; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "aed-loading-after-benzodiazepine-for-seizure-in-lmd-preferre": {
          "indication": "AED loading after benzodiazepine for seizure in LMD; preferred AED in cancer (no CYP interactions with chemotherapy or targeted agents)",
          "doseOptions": [
            {
              "text": "1500 mg",
              "orderSentence": "**Levetiracetam (seizure load)** 1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV over 15 min; avoid phenytoin/fosphenytoin if possible (CYP interactions with chemotherapy and targeted agents); transition to oral 500-1500 mg BID for maintenance",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "post-seizure-maintenance-cortical-irritation-from-leptomenin": {
          "indication": "Post-seizure maintenance; cortical irritation from leptomeningeal disease; preferred AED in cancer (no CYP interactions with chemotherapy)",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "**Levetiracetam (seizure maintenance)** 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO/IV BID; titrate to seizure control (max 1500 mg BID); renal dose adjustment if CrCl <50; IV available if NPO",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "asm-for-recurrent-seizures-after-mgso4-failure-preferred-ove": {
          "indication": "ASM for recurrent seizures after MgSO4 failure; preferred over phenytoin in pregnancy due to better safety profile; for known epilepsy patients needing IV loading",
          "doseOptions": [
            {
              "text": "1000 mg IV load",
              "orderSentence": "Levetiracetam 1000 mg IV load IV"
            },
            {
              "text": "500 mg IV q12h",
              "orderSentence": "Levetiracetam 500 mg IV q12h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load 1000-1500 mg IV over 15 min; maintenance 500-1000 mg IV/PO q12h; renal dosing if CrCl <50",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "preferred-asm-in-pregnancy-low-teratogenicity-safe-in-breast": {
          "indication": "Preferred ASM in pregnancy; low teratogenicity; safe in breastfeeding; renal elimination (no hepatic interactions)",
          "doseOptions": [
            {
              "text": "Individualized per levels",
              "orderSentence": "Levetiracetam Individualized per levels PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Monitor levels each trimester (decreases ~60%); increase dose to maintain seizure control; renal clearance increases in pregnancy; postpartum dose reduction needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "limited-evidence-case-reports-of-benefit": {
          "indication": "Limited evidence; case reports of benefit",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; titrate to 1500-3000 mg/day; adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        },
        "anti-seizure-medication-loading-for-new-seizures-preferred-i-2": {
          "indication": "Anti-seizure medication loading for new seizures; preferred in CNS lymphoma patients due to no CYP enzyme induction (preserves chemotherapy efficacy)",
          "doseOptions": [
            {
              "text": "1500 mg",
              "orderSentence": "Levetiracetam (seizure - loading) 1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV load, then 500-1500 mg PO/IV BID; renal dosing if GFR <50",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "seizure-prevention-after-first-seizure-no-prophylactic-aeds--2": {
          "indication": "Seizure prevention after first seizure; NO prophylactic AEDs in patients without seizures; preferred due to no drug interactions with chemotherapy",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam (maintenance) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; titrate by 500 mg/day q1-2 weeks to seizure control; max 3000 mg/day; renal dosing if GFR <50",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "anti-seizure-medication-if-seizures-have-occurred-prophylaxi": {
          "indication": "Anti-seizure medication if seizures have occurred; prophylaxis if large territory infarction or cortical involvement",
          "doseOptions": [
            {
              "text": "1000-1500 mg BID",
              "orderSentence": "Levetiracetam (seizure prophylaxis/treatment) 1000-1500 mg BID IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 1000-1500 mg IV; Maintenance: 500-1500 mg IV/PO BID; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "acute-symptomatic-seizures-prophylaxis-if-hemorrhagic-infarc": {
          "indication": "Acute symptomatic seizures; prophylaxis if hemorrhagic infarction or cortical involvement",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Levetiracetam (seizure prophylaxis/treatment) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 1000-1500 mg IV; Maintenance: 500-1500 mg IV/PO BID (max 3000 mg/day)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "seizure-prophylaxis-or-treatment-if-seizures-occur-more-comm": {
          "indication": "Seizure prophylaxis or treatment if seizures occur (more common with PRES overlap or cortical SAH)",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Levetiracetam (for seizures) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load 1000-1500 mg IV, then 500-1000 mg BID; adjust for renal function",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "first-line-antiseizure-medication-for-ncc-related-seizures-n": {
          "indication": "First-line antiseizure medication for NCC-related seizures; no hepatic enzyme induction (avoids reducing praziquantel levels); seizures occur in 70-90% of parenchymal NCC",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Levetiracetam (seizure management) (CPT 96374) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV load, then 500-1000 mg IV/PO BID; titrate by 500 mg/day every 2 weeks to 1500 mg BID if seizures persist; max 3000 mg/day; does NOT interact with antiparasitic drugs",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "continue-after-successful-loading-broad-spectrum-maintenance": {
          "indication": "Continue after successful loading; broad-spectrum maintenance",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam (maintenance) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1500 mg PO/IV BID (max 3000 mg/day); adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "seizure-management-in-adem-like-presentation-with-cortical-i": {
          "indication": "Seizure management in ADEM-like presentation with cortical involvement",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; increase by 500 mg/day q1-2wk; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "first-line-for-post-anoxic-seizures-and-ncse-common-in-10-30": {
          "indication": "First-line for post-anoxic seizures and NCSE (common in 10-30% of comatose post-arrest patients); treat all electrographic seizures aggressively",
          "doseOptions": [
            {
              "text": "1000-1500 mg",
              "orderSentence": "Levetiracetam 1000-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV load; then 500-1000 mg IV BID; transition to PO when able; no hepatic metabolism; minimal drug interactions",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "post-anoxic-myoclonus-adjunctive-less-effective-as-monothera": {
          "indication": "Post-anoxic myoclonus (adjunctive; less effective as monotherapy for myoclonus than clonazepam)",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam (myoclonus) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; titrate to 1000-1500 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "myoclonus-treatment-especially-perm-variant-anti-seizure-pro": {
          "indication": "Myoclonus treatment (especially PERM variant); anti-seizure prophylaxis if cortical involvement",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase by 500 mg/day q1-2wk; max 3000 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "seizure-management-in-paraneoplastic-limbic-encephalitis-pre": {
          "indication": "Seizure management in paraneoplastic limbic encephalitis; preferred first-line ASM",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam 500 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 1000-1500 mg IV; Maintenance: 500 mg BID, titrate to 1000-1500 mg BID; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "seizure-prophylaxis-and-treatment-in-cjd-preferred-first-lin": {
          "indication": "Seizure prophylaxis and treatment in CJD; preferred first-line ASM due to minimal drug interactions",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Levetiracetam (seizure management) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load 1000-1500 mg IV; maintenance 500-1500 mg PO/IV BID; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "myoclonus-alternative-or-adjunct-when-benzodiazepine-sedatio": {
          "indication": "Myoclonus -- alternative or adjunct when benzodiazepine sedation is limiting; also provides seizure coverage",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam (adjunctive for myoclonus) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase by 500 mg/day every 1-2 weeks; max 3000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "broad-spectrum-asm-first-line-for-focal-and-generalized-epil": {
          "indication": "Broad-spectrum ASM; first-line for focal and generalized epilepsy; no significant drug interactions; renal elimination",
          "doseOptions": [
            {
              "text": "250 mg BID",
              "orderSentence": "Levetiracetam (Keppra) 250 mg BID PO"
            },
            {
              "text": "500 mg BID",
              "orderSentence": "Levetiracetam (Keppra) 500 mg BID PO"
            },
            {
              "text": "750 mg BID",
              "orderSentence": "Levetiracetam (Keppra) 750 mg BID PO"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Levetiracetam (Keppra) 1000 mg BID PO"
            },
            {
              "text": "1500 mg BID",
              "orderSentence": "Levetiracetam (Keppra) 1500 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250-500 mg BID; increase by 500 mg/day q1-2wk; target 1000-1500 mg BID; max 3000 mg/day; adjust for renal impairment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "seizures": {
          "indication": "Seizures",
          "doseOptions": [
            {
              "text": "500-1500 mg",
              "orderSentence": "Levetiracetam (CPT 96374) 500-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1500 mg PO/IV BID; max 3000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        },
        "anti-seizure-medication-if-seizures-have-occurred-prophylaxi-2": {
          "indication": "Anti-seizure medication if seizures have occurred; prophylaxis if extensive cortical involvement on MRI",
          "doseOptions": [
            {
              "text": "1000 mg BID",
              "orderSentence": "Levetiracetam (seizure prophylaxis/treatment) 1000 mg BID IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 1000-1500 mg IV; Maintenance: 500-1500 mg IV/PO BID; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "post-stroke-seizures-5-10-incidence-higher-with-cortical-inv": {
          "indication": "Post-stroke seizures (5-10% incidence; higher with cortical involvement and hemorrhagic stroke); preferred ASM post-stroke",
          "doseOptions": [
            {
              "text": "500 mg BID",
              "orderSentence": "Levetiracetam 500 mg BID PO"
            },
            {
              "text": "750 mg BID",
              "orderSentence": "Levetiracetam 750 mg BID PO"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Levetiracetam 1000 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; increase by 500 mg q1-2wk; target 500-1000 mg BID; max 3000 mg/day; no hepatic interactions with stroke medications",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "seizure-management-if-seizures-occur-not-routine-prophylaxis-2": {
          "indication": "Seizure management (if seizures occur; NOT routine prophylaxis)",
          "doseOptions": [
            {
              "text": "1000-1500 mg",
              "orderSentence": "Levetiracetam 1000-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV load; then 500-1000 mg IV/PO BID; max 3000 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "seizure-prophylaxis-in-brain-abscess-seizure-incidence-25-50": {
          "indication": "Seizure prophylaxis in brain abscess (seizure incidence 25-50%); recommended for all supratentorial abscesses, especially frontal and temporal locations",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Levetiracetam (seizure prophylaxis) (CPT 96374) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV load; then 500-1000 mg IV/PO BID; titrate to 1500 mg BID if needed; max 3000 mg/day; continue for at least 3-6 months after resolution",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "only-if-sah-confirmed-or-seizure-occurs-not-routine-for-undi": {
          "indication": "ONLY if SAH confirmed or seizure occurs; not routine for undifferentiated thunderclap headache",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Levetiracetam (CPT 96374) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV load; then 500-1000 mg IV/PO BID. Use short-term (3-7 days) in confirmed SAH per AHA guidelines",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "anti-seizure-medication-loading-for-new-seizures-associated-": {
          "indication": "Anti-seizure medication loading for new seizures associated with meningioma; preferred due to no CYP enzyme induction and favorable safety profile",
          "doseOptions": [
            {
              "text": "1500 mg",
              "orderSentence": "Levetiracetam (seizure - loading) 1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV load, then 500-1500 mg PO/IV BID; renal dosing if GFR <50",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "seizure-prevention-after-first-seizure-from-meningioma-no-pr": {
          "indication": "Seizure prevention after first seizure from meningioma; NO prophylactic AEDs in patients without seizures unless high-risk perioperative period",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam (maintenance) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; titrate by 500 mg/day q1-2 weeks to seizure control; max 3000 mg/day; renal dosing if GFR <50",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "short-course-perioperative-seizure-prophylaxis-for-craniotom": {
          "indication": "Short-course perioperative seizure prophylaxis for craniotomy in patients without seizure history; 7-day course only per institutional protocol; NOT recommended beyond 7 days without documented seizure",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Levetiracetam (perioperative prophylaxis) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Levetiracetam 500 mg BID starting day of surgery; discontinue at 7 days post-operatively unless seizure occurs; if seizure occurs, convert to maintenance dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "continued-seizure-prophylaxis-if-seizures-occurred-during-pr": {
          "indication": "Continued seizure prophylaxis if seizures occurred during PRES; typically continue 3-6 months then taper if MRI normalized and EEG normal",
          "doseOptions": [
            {
              "text": "500 mg BID",
              "orderSentence": "Levetiracetam (oral transition) 500 mg BID PO"
            },
            {
              "text": "750 mg BID",
              "orderSentence": "Levetiracetam (oral transition) 750 mg BID PO"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Levetiracetam (oral transition) 1000 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mg PO BID; dose based on acute loading; may taper at 3-6 months if PRES fully resolved on imaging",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pres"
          ]
        },
        "seizure-management-seizures-occur-in-20-30-of-tbm-preferred-": {
          "indication": "Seizure management (seizures occur in 20-30% of TBM); preferred ASM due to minimal hepatic metabolism (important with hepatotoxic RIPE therapy)",
          "doseOptions": [
            {
              "text": "1000-1500 mg",
              "orderSentence": "Levetiracetam 1000-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV load; then 500-1000 mg IV/PO BID; max 3000 mg/day; preferred over phenytoin because no significant hepatic metabolism or CYP interactions with RIPE",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        },
        "first-line-maintenance": {
          "indication": "First-line maintenance",
          "doseOptions": [
            {
              "text": "500-1500 mg",
              "orderSentence": "Levetiracetam 500-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1500 mg PO/IV BID; start 500 mg BID, may increase by 500 mg/dose weekly; max 3000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Known hypersensitivity to levetiracetam"
        ],
        "precautions": [
          "Behavioral/psychiatric adverse events (irritability, aggression, anxiety, depression)",
          "Suicidal ideation (class warning)",
          "Somnolence and fatigue",
          "Coordination difficulties",
          "Anaphylaxis and angioedema (rare)"
        ],
        "drugInteractions": [
          {
            "drug": "CNS depressants",
            "severity": "low",
            "effect": "Additive sedation"
          },
          {
            "drug": "No significant CYP interactions",
            "severity": "none",
            "effect": "Few drug interactions - major advantage"
          }
        ],
        "pregnancyCategory": "C",
        "lactation": "Likely compatible"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {
            "gfr": "≥80",
            "adjustment": "No adjustment needed"
          },
          {
            "gfr": "50-79",
            "adjustment": "500-1000 mg BID (max 2000 mg/day)"
          },
          {
            "gfr": "30-49",
            "adjustment": "250-750 mg BID (max 1500 mg/day)"
          },
          {
            "gfr": "<30",
            "adjustment": "250-500 mg BID (max 1000 mg/day)"
          },
          {
            "gfr": "HD",
            "adjustment": "500-1000 mg daily + 250-500 mg supplement post-dialysis"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment needed - renally eliminated"
      },
      "monitoring": {
        "baseline": [
          "Renal function"
        ],
        "ongoing": [
          "Behavioral changes",
          "Mood",
          "Suicidal ideation"
        ],
        "frequency": "Renal function annually; behavioral assessment at each visit"
      },
      "patientCounseling": [
        "Report mood changes, irritability, aggression, depression, or suicidal thoughts immediately",
        "May cause drowsiness - avoid driving until effects known",
        "Do not stop abruptly - may precipitate seizures",
        "Keppra Rage is real - discuss with provider if mood changes",
        "Pyridoxine (B6) may help with irritability"
      ]
    },
    "levetiracetam-iv": {
      "id": "levetiracetam-iv",
      "name": "Levetiracetam IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "adjunctive-seizure-prophylaxis-not-a-substitute-for-benzodia": {
          "indication": "Adjunctive seizure prophylaxis; NOT a substitute for benzodiazepines for withdrawal management; may be considered if concurrent epilepsy diagnosis or concern for non-withdrawal seizures",
          "doseOptions": [
            {
              "text": "1000-1500 mg",
              "orderSentence": "Levetiracetam IV 1000-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV q12h; does NOT treat withdrawal syndrome itself; use as adjunct only",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "60 mg/kg",
              "orderSentence": "Levetiracetam IV (ESETT dosing) (CPT 96365) 60 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg/kg IV (max 4500 mg) over 10-15 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "second-line-fewest-drug-interactions-renal-dosing-simple": {
          "indication": "Second-line; fewest drug interactions; renal dosing simple",
          "doseOptions": [
            {
              "text": "60 mg/kg (max 4500 mg)",
              "orderSentence": "Levetiracetam IV 60 mg/kg (max 4500 mg) IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg/kg IV (max 4500 mg) infused over 15 min; then maintenance 1000-1500 mg IV/PO BID",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "first-line-acute-loading": {
          "indication": "First-line acute loading",
          "doseOptions": [
            {
              "text": "40-60 mg/kg",
              "orderSentence": "Levetiracetam IV (CPT 96365) 40-60 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40-60 mg/kg IV (max 4500 mg) over 15 min; OR 1500-3000 mg IV",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None absolute",
          "None significant",
          "Renal impairment (adjust dose if CrCl <50)",
          "Renal impairment (adjust dose per CrCl)",
          "reduce dose if CrCl <50",
          "reduce if CrCl <50"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Behavioral changes",
          "EEG",
          "Generally well tolerated",
          "Somnolence, agitation (rare)",
          "agitation",
          "behavioral changes (rage, agitation)",
          "does NOT replace benzodiazepines",
          "renal function",
          "suicidality"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "ncse",
        "new-onset-seizure",
        "status-epilepticus"
      ]
    },
    "levetiracetam-po": {
      "id": "levetiracetam-po",
      "name": "Levetiracetam PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "acute-loading-if-stable": {
          "indication": "Acute loading if stable",
          "doseOptions": [
            {
              "text": "1500-3000 mg",
              "orderSentence": "Levetiracetam PO 1500-3000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1500-3000 mg PO Ã— 1, then start maintenance",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "URGENT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "new-onset-seizure"
      ]
    },
    "levodopa-carbidopa": {
      "id": "levodopa-carbidopa",
      "name": "Levodopa/Carbidopa",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dopa-responsive-dystonia-drd-diagnostic-trial-for-young-onse": {
          "indication": "Dopa-responsive dystonia (DRD); diagnostic trial for young-onset",
          "doseOptions": [
            {
              "text": "25/100 mg",
              "orderSentence": "Levodopa/Carbidopa 25/100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25/100 mg TID; if DRD, dramatic response at low dose; may titrate to 50/200 mg TID; response confirms diagnosis",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "trial-if-dip-fails-to-resolve-after-drug-withdrawal-suggests": {
          "indication": "Trial if DIP fails to resolve after drug withdrawal (suggests unmasked idiopathic PD)",
          "doseOptions": [
            {
              "text": "25/100 mg",
              "orderSentence": "Levodopa/Carbidopa (Sinemet) 25/100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25/100 mg TID with meals; titrate by 25/100 mg q1-2 weeks; response suggests underlying PD",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        },
        "pd-tremor-confirmed-or-strongly-suspected-based-on-clinical-": {
          "indication": "PD tremor confirmed or strongly suspected based on clinical features and/or DaTscan; diagnostic and therapeutic trial",
          "doseOptions": [
            {
              "text": "25/100 mg",
              "orderSentence": "Levodopa/Carbidopa (Sinemet) 25/100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25/100 mg TID with meals; titrate by 25/100 mg q1-2 weeks based on response; robust response supports PD diagnosis",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "parkinsonism-rigidity-bradykinesia": {
          "indication": "Parkinsonism (rigidity, bradykinesia)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Levodopa/Carbidopa 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25/100 mg TID; titrate by 25/100 mg q1-2 weeks; limited efficacy in WD parkinsonism (response variable)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Narrow-angle glaucoma",
          "None absolute",
          "active psychosis (relative - may worsen)",
          "active psychosis (relative)",
          "concurrent non-selective MAOIs",
          "use caution in psychosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dyskinesia, nausea, orthostatic hypotension",
          "Nausea, orthostatic hypotension",
          "Nausea, orthostatic hypotension, dyskinesia (long-term)",
          "Nausea, orthostatic hypotension, dyskinesia, hallucinations (especially if psychotic history)",
          "caution: may worsen psychosis",
          "dramatic improvement suggests DRD",
          "hallucinations",
          "often poor response in WD",
          "response to levodopa is diagnostically supportive of PD"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "drug-induced-parkinsonism",
        "dystonia",
        "tremor-unspecified",
        "wilsons-disease"
      ]
    },
    "levodopa-carbidopa-intestinal-gel": {
      "id": "levodopa-carbidopa-intestinal-gel",
      "name": "Levodopa-carbidopa intestinal gel (Duopa)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Enteral"
      ],
      "formulations": [],
      "contexts": {
        "severe-motor-fluctuations-4-hours-off-day": {
          "indication": "Severe motor fluctuations; 4+ hours OFF/day",
          "doseOptions": [
            {
              "text": "Continuous infusion",
              "orderSentence": "Levodopa-carbidopa intestinal gel (Duopa) Continuous infusion Enteral"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Via PEG-J; 16-hour infusion; morning bolus + continuous rate + extra doses",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI disease preventing PEG-J",
          "coagulopathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Tube site, infections, GI complications"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease"
      ]
    },
    "levofloxacin": {
      "id": "levofloxacin",
      "name": "Levofloxacin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "drug-resistant-tb-mdr-tb-rifampin-resistant-tb-detected-on-g": {
          "indication": "Drug-resistant TB (MDR-TB); rifampin-resistant TB detected on GeneXpert; alternative when first-line agents not tolerated; good CNS penetration",
          "doseOptions": [
            {
              "text": "750-1000 mg",
              "orderSentence": "Levofloxacin 750-1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "750-1000 mg PO/IV daily; superior CNS penetration among fluoroquinolones; critical component of MDR-TB regimen",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "myasthenia gravis (worsens weakness)",
          "pregnancy",
          "tendinopathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "C. diff",
          "QTc",
          "glucose (dysglycemia)",
          "renal function",
          "tendon symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tb-meningitis"
      ]
    },
    "levonorgestrel-iud": {
      "id": "levonorgestrel-iud",
      "name": "Levonorgestrel IUD (Mirena/Liletta)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IUD"
      ],
      "formulations": [],
      "contexts": {
        "reliable-contraception-for-women-on-enzyme-inducing-asms-not": {
          "indication": "Reliable contraception for women on enzyme-inducing ASMs; NOT affected by enzyme induction (unlike oral contraceptives)",
          "doseOptions": [
            {
              "text": "N/A — device placement",
              "orderSentence": "Levonorgestrel IUD (Mirena/Liletta) N/A — device placement IUD"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Place levonorgestrel IUD for reliable contraception; efficacy NOT reduced by enzyme-inducing ASMs; preferred over oral contraceptives for women on phenytoin, carbamazepine, phenobarbital, topiramate >200 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Placement confirmation",
          "string check annually"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epilepsy-chronic-management"
      ]
    },
    "levothyroxine": {
      "id": "levothyroxine",
      "name": "Levothyroxine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "hypothyroidism-contributing-to-encephalopathy": {
          "indication": "Hypothyroidism contributing to encephalopathy",
          "doseOptions": [
            {
              "text": "1.6 mcg/kg",
              "orderSentence": "Levothyroxine (if hypothyroid) 1.6 mcg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1.6 mcg/kg/day PO (adjust for age/cardiac status); IV dose is 75% of oral dose if unable to take PO",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "maintain-euthyroid-state-hypothyroidism-present-in-25-30": {
          "indication": "Maintain euthyroid state; hypothyroidism present in 25-30%",
          "doseOptions": [
            {
              "text": "1.6 mcg/kg",
              "orderSentence": "Levothyroxine (thyroid optimization) 1.6 mcg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1.6 mcg/kg/day PO; adjust to keep TSH 0.5-2.5 mIU/L",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "hormone-replacement-therapy-hrt-for-brain-dead-donors-pituit": {
          "indication": "Hormone replacement therapy (HRT) for brain-dead donors; pituitary failure causes hypothyroidism; improves hemodynamic stability and organ function",
          "doseOptions": [
            {
              "text": "20 mcg",
              "orderSentence": "**Levothyroxine (T4)** 20 mcg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "HRSA protocol: 20 mcg IV bolus then 10 mcg/hr continuous infusion; alternative: T3 (liothyronine) 4 mcg IV bolus then 3 mcg/hr; improves cardiac output and donor hemodynamics",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        },
        "central-hypothyroidism-from-hypothalamic-pituitary-sarcoidos": {
          "indication": "Central hypothyroidism from hypothalamic-pituitary sarcoidosis",
          "doseOptions": [
            {
              "text": "25 mcg",
              "orderSentence": "Levothyroxine 25 mcg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mcg daily (lower in elderly/cardiac disease); titrate q6-8 weeks by 12.5-25 mcg; target free T4 in upper half of normal range (NOT TSH-guided for central hypothyroidism)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-50 mcg",
              "orderSentence": "Levothyroxine (hypothyroidism) 25-50 mcg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mcg daily; titrate per TSH",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "hypothyroidism-treatment-in-dm1-patients-with-confirmed-thyr": {
          "indication": "Hypothyroidism treatment in DM1 patients with confirmed thyroid dysfunction",
          "doseOptions": [
            {
              "text": "25 mcg",
              "orderSentence": "Levothyroxine 25 mcg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mcg PO daily (lower dose in elderly or cardiac disease); titrate by 12.5-25 mcg q6-8 weeks based on TSH; take on empty stomach 30-60 min before breakfast",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Adrenal insufficiency (correct first)",
          "Adrenal insufficiency (must correct cortisol FIRST)",
          "CAD (start low)",
          "None in this context",
          "Untreated adrenal insufficiency",
          "Untreated adrenal insufficiency (check cortisol first)",
          "acute MI",
          "acute MI (start low)",
          "acute cardiac disease",
          "thyrotoxicosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Free T4 (NOT TSH) q6-8 weeks",
          "TSH q6-8 weeks",
          "TSH q6-8 weeks during titration",
          "TSH, free T4 q4-6 weeks",
          "TSH, free T4 q4-6 weeks until stable, then q3-6 months",
          "TSH, free T4 q6-12h",
          "cardiac function",
          "cardiac monitoring in elderly/cardiac patients",
          "cardiac symptoms (arrhythmia risk in DM1)",
          "heart rate",
          "hemodynamic response",
          "monitor for adrenal crisis if cortisol not replaced",
          "then q6-12 months when stable"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "brain-death-evaluation",
        "dementia-evaluation",
        "hashimotos-encephalopathy",
        "myotonic-dystrophy",
        "neurosarcoidosis"
      ]
    },
    "lidocaine-5-patch": {
      "id": "lidocaine-5-patch",
      "name": "Lidocaine 5% patch",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP",
        "Topical",
        "Transdermal"
      ],
      "formulations": [],
      "contexts": {
        "localized-paresthesia-pain": {
          "indication": "Localized paresthesia/pain",
          "doseOptions": [
            {
              "text": "1-3 patches",
              "orderSentence": "Lidocaine 5% patch 1-3 patches Transdermal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply 1-3 patches to painful area for 12 hours on, 12 hours off",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "localized-neuropathic-pain-adjunct-therapy": {
          "indication": "Localized neuropathic pain; adjunct therapy",
          "doseOptions": [
            {
              "text": "1-3 patches",
              "orderSentence": "Lidocaine 5% patch 1-3 patches TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply 1-3 patches to painful area for 12 hours on, 12 hours off; max 3 patches simultaneously",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Lidocaine 5% patch N/A Transdermal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Up to 3 patches daily; 12h on/12h off",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "diabetic-neuropathy"
          ]
        },
        "localized-pain-adjunctive-therapy-allodynia": {
          "indication": "Localized pain; adjunctive therapy; allodynia",
          "doseOptions": [
            {
              "text": "1-3 patches",
              "orderSentence": "Lidocaine 5% patch 1-3 patches Topical"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply to most painful area; up to 3 patches for 12h on/12h off",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "localized-neuropathic-pain": {
          "indication": "Localized neuropathic pain",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Lidocaine 5% patch N/A Transdermal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply 1-3 patches to painful area for 12 hours on, 12 hours off",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "localized-pain": {
          "indication": "Localized pain",
          "doseOptions": [
            {
              "text": "1 patch",
              "orderSentence": "Lidocaine 5% patch 1 patch TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply to wrist/forearm 12h on, 12h off",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        },
        "localized-neck-or-radicular-pain-adjunctive-for-neuropathic-": {
          "indication": "Localized neck or radicular pain; adjunctive for neuropathic pain",
          "doseOptions": [
            {
              "text": "1-3 patches",
              "orderSentence": "Lidocaine 5% patch 1-3 patches TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply up to 3 patches to painful area for 12 hours on, 12 hours off",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Allergy to local anesthetics",
          "Broken skin",
          "Severe hepatic disease",
          "Severe hepatic impairment",
          "application to broken skin",
          "damaged skin",
          "known lidocaine hypersensitivity",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Local irritation",
          "Local skin reaction",
          "Minimal systemic absorption",
          "Skin irritation",
          "cardiac arrhythmia (minimal systemic absorption)",
          "local irritation",
          "local skin irritation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "b12-deficiency-neuropathy",
        "carpal-tunnel-syndrome",
        "cervical-myelopathy",
        "diabetic-neuropathy",
        "paresthesia-numbness-tingling",
        "peripheral-neuropathy",
        "small-fiber-neuropathy"
      ]
    },
    "lidocaine-intranasal": {
      "id": "lidocaine-intranasal",
      "name": "Lidocaine intranasal",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IN"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1 mL",
              "orderSentence": "Lidocaine intranasal 1 mL -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4% lidocaine 1 mL applied to ipsilateral nostril (head tilted back); can repeat",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local anesthetic allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "May provide partial/temporary relief"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cluster-headache"
      ]
    },
    "lidocaine-iv-infusion": {
      "id": "lidocaine-iv-infusion",
      "name": "Lidocaine IV infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "sodium-channel-blockade-for-refractory-status-migrainosus-ty": {
          "indication": "Sodium channel blockade for refractory status migrainosus; typically inpatient protocol",
          "doseOptions": [
            {
              "text": "1-2 mg/kg bolus",
              "orderSentence": "Lidocaine IV infusion 1-2 mg/kg bolus IV"
            },
            {
              "text": "1-2 mg/min",
              "orderSentence": "Lidocaine IV infusion 1-2 mg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load 1-2 mg/kg IV over 20 min, then 1-2 mg/min (60-120 mg/hr) infusion x 24-48h",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart block, severe CHF, hepatic failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous cardiac monitoring, lidocaine level q12h (target <5 mcg/mL), neuro checks for toxicity (perioral numbness, tinnitus, seizures)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "lidocaine-patch-5": {
      "id": "lidocaine-patch-5",
      "name": "Lidocaine patch 5%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "localized-neuropathic-pain-adjunctive-to-systemic-agents": {
          "indication": "Localized neuropathic pain; adjunctive to systemic agents",
          "doseOptions": [
            {
              "text": "1 patch",
              "orderSentence": "Lidocaine patch 5% 1 patch TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply up to 3 patches to painful area for 12h on/12h off",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "localized-radicular-pain": {
          "indication": "Localized radicular pain",
          "doseOptions": [
            {
              "text": "1-3 patches",
              "orderSentence": "Lidocaine patch 5% 1-3 patches TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply 1-3 patches to affected area for 12h on, 12h off",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "localized-plexopathy-pain-shoulder-hip-region": {
          "indication": "Localized plexopathy pain (shoulder, hip region)",
          "doseOptions": [
            {
              "text": "1-3 patches",
              "orderSentence": "Lidocaine patch 5% 1-3 patches TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply 1-3 patches to affected area for 12h on, 12h off",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Allergy to amide anesthetics",
          "Severe hepatic impairment",
          "broken skin",
          "broken skin at application site"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Minimal systemic absorption",
          "Skin irritation at application site",
          "local skin irritation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "critical-illness-myopathy-neuropathy",
        "plexopathy",
        "radiculopathy"
      ]
    },
    "linezolid": {
      "id": "linezolid",
      "name": "Linezolid",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "mrsa-brain-abscess-alternative-to-vancomycin-excellent-cns-p": {
          "indication": "MRSA brain abscess alternative to vancomycin; excellent CNS penetration; useful when vancomycin levels difficult to maintain",
          "doseOptions": [
            {
              "text": "600 mg",
              "orderSentence": "Linezolid 600 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600 mg IV/PO q12h; 100% oral bioavailability; duration limited to 4 weeks ideally due to toxicity (use vancomycin for remainder)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "drug-resistant-tb-mdr-xdr-tb-excellent-cns-penetration-reser": {
          "indication": "Drug-resistant TB (MDR/XDR-TB); excellent CNS penetration; reserve for resistant cases due to toxicity",
          "doseOptions": [
            {
              "text": "600 mg",
              "orderSentence": "Linezolid 600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "600 mg PO/IV daily (some protocols use 600 mg BID initially then reduce to daily); duration limited by toxicity (aim for <6 months if possible)",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAOIs",
          "Concurrent serotonergic medications (serotonin syndrome)",
          "duration >4 weeks increases toxicity risk",
          "myelosuppression",
          "serotonergic agents",
          "thrombocytopenia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC weekly (thrombocytopenia, anemia)",
          "CBC weekly x 4, then monthly",
          "lactic acidosis",
          "lactic acidosis symptoms",
          "optic neuritis (rare but serious with prolonged use >28 days)",
          "peripheral neuropathy",
          "peripheral neuropathy assessment monthly",
          "serotonin syndrome risk",
          "visual acuity (optic neuropathy)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "brain-abscess",
        "tb-meningitis"
      ]
    },
    "lisinopril": {
      "id": "lisinopril",
      "name": "Lisinopril",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "blood-pressure-control-target-130-80-for-secondary-preventio": {
          "indication": "Blood pressure control; target <130/80 for secondary prevention",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Lisinopril 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg daily; titrate to goal BP <130/80; max 40 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "hypertension-target-bp-130-80-for-vascular-protection": {
          "indication": "Hypertension; target BP <130/80 for vascular protection",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Lisinopril 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg daily; titrate q2wk to BP goal",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "blood-pressure-management-for-secondary-stroke-prevention-ta": {
          "indication": "Blood pressure management for secondary stroke prevention; target BP <130/80 after acute phase",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Lisinopril 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg PO daily; titrate to 20-40 mg daily; target BP <130/80",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Lisinopril 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg PO daily; titrate to 20-40 mg daily; target BP <130/80 after acute phase",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "first-line-ace-inhibitor-for-post-stroke-bp-management-targe": {
          "indication": "First-line ACE inhibitor for post-stroke BP management; target BP <130/80 (SPRINT-like targets for secondary prevention)",
          "doseOptions": [
            {
              "text": "5 mg daily",
              "orderSentence": "Lisinopril 5 mg daily PO"
            },
            {
              "text": "10 mg daily",
              "orderSentence": "Lisinopril 10 mg daily PO"
            },
            {
              "text": "20 mg daily",
              "orderSentence": "Lisinopril 20 mg daily PO"
            },
            {
              "text": "40 mg daily",
              "orderSentence": "Lisinopril 40 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase by 5-10 mg q1-2wk; target BP <130/80; max 40 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "first-line-ace-inhibitor-for-bp-management-target-bp-130-80-": {
          "indication": "First-line ACE inhibitor for BP management; target BP <130/80 for symptomatic carotid stenosis (secondary stroke prevention); use caution with severe bilateral carotid stenosis (cerebral perfusion risk if BP drops too low)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Lisinopril 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase by 5-10 mg q1-2wk; target BP <130/80 for symptomatic; <140/90 for asymptomatic (avoid aggressive lowering if bilateral severe stenosis); max 40 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Angioedema history",
          "BP",
          "Bilateral renal artery stenosis",
          "Cr and K+ at 1-2 weeks after initiation",
          "angioedema history",
          "bilateral RAS",
          "bilateral renal artery stenosis",
          "critical bilateral carotid stenosis with hemodynamic compromise (cautious titration)",
          "hyperkalemia",
          "pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP within 2 weeks (creatinine, potassium)",
          "BMP within 2 weeks of starting (creatinine, potassium)",
          "BP",
          "BP at follow-up visits",
          "Cr and K+ at 1-2 weeks",
          "K+, Cr at 1-2 weeks",
          "K+, Cr, BP",
          "cough",
          "cough (switch to ARB if intolerable)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "carotid-stenosis",
        "cervical-artery-dissection",
        "mild-cognitive-impairment",
        "post-stroke-management",
        "vascular-dementia"
      ]
    },
    "lithium": {
      "id": "lithium",
      "name": "Lithium",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Lithium 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg BID-TID; target serum level 0.6-1.0 mEq/L; usual dose 600-1200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache"
          ]
        },
        "downbeat-nystagmus-and-cerebellar-toxicity-may-be-irreversib": {
          "indication": "Downbeat nystagmus and cerebellar toxicity; may be irreversible (\"SILENT syndrome\" — syndrome of irreversible lithium-effectuated neurotoxicity)",
          "doseOptions": [
            {
              "text": "Monitor levels",
              "orderSentence": "**Lithium (supratherapeutic)** Monitor levels PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Lithium level STAT if nystagmus develops in lithium-treated patient; irreversible cerebellar damage possible",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment, thyroid disease, dehydration, sodium depletion"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Lithium level",
          "Lithium level, renal function, TSH q3-6 months",
          "monitor for SILENT syndrome",
          "nystagmus in lithium-treated patient — STAT level"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "cluster-headache",
        "nystagmus-evaluation"
      ]
    },
    "lithium-dose-adjustment-or-discontinuation": {
      "id": "lithium-dose-adjustment-or-discontinuation",
      "name": "Lithium dose adjustment or discontinuation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "lithium-toxicity-causing-cerebellar-ataxia-supratherapeutic-": {
          "indication": "Lithium toxicity causing cerebellar ataxia; supratherapeutic level",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Lithium dose adjustment or discontinuation N/A PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Hold lithium; aggressive IV hydration; recheck level q6-12h; hemodialysis if level >4.0 or severe symptoms; resume at lower dose when level therapeutic",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Psychiatry consult before discontinuation",
          "monitor for rebound mania"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP q6-12h",
          "Lithium level q6-12h",
          "hemodialysis if level >4.0",
          "neurologic exam",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ataxia-evaluation"
      ]
    },
    "loading-dose": {
      "id": "loading-dose",
      "name": "Loading dose (if significantly subtherapeutic)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "15-20 mg",
              "orderSentence": "**Loading dose (if significantly subtherapeutic)** 15-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Phenytoin/Fosphenytoin:** 15-20 mg PE/kg IV (if level very low); **Valproate:** 20-30 mg/kg IV (if level very low); **Levetiracetam:** 1000-1500 mg IV (if not on levetiracetam — can be added); **Note:** Loading the same drug patient is already taking risks toxicity → use cautiously",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "breakthrough-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "For significantly subtherapeutic levels or if need rapid therapeutic concentration",
          "adjust for partial levels"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "breakthrough-seizure"
      ]
    },
    "lomustine": {
      "id": "lomustine",
      "name": "Lomustine (CCNU)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "recurrent-glioblastoma-alkylating-agent-can-be-combined-with": {
          "indication": "Recurrent glioblastoma; alkylating agent; can be combined with bevacizumab; single agent option for recurrence",
          "doseOptions": [
            {
              "text": "110 mg/m2",
              "orderSentence": "Lomustine (CCNU) 110 mg/m2 PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "110 mg/m2 PO as single dose every 6 weeks; reduce to 100 mg/m2 if prior myelosuppression; take on empty stomach; do not repeat until platelets >100K and WBC >4K",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe myelosuppression",
          "WBC <4K",
          "hepatic/renal impairment",
          "platelets <100K",
          "pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC with differential weekly for 6 weeks after each dose (nadir at 4-6 weeks)",
          "LFTs",
          "pulmonary function (cumulative pulmonary toxicity)",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "glioblastoma"
      ]
    },
    "loop-diuretics": {
      "id": "loop-diuretics",
      "name": "Loop diuretics (furosemide, ethacrynic acid)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "ototoxic-especially-iv-high-dose-or-in-renal-impairment-usua": {
          "indication": "Ototoxic, especially IV high-dose or in renal impairment; usually reversible",
          "doseOptions": [
            {
              "text": "-",
              "orderSentence": "**Loop diuretics** (furosemide, ethacrynic acid) - IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Use lowest effective dose; avoid rapid IV bolus; ethacrynic acid more ototoxic than furosemide",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pre-existing hearing loss with high doses (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Monitor hearing",
          "avoid IV bolus",
          "use lowest effective dose"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tinnitus-evaluation"
      ]
    },
    "lorazepam": {
      "id": "lorazepam",
      "name": "Lorazepam",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/PO",
        "PO",
        "PO/IM/IV",
        "PO/IV",
        "PO/SL"
      ],
      "formulations": [],
      "contexts": {
        "severe-chorea-causing-injury-or-exhaustion": {
          "indication": "Severe chorea causing injury or exhaustion",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Lorazepam 0.5 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-2 mg IV/PO q4-6h PRN; short-term use only",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "status-dystonicus-severe-dystonic-storm": {
          "indication": "Status dystonicus; severe dystonic storm",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Lorazepam 1 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg IV slow push or 2-4 mg PO; may repeat q4-6h PRN; monitor respiratory status",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "seizure-secondary-to-cortical-parenchymal-nbd": {
          "indication": "Seizure secondary to cortical/parenchymal NBD",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Lorazepam (CPT 96374) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV push (max 4 mg/dose); repeat x1 in 5 minutes if seizure persists",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "acute-seizure-termination-20-40-of-gbm-patients-present-with": {
          "indication": "Acute seizure termination; 20-40% of GBM patients present with seizures",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Lorazepam (acute seizure) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg/dose); may repeat x1 in 5 min; max 8 mg total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "anxiety-dyspnea-end-of-life": {
          "indication": "Anxiety; dyspnea (end of life)",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Lorazepam 0.5 mg PO/SL"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg PO/SL q8h PRN for anxiety or dyspnea; use low doses due to respiratory depression risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "acute-prolonged-seizure-or-cluster-in-ed-hospital-setting": {
          "indication": "Acute prolonged seizure or cluster in ED/hospital setting",
          "doseOptions": [
            {
              "text": "4 mg IV push",
              "orderSentence": "Lorazepam 4 mg IV push IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV push over 2 min; may repeat x1 in 5 min; max 8 mg; prepare for airway management",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "acute-anxiety-seizure-cluster-prophylaxis-during-high-risk-p": {
          "indication": "Acute anxiety; seizure cluster prophylaxis during high-risk periods (illness, sleep deprivation)",
          "doseOptions": [
            {
              "text": "0.5 mg q8h PRN",
              "orderSentence": "Lorazepam (short-term oral) 0.5 mg q8h PRN PO"
            },
            {
              "text": "1 mg q8h PRN",
              "orderSentence": "Lorazepam (short-term oral) 1 mg q8h PRN PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg PO q8h PRN for anxiety or cluster prophylaxis; limit to 2-4 weeks; chronic use increases tolerance and complicates epilepsy management",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "active-seizure": {
          "indication": "Active seizure",
          "doseOptions": [
            {
              "text": "0.1 mg/kg",
              "orderSentence": "Lorazepam (acute seizure) 0.1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg/dose); repeat x1 in 5 minutes if seizure persists",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "acute-agitation-anxiety-insomnia-catatonia-features": {
          "indication": "Acute agitation, anxiety, insomnia; catatonia features",
          "doseOptions": [
            {
              "text": "1-2 mg",
              "orderSentence": "Lorazepam (agitation/anxiety) 1-2 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 mg IV/PO q4-6h PRN; for catatonia: escalate to 8-24 mg/day as needed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.1 mg/kg",
              "orderSentence": "Lorazepam (seizure rescue) 0.1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg); repeat x1 in 5 min if needed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hsv-encephalitis",
            "autoimmune-encephalitis"
          ]
        },
        "active-seizure-rescue-rare-in-isolated-viral-meningitis-more": {
          "indication": "Active seizure rescue; rare in isolated viral meningitis; more common if encephalitis component",
          "doseOptions": [
            {
              "text": "0.1 mg/kg",
              "orderSentence": "Lorazepam (seizure rescue) 0.1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg); may repeat x1 in 5 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "seizure-secondary-to-cortical-meningeal-sarcoidosis": {
          "indication": "Seizure secondary to cortical/meningeal sarcoidosis",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Lorazepam 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV push (max 4 mg/dose); may repeat x1 in 5 minutes",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "active-seizure-rescue": {
          "indication": "Active seizure rescue",
          "doseOptions": [
            {
              "text": "0.1 mg/kg IV push",
              "orderSentence": "Lorazepam 0.1 mg/kg IV push IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg); may repeat x1 in 5 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosyphilis",
            "tb-meningitis"
          ]
        },
        "active-seizures-in-setting-of-leptomeningeal-disease-with-co": {
          "indication": "Active seizures in setting of leptomeningeal disease with cortical irritation",
          "doseOptions": [
            {
              "text": "0.1 mg/kg",
              "orderSentence": "**Lorazepam (acute seizure)** 0.1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV push (max 4 mg per dose); may repeat x1 in 5 min; max 8 mg total; bridge to AED loading",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "second-line-for-eclamptic-seizure-not-responding-to-mgso4-or": {
          "indication": "Second-line for eclamptic seizure not responding to MgSO4; or while MgSO4 loading in progress",
          "doseOptions": [
            {
              "text": "4 mg IV push",
              "orderSentence": "Lorazepam 4 mg IV push IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV push over 2 min; may repeat x1 in 5 min; max 8 mg; benzodiazepines cross placenta — anticipate neonatal sedation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "acute-seizure-termination-10-20-of-pcnsl-patients-present-wi": {
          "indication": "Acute seizure termination; 10-20% of PCNSL patients present with seizures",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Lorazepam (acute seizure) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg/dose); may repeat x1 in 5 min; max 8 mg total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "acute-seizure-management-seizures-occur-in-10-25-of-pacns-pa": {
          "indication": "Acute seizure management; seizures occur in 10-25% of PACNS patients",
          "doseOptions": [
            {
              "text": "0.1 mg/kg IV push",
              "orderSentence": "Lorazepam (acute seizure) 0.1 mg/kg IV push IV"
            },
            {
              "text": "4 mg max",
              "orderSentence": "Lorazepam (acute seizure) 4 mg max IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg/dose); may repeat x1 in 5 minutes; max 8 mg total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "anxiolysis-and-headache-relief-reduces-sympathetic-drive-whi": {
          "indication": "Anxiolysis and headache relief; reduces sympathetic drive which may worsen vasoconstriction",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Lorazepam 0.5 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg IV/PO q6-8h PRN severe headache or anxiety; short-course only (3-5 days)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "active-seizure-in-ncc-breakthrough-seizure-during-antiparasi": {
          "indication": "Active seizure in NCC; breakthrough seizure during antiparasitic treatment",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Lorazepam (seizure rescue) (CPT 96374) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg) over 2 min; repeat x1 in 5 min if seizure continues; max 8 mg total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "severe-acute-tremor-causing-significant-distress-or-function": {
          "indication": "Severe acute tremor causing significant distress or functional impairment; short-term bridge while definitive evaluation underway",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Lorazepam (short-term) 0.5 mg PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg PO/IV q8h PRN for severe tremor; limit to 48-72 hours acute use; not for chronic management due to dependence risk",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "acute-spasms-alternative-to-diazepam-if-iv-diazepam-unavaila": {
          "indication": "Acute spasms; alternative to diazepam if IV diazepam unavailable; status spasticus",
          "doseOptions": [
            {
              "text": "2-4 mg",
              "orderSentence": "Lorazepam 2-4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-4 mg IV push over 2 minutes; may repeat q5-10 min; max 8 mg in first hour; less lipophilic than diazepam (shorter CNS duration)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "seizure-management-in-paraneoplastic-limbic-encephalitis": {
          "indication": "Seizure management in paraneoplastic limbic encephalitis",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Lorazepam (acute seizure) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg/dose); may repeat x1 in 5 min; max 8 mg total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "acute-seizure-or-status-epilepticus": {
          "indication": "Acute seizure or status epilepticus",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Lorazepam (acute seizure) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg/dose); may repeat x1 in 5 min; max 8 mg total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "agitation-myoclonus-cjd": {
          "indication": "Agitation, myoclonus (CJD)",
          "doseOptions": [
            {
              "text": "0.5-1 mg",
              "orderSentence": "Lorazepam (CPT 96374) 0.5-1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg PO/IV q6-8h PRN",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        },
        "acute-seizure-management-seizures-reported-in-15-20-of-susac": {
          "indication": "Acute seizure management; seizures reported in 15-20% of Susac syndrome patients",
          "doseOptions": [
            {
              "text": "0.1 mg/kg IV",
              "orderSentence": "Lorazepam (acute seizure) 0.1 mg/kg IV IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg/dose); repeat x1 in 5 minutes if needed; max 8 mg total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "acute-severe-agitation-when-de-escalation-fails": {
          "indication": "Acute severe agitation when de-escalation fails",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Lorazepam 0.5 mg PO/IM/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg PO or IM; may repeat q30min PRN; max 4 mg; short-term use only",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "active-seizure-rescue-2": {
          "indication": "Active seizure (rescue)",
          "doseOptions": [
            {
              "text": "0.1 mg/kg",
              "orderSentence": "Lorazepam 0.1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg); may repeat x1",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "active-seizure-breakthrough-seizure-on-prophylaxis": {
          "indication": "Active seizure; breakthrough seizure on prophylaxis",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Lorazepam (seizure rescue) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg) over 2 min; may repeat x1 in 5 min; max 8 mg total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "acute-seizure-termination-seizures-occur-in-20-50-of-convexi": {
          "indication": "Acute seizure termination; seizures occur in 20-50% of convexity meningiomas",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Lorazepam (acute seizure) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg/dose); may repeat x1 in 5 min; max 8 mg total",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "anxiety-autonomic-crisis": {
          "indication": "Anxiety, autonomic crisis",
          "doseOptions": [
            {
              "text": "0.5-1 mg",
              "orderSentence": "Lorazepam 0.5-1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg IV/PO q6-8h PRN",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        },
        "anxiety-agitation-in-intubated-patient": {
          "indication": "Anxiety, agitation in intubated patient",
          "doseOptions": [
            {
              "text": "0.5-1 mg",
              "orderSentence": "Lorazepam (CPT 96374) 0.5-1 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg IV q6-8h PRN; use with caution — may worsen hypotonia",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "botulism"
          ]
        },
        "post-ictal-agitation-if-severe": {
          "indication": "Post-ictal agitation (if severe)",
          "doseOptions": [
            {
              "text": "0.5-2 mg",
              "orderSentence": "Lorazepam 0.5-2 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-2 mg IV/PO PRN; use with caution",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Acute narrow-angle glaucoma",
          "Respiratory compromise",
          "Respiratory compromise (high doses)",
          "Respiratory compromise (use with extreme caution)",
          "Respiratory depression",
          "Respiratory depression (extreme caution if not intubated)",
          "Respiratory depression without ventilator support",
          "Severe respiratory depression",
          "Severe respiratory depression without ventilator support",
          "Severe respiratory depression without ventilatory support",
          "Severe respiratory insufficiency (relative)",
          "acute narrow-angle glaucoma",
          "altered mental status",
          "concurrent CNS depressants",
          "concurrent opioids (relative)",
          "elderly (fall risk)",
          "myasthenia gravis",
          "paradoxical agitation risk in elderly",
          "prior paradoxical response",
          "severe hepatic failure",
          "severe hepatic impairment",
          "severe hepatic insufficiency",
          "severe hypotension",
          "severe respiratory depression without ventilator",
          "short-term use only",
          "use only if MgSO4 inadequate"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Bush-Francis Catatonia Rating Scale",
          "RR, O2 sat, BP, sedation level",
          "RR, SpO2",
          "RR, sedation",
          "RR, sedation level",
          "RR, sedation scale",
          "Respiratory depression, sedation",
          "Respiratory rate",
          "Respiratory status",
          "Respiratory status, sedation",
          "Sedation",
          "Sedation, respiratory rate, fall risk",
          "SpO2",
          "airway",
          "airway equipment at bedside",
          "airway equipment ready",
          "airway patency",
          "avoid if post-ictal confusion resolving",
          "avoid in non-intubated patients",
          "blood pressure",
          "dependence risk",
          "do NOT prescribe for chronic use",
          "have airway equipment ready",
          "neonatal assessment at delivery",
          "oxygen saturation",
          "paradoxical agitation",
          "paradoxical reactions",
          "respiratory rate",
          "respiratory status",
          "sedation",
          "sedation level",
          "tolerance"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 36,
      "_sourcePlans": [
        "als",
        "autoimmune-encephalitis",
        "bacterial-meningitis",
        "botulism",
        "brain-abscess",
        "cns-vasculitis",
        "creutzfeldt-jakob-disease",
        "drug-resistant-epilepsy",
        "dystonia",
        "eclampsia-seizure-pregnancy",
        "frontotemporal-dementia",
        "glioblastoma",
        "guillain-barre-syndrome",
        "hashimotos-encephalopathy",
        "hsv-encephalitis",
        "huntingtons-disease",
        "leptomeningeal-carcinomatosis",
        "meningioma",
        "neuro-behcets-disease",
        "neurocysticercosis",
        "neurosarcoidosis",
        "neurosyphilis",
        "new-onset-seizure",
        "paraneoplastic-neurological-syndrome",
        "primary-cns-lymphoma",
        "rapidly-progressive-dementia",
        "rcvs",
        "stiff-person-syndrome",
        "susac-syndrome",
        "tb-meningitis",
        "tremor-unspecified",
        "viral-meningitis"
      ]
    },
    "lorazepam-iv": {
      "id": "lorazepam-iv",
      "name": "Lorazepam IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-seizure-cessation-and-withdrawal-seizure-prevention": {
          "indication": "Acute seizure cessation and withdrawal seizure prevention",
          "doseOptions": [
            {
              "text": "2-4 mg",
              "orderSentence": "Lorazepam IV 2-4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-4 mg IV push over 2 min; may repeat q5-10min; max 8-10 mg in first hour; preferred in hepatic impairment (no hepatic metabolism)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.1 mg/kg",
              "orderSentence": "Lorazepam IV (CPT 96374) 0.1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg/dose); may repeat x1 in 5 min if still seizing; total max 8 mg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "first-line-for-ncse-serves-as-diagnostic-and-therapeutic-tri": {
          "indication": "First-line for NCSE; serves as diagnostic AND therapeutic trial (clinical AND EEG improvement confirms NCSE)",
          "doseOptions": [
            {
              "text": "0.1 mg/kg",
              "orderSentence": "Lorazepam IV (diagnostic and therapeutic benzodiazepine trial) 0.1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV push over 2 min (max 4 mg/dose); may repeat x1 in 5 min if no response; observe EEG during and after administration",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Acute narrow-angle glaucoma",
          "Respiratory depression",
          "acute narrow-angle glaucoma",
          "severe respiratory depression without ventilator support",
          "severe respiratory failure without ventilator"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "EEG response (look for seizure termination AND clinical improvement -- EEG improvement alone without clinical improvement does not confirm NCSE)",
          "O2 sat",
          "RR, O2 sat, BP, sedation",
          "RR, O2 sat, BP, sedation level",
          "Respiratory rate",
          "airway equipment at bedside",
          "airway equipment ready",
          "have airway equipment ready"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "ncse",
        "status-epilepticus"
      ]
    },
    "lorazepam-iv-im": {
      "id": "lorazepam-iv-im",
      "name": "Lorazepam IV/IM (if actively seizing) (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.1 mg/kg",
              "orderSentence": "Lorazepam IV/IM (if actively seizing) (CPT 96374) 0.1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1 mg/kg IV (max 4 mg); may repeat once in 5 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Respiratory depression, severe hypotension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RR, O2 sat, BP",
          "have airway equipment ready"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "new-onset-seizure"
      ]
    },
    "lorazepam-po": {
      "id": "lorazepam-po",
      "name": "Lorazepam PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "symptom-triggered-withdrawal-management-preferred-in-liver-d": {
          "indication": "Symptom-triggered withdrawal management; preferred in liver disease (no hepatic metabolism required)",
          "doseOptions": [
            {
              "text": "1-2 mg",
              "orderSentence": "Lorazepam PO 1-2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "CIWA-Ar >=10: give 1-2 mg PO q1-2h until CIWA <10; then PRN dosing; shorter half-life requires more frequent dosing; preferred if AST/ALT elevated or known cirrhosis",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe respiratory depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CIWA-Ar q1h during active treatment, then q4h",
          "RR, sedation level",
          "shorter acting - watch for rebound"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure"
      ]
    },
    "lorlatinib": {
      "id": "lorlatinib",
      "name": "Lorlatinib (ALK+ NSCLC)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alk-rearranged-nsclc-with-leptomeningeal-disease-highest-cns": {
          "indication": "ALK-rearranged NSCLC with leptomeningeal disease; highest CNS penetration among ALK inhibitors",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "**Lorlatinib (ALK+ NSCLC)** 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Lorlatinib 100 mg PO daily; alternative: alectinib 600 mg PO BID; intracranial response rates 60-80%",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CNS effects (mood, cognition)",
          "Severe hepatic impairment",
          "concurrent strong CYP3A inducers",
          "hyperlipidemia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "ECG",
          "LFTs monthly",
          "Lipid panel monthly",
          "neuropsychiatric assessment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "losartan": {
      "id": "losartan",
      "name": "Losartan",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "hypertension-alternative-if-ace-i-intolerant": {
          "indication": "Hypertension; alternative if ACE-I intolerant",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Losartan 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg daily; titrate to BP goal; max 100 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Losartan 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; max 100 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "arb-for-post-stroke-bp-management-alternative-if-ace-inhibit": {
          "indication": "ARB for post-stroke BP management; alternative if ACE inhibitor not tolerated (cough); LIFE trial showed stroke reduction",
          "doseOptions": [
            {
              "text": "25 mg daily",
              "orderSentence": "Losartan 25 mg daily PO"
            },
            {
              "text": "50 mg daily",
              "orderSentence": "Losartan 50 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Losartan 100 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg daily; increase by 25-50 mg q2-4wk; target BP <130/80; max 100 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "arb-for-bp-management-alternative-if-ace-inhibitor-not-toler": {
          "indication": "ARB for BP management; alternative if ACE inhibitor not tolerated (cough); LIFE trial showed stroke reduction vs atenolol",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Losartan 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg daily; increase by 25-50 mg q2-4wk; target BP <130/80 (symptomatic) or <140/90 (asymptomatic); max 100 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Angioedema history",
          "Bilateral renal artery stenosis",
          "Cr, K+, BP",
          "bilateral renal artery stenosis",
          "hyperkalemia",
          "pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP within 2 weeks",
          "BP",
          "K+, Cr, BP",
          "less cough than ACEi"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "carotid-stenosis",
        "mild-cognitive-impairment",
        "post-stroke-management"
      ]
    },
    "low-dose-naltrexone": {
      "id": "low-dose-naltrexone",
      "name": "Low-dose naltrexone (LDN)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "emerging-evidence-for-neuropathic-pain-anti-inflammatory": {
          "indication": "Emerging evidence for neuropathic pain; anti-inflammatory",
          "doseOptions": [
            {
              "text": "1.5 mg",
              "orderSentence": "Low-dose naltrexone (LDN) 1.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1.5 mg qHS; increase by 1.5 mg q2wk; max 4.5 mg; compounded",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Current opioid use",
          "hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Vivid dreams, insomnia (take in AM if occurs)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "small-fiber-neuropathy"
      ]
    },
    "low-dose-opioids": {
      "id": "low-dose-opioids",
      "name": "Low-dose opioids",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5-15 mg",
              "orderSentence": "Low-dose opioids 5-15 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Oxycodone 5-15 mg QHS or tramadol 50-100 mg QHS; RESERVE for refractory cases",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "restless-legs-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Addiction risk, respiratory depression, apnea"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dependence, respiratory"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "restless-legs-syndrome"
      ]
    },
    "low-glycemic-index-treatment": {
      "id": "low-glycemic-index-treatment",
      "name": "Low glycemic index treatment (LGIT)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Dietary"
      ],
      "formulations": [],
      "contexts": {
        "least-restrictive-dietary-therapy-for-dre-glycemic-index-50-": {
          "indication": "Least restrictive dietary therapy for DRE; glycemic index <50 for all carbohydrates; may be sufficient for some patients",
          "doseOptions": [
            {
              "text": "40-60 g low-GI carbs/day",
              "orderSentence": "Low glycemic index treatment (LGIT) 40-60 g low-GI carbs/day Dietary"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Restrict to 40-60 g carbohydrate/day; all carbs must have glycemic index <50; liberal fat and protein; most flexible dietary option",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as ketogenic diet"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same as ketogenic diet",
          "monitor glucose and lipids"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "lower-sodium-oxybate": {
      "id": "lower-sodium-oxybate",
      "name": "Lower-sodium oxybate (Xywav)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-for-cataplexy-92-less-sodium-than-xyrem-also-impr": {
          "indication": "First-line for cataplexy; 92% less sodium than Xyrem; also improves EDS and disrupted nocturnal sleep; REMS program (Xywav REMS)",
          "doseOptions": [
            {
              "text": "2.25 g",
              "orderSentence": "Lower-sodium oxybate (Xywav) 2.25 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4.5 g/night divided into 2 equal doses at bedtime and 2.5-4 hours later; titrate by 1.5 g/night every 1-2 weeks; max 9 g/night",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Succinic semialdehyde dehydrogenase deficiency",
          "concurrent opioids",
          "concurrent sedative-hypnotics or alcohol"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CNS depression",
          "Respiratory depression",
          "abuse potential",
          "depression/suicidality",
          "sleepwalking"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "narcolepsy"
      ]
    },
    "lubiprostone": {
      "id": "lubiprostone",
      "name": "Lubiprostone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "constipation-refractory": {
          "indication": "Constipation (refractory)",
          "doseOptions": [
            {
              "text": "24 mcg",
              "orderSentence": "Lubiprostone 24 mcg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "24 mcg BID with food",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Mechanical GI obstruction"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Nausea (common)",
          "diarrhea",
          "dyspnea"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ms-new-diagnosis"
      ]
    },
    "magnesium-oxide": {
      "id": "magnesium-oxide",
      "name": "Magnesium oxide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "400-600 mg",
              "orderSentence": "Magnesium oxide 400-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "adjunctive-preventive-level-b-evidence-low-side-effect-profi": {
          "indication": "Adjunctive preventive; Level B evidence; low side effect profile",
          "doseOptions": [
            {
              "text": "400-600 mg",
              "orderSentence": "Magnesium oxide 400-600 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-600 mg PO daily; use chelated form (glycinate or citrate) if GI intolerance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "first-line-supplement-for-migraine-with-aura-prevention": {
          "indication": "First-line supplement for migraine with aura prevention",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Magnesium oxide 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 400 mg daily; may increase to 400 mg BID; take with food to reduce GI upset",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal failure",
          "Renal failure (CrCl <30)",
          "Renal impairment (CrCl <30) - dose reduce"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Diarrhea",
          "Diarrhea (dose-limiting)",
          "check Mg level if symptomatic or renal disease",
          "check serum Mg if symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "migraine-with-aura"
      ]
    },
    "magnesium-sulfate": {
      "id": "magnesium-sulfate",
      "name": "Magnesium sulfate (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "adjunct-for-refractory-headache-particularly-effective-if-lo": {
          "indication": "Adjunct for refractory headache; particularly effective if low magnesium or suspected migraine",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate (CPT 96365) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV in 100 mL NS over 20-30 min",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "adjunct-for-headache-in-pregnancy-also-seizure-prophylaxis-b": {
          "indication": "Adjunct for headache in pregnancy; also seizure prophylaxis benefit",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate (CPT 96365) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV over 20-30 min",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "low-magnesium-adjunctive-headache-treatment-especially-if-mi": {
          "indication": "Low magnesium; adjunctive headache treatment especially if migraine suspected",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate (CPT 96365) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV in 100 mL NS over 20-30 min",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "correct-hypomagnesemia-magnesium-has-vasodilatory-properties": {
          "indication": "Correct hypomagnesemia; magnesium has vasodilatory properties and may reduce vasospasm",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate (supplemental) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-4 g IV over 1-2h if Mg <2.0; target serum Mg >2.0 mg/dL; maintenance 1-2 g IV q6h if persistently low",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "hypomagnesemia-induced-tremor-and-neuromuscular-excitability": {
          "indication": "Hypomagnesemia-induced tremor and neuromuscular excitability",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate (for hypomagnesemia) (CPT 96365) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Administer 2 g IV over 1 hour; recheck magnesium in 4-6 hours; repeat 1-2 g IV if still low; transition to oral magnesium oxide 400-800 mg daily",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "adjunctive-anti-shivering-lowers-shivering-threshold-and-sei": {
          "indication": "Adjunctive anti-shivering; lowers shivering threshold and seizure threshold",
          "doseOptions": [
            {
              "text": "2-4 g",
              "orderSentence": "Magnesium sulfate 2-4 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-4 g IV bolus then 1-2 g/h infusion; target Mg 3-4 mg/dL",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV once",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "migraine",
            "subarachnoid-hemorrhage"
          ]
        },
        "migraine-with-aura-particularly-effective-refractory-migrain": {
          "indication": "Migraine with aura - particularly effective; refractory migraine",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV in 50 mL NS over 20-30 min; may repeat x1 after 2 hr",
          "settings": {
            "ED": "STAT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart block",
          "Renal failure",
          "Renal failure (GFR <30)",
          "Renal failure (GFR <30), myasthenia gravis, heart block",
          "Renal failure (accumulation)",
          "Renal failure (dose adjust)",
          "heart block",
          "hypermagnesemia",
          "myasthenia gravis",
          "severe bradycardia",
          "severe hypermagnesemia",
          "severe renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP, HR during infusion",
          "HR",
          "Magnesium level, deep tendon reflexes, respiratory status",
          "Mg level q4-6h",
          "Mg levels, patellar reflexes, respiratory rate",
          "Reflexes, respiratory",
          "Reflexes, respiratory rate, Mg level",
          "Serum Mg q12-24h",
          "Serum magnesium levels",
          "deep tendon reflexes",
          "flushing is common and benign",
          "respiratory rate"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 9,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "headache-evaluation",
        "headache-unspecified",
        "migraine",
        "migraine-with-aura",
        "rcvs",
        "subarachnoid-hemorrhage",
        "tremor-unspecified"
      ]
    },
    "magnesium-sulfate-infusion": {
      "id": "magnesium-sulfate-infusion",
      "name": "Magnesium sulfate infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "4-6 g",
              "orderSentence": "Magnesium sulfate infusion 4-6 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-6 g IV over 20 min, then 1-2 g/hr infusion; target Mg 3.5-4 mg/dL",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal failure (relative), myasthenia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Mg levels, reflexes, respiratory status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-epilepticus"
      ]
    },
    "magnesium-sulfate-iv": {
      "id": "magnesium-sulfate-iv",
      "name": "Magnesium sulfate IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "paresthesia-with-documented-hypomagnesemia": {
          "indication": "Paresthesia with documented hypomagnesemia",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate IV (symptomatic hypomagnesemia) 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV over 15-30 min; follow with 4-8 g over 24h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "correct-hypomagnesemia-magnesium-required-for-enzymatic-reac": {
          "indication": "Correct hypomagnesemia; magnesium required for enzymatic reactions involving B12",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate IV 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV over 2 hours if Mg <1.5 mg/dL; then oral magnesium oxide 400 mg PO daily",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-2 g",
              "orderSentence": "Magnesium sulfate IV (CPT 96374) 1-2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 g IV over 1-2 hours; repeat as needed; target Mg >2.0",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wernicke-encephalopathy",
            "migraine"
          ]
        },
        "hypomagnesemia-correction-required-cofactor-for-thiamine-met": {
          "indication": "Hypomagnesemia correction; required cofactor for thiamine metabolism",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate IV 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV over 1 hour initially; then 1 g IV q6h until Mg >2.0 mg/dL; severe deficiency may require 4-6 g over first 24 hours",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "adjunctive-low-magnesium-associated-with-migraine-migraine-w": {
          "indication": "Adjunctive; low magnesium associated with migraine; migraine with aura",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Magnesium sulfate IV 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV over 20-30 min",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "direct-analgesic-effect-in-migraine-low-magnesium-lowers-cor": {
          "indication": "Direct analgesic effect in migraine; low magnesium lowers cortical spreading depression threshold",
          "doseOptions": [
            {
              "text": "2 g IV once",
              "orderSentence": "Magnesium sulfate IV 2 g IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV in 50 mL NS over 20-30 min",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Myasthenia gravis",
          "Renal failure",
          "Renal failure (CrCl <20), myasthenia gravis, heart block",
          "Renal failure (GFR <30), myasthenia gravis, heart block",
          "Renal failure (adjust dose)",
          "Renal failure (monitor levels closely)",
          "Renal failure, myasthenia",
          "heart block",
          "myasthenia gravis",
          "severe renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cardiac monitor",
          "Magnesium level, deep tendon reflexes, respiratory status, flushing",
          "Magnesium levels",
          "Mg levels",
          "Mg levels q12-24h",
          "Mg levels, DTRs, respiratory status",
          "Mg levels, reflexes",
          "cardiac monitoring during IV infusion",
          "deep tendon reflexes",
          "magnesium level q6-8h",
          "reflexes",
          "renal function",
          "respiratory status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "b12-deficiency-neuropathy",
        "chronic-migraine",
        "migraine",
        "paresthesia-numbness-tingling",
        "status-migrainosus",
        "wernicke-encephalopathy"
      ]
    },
    "magnesium-sulfate-loading-dose": {
      "id": "magnesium-sulfate-loading-dose",
      "name": "Magnesium sulfate (MgSO4) — loading dose",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "first-line-for-eclamptic-seizures-and-seizure-prophylaxis-in": {
          "indication": "**FIRST-LINE for eclamptic seizures and seizure prophylaxis in severe preeclampsia**; superior to phenytoin and diazepam for eclampsia",
          "doseOptions": [
            {
              "text": "4-6 g IV over 15-20 min",
              "orderSentence": "Magnesium sulfate (MgSO4) — loading dose 4-6 g IV over 15-20 min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-6 g IV loading dose in 100 mL NS over 15-20 min; Zuspan regimen: 4 g IV load + 1 g/h maintenance; Pritchard regimen: 4 g IV + 10 g IM load (5 g each buttock) + 5 g IM q4h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Myasthenia gravis",
          "heart block",
          "severe renal failure (adjust dose)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Magnesium level q4-6h (target 4-7 mEq/L)",
          "deep tendon reflexes q1h (FIRST SIGN of toxicity = loss of patellar reflex)",
          "have calcium gluconate at bedside",
          "respiratory rate q1h (>12/min)",
          "urine output q1h (>25 mL/h)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy"
      ]
    },
    "magnesium-sulfate-maintenance": {
      "id": "magnesium-sulfate-maintenance",
      "name": "Magnesium sulfate (MgSO4) — maintenance",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "continued-seizure-prophylaxis-after-loading-dose-continue-fo": {
          "indication": "Continued seizure prophylaxis after loading dose; continue for 24-48h postpartum (eclampsia risk persists postpartum)",
          "doseOptions": [
            {
              "text": "1-2 g/h continuous infusion",
              "orderSentence": "Magnesium sulfate (MgSO4) — maintenance 1-2 g/h continuous infusion IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 g/h standard maintenance; increase to 2 g/h if seizure recurs or in severe preeclampsia; continue 24h postpartum (48h if persistent severe features); reduce to 0.5 g/h if CrCl <30",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as loading",
          "monitor for toxicity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same as loading",
          "reduce dose if reflexes diminish or urine output drops"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy"
      ]
    },
    "magnesium-supplementation": {
      "id": "magnesium-supplementation",
      "name": "Magnesium supplementation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "amphotericin-b-causes-renal-magnesium-wasting-hypomagnesemia": {
          "indication": "Amphotericin B causes renal magnesium wasting; hypomagnesemia worsens hypokalemia (refractory hypokalemia until Mg corrected)",
          "doseOptions": [
            {
              "text": "2-4 g",
              "orderSentence": "Magnesium supplementation 2-4 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Magnesium sulfate 2-4 g IV over 2-4 hours for Mg <1.5; oral magnesium oxide 400-800 mg daily for mild depletion",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal failure (use cautiously)",
          "heart block"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Magnesium levels daily during induction",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "mannitol": {
      "id": "mannitol",
      "name": "Mannitol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-elevated-icp-from-large-parenchymal-lesion-or-cvt-with": {
          "indication": "Acute elevated ICP from large parenchymal lesion or CVT with impending herniation",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "Mannitol 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 g/kg IV bolus over 15-20 minutes; repeat 0.5 g/kg q6h; maintain serum osmolality <320 mOsm/kg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "acute-elevated-icp-with-herniation-signs-bridge-to-definitiv": {
          "indication": "Acute elevated ICP with herniation signs; bridge to definitive surgical intervention",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "Mannitol (elevated ICP) 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus over 15-20 min; may repeat 0.25-0.5 g/kg q4-6h; maintain serum osmolality <320 mOsm/kg",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "acute-elevated-icp-from-mass-lesion-or-obstructive-hydroceph": {
          "indication": "Acute elevated ICP from mass lesion or obstructive hydrocephalus pending surgical intervention",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "Mannitol 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 g/kg IV bolus over 15-20 minutes; may repeat 0.5 g/kg q6h; maintain serum osmolality <320 mOsm/kg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "acute-hydrocephalus-with-herniation-signs-pupil-asymmetry-po": {
          "indication": "Acute hydrocephalus with herniation signs (pupil asymmetry, posturing, declining GCS)",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "**Mannitol (acute herniation)** 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus over 15-20 min; may repeat 0.25-0.5 g/kg q4-6h; bridge to emergent CSF diversion or radiation",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "acute-elevated-icp-with-herniation-signs-bridge-to-biopsy-an": {
          "indication": "Acute elevated ICP with herniation signs; bridge to biopsy and definitive treatment",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "Mannitol (elevated ICP) 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus over 15-20 min; may repeat 0.25-0.5 g/kg q4-6h; maintain serum osmolality <320 mOsm/kg",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "emergent-icp-reduction-in-suspected-mass-lesion-with-herniat": {
          "indication": "Emergent ICP reduction in suspected mass lesion with herniation signs",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "Mannitol (CPT 96365) 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus over 15-20 min; may repeat 0.25-0.5 g/kg q6h",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "acute-symptomatic-elevated-icp-with-impending-herniation": {
          "indication": "Acute symptomatic elevated ICP with impending herniation",
          "doseOptions": [
            {
              "text": "0.5-1 g/kg",
              "orderSentence": "Mannitol (acute elevated ICP) 0.5-1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 g/kg IV over 15-20 min; may repeat q6h; target serum osmolality 300-320 mOsm/kg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "elevated-icp-from-posterior-fossa-mass-effect-with-impending": {
          "indication": "Elevated ICP from posterior fossa mass effect with impending herniation; cerebellar stroke with edema",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "Mannitol 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 g/kg IV bolus over 15-20 min; then 0.25-0.5 g/kg q6h PRN; target serum osmolality <320",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "acute-elevated-icp-with-herniation-signs-from-large-meningio": {
          "indication": "Acute elevated ICP with herniation signs from large meningioma; bridge to surgical intervention",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "Mannitol (elevated ICP) 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus over 15-20 min; may repeat 0.25-0.5 g/kg q4-6h; maintain serum osmolality <320 mOsm/kg",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Anuria",
          "Anuria, severe dehydration, active intracranial hemorrhage (relative)",
          "CHF",
          "Severe dehydration",
          "active intracranial bleeding (relative)",
          "active intracranial hemorrhage",
          "anuria",
          "pulmonary edema",
          "renal failure",
          "serum osmolality >320",
          "severe dehydration",
          "severe renal failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP",
          "BMP q6h",
          "I/O",
          "ICP if monitored",
          "Serum osmolality (<320), electrolytes, urine output, neuro checks",
          "Serum osmolality (keep <320 mOsm/kg)",
          "Serum osmolality q6h",
          "Serum osmolality q6h (hold if >320)",
          "Serum osmolality q6h, serum sodium, I/O, renal function",
          "electrolytes",
          "neuro exam",
          "renal function",
          "urine output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 9,
      "_sourcePlans": [
        "ataxia-evaluation",
        "cerebral-venous-thrombosis",
        "glioblastoma",
        "headache-evaluation",
        "leptomeningeal-carcinomatosis",
        "meningioma",
        "neuro-behcets-disease",
        "neurosarcoidosis",
        "primary-cns-lymphoma"
      ]
    },
    "mannitol-20": {
      "id": "mannitol-20",
      "name": "Mannitol 20%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-elevated-icp-with-signs-of-herniation-declining-consci": {
          "indication": "Acute elevated ICP with signs of herniation (declining consciousness, pupil asymmetry); bridge to therapeutic LP or VP shunt",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "Mannitol 20% 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus; then 0.25-0.5 g/kg q4-6h; maintain serum osmolality <320 mOsm/kg",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "cerebral-edema-elevated-icp": {
          "indication": "Cerebral edema / elevated ICP",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "Mannitol 20% 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus; then 0.25-0.5 g/kg q4-6h",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hsv-encephalitis"
          ]
        },
        "elevated-icp-management-rare-in-viral-meningitis-suggests-al": {
          "indication": "Elevated ICP management (rare in viral meningitis; suggests alternative diagnosis or complication)",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "Mannitol 20% (if elevated ICP) 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus; then 0.25-0.5 g/kg q4-6h",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "acute-cerebral-edema-from-large-territory-infarct-due-to-dis": {
          "indication": "Acute cerebral edema from large territory infarct due to dissection-related stroke",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "Mannitol 20% 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus for acute herniation; then 0.25-0.5 g/kg q4-6h maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "elevated-icp-from-cysticercal-encephalitis-large-perilesiona": {
          "indication": "Elevated ICP from cysticercal encephalitis, large perilesional edema, or obstructive hydrocephalus; bridge to definitive treatment",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "Mannitol 20% (CPT 96365) 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus over 20 min; then 0.25-0.5 g/kg q4-6h PRN for ICP >22; hold if serum osm >320",
          "settings": {
            "ED": "STAT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "elevated-icp-with-clinical-signs-of-herniation-post-anoxic-c": {
          "indication": "Elevated ICP with clinical signs of herniation (post-anoxic cerebral edema); acute temporizing measure",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "Mannitol 20% 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus for acute herniation; 0.25-0.5 g/kg q4-6h maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "elevated-icp-management": {
          "indication": "Elevated ICP management",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "Mannitol 20% 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus; then 0.25-0.5 g/kg q4-6h",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "elevated-icp-management-acute-cerebral-herniation-bridge-to-": {
          "indication": "Elevated ICP management; acute cerebral herniation; bridge to surgical decompression",
          "doseOptions": [
            {
              "text": "1 g/kg",
              "orderSentence": "Mannitol 20% 1 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus over 20 min; then 0.25-0.5 g/kg q4-6h PRN for ICP >22; hold if serum osm >320",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "elevated-icp-cerebral-edema-management-before-definitive-hyd": {
          "indication": "Elevated ICP / cerebral edema management (before definitive hydrocephalus treatment)",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "Mannitol 20% 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus; then 0.25-0.5 g/kg q4-6h; maintain serum osm <320",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Anuria",
          "active intracranial bleeding",
          "renal failure",
          "serum osmolality >320",
          "severe dehydration"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cr",
          "I/O",
          "Serum osm (<320)",
          "Serum osm <320",
          "Serum osmolality",
          "Serum osmolality (<320 mOsm/kg)",
          "Serum osmolality (<320)",
          "Serum osmolality (hold if >320 mOsm/kg)",
          "Serum osmolality q4-6h",
          "electrolytes",
          "osmolar gap",
          "renal function",
          "serum Na",
          "urine output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 9,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "bacterial-meningitis",
        "brain-abscess",
        "cervical-artery-dissection",
        "fungal-meningitis",
        "hsv-encephalitis",
        "neurocysticercosis",
        "tb-meningitis",
        "viral-meningitis"
      ]
    },
    "maraviroc": {
      "id": "maraviroc",
      "name": "Maraviroc (Selzentry)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "ccr5-antagonist-with-high-cpe-score-cpe-3-requires-tropism-t": {
          "indication": "CCR5 antagonist with high CPE score (CPE 3); requires tropism testing; unique anti-inflammatory CNS mechanism relevant to HAND",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Maraviroc (Selzentry) 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300 mg PO BID (with CYP3A4 inhibitors: 150 mg BID; with inducers: 600 mg BID)",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Non-CCR5-tropic virus (must confirm R5 tropism before use)",
          "hepatotoxicity risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CYP3A4 interactions",
          "LFTs",
          "Tropism assay mandatory",
          "cough, URI symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "mechanical-insufflation-exsufflation": {
      "id": "mechanical-insufflation-exsufflation",
      "name": "Mechanical insufflation-exsufflation (Cough Assist)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "—"
      ],
      "formulations": [],
      "contexts": {
        "weak-cough-peak-cough-flow-270-l-min": {
          "indication": "Weak cough; peak cough flow <270 L/min",
          "doseOptions": [
            {
              "text": "+40/-40 cmH2O",
              "orderSentence": "Mechanical insufflation-exsufflation (Cough Assist) +40/-40 cmH2O —"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Set insufflation +40 cmH2O, exsufflation -40 cmH2O; 2-4 cycles per session; 2-4 sessions daily; use before meals and PRN",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bullous emphysema",
          "pneumothorax"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Secretion clearance, respiratory status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "meclizine": {
      "id": "meclizine",
      "name": "Meclizine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "vertigo-from-vertebral-artery-dissection-with-posterior-circ": {
          "indication": "Vertigo from vertebral artery dissection with posterior circulation ischemia",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Meclizine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg PO q6-8h PRN vertigo; short-term use only (may mask central symptoms)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "acute-vestibular-symptoms-short-term-only": {
          "indication": "Acute vestibular symptoms (short-term only)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Meclizine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg PO q8h PRN; short-term only (<1-2 weeks); avoid chronic use",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "vestibular-symptoms-vertigo-nausea-associated-with-cerebella": {
          "indication": "Vestibular symptoms (vertigo, nausea) associated with cerebellar ataxia; short-term use only",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Meclizine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg PO q6-8h PRN; short-term use only (48-72h); do NOT use chronically — delays vestibular compensation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "vertigo-and-vestibular-symptoms-from-cerebellar-involvement": {
          "indication": "Vertigo and vestibular symptoms from cerebellar involvement",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Meclizine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg PO q8h PRN vertigo; max 75 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "acute-peripheral-vestibular-nystagmus-with-oscillopsia-nause": {
          "indication": "Acute peripheral vestibular nystagmus with oscillopsia, nausea, or vertigo; **SHORT-TERM ONLY (24-72h)**; avoid in central nystagmus until etiology established",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "**Meclizine** 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Meclizine 25 mg PO q6-8h PRN**; limit to 48-72h maximum; taper as tolerated",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "vertigo-associated-with-cranial-nerve-viii-involvement-vesti": {
          "indication": "Vertigo associated with cranial nerve VIII involvement (vestibulocochlear nerve)",
          "doseOptions": [
            {
              "text": "25 mg q6-8h PRN",
              "orderSentence": "Meclizine 25 mg q6-8h PRN PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg PO q6-8h as needed for vertigo; max 100 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Avoid in central nystagmus until etiology established",
          "Concurrent anticholinergic use",
          "Elderly (anticholinergic effects)",
          "Glaucoma",
          "Glaucoma, urinary retention",
          "Urinary retention",
          "anticholinergic effects in elderly",
          "glaucoma",
          "prolonged use delays vestibular compensation",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Limit to 72h",
          "Sedation",
          "anticholinergic effects",
          "discontinue within 72 hours",
          "does not treat underlying cause",
          "early vestibular rehabilitation once acute phase resolved",
          "may impair vestibular compensation if used chronically",
          "monitor for central vertigo signs",
          "sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "ataxia-evaluation",
        "cervical-artery-dissection",
        "lyme-neuroborreliosis",
        "nystagmus-evaluation",
        "paraneoplastic-neurological-syndrome",
        "post-concussion-syndrome"
      ]
    },
    "melatonin": {
      "id": "melatonin",
      "name": "Melatonin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "sleep-disturbance-circadian-rhythm-dysfunction-sundowning": {
          "indication": "Sleep disturbance; circadian rhythm dysfunction; sundowning",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Melatonin 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3 mg qHS, 30 min before bed; may increase to 6 mg if needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia",
            "frontotemporal-dementia"
          ]
        },
        "insomnia-circadian-rhythm-disturbance": {
          "indication": "Insomnia; circadian rhythm disturbance",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Melatonin 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3 mg 30 min before bed; may increase to 9 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "disrupted-nocturnal-sleep-circadian-rhythm-support": {
          "indication": "Disrupted nocturnal sleep; circadian rhythm support",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Melatonin 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg 30 minutes before bedtime; may help consolidate nighttime sleep",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        },
        "insomnia-steroid-induced": {
          "indication": "Insomnia (steroid-induced)",
          "doseOptions": [
            {
              "text": "3-5 mg",
              "orderSentence": "Melatonin 3-5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "sleep-disturbance-common-in-dre-sleep-deprivation-is-major-s": {
          "indication": "Sleep disturbance (common in DRE); sleep deprivation is major seizure trigger; may have mild anticonvulsant properties",
          "doseOptions": [
            {
              "text": "3 mg qHS",
              "orderSentence": "Melatonin 3 mg qHS PO"
            },
            {
              "text": "5 mg qHS",
              "orderSentence": "Melatonin 5 mg qHS PO"
            },
            {
              "text": "10 mg qHS",
              "orderSentence": "Melatonin 10 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3 mg 30 min before bedtime; may increase to 5-10 mg; use extended-release for sleep maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "tinnitus-with-insomnia": {
          "indication": "Tinnitus with insomnia",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "**Melatonin** 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg at bedtime; improves sleep in tinnitus patients; modest direct effect on tinnitus",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        },
        "sleep-disturbance-circadian-rhythm-support": {
          "indication": "Sleep disturbance; circadian rhythm support",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Melatonin 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1-3 mg qHS; may increase to 5 mg; take 30 min before bed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "insomnia-common-fnd-comorbidity": {
          "indication": "Insomnia (common FND comorbidity)",
          "doseOptions": [
            {
              "text": "3-10 mg qHS",
              "orderSentence": "Melatonin 3-10 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-10 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "functional-neurological-disorder"
          ]
        },
        "sleep-disruption-common-in-he": {
          "indication": "Sleep disruption (common in HE)",
          "doseOptions": [
            {
              "text": "3-10 mg",
              "orderSentence": "Melatonin (sleep-wake disturbance) 3-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-10 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "rem-sleep-behavior-disorder-first-line": {
          "indication": "REM sleep behavior disorder (first-line)",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Melatonin 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3-6 mg 30 min before bed; may increase to 12 mg; first-line for RBD",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "icu-delirium-prevention-and-sleep-wake-cycle-restoration-dis": {
          "indication": "ICU delirium prevention and sleep-wake cycle restoration; disrupted sleep worsens ICUAW",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Melatonin 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg PO qHS; administer at consistent time to promote circadian rhythm",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "insomnia-sleep-wake-dysregulation-common-in-pnes-trauma": {
          "indication": "Insomnia; sleep-wake dysregulation (common in PNES/trauma)",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Melatonin 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-10 mg PO qHS; take 30-60 min before bedtime; max 10 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "9-10 mg",
              "orderSentence": "Melatonin 9-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "9-10 mg QHS (higher than sleep doses)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "cluster-headache",
            "autoimmune-encephalitis"
          ]
        },
        "insomnia-related-to-high-dose-corticosteroids-sleep-wake-dis": {
          "indication": "Insomnia related to high-dose corticosteroids; sleep-wake disruption during hospitalization",
          "doseOptions": [
            {
              "text": "3-5 mg qHS",
              "orderSentence": "Melatonin 3-5 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg PO at bedtime; up to 10 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis",
            "susac-syndrome"
          ]
        },
        "insomnia-circadian-rhythm-disruption-post-tbi": {
          "indication": "Insomnia, circadian rhythm disruption post-TBI",
          "doseOptions": [
            {
              "text": "3-5 mg",
              "orderSentence": "Melatonin 3-5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg PO 30-60 minutes before bedtime; may increase to 10 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "insomnia-sleep-wake-disturbance": {
          "indication": "Insomnia; sleep-wake disturbance",
          "doseOptions": [
            {
              "text": "3-10 mg qHS",
              "orderSentence": "Melatonin 3-10 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-10 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "insomnia-and-sleep-wake-cycle-disturbance-safe-first-line-sl": {
          "indication": "Insomnia and sleep-wake cycle disturbance; safe first-line sleep aid",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Melatonin 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg at bedtime; extended-release may be better for sleep maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "insomnia-adjunct": {
          "indication": "Insomnia (adjunct)",
          "doseOptions": [
            {
              "text": "3-5 mg",
              "orderSentence": "Melatonin 3-5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg qHS 30 minutes before bed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "sleep-wake-disturbance-circadian-dysregulation": {
          "indication": "Sleep-wake disturbance; circadian dysregulation",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Melatonin 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3 mg qHS; may increase to 5-10 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "sleep-wake-cycle-disruption-may-be-tried-first-given-excelle": {
          "indication": "Sleep-wake cycle disruption -- may be tried first given excellent safety profile",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Melatonin (insomnia) 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-10 mg PO qHS; start at 3 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "sleep-disturbance-sleep-deprivation-is-major-seizure-trigger": {
          "indication": "Sleep disturbance (sleep deprivation is major seizure trigger); mild anticonvulsant properties; safe in epilepsy",
          "doseOptions": [
            {
              "text": "3 mg qHS",
              "orderSentence": "Melatonin 3 mg qHS PO"
            },
            {
              "text": "5 mg qHS",
              "orderSentence": "Melatonin 5 mg qHS PO"
            },
            {
              "text": "10 mg qHS",
              "orderSentence": "Melatonin 10 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3 mg 30 min before bed; may increase to 5-10 mg; use extended-release for sleep maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "insomnia": {
          "indication": "Insomnia",
          "doseOptions": [
            {
              "text": "3-10 mg",
              "orderSentence": "Melatonin 3-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-10 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        },
        "sleep-disturbance-circadian-rhythm-dysfunction": {
          "indication": "Sleep disturbance; circadian rhythm dysfunction",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Melatonin 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3 mg qHS, 30 min before bed; may increase to 6-9 mg if needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        },
        "rem-sleep-behavior-disorder-rbd-first-line-fewer-side-effect": {
          "indication": "REM sleep behavior disorder (RBD) — first-line; fewer side effects than clonazepam",
          "doseOptions": [
            {
              "text": "3 mg QHS",
              "orderSentence": "Melatonin 3 mg QHS PO"
            },
            {
              "text": "6 mg QHS",
              "orderSentence": "Melatonin 6 mg QHS PO"
            },
            {
              "text": "9 mg QHS",
              "orderSentence": "Melatonin 9 mg QHS PO"
            },
            {
              "text": "12 mg QHS",
              "orderSentence": "Melatonin 12 mg QHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3 mg at bedtime; titrate by 3 mg q1-2 weeks; max 12 mg; take 30-60 min before bed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "insomnia-icu-delirium-prevention": {
          "indication": "Insomnia (ICU delirium prevention)",
          "doseOptions": [
            {
              "text": "3-5 mg",
              "orderSentence": "Melatonin 3-5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        },
        "insomnia-circadian-rhythm-disruption-during-hospitalization-": {
          "indication": "Insomnia; circadian rhythm disruption during hospitalization; safer alternative in elderly",
          "doseOptions": [
            {
              "text": "3-5 mg",
              "orderSentence": "Melatonin 3-5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg PO 30 minutes before bedtime",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "insomnia-icu-delirium-prevention-2": {
          "indication": "Insomnia, ICU delirium prevention",
          "doseOptions": [
            {
              "text": "3-5 mg",
              "orderSentence": "Melatonin 3-5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "botulism"
          ]
        },
        "sleep-disturbance": {
          "indication": "Sleep disturbance",
          "doseOptions": [
            {
              "text": "3-5 mg",
              "orderSentence": "Melatonin 3-5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-5 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        },
        "rem-sleep-behavior-disorder-sleep-disturbance": {
          "indication": "REM sleep behavior disorder; sleep disturbance",
          "doseOptions": [
            {
              "text": "3 mg qHS",
              "orderSentence": "Melatonin 3 mg qHS PO"
            },
            {
              "text": "6 mg qHS",
              "orderSentence": "Melatonin 6 mg qHS PO"
            },
            {
              "text": "9 mg qHS",
              "orderSentence": "Melatonin 9 mg qHS PO"
            },
            {
              "text": "12 mg qHS",
              "orderSentence": "Melatonin 12 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3-6 mg qHS; may increase to 12 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Autoimmune conditions (theoretical)",
          "Autoimmune disease (theoretical — immunostimulant)",
          "Few",
          "Few contraindications",
          "None",
          "None absolute",
          "None significant",
          "caution with immunosuppressants",
          "caution with warfarin (may potentiate)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Daytime drowsiness",
          "Daytime drowsiness (minimal)",
          "Daytime sedation",
          "Generally well-tolerated",
          "RBD episode frequency (bed partner report), daytime sedation",
          "Sedation",
          "Sleep quality",
          "Well tolerated",
          "[Hurtuk et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21859051/): melatonin improved tinnitus scores in patients with sleep disturbance",
          "daytime drowsiness",
          "delirium assessment",
          "limited long-term data",
          "low side effect profile",
          "may help with ASM-related sleep disruption",
          "minimal side effects",
          "next-day grogginess",
          "no significant drug interactions",
          "safe",
          "sleep quality",
          "vivid dreams"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 32,
      "_sourcePlans": [
        "alzheimers-disease",
        "autoimmune-encephalitis",
        "botulism",
        "cervical-myelopathy",
        "cluster-headache",
        "cns-vasculitis",
        "creutzfeldt-jakob-disease",
        "critical-illness-myopathy-neuropathy",
        "drug-resistant-epilepsy",
        "epilepsy-chronic-management",
        "frontotemporal-dementia",
        "functional-neurological-disorder",
        "guillain-barre-syndrome",
        "hashimotos-encephalopathy",
        "huntingtons-disease",
        "inflammatory-myopathy",
        "lewy-body-dementia",
        "mild-cognitive-impairment",
        "multiple-system-atrophy",
        "narcolepsy",
        "new-onset-seizure",
        "nmosd",
        "paraneoplastic-neurological-syndrome",
        "parkinsons-disease",
        "peripheral-neuropathy",
        "pnes",
        "post-concussion-syndrome",
        "progressive-supranuclear-palsy",
        "rapidly-progressive-dementia",
        "susac-syndrome",
        "tinnitus-evaluation",
        "vascular-dementia"
      ]
    },
    "meloxicam": {
      "id": "meloxicam",
      "name": "Meloxicam",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "radicular-pain-once-daily-dosing": {
          "indication": "Radicular pain (once daily dosing)",
          "doseOptions": [
            {
              "text": "7.5 mg",
              "orderSentence": "Meloxicam 7.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "7.5-15 mg daily; max 15 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CrCl <30",
          "active GI bleed",
          "aspirin allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "radiculopathy"
      ]
    },
    "memantine": {
      "id": "memantine",
      "name": "Memantine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "moderate-severe-vascular-dementia-add-to-cholinesterase-inhi": {
          "indication": "Moderate-severe vascular dementia; add to cholinesterase inhibitor",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Memantine (Namenda) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily x 1 week; increase by 5 mg/week: 5 mg BID, then 5/10 mg, then 10 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "moderate-severe-cognitive-impairment-neuroprotective-theory": {
          "indication": "Moderate-severe cognitive impairment; neuroprotective theory",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Memantine 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; titrate by 5 mg/wk; target 10 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "cognitive-protection-during-radiation-therapy-rtog-0614-show": {
          "indication": "Cognitive protection during radiation therapy; RTOG 0614 showed reduced cognitive decline at 24 weeks (emerging evidence; not yet standard of care)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Memantine (neuroprotection during RT) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily; increase by 5 mg weekly (5 mg daily, 5 mg BID, 10 mg AM/5 mg PM, 10 mg BID); continue during and after radiation; max 20 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "cognitive-symptoms-may-provide-modest-benefit-pending-surger": {
          "indication": "Cognitive symptoms; may provide modest benefit pending surgery",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Memantine 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase by 5 mg/week; target 10 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "normal-pressure-hydrocephalus"
          ]
        },
        "cognitive-neuroprotection-during-whole-brain-radiation-thera": {
          "indication": "Cognitive neuroprotection during whole-brain radiation therapy",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**Memantine (with WBRT)** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily x 1 week, then 5 mg BID x 1 week, then 10 mg AM + 5 mg PM x 1 week, then 10 mg BID; continue for 6 months total; start day 1 of WBRT",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "moderate-severe-dementia-add-to-cholinesterase-inhibitor": {
          "indication": "Moderate-severe dementia; add to cholinesterase inhibitor",
          "doseOptions": [
            {
              "text": "5 mg daily",
              "orderSentence": "Memantine 5 mg daily PO"
            },
            {
              "text": "10 mg BID",
              "orderSentence": "Memantine 10 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase by 5 mg/wk; target 10 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia",
            "parkinsons-disease"
          ]
        },
        "nmda-receptor-mediated-neurotoxicity-in-hiv-moderate-severe-": {
          "indication": "NMDA receptor-mediated neurotoxicity in HIV; moderate-severe HAND; limited but emerging evidence for neuroprotection in HAND; [Schifitto et al., AIDS 2007](https://pubmed.ncbi.nlm.nih.gov/17721095/)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Memantine (Namenda) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase by 5 mg/week to 10 mg BID; max 20 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Memantine (Namenda) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase by 5 mg/week to 10 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "may-help-some-behavioral-symptoms-limited-evidence": {
          "indication": "May help some behavioral symptoms; limited evidence",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Memantine (Namenda) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase by 5 mg/week to 10 mg BID; evidence weak in FTD",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "third-line-for-pan-nmda-receptor-antagonist-affects-velocity": {
          "indication": "Third-line for PAN; NMDA receptor antagonist affects velocity storage",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**Memantine** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Memantine 5 mg PO daily, titrate by 5 mg weekly to 10 mg BID**; limited evidence but rational mechanism",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "alternative-first-line-for-acquired-pendular-nystagmus-ms-as": {
          "indication": "Alternative first-line for acquired pendular nystagmus (MS-associated); NMDA receptor antagonist; [Starck et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9007739/)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**Memantine** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Memantine 5 mg PO daily, titrate by 5 mg weekly to 10 mg BID**",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "moderate-severe-ad-add-to-cholinesterase-inhibitor": {
          "indication": "Moderate-severe AD; add to cholinesterase inhibitor",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Memantine (Namenda) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily x 1 week; increase by 5 mg/week: 5 mg BID, then 5 mg/10 mg, then 10 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment",
          "Renal impairment (dose adjustment if CrCl <30)",
          "Severe renal impairment",
          "Severe renal impairment (CrCl <30)",
          "Severe renal impairment (CrCl <5)",
          "Severe renal impairment (adjust dose if CrCl <30)",
          "Severe renal impairment (dose adjust CrCl <30)",
          "Severe renal impairment (dose adjust)",
          "Severe renal impairment (reduce dose if CrCl 5-29: max 5 mg BID)",
          "Severe renal impairment (reduce dose)",
          "concurrent use of other NMDA antagonists",
          "known hypersensitivity",
          "seizure history"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cognitive function monitoring",
          "Confusion",
          "Confusion, constipation",
          "Confusion, dizziness",
          "Confusion, dizziness, constipation",
          "Confusion, dizziness, constipation, headache",
          "Renal function",
          "clinical response at 2-4 weeks",
          "confusion",
          "constipation",
          "dizziness",
          "generally well tolerated",
          "reassess benefit at 6 months",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 13,
      "_sourcePlans": [
        "alzheimers-disease",
        "dementia-evaluation",
        "frontotemporal-dementia",
        "glioblastoma",
        "hiv-associated-neurocognitive-disorder",
        "huntingtons-disease",
        "leptomeningeal-carcinomatosis",
        "lewy-body-dementia",
        "normal-pressure-hydrocephalus",
        "nystagmus-evaluation",
        "parkinsons-disease",
        "vascular-dementia"
      ]
    },
    "memantine-donepezil": {
      "id": "memantine-donepezil",
      "name": "Memantine/Donepezil (Namzaric)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "combination-for-moderate-severe-ad-already-on-both": {
          "indication": "Combination for moderate-severe AD already on both",
          "doseOptions": [
            {
              "text": "28/10 mg",
              "orderSentence": "Memantine/Donepezil (Namzaric) 28/10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "One capsule (28 mg memantine XR + 10 mg donepezil) once daily at bedtime; must be stable on both drugs first",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe renal impairment",
          "second/third degree heart block",
          "sick sinus syndrome"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Confusion, dizziness, GI symptoms, vivid dreams"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alzheimers-disease"
      ]
    },
    "memantine-xr": {
      "id": "memantine-xr",
      "name": "Memantine XR (Namenda XR)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "7 mg",
              "orderSentence": "Memantine XR (Namenda XR) 7 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7 mg daily; increase weekly to 28 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "once-daily-option-for-adherence": {
          "indication": "Once-daily option for adherence",
          "doseOptions": [
            {
              "text": "7 mg",
              "orderSentence": "Memantine XR (Namenda XR) 7 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7 mg daily; increase by 7 mg/week; target 28 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same",
          "Severe renal impairment (reduce dose if CrCl 5-29: max 14 mg daily)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Confusion, dizziness, constipation, headache",
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "alzheimers-disease",
        "dementia-evaluation"
      ]
    },
    "meperidine": {
      "id": "meperidine",
      "name": "Meperidine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "treatment-of-amphotericin-b-related-rigors-unresponsive-to-a": {
          "indication": "Treatment of amphotericin B-related rigors unresponsive to acetaminophen premedication",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Meperidine 25-50 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV PRN for rigors during amphotericin B infusion; avoid repeated dosing (normeperidine accumulation)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "shivering-during-ttm-counterproductive-increases-metabolic-d": {
          "indication": "Shivering during TTM (counterproductive; increases metabolic demand and defeats cooling); first-line anti-shivering agent",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Meperidine (Demerol) 25-50 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg IV q4h PRN shivering; first-line anti-shivering agent",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "MAOI use",
          "MAOIs",
          "Seizure history (lowers threshold)",
          "renal failure (normeperidine accumulation)",
          "renal impairment (normeperidine accumulation)",
          "seizure disorder (lowers threshold)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation",
          "Shivering scale (BSAS)",
          "renal function",
          "respiratory status",
          "sedation",
          "seizure risk"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "fungal-meningitis"
      ]
    },
    "meropenem": {
      "id": "meropenem",
      "name": "Meropenem",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "extended-spectrum-beta-lactamase-esbl-producers-or-multi-dru": {
          "indication": "Extended-spectrum beta-lactamase (ESBL) producers or multi-drug resistant",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Meropenem 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q8h",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "broad-spectrum-alternative-if-cephalosporin-allergy-esbl-gra": {
          "indication": "Broad-spectrum alternative if cephalosporin allergy; ESBL gram-negative organisms; polymicrobial abscess; Nocardia (some species)",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Meropenem 2 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g IV q8h (meningitic dosing for CNS penetration); duration 6-8 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Carbapenem allergy",
          "lowers seizure threshold (less than imipenem)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "LFTs",
          "Renal function",
          "seizure monitoring",
          "seizure threshold"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "bacterial-meningitis",
        "brain-abscess"
      ]
    },
    "metformin": {
      "id": "metformin",
      "name": "Metformin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-for-type-2-diabetes-if-egfr-30": {
          "indication": "First-line for type 2 diabetes if eGFR >30",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Metformin 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg daily with meal; titrate by 500 mg weekly; max 2000-2550 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "type-2-diabetes-potential-neuroprotective-effects": {
          "indication": "Type 2 diabetes; potential neuroprotective effects",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Metformin 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg daily with meal; increase by 500 mg weekly; max 2000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "first-line-for-type-2-diabetes-in-post-stroke-patients-cardi": {
          "indication": "First-line for type 2 diabetes in post-stroke patients; cardiovascular benefit; weight neutral",
          "doseOptions": [
            {
              "text": "500 mg daily",
              "orderSentence": "Metformin 500 mg daily PO"
            },
            {
              "text": "500 mg BID",
              "orderSentence": "Metformin 500 mg BID PO"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Metformin 1000 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg daily with meals; increase by 500 mg q1-2wk; target 1000 mg BID; max 2550 mg/day; extended-release for GI tolerability",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "insulin-resistance-and-type-2-diabetes-mellitus-in-dm1-first": {
          "indication": "Insulin resistance and type 2 diabetes mellitus in DM1; first-line oral hypoglycemic",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Metformin 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO daily with meals; increase by 500 mg weekly; target 1000 mg BID; max 2550 mg/day; take with food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "acute illness",
          "acute illness with risk of lactic acidosis",
          "contrast dye (hold 48h)",
          "contrast within 48h",
          "eGFR <30",
          "heavy alcohol use",
          "hold for contrast procedures",
          "metabolic acidosis",
          "risk of lactic acidosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 annually",
          "B12 annually (depletion)",
          "B12 annually (long-term use)",
          "B12 annually (metformin reduces absorption)",
          "BMP q3-6 months",
          "HbA1c q3 months",
          "HbA1c q3 months until <7% then q6 months",
          "HbA1c q3mo",
          "eGFR",
          "lactic acidosis symptoms",
          "renal function q6-12 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "mild-cognitive-impairment",
        "myotonic-dystrophy",
        "post-stroke-management",
        "vascular-dementia"
      ]
    },
    "methadone": {
      "id": "methadone",
      "name": "Methadone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "severe-refractory-neuropathic-pain": {
          "indication": "Severe refractory neuropathic pain",
          "doseOptions": [
            {
              "text": "2.5-5 mg",
              "orderSentence": "Methadone 2.5-5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5-5 mg TID; titrate slowly (long half-life); specialist management",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Methadone (specialist use) 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg QHS; specialist prescribing only",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "restless-legs-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "Same",
          "concurrent QT-prolonging drugs"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG at baseline and with dose changes",
          "QTc monitoring",
          "QTc, respiratory"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "peripheral-neuropathy",
        "restless-legs-syndrome"
      ]
    },
    "methimazole": {
      "id": "methimazole",
      "name": "Methimazole",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "hyperthyroid-tremor-first-line-antithyroid-agent-for-graves-": {
          "indication": "Hyperthyroid tremor; first-line antithyroid agent for Graves disease causing tremor",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Methimazole 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg daily; titrate per thyroid function; typical range 5-30 mg daily; tremor resolves with euthyroid state; endocrinology co-management",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy first trimester (use PTU instead)",
          "prior agranulocytosis from antithyroid drugs",
          "severe hepatic disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC (agranulocytosis risk -- instruct patient to report fever/sore throat immediately)",
          "LFTs",
          "Thyroid function tests q4-8 weeks initially"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tremor-unspecified"
      ]
    },
    "methocarbamol": {
      "id": "methocarbamol",
      "name": "Methocarbamol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "muscle-spasm-less-sedating": {
          "indication": "Muscle spasm (less sedating)",
          "doseOptions": [
            {
              "text": "1500 mg",
              "orderSentence": "Methocarbamol 1500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1500 mg QID x 2-3 days, then 750 mg QID or 1500 mg TID",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "muscle-spasm-alternative-to-cyclobenzaprine-with-less-sedati": {
          "indication": "Muscle spasm; alternative to cyclobenzaprine with less sedation",
          "doseOptions": [
            {
              "text": "1500 mg",
              "orderSentence": "Methocarbamol 1500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1500 mg PO QID x 2-3 days, then 750 mg PO q6h PRN; max 4500 mg/day maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Myasthenia gravis",
          "Renal impairment (use caution)",
          "myasthenia gravis",
          "renal impairment (accumulates)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation",
          "discolored urine (brown-black, benign)",
          "dizziness",
          "dizziness (less than other relaxants)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "cervical-myelopathy",
        "radiculopathy"
      ]
    },
    "methotrexate": {
      "id": "methotrexate",
      "name": "Methotrexate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO",
        "PO/SC",
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "steroid-sparing-agent-refractory-mucocutaneous-and-neurologi": {
          "indication": "Steroid-sparing agent; refractory mucocutaneous and neurological disease; alternative to azathioprine",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Methotrexate 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5-10 mg PO once weekly; increase by 2.5-5 mg q2-4wk; target 15-25 mg weekly; co-prescribe folic acid 1 mg daily (except MTX day)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "first-line-steroid-sparing-agent-for-pm-and-dm-anti-syntheta": {
          "indication": "First-line steroid-sparing agent for PM and DM; anti-synthetase syndrome arthritis; onset 3-6 months",
          "doseOptions": [
            {
              "text": "10-15 mg",
              "orderSentence": "Methotrexate 10-15 mg PO/SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-15 mg PO/SC once weekly; increase by 5 mg every 4 weeks to target 20-25 mg/week; folic acid 1 mg PO daily (except methotrexate day) mandatory",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "steroid-sparing-alternative-relapsing-he": {
          "indication": "Steroid-sparing alternative; relapsing HE",
          "doseOptions": [
            {
              "text": "7.5 mg",
              "orderSentence": "Methotrexate 7.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5 mg PO weekly; increase to 15-25 mg weekly over 4-8 weeks; supplement with folic acid 1 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "steroid-sparing-immunosuppression-relapsing-neurosarcoidosis": {
          "indication": "Steroid-sparing immunosuppression; relapsing neurosarcoidosis; inability to taper steroids below 10 mg/day",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Methotrexate 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5-10 mg PO once weekly; increase by 2.5-5 mg q2-4wk; target 15-25 mg weekly; always co-prescribe folic acid 1 mg daily (except MTX day)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "alternative-maintenance-therapy-particularly-if-granulomatou": {
          "indication": "Alternative maintenance therapy; particularly if granulomatous histology on biopsy; steroid-sparing agent",
          "doseOptions": [
            {
              "text": "15-25 mg weekly",
              "orderSentence": "Methotrexate 15-25 mg weekly PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 15 mg PO/SC weekly; increase by 5 mg q2-4 weeks to target 20-25 mg weekly; give folic acid 1 mg PO daily (except on methotrexate day)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "time-limited-trial-if-polymyositis-remains-in-differential-a": {
          "indication": "Time-limited trial if polymyositis remains in differential and steroid trial inconclusive; NOT effective for IBM in clinical trials",
          "doseOptions": [
            {
              "text": "10-15 mg",
              "orderSentence": "Methotrexate (limited trial) 10-15 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-15 mg PO once weekly; folic acid 1 mg PO daily (except methotrexate day); assess at 3-6 months; discontinue if no objective improvement",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "steroid-sparing-agent-for-subarachnoid-racemose-ncc-requirin": {
          "indication": "Steroid-sparing agent for subarachnoid/racemose NCC requiring prolonged anti-inflammatory therapy (months to years); allows corticosteroid taper while maintaining anti-inflammatory effect",
          "doseOptions": [
            {
              "text": "7.5-20 mg",
              "orderSentence": "Methotrexate (steroid-sparing agent) 7.5-20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5 mg PO weekly; titrate to 15-20 mg weekly as tolerated; supplement with folic acid 1 mg daily (except on MTX day); onset of effect 4-6 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "steroid-sparing-alternative-weaker-evidence-than-tocilizumab": {
          "indication": "Steroid-sparing alternative (weaker evidence than tocilizumab); relapse prevention",
          "doseOptions": [
            {
              "text": "7.5 mg",
              "orderSentence": "Methotrexate 7.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5-10 mg PO weekly; titrate to 15-25 mg/week; take with folic acid 1 mg daily (except MTX day)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Methotrexate 10-20 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg PO or SC once weekly with folic acid 1 mg daily (except methotrexate day); onset 6-12 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis"
          ]
        },
        "steroid-sparing-agent-for-chronic-inflammatory-plexopathy": {
          "indication": "Steroid-sparing agent for chronic inflammatory plexopathy",
          "doseOptions": [
            {
              "text": "7.5 mg",
              "orderSentence": "Methotrexate 7.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5 mg weekly; increase by 2.5 mg q2-4 weeks; max 25 mg weekly; add folic acid 1 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CrCl <30",
          "Hepatic disease",
          "Pregnancy",
          "Pregnancy (Category X -- teratogenic)",
          "Pregnancy (Category X)",
          "Pregnancy (teratogenic)",
          "active infection",
          "bone marrow suppression",
          "concurrent TMP-SMX",
          "concurrent TMP-SMX (increases toxicity)",
          "concurrent trimethoprim",
          "hepatic disease",
          "immunodeficiency",
          "interstitial lung disease",
          "pregnancy",
          "pulmonary fibrosis",
          "pulmonary fibrosis (caution -- methotrexate pneumonitis vs ILD)",
          "renal impairment",
          "renal impairment (CrCl <30)",
          "renal impairment (GFR <30)",
          "severe hepatic/renal disease",
          "severe hepatic/renal impairment",
          "significant pleural effusion/ascites"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC monthly",
          "CBC q2 weeks x 2 months, then monthly",
          "CBC q2-4 weeks during titration then q8-12 weeks",
          "CBC q2-4 weeks initially, then q1-3 months",
          "CBC q2-4 weeks x 3 months, then monthly",
          "CBC q4 weeks",
          "CBC with differential monthly",
          "CBC, LFTs, creatinine q2-4 weeks x 3 months then q3 months",
          "CrCl",
          "LFTs",
          "LFTs monthly",
          "LFTs q1-3 months",
          "LFTs q8-12 weeks",
          "chest X-ray annually",
          "folate supplementation",
          "folic acid compliance",
          "folic acid supplementation",
          "folic acid supplementation mandatory",
          "hepatic fibrosis screen (FibroScan or liver biopsy if cumulative dose >1.5g)",
          "mucositis",
          "pulmonary symptoms",
          "pulmonary symptoms (methotrexate pneumonitis)",
          "pulmonary symptoms (pneumonitis)",
          "pulmonary toxicity (cough, dyspnea)",
          "pulmonary toxicity screen",
          "renal function",
          "renal function monthly",
          "renal function q3 months",
          "strength assessment q3 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "cns-vasculitis",
        "giant-cell-arteritis",
        "hashimotos-encephalopathy",
        "inclusion-body-myositis",
        "inflammatory-myopathy",
        "myasthenia-gravis-new-diagnosis",
        "neuro-behcets-disease",
        "neurocysticercosis",
        "neurosarcoidosis",
        "plexopathy"
      ]
    },
    "methylcobalamin-sl": {
      "id": "methylcobalamin-sl",
      "name": "Methylcobalamin SL",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SL"
      ],
      "formulations": [],
      "contexts": {
        "alternative-oral-b12-formulation-may-have-improved-bioavaila": {
          "indication": "Alternative oral B12 formulation; may have improved bioavailability",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "Methylcobalamin SL 1000 mcg SL"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-5000 mcg sublingual daily; dissolve under tongue; efficacy data limited compared to IM",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 and MMA levels at 2-3 months",
          "switch to parenteral if inadequate response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "b12-deficiency-neuropathy"
      ]
    },
    "methylphenidate": {
      "id": "methylphenidate",
      "name": "Methylphenidate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "apathy-refractory-to-antidepressants-psychomotor-retardation": {
          "indication": "Apathy refractory to antidepressants; psychomotor retardation",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Methylphenidate 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5-5 mg BID (morning and noon); titrate by 2.5-5 mg every 3-5 days; max 30 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "apathy-bradyphrenia-fatigue": {
          "indication": "Apathy; bradyphrenia; fatigue",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg at breakfast and lunch; titrate by 5-10 mg q1wk; max 60 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "eds-refractory-to-first-line-agents-rapid-onset-of-action": {
          "indication": "EDS refractory to first-line agents; rapid onset of action",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate (Ritalin) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID (morning and early afternoon); titrate by 5-10 mg/week; max 60 mg/day; avoid evening dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        },
        "cancer-related-fatigue-cognitive-slowing-from-tumor-or-treat": {
          "indication": "Cancer-related fatigue; cognitive slowing from tumor or treatment; may improve alertness and concentration during chemoradiation",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate (cancer-related fatigue) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO BID (morning and noon); titrate by 5 mg/dose q3-7 days; max 40 mg/day; avoid evening dosing; reassess need monthly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "cancer-related-fatigue-and-cognitive-slowing-from-tumor-chem": {
          "indication": "Cancer-related fatigue and cognitive slowing from tumor, chemotherapy, or radiation; may improve alertness during treatment",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate (cancer-related fatigue) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO BID (morning and noon); titrate by 5 mg/dose q3-7 days; max 40 mg/day; avoid evening dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "severe-fatigue-and-cognitive-impairment-during-icuaw-recover": {
          "indication": "Severe fatigue and cognitive impairment during ICUAW recovery when non-pharmacologic measures insufficient",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO BID (morning and noon); max 20 mg BID; avoid afternoon dosing to prevent insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "cognitive-fatigue-processing-speed-deficits-attention-impair": {
          "indication": "Cognitive fatigue, processing speed deficits, attention impairment",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO BID (morning and noon); increase by 5 mg/dose every 3-7 days; target 10-20 mg BID; max 60 mg/day; avoid afternoon dosing",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "psychomotor-slowing-apathy-and-fatigue-in-hand-evidence-for-": {
          "indication": "Psychomotor slowing, apathy, and fatigue in HAND; evidence for improved attention and processing speed in HIV cognitive impairment; [Hinkin et al., J Neuropsychiatry Clin Neurosci 2001](https://pubmed.ncbi.nlm.nih.gov/11449032/)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID (morning and noon); increase by 5-10 mg/week; target 20-40 mg/day in divided doses; avoid evening dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "apathy-and-abulia-not-responsive-to-other-measures-off-label": {
          "indication": "Apathy and abulia not responsive to other measures; off-label for frontal symptoms",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg in AM and at noon; titrate to 10 mg BID; max 20 mg BID; avoid afternoon dosing",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "cognitive-impairment-and-attention-deficits-in-abi-survivors": {
          "indication": "Cognitive impairment and attention deficits in ABI survivors; post-anoxic apathy/abulia",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO BID (morning and noon); titrate by 5 mg q3-5 days; max 60 mg/day; avoid afternoon dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "adhd-comorbidity-does-not-worsen-tics-aan-level-a-evidence": {
          "indication": "ADHD comorbidity; does NOT worsen tics (AAN Level A evidence)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate (Ritalin, Concerta) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID (IR) or 18 mg daily (ER); increase by 5-10 mg/wk; target 20-60 mg/day; max 72 mg/day (ER)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        },
        "fatigue": {
          "indication": "Fatigue",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID (morning and noon); max 60 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "severe-apathy-unresponsive-to-other-treatments": {
          "indication": "Severe apathy unresponsive to other treatments",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Methylphenidate 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5-5 mg BID (morning and noon); titrate slowly; max 20 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "excessive-daytime-somnolence-refractory-to-modafinil-also-he": {
          "indication": "Excessive daytime somnolence refractory to modafinil; also helps apathy and cognitive sluggishness in DM1",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Methylphenidate 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO BID (morning and noon); increase by 5-10 mg/day weekly; max 60 mg/day; avoid evening dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cardiac arrhythmia",
          "Concurrent MAO-I use",
          "Concurrent MAOIs",
          "Marked anxiety",
          "Severe anxiety",
          "Severe anxiety, agitation",
          "Severe hypertension",
          "Uncontrolled HTN, cardiac arrhythmia, glaucoma, anxiety disorder (relative), substance abuse history",
          "Uncontrolled hypertension",
          "active psychosis",
          "agitation",
          "cardiac arrhythmia",
          "cardiac arrhythmias",
          "concurrent MAO inhibitors",
          "concurrent MAOI",
          "concurrent MAOIs",
          "glaucoma",
          "hyperthyroidism",
          "motor tics/Tourette",
          "pheochromocytoma",
          "psychosis",
          "severe anxiety",
          "severe anxiety or agitation",
          "severe hypertension",
          "structural cardiac abnormalities",
          "substance abuse history (relative)",
          "tachyarrhythmia",
          "tics/Tourette",
          "uncontrolled hypertension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP, HR",
          "BP, HR, mood",
          "Blood pressure",
          "ECG at baseline (cardiac conduction disease in DM1)",
          "HR",
          "HR, BP",
          "HR, BP, appetite, insomnia",
          "Heart rate",
          "Heart rate, BP, appetite, sleep quality, mood (agitation)",
          "Heart rate, blood pressure, appetite, sleep",
          "Schedule II",
          "abuse potential",
          "abuse potential (low in this population)",
          "agitation",
          "anxiety",
          "appetite",
          "appetite, weight, sleep",
          "appetite/weight",
          "behavioral changes",
          "blood pressure",
          "growth (pediatric)",
          "heart rate",
          "insomnia",
          "mood",
          "potential for abuse",
          "psychiatric symptoms",
          "sleep",
          "tic severity (monitor but stimulants generally safe)",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 14,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "critical-illness-myopathy-neuropathy",
        "frontotemporal-dementia",
        "glioblastoma",
        "hiv-associated-neurocognitive-disorder",
        "huntingtons-disease",
        "ms-new-diagnosis",
        "myotonic-dystrophy",
        "narcolepsy",
        "post-concussion-syndrome",
        "primary-cns-lymphoma",
        "progressive-supranuclear-palsy",
        "tics-tourette-syndrome",
        "vascular-dementia"
      ]
    },
    "methylprednisolone": {
      "id": "methylprednisolone",
      "name": "Methylprednisolone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-parenchymal-nbd-brainstem-syndrome-myelopathy-encephal": {
          "indication": "Acute parenchymal NBD (brainstem syndrome, myelopathy, encephalitis, optic neuropathy); acute severe exacerbation",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone (CPT 96365) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 5-10 days; infuse over 1-2 hours; transition to oral prednisone taper",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "hormone-replacement-therapy-component-reduces-inflammation-s": {
          "indication": "Hormone replacement therapy component; reduces inflammation; supports hemodynamic stability; decreases vasopressor requirement; improves oxygenation",
          "doseOptions": [
            {
              "text": "15 mg/kg",
              "orderSentence": "**Methylprednisolone** 15 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "HRSA protocol: 15 mg/kg IV bolus (max 1 g); single dose; alternative: hydrocortisone 100 mg IV q8h or stress dose 50 mg q6h; reduces inflammatory cytokines; improves lung and cardiac donation outcomes",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        },
        "acute-severe-neurosarcoidosis-optic-neuropathy-myelopathy-cr": {
          "indication": "Acute severe neurosarcoidosis (optic neuropathy, myelopathy, cranial neuropathy, acute hydrocephalus, mass lesion with edema)",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 3-5 days; infuse over 1-2 hours",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "prevention-of-severe-jarisch-herxheimer-reaction-in-patients": {
          "indication": "Prevention of severe Jarisch-Herxheimer reaction in patients at high risk (high RPR titer, HIV co-infection, ocular/otic syphilis with risk of permanent vision/hearing loss, meningovascular syphilis with stroke risk)",
          "doseOptions": [
            {
              "text": "60-125 mg",
              "orderSentence": "Methylprednisolone (severe Jarisch-Herxheimer prevention) 60-125 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60-125 mg IV 30 min before first penicillin dose to attenuate Jarisch-Herxheimer reaction",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "acute-optic-neuritis-accelerates-visual-recovery-per-ontt": {
          "indication": "Acute optic neuritis - accelerates visual recovery per ONTT",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 3 days; infuse over 1-2 hours; followed by oral prednisone taper",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1 g",
              "orderSentence": "Methylprednisolone (CPT 96374) 1 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 g IV daily × 3-5 days; taper (may use if IVIG unavailable)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "diabetic-neuropathy"
          ]
        },
        "severe-acute-radiculopathy-with-significant-weakness": {
          "indication": "Severe acute radiculopathy with significant weakness",
          "doseOptions": [
            {
              "text": "125 mg",
              "orderSentence": "Methylprednisolone 125 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "125 mg IV once; may give for severe acute radicular symptoms",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "paradoxical-worsening-expanding-tuberculomas-worsening-sympt": {
          "indication": "Paradoxical worsening (expanding tuberculomas, worsening symptoms) despite adequate anti-TB therapy; TB-IRIS in HIV patients starting ART",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone (paradoxical reaction/IRIS) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily x 3-5 days; followed by oral prednisone taper over 4-8 weeks; for severe paradoxical reaction or IRIS not responding to dexamethasone taper adjustment",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        },
        "alternative-to-dexamethasone-for-acute-cord-compression-with": {
          "indication": "Alternative to dexamethasone for acute cord compression with progressive neurologic decline",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 3 days; infuse over 1 hour; reserve for severe acute deterioration",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "severe-acute-inflammatory-plexopathy-neuralgic-amyotrophy-wi": {
          "indication": "Severe acute inflammatory plexopathy (neuralgic amyotrophy with progressive weakness); neoplastic plexopathy with impending cord/nerve compromise",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone (CPT 96365, 96366) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily x 3-5 days then transition to oral prednisone taper",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "Active untreated infection",
          "Active untreated infection (especially TB)",
          "Active untreated infection (relative)",
          "GI bleeding",
          "Uncontrolled DM (relative)",
          "Uncontrolled infection",
          "active GI bleeding",
          "active psychosis",
          "psychosis",
          "psychosis from steroids",
          "severe hypertension",
          "uncontrolled diabetes",
          "uncontrolled diabetes (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Blood glucose (hyperglycemia common)",
          "Blood glucose q6h",
          "GI prophylaxis",
          "GI prophylaxis with PPI",
          "GI symptoms",
          "Glucose",
          "Glucose q6h",
          "Glucose q6h (target <180 mg/dL)",
          "Glucose q6h (target <180)",
          "I/O",
          "WBC (may be falsely elevated)",
          "blood pressure",
          "electrolytes",
          "hemodynamic response",
          "infection",
          "infection surveillance",
          "insomnia",
          "mood",
          "mood/sleep",
          "neuroimaging response",
          "psychiatric effects",
          "psychosis risk",
          "sleep"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "brain-death-evaluation",
        "cervical-myelopathy",
        "diabetic-neuropathy",
        "neuro-behcets-disease",
        "neurosarcoidosis",
        "neurosyphilis",
        "optic-neuritis",
        "plexopathy",
        "radiculopathy",
        "tb-meningitis"
      ]
    },
    "methylprednisolone-acetate-injection": {
      "id": "methylprednisolone-acetate-injection",
      "name": "Methylprednisolone acetate injection",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Local injection"
      ],
      "formulations": [],
      "contexts": {
        "moderate-cts-failing-conservative-therapy-bridge-to-surgery-": {
          "indication": "Moderate CTS failing conservative therapy; bridge to surgery; pregnancy-related CTS",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Methylprednisolone acetate injection 40 mg Local injection"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg (1 mL) injected into carpal tunnel under ultrasound guidance preferred; may repeat x1 at 4-6 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local infection",
          "bleeding disorder",
          "uncontrolled diabetes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood glucose (diabetics) 24-48h post-injection",
          "tendon rupture (rare)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "carpal-tunnel-syndrome"
      ]
    },
    "methylprednisolone-iv": {
      "id": "methylprednisolone-iv",
      "name": "Methylprednisolone IV (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-myelopathy-with-sensory-level-and-suspected-inflammato": {
          "indication": "Acute myelopathy with sensory level and suspected inflammatory/demyelinating etiology",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone IV (acute myelopathy/transverse myelitis) (CPT 96365, 96366) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily x 3-5 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone IV (CPT 96365) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily × 3-5 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "bells-palsy",
            "status-epilepticus",
            "ms-new-diagnosis",
            "myasthenia-gravis-new-diagnosis",
            "autoimmune-encephalitis"
          ]
        },
        "severe-active-myositis-rapidly-progressive-ild-anti-mda5-dys": {
          "indication": "Severe active myositis; rapidly progressive ILD (anti-MDA5); dysphagia with aspiration risk; respiratory failure from ILD",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone IV (pulse therapy) (CPT 96365) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 3-5 days; infuse over 60-90 min; followed by oral prednisone taper",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "first-line-treatment-dramatic-steroid-response-is-hallmark-o": {
          "indication": "First-line treatment; dramatic steroid response is hallmark of HE",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone IV (CPT 96365) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily x 3-5 days; infuse over 1-2 hours; most patients show improvement within 24-72 hours",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "induction-immunosuppression-for-confirmed-or-strongly-suspec": {
          "indication": "Induction immunosuppression for confirmed or strongly suspected PACNS; reduces CNS inflammation and prevents further ischemic injury",
          "doseOptions": [
            {
              "text": "1000 mg daily x 3-5 days",
              "orderSentence": "Methylprednisolone IV (CPT 96365) 1000 mg daily x 3-5 days IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 3-5 days; infuse over 1-2 hours; begin upon strong clinical suspicion or biopsy-confirmed PACNS",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "pres-type-cerebral-edema-with-seizures-or-encephalopathy-ove": {
          "indication": "PRES-type cerebral edema with seizures or encephalopathy overlapping with RCVS; NOT standard for uncomplicated RCVS",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone IV (if PRES overlap with edema) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mg IV daily for 3-5 days; infuse over 1 hour. Use ONLY for PRES overlap with significant edema; steroids are NOT routinely recommended for RCVS and may worsen outcomes if PACNS is misdiagnosed",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "first-line-acute-attack-treatment-for-mogad-optic-neuritis-t": {
          "indication": "First-line acute attack treatment for MOGAD optic neuritis, transverse myelitis, or ADEM-like attacks",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone IV (CPT 96365) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 5 days; infuse over 1-2 hours; follow with slow oral prednisone taper",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "acute-nmosd-relapse-optic-neuritis-myelitis-area-postrema-sy": {
          "indication": "Acute NMOSD relapse (optic neuritis, myelitis, area postrema syndrome)",
          "doseOptions": [
            {
              "text": "1000 mg daily x 5 days",
              "orderSentence": "Methylprednisolone IV 1000 mg daily x 5 days IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 5 days; infuse over 1-2 hours; follow with oral prednisone taper",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "first-line-immunotherapy-for-acute-paraneoplastic-neurologic": {
          "indication": "First-line immunotherapy for acute paraneoplastic neurological syndrome; reduces CNS inflammation",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone IV 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 3-5 days; infuse over 1-2 hours",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "acute-immunosuppression-for-confirmed-or-strongly-suspected-": {
          "indication": "Acute immunosuppression for confirmed or strongly suspected Susac syndrome; reduces endothelial inflammation and prevents further ischemic injury to brain, retina, and cochlea",
          "doseOptions": [
            {
              "text": "1000 mg daily",
              "orderSentence": "Methylprednisolone IV (CPT 96365) 1000 mg daily IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 3-5 days; infuse over 1-2 hours; begin upon strong clinical suspicion; cornerstone of acute management along with IVIG",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "alternative-to-dexamethasone-for-acute-anti-inflammatory-eff": {
          "indication": "Alternative to dexamethasone for acute anti-inflammatory effect in severe cases",
          "doseOptions": [
            {
              "text": "125 mg IV once",
              "orderSentence": "Methylprednisolone IV 125 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "125 mg IV once",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "Active infection (relative), uncontrolled DM",
          "Active infection, uncontrolled DM",
          "Active untreated infection",
          "Active untreated infection (especially VZV vasculopathy must be excluded)",
          "Active untreated infection (relative)",
          "Active untreated infection, uncontrolled diabetes",
          "Active untreated infection, uncontrolled diabetes, psychosis history",
          "GI bleeding",
          "Same",
          "active GI bleeding",
          "poorly controlled diabetes",
          "psychosis",
          "psychosis from steroids",
          "uncontrolled diabetes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Blood glucose q6h",
          "Blood glucose, mood",
          "GI prophylaxis",
          "GI prophylaxis with PPI",
          "Glucose monitoring Q6h",
          "Glucose q6h (target <180 mg/dL)",
          "Glucose q6h (target <180)",
          "Glucose q6h (target <180), BP, mood, sleep, I/O",
          "Glucose q6h, BP, GI prophylaxis, infection signs",
          "Glucose, BP, sleep, psychiatric",
          "I/O",
          "Same",
          "blood pressure",
          "cardiac monitoring",
          "cardiac monitoring during infusion",
          "infection signs",
          "insomnia management",
          "mood",
          "mood and sleep disturbance",
          "mood/sleep",
          "psychiatric effects"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 16,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "bells-palsy",
        "cns-vasculitis",
        "hashimotos-encephalopathy",
        "inflammatory-myopathy",
        "mogad",
        "ms-chronic-management",
        "ms-new-diagnosis",
        "myasthenia-gravis-new-diagnosis",
        "nmosd",
        "paraneoplastic-neurological-syndrome",
        "paresthesia-numbness-tingling",
        "rcvs",
        "status-epilepticus",
        "status-migrainosus",
        "susac-syndrome"
      ]
    },
    "methylprednisolone-iv-pulse": {
      "id": "methylprednisolone-iv-pulse",
      "name": "Methylprednisolone IV pulse (vision-threatening)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "visual-symptoms-acute-vision-loss-amaurosis-fugax-diplopia-a": {
          "indication": "Visual symptoms: acute vision loss, amaurosis fugax, diplopia, AION, CRAO, cranial nerve palsy",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Methylprednisolone IV pulse (vision-threatening) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily for 3 days (some protocols use 500 mg-1000 mg); infuse over 1-2 hours; then transition to oral prednisone 1 mg/kg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active untreated infection",
          "psychosis from steroids",
          "uncontrolled diabetes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "GI prophylaxis",
          "Glucose q6h (target <180)",
          "electrolytes",
          "mood"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "giant-cell-arteritis"
      ]
    },
    "metoclopramide": {
      "id": "metoclopramide",
      "name": "Metoclopramide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nausea-refractory-to-ondansetron-also-has-prokinetic-effect": {
          "indication": "Nausea refractory to ondansetron; also has prokinetic effect",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV q6-8h PRN; max 30 days use (tardive dyskinesia risk)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "anti-headache-properties-independent-of-anti-emetic-effect-d": {
          "indication": "Anti-headache properties independent of anti-emetic effect; dopamine antagonist effective for undifferentiated headache",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV over 15 min; repeat once in 30 min if needed; always co-administer diphenhydramine to prevent akathisia",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "nausea-with-headache-has-independent-anti-headache-propertie": {
          "indication": "Nausea with headache; has independent anti-headache properties",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg PO at headache onset; repeat in 8h if needed; max 30 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "safe-in-pregnancy-anti-headache-and-anti-emetic": {
          "indication": "Safe in pregnancy; anti-headache and anti-emetic",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV q8h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "safe-in-pregnancy-anti-headache-and-anti-emetic-for-outpatie": {
          "indication": "Safe in pregnancy; anti-headache and anti-emetic for outpatient use",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg PO q8h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "gastroparesis-visceral-autonomic-neuropathy-in-tabes-dorsali": {
          "indication": "Gastroparesis (visceral autonomic neuropathy in tabes dorsalis)",
          "doseOptions": [
            {
              "text": "10 mg TID",
              "orderSentence": "Metoclopramide 10 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg PO 30 min before meals and at bedtime; max 40 mg/day; limit to 12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "gastroparesis-prokinetic": {
          "indication": "Gastroparesis; prokinetic",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Metoclopramide 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg 30 min before meals and at bedtime; limit to <12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "moderate-severe-headache-with-nausea-alternative-to-prochlor": {
          "indication": "Moderate-severe headache with nausea; alternative to prochlorperazine",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Metoclopramide (CPT 96374) 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV over 15-30 min; may repeat once in 30 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "nausea-associated-with-headache-or-elevated-icp": {
          "indication": "Nausea associated with headache or elevated ICP",
          "doseOptions": [
            {
              "text": "10 mg q6h PRN",
              "orderSentence": "Metoclopramide 10 mg q6h PRN IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV q6-8h PRN; max 30 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "nausea-vomiting-alternative-to-ondansetron": {
          "indication": "Nausea/vomiting (alternative to ondansetron)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV q6-8h PRN; max 40 mg/day; limit use to 5 days",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "antiemetic-with-mild-analgesic-properties-for-headache-assoc": {
          "indication": "Antiemetic with mild analgesic properties for headache-associated nausea",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV q8h PRN nausea; give with diphenhydramine 25 mg to prevent akathisia",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "gastroparesis": {
          "indication": "Gastroparesis",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Metoclopramide 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg 30 minutes before meals and qHS; max 40 mg/day; limit to 12 weeks (FDA black box: tardive dyskinesia risk)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV/PO q8h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "nausea-associated-with-headache-ivig-infusion-or-vestibular-": {
          "indication": "Nausea associated with headache, IVIG infusion, or vestibular symptoms from cochlear involvement",
          "doseOptions": [
            {
              "text": "10 mg q6h PRN",
              "orderSentence": "Metoclopramide 10 mg q6h PRN IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV q6-8h PRN; max 30 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "alternative-antiemetic-also-has-analgesic-properties-for-hea": {
          "indication": "Alternative antiemetic; also has analgesic properties for headache",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV over 15 min; may repeat once. Avoid in patients with Parkinson's or dystonic reactions",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "acute-headache-with-nausea-has-anti-headache-properties": {
          "indication": "Acute headache with nausea; has anti-headache properties",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV over 15 min; pretreat with diphenhydramine 25 mg to prevent akathisia",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "gastroparesis-and-gi-dysmotility-in-dm1-promotes-gastric-emp": {
          "indication": "Gastroparesis and GI dysmotility in DM1; promotes gastric emptying",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Metoclopramide 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO 30 minutes before meals and at bedtime; max 40 mg/day; limit use to <12 weeks due to tardive dyskinesia risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "gastroparesis-nausea-autonomic-dysfunction": {
          "indication": "Gastroparesis, nausea (autonomic dysfunction)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV/PO q6h PRN; max 40 mg/day; limit duration to <12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        },
        "gastroparesis-nausea-ileus-autonomic-dysfunction-common": {
          "indication": "Gastroparesis, nausea, ileus (autonomic dysfunction common)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV q6h PRN; max 40 mg/day; limit to <12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "botulism"
          ]
        },
        "antiemetic-with-anti-migraine-properties": {
          "indication": "Antiemetic with anti-migraine properties",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Metoclopramide 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV over 15 min; pretreat with diphenhydramine 25 mg IV to prevent akathisia",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bowel obstruction",
          "GI obstruction",
          "Parkinson disease",
          "Parkinson's",
          "Parkinson's disease",
          "Parkinsonian features",
          "Parkinsonian symptoms",
          "Parkinsonism",
          "QT prolongation, Parkinson disease, seizure disorder, bowel obstruction",
          "QTc >500 ms",
          "Seizure history, Parkinson disease, GI obstruction",
          "Tardive dyskinesia (limit duration)",
          "bowel obstruction",
          "concurrent use of drugs causing EPS",
          "history of tardive dyskinesia",
          "pheochromocytoma",
          "seizure disorder",
          "seizure history",
          "seizure history (relative)",
          "tardive dyskinesia",
          "tardive dyskinesia history"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Akathisia",
          "Akathisia (restlessness), dystonic reaction, QTc",
          "Akathisia, dystonia",
          "Akathisia, dystonic reaction",
          "Dystonic reactions",
          "EPS",
          "EPS (limit duration)",
          "Extrapyramidal symptoms",
          "QT prolongation",
          "QTc",
          "QTc prolongation",
          "QTc, akathisia, dystonic reaction",
          "Tardive dyskinesia",
          "Tardive dyskinesia (limit duration)",
          "Tardive dyskinesia with prolonged use",
          "akathisia",
          "discontinue if EPS",
          "extrapyramidal symptoms",
          "limit to <12 weeks continuous use",
          "prolactin elevation",
          "tardive dyskinesia",
          "tardive dyskinesia (limit duration)",
          "tardive dyskinesia with prolonged use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 20,
      "_sourcePlans": [
        "botulism",
        "cerebral-venous-thrombosis",
        "cns-vasculitis",
        "guillain-barre-syndrome",
        "headache-evaluation",
        "headache-unspecified",
        "migraine",
        "migraine-with-aura",
        "myotonic-dystrophy",
        "neurosyphilis",
        "peripheral-neuropathy",
        "rcvs",
        "small-fiber-neuropathy",
        "susac-syndrome",
        "tension-headache",
        "thunderclap-headache-evaluation",
        "viral-meningitis"
      ]
    },
    "metoclopramide-iv": {
      "id": "metoclopramide-iv",
      "name": "Metoclopramide IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Metoclopramide IV 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV over 15-30 min; may repeat in 30 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "alternative-to-prochlorperazine-migraine-nausea": {
          "indication": "Alternative to prochlorperazine; migraine + nausea",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Metoclopramide IV 10-20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV over 15-30 min; may repeat x1 in 30 min; give with diphenhydramine",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "first-line-antiemetic-and-primary-analgesic-for-acute-migrai": {
          "indication": "First-line antiemetic and primary analgesic for acute migraine via dopamine antagonism; alternative to prochlorperazine",
          "doseOptions": [
            {
              "text": "10 mg IV once",
              "orderSentence": "Metoclopramide IV 10 mg IV once IV"
            },
            {
              "text": "20 mg IV once",
              "orderSentence": "Metoclopramide IV 20 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg IV over 15-30 min; may repeat x1 in 30 min; max 40 mg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation, Parkinson disease, seizure disorder, bowel obstruction",
          "QT prolongation, Parkinson's, seizure disorder",
          "QT prolongation, Parkinson's, seizures"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "QTc, akathisia, dystonia",
          "QTc, akathisia, dystonic reaction, sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "status-migrainosus"
      ]
    },
    "metoprolol": {
      "id": "metoprolol",
      "name": "Metoprolol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Metoprolol 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg BID; target 100-200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as propranolol"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HR, BP"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine"
      ]
    },
    "metoprolol-succinate": {
      "id": "metoprolol-succinate",
      "name": "Metoprolol succinate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Metoprolol succinate 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO daily; titrate to 200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "alternative-beta-blocker-comorbid-hypertension": {
          "indication": "Alternative beta-blocker; comorbid hypertension",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Metoprolol succinate 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg daily; target 100-200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Asthma/severe COPD, bradycardia (<60), heart block (2nd/3rd degree), decompensated HF, depression (relative)",
          "HR, BP"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HR, BP, fatigue"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "chronic-migraine"
      ]
    },
    "metronidazole": {
      "id": "metronidazole",
      "name": "Metronidazole (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "empiric-anaerobic-coverage-bacteroides-fusobacterium-prevote": {
          "indication": "Empiric anaerobic coverage (Bacteroides, Fusobacterium, Prevotella); excellent CNS penetration; essential for abscess from dental, sinus, or otogenic source",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Metronidazole (CPT 96374) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV q8h; then transition to 500 mg PO q8h when clinically stable; duration 6-8 weeks total; excellent oral bioavailability allows early PO switch",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "wound-botulism-eradicate-c-botulinum-from-wound-adjunct-to-d": {
          "indication": "Wound botulism — eradicate C. botulinum from wound; adjunct to debridement",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Metronidazole (wound botulism) (CPT 96365) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV q8h x 10-14 days; alternative to penicillin (avoids aminoglycoside interaction concern)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "botulism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Disulfiram-like reaction with alcohol",
          "Severe hepatic impairment",
          "disulfiram-like reaction with alcohol",
          "first-trimester pregnancy",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs",
          "Peripheral neuropathy with prolonged use (>4 weeks: reassess)",
          "metallic taste",
          "neuropathy (prolonged use)",
          "seizure threshold",
          "seizures (rare)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "botulism",
        "brain-abscess"
      ]
    },
    "mexiletine": {
      "id": "mexiletine",
      "name": "Mexiletine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "muscle-cramps-refractory": {
          "indication": "Muscle cramps (refractory)",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Mexiletine 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 150 mg PO BID; may increase to 300 mg BID; max 1200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "sodium-channel-blocker-especially-if-scn9a-mutation-suspecte": {
          "indication": "Sodium channel blocker; especially if SCN9A mutation suspected",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Mexiletine 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 150 mg TID; titrate by 150 mg q3d; max 1200 mg/day; take with food",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "first-line-treatment-for-symptomatic-myotonia-grip-myotonia-": {
          "indication": "First-line treatment for symptomatic myotonia (grip myotonia, jaw myotonia, difficulty releasing objects); sodium channel blocker that reduces myotonic stiffness",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Mexiletine 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 150 mg PO BID; increase to 150 mg TID after 1-2 weeks; may increase to 200 mg TID; max 900 mg/day; take with food to reduce GI side effects",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "2nd/3rd degree AV block without pacemaker",
          "CRITICAL: obtain ECG before starting -- cardiac conduction disease common in DM1",
          "Cardiogenic shock",
          "Cardiomyopathy",
          "QTc prolongation",
          "Second- or third-degree AV block (without pacemaker)",
          "cardiogenic shock",
          "hepatic impairment",
          "second/third degree AV block"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Baseline ECG",
          "CBC",
          "ECG",
          "ECG at baseline and 1-2 weeks after dose changes",
          "GI tolerance",
          "GI upset",
          "LFTs q6-12 months",
          "arrhythmia monitoring",
          "cardiac symptoms",
          "heart rate",
          "monitor for arrhythmia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "als",
        "myotonic-dystrophy",
        "small-fiber-neuropathy"
      ]
    },
    "midazolam": {
      "id": "midazolam",
      "name": "Midazolam",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM",
        "IN",
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-seizure-clusters-rescue-first-line-outpatient-rescue-f": {
          "indication": "Acute seizure clusters/rescue; first-line outpatient rescue for DRE patients",
          "doseOptions": [
            {
              "text": "5 mg single spray",
              "orderSentence": "Midazolam (Nayzilam) 5 mg single spray IN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg intranasal single spray into one nostril; may repeat x1 in 10 min if seizure continues; max 10 mg per episode; max 5 episodes/month",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "acute-seizure-when-iv-access-unavailable": {
          "indication": "Acute seizure when IV access unavailable",
          "doseOptions": [
            {
              "text": "10 mg IM",
              "orderSentence": "Midazolam 10 mg IM IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IM single dose (RAMPART trial); faster onset than IV lorazepam when IV access delayed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "active-seizure-without-iv-access": {
          "indication": "Active seizure without IV access",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Midazolam (if no IV access) 10 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IM (adults >40 kg) or 0.2 mg/kg intranasal",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "alternative-adjunctive-sedation-if-propofol-contraindicated-": {
          "indication": "Alternative/adjunctive sedation if propofol contraindicated; anti-seizure properties",
          "doseOptions": [
            {
              "text": "0.02-0.1 mg/kg/h",
              "orderSentence": "Midazolam 0.02-0.1 mg/kg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.02-0.1 mg/kg/h continuous; accumulates with prolonged use; prolongs sedation washout (confounder for prognostication)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "status-spasticus-requiring-continuous-infusion-icu-setting": {
          "indication": "Status spasticus requiring continuous infusion; ICU setting",
          "doseOptions": [
            {
              "text": "0.05 mg/kg/hr",
              "orderSentence": "Midazolam 0.05 mg/kg/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg IV bolus, then 0.05-0.2 mg/kg/hr continuous infusion; titrate to spasm control; taper gradually over days once spasms controlled",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "seizure-cluster-rescue-all-epilepsy-patients-should-have-res": {
          "indication": "Seizure cluster rescue; all epilepsy patients should have rescue plan",
          "doseOptions": [
            {
              "text": "5 mg single spray",
              "orderSentence": "Midazolam (Nayzilam) 5 mg single spray IN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg intranasal into one nostril; may repeat x1 in 10 min; max 10 mg/episode; max 5 episodes/month; prescribe for all patients with history of clusters",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Midazolam (if no IV access) 10 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IM (adults >40 kg) or 0.2 mg/kg intranasal",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Acute narrow-angle glaucoma",
          "Respiratory depression",
          "Respiratory depression (requires mechanical ventilation for continuous infusion)",
          "Severe hepatic impairment",
          "Severe respiratory depression",
          "acute narrow-angle glaucoma",
          "prolonged use delays prognostication",
          "severe respiratory depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Continuous SpO2",
          "RASS",
          "Respiratory status",
          "Same as lorazepam",
          "SpO2",
          "airway patency",
          "cEEG",
          "oxygen saturation",
          "respiratory rate",
          "sedation",
          "sedation level",
          "sedation level (RASS)",
          "train caregivers on use",
          "ventilator settings",
          "watch for prolonged effect delaying prognostication"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "autoimmune-encephalitis",
        "drug-resistant-epilepsy",
        "epilepsy-chronic-management",
        "hashimotos-encephalopathy",
        "stiff-person-syndrome"
      ]
    },
    "midazolam-buccal": {
      "id": "midazolam-buccal",
      "name": "Midazolam buccal",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Midazolam buccal 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg buccal (if available)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Oral trauma"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RR, O2 sat"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-epilepticus"
      ]
    },
    "midazolam-im": {
      "id": "midazolam-im",
      "name": "Midazolam IM",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM",
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-seizure-if-no-iv-access": {
          "indication": "Acute seizure if no IV access",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Midazolam IM 10 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IM (if >=40 kg) or 0.2 mg/kg IM; single dose; obtain IV access urgently",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Midazolam IM 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IM (≥40 kg) or 0.2 mg/kg IM (if no IV access); single dose",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus",
            "new-onset-seizure"
          ]
        },
        "no-iv-access-rapid-administration-needed": {
          "indication": "No IV access; rapid administration needed",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Midazolam IM (if no IV access) 10 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IM (adults >40 kg) or 0.2 mg/kg intranasal/buccal",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Respiratory compromise",
          "Respiratory depression",
          "Same as lorazepam"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RR, O2 sat",
          "Same as lorazepam",
          "have airway equipment ready",
          "prepare IV access",
          "prepare IV access immediately"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "ncse",
        "new-onset-seizure",
        "status-epilepticus"
      ]
    },
    "midazolam-infusion": {
      "id": "midazolam-infusion",
      "name": "Midazolam infusion (refractory SE)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-status-epilepticus": {
          "indication": "Refractory status epilepticus",
          "doseOptions": [
            {
              "text": "0.2 mg/kg",
              "orderSentence": "Midazolam infusion (refractory SE) 0.2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bolus: 0.2 mg/kg IV; Infusion: 0.1-2.0 mg/kg/hr; titrate to EEG burst suppression",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.2 mg/kg",
              "orderSentence": "Midazolam infusion 0.2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 0.2 mg/kg IV bolus; Infusion: start 0.1 mg/kg/hr, titrate by 0.1 mg/kg/hr q15min to seizure suppression; max 2 mg/kg/hr; target burst suppression on cEEG",
          "settings": {
            "ED": "URGENT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus",
            "autoimmune-encephalitis"
          ]
        },
        "refractory-ncse-failing-2-asms-requires-intubation-icu": {
          "indication": "Refractory NCSE failing 2+ ASMs; requires intubation/ICU",
          "doseOptions": [
            {
              "text": "0.2 mg/kg",
              "orderSentence": "Midazolam infusion 0.2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bolus: 0.2 mg/kg IV; Infusion: start 0.1 mg/kg/hr; titrate to EEG seizure suppression or burst suppression; max 2 mg/kg/hr; weaning trials q24-48h",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "continuous-seizure-activity-despite-two-asms-refractory-stat": {
          "indication": "Continuous seizure activity despite two ASMs (refractory status epilepticus protocol)",
          "doseOptions": [
            {
              "text": "0.2 mg/kg",
              "orderSentence": "Midazolam infusion (RSE) 0.2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.2 mg/kg IV bolus, then start 0.1 mg/kg/h; titrate q15min by 0.1 mg/kg/h to EEG seizure suppression or burst-suppression; max 2 mg/kg/h",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hemodynamic instability (may worsen)",
          "Hemodynamic instability (relative)",
          "Unprotected airway (requires intubation)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Continuous EEG",
          "cEEG mandatory",
          "cEEG, BP (hypotension common), sedation scale",
          "hemodynamics",
          "respiratory status",
          "sedation depth",
          "tachyphylaxis",
          "tachyphylaxis (may need escalating doses)",
          "vasopressor requirements"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "autoimmune-encephalitis",
        "hashimotos-encephalopathy",
        "ncse",
        "status-epilepticus"
      ]
    },
    "midazolam-intranasal": {
      "id": "midazolam-intranasal",
      "name": "Midazolam intranasal",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Midazolam intranasal 5 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg per nostril (10 mg total) if no IV/IM access",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus",
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Nasal obstruction",
          "Respiratory depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RR, O2 sat"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "new-onset-seizure",
        "status-epilepticus"
      ]
    },
    "midazolam-iv": {
      "id": "midazolam-iv",
      "name": "Midazolam IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.2 mg/kg",
              "orderSentence": "Midazolam IV 0.2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.2 mg/kg IV (max 10 mg); may repeat x1",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as lorazepam"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RR, O2 sat, BP"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-epilepticus"
      ]
    },
    "midodrine": {
      "id": "midodrine",
      "name": "Midodrine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2.5-10 mg",
              "orderSentence": "Midodrine 2.5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2.5-10 mg TID (refractory cases)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "syncope"
          ]
        },
        "orthostatic-hypotension-alpha-1-agonist-vasoconstrictor": {
          "indication": "Orthostatic hypotension; alpha-1 agonist vasoconstrictor",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Midodrine 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5 mg TID (with meals); titrate to 5-10 mg TID; last dose 4h before bed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "orthostatic-hypotension": {
          "indication": "Orthostatic hypotension",
          "doseOptions": [
            {
              "text": "2.5 mg TID",
              "orderSentence": "Midodrine 2.5 mg TID PO"
            },
            {
              "text": "5 mg TID",
              "orderSentence": "Midodrine 5 mg TID PO"
            },
            {
              "text": "10 mg TID",
              "orderSentence": "Midodrine 10 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5 mg TID (before arising, lunch, mid-afternoon); titrate by 2.5 mg/dose; max 10 mg TID; last dose by 6 PM",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia",
            "parkinsons-disease"
          ]
        },
        "orthostatic-hypotension-contributing-to-dizziness": {
          "indication": "Orthostatic hypotension contributing to dizziness",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Midodrine 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5 mg PO TID; increase to 5-10 mg TID; avoid evening dose",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "orthostatic-hypotension-contributing-to-falls": {
          "indication": "Orthostatic hypotension contributing to falls",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Midodrine 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5 mg TID; titrate to 5-10 mg TID; last dose by 4 PM (avoid supine hypertension); max 30 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "orthostatic-hypotension-from-autonomic-dysfunction-in-lems": {
          "indication": "Orthostatic hypotension from autonomic dysfunction in LEMS",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Midodrine 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5 mg TID; titrate by 2.5 mg per dose every 1-2 weeks; max 10 mg TID; avoid dosing within 4 hours of bedtime",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "acute-symptomatic-orthostatic-hypotension-not-responding-to-": {
          "indication": "Acute symptomatic orthostatic hypotension not responding to fluids",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Midodrine (acute dosing) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg PO for symptomatic OH; onset 30-45 min; do NOT give within 4 hours of bedtime",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "neurogenic-orthostatic-hypotension-first-line-pharmacotherap": {
          "indication": "Neurogenic orthostatic hypotension — first-line pharmacotherapy",
          "doseOptions": [
            {
              "text": "2.5 mg TID",
              "orderSentence": "Midodrine (Proamatine) 2.5 mg TID PO"
            },
            {
              "text": "5 mg TID",
              "orderSentence": "Midodrine (Proamatine) 5 mg TID PO"
            },
            {
              "text": "10 mg TID",
              "orderSentence": "Midodrine (Proamatine) 10 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5 mg TID (upon awakening, midday, mid-afternoon); titrate by 2.5 mg q1-2 weeks; max 10 mg TID; last dose no later than 4 PM to avoid supine hypertension",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe cardiac disease",
          "Supine HTN, urinary retention",
          "Supine HTN, urinary retention, pheochromocytoma",
          "Supine hypertension",
          "Supine hypertension (SBP >180), urinary retention, pheochromocytoma, thyrotoxicosis",
          "Supine hypertension, urinary retention, severe cardiac disease, pheochromocytoma",
          "pheochromocytoma",
          "severe cardiac disease",
          "severe organic heart disease",
          "supine hypertension",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Supine BP",
          "Supine BP (check 1 hour after first dose)",
          "Supine BP (check 30 min after dose), standing BP",
          "Supine BP (check 30 min post-dose)",
          "Supine BP (check for supine hypertension)",
          "Supine BP (must avoid lying flat for 4 hours after dose)",
          "Supine HTN",
          "Supine blood pressure",
          "avoid at bedtime",
          "avoid lying flat 4 hours after dose",
          "avoid supine position for 4h after dosing",
          "scalp tingling (expected)",
          "standing BP",
          "urinary retention",
          "urinary retention symptoms",
          "urinary symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "lambert-eaton-syndrome",
        "lewy-body-dementia",
        "multiple-system-atrophy",
        "parkinsons-disease",
        "post-concussion-syndrome",
        "progressive-supranuclear-palsy",
        "small-fiber-neuropathy",
        "syncope"
      ]
    },
    "mifepristone": {
      "id": "mifepristone",
      "name": "Mifepristone (RU-486)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "progesterone-receptor-positive-meningioma-mostly-who-grade-i": {
          "indication": "Progesterone receptor-positive meningioma (mostly WHO grade I); antiprogesterone therapy; SWOG S9005 showed no significant benefit overall but some individual responses",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Mifepristone (RU-486) 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg PO daily continuously; efficacy data limited and conflicting",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy (abortifacient)",
          "chronic adrenal failure",
          "concurrent corticosteroid use for life-threatening conditions",
          "hemorrhagic disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cortisol levels (adrenal insufficiency)",
          "endometrial thickness in women",
          "potassium",
          "vaginal bleeding"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "meningioma"
      ]
    },
    "milrinone-iv": {
      "id": "milrinone-iv",
      "name": "Milrinone IV (alternative vasospasm treatment)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.25-0.75 µg/kg/min",
              "orderSentence": "Milrinone IV (alternative vasospasm treatment) 0.25-0.75 µg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.25-0.75 µg/kg/min IV continuous; some centers use as rescue for vasospasm not responding to induced hypertension; acts as cerebral vasodilator",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hypotension",
          "arrhythmia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP (may cause hypotension)",
          "HR",
          "cardiac output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "subarachnoid-hemorrhage"
      ]
    },
    "mirabegron": {
      "id": "mirabegron",
      "name": "Mirabegron",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "urinary-urgency-if-anticholinergics-contraindicated-or-cause": {
          "indication": "Urinary urgency if anticholinergics contraindicated or cause cognitive worsening",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Mirabegron 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; may increase to 50 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "normal-pressure-hydrocephalus"
          ]
        },
        "bladder-urgency-beta-3-agonist-non-anticholinergic": {
          "indication": "Bladder urgency; beta-3 agonist (non-anticholinergic)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Mirabegron 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; may increase to 50 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "bladder-urgency": {
          "indication": "Bladder urgency",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Mirabegron 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; may increase to 50 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy",
            "ms-new-diagnosis"
          ]
        },
        "neurogenic-detrusor-overactivity-preferred-over-antimuscarin": {
          "indication": "Neurogenic detrusor overactivity — preferred over antimuscarinics due to less cognitive impairment",
          "doseOptions": [
            {
              "text": "25 mg daily",
              "orderSentence": "Mirabegron (Myrbetriq) 25 mg daily PO"
            },
            {
              "text": "50 mg daily",
              "orderSentence": "Mirabegron (Myrbetriq) 50 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase to 50 mg after 4-8 weeks if needed; no anticholinergic side effects",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "neurogenic-bladder-with-urgency-alternative-to-anticholinerg": {
          "indication": "Neurogenic bladder with urgency; alternative to anticholinergics with fewer cognitive side effects",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Mirabegron 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO daily; increase to 50 mg daily after 8 weeks if needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe uncontrolled hypertension",
          "Uncontrolled hypertension",
          "Uncontrolled hypertension (may raise BP 1-2 mmHg), severe hepatic impairment",
          "end-stage renal disease",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP monitoring",
          "Blood pressure",
          "Blood pressure, urinary retention, UTI",
          "fewer anticholinergic effects",
          "fewer anticholinergic effects (beta-3 agonist)",
          "hepatic function",
          "urinary retention"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "cervical-myelopathy",
        "ms-new-diagnosis",
        "multiple-system-atrophy",
        "normal-pressure-hydrocephalus",
        "peripheral-neuropathy",
        "small-fiber-neuropathy"
      ]
    },
    "mirtazapine": {
      "id": "mirtazapine",
      "name": "Mirtazapine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "depression-with-poor-appetite-weight-loss-and-insomnia": {
          "indication": "Depression with poor appetite, weight loss, and insomnia",
          "doseOptions": [
            {
              "text": "7.5 mg",
              "orderSentence": "Mirtazapine (Remeron) 7.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5-15 mg qHS; may increase to 30-45 mg qHS; lower doses more sedating",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia",
            "frontotemporal-dementia"
          ]
        },
        "depression-with-insomnia-and-weight-loss-promotes-appetite": {
          "indication": "Depression with insomnia and weight loss; promotes appetite",
          "doseOptions": [
            {
              "text": "7.5 mg",
              "orderSentence": "Mirtazapine 7.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5-15 mg qHS; titrate q1-2wk; max 45 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "depression-with-poor-appetite-insomnia-and-weight-loss": {
          "indication": "Depression with poor appetite, insomnia, and weight loss",
          "doseOptions": [
            {
              "text": "7.5 mg",
              "orderSentence": "Mirtazapine 7.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5-15 mg qHS; may increase to 30 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment",
            "alzheimers-disease"
          ]
        },
        "depression-with-poor-appetite-and-insomnia": {
          "indication": "Depression with poor appetite and insomnia",
          "doseOptions": [
            {
              "text": "7.5 mg",
              "orderSentence": "Mirtazapine 7.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5-15 mg qHS; may increase to 30 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "depression-with-insomnia-and-weight-loss-common-in-hiv-appet": {
          "indication": "Depression with insomnia and weight loss (common in HIV); appetite stimulation; dual benefit in HIV wasting with depression",
          "doseOptions": [
            {
              "text": "15 mg",
              "orderSentence": "Mirtazapine 15 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 15 mg QHS; increase to 30-45 mg; lower dose more sedating",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "depression-insomnia": {
          "indication": "Depression/insomnia",
          "doseOptions": [
            {
              "text": "15 mg",
              "orderSentence": "Mirtazapine 15 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 15 mg qHS; may increase by 15 mg every 1-2 weeks; max 45 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "7.5-15 mg",
              "orderSentence": "Mirtazapine (sleep, appetite, mood) 7.5-15 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "7.5-15 mg QHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "prevention-comorbid-insomnia-depression-or-poor-appetite": {
          "indication": "Prevention; comorbid insomnia, depression, or poor appetite",
          "doseOptions": [
            {
              "text": "7.5 mg",
              "orderSentence": "Mirtazapine 7.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 7.5-15 mg qHS; may increase to 30 mg qHS; more sedating at lower doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAOIs",
          "MAOIs",
          "None significant",
          "angle-closure glaucoma",
          "caution with CYP3A4 inhibitors (PIs may increase levels)",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation, increased appetite, weight gain",
          "Weight gain",
          "Weight gain (desired in wasting)",
          "Weight gain (may be beneficial), sedation",
          "Weight gain (often desired in FTD)",
          "Weight gain (often desired)",
          "Weight gain, sedation",
          "Weight, sedation",
          "agranulocytosis (rare)",
          "hyperlipidemia",
          "neutropenia (rare)",
          "sedation",
          "sedation (lower at higher doses)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "alzheimers-disease",
        "dementia-evaluation",
        "frontotemporal-dementia",
        "hiv-associated-neurocognitive-disorder",
        "huntingtons-disease",
        "lewy-body-dementia",
        "mild-cognitive-impairment",
        "ms-new-diagnosis",
        "tension-headache",
        "vascular-dementia"
      ]
    },
    "mixed-amphetamine-salts": {
      "id": "mixed-amphetamine-salts",
      "name": "Mixed amphetamine salts (Adderall)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "eds-refractory-to-first-line-agents-combined-amphetamine-for": {
          "indication": "EDS refractory to first-line agents; combined amphetamine formulation",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Mixed amphetamine salts (Adderall) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg once or twice daily; titrate by 5-10 mg/week; max 60 mg/day; avoid evening dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAOIs",
          "advanced atherosclerosis",
          "agitated states",
          "glaucoma",
          "history of drug abuse",
          "moderate-severe hypertension",
          "symptomatic cardiovascular disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood pressure",
          "abuse potential (Schedule II)",
          "appetite",
          "heart rate",
          "psychiatric symptoms",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "narcolepsy"
      ]
    },
    "modafinil": {
      "id": "modafinil",
      "name": "Modafinil",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "apathy-fatigue-excessive-daytime-sleepiness": {
          "indication": "Apathy; fatigue; excessive daytime sleepiness",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg each morning; may increase to 200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "apathy-excessive-daytime-sleepiness": {
          "indication": "Apathy; excessive daytime sleepiness",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg each morning; may increase to 200 mg; avoid afternoon dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "first-line-wake-promoting-agent-for-eds": {
          "indication": "First-line wake-promoting agent for EDS",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil (Provigil) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg each morning; increase to 200 mg daily after 1 week; may split 200 mg AM + 200 mg early afternoon if needed; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        },
        "fatigue-from-brainstem-parenchymal-nbd-involvement-disease-r": {
          "indication": "Fatigue from brainstem/parenchymal NBD involvement; disease-related fatigue",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO every morning; increase to 200 mg daily after 1 week if needed; max 400 mg/day; take in morning to avoid insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "fatigue": {
          "indication": "Fatigue",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO every morning; may increase to 200 mg; avoid afternoon dosing",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als",
            "nmosd",
            "ms-new-diagnosis"
          ]
        },
        "persistent-fatigue-during-icuaw-recovery-alternative-to-meth": {
          "indication": "Persistent fatigue during ICUAW recovery; alternative to methylphenidate",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO daily in AM; max 200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "excessive-daytime-sleepiness-fatigue-off-label-for-tbi": {
          "indication": "Excessive daytime sleepiness, fatigue (off-label for TBI)",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO every morning; may increase to 200 mg daily; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "daytime-fatigue-and-somnolence-associated-with-chronic-progr": {
          "indication": "Daytime fatigue and somnolence associated with chronic progressive disease",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO every morning; may increase to 200 mg daily; avoid afternoon dosing",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "fatigue-and-excessive-daytime-sleepiness-in-hand-alternative": {
          "indication": "Fatigue and excessive daytime sleepiness in HAND; alternative to methylphenidate with lower abuse potential",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg QAM; increase to 200 mg QAM after 1 week; max 200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "excessive-daytime-sleepiness-fatigue-and-apathy-in-psp": {
          "indication": "Excessive daytime sleepiness, fatigue, and apathy in PSP",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg every morning; may increase to 200 mg daily; avoid afternoon dosing",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "excessive-daytime-somnolence-and-fatigue-in-abi-survivors": {
          "indication": "Excessive daytime somnolence and fatigue in ABI survivors",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO daily in morning; increase to 200 mg; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "fatigue-associated-with-chronic-cerebellar-disease-daytime-s": {
          "indication": "Fatigue associated with chronic cerebellar disease; daytime somnolence from medications or disease",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg each morning; may increase to 200 mg daily; take before noon to avoid insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "post-stroke-fatigue-affects-30-70-of-survivors-not-responsiv": {
          "indication": "Post-stroke fatigue (affects 30-70% of survivors); not responsive to treating depression alone; wakefulness-promoting agent",
          "doseOptions": [
            {
              "text": "100 mg daily",
              "orderSentence": "Modafinil 100 mg daily PO"
            },
            {
              "text": "200 mg daily",
              "orderSentence": "Modafinil 200 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg each morning; may increase to 200 mg daily; take in morning to avoid insomnia; Schedule IV",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "excessive-daytime-sleepiness-refractory-to-sleep-optimizatio": {
          "indication": "Excessive daytime sleepiness refractory to sleep optimization",
          "doseOptions": [
            {
              "text": "100 mg QAM",
              "orderSentence": "Modafinil 100 mg QAM PO"
            },
            {
              "text": "200 mg QAM",
              "orderSentence": "Modafinil 200 mg QAM PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg each morning; may increase to 200 mg; take early morning to avoid insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "excessive-daytime-somnolence-eds-and-central-hypersomnia-in-": {
          "indication": "Excessive daytime somnolence (EDS) and central hypersomnia in DM1 (CNS-mediated, not solely from sleep apnea); improves alertness and quality of life",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Modafinil 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO every morning; may increase to 200 mg daily after 1-2 weeks; max 400 mg/day; avoid afternoon dosing to prevent insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Arrhythmias",
          "Cardiac arrhythmia",
          "Cardiac arrhythmia, mitral valve prolapse, hepatic impairment",
          "Hypersensitivity",
          "LV hypertrophy",
          "Mitral valve prolapse (relative), cardiac arrhythmia, hepatic impairment",
          "Severe hepatic impairment",
          "arrhythmia",
          "cardiac arrhythmia",
          "cardiac arrhythmia (common in DM1 -- use with caution)",
          "cardiac arrhythmias",
          "concurrent CYP3A4 concerns (may reduce PI levels -- monitor)",
          "concurrent hormonal contraceptives (reduces efficacy)",
          "hepatic impairment",
          "hepatic impairment (reduce dose)",
          "history of angioedema with modafinil",
          "history of left ventricular hypertrophy",
          "may reduce efficacy of hormonal contraceptives",
          "mitral valve prolapse with left ventricular hypertrophy",
          "severe anxiety",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP, HR",
          "Blood pressure",
          "Blood pressure, heart rate",
          "Blood pressure, heart rate, sleep quality, mood",
          "HR",
          "HR, BP",
          "Headache, insomnia, cardiac monitoring if history",
          "Insomnia, anxiety, BP",
          "SJS risk (rare)",
          "Schedule IV",
          "Stevens-Johnson (rare)",
          "cardiac rhythm",
          "contraceptive efficacy",
          "headache",
          "heart rate",
          "hepatic function",
          "insomnia",
          "interactions with PIs (may reduce darunavir levels)",
          "may reduce OCP efficacy",
          "may reduce efficacy of hormonal contraception",
          "may reduce efficacy of hormonal contraceptives",
          "mood",
          "psychiatric symptoms",
          "rash (rare Stevens-Johnson)",
          "reduces efficacy of hormonal contraceptives",
          "sleep",
          "sleep disturbance",
          "sleep quality"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 17,
      "_sourcePlans": [
        "als",
        "anoxic-brain-injury",
        "ataxia-evaluation",
        "critical-illness-myopathy-neuropathy",
        "hiv-associated-neurocognitive-disorder",
        "huntingtons-disease",
        "inclusion-body-myositis",
        "ms-new-diagnosis",
        "multiple-system-atrophy",
        "myotonic-dystrophy",
        "narcolepsy",
        "neuro-behcets-disease",
        "nmosd",
        "post-concussion-syndrome",
        "post-stroke-management",
        "progressive-supranuclear-palsy",
        "vascular-dementia"
      ]
    },
    "modified-atkins-diet": {
      "id": "modified-atkins-diet",
      "name": "Modified Atkins diet",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Dietary"
      ],
      "formulations": [],
      "contexts": {
        "more-tolerable-alternative-to-classic-ketogenic-diet-for-adu": {
          "indication": "More tolerable alternative to classic ketogenic diet for adult DRE; 20 g/day net carb limit; less restrictive",
          "doseOptions": [
            {
              "text": "20 g net carbs/day",
              "orderSentence": "Modified Atkins diet 20 g net carbs/day Dietary"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Limit net carbohydrates to 20 g/day; high-fat intake encouraged; no caloric restriction; no protein restriction; less dietitian oversight needed than classic KD",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as ketogenic diet"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same as ketogenic diet",
          "better compliance and quality of life in adults"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "monomethyl-fumarate": {
      "id": "monomethyl-fumarate",
      "name": "Monomethyl fumarate (Bafiertam)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "95 mg",
              "orderSentence": "Monomethyl fumarate (Bafiertam) 95 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "95 mg BID × 7 days, then 190 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same",
          "Same as Tecfidera"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "morphine": {
      "id": "morphine",
      "name": "Morphine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO/SL"
      ],
      "formulations": [],
      "contexts": {
        "dyspnea-palliative": {
          "indication": "Dyspnea (palliative)",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Morphine 2.5 mg PO/SL"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5-5 mg PO/SL q4h PRN for dyspnea; titrate to comfort; may reduce respiratory distress without significantly worsening ventilation",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "severe-headache-refractory-to-acetaminophen-nsaids-use-spari": {
          "indication": "Severe headache refractory to acetaminophen + NSAIDs; use sparingly and short-term only; avoid in patients who can tolerate oral analgesics",
          "doseOptions": [
            {
              "text": "2-4 mg",
              "orderSentence": "Morphine 2-4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-4 mg IV q3-4h PRN; titrate to pain relief; minimize use; transition to non-opioid regimen as soon as possible",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "moderate-to-severe-headache-or-radicular-pain-not-responsive": {
          "indication": "Moderate to severe headache or radicular pain not responsive to acetaminophen and gabapentin",
          "doseOptions": [
            {
              "text": "2-4 mg",
              "orderSentence": "**Morphine (moderate-severe pain)** 2-4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Morphine 2-4 mg IV q4h PRN severe pain; titrate to pain control; start bowel regimen (docusate 100 mg BID + senna) concurrently; avoid NSAIDs with IT MTX or thrombocytopenia",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "pain-suffering-and-distress-in-advanced-cjd-palliative-inten": {
          "indication": "Pain, suffering, and distress in advanced CJD -- palliative intent; myoclonus can be painful",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Morphine (pain and distress) 2 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1-2 mg IV q2-4h PRN; titrate to comfort; convert to scheduled dosing if frequent PRN use",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "severe-acute-radicular-pain": {
          "indication": "Severe acute radicular pain",
          "doseOptions": [
            {
              "text": "2-4 mg",
              "orderSentence": "Morphine 2-4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-4 mg IV q2-4h PRN severe pain; titrate to effect",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "severe-acute-plexopathy-pain-unresponsive-to-non-opioids": {
          "indication": "Severe acute plexopathy pain unresponsive to non-opioids",
          "doseOptions": [
            {
              "text": "2-4 mg",
              "orderSentence": "Morphine (CPT 96374) 2-4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-4 mg IV q2-4h PRN severe pain; titrate to effect",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active respiratory failure without comfort focus",
          "Respiratory depression",
          "Respiratory depression (acceptable in comfort-focused care)",
          "altered mental status",
          "concurrent CNS depressants (dose reduce)",
          "ileus",
          "obtundation",
          "opioid allergy",
          "paralytic ileus",
          "severe asthma",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Pain scores q4h",
          "Respiratory rate",
          "Respiratory rate, comfort, sedation",
          "Respiratory status",
          "bowel function",
          "bowel function (constipation prophylaxis)",
          "bowel regimen compliance",
          "comfort level",
          "constipation",
          "pain scores",
          "respiratory rate (hold if RR <10)",
          "sedation",
          "sedation level"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "als",
        "creutzfeldt-jakob-disease",
        "leptomeningeal-carcinomatosis",
        "plexopathy",
        "radiculopathy",
        "viral-meningitis"
      ]
    },
    "morphine-iv": {
      "id": "morphine-iv",
      "name": "Morphine IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "severe-pain-unresponsive-to-above": {
          "indication": "Severe pain unresponsive to above",
          "doseOptions": [
            {
              "text": "2-4 mg",
              "orderSentence": "Morphine IV 2-4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-4 mg IV q3-4h PRN; use with caution — respiratory depression risk especially with respiratory compromise",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Respiratory failure (relative — monitor closely), ileus"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RR, SpO2, sedation scale",
          "bowel function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "guillain-barre-syndrome"
      ]
    },
    "morphine-oral-sublingual": {
      "id": "morphine-oral-sublingual",
      "name": "Morphine oral/sublingual (outpatient palliative)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "pain-and-distress-management-in-home-hospice-setting": {
          "indication": "Pain and distress management in home hospice setting",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Morphine oral/sublingual (outpatient palliative) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Immediate release: 5-10 mg PO q4h PRN; convert to sustained-release when dose established; sublingual concentrated solution for dysphagia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Respiratory depression (acceptable in comfort-focused care)",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Respiratory rate",
          "bowel function",
          "comfort level",
          "sedation",
          "stool softener/laxative prophylaxis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "creutzfeldt-jakob-disease"
      ]
    },
    "moxifloxacin": {
      "id": "moxifloxacin",
      "name": "Moxifloxacin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "drug-resistant-tb-alternative-fluoroquinolone-with-excellent": {
          "indication": "Drug-resistant TB; alternative fluoroquinolone with excellent CNS penetration; useful in MDR-TB meningitis regimens",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Moxifloxacin 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400 mg PO/IV daily; excellent CNS penetration; some studies suggest benefit even in drug-susceptible TBM (moxifloxacin-containing regimens)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation (more than levofloxacin)",
          "hepatic disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs",
          "QTc",
          "tendon symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tb-meningitis"
      ]
    },
    "ms-dmt": {
      "id": "ms-dmt",
      "name": "MS DMT (various)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Variable"
      ],
      "formulations": [],
      "contexts": {
        "if-ms-diagnosed-based-on-mri-clinical-criteria": {
          "indication": "If MS diagnosed based on MRI + clinical criteria",
          "doseOptions": [
            {
              "text": "See MS - New Diagnosis template",
              "orderSentence": "MS DMT (various) See MS - New Diagnosis template -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "See MS - New Diagnosis template",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per specific DMT"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Per specific DMT"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "optic-neuritis"
      ]
    },
    "multivitamin-po": {
      "id": "multivitamin-po",
      "name": "Multivitamin PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nutritional-supplementation-multiple-micronutrient-deficienc": {
          "indication": "Nutritional supplementation; multiple micronutrient deficiencies in chronic alcohol use",
          "doseOptions": [
            {
              "text": "1 tablet",
              "orderSentence": "Multivitamin PO 1 tablet PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 multivitamin tablet PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Nutritional status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure"
      ]
    },
    "mycophenolate-mofetil": {
      "id": "mycophenolate-mofetil",
      "name": "Mycophenolate mofetil",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase to 1000 mg PO BID after 2 weeks; max 1500 mg BID; onset 6-12 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "cidp",
            "myasthenia-gravis-new-diagnosis",
            "acute-myelopathy",
            "autoimmune-encephalitis"
          ]
        },
        "steroid-sparing-agent-alternative-to-azathioprine-relapsing-": {
          "indication": "Steroid-sparing agent; alternative to azathioprine; relapsing NBD",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase by 500 mg every 2 weeks; target 1000-1500 mg BID (2000-3000 mg/day total)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "steroid-sparing-agent-for-dm-and-pm-ild-associated-with-anti": {
          "indication": "Steroid-sparing agent for DM and PM; ILD associated with anti-synthetase syndrome; onset 3-6 months",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil (CellCept) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase to 1000 mg BID after 2 weeks; target 2000-3000 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "steroid-sparing-maintenance-relapsing-he": {
          "indication": "Steroid-sparing maintenance; relapsing HE",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil (CellCept) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase to 1000 mg PO BID over 2-4 weeks (target 1500-3000 mg/day)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "steroid-sparing-maintenance-relapse-prevention": {
          "indication": "Steroid-sparing maintenance; relapse prevention",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Mycophenolate mofetil (maintenance) 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO BID (established dose)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "steroid-sparing-agent-alternative-to-methotrexate-relapsing-": {
          "indication": "Steroid-sparing agent; alternative to methotrexate; relapsing neurosarcoidosis",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase by 500 mg every 2 weeks; target 1000-1500 mg BID (2000-3000 mg/day total)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "steroid-sparing-alternative-to-azathioprine": {
          "indication": "Steroid-sparing; alternative to azathioprine",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; increase to 1000 mg BID after 2 weeks; may increase to 1500 mg BID if needed; takes 3-6 months for effect",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "steroid-sparing-maintenance-immunotherapy-alternative-to-aza": {
          "indication": "Steroid-sparing maintenance immunotherapy; alternative to azathioprine; takes 2-3 months for full effect",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil (CellCept) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase to 1000 mg PO BID over 2-4 weeks; target 2000-3000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "steroid-sparing-maintenance-aqp4-or-aqp4-nmosd": {
          "indication": "Steroid-sparing maintenance; AQP4+ or AQP4- NMOSD",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil (off-label) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase to 1000-1500 mg BID over 2-4 weeks; target 2000-3000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "steroid-sparing-for-cidp-vasculitis": {
          "indication": "Steroid-sparing for CIDP, vasculitis",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg BID Ãƒâ€” 2 weeks, then 1000 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "steroid-sparing-agent-for-a-lems-alternative-to-azathioprine": {
          "indication": "Steroid-sparing agent for A-LEMS; alternative to azathioprine; onset 6-12 months",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil (CellCept) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; increase to 1000 mg BID after 2 weeks; target 2000-3000 mg/day; onset 6-12 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "steroid-sparing-agent-for-chronic-autoimmune-cerebellar-atax": {
          "indication": "Steroid-sparing agent for chronic autoimmune cerebellar ataxia; maintenance immunosuppression",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; increase to 1000 mg BID after 2 weeks; max 3000 mg/day (rarely needed)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "steroid-sparing-maintenance-for-chronic-autoimmune-cerebella": {
          "indication": "Steroid-sparing maintenance for chronic autoimmune cerebellar ataxia",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Mycophenolate mofetil (maintenance) 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg BID; dose adjust based on CBC and GI tolerance",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "steroid-sparing-immunosuppression-adjunctive-to-ivig-or-ritu": {
          "indication": "Steroid-sparing immunosuppression; adjunctive to IVIg or rituximab",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase by 500 mg every 2 weeks; target 1000-1500 mg BID (2000-3000 mg/day total); onset of effect 2-3 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "steroid-sparing-immunosuppression-for-maintenance-prevents-r": {
          "indication": "Steroid-sparing immunosuppression for maintenance; prevents relapse",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil (CellCept) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase to 1000 mg PO BID over 2-4 weeks; target 1500-3000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "long-term-steroid-sparing-immunosuppression-maintenance-agen": {
          "indication": "Long-term steroid-sparing immunosuppression; maintenance agent in Susac syndrome; prevents relapse",
          "doseOptions": [
            {
              "text": "500 mg BID",
              "orderSentence": "Mycophenolate mofetil (CellCept) 500 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase to 1000 mg PO BID over 2-4 weeks; target 2000-3000 mg/day in divided doses; minimum 2 years; some patients require indefinite therapy",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "steroid-sparing-for-chronic-inflammatory-plexopathy-alternat": {
          "indication": "Steroid-sparing for chronic inflammatory plexopathy (alternative)",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Mycophenolate mofetil 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; increase to 1000 mg BID over 2-4 weeks; max 3000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CBC q2 weeks x 3 months, then monthly",
          "GI symptoms",
          "LFTs",
          "Pregnancy",
          "Pregnancy (Category D - teratogenic)",
          "Pregnancy (Category D -- teratogenic",
          "Pregnancy (Category D -- teratogenic)",
          "Pregnancy (Category D — teratogenic)",
          "Pregnancy (Category D)",
          "Pregnancy (Category D), breastfeeding",
          "Pregnancy (teratogenic)",
          "Pregnancy, severe GI disease",
          "active infection",
          "breastfeeding",
          "concurrent azathioprine",
          "concurrent live vaccines",
          "hypersensitivity",
          "infection surveillance",
          "live vaccines",
          "pregnancy prevention",
          "requires two forms of contraception)",
          "severe GI disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "CBC every 2 weeks x 2 months, then monthly x 4 months, then q3 months",
          "CBC monthly",
          "CBC q1 week x 1 month, then biweekly x 2 months, then monthly",
          "CBC q2 weeks x 3 months then monthly",
          "CBC q2 weeks x 3 months, then monthly",
          "CBC q2 weeks Ãƒâ€” 3 months, then monthly",
          "CBC q2 weeks × 3 months, then monthly",
          "CBC, LFTs",
          "GI side effects (diarrhea, nausea)",
          "GI side effects common",
          "GI symptoms",
          "GI symptoms (diarrhea, nausea)",
          "GI symptoms (nausea, diarrhea)",
          "GI tolerance",
          "GI upset",
          "LFTs",
          "LFTs monthly",
          "LFTs q3 months",
          "REMS pregnancy prevention",
          "infection surveillance",
          "infections",
          "live vaccines contraindicated",
          "lymphopenia",
          "malignancy surveillance (skin exam annually)",
          "opportunistic infections",
          "pregnancy prevention",
          "pregnancy prevention (two forms of contraception)",
          "pregnancy prevention (two methods required)",
          "pregnancy test (teratogenic)",
          "renal function",
          "renal function q3 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 21,
      "_sourcePlans": [
        "acute-myelopathy",
        "ataxia-evaluation",
        "autoimmune-encephalitis",
        "cidp",
        "hashimotos-encephalopathy",
        "inflammatory-myopathy",
        "lambert-eaton-syndrome",
        "mogad",
        "myasthenia-gravis",
        "myasthenia-gravis-crisis",
        "myasthenia-gravis-new-diagnosis",
        "neuro-behcets-disease",
        "neurosarcoidosis",
        "nmosd",
        "paraneoplastic-neurological-syndrome",
        "peripheral-neuropathy",
        "plexopathy",
        "stiff-person-syndrome",
        "susac-syndrome"
      ]
    },
    "mycophenolate-mofetil-as-alternative-to-azathioprine": {
      "id": "mycophenolate-mofetil-as-alternative-to-azathioprine",
      "name": "Mycophenolate mofetil (CellCept) -- as alternative to azathioprine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "maintenance-immunosuppression-alternative-when-azathioprine-": {
          "indication": "Maintenance immunosuppression alternative when azathioprine not tolerated; steroid-sparing agent; lower relapse rate in some series",
          "doseOptions": [
            {
              "text": "500 mg BID",
              "orderSentence": "Mycophenolate mofetil (CellCept) -- as alternative to azathioprine 500 mg BID PO"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Mycophenolate mofetil (CellCept) -- as alternative to azathioprine 1000 mg BID PO"
            },
            {
              "text": "1500 mg BID",
              "orderSentence": "Mycophenolate mofetil (CellCept) -- as alternative to azathioprine 1500 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase to 1000 mg PO BID over 2-4 weeks; target 2000-3000 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy (Category D -- teratogenic)",
          "active infection",
          "severe GI disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC q2 weeks x 3 months, then monthly",
          "GI symptoms (diarrhea, nausea)",
          "LFTs",
          "infection surveillance",
          "pregnancy prevention"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cns-vasculitis"
      ]
    },
    "mycophenolate-mofetil-maintenance": {
      "id": "mycophenolate-mofetil-maintenance",
      "name": "Mycophenolate mofetil (CellCept) -- maintenance",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-maintenance-immunosuppression-better-gi-tolerabi": {
          "indication": "Alternative maintenance immunosuppression; better GI tolerability than azathioprine in some patients; steroid-sparing agent",
          "doseOptions": [
            {
              "text": "500 mg BID",
              "orderSentence": "Mycophenolate mofetil (CellCept) -- maintenance 500 mg BID PO"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Mycophenolate mofetil (CellCept) -- maintenance 1000 mg BID PO"
            },
            {
              "text": "1500 mg BID",
              "orderSentence": "Mycophenolate mofetil (CellCept) -- maintenance 1500 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg PO BID; increase to 1000 mg PO BID over 2-4 weeks; target 2000-3000 mg/day; minimum 18-24 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CBC q2 weeks x 3 months, then monthly",
          "GI symptoms",
          "LFTs",
          "infection surveillance",
          "mycophenolic acid levels if subtherapeutic response",
          "pregnancy prevention (two forms of contraception)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cns-vasculitis"
      ]
    },
    "mycophenolate-sodium": {
      "id": "mycophenolate-sodium",
      "name": "Mycophenolate sodium (Myfortic)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-formulation-with-less-gi-side-effects": {
          "indication": "Alternative formulation with less GI side effects",
          "doseOptions": [
            {
              "text": "360 mg",
              "orderSentence": "Mycophenolate sodium (Myfortic) 360 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 360 mg BID; increase to 720 mg BID; 720 mg = 1000 mg mycophenolate mofetil",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy (teratogenic)",
          "breastfeeding",
          "hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC every 2 weeks x 2 months, then monthly x 4 months, then q3 months",
          "GI side effects common",
          "LFTs q3 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "myasthenia-gravis"
      ]
    },
    "n-acetylcysteine": {
      "id": "n-acetylcysteine",
      "name": "N-acetylcysteine (NAC)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "fulminant-hepatic-failure-hepatoprotection": {
          "indication": "Fulminant hepatic failure; hepatoprotection",
          "doseOptions": [
            {
              "text": "150 mg/kg",
              "orderSentence": "N-acetylcysteine (NAC) 150 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150 mg/kg IV over 1h, then 50 mg/kg over 4h, then 100 mg/kg over 16h (standard NAC protocol for liver failure)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None absolute"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anaphylactoid reaction, bronchospasm",
          "monitor LFTs, INR"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wilsons-disease"
      ]
    },
    "nadolol": {
      "id": "nadolol",
      "name": "Nadolol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "40-160 mg",
              "orderSentence": "Nadolol 40-160 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40-160 mg daily; long-acting, once daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "essential-tremor"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as propranolol"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HR, BP"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "essential-tremor"
      ]
    },
    "naltrexone-xr": {
      "id": "naltrexone-xr",
      "name": "Naltrexone XR (Vivitrol)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "alcohol-use-disorder-comorbid-with-hand-alcohol-worsens-cogn": {
          "indication": "Alcohol use disorder comorbid with HAND; alcohol worsens cognitive impairment and ART non-adherence",
          "doseOptions": [
            {
              "text": "380 mg",
              "orderSentence": "Naltrexone XR (Vivitrol) 380 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "380 mg IM gluteal injection monthly; patient must be opioid-free >=7-10 days",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Acute opioid use",
          "acute hepatitis",
          "hepatic failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs",
          "depression screening",
          "injection site reaction",
          "opioid-free confirmation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "naproxen": {
      "id": "naproxen",
      "name": "Naproxen",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "acute-pain-inflammation-alternative-nsaid": {
          "indication": "Acute pain/inflammation (alternative NSAID)",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Naproxen 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Naproxen 500 mg BID with food; short course 7-14 days",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peroneal-neuropathy"
          ]
        },
        "radicular-pain-inflammation-longer-duration": {
          "indication": "Radicular pain, inflammation (longer duration)",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Naproxen 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250-500 mg BID with food; max 1500 mg/day",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "first-line-acute-treatment-longer-duration-than-ibuprofen": {
          "indication": "First-line acute treatment; longer duration than ibuprofen",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Naproxen 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-550 mg PO at onset; may repeat 250 mg in 12 hr; max 1250 mg/day; limit to <10 days/month",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "axial-neck-pain-and-musculoskeletal-pain-anti-inflammatory-f": {
          "indication": "Axial neck pain and musculoskeletal pain; anti-inflammatory for spondylotic pain",
          "doseOptions": [
            {
              "text": "250-500 mg",
              "orderSentence": "Naproxen 250-500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250-500 mg PO BID with food; max 1000 mg/day; limit to 2 weeks when possible",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "mild-moderate-plexopathy-pain-longer-duration-nsaid": {
          "indication": "Mild-moderate plexopathy pain (longer duration NSAID)",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Naproxen 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250-500 mg BID with food; max 1500 mg/day",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active GI bleeding",
          "CKD stage 4-5",
          "CrCl <30",
          "GI bleed history",
          "GI bleeding",
          "Renal impairment",
          "active GI bleed",
          "aspirin allergy",
          "aspirin-sensitive asthma",
          "cardiovascular disease",
          "concurrent anticoagulation",
          "renal impairment",
          "third trimester",
          "third trimester pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "Renal function",
          "blood pressure",
          "concurrent anticoagulant use",
          "renal function",
          "renal function if prolonged use",
          "renal function with prolonged use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "cervical-myelopathy",
        "peroneal-neuropathy",
        "plexopathy",
        "radiculopathy",
        "tension-headache"
      ]
    },
    "naproxen-sodium": {
      "id": "naproxen-sodium",
      "name": "Naproxen sodium",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-oral-nsaid-longer-duration-of-action-than-ibuprof": {
          "indication": "First-line oral NSAID; longer duration of action than ibuprofen",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Naproxen sodium 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-550 mg PO at onset; repeat 250 mg in 12h if needed; max 1250 mg/day; limit to <15 days/month",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "bridge-therapy-for-recurrent-headache-pending-outpatient-eva": {
          "indication": "Bridge therapy for recurrent headache pending outpatient evaluation",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Naproxen sodium 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg PO BID with food for 5-7 days; then PRN",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "mild-moderate-headache-pain-during-workup": {
          "indication": "Mild-moderate headache pain during workup",
          "doseOptions": [
            {
              "text": "500-825 mg",
              "orderSentence": "Naproxen sodium 500-825 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-825 mg PO once; may repeat 250-500 mg in 6-8h; max 1250 mg first day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "mild-moderate-post-traumatic-headache": {
          "indication": "Mild-moderate post-traumatic headache",
          "doseOptions": [
            {
              "text": "250-500 mg",
              "orderSentence": "Naproxen sodium 250-500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250-500 mg PO BID PRN; max 1250 mg/day; limit to <15 days/month",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500-825 mg",
              "orderSentence": "Naproxen sodium 500-825 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-825 mg PO once",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "mild-moderate-migraine-attack": {
          "indication": "Mild-moderate migraine attack",
          "doseOptions": [
            {
              "text": "500-825 mg",
              "orderSentence": "Naproxen sodium 500-825 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-825 mg PO once; limit to ≤14 days/month",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "mild-moderate-aura-migraine-menstrual-migraine-prevention": {
          "indication": "Mild-moderate aura migraine; menstrual migraine prevention",
          "doseOptions": [
            {
              "text": "550 mg",
              "orderSentence": "Naproxen sodium 550 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "550 mg PO at onset; may add 275 mg in 12 hr; max 1375 mg day 1, then 1100 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "3rd trimester pregnancy",
          "GI bleed",
          "GI bleed history",
          "Renal disease, GI bleeding",
          "Renal disease, GI bleeding history, aspirin allergy, third trimester pregnancy",
          "Renal disease, GI bleeding, aspirin-exacerbated respiratory disease",
          "Renal impairment",
          "Same as ibuprofen",
          "active GI bleed",
          "aspirin allergy",
          "aspirin/NSAID allergy",
          "third trimester pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "Renal function",
          "Renal function, GI symptoms",
          "medication days/month",
          "renal function",
          "renal function if prolonged",
          "risk of MOH"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "chronic-migraine",
        "headache-evaluation",
        "headache-unspecified",
        "migraine",
        "migraine-with-aura",
        "post-concussion-syndrome"
      ]
    },
    "naproxen-sodium-po": {
      "id": "naproxen-sodium-po",
      "name": "Naproxen sodium PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "transitional-therapy-for-recurrence-prevention-after-dischar": {
          "indication": "Transitional therapy for recurrence prevention after discharge; scheduled dosing more effective than PRN",
          "doseOptions": [
            {
              "text": "500 mg BID",
              "orderSentence": "Naproxen sodium PO 500 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg PO BID with food x 5-7 days as bridge",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI bleeding, renal disease, third trimester pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function, GI symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "naratriptan": {
      "id": "naratriptan",
      "name": "Naratriptan",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "migraine-with-aura-longer-duration-menstrual-migraine": {
          "indication": "Migraine with aura; longer duration; menstrual migraine",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Naratriptan 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2.5 mg PO; may repeat after 4 hr; max 5 mg/24hr; slower onset but longer lasting",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**HEMIPLEGIC MIGRAINE (motor aura)**",
          "CAD",
          "MAOIs within 14 days",
          "ergots within 24 hr",
          "moderate-severe renal/hepatic impairment",
          "prior stroke/TIA",
          "uncontrolled HTN"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Triptan sensation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine-with-aura"
      ]
    },
    "nasal-ammonia-capsule": {
      "id": "nasal-ammonia-capsule",
      "name": "Nasal ammonia capsule (smelling salts)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "INH"
      ],
      "formulations": [],
      "contexts": {
        "functional-unresponsiveness-can-help-break-functional-event": {
          "indication": "Functional unresponsiveness; can help break functional event",
          "doseOptions": [
            {
              "text": "1 capsule",
              "orderSentence": "Nasal ammonia capsule (smelling salts) 1 capsule INH"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Break capsule under nose; response (grimace, withdrawal) confirms awareness and supports functional diagnosis",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "functional-neurological-disorder"
          ]
        },
        "functional-unresponsiveness-aids-differentiation-from-epilep": {
          "indication": "Functional unresponsiveness; aids differentiation from epileptic postictal state",
          "doseOptions": [
            {
              "text": "1 capsule",
              "orderSentence": "Nasal ammonia capsule (smelling salts) 1 capsule INH"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Break capsule 6 inches from nose; grimace or withdrawal response confirms awareness and supports functional diagnosis",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Response",
          "Response to stimulation",
          "document",
          "document findings"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "functional-neurological-disorder",
        "pnes"
      ]
    },
    "natalizumab": {
      "id": "natalizumab",
      "name": "Natalizumab (Tysabri)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Natalizumab (Tysabri) 300 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300 mg IV q4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        },
        "emerging-option-for-refractory-susac-syndrome-anti-vla4-anti": {
          "indication": "Emerging option for refractory Susac syndrome; anti-VLA4 antibody reduces lymphocyte trafficking across blood-brain barrier; case reports of efficacy",
          "doseOptions": [
            {
              "text": "300 mg IV q4 weeks",
              "orderSentence": "Natalizumab (CPT 96365) 300 mg IV q4 weeks IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300 mg IV every 4 weeks; JC virus antibody testing required before initiation",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "JC virus antibody positive (PML risk)",
          "JCV antibody positive with index >1.5 and prior immunosuppression (high PML risk)",
          "PML risk (JCV+, prior immunosuppression, duration >2y)",
          "active infection",
          "concurrent immunosuppression (PML risk)",
          "progressive multifocal leukoencephalopathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "JC virus antibody index q6 months",
          "JCV antibody q6 months",
          "JCV antibody q6mo",
          "LFTs",
          "MRI brain q6-12 months for PML surveillance",
          "MRI for PML surveillance q6-12mo",
          "MRI q6-12 months",
          "REMS program required",
          "infusion reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis",
        "susac-syndrome"
      ]
    },
    "neostigmine-iv": {
      "id": "neostigmine-iv",
      "name": "Neostigmine IV (if NPO or intubated)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.5-2.5 mg",
              "orderSentence": "Neostigmine IV (if NPO or intubated) 0.5-2.5 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-2.5 mg IV/IM q1-3h; 1 mg IV neostigmine ≈ 30 mg oral pyridostigmine",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same",
          "cardiac monitoring required"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous cardiac monitoring",
          "have atropine at bedside for bradycardia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "myasthenia-gravis-new-diagnosis"
      ]
    },
    "nerve-block": {
      "id": "nerve-block",
      "name": "Nerve block (greater occipital)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "local injection"
      ],
      "formulations": [],
      "contexts": {
        "refractory-headache-during-evaluation-suspected-occipital-ne": {
          "indication": "Refractory headache during evaluation; suspected occipital neuralgia; adjunctive for migraine/cluster",
          "doseOptions": [
            {
              "text": "2-3 mL per side",
              "orderSentence": "Nerve block (greater occipital) 2-3 mL per side local injection"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Lidocaine 1% or bupivacaine 0.25%, 2-3 mL per side at greater occipital nerve",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local anesthetic allergy, overlying skin infection, anticoagulation (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Local reaction, vasovagal response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "headache-evaluation"
      ]
    },
    "neuromuscular-blockade": {
      "id": "neuromuscular-blockade",
      "name": "Neuromuscular blockade",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.1-0.2 mg/kg",
              "orderSentence": "**Neuromuscular blockade** 0.1-0.2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "For refractory ICP spikes with ventilator dyssynchrony, coughing, posturing; **Cisatracurium** 0.1-0.2 mg/kg bolus → 1-3 mcg/kg/min infusion (organ-independent metabolism); **Rocuronium** 0.6-1 mg/kg bolus → 0.6 mg/kg/hr; **Requires:** Concurrent sedation/analgesia; train-of-four monitoring; prevents detection of seizures (need cEEG)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "elevated-icp-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Prevents ICP spikes from coughing, posturing",
          "reduces intrathoracic pressure",
          "requires cEEG monitoring",
          "use judiciously — obscures neuro exam and seizure detection"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "elevated-icp-management"
      ]
    },
    "neuromuscular-blocking-agent-minimization": {
      "id": "neuromuscular-blocking-agent-minimization",
      "name": "Neuromuscular blocking agent (NMBA) minimization",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "minimize-nmba-exposure-as-risk-factor-for-icuaw-use-train-of": {
          "indication": "Minimize NMBA exposure as risk factor for ICUAW; use train-of-four monitoring to avoid deep paralysis",
          "doseOptions": [
            {
              "text": "Individualized",
              "orderSentence": "Neuromuscular blocking agent (NMBA) minimization Individualized IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If NMBA required (e.g., ARDS, refractory ICP), use lowest effective dose guided by train-of-four (TOF) monitoring; target 1-2/4 twitches; daily sedation/paralysis vacation if feasible; discontinue NMBA as soon as clinically possible",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent high-dose corticosteroids (greatly increases CIM risk)",
          "avoid unless absolutely necessary"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Train-of-four q4h",
          "daily attempt to discontinue",
          "document indication daily"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "critical-illness-myopathy-neuropathy"
      ]
    },
    "neuropathic-pain-management": {
      "id": "neuropathic-pain-management",
      "name": "Neuropathic pain management",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "**Neuropathic pain management** 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Gabapentin 300 mg PO TID → titrate to 600-900 mg TID over 1-2 weeks; OR pregabalin 75 mg BID → 150-300 mg BID; duloxetine 30 mg daily → 60 mg daily; amitriptyline 10-25 mg HS (caution: urinary retention may worsen); topical lidocaine 5% patches for localized radicular pain",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cauda-equina-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Neuropathic pain (burning, tingling, electric shocks in perineum, legs) is common and debilitating after CES",
          "may persist chronically",
          "multimodal approach needed"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cauda-equina-syndrome"
      ]
    },
    "nevirapine": {
      "id": "nevirapine",
      "name": "Nevirapine (Viramune)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nnrti-with-high-cpe-score-cpe-4-alternative-for-cns-optimiza": {
          "indication": "NNRTI with high CPE score (CPE 4); alternative for CNS optimization; hepatotoxicity and rash risk limit use",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Nevirapine (Viramune) 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200 mg PO daily x 14 days lead-in, then 200 mg BID; extended release: 400 mg daily after lead-in",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CD4 >250 (women) or >400 (men) for treatment-naive (hepatotoxicity risk)",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs at baseline, 2 wks, 4 wks, then q3 months",
          "discontinue if LFTs >5x ULN",
          "rash monitoring (SJS risk first 18 weeks)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "nicardipine": {
      "id": "nicardipine",
      "name": "Nicardipine (if BP too high with hemorrhage)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "bp-reduction-only-if-hemorrhagic-presentation-with-sbp-180-o": {
          "indication": "BP reduction ONLY if hemorrhagic presentation with SBP >180; or hypertensive emergency with end-organ damage",
          "doseOptions": [
            {
              "text": "5 mg/h titrated",
              "orderSentence": "Nicardipine (if BP too high with hemorrhage) 5 mg/h titrated IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg/h; increase by 2.5 mg/h q5-15min; target SBP 140-160 for hemorrhagic moyamoya; AVOID dropping below 140",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe aortic stenosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Arterial line preferred",
          "avoid over-lowering",
          "neuro checks q1h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "moyamoya-disease"
      ]
    },
    "nicardipine-drip": {
      "id": "nicardipine-drip",
      "name": "Nicardipine drip (CPT 96365, 96366)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "perioperative-bp-control-for-cea-cas-prevent-hyperperfusion-": {
          "indication": "Perioperative BP control for CEA/CAS; prevent hyperperfusion syndrome; maintain BP 100-150 systolic post-CEA; rapid onset and easy titration",
          "doseOptions": [
            {
              "text": "5 mg/hr",
              "orderSentence": "Nicardipine drip (CPT 96365, 96366) 5 mg/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg/hr IV infusion; titrate by 2.5 mg/hr every 5-15 minutes; target SBP 100-150 (post-CEA) or per surgeon guidance; max 15 mg/hr; transition to oral antihypertensives when stable",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe aortic stenosis",
          "advanced heart failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous arterial line BP",
          "HR",
          "neuro checks q1h",
          "transition to oral agents within 24-48h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "carotid-stenosis"
      ]
    },
    "nicardipine-infusion": {
      "id": "nicardipine-infusion",
      "name": "Nicardipine infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-severe-hypertension-not-controlled-by-labetalol-h": {
          "indication": "Refractory severe hypertension not controlled by labetalol + hydralazine; ICU setting",
          "doseOptions": [
            {
              "text": "5 mg/h titrated to 15 mg/h",
              "orderSentence": "Nicardipine infusion 5 mg/h titrated to 15 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg/h IV; increase by 2.5 mg/h q5-15min; max 15 mg/h; target SBP 140-155; reduce BP no more than 25% in first hour",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe aortic stenosis",
          "compensatory hypertension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Arterial line",
          "continuous BP",
          "fetal monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy"
      ]
    },
    "nicardipine-iv": {
      "id": "nicardipine-iv",
      "name": "Nicardipine IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "continuous-bp-control-in-acute-dissection-with-stroke-or-sev": {
          "indication": "Continuous BP control in acute dissection with stroke or severe hypertension",
          "doseOptions": [
            {
              "text": "5 mg/h",
              "orderSentence": "Nicardipine IV 5 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/h IV infusion; increase by 2.5 mg/h q5-15min; max 15 mg/h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "hypertensive-emergency-sbp-180-sah-with-sbp-160-hypertensive": {
          "indication": "Hypertensive emergency (SBP >180); SAH with SBP >160; hypertensive crisis with thunderclap",
          "doseOptions": [
            {
              "text": "5 mg/h",
              "orderSentence": "Nicardipine IV (CPT 96365) 5 mg/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/h IV; titrate by 2.5 mg/h q5-15min; max 15 mg/h. Target SBP <160 if SAH suspected (until aneurysm secured). For hypertensive emergency: reduce MAP by 20-25% in first hour",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe aortic stenosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP continuous monitoring",
          "Continuous arterial BP",
          "headache and flushing common",
          "neuro checks q1h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "cervical-artery-dissection",
        "thunderclap-headache-evaluation"
      ]
    },
    "niclosamide": {
      "id": "niclosamide",
      "name": "Niclosamide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "treatment-of-intestinal-taenia-solium-taeniasis-to-eliminate": {
          "indication": "Treatment of intestinal Taenia solium (taeniasis) to eliminate tapeworm and prevent ongoing autoinfection and community transmission",
          "doseOptions": [
            {
              "text": "2 g",
              "orderSentence": "Niclosamide 2 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g PO as single dose (chew thoroughly then swallow with water); take on empty stomach; purge 2h after to expel worm segments",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Allergy",
          "none significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Stool follow-up at 1 and 3 months post-treatment to confirm eradication",
          "household contacts screened"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neurocysticercosis"
      ]
    },
    "nifedipine": {
      "id": "nifedipine",
      "name": "Nifedipine (immediate-release)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "oral-antihypertensive-for-severe-hypertension-when-iv-access": {
          "indication": "Oral antihypertensive for severe hypertension when IV access delayed or as transition from IV therapy",
          "doseOptions": [
            {
              "text": "10 mg PO",
              "orderSentence": "Nifedipine (immediate-release) 10 mg PO PO"
            },
            {
              "text": "20 mg PO",
              "orderSentence": "Nifedipine (immediate-release) 20 mg PO PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-20 mg PO; may repeat in 30 min if needed; max 30 mg in acute setting; transition to extended-release 30-60 mg daily",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MgSO4 (theoretical concern for potentiated hypotension — monitor closely but combination is used)",
          "severe aortic stenosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q15 min after first dose",
          "avoid sublingual route (unpredictable absorption)",
          "fetal monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy"
      ]
    },
    "nifedipine-extended-release": {
      "id": "nifedipine-extended-release",
      "name": "Nifedipine extended-release",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "oral-antihypertensive-maintenance-for-preeclampsia-calcium-c": {
          "indication": "Oral antihypertensive maintenance for preeclampsia; calcium channel blocker safe in pregnancy",
          "doseOptions": [
            {
              "text": "30 mg daily",
              "orderSentence": "Nifedipine extended-release 30 mg daily PO"
            },
            {
              "text": "60 mg daily",
              "orderSentence": "Nifedipine extended-release 60 mg daily PO"
            },
            {
              "text": "90 mg daily",
              "orderSentence": "Nifedipine extended-release 90 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg daily; increase by 30 mg q3-7d; max 120 mg/day; swallow whole, do not crush",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe aortic stenosis",
          "hypotension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "fetal monitoring",
          "heart rate",
          "peripheral edema"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy"
      ]
    },
    "nimodipine": {
      "id": "nimodipine",
      "name": "Nimodipine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "suspected-sah-with-vasospasm-rcvs": {
          "indication": "Suspected SAH with vasospasm; RCVS",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Nimodipine 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg PO q4h x 21 days; reduce to 30 mg q4h if hypotension",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "calcium-channel-blocker-with-preferential-cerebral-vascular-": {
          "indication": "Calcium channel blocker with preferential cerebral vascular selectivity; alternative to verapamil",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Nimodipine (alternative first-line CCB) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg PO q4h (or 30 mg q2h if hypotension); continue for 4-12 weeks until imaging resolution; do NOT give IV (severe hypotension)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "persistent-thunderclap-headaches-or-worsening-vasoconstricti": {
          "indication": "Persistent thunderclap headaches or worsening vasoconstriction on standard dose",
          "doseOptions": [
            {
              "text": "90 mg",
              "orderSentence": "Nimodipine (dose escalation) 90 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Increase from 60 mg to 90 mg PO q4h; monitor BP closely; max 540 mg/day; higher doses increase hypotension risk",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "alternative-to-verapamil-for-ongoing-ccb-therapy-during-reco": {
          "indication": "Alternative to verapamil for ongoing CCB therapy during recovery phase",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Nimodipine (maintenance course) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Continue 60 mg PO q4h for 8-12 weeks; taper by reducing frequency to q6h then q8h over 2-4 weeks once imaging confirms resolution",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Nimodipine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg TID; limited evidence",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "EXT",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "essential-tremor",
            "subarachnoid-hemorrhage"
          ]
        },
        "cochlear-and-retinal-vasodilation-calcium-channel-blocker-im": {
          "indication": "Cochlear and retinal vasodilation; calcium channel blocker improves microvascular perfusion; used empirically in Susac protocols for cochlear and retinal ischemia",
          "doseOptions": [
            {
              "text": "30 mg q8h",
              "orderSentence": "Nimodipine 30 mg q8h PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg PO q8h; titrate based on blood pressure tolerance; increase to 60 mg q8h if tolerated",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "sah-confirmed-vasospasm-prevention-cornerstone-therapy": {
          "indication": "SAH confirmed — vasospasm prevention (CORNERSTONE therapy)",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Nimodipine (if SAH confirmed) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg PO/NG q4h x 21 days. START within 96h of SAH. If hypotension: 30 mg q2h. Do NOT give IV — oral only",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "rcvs-empiric-calcium-channel-blocker-off-label-but-widely-us": {
          "indication": "RCVS — empiric calcium channel blocker; off-label but widely used",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Nimodipine (if RCVS confirmed) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg PO q4h; duration 4-12 weeks until vasoconstriction resolves on follow-up imaging",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypotension",
          "Hypotension (SBP <90 — reduce dose)",
          "Hypotension (SBP <90 — reduce to 30 mg q2h)",
          "Hypotension (SBP <90)",
          "do NOT crush extended-release formulations",
          "do NOT give IV (severe hypotension risk)",
          "hepatic failure",
          "hepatic impairment",
          "hepatic impairment (reduce dose)",
          "severe hepatic impairment",
          "use oral syringe if NG"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP q2h during escalation",
          "BP with dose changes",
          "BP with each dose",
          "Blood pressure",
          "Blood pressure q1h initially, then q4h",
          "do NOT give IV",
          "ensure enteral route only",
          "enteral route ONLY (never IV)",
          "follow-up CTA/MRA at 8-12 weeks",
          "heart rate",
          "hepatic function",
          "may cause hypotension especially in first 24-48h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "essential-tremor",
        "headache-evaluation",
        "rcvs",
        "subarachnoid-hemorrhage",
        "susac-syndrome",
        "thunderclap-headache-evaluation"
      ]
    },
    "noninvasive-ventilation": {
      "id": "noninvasive-ventilation",
      "name": "Noninvasive ventilation (acute)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "INH"
      ],
      "formulations": [],
      "contexts": {
        "acute-respiratory-failure": {
          "indication": "Acute respiratory failure",
          "doseOptions": [
            {
              "text": "IPAP 12-20",
              "orderSentence": "Noninvasive ventilation (acute) IPAP 12-20 INH"
            },
            {
              "text": "EPAP 5-8",
              "orderSentence": "Noninvasive ventilation (acute) EPAP 5-8 INH"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "IPAP 12-20 cmH2O, EPAP 5-8 cmH2O; FiO2 to maintain SpO2 >92%; close monitoring for escalation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Inability to protect airway",
          "hemodynamic instability"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ABG, respiratory rate, work of breathing"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "norepinephrine": {
      "id": "norepinephrine",
      "name": "Norepinephrine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "vasopressor-for-hemodynamic-support-neurogenic-shock-loss-of": {
          "indication": "Vasopressor for hemodynamic support; neurogenic shock (loss of sympathetic tone) common in brain death; maintain MAP ≥60 mmHg for valid examination",
          "doseOptions": [
            {
              "text": "0.1-0.5 mcg/kg/min",
              "orderSentence": "**Norepinephrine** 0.1-0.5 mcg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.05-0.1 mcg/kg/min; titrate to MAP ≥60 mmHg (or ≥70 for donor management); max 0.5 mcg/kg/min; consider adding vasopressin if escalating",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        },
        "second-line-vasopressor-if-vasopressin-insufficient-maintain": {
          "indication": "Second-line vasopressor if vasopressin insufficient; maintain MAP ≥60 mmHg; minimize dose to reduce end-organ catecholamine toxicity",
          "doseOptions": [
            {
              "text": "0.05-0.2 mcg/kg/min",
              "orderSentence": "**Norepinephrine (donor management)** 0.05-0.2 mcg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.05 mcg/kg/min; titrate to MAP ≥60; goal: minimize catecholamine use (excess catecholamines damage transplantable organs, especially heart); transition to vasopressin-dominant regimen",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        },
        "hypotension-from-anesthetics": {
          "indication": "Hypotension from anesthetics",
          "doseOptions": [
            {
              "text": "0.1 mcg/kg",
              "orderSentence": "Norepinephrine 0.1 mcg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mcg/kg/min; titrate to MAP ≥65",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "post-arrest-myocardial-dysfunction-with-map-65-mmhg-first-li": {
          "indication": "Post-arrest myocardial dysfunction with MAP <65 mmHg; first-line vasopressor for post-arrest shock",
          "doseOptions": [
            {
              "text": "0.1-0.5 mcg/kg/min",
              "orderSentence": "Norepinephrine 0.1-0.5 mcg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.05-0.1 mcg/kg/min; titrate to MAP >65 (or >80 if signs of cerebral hypoperfusion); max 2 mcg/kg/min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.1-0.5 mcg/kg",
              "orderSentence": "Norepinephrine (autonomic hypotension) 0.1-0.5 mcg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1-0.5 mcg/kg/min IV; titrate to MAP >65",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypovolemia (correct first)",
          "Peripheral administration (central line required)",
          "Peripheral extravasation (central line required)",
          "Peripheral ischemia risk at high doses",
          "Peripheral line extravasation (central access preferred)",
          "excessive doses damage cardiac allografts"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Arterial line",
          "Arterial line BP",
          "Arterial line, MAP",
          "Continuous arterial BP monitoring",
          "MAP",
          "MAP target ≥60",
          "assess for adequate organ perfusion",
          "cardiac function",
          "lactate",
          "lactate q4-6h",
          "limit escalation if possible for donor management",
          "troponin trends",
          "try to wean as vasopressin and HRT take effect",
          "urine output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "autoimmune-encephalitis",
        "brain-death-evaluation",
        "status-epilepticus"
      ]
    },
    "normal-saline": {
      "id": "normal-saline",
      "name": "Normal saline (0.9% NaCl)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "critical-maintain-euvolemia-dehydration-is-major-trigger-for": {
          "indication": "**CRITICAL: Maintain euvolemia**; dehydration is major trigger for ischemic events in moyamoya; aggressive hydration during acute presentation",
          "doseOptions": [
            {
              "text": "125-250 mL/h",
              "orderSentence": "Normal saline (0.9% NaCl) 125-250 mL/h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "125-250 mL/h isotonic crystalloid; maintain euvolemia; target urine output >0.5 mL/kg/h; AVOID hypovolemia (reduces perfusion through collaterals)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart failure (reduce rate)",
          "pulmonary edema"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BMP q12h",
          "Fluid balance",
          "avoid overhydration",
          "urine output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "moyamoya-disease"
      ]
    },
    "normal-saline-iv": {
      "id": "normal-saline-iv",
      "name": "Normal saline IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "volume-resuscitation-for-orthostatic-hypotension-from-autono": {
          "indication": "Volume resuscitation for orthostatic hypotension from autonomic dysfunction",
          "doseOptions": [
            {
              "text": "500-1000 mL",
              "orderSentence": "Normal saline IV 500-1000 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mL NS bolus then 75-125 mL/hr maintenance as needed for orthostatic symptoms",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "rehydration-prolonged-vomiting-and-poor-oral-intake-common-i": {
          "indication": "Rehydration; prolonged vomiting and poor oral intake common in status migrainosus",
          "doseOptions": [
            {
              "text": "1000 mL bolus",
              "orderSentence": "Normal saline IV 1000 mL bolus IV"
            },
            {
              "text": "75-125 mL/hr",
              "orderSentence": "Normal saline IV 75-125 mL/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "NS 1L bolus over 1-2h, then 75-125 mL/hr maintenance",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart failure",
          "Heart failure, volume overload",
          "volume overload"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "I/O",
          "I/O, signs of fluid overload",
          "orthostatic vitals",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "lambert-eaton-syndrome",
        "status-migrainosus"
      ]
    },
    "normal-saline-pre-hydration": {
      "id": "normal-saline-pre-hydration",
      "name": "Normal saline pre-hydration",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "nephroprotection-during-amphotericin-b-therapy-prevents-amph": {
          "indication": "Nephroprotection during amphotericin B therapy; prevents amphotericin-induced renal vasoconstriction",
          "doseOptions": [
            {
              "text": "500-1000 mL",
              "orderSentence": "Normal saline pre-hydration 500-1000 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mL IV normal saline infused before each amphotericin B dose",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Volume overload",
          "decompensated heart failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "I/O",
          "electrolytes",
          "signs of volume overload",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "nortriptyline": {
      "id": "nortriptyline",
      "name": "Nortriptyline",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "neuropathic-pain-second-line-better-tolerated-tca": {
          "indication": "Neuropathic pain (second-line; better tolerated TCA)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Nortriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "neuropathic-pain-second-line-fewer-anticholinergic-effects-t": {
          "indication": "Neuropathic pain (second-line); fewer anticholinergic effects than amitriptyline",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Nortriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "tinnitus-with-comorbid-depression-alternative-to-amitriptyli": {
          "indication": "Tinnitus with comorbid depression; alternative to amitriptyline with fewer anticholinergic effects",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "**Nortriptyline** 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg QHS, titrate to 50-75 mg; less sedating than amitriptyline",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-25 mg",
              "orderSentence": "Nortriptyline 10-25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-25 mg QHS; titrate to 75 mg QHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "diabetic-neuropathy"
          ]
        },
        "tca-with-less-sedation-and-anticholinergic-effects-than-amit": {
          "indication": "TCA with less sedation and anticholinergic effects than amitriptyline",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Nortriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "alternative-tca-for-post-traumatic-headache-fewer-anticholin": {
          "indication": "Alternative TCA for post-traumatic headache (fewer anticholinergic effects)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Nortriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg PO QHS; increase by 10 mg every 1-2 weeks; target 25-75 mg QHS; max 150 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "neuropathic-pain-second-line": {
          "indication": "Neuropathic pain (second-line)",
          "doseOptions": [
            {
              "text": "10-25 mg",
              "orderSentence": "Nortriptyline 10-25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "neuropathic-pain-second-line-less-sedating-than-amitriptylin": {
          "indication": "Neuropathic pain (second-line, less sedating than amitriptyline)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Nortriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "prevention-if-amitriptyline-not-tolerated-less-sedating-chro": {
          "indication": "Prevention if amitriptyline not tolerated (less sedating); chronic TTH",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Nortriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg qHS; titrate by 10-25 mg every 1-2 weeks; target 25-75 mg qHS; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "neuropathic-pain-second-line-less-sedating-than-amitriptylin-2": {
          "indication": "Neuropathic pain (second-line; less sedating than amitriptyline)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Nortriptyline 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cardiac arrhythmia, glaucoma, urinary retention, recent MI",
          "Cardiac conduction abnormality",
          "Cardiac conduction abnormality (QTc >450 ms)",
          "Cardiac conduction disease",
          "Same as amitriptyline",
          "concurrent MAOIs",
          "elderly",
          "elderly (anticholinergic burden)",
          "elderly (anticholinergic risk)",
          "glaucoma",
          "narrow-angle glaucoma",
          "recent MI",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG at baseline",
          "ECG at baseline if dose >75 mg",
          "ECG if dose >100 mg/day",
          "ECG if dose >100 mg/day or cardiac risk factors",
          "Same",
          "Sedation (less than amitriptyline), dry mouth, weight gain, constipation",
          "[Sullivan et al. (1993)](https://pubmed.ncbi.nlm.nih.gov/8215728/): RCT showed nortriptyline reduced tinnitus loudness and depression scores",
          "anticholinergic effects (fewer than amitriptyline)",
          "anticholinergic effects (less than amitriptyline)",
          "fewer anticholinergic effects",
          "fewer anticholinergic effects than amitriptyline",
          "monitor for anticholinergic side effects",
          "sedation",
          "weight gain"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "b12-deficiency-neuropathy",
        "diabetic-neuropathy",
        "paresthesia-numbness-tingling",
        "peripheral-neuropathy",
        "plexopathy",
        "post-concussion-syndrome",
        "radiculopathy",
        "small-fiber-neuropathy",
        "tension-headache",
        "tinnitus-evaluation"
      ]
    },
    "nsaid-therapy": {
      "id": "nsaid-therapy",
      "name": "NSAID therapy (short-term)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "acute-symptom-relief-limited-evidence-for-cts-specific-benef": {
          "indication": "Acute symptom relief; limited evidence for CTS-specific benefit",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "NSAID therapy (short-term) 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ibuprofen 400 mg TID or Naproxen 500 mg BID; short course (7-14 days); take with food; not for long-term use",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI bleeding",
          "cardiovascular disease",
          "renal impairment",
          "third trimester pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "carpal-tunnel-syndrome"
      ]
    },
    "nsaids": {
      "id": "nsaids",
      "name": "NSAIDs (concurrent with methotrexate)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nsaids-reduce-renal-clearance-of-methotrexate-increasing-sys": {
          "indication": "NSAIDs reduce renal clearance of methotrexate, increasing systemic toxicity risk even with IT administration",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "NSAIDs (concurrent with methotrexate) N/A PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Avoid ibuprofen, naproxen, ketorolac while receiving IT or systemic methotrexate; use acetaminophen for pain",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent IT or systemic methotrexate use",
          "thrombocytopenia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "Methotrexate levels",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "occipital-nerve-block": {
      "id": "occipital-nerve-block",
      "name": "Occipital nerve block (CPT 64405)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "INJ",
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "refractory-headache-occipital-predominant-pain-avoids-system": {
          "indication": "Refractory headache; occipital-predominant pain; avoids systemic medications",
          "doseOptions": [
            {
              "text": "2-3 mL",
              "orderSentence": "Occipital nerve block (CPT 64405) 2-3 mL SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-3 mL 2% lidocaine (or 0.25% bupivacaine) with or without 40 mg triamcinolone at greater occipital nerve bilaterally",
          "settings": {
            "ED": "EXT",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "refractory-post-traumatic-headache-occipital-neuralgia": {
          "indication": "Refractory post-traumatic headache; occipital neuralgia",
          "doseOptions": [
            {
              "text": "Bupivacaine 0.25-0.5%",
              "orderSentence": "Occipital nerve block (CPT 64405) Bupivacaine 0.25-0.5% INJ"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-3 mL per side with or without methylprednisolone 40 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "refractory-migraine-occipital-predominant-pain": {
          "indication": "Refractory migraine; occipital-predominant pain",
          "doseOptions": [
            {
              "text": "2.5 mL",
              "orderSentence": "Occipital nerve block 2.5 mL SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Inject bupivacaine 0.5% 2-3 mL + triamcinolone 40 mg at greater occipital nerve bilaterally; may add lesser occipital, supraorbital",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local anesthetic allergy",
          "Local anesthetic allergy, infection at site",
          "anticoagulation (relative)",
          "infection at injection site"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Immediate pain response",
          "Local reaction",
          "Vasovagal reaction",
          "immediate pain assessment",
          "local bruising",
          "transient dizziness",
          "vasovagal reaction"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "headache-unspecified",
        "migraine-with-aura",
        "post-concussion-syndrome"
      ]
    },
    "occipital-nerve-block-lidocaine": {
      "id": "occipital-nerve-block-lidocaine",
      "name": "Occipital nerve block - lidocaine (CPT 64405)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "non-systemic-option-safe-in-pregnancy": {
          "indication": "Non-systemic option; safe in pregnancy",
          "doseOptions": [
            {
              "text": "2-3 mL",
              "orderSentence": "Occipital nerve block - lidocaine (CPT 64405) 2-3 mL SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2% lidocaine 2-3 mL per side at greater occipital nerve",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local anesthetic allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Local reaction",
          "vasovagal"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "headache-unspecified"
      ]
    },
    "ocrelizumab": {
      "id": "ocrelizumab",
      "name": "Ocrelizumab (Ocrevus)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Ocrelizumab (Ocrevus) 300 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300 mg IV × 2 doses (2 weeks apart), then 600 mg IV q6 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active Hep B, active infection",
          "Active Hepatitis B",
          "Per above",
          "active infection"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HBV screening",
          "Immunoglobulins annually",
          "Per above",
          "Pre-infusion CBC, LFTs",
          "infection monitoring",
          "infusion reactions (premedicate with methylprednisolone, antihistamine, acetaminophen)",
          "malignancy screening",
          "only approved for PPMS"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "octreotide": {
      "id": "octreotide",
      "name": "Octreotide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "refractory-postprandial-hypotension-somatostatin-analogue": {
          "indication": "Refractory postprandial hypotension — somatostatin analogue",
          "doseOptions": [
            {
              "text": "25 mcg before meals",
              "orderSentence": "Octreotide 25 mcg before meals SC"
            },
            {
              "text": "50 mcg before meals",
              "orderSentence": "Octreotide 50 mcg before meals SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mcg SC 30 min before meals; increase to 50 mcg if needed; max 50 mcg TID; reduces splanchnic blood pooling",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Gallstones (long-term risk), diabetes (alters glucose)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood glucose, GI tolerance, gallbladder ultrasound annually if chronic use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "multiple-system-atrophy"
      ]
    },
    "octreotide-sc": {
      "id": "octreotide-sc",
      "name": "Octreotide SC",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100 mcg",
              "orderSentence": "Octreotide SC 100 mcg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mcg SC; second-line if triptans contraindicated",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI upset"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cluster-headache"
      ]
    },
    "ofatumumab": {
      "id": "ofatumumab",
      "name": "Ofatumumab (Kesimpta)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Ofatumumab (Kesimpta) 20 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg SC weeks 0, 1, 2, then 20 mg SC monthly",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active Hepatitis B",
          "Same as ocrelizumab",
          "active infection"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same",
          "Same as ocrelizumab",
          "self-administered SC",
          "self-administered at home"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "olanzapine": {
      "id": "olanzapine",
      "name": "Olanzapine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM",
        "PO",
        "PO/IM"
      ],
      "formulations": [],
      "contexts": {
        "acute-agitation-with-psychosis-alternative-to-haloperidol": {
          "indication": "Acute agitation with psychosis; alternative to haloperidol",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Olanzapine 5 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg IM; may repeat in 2 hours; max 30 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "chorea-with-weight-loss-promotes-weight-gain": {
          "indication": "Chorea with weight loss; promotes weight gain",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Olanzapine 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5-5 mg qHS; titrate to effect; typical 5-15 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "moderate-agitation-or-psychosis": {
          "indication": "Moderate agitation or psychosis",
          "doseOptions": [
            {
              "text": "2.5-5 mg",
              "orderSentence": "Olanzapine (agitation/psychosis) 2.5-5 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2.5-5 mg PO/IM BID (start low); max 20 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "severe-agitation-when-other-options-fail-im-for-acute-crisis": {
          "indication": "Severe agitation when other options fail; IM for acute crisis",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Olanzapine 2.5 mg PO/IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "PO: Start 2.5 mg daily; increase slowly; max 10 mg; IM: 2.5-5 mg for acute crisis",
          "settings": {
            "ED": "EXT",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2.5-5 mg",
              "orderSentence": "Olanzapine (agitation/psychosis) 2.5-5 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2.5-5 mg PO/IM BID (start low); max 20 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Black box: increased mortality in dementia",
          "Concurrent benzodiazepines (caution)",
          "Diabetes",
          "QT prolongation",
          "QTc prolongation",
          "diabetes",
          "metabolic syndrome",
          "significant metabolic risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "EPS",
          "Glucose",
          "Glucose, sedation, EPS",
          "QTc",
          "Weight gain",
          "Weight, glucose, lipids",
          "lipids",
          "metabolic syndrome",
          "sedation",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "frontotemporal-dementia",
        "hashimotos-encephalopathy",
        "huntingtons-disease"
      ]
    },
    "omaveloxolone": {
      "id": "omaveloxolone",
      "name": "Omaveloxolone (Skyclarys)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "friedreich-ataxia-fda-approved-nrf2-activator-first-approved": {
          "indication": "Friedreich ataxia — FDA-approved Nrf2 activator; first approved therapy for Friedreich ataxia (2023)",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Omaveloxolone (Skyclarys) 150 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150 mg PO once daily on empty stomach (1 hour before first meal); swallow capsule whole",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Moderate-to-severe hepatic impairment",
          "avoid strong CYP3A4 inhibitors",
          "concurrent hepatotoxic drugs"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BNP (cardiac)",
          "LFTs at baseline, monthly x 3 months, then q3 months",
          "clinical ataxia scores (mFARS)",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ataxia-evaluation"
      ]
    },
    "omeprazole": {
      "id": "omeprazole",
      "name": "Omeprazole",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/PO",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "gi-protection-during-high-dose-corticosteroid-therapy": {
          "indication": "GI protection during high-dose corticosteroid therapy",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Omeprazole 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg PO daily during steroid course and oral taper; IV if NPO",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease",
            "neurosarcoidosis"
          ]
        },
        "gi-protection-during-high-dose-corticosteroids": {
          "indication": "GI protection during high-dose corticosteroids",
          "doseOptions": [
            {
              "text": "20-40 mg",
              "orderSentence": "Omeprazole (GI prophylaxis during steroids) 20-40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mg PO daily while on steroids",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "gi-protection-during-high-dose-steroid-therapy": {
          "indication": "GI protection during high-dose steroid therapy",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Omeprazole (GI prophylaxis during steroids) 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily during steroid course and taper",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "gi-protection-while-on-dexamethasone-critical-illness-with-s": {
          "indication": "GI protection while on dexamethasone; critical illness with steroid use",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "**Omeprazole (stress ulcer prophylaxis)** 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Omeprazole 20 mg PO daily or pantoprazole 40 mg IV daily if NPO; continue throughout steroid course",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "gi-prophylaxis-during-steroids": {
          "indication": "GI prophylaxis during steroids",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Omeprazole 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mg daily during steroid course",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "gi-protection-during-high-dose-steroids": {
          "indication": "GI protection during high-dose steroids",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Omeprazole 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mg PO daily while on high-dose prednisone; consider tapering off when steroids reduced",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "myasthenia-gravis",
            "nmosd"
          ]
        },
        "prevention-of-steroid-induced-gi-bleeding-during-high-dose-c": {
          "indication": "Prevention of steroid-induced GI bleeding during high-dose corticosteroid therapy",
          "doseOptions": [
            {
              "text": "40 mg daily",
              "orderSentence": "Omeprazole (GI prophylaxis) 40 mg daily IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV or PO daily during high-dose steroid course and subsequent oral taper",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cns-vasculitis",
            "susac-syndrome"
          ]
        },
        "gerd-management-in-patients-with-dysphagia-gi-protection-if-": {
          "indication": "GERD management in patients with dysphagia; GI protection if aspirin or NSAID use",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Omeprazole 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg PO daily; take 30 minutes before breakfast",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "gi-ulcer-prevention-during-high-dose-steroid-therapy": {
          "indication": "GI ulcer prevention during high-dose steroid therapy",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Omeprazole (GI prophylaxis during steroids) 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg PO/IV daily during IV steroid course and oral taper",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "gi-protection-during-high-dose-steroids-aspirin": {
          "indication": "GI protection during high-dose steroids + aspirin",
          "doseOptions": [
            {
              "text": "40 mg daily",
              "orderSentence": "Omeprazole (GI prophylaxis) 40 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg PO/IV daily while on steroids",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20-40 mg",
              "orderSentence": "Omeprazole 20-40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mg daily during steroids",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ms-new-diagnosis",
            "myasthenia-gravis-new-diagnosis",
            "autoimmune-encephalitis"
          ]
        },
        "stress-ulcer-prevention-during-high-dose-corticosteroids": {
          "indication": "Stress ulcer prevention during high-dose corticosteroids",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Omeprazole (GI prophylaxis during steroids) 40 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily during steroid course and taper",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "gi-protection-during-chelation-therapy": {
          "indication": "GI protection during chelation therapy",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Omeprazole 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg PO daily; take 30 min before chelator",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Known hypersensitivity",
          "Long-term use increases C. diff risk",
          "None absolute",
          "PPI allergy",
          "consider C. difficile risk with prolonged PPI use",
          "long-term use concerns (B12, Mg, bone density)",
          "osteoporosis (long-term)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 level",
          "GI symptoms",
          "Limit duration",
          "Long-term: B12, Mg levels",
          "Magnesium if prolonged use",
          "None routine",
          "consider H. pylori testing if prolonged use",
          "consider H2 blocker alternative"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 18,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "cns-vasculitis",
        "giant-cell-arteritis",
        "hashimotos-encephalopathy",
        "inclusion-body-myositis",
        "inflammatory-myopathy",
        "leptomeningeal-carcinomatosis",
        "mogad",
        "ms-new-diagnosis",
        "myasthenia-gravis",
        "myasthenia-gravis-new-diagnosis",
        "neuro-behcets-disease",
        "neurosarcoidosis",
        "nmosd",
        "optic-neuritis",
        "paraneoplastic-neurological-syndrome",
        "susac-syndrome",
        "wilsons-disease"
      ]
    },
    "onabotulinumtoxin-a": {
      "id": "onabotulinumtoxin-a",
      "name": "Onabotulinumtoxin A (Botox)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "chronic-migraine-with-aura-15-days-month-failed-oral-prevent": {
          "indication": "Chronic migraine with aura (≥15 days/month); failed oral preventives",
          "doseOptions": [
            {
              "text": "155 units",
              "orderSentence": "Onabotulinumtoxin A (Botox) 155 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "155-195 units across 31-39 injection sites per PREEMPT protocol; repeat q12 weeks; effect may take 2-3 cycles",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Infection at injection sites",
          "myasthenia gravis",
          "neuromuscular disorder"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Neck weakness",
          "antibody formation if loss of effect",
          "ptosis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine-with-aura"
      ]
    },
    "onabotulinumtoxina": {
      "id": "onabotulinumtoxina",
      "name": "OnabotulinumtoxinA (Botox) (CPT J0585)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "155-195 units",
              "orderSentence": "OnabotulinumtoxinA (CPT J0585) 155-195 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "155-195 units IM q12 weeks (if chronic migraine criteria met)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache",
            "migraine"
          ]
        },
        "chronic-post-traumatic-headache-15-days-month-for-3-months": {
          "indication": "Chronic post-traumatic headache (>15 days/month for >3 months)",
          "doseOptions": [
            {
              "text": "155-195 units",
              "orderSentence": "OnabotulinumtoxinA (Botox) (CPT J0585) 155-195 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "155-195 units IM q12 weeks per PREEMPT protocol",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "focal-post-stroke-spasticity-not-adequately-controlled-with-": {
          "indication": "Focal post-stroke spasticity not adequately controlled with oral agents; upper or lower limb; reduces spasticity and improves function",
          "doseOptions": [
            {
              "text": "Individualized per muscle",
              "orderSentence": "OnabotulinumtoxinA (Botox) Individualized per muscle IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Upper limb: biceps 100-200 units, flexor digitorum 30-50 units per site; lower limb: gastrocnemius 150-300 units; effect onset 1-2 weeks; duration 3-4 months; repeat q3 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "chronic-migraine-only-15-ha-days-month-level-a-evidence-fda-": {
          "indication": "Chronic migraine ONLY (≥15 HA days/month); Level A evidence; FDA-approved for chronic migraine",
          "doseOptions": [
            {
              "text": "155 units",
              "orderSentence": "OnabotulinumtoxinA (Botox) (CPT 64615, J0585) 155 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "155-195 units IM across 31-39 injection sites q12 weeks; PREEMPT protocol: 7 head/neck muscle groups (frontalis, corrugator, procerus, temporalis, occipitalis, cervical paraspinal, trapezius); 5 units per site",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "sialorrhea-refractory-to-oral-therapy": {
          "indication": "Sialorrhea refractory to oral therapy",
          "doseOptions": [
            {
              "text": "100 units total",
              "orderSentence": "OnabotulinumtoxinA (salivary glands) 100 units total IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30-50 units per parotid, 10-20 units per submandibular; repeat q3-4 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection at injection sites, myasthenia gravis, Lambert-Eaton syndrome, known hypersensitivity to botulinum toxin",
          "Infection at injection site",
          "Infection at injection sites, myasthenia",
          "Infection at injection sites, myasthenia gravis",
          "Infection at site",
          "Infection at site, myasthenia",
          "concurrent aminoglycosides",
          "generalized neuromuscular disease (MG, ALS)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dysphagia (rare), dry mouth",
          "Excessive weakness",
          "Injection site pain, neck pain, eyelid ptosis (1-2%)",
          "Spread of effect",
          "Spread of toxin effect",
          "antibody development (rare)",
          "assess response at 2nd-3rd cycle (minimum 2 cycles before declaring failure)",
          "document headache days reduction",
          "dysphagia if cervical muscles injected",
          "neck weakness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "chronic-migraine",
        "medication-overuse-headache",
        "migraine",
        "parkinsons-disease",
        "post-concussion-syndrome",
        "post-stroke-management"
      ]
    },
    "onabotulinumtoxina-blepharospasm": {
      "id": "onabotulinumtoxina-blepharospasm",
      "name": "OnabotulinumtoxinA (Botox) - Blepharospasm",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "first-line-for-blepharospasm": {
          "indication": "First-line for blepharospasm",
          "doseOptions": [
            {
              "text": "25 units",
              "orderSentence": "OnabotulinumtoxinA (Botox) - Blepharospasm 25 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1.25-5 units per site; inject orbicularis oculi at multiple points; total 25-50 units per eye; repeat q12wk",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "blepharospasm-causing-functional-blindness-involuntary-eyeli": {
          "indication": "Blepharospasm causing functional blindness; involuntary eyelid closure",
          "doseOptions": [
            {
              "text": "2.5-5 units/site",
              "orderSentence": "OnabotulinumtoxinA (Botox) - blepharospasm 2.5-5 units/site IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2.5-5 units per injection site in orbicularis oculi; total 10-30 units per eye; repeat q12 weeks; specialist administration",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ALS",
          "Infection at injection site",
          "Infection at site",
          "aminoglycoside use",
          "myasthenia gravis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ptosis, diplopia, dry eyes, lagophthalmos",
          "Ptosis, dry eye, excessive tearing, hematoma",
          "reassess at each visit"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "dystonia",
        "progressive-supranuclear-palsy"
      ]
    },
    "onabotulinumtoxina-cervical-dystonia": {
      "id": "onabotulinumtoxina-cervical-dystonia",
      "name": "OnabotulinumtoxinA (Botox) - Cervical dystonia",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "first-line-for-cervical-dystonia-torticollis": {
          "indication": "First-line for cervical dystonia/torticollis",
          "doseOptions": [
            {
              "text": "100 units",
              "orderSentence": "OnabotulinumtoxinA (Botox) - Cervical dystonia 100 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100-200 units divided among affected muscles (SCM, splenius, trapezius, levator scapulae); adjust based on response; max 300 units/session; repeat q12wk",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ALS",
          "Infection at site",
          "myasthenia gravis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dysphagia (especially bilateral SCM)",
          "antibody formation",
          "neck weakness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "dystonia"
      ]
    },
    "onabotulinumtoxina-cervical-tics": {
      "id": "onabotulinumtoxina-cervical-tics",
      "name": "OnabotulinumtoxinA (Botox) - cervical tics (CPT 64616, J0585)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "focal-motor-tics-causing-pain-or-disability-cervical-facial-": {
          "indication": "Focal motor tics causing pain or disability (cervical, facial); phonic tics (vocal cord injection)",
          "doseOptions": [
            {
              "text": "25-100 units",
              "orderSentence": "OnabotulinumtoxinA (Botox) - cervical tics (CPT 64616, J0585) 25-100 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Inject affected muscles; cervical tics 25-100 units divided; facial tics 5-25 units per site; repeat q12wk; EMG guidance for small muscles",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ALS",
          "Infection at site",
          "myasthenia gravis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dysphagia (if neck muscles)",
          "antibody formation with repeated use",
          "local weakness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tics-tourette-syndrome"
      ]
    },
    "onabotulinumtoxina-dystonia": {
      "id": "onabotulinumtoxina-dystonia",
      "name": "OnabotulinumtoxinA (Botox) - dystonia",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "dystonia-retrocollis-limb-dystonia-causing-pain-or-functiona": {
          "indication": "Dystonia (retrocollis, limb dystonia) causing pain or functional impairment",
          "doseOptions": [
            {
              "text": "Dose varies by muscle",
              "orderSentence": "OnabotulinumtoxinA (Botox) - dystonia Dose varies by muscle IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "EMG-guided injection; retrocollis: splenius capitis 50-200 units; dose per target muscle; repeat q12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Infection at injection site",
          "aminoglycoside use",
          "myasthenia gravis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dysphagia (especially cervical injections), weakness, pain at injection site"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "progressive-supranuclear-palsy"
      ]
    },
    "onabotulinumtoxina-phonic-vocal-tics": {
      "id": "onabotulinumtoxina-phonic-vocal-tics",
      "name": "OnabotulinumtoxinA (Botox) - phonic/vocal tics (CPT 64617, J0585)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "disabling-vocal-tics-coprolalia-loud-vocalizations-refractor": {
          "indication": "Disabling vocal tics (coprolalia, loud vocalizations); refractory to systemic therapy",
          "doseOptions": [
            {
              "text": "1.25-2.5 units",
              "orderSentence": "OnabotulinumtoxinA (Botox) - phonic/vocal tics (CPT 64617, J0585) 1.25-2.5 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1.25-2.5 units per vocal cord via EMG-guided injection; repeat q12wk; specialist procedure",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ALS",
          "Infection at site",
          "myasthenia gravis",
          "vocal cord paralysis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Breathy voice",
          "dysphagia",
          "periodic indirect laryngoscopy"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tics-tourette-syndrome"
      ]
    },
    "onabotulinumtoxina-sialorrhea": {
      "id": "onabotulinumtoxina-sialorrhea",
      "name": "OnabotulinumtoxinA (Botox) - sialorrhea",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "sialorrhea-drooling-not-responsive-to-oral-anticholinergics": {
          "indication": "Sialorrhea (drooling) not responsive to oral anticholinergics",
          "doseOptions": [
            {
              "text": "30 units/parotid",
              "orderSentence": "OnabotulinumtoxinA (Botox) - sialorrhea 30 units/parotid IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 units per parotid gland; 20 units per submandibular gland; repeat q12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Infection at injection site",
          "myasthenia gravis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dry mouth, dysphagia, jaw weakness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "progressive-supranuclear-palsy"
      ]
    },
    "onabotulinumtoxina-writer-s-cramp": {
      "id": "onabotulinumtoxina-writer-s-cramp",
      "name": "OnabotulinumtoxinA (Botox) - Writer's cramp",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "focal-hand-dystonia-refractory-to-therapy-modification": {
          "indication": "Focal hand dystonia refractory to therapy modification",
          "doseOptions": [
            {
              "text": "50 units",
              "orderSentence": "OnabotulinumtoxinA (Botox) - Writer's cramp 50 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-50 units per muscle; EMG guidance required; target FCR, FCU, FDS as needed; repeat q12wk",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ALS",
          "Infection at site",
          "myasthenia gravis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Finger weakness (may impair function)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "dystonia"
      ]
    },
    "oncology-directed-chemotherapy": {
      "id": "oncology-directed-chemotherapy",
      "name": "Oncology-directed chemotherapy (cisplatin/etoposide)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "standard-first-line-for-sclc-in-p-lems-treatment-of-underlyi": {
          "indication": "Standard first-line for SCLC in P-LEMS; treatment of underlying malignancy is the primary therapy for paraneoplastic LEMS; neurological symptoms often improve with cancer treatment",
          "doseOptions": [
            {
              "text": "Per oncology protocol",
              "orderSentence": "Oncology-directed chemotherapy (cisplatin/etoposide) Per oncology protocol IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Cisplatin 60-80 mg/m2 day 1 + etoposide 100-120 mg/m2 days 1-3 q21d x 4-6 cycles; defer to oncology for specific regimen",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per oncology assessment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "FVC if respiratory symptoms",
          "Neuromuscular function during treatment",
          "electrolytes",
          "myelosuppression",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "lambert-eaton-syndrome"
      ]
    },
    "ondansetron": {
      "id": "ondansetron",
      "name": "Ondansetron",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/PO",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nausea-ivig-related": {
          "indication": "Nausea (IVIG-related)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV/PO q6h PRN",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis"
          ]
        },
        "nausea-vomiting-from-elevated-icp-chemotherapy-or-radiation": {
          "indication": "Nausea/vomiting from elevated ICP, chemotherapy, or radiation",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV/PO q8h PRN nausea; max 24 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "non-dopaminergic-antiemetic-substitute-for-acute-settings-wh": {
          "indication": "Non-dopaminergic antiemetic substitute for acute settings when metoclopramide or prochlorperazine is causative agent",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron (Zofran) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV q8h PRN for nausea; max 24 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        },
        "nausea-vomiting-posterior-fossa-hemorrhage-elevated-icp": {
          "indication": "Nausea/vomiting (posterior fossa hemorrhage; elevated ICP)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV q6h PRN",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "nausea-and-vomiting-from-elevated-icp-medications-flucytosin": {
          "indication": "Nausea and vomiting from elevated ICP, medications (flucytosine, azoles), or meningeal irritation",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV or PO q6h PRN nausea; max 16 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "nausea-vomiting": {
          "indication": "Nausea/vomiting",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV/PO q6h PRN",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hsv-encephalitis",
            "bacterial-meningitis"
          ]
        },
        "nausea-and-vomiting-common-with-meningitis-worsened-by-menin": {
          "indication": "Nausea and vomiting (common with meningitis; worsened by meningeal irritation)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV/PO q6h PRN; may increase to 8 mg q6h if refractory",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "anti-emetic-adjunct-caution-in-first-trimester": {
          "indication": "Anti-emetic adjunct; caution in first trimester",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron (CPT 96374) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV q8h",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "anti-emetic-adjunct-for-outpatient-use-caution-in-first-trim": {
          "indication": "Anti-emetic adjunct for outpatient use; caution in first trimester",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg PO q8h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "nausea-and-vomiting-vertebral-dissection-with-posterior-circ": {
          "indication": "Nausea and vomiting (vertebral dissection with posterior circulation symptoms)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV/PO q6h PRN nausea",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "nausea-and-vomiting-from-elevated-icp-chemotherapy-or-radiat": {
          "indication": "Nausea and vomiting from elevated ICP, chemotherapy, or radiation therapy",
          "doseOptions": [
            {
              "text": "4-8 mg",
              "orderSentence": "**Ondansetron** 4-8 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ondansetron 4-8 mg IV/PO q8h PRN nausea/vomiting; use around the clock during IT chemotherapy and radiation; dexamethasone itself provides anti-emetic effect",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "nausea-associated-with-orthostatic-symptoms-and-sih": {
          "indication": "Nausea associated with orthostatic symptoms and SIH",
          "doseOptions": [
            {
              "text": "4 mg q8h PRN",
              "orderSentence": "Ondansetron 4 mg q8h PRN IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV or PO q8h PRN nausea; max 24 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        },
        "nausea-vomiting-in-eclampsia-severe-preeclampsia-safe-in-pre": {
          "indication": "Nausea/vomiting in eclampsia/severe preeclampsia; safe in pregnancy",
          "doseOptions": [
            {
              "text": "4 mg IV",
              "orderSentence": "Ondansetron 4 mg IV IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV/PO q8h PRN; max 16 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "nausea-vomiting-from-elevated-icp-chemotherapy-methotrexate-": {
          "indication": "Nausea/vomiting from elevated ICP, chemotherapy (methotrexate, cytarabine), or radiation",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV/PO q8h PRN nausea; max 24 mg/day; give 30 min before chemotherapy",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "nausea-vomiting-common-in-withdrawal": {
          "indication": "Nausea/vomiting (common in withdrawal)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV q8h PRN; may also use PO/ODT formulation",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "nausea-vomiting-when-dopamine-antagonists-contraindicated-pa": {
          "indication": "Nausea/vomiting when dopamine antagonists contraindicated (Parkinson, QTc prolongation)",
          "doseOptions": [
            {
              "text": "4-8 mg",
              "orderSentence": "Ondansetron (CPT 96374) 4-8 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV/PO once; may repeat q8h",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "nausea-and-vomiting-management": {
          "indication": "Nausea and vomiting management",
          "doseOptions": [
            {
              "text": "4 mg q6h PRN",
              "orderSentence": "Ondansetron 4 mg q6h PRN IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV q6-8h PRN; max 16 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "nausea-associated-with-vestibular-dysfunction": {
          "indication": "Nausea associated with vestibular dysfunction",
          "doseOptions": [
            {
              "text": "4-8 mg",
              "orderSentence": "Ondansetron 4-8 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg PO/IV q8h PRN",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "nausea-vomiting-from-elevated-icp": {
          "indication": "Nausea/vomiting from elevated ICP",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV/PO q6-8h PRN",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "antiemetic-for-nausea-vomiting-associated-with-thunderclap-h": {
          "indication": "Antiemetic for nausea/vomiting associated with thunderclap headache",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV/PO q6-8h PRN nausea; max 16 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "nausea-and-vomiting-common-with-elevated-icp-and-antiparasit": {
          "indication": "Nausea and vomiting (common with elevated ICP and antiparasitic therapy; albendazole commonly causes nausea)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron (CPT 96374) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV/PO q6h PRN nausea; max 16 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "intractable-nausea-vomiting-area-postrema-syndrome": {
          "indication": "Intractable nausea/vomiting (area postrema syndrome)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg PO/IV q6-8h PRN",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "nausea-vomiting-posterior-circulation-stroke": {
          "indication": "Nausea/vomiting (posterior circulation stroke)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV/PO q6h PRN",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "nausea-and-vomiting-associated-with-acute-cerebellar-dysfunc": {
          "indication": "Nausea and vomiting associated with acute cerebellar dysfunction and vertigo",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV/PO q8h PRN nausea; max 24 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "4-8 mg",
              "orderSentence": "Ondansetron 4-8 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV/PO q8h",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "nausea-vomiting-from-cerebellar-involvement-or-brainstem-dys": {
          "indication": "Nausea/vomiting from cerebellar involvement or brainstem dysfunction",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV/PO q8h PRN nausea; max 24 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "nausea-and-vomiting-may-occur-with-brainstem-involvement-or-": {
          "indication": "Nausea and vomiting -- may occur with brainstem involvement or medication side effects",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron (nausea) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV q8h PRN; or 4-8 mg PO q8h PRN",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "nausea-and-vomiting-management-particularly-during-ivig-or-p": {
          "indication": "Nausea and vomiting management; particularly during IVIG or plasma exchange",
          "doseOptions": [
            {
              "text": "4 mg q6h PRN",
              "orderSentence": "Ondansetron 4 mg q6h PRN IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV q6-8h PRN; max 16 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "nausea-and-vomiting-associated-with-acute-vestibular-nystagm": {
          "indication": "Nausea and vomiting associated with acute vestibular nystagmus; antiemetic without vestibular suppressant effect",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "**Ondansetron** 4 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Ondansetron 4-8 mg IV or PO q8h PRN for nausea**",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "nausea-and-vomiting-common-with-elevated-icp-and-metronidazo": {
          "indication": "Nausea and vomiting (common with elevated ICP and metronidazole use)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV/PO q6h PRN nausea; max 16 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "nausea-vomiting-common-with-thunderclap-headache-and-elevate": {
          "indication": "Nausea/vomiting (common with thunderclap headache and elevated ICP)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron (CPT 96374) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV q6h PRN",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "nausea-vomiting-from-elevated-icp-or-perioperative": {
          "indication": "Nausea/vomiting from elevated ICP or perioperative",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV/PO q8h PRN nausea; max 24 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "nausea-and-vomiting-associated-with-hypertensive-encephalopa": {
          "indication": "Nausea and vomiting associated with hypertensive encephalopathy and elevated ICP",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV q6h PRN nausea; max 16 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        },
        "nausea-vomiting-common-with-ripe-therapy-especially-pyrazina": {
          "indication": "Nausea/vomiting (common with RIPE therapy, especially pyrazinamide)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV/PO q6h PRN",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        },
        "nausea-and-vomiting-foodborne-botulism-gi-symptoms": {
          "indication": "Nausea and vomiting (foodborne botulism GI symptoms)",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron (CPT 96374) 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV q6-8h PRN",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "botulism"
          ]
        },
        "nausea-and-vomiting-associated-with-lyme-meningitis-or-verti": {
          "indication": "Nausea and vomiting associated with Lyme meningitis or vertigo",
          "doseOptions": [
            {
              "text": "4 mg q6-8h PRN",
              "orderSentence": "Ondansetron 4 mg q6-8h PRN IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV/PO q6-8h as needed; max 24 mg/day",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        },
        "post-ictal-nausea": {
          "indication": "Post-ictal nausea",
          "doseOptions": [
            {
              "text": "4-8 mg",
              "orderSentence": "Ondansetron 4-8 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg IV/PO q8h PRN",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        },
        "nausea-vomiting-with-migraine": {
          "indication": "Nausea/vomiting with migraine",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron 4 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV or 8 mg PO/ODT; may repeat q8h as needed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "QT prolongation (QTc >500ms)",
          "QT prolongation (caution 1st trimester)",
          "QT prolongation (dose-dependent), serotonin syndrome risk with concurrent serotonergic drugs",
          "QT prolongation, serotonin syndrome risk",
          "QT prolongation, severe hepatic impairment",
          "QTc >500 ms",
          "QTc prolongation",
          "QTc prolongation (check ECG if risk factors)",
          "allergy",
          "concomitant apomorphine",
          "concurrent use of QT-prolonging agents",
          "congenital long QT",
          "congenital long QT syndrome",
          "first trimester (relative -- limited data)",
          "first trimester concern (some data, generally considered safe)",
          "hepatic impairment (max 8 mg/day)",
          "serotonin syndrome risk",
          "serotonin syndrome risk with serotonergic agents",
          "serotonin syndrome with concurrent serotonergic agents",
          "severe hepatic impairment",
          "severe hepatic impairment (max 8 mg/day)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG if QT concern",
          "QTc",
          "QTc if concurrent QT-prolonging agents",
          "QTc if multiple QT-prolonging medications",
          "QTc if multiple doses",
          "QTc if multiple doses or baseline prolongation",
          "QTc if repeated doses",
          "QTc if repeated dosing",
          "QTc if risk factors",
          "QTc if risk factors or concurrent QT-prolonging medications",
          "QTc if risk factors, constipation",
          "QTc monitoring",
          "QTc monitoring if prolonged use",
          "QTc on ECG",
          "constipation",
          "headache",
          "hepatic function",
          "serotonin syndrome risk with SSRIs"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 39,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "alcohol-withdrawal-seizure",
        "ataxia-evaluation",
        "bacterial-meningitis",
        "botulism",
        "brain-abscess",
        "cerebral-venous-thrombosis",
        "cervical-artery-dissection",
        "cns-vasculitis",
        "creutzfeldt-jakob-disease",
        "drug-induced-parkinsonism",
        "eclampsia-seizure-pregnancy",
        "fungal-meningitis",
        "glioblastoma",
        "headache-evaluation",
        "headache-unspecified",
        "hsv-encephalitis",
        "intracerebral-hemorrhage",
        "leptomeningeal-carcinomatosis",
        "low-pressure-headache",
        "lyme-neuroborreliosis",
        "meningioma",
        "migraine",
        "migraine-with-aura",
        "myasthenia-gravis-crisis",
        "neurocysticercosis",
        "new-onset-seizure",
        "nmosd",
        "nystagmus-evaluation",
        "paraneoplastic-neurological-syndrome",
        "post-concussion-syndrome",
        "pres",
        "primary-cns-lymphoma",
        "rcvs",
        "susac-syndrome",
        "tb-meningitis",
        "thunderclap-headache-evaluation",
        "viral-meningitis"
      ]
    },
    "ondansetron-iv": {
      "id": "ondansetron-iv",
      "name": "Ondansetron IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "antiemetic-for-nausea-vomiting-when-dopamine-antagonists-con": {
          "indication": "Antiemetic for nausea/vomiting when dopamine antagonists contraindicated (Parkinson disease)",
          "doseOptions": [
            {
              "text": "4 mg IV once",
              "orderSentence": "Ondansetron IV 4 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV over 2-5 min; may repeat q6-8h; max 16 mg/24h (FDA max single IV dose 16 mg due to QT risk)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation (dose-dependent), concurrent serotonergic drugs (caution)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "QTc at higher doses"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "ondansetron-odt": {
      "id": "ondansetron-odt",
      "name": "Ondansetron ODT",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "anti-emetic-rescue-for-nausea-vomiting-with-headache-recurre": {
          "indication": "Anti-emetic rescue for nausea/vomiting with headache recurrence",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron ODT 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg ODT q8h PRN",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "QTc if chronic use",
          "constipation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "headache-unspecified"
      ]
    },
    "ondansetron-po": {
      "id": "ondansetron-po",
      "name": "Ondansetron (Zofran) PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "non-dopaminergic-antiemetic-substitute-for-oral-maintenance-": {
          "indication": "Non-dopaminergic antiemetic substitute for oral maintenance when dopaminergic antiemetic is causative agent",
          "doseOptions": [
            {
              "text": "4 mg",
              "orderSentence": "Ondansetron (Zofran) PO 4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg PO q8h PRN for nausea; max 24 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "severe hepatic impairment (max 8 mg/day)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "QTc if risk factors, constipation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-induced-parkinsonism"
      ]
    },
    "opicapone": {
      "id": "opicapone",
      "name": "Opicapone (Ongentys)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Opicapone (Ongentys) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg daily at bedtime; separate from levodopa by 1 hour",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "comt-inhibitor-once-daily-alternative-to-entacapone": {
          "indication": "COMT inhibitor; once daily alternative to entacapone",
          "doseOptions": [
            {
              "text": "50 mg qHS",
              "orderSentence": "Opicapone 50 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg once daily at bedtime; take 1 hour before or after levodopa",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None absolute",
          "Pheochromocytoma",
          "paraganglioma"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dyskinesia, constipation",
          "Dyskinesias, constipation, dry mouth"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "oral-antibiotic-transition": {
      "id": "oral-antibiotic-transition",
      "name": "Oral antibiotic transition (selected cases)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "750 mg",
              "orderSentence": "**Oral antibiotic transition (selected cases)** 750 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**OVIVA trial (2019):** Oral antibiotics non-inferior to IV for bone/joint infections after initial 2 weeks IV in stable patients; **Candidates:** Clinically improving; afebrile; tolerating PO; CRP trending down; adherent; close follow-up available; **Oral options:** Fluoroquinolone (levofloxacin 750 mg daily or ciprofloxacin 750 mg BID) + rifampin 300 mg BID (NOT monotherapy); linezolid 600 mg BID (monitor CBC, neuropathy); TMP-SMX DS 2 tabs BID (for MRSA); **NOT for:** Endocarditis, undrained abscess, persistent bacteremia, non-adherent patient",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epidural-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "NOT standard for all SEA cases",
          "OVIVA trial showed oral switch after 2 weeks IV is non-inferior for bone/joint infections",
          "reduces costs, IV complications, hospital stay",
          "requires careful patient selection and close monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epidural-abscess"
      ]
    },
    "oral-antihypertensive-amlodipine": {
      "id": "oral-antihypertensive-amlodipine",
      "name": "Oral antihypertensive: Amlodipine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "long-term-bp-control-to-prevent-pres-recurrence-calcium-chan": {
          "indication": "Long-term BP control to prevent PRES recurrence; calcium channel blocker provides smooth BP reduction",
          "doseOptions": [
            {
              "text": "5 mg daily",
              "orderSentence": "Oral antihypertensive: Amlodipine 5 mg daily PO"
            },
            {
              "text": "10 mg daily",
              "orderSentence": "Oral antihypertensive: Amlodipine 10 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily; increase to 10 mg if needed after 1-2 weeks; max 10 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe aortic stenosis",
          "cardiogenic shock"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Home BP monitoring",
          "heart rate",
          "pedal edema"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "oral-antihypertensive-lisinopril": {
      "id": "oral-antihypertensive-lisinopril",
      "name": "Oral antihypertensive: Lisinopril",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "long-term-bp-control-renoprotective-preferred-if-proteinuria": {
          "indication": "Long-term BP control; renoprotective; preferred if proteinuria present (preeclampsia history)",
          "doseOptions": [
            {
              "text": "5 mg daily",
              "orderSentence": "Oral antihypertensive: Lisinopril 5 mg daily PO"
            },
            {
              "text": "10 mg daily",
              "orderSentence": "Oral antihypertensive: Lisinopril 10 mg daily PO"
            },
            {
              "text": "20 mg daily",
              "orderSentence": "Oral antihypertensive: Lisinopril 20 mg daily PO"
            },
            {
              "text": "40 mg daily",
              "orderSentence": "Oral antihypertensive: Lisinopril 40 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg PO daily; titrate q1-2 weeks; max 40 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "K >5.5",
          "Pregnancy (ABSOLUTE -- teratogenic)",
          "angioedema history",
          "bilateral renal artery stenosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Cr and K+ at 1-2 weeks after initiation",
          "angioedema watch"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "oral-antihypertensive-metoprolol-succinate": {
      "id": "oral-antihypertensive-metoprolol-succinate",
      "name": "Oral antihypertensive: Metoprolol succinate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "long-term-bp-control-preferred-if-concurrent-tachycardia-or-": {
          "indication": "Long-term BP control; preferred if concurrent tachycardia or coronary disease",
          "doseOptions": [
            {
              "text": "25 mg daily",
              "orderSentence": "Oral antihypertensive: Metoprolol succinate 25 mg daily PO"
            },
            {
              "text": "50 mg daily",
              "orderSentence": "Oral antihypertensive: Metoprolol succinate 50 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Oral antihypertensive: Metoprolol succinate 100 mg daily PO"
            },
            {
              "text": "200 mg daily",
              "orderSentence": "Oral antihypertensive: Metoprolol succinate 200 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg PO daily; titrate q1-2 weeks; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart block (2nd/3rd degree)",
          "decompensated heart failure",
          "severe asthma",
          "severe bradycardia (<50 bpm)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Heart rate",
          "bronchospasm",
          "signs of heart failure"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "oral-corticosteroid-taper": {
      "id": "oral-corticosteroid-taper",
      "name": "Oral corticosteroid taper (cervical/lumbar radiculopathy)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "acute-radiculopathy-with-significant-pain-and-function-limit": {
          "indication": "Acute radiculopathy with significant pain and function limitation",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Oral corticosteroid taper (cervical/lumbar radiculopathy) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Methylprednisolone dose pack or prednisone 60 mg x 5 days, 40 mg x 5 days, 20 mg x 5 days (15-day taper)",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection, uncontrolled diabetes, GI bleed"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose",
          "short course so bone density not needed"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "paresthesia-numbness-tingling"
      ]
    },
    "oral-nutritional-supplements": {
      "id": "oral-nutritional-supplements",
      "name": "Oral nutritional supplements",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "weight-loss-inadequate-oral-intake": {
          "indication": "Weight loss; inadequate oral intake",
          "doseOptions": [
            {
              "text": "1-3 supplements daily",
              "orderSentence": "Oral nutritional supplements 1-3 supplements daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "High-calorie, high-protein supplements (e.g., Ensure Plus, Boost Plus) 1-3 daily between meals",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Aspiration risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Weight, caloric intake, albumin"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "oral-prednisone": {
      "id": "oral-prednisone",
      "name": "Oral prednisone (low-dose maintenance)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "relapse-prevention-some-patients-require-long-term-low-dose-": {
          "indication": "Relapse prevention; some patients require long-term low-dose steroids",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Oral prednisone (low-dose maintenance) 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO daily; aim to taper off if on steroid-sparing agent; some patients require indefinite low-dose",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "bridge-immunosuppression-while-steroid-sparing-agent-takes-e": {
          "indication": "Bridge immunosuppression while steroid-sparing agent takes effect; some patients require low-dose maintenance long-term",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Oral prednisone (low-dose maintenance) 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO daily; aim to taper off within 3-6 months once steroid-sparing agent established; some patients require indefinite low-dose (5 mg)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "low-dose-maintenance-immunosuppression-while-steroid-sparing": {
          "indication": "Low-dose maintenance immunosuppression while steroid-sparing agent reaches full effect",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oral prednisone (low-dose maintenance) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO daily; aim to taper off within 3-6 months if on steroid-sparing agent",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Oral prednisone (low-dose maintenance) 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO daily; aim to taper off within 3-6 months if on steroid-sparing agent",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "Poorly controlled diabetes",
          "active infection",
          "avascular necrosis",
          "uncontrolled diabetes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Glucose",
          "adrenal assessment on taper",
          "bone density (DEXA if >3 months)",
          "cataracts",
          "mood",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "hashimotos-encephalopathy",
        "mogad",
        "paraneoplastic-neurological-syndrome"
      ]
    },
    "oral-prednisone-taper": {
      "id": "oral-prednisone-taper",
      "name": "Oral prednisone taper (following IV methylprednisolone)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "maintenance-after-iv-pulse-prevent-relapse": {
          "indication": "Maintenance after IV pulse; prevent relapse",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Oral prednisone taper (following IV methylprednisolone) 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg/day (max 60-80 mg) x 2-4 weeks; taper by 10 mg every 1-2 weeks to 20 mg; then taper by 5 mg every 1-2 weeks; total taper over 3-6 months; SLOW taper critical (relapse rate 40-50% with rapid taper)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "post-iv-steroid-taper-high-relapse-rate-with-rapid-taper-in-": {
          "indication": "Post-IV steroid taper; HIGH RELAPSE RATE with rapid taper in MOGAD -- taper over 3-6 months minimum",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Oral prednisone taper (CRITICAL: slow taper) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg/kg/day (max 60 mg) after IV pulse; taper: 60 mg x 2 wk; 50 mg x 2 wk; 40 mg x 2 wk; 30 mg x 2 wk; 20 mg x 2 wk; 15 mg x 2 wk; 10 mg x 2 wk; 5 mg x 2 wk; then stop; do NOT taper faster than 5 mg/month below 20 mg; relapse risk highest when prednisone <20 mg or within 2 months of discontinuation",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "transition-from-iv-steroids-prevent-rebound-relapse": {
          "indication": "Transition from IV steroids; prevent rebound relapse",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Oral prednisone taper (after IV steroids) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Prednisone taper over 4-6 weeks: 60 mg x 1 wk; 40 mg x 1 wk; 20 mg x 1 wk; 10 mg x 1 wk; longer taper if severe attack or slow recovery",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "transition-from-iv-methylprednisolone-sustained-immunosuppre": {
          "indication": "Transition from IV methylprednisolone; sustained immunosuppression during tumor workup",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Oral prednisone taper 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg/day (max 60 mg) x 2 weeks; taper by 10 mg/week to 20 mg; then by 5 mg/week to discontinuation or low-dose maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "inflammatory-myelitis-nmosd": {
          "indication": "Inflammatory myelitis; NMOSD",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Oral prednisone taper (after IV pulse) 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg/day (max 60-80 mg) tapered over 4-8 weeks for first episode; longer taper for NMOSD/MOGAD",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-myelopathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Oral prednisone taper (following IV methylprednisolone) 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg/day (max 60 mg) x 2 weeks; taper by 10 mg/week to 20 mg; then taper by 5 mg/week to discontinuation OR low-dose maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "See steroid contraindications",
          "avascular necrosis",
          "poorly controlled diabetes",
          "psychosis",
          "uncontrolled diabetes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Glucose",
          "adrenal insufficiency assessment on taper",
          "adrenal insufficiency on taper",
          "bone density (DEXA if >3 months)",
          "bone density if prolonged",
          "bone health",
          "cataracts",
          "mood",
          "relapse monitoring",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "acute-myelopathy",
        "autoimmune-encephalitis",
        "hashimotos-encephalopathy",
        "mogad",
        "nmosd",
        "paraneoplastic-neurological-syndrome"
      ]
    },
    "osimertinib": {
      "id": "osimertinib",
      "name": "Osimertinib (EGFR+ NSCLC)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "egfr-mutant-nsclc-with-leptomeningeal-disease-excellent-csf-": {
          "indication": "EGFR-mutant NSCLC with leptomeningeal disease; excellent CSF penetration",
          "doseOptions": [
            {
              "text": "80 mg",
              "orderSentence": "**Osimertinib (EGFR+ NSCLC)** 80 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Osimertinib 80 mg PO daily; CSF penetration ~2-7% (sufficient for activity); may increase to 160 mg daily for LMD per BLOOM trial; continue until progression or intolerance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Interstitial lung disease/pneumonitis",
          "QTc >500 ms",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "ECG at baseline and monthly (QTc)",
          "LFTs monthly",
          "monitor for pneumonitis",
          "ophthalmologic exam if visual symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "osmotherapy-hypertonic-saline": {
      "id": "osmotherapy-hypertonic-saline",
      "name": "Osmotherapy — Hypertonic Saline",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "**Osmotherapy — Hypertonic Saline** 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**23.4% NaCl:** 30 mL IV bolus over 15-20 min via central line (preferred for acute crisis); **3% NaCl:** 250-500 mL IV bolus over 30 min (can give peripherally); **Continuous infusion:** 3% NaCl at 30-50 mL/hr to maintain Na 145-155 mEq/L; **Target sodium:** 145-155 mEq/L; avoid >160; correct slowly if hypernatremia develops (no faster than 8-10 mEq/24h decrease)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "elevated-icp-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Equivalent or superior to mannitol for ICP reduction",
          "SAFE-TBI trial (2021): 20% mannitol = HTS for ICP control",
          "does NOT cause diuresis (better for hypovolemic patients)",
          "does not accumulate in injured brain (mannitol may)",
          "no osmolality ceiling (unlike mannitol)",
          "preferred in many centers"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "elevated-icp-management"
      ]
    },
    "osmotherapy-hypertonic-saline-23-4": {
      "id": "osmotherapy-hypertonic-saline-23-4",
      "name": "Osmotherapy: Hypertonic saline 23.4%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "30 mL",
              "orderSentence": "Osmotherapy: Hypertonic saline 23.4% 30 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mL IV bolus via central line over 10-20 min for acute herniation",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "No central access for 23.4%",
          "hypokalemia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Serum sodium (target 145-155 mEq/L), osmolality, central line integrity"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-ischemic-stroke"
      ]
    },
    "osmotherapy-mannitol": {
      "id": "osmotherapy-mannitol",
      "name": "Osmotherapy — Mannitol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "**Osmotherapy — Mannitol** 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Mannitol 20%:** 1-1.5 g/kg IV bolus (e.g., 100g = 500 mL of 20% for 70 kg patient) over 15-20 minutes; repeat doses: 0.25-0.5 g/kg q4-6h PRN; **Hold if:** serum osmolality >320 mOsm/kg, osmolar gap >15-20; **Requires:** Foley catheter (massive diuresis); volume replacement; **Onset:** 15-30 min; **Duration:** 2-6 hours",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "elevated-icp-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BTF: Level II evidence",
          "Creates osmotic gradient → draws water from brain parenchyma",
          "also improves blood rheology",
          "monitor for renal toxicity (ATN), hypovolemia, rebound edema",
          "reduces brain volume"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "elevated-icp-management"
      ]
    },
    "osmotherapy-mannitol-20": {
      "id": "osmotherapy-mannitol-20",
      "name": "Osmotherapy: Mannitol 20%",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-1.5 g/kg",
              "orderSentence": "Osmotherapy: Mannitol 20% 1-1.5 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g/kg IV bolus for acute herniation; 0.25-0.5 g/kg q4-6h maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Anuria, severe dehydration"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Serum osmolality (hold if >320 mOsm/kg), osmolar gap, renal function, I/O"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-ischemic-stroke"
      ]
    },
    "outpatient-parenteral-antibiotic-therapy": {
      "id": "outpatient-parenteral-antibiotic-therapy",
      "name": "Outpatient parenteral antibiotic therapy (OPAT)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "**Outpatient parenteral antibiotic therapy (OPAT)** N/A PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Once clinically stable (afebrile, pain controlled, neurologically stable, adequate PO intake, safe home environment); PICC in place; infusion teaching completed; close ID follow-up (weekly visits); VNA nursing for line care",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epidural-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Reduces hospital stay",
          "comparable outcomes to inpatient therapy in appropriate patients",
          "weekly ID visits with labs (CBC, CMP, drug levels, CRP)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epidural-abscess"
      ]
    },
    "oxazepam-po": {
      "id": "oxazepam-po",
      "name": "Oxazepam PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "withdrawal-management-in-severe-liver-disease-no-active-meta": {
          "indication": "Withdrawal management in severe liver disease; no active metabolites",
          "doseOptions": [
            {
              "text": "15-30 mg",
              "orderSentence": "Oxazepam PO 15-30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-30 mg PO q6-8h; CIWA-Ar guided; no active metabolites; safest in severe hepatic impairment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe respiratory depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CIWA-Ar",
          "shorter half-life requires frequent monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure"
      ]
    },
    "oxcarbazepine": {
      "id": "oxcarbazepine",
      "name": "Oxcarbazepine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "150-300 mg",
              "orderSentence": "Oxcarbazepine (Trileptal) 150-300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150-300 mg BID; increase by 300 mg/week; target 600-1800 mg/day",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "trigeminal-neuralgia"
          ]
        },
        "trigeminal-neuralgia-lancinating-pain": {
          "indication": "Trigeminal neuralgia, lancinating pain",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Oxcarbazepine 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg BID; increase by 300 mg every 3 days; max 1200 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "trigeminal-neuralgia": {
          "indication": "Trigeminal neuralgia",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Oxcarbazepine 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg BID; increase by 300 mg every 3 days; max 1200 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "focal-epilepsy-better-tolerated-than-carbamazepine-fewer-dru": {
          "indication": "Focal epilepsy; better tolerated than carbamazepine; fewer drug interactions",
          "doseOptions": [
            {
              "text": "150 mg BID",
              "orderSentence": "Oxcarbazepine (Trileptal) 150 mg BID PO"
            },
            {
              "text": "300 mg BID",
              "orderSentence": "Oxcarbazepine (Trileptal) 300 mg BID PO"
            },
            {
              "text": "600 mg BID",
              "orderSentence": "Oxcarbazepine (Trileptal) 600 mg BID PO"
            },
            {
              "text": "900 mg BID",
              "orderSentence": "Oxcarbazepine (Trileptal) 900 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 150-300 mg BID; increase by 300 mg/day q1wk; target 600-1200 mg BID; max 2400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "focal-seizures": {
          "indication": "Focal seizures",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Oxcarbazepine 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 300 mg PO BID; increase by 300-600 mg/day every week; target 1200-2400 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "HLA-B*15:02 positive (SJS risk)",
          "Hypersensitivity to carbamazepine",
          "Severe hyponatremia",
          "hyponatremia",
          "less drug interactions than CBZ"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC, LFTs less critical",
          "HLA-B*1502 screening",
          "HLA-B*1502 screening in at-risk populations",
          "MHD level if needed",
          "Na (hyponatremia more common)",
          "Sodium (hyponatremia in 2-3%)",
          "Sodium (hyponatremia risk)",
          "Sodium q1-3 months (SIADH in 2-3%)",
          "rash"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "epilepsy-chronic-management",
        "ms-new-diagnosis",
        "new-onset-seizure",
        "peripheral-neuropathy",
        "trigeminal-neuralgia"
      ]
    },
    "oxybutynin": {
      "id": "oxybutynin",
      "name": "Oxybutynin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "neurogenic-bladder-urgency-frequency-from-myelopathic-nbd": {
          "indication": "Neurogenic bladder (urgency, frequency) from myelopathic NBD",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxybutynin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO BID; increase to 5 mg TID as needed; max 20 mg/day; extended-release 5-30 mg daily available",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "urinary-urgency-incontinence": {
          "indication": "Urinary urgency/incontinence",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxybutynin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID; may increase to 5 mg TID; or use ER 10-30 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "normal-pressure-hydrocephalus"
          ]
        },
        "bladder-dysfunction-neurogenic-bladder-in-tabes-dorsalis-urg": {
          "indication": "Bladder dysfunction (neurogenic bladder in tabes dorsalis; urgency/incontinence)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxybutynin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID; may increase to 5 mg TID; max 15 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "bladder-urgency-frequency": {
          "indication": "Bladder urgency/frequency",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxybutynin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID or 10 mg XL daily; max 30 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "urinary-urgency-use-with-extreme-caution": {
          "indication": "Urinary urgency (use with extreme caution)",
          "doseOptions": [
            {
              "text": "2.5 mg",
              "orderSentence": "Oxybutynin 2.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2.5 mg BID only; avoid higher doses; anticholinergic burden worsens cognition",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "neurogenic-bladder-urgency-frequency-from-myelitis": {
          "indication": "Neurogenic bladder urgency/frequency from myelitis",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxybutynin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID; max 5 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "neurogenic-bladder-urgency-frequency": {
          "indication": "Neurogenic bladder urgency/frequency",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxybutynin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID; max 5 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "neurogenic-detrusor-overactivity-urinary-urgency-frequency-i": {
          "indication": "Neurogenic detrusor overactivity — urinary urgency/frequency/incontinence",
          "doseOptions": [
            {
              "text": "2.5 mg BID",
              "orderSentence": "Oxybutynin (Ditropan) 2.5 mg BID PO"
            },
            {
              "text": "5 mg BID",
              "orderSentence": "Oxybutynin (Ditropan) 5 mg BID PO"
            },
            {
              "text": "5 mg TID",
              "orderSentence": "Oxybutynin (Ditropan) 5 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2.5 mg BID; titrate to 5 mg BID-TID; max 20 mg/day; ER formulation preferred (less cognitive impairment)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "neurogenic-bladder-with-urgency-and-urge-incontinence-from-u": {
          "indication": "Neurogenic bladder with urgency and urge incontinence from upper motor neuron dysfunction",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxybutynin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg PO BID-TID; extended-release: 5-10 mg PO daily; max 20 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "neurogenic-bladder-overactive": {
          "indication": "Neurogenic bladder (overactive)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxybutynin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg PO BID-TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI obstruction",
          "Narrow-angle glaucoma",
          "Uncontrolled narrow-angle glaucoma",
          "Uncontrolled narrow-angle glaucoma, urinary retention, GI obstruction, myasthenia gravis",
          "Urinary retention",
          "Urinary retention (use only for overactive bladder, NOT retention)",
          "angle-closure glaucoma",
          "dementia (relative)",
          "myasthenia gravis",
          "uncontrolled narrow-angle glaucoma",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anticholinergic effects",
          "Anticholinergic effects (dry mouth, constipation, confusion)",
          "Anticholinergic side effects",
          "Cognitive function (especially elderly), post-void residual, dry mouth, constipation",
          "Cognitive worsening",
          "PVR",
          "Post-void residual",
          "anticholinergic effects (cognition in elderly)",
          "anticholinergic side effects (dry mouth, constipation, cognitive impairment in elderly)",
          "cognition in elderly",
          "cognitive effects (especially elderly)",
          "cognitive effects in elderly",
          "cognitive worsening",
          "dry mouth",
          "post-void residual",
          "post-void residual if retention suspected"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "acute-myelopathy",
        "cervical-myelopathy",
        "lewy-body-dementia",
        "mogad",
        "multiple-system-atrophy",
        "neuro-behcets-disease",
        "neurosyphilis",
        "nmosd",
        "normal-pressure-hydrocephalus",
        "small-fiber-neuropathy"
      ]
    },
    "oxybutynin-er": {
      "id": "oxybutynin-er",
      "name": "Oxybutynin ER",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "bladder-urgency": {
          "indication": "Bladder urgency",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Oxybutynin ER 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg daily; max 30 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as IR"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same",
          "fewer anticholinergic side effects than IR"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ms-new-diagnosis"
      ]
    },
    "oxybutynin-ir": {
      "id": "oxybutynin-ir",
      "name": "Oxybutynin IR",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "bladder-urgency-anticholinergic-caution-in-neuropathy": {
          "indication": "Bladder urgency (anticholinergic caution in neuropathy)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxybutynin IR 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID-TID; max 5 mg QID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "bladder-urgency": {
          "indication": "Bladder urgency",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxybutynin IR 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg BID-TID; max 5 mg QID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI obstruction",
          "Urinary retention",
          "narrow-angle glaucoma",
          "uncontrolled narrow-angle glaucoma"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dry mouth, constipation, cognitive impairment",
          "Dry mouth, constipation, cognitive impairment (especially elderly)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-new-diagnosis",
        "peripheral-neuropathy"
      ]
    },
    "oxycodone": {
      "id": "oxycodone",
      "name": "Oxycodone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "moderate-to-severe-pain-for-patients-tolerating-oral-medicat": {
          "indication": "Moderate to severe pain for patients tolerating oral medications; transition from IV opioids",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "**Oxycodone (oral pain management)** 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Oxycodone 5-10 mg PO q4-6h PRN; titrate to pain control; start bowel regimen concurrently; avoid NSAIDs with IT MTX or thrombocytopenia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "moderate-severe-radicular-pain-short-term": {
          "indication": "Moderate-severe radicular pain (short-term)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Oxycodone 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO q4-6h PRN; for short-term use only",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "moderate-severe-pain-if-able-to-swallow": {
          "indication": "Moderate-severe pain (if able to swallow)",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Oxycodone 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO q4-6h PRN",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "MAOIs",
          "Respiratory depression",
          "Same as morphine",
          "concurrent CNS depressants",
          "obtundation",
          "paralytic ileus",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Pain scores q4h",
          "Same as morphine",
          "Sedation",
          "bowel regimen compliance",
          "constipation",
          "dependence (Schedule II)",
          "respiratory status",
          "sedation level"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "guillain-barre-syndrome",
        "leptomeningeal-carcinomatosis",
        "radiculopathy"
      ]
    },
    "oxycodone-acetaminophen": {
      "id": "oxycodone-acetaminophen",
      "name": "Oxycodone/Acetaminophen",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "moderate-severe-radicular-pain-short-term": {
          "indication": "Moderate-severe radicular pain (short-term)",
          "doseOptions": [
            {
              "text": "5/325 mg",
              "orderSentence": "Oxycodone/Acetaminophen 5/325 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10/325 mg q4-6h PRN; max acetaminophen 3000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Respiratory depression",
          "hepatic impairment",
          "paralytic ileus"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs",
          "Sedation",
          "respiratory status",
          "total acetaminophen intake"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "radiculopathy"
      ]
    },
    "oxycodone-er": {
      "id": "oxycodone-er",
      "name": "Oxycodone ER",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "severe-refractory-pain": {
          "indication": "Severe refractory pain",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Oxycodone ER 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg q12h; titrate every 1-2 days",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as morphine"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same",
          "Schedule II"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "peripheral-neuropathy"
      ]
    },
    "oxygen": {
      "id": "oxygen",
      "name": "Oxygen (high-flow)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "INH"
      ],
      "formulations": [],
      "contexts": {
        "suspected-cluster-headache-unilateral-periorbital-pain-with-": {
          "indication": "Suspected cluster headache (unilateral periorbital pain with autonomic features)",
          "doseOptions": [
            {
              "text": "100%",
              "orderSentence": "Oxygen (high-flow) 100% INH"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100% O2 via non-rebreather mask at 12-15 L/min x 15-20 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Oxygen saturation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "headache-evaluation"
      ]
    },
    "oxygen-supplementation": {
      "id": "oxygen-supplementation",
      "name": "Oxygen supplementation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "INH"
      ],
      "formulations": [],
      "contexts": {
        "hypoxemia": {
          "indication": "Hypoxemia",
          "doseOptions": [
            {
              "text": "1-4 L/min NC PRN",
              "orderSentence": "Oxygen supplementation 1-4 L/min NC PRN INH"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Use cautiously; O2 may suppress respiratory drive; BiPAP preferred; use only for hypoxemia with BiPAP",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "May suppress respiratory drive in hypercapnic patients"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "SpO2, pCO2, respiratory rate"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "ozanimod": {
      "id": "ozanimod",
      "name": "Ozanimod (Zeposia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.23 mg",
              "orderSentence": "Ozanimod (Zeposia) 0.23 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Titration: 0.23 mg × 4d, 0.46 mg × 3d, then 0.92 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same",
          "Same as fingolimod",
          "concurrent MAOIs"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same",
          "Similar to fingolimod",
          "less first-dose effect",
          "macular edema screen",
          "no first-dose observation required (slower titration)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "pain-crisis-management": {
      "id": "pain-crisis-management",
      "name": "Pain crisis management",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "severe-acute-neuropathic-pain-flare-not-responding-to-outpat": {
          "indication": "Severe acute neuropathic pain flare not responding to outpatient regimen",
          "doseOptions": [
            {
              "text": "Multimodal",
              "orderSentence": "Pain crisis management Multimodal IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "IV lidocaine infusion (1-3 mg/kg/hr) if refractory; avoid chronic opioids",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Lidocaine: cardiac conduction abnormality"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Pain scores",
          "cardiac monitoring for lidocaine"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "small-fiber-neuropathy"
      ]
    },
    "pain-management": {
      "id": "pain-management",
      "name": "Pain management",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "**Pain management** 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Pain in GBS is common (60-90%) and often severe; neuropathic pain; back pain; radicular pain; **Treatment:** Gabapentin 300 mg TID → titrate; pregabalin; opioids PRN; AVOID NSAIDs if renal concerns",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuromuscular-respiratory-failure",
            "epidural-abscess",
            "spinal-cord-compression-malignant",
            "cauda-equina-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Adequate analgesia essential for patient assessment and MRI tolerance",
          "Pain can be as debilitating as weakness",
          "Pain is the presenting symptom in 83-95% of patients",
          "Severe pain is hallmark of SEA",
          "adequate analgesia essential for function and quality of life",
          "adequate analgesia is essential",
          "balance with need for neurologic monitoring",
          "gabapentinoids first-line",
          "median 7 weeks before diagnosis",
          "multimodal approach"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "cauda-equina-syndrome",
        "epidural-abscess",
        "neuromuscular-respiratory-failure",
        "spinal-cord-compression-malignant"
      ]
    },
    "pantoprazole": {
      "id": "pantoprazole",
      "name": "Pantoprazole",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/PO",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "gi-prophylaxis-if-on-steroids": {
          "indication": "GI prophylaxis (if on steroids)",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis"
          ]
        },
        "gi-bleed-prevention-while-on-dexamethasone-combined-corticos": {
          "indication": "GI bleed prevention while on dexamethasone; combined corticosteroid + critical illness increases risk",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole (stress ulcer prophylaxis) 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Pantoprazole 40 mg IV/PO daily OR omeprazole 20 mg PO daily; continue throughout steroid course",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "gi-prophylaxis-cushing-ulcer-risk-from-elevated-icp": {
          "indication": "GI prophylaxis (Cushing ulcer risk from elevated ICP)",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        },
        "gi-prophylaxis-during-steroid-therapy-for-iris-stress-ulcer-": {
          "indication": "GI prophylaxis during steroid therapy for IRIS; stress ulcer prevention in ICU",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV or PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "gi-prophylaxis-if-steroids-or-critical-illness": {
          "indication": "GI prophylaxis (if steroids or critical illness)",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "hsv-encephalitis"
          ]
        },
        "gi-prophylaxis-if-receiving-dexamethasone-or-if-critical-ill": {
          "indication": "GI prophylaxis if receiving dexamethasone or if critical illness",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily; discontinue when dexamethasone stopped",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "gi-prophylaxis-for-patients-on-antithrombotic-therapy-stress": {
          "indication": "GI prophylaxis for patients on antithrombotic therapy; stress ulcer prevention",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "gi-bleed-prevention-while-on-dexamethasone-if-steroids-were-": {
          "indication": "GI bleed prevention while on dexamethasone (if steroids were initiated); combined corticosteroid + critical illness increases risk",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole (stress ulcer prophylaxis) 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Pantoprazole 40 mg IV/PO daily OR omeprazole 20 mg PO daily; continue throughout steroid course",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "stress-ulcer-prophylaxis": {
          "indication": "Stress ulcer prophylaxis",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "gi-prophylaxis-during-corticosteroid-therapy-stress-ulcer-pr": {
          "indication": "GI prophylaxis during corticosteroid therapy; stress ulcer prevention in ICU; steroid-induced gastropathy prevention",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole (CPT 96374) 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily; discontinue when steroids stopped and no longer in ICU",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "gi-prophylaxis-stress-ulcer": {
          "indication": "GI prophylaxis (stress ulcer)",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "gi-stress-ulcer-prophylaxis-post-arrest-patients-at-high-ris": {
          "indication": "GI stress ulcer prophylaxis; post-arrest patients at high risk",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV daily; transition to PO when tolerating",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "gi-prophylaxis-steroids-critical-illness": {
          "indication": "GI prophylaxis (steroids + critical illness)",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "gi-prophylaxis-with-steroids-and-critical-illness-stress-ulc": {
          "indication": "GI prophylaxis with steroids and critical illness; stress ulcer prevention",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily; discontinue when steroids stopped and no longer in ICU",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "icu-admission-or-steroid-use": {
          "indication": "ICU admission or steroid use",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole (stress ulcer prophylaxis) (CPT 96374) 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        },
        "gi-bleed-prevention-while-on-dexamethasone-combined-corticos-2": {
          "indication": "GI bleed prevention while on dexamethasone; combined corticosteroid use increases risk",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole (stress ulcer prophylaxis) 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Pantoprazole 40 mg IV/PO daily OR omeprazole 20 mg PO daily; continue throughout steroid course",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "gi-prophylaxis-stress-ulcer-prevention-in-icu-patients": {
          "indication": "GI prophylaxis; stress ulcer prevention in ICU patients",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV or PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "pres"
          ]
        },
        "gi-prophylaxis-steroids-critical-illness-gastroprotection-du": {
          "indication": "GI prophylaxis (steroids + critical illness); gastroprotection during RIPE therapy",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        },
        "alternative-gi-prophylaxis-during-corticosteroid-therapy": {
          "indication": "Alternative GI prophylaxis during corticosteroid therapy",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Pantoprazole 40 mg IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV or PO daily while on corticosteroids",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "C. diff risk",
          "C. diff risk (long-term)",
          "C. diff risk long-term",
          "C. diff risk with prolonged use",
          "C. difficile risk with prolonged use",
          "Hypersensitivity",
          "Long-term use risks (C. diff, hypomagnesemia)",
          "None significant",
          "PPI allergy",
          "Prolonged use C. diff risk",
          "Prolonged use risks",
          "Prolonged use risks (C. diff, osteoporosis)",
          "Prolonged use risks (C. difficile, hypomagnesemia)",
          "avoid long-term use if possible",
          "only while on steroids",
          "only while on steroids or in ICU"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI bleeding",
          "GI symptoms",
          "consider discontinuation when steroids stopped",
          "discontinue when steroids tapered",
          "magnesium with prolonged use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 19,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "anoxic-brain-injury",
        "bacterial-meningitis",
        "brain-abscess",
        "cervical-artery-dissection",
        "cervical-myelopathy",
        "fungal-meningitis",
        "glioblastoma",
        "hsv-encephalitis",
        "intracerebral-hemorrhage",
        "meningioma",
        "myasthenia-gravis-crisis",
        "neurocysticercosis",
        "pres",
        "primary-cns-lymphoma",
        "status-epilepticus",
        "tb-meningitis",
        "thunderclap-headache-evaluation",
        "viral-meningitis"
      ]
    },
    "patisiran": {
      "id": "patisiran",
      "name": "Patisiran (Onpattro)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "hattr-amyloidosis-with-polyneuropathy": {
          "indication": "hATTR amyloidosis with polyneuropathy",
          "doseOptions": [
            {
              "text": "0.3 mg/kg",
              "orderSentence": "Patisiran (Onpattro) 0.3 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.3 mg/kg IV every 3 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None absolute"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Vitamin A supplementation at RDA required (patisiran reduces serum vitamin A via TTR reduction)",
          "infusion reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "peripheral-neuropathy"
      ]
    },
    "pcsk9-inhibitor": {
      "id": "pcsk9-inhibitor",
      "name": "PCSK9 inhibitor (evolocumab or alirocumab)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "140 mg",
              "orderSentence": "PCSK9 inhibitor (evolocumab) 140 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "140 mg SC q2 weeks or 420 mg SC monthly; if LDL not at goal on max statin + ezetimibe",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke",
            "transient-ischemic-attack"
          ]
        },
        "ldl-not-at-goal-despite-max-statin-ezetimibe-fourier-trial-e": {
          "indication": "LDL not at goal despite max statin + ezetimibe; FOURIER trial (evolocumab) showed stroke reduction; Lp(a) elevated",
          "doseOptions": [
            {
              "text": "Evolocumab 140 mg q2wk",
              "orderSentence": "PCSK9 inhibitor (evolocumab or alirocumab) Evolocumab 140 mg q2wk SC"
            },
            {
              "text": "alirocumab 75 mg q2wk",
              "orderSentence": "PCSK9 inhibitor (evolocumab or alirocumab) alirocumab 75 mg q2wk SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Evolocumab 140 mg SC q2 weeks or 420 mg monthly; alirocumab 75 mg SC q2wk (may increase to 150 mg); self-injection training",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity",
          "Lipid panel q4-12 weeks",
          "injection site",
          "injection site reactions"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Lipid panel q3 months",
          "cost/insurance coverage",
          "injection site reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "post-stroke-management",
        "transient-ischemic-attack"
      ]
    },
    "peg-3350": {
      "id": "peg-3350",
      "name": "PEG 3350 (Miralax)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "neurogenic-bowel-constipation-from-myelitis": {
          "indication": "Neurogenic bowel/constipation from myelitis",
          "doseOptions": [
            {
              "text": "17 g daily",
              "orderSentence": "PEG 3350 (Miralax) 17 g daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g (1 capful) in 8 oz water daily; adjust per response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bowel obstruction"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bowel frequency",
          "dehydration"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "nmosd"
      ]
    },
    "peginterferon-beta-1a": {
      "id": "peginterferon-beta-1a",
      "name": "Peginterferon beta-1a (Plegridy)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "125 mcg",
              "orderSentence": "Peginterferon beta-1a (Plegridy) 125 mcg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "125 mcg SC q2 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same",
          "Same as Avonex"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same",
          "less frequent dosing"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "pemetrexed": {
      "id": "pemetrexed",
      "name": "Pemetrexed",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "relapsed-refractory-pcnsl-antifolate-with-cns-activity-singl": {
          "indication": "Relapsed/refractory PCNSL; antifolate with CNS activity; single agent or combination",
          "doseOptions": [
            {
              "text": "900 mg/m2",
              "orderSentence": "Pemetrexed 900 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "900 mg/m2 IV over 10 min q3 weeks; supplement with folic acid 1 mg PO daily and B12 1000 mcg IM q9 weeks (start 7 days before first dose); dexamethasone 4 mg PO BID x3 days starting day before pemetrexed",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CrCl <45",
          "inability to take folic acid/B12 supplementation",
          "pleural effusion (3rd space - delays clearance)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC weekly",
          "LFTs",
          "folic acid and B12 compliance",
          "rash",
          "renal function",
          "signs of toxicity"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "penicillin-desensitization-protocol": {
      "id": "penicillin-desensitization-protocol",
      "name": "Penicillin desensitization protocol (for penicillin-allergic patients)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO then IV"
      ],
      "formulations": [],
      "contexts": {
        "penicillin-allergy-with-no-acceptable-alternative-allows-saf": {
          "indication": "Penicillin allergy with no acceptable alternative; allows safe IV penicillin G administration. Desensitization takes 4-6 hours and must be done in monitored setting (ICU or equivalent)",
          "doseOptions": [
            {
              "text": "See Appendix A",
              "orderSentence": "Penicillin desensitization protocol (for penicillin-allergic patients) See Appendix A PO then IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Oral desensitization protocol over 4-6h (see Appendix A); begin IV penicillin G immediately after desensitization complete; patient must remain on continuous penicillin (no gaps >8h or desensitization is lost)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Anaphylaxis to penicillin (proceed with extreme caution in ICU)",
          "unstable cardiac/respiratory status"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q15min during protocol",
          "Continuous cardiac monitoring",
          "IV access x2",
          "SpO2",
          "crash cart available",
          "epinephrine at bedside"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neurosyphilis"
      ]
    },
    "penicillin-g": {
      "id": "penicillin-g",
      "name": "Penicillin G (aqueous crystalline) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "first-line-treatment-for-all-forms-of-neurosyphilis-meningea": {
          "indication": "First-line treatment for ALL forms of neurosyphilis (meningeal, meningovascular, general paresis, tabes dorsalis, ocular syphilis, otic syphilis)",
          "doseOptions": [
            {
              "text": "3-4 million units q4h",
              "orderSentence": "Penicillin G (aqueous crystalline) (CPT 96365) 3-4 million units q4h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "18-24 million units/day IV, given as 3-4 million units IV q4h continuously for 10-14 days. Infuse each dose over 30-60 min. Alternative: continuous IV infusion 18-24 million units/day. Duration: minimum 10-14 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "s-pneumoniae-sensitive": {
          "indication": "S. pneumoniae (sensitive)",
          "doseOptions": [
            {
              "text": "4 million units",
              "orderSentence": "Penicillin G (if penicillin-sensitive S. pneumoniae, MIC <0.06) 4 million units IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 million units IV q4h",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        },
        "targeted-therapy-for-penicillin-sensitive-streptococci-most-": {
          "indication": "Targeted therapy for penicillin-sensitive Streptococci (most common brain abscess isolate); adjust based on culture sensitivities",
          "doseOptions": [
            {
              "text": "4 million units",
              "orderSentence": "Penicillin G 4 million units IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 million units IV q4h (24 million units/day); duration 6-8 weeks total; excellent CNS penetration",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "wound-botulism-alternative-to-metronidazole-for-c-botulinum-": {
          "indication": "Wound botulism — alternative to metronidazole for C. botulinum eradication",
          "doseOptions": [
            {
              "text": "3 million units",
              "orderSentence": "Penicillin G (wound botulism — alternative) (CPT 96365) 3 million units IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3 million units IV q4h x 10-14 days",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "botulism"
          ]
        },
        "alternative-parenteral-antibiotic-for-neuroborreliosis-effec": {
          "indication": "Alternative parenteral antibiotic for neuroborreliosis; effective but less commonly used than ceftriaxone due to q4h dosing requirement; reserved for beta-lactam-tolerant patients when ceftriaxone unavailable",
          "doseOptions": [
            {
              "text": "18-24 million units/day",
              "orderSentence": "Penicillin G (aqueous crystalline) 18-24 million units/day IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3-4 million units IV q4h (total 18-24 million units/day) for 14-28 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "AVOID aminoglycosides concurrently (potentiate neuromuscular blockade)",
          "Penicillin allergy",
          "Penicillin anaphylaxis",
          "Penicillin anaphylaxis (perform desensitization -- see below)",
          "dose adjust for severe renal impairment (CrCl <10: 2-3 million units q4h)",
          "use ceftriaxone or meropenem alternative"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Allergic reaction",
          "CBC",
          "Renal function",
          "Renal function (BUN, Cr) daily",
          "interstitial nephritis with prolonged use",
          "monitor for Jarisch-Herxheimer reaction in first 24h",
          "monitor for seizures at very high doses",
          "rash",
          "renal function",
          "seizure risk at very high doses",
          "serum potassium (high-dose penicillin contains potassium)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "bacterial-meningitis",
        "botulism",
        "brain-abscess",
        "lyme-neuroborreliosis",
        "neurosyphilis"
      ]
    },
    "penicillin-g-iv": {
      "id": "penicillin-g-iv",
      "name": "Penicillin G IV (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "18-24 million units",
              "orderSentence": "Penicillin G IV (CPT 96365) 18-24 million units IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "18-24 million units/day IV (3-4 MU q4h) x 14 days",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RPR titer follow-up q3-6 months (4-fold decline expected)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "rapidly-progressive-dementia"
      ]
    },
    "penicillin-g-or-ceftriaxone": {
      "id": "penicillin-g-or-ceftriaxone",
      "name": "Penicillin G or ceftriaxone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "n-meningitidis": {
          "indication": "N. meningitidis",
          "doseOptions": [
            {
              "text": "2g",
              "orderSentence": "Penicillin G or ceftriaxone 2g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Penicillin G 4 MU IV q4h OR Ceftriaxone 2g IV q12h",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "bacterial-meningitis"
      ]
    },
    "pentobarbital": {
      "id": "pentobarbital",
      "name": "Pentobarbital",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "super-refractory-post-anoxic-status-epilepticus-when-midazol": {
          "indication": "Super-refractory post-anoxic status epilepticus (when midazolam/propofol infusions fail)",
          "doseOptions": [
            {
              "text": "5 mg/kg",
              "orderSentence": "Pentobarbital 5 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/kg IV load over 1h (may repeat 5 mg/kg boluses); maintenance 1-5 mg/kg/h; titrate to burst-suppression on cEEG",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hemodynamic instability (severe myocardial depression)",
          "porphyria"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "arterial line",
          "cEEG",
          "ileus",
          "temperature (poikilothermia)",
          "vasopressors (nearly always required)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "anoxic-brain-injury"
      ]
    },
    "pentobarbital-coma": {
      "id": "pentobarbital-coma",
      "name": "Pentobarbital coma",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5-10 mg/kg",
              "orderSentence": "**Pentobarbital coma** 5-10 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**LAST RESORT for refractory ICP**; **Protocol:** Pentobarbital 5-10 mg/kg IV load over 30 min → 1-3 mg/kg/hr infusion; titrate to ICP <22 mmHg or burst suppression on EEG; **Target:** Burst suppression (3-10 second bursts with 10-20 second suppression); **Monitor:** Continuous EEG; drug levels (30-50 mcg/mL); hemodynamics (causes hypotension — often need vasopressors); **Duration:** 24-48h then attempt to wean; may need 3-5 days",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "elevated-icp-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Reduces CMRO2 to minimal levels",
          "causes severe hypotension (need vasopressors)",
          "dramatic ICP reduction",
          "ileus",
          "immunosuppression",
          "no proven mortality benefit but reduces ICP",
          "prolonged sedation",
          "requires ICU expertise"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "elevated-icp-management"
      ]
    },
    "pentobarbital-infusion": {
      "id": "pentobarbital-infusion",
      "name": "Pentobarbital infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5-15 mg/kg",
              "orderSentence": "Pentobarbital infusion 5-15 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 5-15 mg/kg IV at 50 mg/min; Infusion: start 0.5-1 mg/kg/hr, titrate to burst suppression; max 5 mg/kg/hr",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "super-refractory-ncse-failing-midazolam-and-propofol": {
          "indication": "Super-refractory NCSE failing midazolam and propofol",
          "doseOptions": [
            {
              "text": "5 mg/kg",
              "orderSentence": "Pentobarbital infusion 5 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Loading: 5-15 mg/kg IV (max rate 50 mg/min); Infusion: 0.5-5 mg/kg/hr; titrate to EEG burst suppression; very prolonged recovery; paralytic ileus common",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe cardiac dysfunction",
          "Severe hemodynamic instability without vasopressor support",
          "porphyria"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous EEG",
          "cEEG, BP (significant hypotension - need pressors), cardiac output",
          "drug level",
          "hemodynamics (vasopressors usually needed)",
          "ileus",
          "immunosuppression (prolonged use)",
          "longest half-life",
          "temperature (hypothermia)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ncse",
        "status-epilepticus"
      ]
    },
    "per-oral-image-guided-gastrostomy": {
      "id": "per-oral-image-guided-gastrostomy",
      "name": "Per-oral image-guided gastrostomy (PIG)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "—"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-peg-rig": {
          "indication": "Alternative to PEG/RIG",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Per-oral image-guided gastrostomy (PIG) N/A —"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Transoral placement under endoscopic and radiologic guidance; may tolerate lower FVC",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as RIG"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Weight, tube site"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "perampanel": {
      "id": "perampanel",
      "name": "Perampanel (Fycompa)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-adjunctive-therapy-non-competitive-ampa-receptor-antagon": {
          "indication": "DRE adjunctive therapy; non-competitive AMPA receptor antagonist; unique mechanism for rational polytherapy",
          "doseOptions": [
            {
              "text": "2 mg qHS",
              "orderSentence": "Perampanel (Fycompa) 2 mg qHS PO"
            },
            {
              "text": "4 mg qHS",
              "orderSentence": "Perampanel (Fycompa) 4 mg qHS PO"
            },
            {
              "text": "8 mg qHS",
              "orderSentence": "Perampanel (Fycompa) 8 mg qHS PO"
            },
            {
              "text": "12 mg qHS",
              "orderSentence": "Perampanel (Fycompa) 12 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg qHS; increase by 2 mg every 1-2 weeks; target 4-8 mg qHS; max 12 mg qHS (8 mg with enzyme inducers); take at bedtime",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "4-8 mg",
              "orderSentence": "Perampanel (enteral) 4-8 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4-8 mg via NGT daily; titrate to 12 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "adjunctive-for-focal-or-gtcs": {
          "indication": "Adjunctive for focal or GTCS",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Perampanel 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg qHS; increase by 2 mg weekly; target 8-12 mg qHS; max 12 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None absolute",
          "Severe hepatic/renal impairment",
          "concurrent enzyme inducers accelerate metabolism"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "**BLACK BOX: Serious psychiatric/behavioral reactions** (aggression, hostility, irritability, homicidal ideation)",
          "Aggression, sedation",
          "Psychiatric effects (aggression, hostility)",
          "Schedule III",
          "dizziness",
          "falls (especially elderly)",
          "mood monitoring",
          "take at bedtime"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "drug-resistant-epilepsy",
        "new-onset-seizure",
        "status-epilepticus"
      ]
    },
    "percutaneous-endoscopic-gastrostomy": {
      "id": "percutaneous-endoscopic-gastrostomy",
      "name": "Percutaneous endoscopic gastrostomy (PEG)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "—"
      ],
      "formulations": [],
      "contexts": {
        "dysphagia-with-weight-loss-10-or-fvc-declining-toward-50": {
          "indication": "Dysphagia with weight loss >10% or FVC declining toward 50%",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Percutaneous endoscopic gastrostomy (PEG) N/A —"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Place electively when FVC >50% predicted; allows continued oral intake for pleasure; start tube feeds gradually",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "FVC <50% (higher risk",
          "consider RIG or PIG)",
          "severe coagulopathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Weight, tube site, aspiration"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "phenobarbital": {
      "id": "phenobarbital",
      "name": "Phenobarbital",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-post-anoxic-status-epilepticus-third-line-asm": {
          "indication": "Refractory post-anoxic status epilepticus (third-line ASM)",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Phenobarbital 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg IV load at 50-75 mg/min; then 1-3 mg/kg/day maintenance; target level 20-40 ug/mL",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "refractory-or-resource-limited": {
          "indication": "Refractory or resource-limited",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Phenobarbital 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load 15-20 mg/kg IV; maintenance 1-3 mg/kg/day (60-180 mg/day); target level 15-40 Î¼g/mL",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Phenobarbital (refractory) 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 15-20 mg/kg IV (max rate 60 mg/min); Maintenance: 1-3 mg/kg/day (target level 15-40 mcg/mL)",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Porphyria",
          "Severe respiratory depression",
          "Severe respiratory depression (intubated patients only)",
          "acute intermittent porphyria",
          "porphyria",
          "severe respiratory disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP (causes hypotension)",
          "Drug level",
          "Respiratory depression",
          "Sedation",
          "cognitive effects",
          "drug interactions (CYP inducer)",
          "drug level",
          "hypotension",
          "level monitoring",
          "respiratory status",
          "sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "autoimmune-encephalitis",
        "new-onset-seizure"
      ]
    },
    "phenobarbital-iv": {
      "id": "phenobarbital-iv",
      "name": "Phenobarbital IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-alcohol-withdrawal-not-controlled-by-benzodiazepi": {
          "indication": "Refractory alcohol withdrawal not controlled by benzodiazepines alone; synergistic with benzodiazepines at GABA-A receptor",
          "doseOptions": [
            {
              "text": "130-260 mg",
              "orderSentence": "Phenobarbital IV 130-260 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "130-260 mg IV q15-30 min, titrate to symptom control; max loading 10-20 mg/kg; maintenance 32-65 mg IV/PO q8-12h; can be used as primary agent or adjunct",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Phenobarbital IV 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg IV at 50-100 mg/min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "second-line-if-other-agents-fail-potent-gabaergic": {
          "indication": "Second-line if other agents fail; potent GABAergic",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Phenobarbital IV 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg IV (max rate 60 mg/min); additional 5-10 mg/kg if needed; maintenance: 1-3 mg/kg/day (target level 15-40 mcg/mL)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Porphyria",
          "Severe respiratory depression",
          "Severe respiratory disease, porphyria",
          "hepatic failure",
          "porphyria",
          "severe respiratory disease (unless intubated)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "RR (respiratory depression additive with benzodiazepines)",
          "Respiratory depression",
          "drug level",
          "hypotension",
          "intubation equipment at bedside",
          "intubation may be needed",
          "often requires intubation at this dose",
          "phenobarbital level if prolonged use",
          "sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "ncse",
        "status-epilepticus"
      ]
    },
    "phenylephrine": {
      "id": "phenylephrine",
      "name": "Phenylephrine (CPT 96365, 96366)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "post-cea-or-post-cas-hypotension-from-baroreceptor-stimulati": {
          "indication": "Post-CEA or post-CAS hypotension from baroreceptor stimulation; more common after CAS (carotid sinus manipulation); maintain cerebral perfusion",
          "doseOptions": [
            {
              "text": "40 mcg",
              "orderSentence": "Phenylephrine (CPT 96365, 96366) 40 mcg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40-100 mcg IV bolus q1-2min PRN; or infusion 10-200 mcg/min; titrate to SBP >100 or per clinical status; baroreceptor-mediated hypotension usually self-limited (24-72h)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "MAO inhibitor use",
          "Severe hypertension",
          "peripheral vascular disease (digital ischemia)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous BP and HR via arterial line",
          "I/O",
          "end-organ perfusion",
          "typically wean within 24-72h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "carotid-stenosis"
      ]
    },
    "phenytoin": {
      "id": "phenytoin",
      "name": "Phenytoin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO",
        "PO/IV"
      ],
      "formulations": [],
      "contexts": {
        "third-line-for-eclamptic-seizures-refractory-to-mgso4-loraze": {
          "indication": "Third-line for eclamptic seizures refractory to MgSO4 + lorazepam; historically used but INFERIOR to MgSO4 for eclampsia",
          "doseOptions": [
            {
              "text": "20 mg PE/kg IV",
              "orderSentence": "Phenytoin (fosphenytoin) 20 mg PE/kg IV IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg phenytoin equivalents (PE)/kg IV at ≤150 mg PE/min; maintenance 5 mg PE/kg/day; check free phenytoin level (protein binding altered in pregnancy)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "continue-after-fosphenytoin-loading": {
          "indication": "Continue after fosphenytoin loading",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Phenytoin (maintenance) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-200 mg PO BID or TID (target level 10-20 mcg/mL total; 1-2 mcg/mL free)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "nystagmus-is-dose-dependent-toxicity-sign-gaze-evoked-nystag": {
          "indication": "Nystagmus is dose-dependent toxicity sign; gaze-evoked nystagmus appears before ataxia; monitor levels",
          "doseOptions": [
            {
              "text": "Monitor levels",
              "orderSentence": "**Phenytoin (high-dose / supratherapeutic)** Monitor levels PO/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Free phenytoin level; nystagmus = early toxicity warning; reduce dose immediately if nystagmus develops",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        },
        "second-line-for-myotonia-if-mexiletine-and-carbamazepine-not": {
          "indication": "Second-line for myotonia if mexiletine and carbamazepine not tolerated; sodium channel blocker with antimyotonic properties",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Phenytoin 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg PO TID; adjust based on levels; target level 10-20 mcg/mL; extended-release: 200-300 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "focal-or-generalized": {
          "indication": "Focal or generalized",
          "doseOptions": [
            {
              "text": "300-400 mg",
              "orderSentence": "Phenytoin 300-400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300-400 mg daily (extended release) or divided TID (immediate release); adjust by level",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**TERATOGENIC** (fetal hydantoin syndrome) — use only if no alternative",
          "AV block",
          "AV block (without pacemaker)",
          "Avoid in absence seizures",
          "Pregnancy (relative - fetal hydantoin syndrome)",
          "Sinus bradycardia",
          "Stokes-Adams syndrome",
          "cardiac conduction disease in DM1 (use with extreme caution)",
          "hepatic disease",
          "hypersensitivity",
          "porphyria",
          "second/third-degree AV block"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "CBC",
          "CBC, LFTs",
          "Cardiac monitoring during infusion",
          "Drug level (total and free)",
          "ECG",
          "Free phenytoin level",
          "Free phenytoin level (target 1-2 Î¼g/mL)",
          "LFTs",
          "Phenytoin level (therapeutic 10-20 mcg/mL)",
          "calcium/vitamin D (chronic use depletes)",
          "drug interactions (potent enzyme inducer)",
          "fetal monitoring",
          "free phenytoin level (not total)",
          "gingival health",
          "gingival hyperplasia",
          "gingival hyperplasia, hirsutism",
          "nystagmus is early warning sign of toxicity",
          "osteoporosis",
          "total level 10-20 Î¼g/mL"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy",
        "myotonic-dystrophy",
        "ncse",
        "new-onset-seizure",
        "nystagmus-evaluation"
      ]
    },
    "phenytoin-dose-adjustment-or-discontinuation": {
      "id": "phenytoin-dose-adjustment-or-discontinuation",
      "name": "Phenytoin dose adjustment or discontinuation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "phenytoin-toxicity-causing-cerebellar-ataxia-most-common-dru": {
          "indication": "Phenytoin toxicity causing cerebellar ataxia (most common drug-induced cause); supratherapeutic level",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Phenytoin dose adjustment or discontinuation N/A IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Hold phenytoin; recheck level in 24-48h; resume at lower dose or switch to alternative AED; chronic toxicity may cause permanent cerebellar damage",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Do not abruptly discontinue if on for seizures — taper and bridge"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Repeat phenytoin level q12-24h until therapeutic",
          "monitor for seizure breakthrough if reducing dose"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ataxia-evaluation"
      ]
    },
    "phenytoin-fosphenytoin": {
      "id": "phenytoin-fosphenytoin",
      "name": "Phenytoin/fosphenytoin (acute refractory)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-seizure-control-if-first-line-agents-insufficient": {
          "indication": "Acute seizure control if first-line agents insufficient",
          "doseOptions": [
            {
              "text": "20 mg PE/kg",
              "orderSentence": "Phenytoin/fosphenytoin (acute refractory) 20 mg PE/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Fosphenytoin: 20 mg PE/kg IV (max rate 150 mg PE/min); Maintenance: 5-7 mg/kg/day divided BID-TID (target level 10-20 mcg/mL)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "refractory-seizures-second-line-after-levetiracetam": {
          "indication": "Refractory seizures (second-line after levetiracetam)",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Phenytoin/Fosphenytoin 20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Fosphenytoin 20 mg PE/kg IV at 150 mg PE/min; maintenance 100 mg PE q8h; target level 10-20 µg/mL",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hsv-encephalitis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Phenytoin/fosphenytoin (refractory) 20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Fosphenytoin: 20 mg PE/kg IV (max rate 150 mg PE/min); Maintenance: 5-7 mg/kg/day divided BID-TID (target level 10-20 mcg/mL)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "AV block",
          "Bradycardia, heart block, hypotension (infusion rate-related)",
          "bradycardia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous cardiac monitoring during load",
          "Continuous telemetry during load",
          "LFTs",
          "drug level",
          "free phenytoin level",
          "gingival hyperplasia",
          "purple glove syndrome (peripheral IV)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "hashimotos-encephalopathy",
        "hsv-encephalitis"
      ]
    },
    "phenytoin-iv": {
      "id": "phenytoin-iv",
      "name": "Phenytoin IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg/kg",
              "orderSentence": "Phenytoin IV 20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg/kg IV at max 50 mg/min (if fosphenytoin unavailable)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "if-fosphenytoin-unavailable": {
          "indication": "If fosphenytoin unavailable",
          "doseOptions": [
            {
              "text": "20 mg/kg",
              "orderSentence": "Phenytoin IV 20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg/kg IV at max 50 mg/min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "AV block, sinus bradycardia",
          "AV block, sinus bradycardia, pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cardiac monitor",
          "Cardiac monitor, BP",
          "MUST use large vein, tissue necrosis risk",
          "give via large vein (tissue necrosis risk)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "new-onset-seizure",
        "status-epilepticus"
      ]
    },
    "phosphorus-replacement": {
      "id": "phosphorus-replacement",
      "name": "Phosphorus replacement",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Phosphorus replacement N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If low (refeeding); K-Phos or Na-Phos IV/PO",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wernicke-encephalopathy"
          ]
        },
        "hypophosphatemia-correction-common-in-alcoholism-and-refeedi": {
          "indication": "Hypophosphatemia correction; common in alcoholism and refeeding",
          "doseOptions": [
            {
              "text": "15-45 mmol IV or 250 mg PO",
              "orderSentence": "Phosphorus replacement 15-45 mmol IV or 250 mg PO IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Mild (2.0-2.5): K-Phos 250 mg PO TID; Moderate (1.0-2.0): NaPhos 15-30 mmol IV over 4-6h; Severe (<1.0): 30-45 mmol IV over 6h",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypercalcite",
          "Hyperphosphatemia",
          "renal failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Phos levels",
          "Phosphorus levels q12-24h",
          "calcium (inversely related)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "wernicke-encephalopathy"
      ]
    },
    "picc-line-placement": {
      "id": "picc-line-placement",
      "name": "PICC line placement",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "**PICC line placement** N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If prolonged IV antibiotics planned (6-8 weeks); enables outpatient IV therapy (OPAT); placed once stabilized and duration confirmed; confirm tip position with X-ray",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epidural-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Required for OPAT",
          "monitor for PICC-associated infection",
          "reduces peripheral IV complications"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epidural-abscess"
      ]
    },
    "pimavanserin": {
      "id": "pimavanserin",
      "name": "Pimavanserin (Nuplazid)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "visual-hallucinations-and-psychosis": {
          "indication": "Visual hallucinations and psychosis",
          "doseOptions": [
            {
              "text": "34 mg",
              "orderSentence": "Pimavanserin (Nuplazid) 34 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "34 mg once daily; takes 4-6 weeks for effect; no titration; selective 5-HT2A inverse agonist",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "34 mg",
              "orderSentence": "Pimavanserin (Nuplazid) 34 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "34 mg daily; for PD psychosis",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis",
            "dementia-evaluation"
          ]
        },
        "parkinson-s-disease-psychosis-hallucinations-delusions": {
          "indication": "Parkinson's disease psychosis (hallucinations, delusions)",
          "doseOptions": [
            {
              "text": "34 mg daily",
              "orderSentence": "Pimavanserin (Nuplazid) 34 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "34 mg once daily; takes 4-6 weeks for effect; no titration needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "QTc prolongation",
          "Severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "QTc",
          "QTc at baseline",
          "QTc monitoring",
          "QTc, efficacy assessment at 6 weeks",
          "efficacy assessment 6 weeks"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "dementia-evaluation",
        "lewy-body-dementia",
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "pimozide": {
      "id": "pimozide",
      "name": "Pimozide (Orap)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "fda-approved-for-tourette-syndrome-reserved-for-refractory-c": {
          "indication": "FDA-approved for Tourette syndrome; reserved for refractory cases due to QTc risk",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Pimozide (Orap) 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg qHS; increase by 0.5-1 mg q1wk; target 2-4 mg/day; max 10 mg/day (0.2 mg/kg/day in children); CYP2D6 genotyping recommended at doses >4 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QTc >440 msec (males) or >450 msec (females)",
          "concurrent QTc-prolonging drugs",
          "congenital long QT",
          "hypokalemia",
          "strong CYP3A4/CYP2D6 inhibitors"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CYP2D6 genotyping",
          "ECG at baseline, each dose increase, and q6mo",
          "EPS/TD (AIMS q3-6mo)",
          "QTc must remain <470 msec",
          "sedation",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tics-tourette-syndrome"
      ]
    },
    "pimozide-dose-reduction": {
      "id": "pimozide-dose-reduction",
      "name": "Pimozide dose reduction",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "when-pimozide-is-causative-agent-slow-taper-required": {
          "indication": "When pimozide is causative agent; slow taper required",
          "doseOptions": [
            {
              "text": "-",
              "orderSentence": "Pimozide dose reduction - PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Reduce by 25% q1-2 weeks; do not discontinue abruptly; coordinate with psychiatry for alternative",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active psychosis without alternative (coordinate with psychiatry)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG (QTc prolongation), psychiatric status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-induced-parkinsonism"
      ]
    },
    "piracetam": {
      "id": "piracetam",
      "name": "Piracetam (adjunctive for myoclonus)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "cortical-myoclonus-may-be-effective-for-cjd-myoclonus-not-fd": {
          "indication": "Cortical myoclonus -- may be effective for CJD myoclonus; not FDA-approved in US but available internationally",
          "doseOptions": [
            {
              "text": "2400 mg",
              "orderSentence": "Piracetam (adjunctive for myoclonus) 2400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2400 mg PO TID; may increase to 4800 mg TID; max 24 g/day",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe renal impairment",
          "cerebral hemorrhage"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Renal function",
          "clinical response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "creutzfeldt-jakob-disease"
      ]
    },
    "pitolisant": {
      "id": "pitolisant",
      "name": "Pitolisant (Wakix)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "eds-and-cataplexy-in-narcolepsy-histamine-3-receptor-antagon": {
          "indication": "EDS and cataplexy in narcolepsy; histamine-3 receptor antagonist/inverse agonist",
          "doseOptions": [
            {
              "text": "8.9 mg",
              "orderSentence": "Pitolisant (Wakix) 8.9 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 8.9 mg once daily upon awakening; titrate weekly: 8.9 mg to 17.8 mg to 35.6 mg; max 35.6 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT-prolonging drugs",
          "Severe hepatic impairment",
          "concurrent strong CYP2D6 inhibitors (max 17.8 mg)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "QTc interval if risk factors",
          "headache",
          "hepatic function",
          "insomnia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "narcolepsy"
      ]
    },
    "pjp-prophylaxis": {
      "id": "pjp-prophylaxis",
      "name": "PJP prophylaxis",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "**PJP prophylaxis** 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If dexamethasone >20 mg/week AND concomitant temozolomide or immunosuppression: TMP-SMX 1 DS tablet 3x/week (Mon/Wed/Fri) OR atovaquone 1500 mg daily if sulfa allergic",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "brain-metastases"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Risk of Pneumocystis with prolonged corticosteroids + additional immunosuppression"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-metastases"
      ]
    },
    "plasma-exchange": {
      "id": "plasma-exchange",
      "name": "Plasma exchange (PLEX) (CPT 36514)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "gbs-cidp-alternative-to-ivig": {
          "indication": "GBS, CIDP (alternative to IVIG)",
          "doseOptions": [
            {
              "text": "1 plasma volume",
              "orderSentence": "Plasma exchange (PLEX) (CPT 36514) 1 plasma volume IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-7 exchanges of 1 plasma volume each over 10-14 days",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "acute-lems-exacerbation-alternative-to-ivig-lems-crisis-with": {
          "indication": "Acute LEMS exacerbation; alternative to IVIg; LEMS crisis with respiratory compromise; pre-thymectomy optimization if concurrent thymoma",
          "doseOptions": [
            {
              "text": "1-1.5 plasma volumes",
              "orderSentence": "Plasma exchange (PLEX) (CPT 36514) 1-1.5 plasma volumes IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-7 exchanges over 10-14 days; exchange 1-1.5 plasma volumes per session every other day; albumin replacement preferred",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "chronic-lems-refractory-to-ivig-and-oral-immunotherapy": {
          "indication": "Chronic LEMS refractory to IVIg and oral immunotherapy",
          "doseOptions": [
            {
              "text": "1 plasma volume",
              "orderSentence": "Plasma exchange (maintenance) 1 plasma volume IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Single volume exchange every 2-4 weeks; adjust frequency based on clinical response and antibody levels; albumin replacement",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "autoimmune-cerebellar-ataxia-refractory-to-steroids-ivig-mil": {
          "indication": "Autoimmune cerebellar ataxia refractory to steroids/IVIG; Miller Fisher syndrome; paraneoplastic cerebellar degeneration (limited benefit once neuronal loss established)",
          "doseOptions": [
            {
              "text": "1-1.5 plasma volumes",
              "orderSentence": "Plasma exchange (PLEX) 1-1.5 plasma volumes IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange; albumin replacement",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "refractory-susac-syndrome-not-responding-to-steroids-ivig-ac": {
          "indication": "Refractory Susac syndrome not responding to steroids + IVIG; acute deterioration; removal of circulating anti-endothelial cell antibodies and inflammatory mediators",
          "doseOptions": [
            {
              "text": "5 exchanges over 10-14 days",
              "orderSentence": "Plasma exchange (plasmapheresis, PLEX) (CPT 36514) 5 exchanges over 10-14 days IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 plasma volumes per exchange; albumin replacement; 5-7 sessions over 10-14 days; extend to 10 sessions in severe cases",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "severe-inflammatory-plexopathy-refractory-to-steroids-and-iv": {
          "indication": "Severe inflammatory plexopathy refractory to steroids and IVIg; CIDP-like plexopathy",
          "doseOptions": [
            {
              "text": "5 exchanges",
              "orderSentence": "Plasma exchange (PLEX) (CPT 36514) 5 exchanges IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hemodynamic instability",
          "Hemodynamic instability, sepsis",
          "active infection",
          "central line complications",
          "central line contraindication",
          "heparin allergy",
          "hypocalcemia risk",
          "line complications",
          "poor IV access",
          "sepsis",
          "severe coagulopathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP during exchange",
          "BP, electrolytes, coagulation studies, fibrinogen",
          "Electrolytes (calcium, magnesium) q exchange",
          "Hemodynamics during exchange",
          "blood pressure",
          "calcium (citrate-induced hypocalcemia)",
          "coags",
          "coagulation",
          "coagulation studies",
          "electrolytes",
          "electrolytes (Ca, K, Mg)",
          "fibrinogen",
          "fibrinogen post-exchange",
          "hypotension",
          "infection",
          "line complications",
          "line site",
          "line site infection",
          "line-site infection"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "ataxia-evaluation",
        "lambert-eaton-syndrome",
        "paresthesia-numbness-tingling",
        "plexopathy",
        "susac-syndrome"
      ]
    },
    "plasmapheresis": {
      "id": "plasmapheresis",
      "name": "Plasmapheresis (PLEX)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PLEX"
      ],
      "formulations": [],
      "contexts": {
        "steroid-refractory-or-severe-vision-loss": {
          "indication": "Steroid-refractory or severe vision loss",
          "doseOptions": [
            {
              "text": "5-7 exchanges",
              "orderSentence": "Plasmapheresis (PLEX) 5-7 exchanges PLEX"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-7 exchanges every other day; typical volume 1-1.5 plasma volumes",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "acute-severe-sps-or-status-spasticus-not-responding-to-benzo": {
          "indication": "Acute severe SPS or status spasticus not responding to benzodiazepines and IVIg; removes pathogenic antibodies",
          "doseOptions": [
            {
              "text": "1-1.5 plasma volumes",
              "orderSentence": "Plasmapheresis (PLEX) 1-1.5 plasma volumes IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 exchanges over 10-14 days (every other day); 1-1.5 plasma volume exchanges per session; albumin replacement (NOT FFP unless coagulopathy); central venous catheter required",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "first-line-immunotherapy-removes-pathogenic-antibodies-prefe": {
          "indication": "First-line immunotherapy; removes pathogenic antibodies; preferred for cell-surface antibody syndromes",
          "doseOptions": [
            {
              "text": "1-1.5 plasma volumes",
              "orderSentence": "Plasmapheresis (PLEX) 1-1.5 plasma volumes IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange; albumin replacement preferred",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active sepsis",
          "Hemodynamic instability",
          "coagulopathy",
          "hemodynamic instability",
          "heparin allergy (if used)",
          "line contraindication",
          "poor vascular access",
          "sepsis",
          "unable to establish vascular access"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP and vitals during sessions",
          "BP during exchanges",
          "CBC",
          "calcium (citrate-induced hypocalcemia)",
          "citrate reactions",
          "coags",
          "coagulation (fibrinogen)",
          "coagulation studies",
          "electrolytes",
          "electrolytes (Ca, K, Mg)",
          "fibrinogen",
          "line infection",
          "line infections",
          "line site"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "optic-neuritis",
        "paraneoplastic-neurological-syndrome",
        "stiff-person-syndrome"
      ]
    },
    "platelet-rich-plasma-injection": {
      "id": "platelet-rich-plasma-injection",
      "name": "Platelet-rich plasma (PRP) injection",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Local injection"
      ],
      "formulations": [],
      "contexts": {
        "experimental-refractory-cases-patient-preference-to-avoid-su": {
          "indication": "Experimental; refractory cases; patient preference to avoid surgery",
          "doseOptions": [
            {
              "text": "2-3 mL PRP",
              "orderSentence": "Platelet-rich plasma (PRP) injection 2-3 mL PRP Local injection"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Single injection under ultrasound; emerging evidence",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Infection",
          "malignancy",
          "thrombocytopenia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Observe 15 min post-injection"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "carpal-tunnel-syndrome"
      ]
    },
    "platelet-transfusion": {
      "id": "platelet-transfusion",
      "name": "Platelet transfusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "thrombocytopenia-with-active-bleeding-or-pre-procedure": {
          "indication": "Thrombocytopenia with active bleeding or pre-procedure",
          "doseOptions": [
            {
              "text": "Dose per protocol",
              "orderSentence": "Platelet transfusion Dose per protocol IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 unit apheresis platelets; target >50K for procedures, >10K if no bleeding",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ITP, TTP (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Platelet count post-transfusion"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wilsons-disease"
      ]
    },
    "polyethylene-glycol": {
      "id": "polyethylene-glycol",
      "name": "Polyethylene glycol (MiraLAX)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "constipation-common-with-reduced-mobility-and-anticholinergi": {
          "indication": "Constipation (common with reduced mobility and anticholinergics)",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol (MiraLAX) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g in 8 oz liquid daily; may increase to BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "constipation": {
          "indication": "Constipation",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol (MiraLAX) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g (1 capful) in 8 oz liquid daily; may increase to BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "constipation-refractory-to-docusate-and-senna": {
          "indication": "Constipation refractory to docusate and senna",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol (MiraLAX) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g PO daily dissolved in 8 oz water",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "constipation-immobility-related-common-in-ibm-due-to-reduced": {
          "indication": "Constipation (immobility-related, common in IBM due to reduced activity)",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol (MiraLAX) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g (1 capful) dissolved in 8 oz liquid PO daily; adjust frequency based on response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol (constipation) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g daily in water",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "constipation-refractory-to-docusate-senna": {
          "indication": "Constipation refractory to docusate/senna",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol (PEG 3350) (constipation) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g PO daily in 8 oz water; may increase to BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "constipation-gi-dysmotility-from-smooth-muscle-involvement-i": {
          "indication": "Constipation (GI dysmotility from smooth muscle involvement in DM1; reduced physical activity)",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol (MiraLAX) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g (1 capful) dissolved in 8 oz liquid PO daily; adjust frequency based on response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "constipation-if-docusate-insufficient": {
          "indication": "Constipation (if docusate insufficient)",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol (MiraLAX) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g PO daily in 8 oz water",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome",
            "botulism"
          ]
        },
        "constipation-ubiquitous-in-pd": {
          "indication": "Constipation (ubiquitous in PD)",
          "doseOptions": [
            {
              "text": "17 g daily",
              "orderSentence": "Polyethylene glycol (MiraLAX) 17 g daily PO"
            },
            {
              "text": "17 g BID",
              "orderSentence": "Polyethylene glycol (MiraLAX) 17 g BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g (1 capful) in 8 oz liquid daily; may increase to BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bowel obstruction",
          "GI obstruction",
          "bowel perforation",
          "ileus"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bowel frequency",
          "Bowel function",
          "Bowel movements",
          "Diarrhea if excessive",
          "electrolytes if prolonged use",
          "electrolytes with prolonged use",
          "hydration status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 10,
      "_sourcePlans": [
        "botulism",
        "creutzfeldt-jakob-disease",
        "critical-illness-myopathy-neuropathy",
        "guillain-barre-syndrome",
        "huntingtons-disease",
        "inclusion-body-myositis",
        "lewy-body-dementia",
        "myotonic-dystrophy",
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "polyethylene-glycol-3350": {
      "id": "polyethylene-glycol-3350",
      "name": "Polyethylene glycol 3350 (MiraLAX)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "constipation-from-neurogenic-bowel-or-immobility": {
          "indication": "Constipation from neurogenic bowel or immobility",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol 3350 (MiraLAX) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g (1 capful) dissolved in 8 oz water daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "constipation-from-autonomic-dysfunction-in-lems": {
          "indication": "Constipation from autonomic dysfunction in LEMS",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol 3350 (MiraLAX) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g (1 capful) dissolved in 8 oz liquid once daily; adjust frequency to bowel response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "constipation-neurogenic-bowel-dysfunction-common-in-msa": {
          "indication": "Constipation — neurogenic bowel dysfunction; common in MSA",
          "doseOptions": [
            {
              "text": "17 g daily",
              "orderSentence": "Polyethylene glycol 3350 (MiraLAX) 17 g daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g (1 capful) dissolved in 8 oz water daily; titrate frequency to effect; target 1 soft stool daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "chronic-constipation-from-neurogenic-bowel-osmotic-laxative": {
          "indication": "Chronic constipation from neurogenic bowel; osmotic laxative",
          "doseOptions": [
            {
              "text": "17 g",
              "orderSentence": "Polyethylene glycol 3350 (MiraLAX) 17 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "17 g dissolved in 8 oz water PO daily; adjust frequency based on response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bowel obstruction",
          "Bowel obstruction, ileus",
          "Intestinal obstruction",
          "Known bowel obstruction",
          "bowel perforation"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bowel frequency",
          "Bowel frequency, abdominal distension, electrolytes if prolonged use",
          "Bowel function",
          "Bowel habits",
          "electrolytes",
          "electrolytes if prolonged",
          "electrolytes if prolonged use",
          "hydration status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "cervical-myelopathy",
        "lambert-eaton-syndrome",
        "mogad",
        "multiple-system-atrophy"
      ]
    },
    "ponesimod": {
      "id": "ponesimod",
      "name": "Ponesimod (Ponvory)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Ponesimod (Ponvory) 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Titration over 14 days to 20 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same",
          "Same as fingolimod"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same",
          "Similar",
          "no first-dose observation required"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "portable-suction": {
      "id": "portable-suction",
      "name": "Portable suction",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "—"
      ],
      "formulations": [],
      "contexts": {
        "secretion-management": {
          "indication": "Secretion management",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Portable suction N/A —"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Oral or pharyngeal suction PRN for secretion management",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Secretion burden, mucosal trauma"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "posaconazole": {
      "id": "posaconazole",
      "name": "Posaconazole",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "salvage-therapy-for-refractory-aspergillus-or-mucorales-cns-": {
          "indication": "Salvage therapy for refractory Aspergillus or Mucorales CNS infection; delayed-release tablets preferred",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Posaconazole 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Loading: 300 mg PO BID on day 1; Maintenance: 300 mg PO daily; delayed-release tablets preferred (consistent absorption)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "Severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          ">1.5 for treatment)",
          "LFTs",
          "QTc",
          "Trough levels (target >1.0 mcg/mL for prophylaxis",
          "drug interactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "potassium-chloride": {
      "id": "potassium-chloride",
      "name": "Potassium chloride",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "hypokalemia-correction-common-in-alcoholism-and-with-vomitin": {
          "indication": "Hypokalemia correction; common in alcoholism and with vomiting",
          "doseOptions": [
            {
              "text": "20-40 mEq",
              "orderSentence": "Potassium chloride 20-40 mEq IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Replace per level: K 3.0-3.5: 40 mEq PO; K <3.0: 20-40 mEq IV over 1-2 hours; check Mg (must replete Mg for K to correct)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal failure",
          "hyperkalemia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "K levels q6-12h",
          "cardiac monitor if IV replacement"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure"
      ]
    },
    "potassium-chloride-supplementation": {
      "id": "potassium-chloride-supplementation",
      "name": "Potassium chloride supplementation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "amphotericin-b-causes-renal-potassium-wasting-in-80-of-patie": {
          "indication": "Amphotericin B causes renal potassium wasting in >80% of patients; severe hypokalemia can cause cardiac arrhythmias",
          "doseOptions": [
            {
              "text": "20-40 mEq",
              "orderSentence": "Potassium chloride supplementation 20-40 mEq IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Replace per institutional protocol; target K >3.5 mEq/L; oral preferred if tolerated; IV replacement for K <3.0 or symptomatic",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hyperkalemia",
          "renal failure (use cautiously)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG if K <3.0 or >5.5",
          "Potassium levels twice daily during induction"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "fungal-meningitis"
      ]
    },
    "potassium-supplementation": {
      "id": "potassium-supplementation",
      "name": "Potassium supplementation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "prevent-hypokalemia-during-b12-replacement-erythropoiesis-co": {
          "indication": "Prevent hypokalemia during B12 replacement; erythropoiesis consumes potassium",
          "doseOptions": [
            {
              "text": "20 mEq",
              "orderSentence": "Potassium supplementation 20 mEq PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mEq PO daily; monitor potassium q12-24h during first 48 hours of B12 replacement; supplement if K <3.5 mEq/L",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hyperkalemia",
          "renal failure (use cautiously)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Potassium levels q12-24h during initial treatment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "b12-deficiency-neuropathy"
      ]
    },
    "ppi": {
      "id": "ppi",
      "name": "PPI (stress ulcer/GI prophylaxis)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "**PPI (stress ulcer/GI prophylaxis)** 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Omeprazole 20 mg daily or pantoprazole 40 mg daily while on dexamethasone",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "spinal-cord-compression-malignant"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Steroid + critical illness increases GI bleed risk"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "spinal-cord-compression-malignant"
      ]
    },
    "pramipexole": {
      "id": "pramipexole",
      "name": "Pramipexole (Mirapex)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.125 mg",
              "orderSentence": "Pramipexole (Mirapex) 0.125 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.125 mg TID; titrate weekly to 0.5-1.5 mg TID; max 4.5 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis",
            "restless-legs-syndrome"
          ]
        },
        "adjunct-to-levodopa-monotherapy-in-early-pd-tremor": {
          "indication": "Adjunct to levodopa; monotherapy in early PD; tremor",
          "doseOptions": [
            {
              "text": "0.125 mg TID",
              "orderSentence": "Pramipexole 0.125 mg TID PO"
            },
            {
              "text": "0.25 mg TID",
              "orderSentence": "Pramipexole 0.25 mg TID PO"
            },
            {
              "text": "0.5 mg TID",
              "orderSentence": "Pramipexole 0.5 mg TID PO"
            },
            {
              "text": "1 mg TID",
              "orderSentence": "Pramipexole 1 mg TID PO"
            },
            {
              "text": "1.5 mg TID",
              "orderSentence": "Pramipexole 1.5 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.125 mg TID; titrate by 0.125-0.25 mg TID q5-7 days; max 1.5 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Impulse control disorders (relative)",
          "Impulse control history",
          "Severe renal impairment",
          "renal impairment (reduce dose)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "AUGMENTATION, ICDs, sleepiness",
          "ICDs (gambling, hypersexuality, shopping), sleepiness, hallucinations",
          "Impulse control disorders, somnolence, leg edema"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis",
        "restless-legs-syndrome"
      ]
    },
    "pramipexole-er": {
      "id": "pramipexole-er",
      "name": "Pramipexole ER",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.375 mg",
              "orderSentence": "Pramipexole ER 0.375 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.375 mg daily; titrate weekly; max 4.5 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "praziquantel": {
      "id": "praziquantel",
      "name": "Praziquantel",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "combined-with-albendazole-for-2-viable-parenchymal-cysts-com": {
          "indication": "**Combined with albendazole** for >2 viable parenchymal cysts (combination more effective than either alone per RCTs); single agent if albendazole intolerance; **NOTE: levels reduced 50-75% by enzyme-inducing AEDs (carbamazepine, phenytoin) and by dexamethasone — increase dose or use cimetidine to boost levels**",
          "doseOptions": [
            {
              "text": "50 mg/kg/day",
              "orderSentence": "Praziquantel 50 mg/kg/day PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg/kg/day PO divided TID; take with fatty meal; combine with albendazole for >2 viable cysts; duration 10-14 days for parenchymal NCC; if on enzyme-inducing AEDs: increase dose to 100 mg/kg/day or add cimetidine 400 mg TID to inhibit metabolism",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**Ocular cysticercosis** (ABSOLUTE)",
          "concurrent rifampin (reduces levels markedly)",
          "cysticercal encephalitis with uncontrolled edema",
          "pregnancy (Category B but avoid during treatment)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs",
          "clinical response",
          "drug interactions (enzyme-inducing AEDs reduce levels by 50-75%)",
          "repeat imaging at 3-6 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neurocysticercosis"
      ]
    },
    "prazosin": {
      "id": "prazosin",
      "name": "Prazosin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "ptsd-related-nightmares-and-sleep-disruption-common-in-pnes-": {
          "indication": "PTSD-related nightmares and sleep disruption (common in PNES patients with trauma history)",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Prazosin 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg PO qHS; titrate by 1-2 mg q1wk; max 15 mg qHS; monitor for first-dose hypotension (give first dose at bedtime)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypotension",
          "concurrent PDE5 inhibitors"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Orthostatic BP (especially first dose)",
          "dizziness",
          "nightmare frequency",
          "syncope"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pnes"
      ]
    },
    "prednisolone": {
      "id": "prednisolone",
      "name": "Prednisolone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "60-80 mg",
              "orderSentence": "Prednisolone 60-80 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60-80 mg PO daily × 7 days (equivalent alternative)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "bells-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "bells-palsy"
      ]
    },
    "prednisone": {
      "id": "prednisone",
      "name": "Prednisone",
      "genericName": "prednisone",
      "brandNames": [
        "Deltasone",
        "Rayos"
      ],
      "drugClass": "Corticosteroid / Glucocorticoid",
      "mechanisms": [
        "Binds glucocorticoid receptor",
        "Suppresses inflammatory and immune responses",
        "Reduces cytokine production"
      ],
      "routes": [
        "PO"
      ],
      "formulations": [
        "1 mg tablet",
        "2.5 mg tablet",
        "5 mg tablet",
        "10 mg tablet",
        "20 mg tablet",
        "50 mg tablet",
        "5 mg/mL solution"
      ],
      "contexts": {
        "ms-acute-relapse": {
          "indication": "Multiple sclerosis acute relapse",
          "doseOptions": [
            {
              "text": "1000 mg IV daily x3-5 days",
              "orderSentence": "Methylprednisolone 1000 mg IV daily x3-5 days"
            },
            {
              "text": "1250 mg PO daily x3-5 days",
              "orderSentence": "Prednisone 1250 mg PO daily x3-5 days"
            }
          ],
          "startingDose": "1000 mg IV methylprednisolone (or 1250 mg PO prednisone equivalent)",
          "maxDose": "1000-1250 mg/day x 3-5 days",
          "titration": "No taper needed for short courses",
          "notes": "High-dose steroids speed recovery from relapse but don't affect long-term disability"
        },
        "myasthenia-gravis": {
          "indication": "Myasthenia gravis",
          "doseOptions": [
            {
              "text": "20 mg daily",
              "orderSentence": "Prednisone 20 mg PO daily"
            },
            {
              "text": "40 mg daily",
              "orderSentence": "Prednisone 40 mg PO daily"
            },
            {
              "text": "60 mg daily",
              "orderSentence": "Prednisone 60 mg PO daily"
            },
            {
              "text": "1 mg/kg daily",
              "orderSentence": "Prednisone 1 mg/kg PO daily"
            }
          ],
          "startingDose": "10-20 mg daily (or low-dose escalation to avoid exacerbation)",
          "maxDose": "1-1.5 mg/kg/day (usually 60-100 mg)",
          "titration": "Increase by 10 mg every 3-5 days OR start high and taper; risk of transient worsening",
          "notes": "May cause transient worsening in first 2-3 weeks; inpatient initiation may be safer"
        },
        "inflammatory-neuropathy": {
          "indication": "CIDP, vasculitic neuropathy, inflammatory neuropathies",
          "doseOptions": [
            {
              "text": "60 mg daily",
              "orderSentence": "Prednisone 60 mg PO daily"
            },
            {
              "text": "1 mg/kg daily",
              "orderSentence": "Prednisone 1 mg/kg PO daily"
            }
          ],
          "startingDose": "60 mg daily or 1 mg/kg/day",
          "maxDose": "100 mg/day",
          "titration": "Treat for 2-4 weeks then taper over months",
          "notes": "For CIDP, IVIG often preferred first-line; steroids for refractory cases or vasculitis"
        },
        "bells-palsy": {
          "indication": "Bell's palsy",
          "doseOptions": [
            {
              "text": "60 mg daily x7 days then taper",
              "orderSentence": "Prednisone 60 mg PO daily x7 days then taper"
            },
            {
              "text": "50 mg daily x10 days",
              "orderSentence": "Prednisone 50 mg PO daily x10 days"
            }
          ],
          "startingDose": "60 mg daily",
          "maxDose": "60 mg/day",
          "titration": "7-10 day course; can taper over 5 days or stop",
          "notes": "Start within 72 hours of onset for best effect"
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Prednisone (oral uptitration) 10-20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-20 mg PO daily; increase by 10 mg every 3-5 days to target 1 mg/kg/day (max 60-80 mg); maintain for 4-8 weeks, then slow taper over months",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "bells-palsy",
            "myasthenia-gravis-new-diagnosis"
          ]
        },
        "cidp-vasculitic-neuropathy-sarcoid-neuropathy": {
          "indication": "CIDP, vasculitic neuropathy, sarcoid neuropathy",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Prednisone 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg/day (max 80 mg) x 4-6 weeks; taper over 3-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "transition-from-iv-steroids-maintenance-corticosteroid-thera": {
          "indication": "Transition from IV steroids; maintenance corticosteroid therapy for pNBD",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Prednisone 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg/kg/day (max 60 mg) after IV pulse; taper by 10 mg every 2 weeks to 20 mg, then by 5 mg every 2-4 weeks; goal <10 mg daily by 6 months; taper over 6-12+ months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "active-inflammatory-myopathy-transition-from-iv-pulse-therap": {
          "indication": "Active inflammatory myopathy; transition from IV pulse therapy",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Prednisone (high-dose oral) 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg/day (max 80 mg) as single morning dose; maintain 4-8 weeks until CK normalizes and strength improves, then taper",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "long-term-immunosuppression-taper-target-lowest-effective-do": {
          "indication": "Long-term immunosuppression taper; target lowest effective dose with steroid-sparing agent",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Prednisone (chronic taper) 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Once stable on target dose with steroid-sparing agent for 4-8 weeks: decrease by 5-10 mg every 2-4 weeks until 20 mg, then 2.5-5 mg monthly; target <10 mg daily or off; many patients require long-term low-dose (5-10 mg)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "transition-from-iv-steroids-maintenance-corticosteroid-thera-2": {
          "indication": "Transition from IV steroids; maintenance corticosteroid therapy",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Prednisone 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg/kg/day (max 60 mg) after IV pulse; taper by 10 mg every 2 weeks to 20 mg, then by 5 mg every 2-4 weeks to lowest effective dose (goal 5-10 mg daily or off); total taper over 6-12 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "outpatient-management-of-refractory-sih-meningeal-inflammati": {
          "indication": "Outpatient management of refractory SIH; meningeal inflammation",
          "doseOptions": [
            {
              "text": "60 mg daily",
              "orderSentence": "Prednisone (oral taper) 60 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg PO daily x 5 days, then taper by 10 mg every 3-5 days over 3-4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        },
        "ocular-or-mild-generalized-mg-outpatient-initiation": {
          "indication": "Ocular or mild generalized MG; outpatient initiation",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Prednisone (low-dose start) 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-20 mg daily; increase by 10 mg every 5-7 days to target 1 mg/kg/day (max 60-80 mg); LOW-DOSE START prevents transient worsening in outpatient setting",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "hospital-setting-with-crisis-protection-post-ivig-plex": {
          "indication": "Hospital setting with crisis protection (post-IVIg/PLEX)",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Prednisone (high-dose) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60-80 mg or 1 mg/kg daily; only start high-dose after IVIg/PLEX coverage in hospital or if admitted for monitoring",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "chronic-mg-on-stable-steroids": {
          "indication": "Chronic MG on stable steroids",
          "doseOptions": [
            {
              "text": "Per taper",
              "orderSentence": "Prednisone (maintenance/taper) Per taper PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Once stable on target dose x 2-4 weeks, begin slow taper: reduce by 10 mg q2-4 weeks until 20 mg, then by 5 mg q2-4 weeks until 10 mg, then by 2.5 mg q month; may need minimum maintenance dose indefinitely",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "oral-corticosteroid-taper-following-iv-methylprednisolone-pu": {
          "indication": "Oral corticosteroid taper following IV methylprednisolone pulse; bridge to steroid-sparing maintenance therapy",
          "doseOptions": [
            {
              "text": "1 mg/kg daily",
              "orderSentence": "Prednisone (oral, following IV pulse) 1 mg/kg daily PO"
            },
            {
              "text": "0.75 mg/kg daily",
              "orderSentence": "Prednisone (oral, following IV pulse) 0.75 mg/kg daily PO"
            },
            {
              "text": "0.5 mg/kg daily",
              "orderSentence": "Prednisone (oral, following IV pulse) 0.5 mg/kg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg/kg/day PO (max 80 mg) after IV pulse; taper by 10 mg every 2 weeks to 20 mg/day; then taper by 5 mg every 2 weeks to 10 mg/day; then 2.5 mg every 2-4 weeks; target off steroids or lowest effective dose by 6-12 months",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis",
            "susac-syndrome"
          ]
        },
        "time-limited-trial-12-weeks-only-if-diagnosis-uncertain-and-": {
          "indication": "Time-limited trial (12 weeks) ONLY if diagnosis uncertain and polymyositis remains in differential; most IBM patients do NOT respond; steroid myopathy may worsen weakness",
          "doseOptions": [
            {
              "text": "0.5-1 mg/kg",
              "orderSentence": "Prednisone (limited trial) 0.5-1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5-1 mg/kg/day (max 60 mg) as single morning dose; assess strength and CK at 4, 8, 12 weeks; taper and discontinue if no objective improvement by 12 weeks; steroid myopathy can WORSEN IBM weakness",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "transition-from-iv-dexamethasone-prolonged-steroid-course-fo": {
          "indication": "Transition from IV dexamethasone; prolonged steroid course for subarachnoid NCC; maintenance anti-inflammatory therapy during outpatient antiparasitic treatment",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Prednisone (oral steroid taper) 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg/day PO (max 60 mg) then taper over 2-4 weeks for parenchymal NCC; for subarachnoid/racemose NCC: prolonged taper over months (years for chronic arachnoiditis)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurocysticercosis"
          ]
        },
        "cidp-vasculitic-neuropathy": {
          "indication": "CIDP, vasculitic neuropathy",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Prednisone 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg/day (max 80 mg) Ãƒâ€” 4-6 weeks; taper over 3-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "autoimmune-lems-a-lems-with-inadequate-response-to-3-4-dap-a": {
          "indication": "Autoimmune LEMS (A-LEMS) with inadequate response to 3,4-DAP alone; bridge to steroid-sparing agent; NOT first-line for P-LEMS (treat cancer first)",
          "doseOptions": [
            {
              "text": "10-20 mg",
              "orderSentence": "Prednisone 10-20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-20 mg daily; increase by 10 mg every 5-7 days to 0.5-1 mg/kg/day; maintain 4-8 weeks then taper by 5-10 mg/month to lowest effective dose",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "gca-without-visual-symptoms-after-iv-pulse-for-vision-threat": {
          "indication": "GCA without visual symptoms; after IV pulse for vision-threatening GCA",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Prednisone (initial high-dose) 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg/day PO (max 60 mg); take in morning with food; maintain initial dose 2-4 weeks until symptoms resolve and ESR/CRP normalize",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "after-2-4-weeks-at-initial-dose-with-symptom-resolution": {
          "indication": "After 2-4 weeks at initial dose with symptom resolution",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Prednisone (taper phase 1: 40 mg → 20 mg) 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Reduce by 5-10 mg every 2 weeks from 40 mg to 20 mg; monitor symptoms and ESR/CRP at each step",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "continued-improvement-normal-inflammatory-markers": {
          "indication": "Continued improvement; normal inflammatory markers",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Prednisone (taper phase 2: 20 mg → 10 mg) 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Reduce by 2.5 mg every 2-4 weeks from 20 mg to 10 mg; slower taper reduces relapse risk",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "near-remission-on-steroid-sparing-agent-if-available": {
          "indication": "Near-remission; on steroid-sparing agent if available",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Prednisone (taper phase 3: 10 mg → off) 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Reduce by 1 mg every month from 10 mg to off; total steroid duration typically 12-24 months; some patients require low-dose indefinitely",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "adjunctive-immunosuppression-short-term-during-acute-flares-": {
          "indication": "Adjunctive immunosuppression; short-term during acute flares; bridge while waiting for IVIg/rituximab effect; less effective as monotherapy for SPS",
          "doseOptions": [
            {
              "text": "0.5-1 mg/kg/day",
              "orderSentence": "Prednisone 0.5-1 mg/kg/day PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg/kg/day (max 60 mg); taper by 10 mg every 2 weeks to 20 mg, then by 5 mg every 2-4 weeks; attempt to discontinue or reach lowest effective dose; avoid prolonged use (less effective for SPS than for other autoimmune conditions)",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "acute-radiculopathy-with-moderate-severe-symptoms": {
          "indication": "Acute radiculopathy with moderate-severe symptoms",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Prednisone 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg daily x 5 days then taper; OR Medrol dose pack",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "acute-inflammatory-plexopathy-parsonage-turner-diabetic-amyo": {
          "indication": "Acute inflammatory plexopathy (Parsonage-Turner); diabetic amyotrophy (controversial)",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Prednisone 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg PO daily x 5-7 days then taper over 2-4 weeks; total course 4-6 weeks for inflammatory etiology",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        },
        "short-course-for-acute-facial-nerve-palsy-to-reduce-inflamma": {
          "indication": "Short course for acute facial nerve palsy to reduce inflammation and improve recovery; evidence extrapolated from Bell's palsy data; NOT standard of care for Lyme facial palsy and NOT recommended by most experts; discuss with specialist",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Prednisone (facial palsy adjunctive -- controversial) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg daily x 5 days, then taper over 5 days; controversial in Lyme -- some experts avoid due to concern for impaired immune clearance of Borrelia; use ONLY with concurrent antibiotics",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Systemic fungal infections",
          "Known hypersensitivity"
        ],
        "precautions": [
          "Hyperglycemia - monitor blood glucose in diabetics",
          "Immunosuppression - increased infection risk",
          "Adrenal suppression with prolonged use - taper required",
          "Osteoporosis with chronic use",
          "GI bleeding risk - consider PPI if risk factors",
          "Psychiatric effects (insomnia, mood changes, psychosis)",
          "Hypertension, fluid retention",
          "Cataracts and glaucoma with prolonged use",
          "AVN of femoral head (rare)"
        ],
        "drugInteractions": [
          {
            "drug": "NSAIDs",
            "severity": "moderate",
            "effect": "Increased GI bleeding risk"
          },
          {
            "drug": "CYP3A4 inducers (phenytoin, rifampin)",
            "severity": "moderate",
            "effect": "Decreased prednisone effect"
          },
          {
            "drug": "Warfarin",
            "severity": "moderate",
            "effect": "Variable effect on INR - monitor closely"
          },
          {
            "drug": "Fluoroquinolones",
            "severity": "moderate",
            "effect": "Increased tendon rupture risk"
          },
          {
            "drug": "Live vaccines",
            "severity": "high",
            "effect": "Avoid live vaccines during immunosuppression"
          }
        ],
        "pregnancyCategory": "C (D in first trimester at high doses)",
        "lactation": "Compatible at low doses"
      },
      "renalAdjustment": {
        "required": false,
        "tiers": [
          {
            "gfr": "any",
            "adjustment": "No adjustment needed"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment typically needed; prednisone is prodrug converted to prednisolone"
      },
      "monitoring": {
        "baseline": [
          "Blood glucose",
          "Blood pressure",
          "BMD if chronic use anticipated"
        ],
        "ongoing": [
          "Blood glucose",
          "Blood pressure",
          "Weight",
          "Signs of infection",
          "Mood changes"
        ],
        "frequency": "Glucose frequently during high-dose; BP at each visit"
      },
      "patientCounseling": [
        "Take with food to reduce stomach upset",
        "Do not stop abruptly if on >7-10 days - must taper",
        "May cause insomnia - take in morning",
        "Monitor blood sugar if diabetic",
        "Report signs of infection, GI bleeding, or mood changes",
        "Consider calcium/vitamin D supplementation if prolonged use"
      ]
    },
    "prednisone-oral": {
      "id": "prednisone-oral",
      "name": "Prednisone oral (alternative)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1250 mg",
              "orderSentence": "Prednisone oral (alternative) 1250 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1250 mg PO daily × 3-5 days (bioequivalent to IV)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ms-chronic-management"
      ]
    },
    "prednisone-oral-taper": {
      "id": "prednisone-oral-taper",
      "name": "Prednisone oral taper",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "following-iv-methylprednisolone-per-ontt-protocol": {
          "indication": "Following IV methylprednisolone per ONTT protocol",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Prednisone oral taper 1 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg/kg/day (max 80 mg) x 11 days following 3 days IV steroids; then discontinue or rapid taper",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "60 mg",
              "orderSentence": "Prednisone oral taper (optional) 60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "60 mg daily Ã— 7 days, then taper over 2 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as IV steroids"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "GI prophylaxis",
          "Glucose",
          "Glucose, BP, mood",
          "mood"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-new-diagnosis",
        "optic-neuritis"
      ]
    },
    "pregabalin": {
      "id": "pregabalin",
      "name": "Pregabalin",
      "genericName": "pregabalin",
      "brandNames": [
        "Lyrica",
        "Lyrica CR"
      ],
      "drugClass": "Gabapentinoid / Anticonvulsant",
      "mechanisms": [
        "Binds alpha-2-delta subunit of voltage-gated calcium channels",
        "Reduces excitatory neurotransmitter release"
      ],
      "routes": [
        "PO"
      ],
      "formulations": [
        "25 mg capsule",
        "50 mg capsule",
        "75 mg capsule",
        "100 mg capsule",
        "150 mg capsule",
        "200 mg capsule",
        "225 mg capsule",
        "300 mg capsule"
      ],
      "contexts": {
        "neuropathic-pain": {
          "indication": "Neuropathic pain (diabetic neuropathy, post-herpetic neuralgia, small fiber neuropathy)",
          "doseOptions": [
            {
              "text": "50 mg TID",
              "orderSentence": "Pregabalin 50 mg PO TID"
            },
            {
              "text": "75 mg BID",
              "orderSentence": "Pregabalin 75 mg PO BID"
            },
            {
              "text": "100 mg TID",
              "orderSentence": "Pregabalin 100 mg PO TID"
            },
            {
              "text": "150 mg BID",
              "orderSentence": "Pregabalin 150 mg PO BID"
            },
            {
              "text": "200 mg BID",
              "orderSentence": "Pregabalin 200 mg PO BID"
            },
            {
              "text": "300 mg BID",
              "orderSentence": "Pregabalin 300 mg PO BID"
            }
          ],
          "startingDose": "75 mg BID or 50 mg TID",
          "maxDose": "600 mg/day",
          "titration": "May increase to 150 mg BID after 1 week, then to 300 mg BID after another week",
          "notes": "First-line for neuropathic pain; faster onset than gabapentin",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          }
        },
        "fibromyalgia": {
          "indication": "Fibromyalgia",
          "doseOptions": [
            {
              "text": "75 mg BID",
              "orderSentence": "Pregabalin 75 mg PO BID"
            },
            {
              "text": "150 mg BID",
              "orderSentence": "Pregabalin 150 mg PO BID"
            },
            {
              "text": "225 mg BID",
              "orderSentence": "Pregabalin 225 mg PO BID"
            }
          ],
          "startingDose": "75 mg BID",
          "maxDose": "450 mg/day",
          "titration": "May increase to 150 mg BID within 1 week; max 225 mg BID",
          "notes": "FDA-approved for fibromyalgia"
        },
        "epilepsy": {
          "indication": "Adjunctive therapy for partial seizures",
          "doseOptions": [
            {
              "text": "50 mg TID",
              "orderSentence": "Pregabalin 50 mg PO TID"
            },
            {
              "text": "100 mg TID",
              "orderSentence": "Pregabalin 100 mg PO TID"
            },
            {
              "text": "150 mg BID",
              "orderSentence": "Pregabalin 150 mg PO BID"
            },
            {
              "text": "200 mg BID",
              "orderSentence": "Pregabalin 200 mg BID"
            },
            {
              "text": "300 mg BID",
              "orderSentence": "Pregabalin 300 mg PO BID"
            }
          ],
          "startingDose": "50 mg TID or 75 mg BID",
          "maxDose": "600 mg/day",
          "titration": "Increase based on response and tolerability",
          "notes": "Adjunctive therapy only"
        },
        "neuropathic-pain-painful-paresthesia-first-line": {
          "indication": "Neuropathic pain, painful paresthesia (first-line)",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "neuropathic-pain-alternative-to-gabapentin": {
          "indication": "Neuropathic pain; alternative to gabapentin",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; increase q1wk; max 600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease",
            "neurosarcoidosis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin (neuropathic pain) 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; titrate to 150-300 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cidp",
            "diabetic-neuropathy",
            "trigeminal-neuralgia",
            "restless-legs-syndrome"
          ]
        },
        "neuropathic-pain-first-line-alternative": {
          "indication": "Neuropathic pain (first-line alternative)",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; may increase to 150 mg BID after 1 week; max 300 mg BID (600 mg/day); adjust for renal function (CrCl <60: reduce dose); Schedule V controlled substance",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "neuropathic-pain-tabes-dorsalis-alternative-to-gabapentin": {
          "indication": "Neuropathic pain (tabes dorsalis; alternative to gabapentin)",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; may increase to 150-300 mg BID q1wk; max 600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "alternative-to-gabapentin-for-neuropathic-pain-component": {
          "indication": "Alternative to gabapentin for neuropathic pain component",
          "doseOptions": [
            {
              "text": "75 mg BID",
              "orderSentence": "Pregabalin 75 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg PO BID; increase to 150 mg BID after 1 week; max 300 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        },
        "first-line-for-neuropathic-pain-fda-approved-for-postherpeti": {
          "indication": "First-line for neuropathic pain; FDA-approved for postherpetic neuralgia and DPN",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Pregabalin 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg TID or 75 mg BID; titrate q3-7d; max 300 mg/day; reduce if CrCl <60",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "neuropathic-pain-alternative-to-gabapentin-may-be-better-tol": {
          "indication": "Neuropathic pain alternative to gabapentin; may be better tolerated",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg PO BID; increase to 150 mg BID after 3-7 days; max 300 mg BID (600 mg/day); dose adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "neuropathic-pain-alternative-to-gabapentin-2": {
          "indication": "Neuropathic pain (alternative to gabapentin)",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg/day for neuropathic pain",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peroneal-neuropathy",
            "nmosd"
          ]
        },
        "neuropathic-pain-or-muscle-cramps-if-gabapentin-not-tolerate": {
          "indication": "Neuropathic pain or muscle cramps if gabapentin not tolerated",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg PO BID; may increase to 150 mg BID after 1 week; max 300 mg BID; reduce dose if CrCl <60",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "neuropathic-pain-from-transverse-myelitis-alternative-to-gab": {
          "indication": "Neuropathic pain from transverse myelitis; alternative to gabapentin",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; may increase q1wk to 150 mg BID; max 600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "neuropathic-pain-first-line": {
          "indication": "Neuropathic pain (first-line)",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "neuropathic-pain-in-sensory-ataxia-may-help-cerebellar-tremo": {
          "indication": "Neuropathic pain in sensory ataxia; may help cerebellar tremor",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; increase to 150 mg BID after 1 week; max 600 mg/day; adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "adjunctive-therapy-for-rigidity-spasms-and-neuropathic-pain-": {
          "indication": "Adjunctive therapy for rigidity, spasms, and neuropathic pain; alternative to gabapentin",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; may increase q1wk; target 150-300 mg BID; max 600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "neuropathic-pain-paresthesias": {
          "indication": "Neuropathic pain/paresthesias",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; may increase to 150 mg BID after 1 week",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        },
        "neuropathic-pain-from-paraneoplastic-sensory-neuropathy-alte": {
          "indication": "Neuropathic pain from paraneoplastic sensory neuropathy; alternative to gabapentin",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; may increase q1wk to 150-300 mg BID; max 600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "central-post-stroke-pain-alternative-to-gabapentin-scheduled": {
          "indication": "Central post-stroke pain; alternative to gabapentin; scheduled dosing (no TID)",
          "doseOptions": [
            {
              "text": "25 mg BID",
              "orderSentence": "Pregabalin 25 mg BID PO"
            },
            {
              "text": "75 mg BID",
              "orderSentence": "Pregabalin 75 mg BID PO"
            },
            {
              "text": "150 mg BID",
              "orderSentence": "Pregabalin 150 mg BID PO"
            },
            {
              "text": "300 mg BID",
              "orderSentence": "Pregabalin 300 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-75 mg BID; increase by 75 mg q1wk; target 150-300 mg BID; max 600 mg/day; renal dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "neuropathic-radicular-pain-first-line-alternative": {
          "indication": "Neuropathic/radicular pain (first-line alternative)",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg BID (600 mg/day)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "neuropathic-pain-or-muscle-cramps-if-gabapentin-not-tolerate-2": {
          "indication": "Neuropathic pain or muscle cramps if gabapentin not tolerated; concurrent pain conditions",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg PO BID; may increase to 150 mg BID after 1 week; max 300 mg BID; reduce dose if CrCl <60",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "neuropathic-pain-alternative": {
          "indication": "Neuropathic pain (alternative)",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg PO BID; increase to 150 mg BID after 3-7 days; max 300 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        },
        "neuropathic-pain-alternative-to-gabapentin-with-more-predict": {
          "indication": "Neuropathic pain; alternative to gabapentin with more predictable pharmacokinetics",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; increase to 150 mg BID after 1 week; max 600 mg/day; adjust for renal function",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "neuropathic-pain-from-plexopathy-first-line-alternative": {
          "indication": "Neuropathic pain from plexopathy (first-line alternative)",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg BID (600 mg/day)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "plexopathy"
          ]
        },
        "neuropathic-pain-lyme-radiculopathy-peripheral-neuropathy-al": {
          "indication": "Neuropathic pain (Lyme radiculopathy; peripheral neuropathy); alternative to gabapentin",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Pregabalin 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg BID; may increase to 150 mg BID after 1 wk; max 300 mg BID (600 mg/day); dose adjust for renal impairment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lyme-neuroborreliosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Known hypersensitivity to pregabalin"
        ],
        "precautions": [
          "Respiratory depression risk when combined with CNS depressants or opioids",
          "Suicidal ideation (class warning for antiepileptics)",
          "Angioedema (rare but serious)",
          "Peripheral edema and weight gain",
          "Schedule V controlled substance - abuse potential",
          "Dizziness and somnolence - fall risk"
        ],
        "drugInteractions": [
          {
            "drug": "Opioids",
            "severity": "high",
            "effect": "Increased respiratory depression risk"
          },
          {
            "drug": "CNS depressants",
            "severity": "moderate",
            "effect": "Additive sedation"
          },
          {
            "drug": "Thiazolidinediones (pioglitazone, rosiglitazone)",
            "severity": "moderate",
            "effect": "Increased peripheral edema and weight gain"
          }
        ],
        "pregnancyCategory": "C",
        "lactation": "Likely compatible but limited data"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {
            "gfr": "≥60",
            "adjustment": "No adjustment needed"
          },
          {
            "gfr": "30-59",
            "adjustment": "Reduce dose by 50% (max 300 mg/day)"
          },
          {
            "gfr": "15-29",
            "adjustment": "Reduce dose by 75% (max 150 mg/day)"
          },
          {
            "gfr": "<15",
            "adjustment": "Max 75 mg/day"
          },
          {
            "gfr": "HD",
            "adjustment": "25-75 mg daily; supplemental dose after dialysis"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment needed - not hepatically metabolized"
      },
      "monitoring": {
        "baseline": [
          "Renal function (BMP/CrCl)"
        ],
        "ongoing": [
          "Renal function periodically",
          "Weight",
          "Peripheral edema",
          "Suicidal ideation"
        ],
        "frequency": "Renal function annually or with changes"
      },
      "patientCounseling": [
        "Do not stop abruptly - taper over 1 week minimum",
        "Controlled substance - take only as prescribed",
        "May cause drowsiness, weight gain, swelling",
        "Report mood changes, swelling of face/tongue, or difficulty breathing immediately"
      ]
    },
    "preservative-containing-solutions-via-it-route": {
      "id": "preservative-containing-solutions-via-it-route",
      "name": "Preservative-containing solutions via IT route",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IT"
      ],
      "formulations": [],
      "contexts": {
        "preservatives-benzyl-alcohol-methylparaben-are-directly-neur": {
          "indication": "Preservatives (benzyl alcohol, methylparaben) are directly neurotoxic when administered intrathecally; can cause fatal chemical arachnoiditis",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Preservative-containing solutions via IT route N/A IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "ALL IT medications must be preservative-free; only preservative-free normal saline for reconstitution",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ANY preservative-containing solution is ABSOLUTELY CONTRAINDICATED intrathecally"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Acute chemical meningitis",
          "death if preservative administered IT",
          "seizures"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "primidone": {
      "id": "primidone",
      "name": "Primidone (Mysoline)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-first-line-for-action-postural-tremor-use-when-p": {
          "indication": "Alternative first-line for action/postural tremor; use when propranolol is contraindicated or inadequate",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Primidone (Mysoline) 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5-25 mg QHS (ultra-low dose); titrate very slowly by 12.5-25 mg/week; target 250-750 mg/day in divided doses; initiation reaction (nausea, dizziness, sedation) common -- start very low",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "12.5-25 mg",
              "orderSentence": "Primidone (Mysoline) 12.5-25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5-25 mg QHS; titrate very slowly by 12.5-25 mg/week to 250-750 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "essential-tremor"
          ]
        },
        "tremor": {
          "indication": "Tremor",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Primidone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg qHS; increase by 25 mg every week to 250 mg TID; usual dose 50-250 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Porphyria",
          "Porphyria, severe sedation",
          "hypersensitivity to phenobarbital",
          "pregnancy (teratogenic)",
          "severe sedation to initial dose"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC periodically",
          "Sedation, ataxia, nausea (especially first dose -- warn patient)",
          "Sedation, ataxia, nausea (start very low)",
          "Severe sedation initially (start very low)",
          "ataxia",
          "cognitive effects in elderly",
          "nausea"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "essential-tremor",
        "ms-new-diagnosis",
        "tremor-unspecified"
      ]
    },
    "probenecid": {
      "id": "probenecid",
      "name": "Probenecid (with IM penicillin alternative)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "used-only-with-procaine-penicillin-g-im-regimen-alternative-": {
          "indication": "Used ONLY with procaine penicillin G IM regimen (alternative to IV penicillin when IV access impossible); blocks renal excretion of penicillin to maintain treponemicidal CSF levels",
          "doseOptions": [
            {
              "text": "500 mg QID",
              "orderSentence": "Probenecid (with IM penicillin alternative) 500 mg QID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg PO QID for 10-14 days (must be given with each IM penicillin dose); ensure adequate hydration",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Uric acid nephrolithiasis",
          "blood dyscrasias",
          "sulfonamide allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Uric acid",
          "ensure compliance (QID dosing)",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neurosyphilis"
      ]
    },
    "procaine-penicillin-g-im": {
      "id": "procaine-penicillin-g-im",
      "name": "Procaine penicillin G IM (alternative ONLY if IV not feasible)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-iv-penicillin-g-only-when-iv-access-is-imposs": {
          "indication": "Alternative to IV penicillin G ONLY when IV access is impossible. MUST be combined with probenecid. CDC considers this acceptable but less preferred than IV",
          "doseOptions": [
            {
              "text": "2.4 million units daily",
              "orderSentence": "Procaine penicillin G IM (alternative ONLY if IV not feasible) 2.4 million units daily IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2.4 million units IM daily for 10-14 days PLUS probenecid 500 mg PO QID. This regimen REQUIRES strict compliance with probenecid; any missed doses compromise CSF levels",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Procaine allergy",
          "injection site concerns"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Injection sites",
          "clinical response",
          "compliance with probenecid"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neurosyphilis"
      ]
    },
    "procarbazine": {
      "id": "procarbazine",
      "name": "Procarbazine (R-MPV regimen component)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "component-of-r-mpv-regimen-rituximab-methotrexate-procarbazi": {
          "indication": "Component of R-MPV regimen (Rituximab, Methotrexate, Procarbazine, Vincristine); alkylating agent with CNS penetration",
          "doseOptions": [
            {
              "text": "100 mg/m2",
              "orderSentence": "Procarbazine (R-MPV regimen component) 100 mg/m2 PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg/m2 PO daily x 7 days on odd-numbered cycles (cycles 1, 3, 5); take on empty stomach; tyramine-free diet during and 2 weeks after (MAO inhibitor properties)",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CBC before each cycle",
          "LFTs",
          "educate on dietary restrictions (tyramine)",
          "rash (allergic dermatitis common, may require discontinuation)",
          "signs of peripheral neuropathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "prochlorperazine": {
      "id": "prochlorperazine",
      "name": "Prochlorperazine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "nausea-and-vomiting-refractory-to-ondansetron-also-effective": {
          "indication": "Nausea and vomiting refractory to ondansetron; also effective for headache with nausea",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Prochlorperazine 5-10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg IV q6-8h PRN; max 40 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "alternative-to-metoclopramide-preferred-if-stronger-anti-eme": {
          "indication": "Alternative to metoclopramide; preferred if stronger anti-emetic effect needed",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Prochlorperazine (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV slow push over 5-10 min; co-administer diphenhydramine 25 mg IV",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "moderate-severe-headache-with-nausea-dopamine-mediated-heada": {
          "indication": "Moderate-severe headache with nausea; dopamine-mediated headache relief",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Prochlorperazine (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV slow push over 5-10 min; may repeat once in 30 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "dopamine-antagonist-for-acute-migraine-with-prominent-nausea": {
          "indication": "Dopamine antagonist for acute migraine with prominent nausea",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Prochlorperazine 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV slowly over 2 min; pretreat with diphenhydramine 25 mg IV",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CNS depression",
          "Parkinson disease",
          "Parkinson's disease",
          "QT prolongation",
          "QT prolongation (QTc >500ms)",
          "QT prolongation, Parkinson disease, history of dystonic reaction",
          "neuroleptic malignant syndrome history",
          "seizure history (lowers threshold)",
          "severe hypotension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "EPS",
          "Extrapyramidal symptoms",
          "QTc",
          "QTc if baseline prolonged",
          "QTc, akathisia, dystonia, hypotension",
          "QTc, akathisia, dystonic reaction",
          "sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "headache-evaluation",
        "headache-unspecified",
        "migraine-with-aura",
        "viral-meningitis"
      ]
    },
    "prochlorperazine-iv": {
      "id": "prochlorperazine-iv",
      "name": "Prochlorperazine IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Prochlorperazine IV (CPT 96374) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV slow push over 5-10 min; may repeat in 30 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "first-line-ed-migraine-treatment-antiemetic-analgesic": {
          "indication": "First-line ED migraine treatment; antiemetic + analgesic",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Prochlorperazine IV 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV slow push over 5-10 min; may repeat x1 in 30 min; give with diphenhydramine",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "first-line-antiemetic-and-primary-analgesic-for-acute-migrai": {
          "indication": "First-line antiemetic and primary analgesic for acute migraine via dopamine antagonism",
          "doseOptions": [
            {
              "text": "10 mg IV once",
              "orderSentence": "Prochlorperazine IV 10 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV slow push over 5-10 min; may repeat x1 in 30 min; max 20 mg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation (QTc >500 ms), Parkinson disease, pheochromocytoma",
          "QT prolongation, Parkinson's",
          "QT prolongation, Parkinson's disease, seizure disorder"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "QTc, akathisia, dystonia",
          "QTc, akathisia, dystonic reaction, sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "status-migrainosus"
      ]
    },
    "prochlorperazine-suppository": {
      "id": "prochlorperazine-suppository",
      "name": "Prochlorperazine suppository",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PR"
      ],
      "formulations": [],
      "contexts": {
        "rescue-therapy-at-home-for-recurrent-nausea-headache": {
          "indication": "Rescue therapy at home for recurrent nausea/headache",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Prochlorperazine suppository 25 mg PR"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg PR q12h PRN; max 3 days",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Parkinson's disease",
          "QT prolongation"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Akathisia",
          "sedation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "headache-unspecified"
      ]
    },
    "promethazine-iv-im": {
      "id": "promethazine-iv-im",
      "name": "Promethazine IV/IM",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV, IM"
      ],
      "formulations": [],
      "contexts": {
        "antiemetic-and-sedative-adjunct-for-nausea-predominant-statu": {
          "indication": "Antiemetic and sedative adjunct for nausea-predominant status migrainosus when other antiemetics inadequate",
          "doseOptions": [
            {
              "text": "12.5 mg IV once",
              "orderSentence": "Promethazine IV/IM 12.5 mg IV once IV, IM"
            },
            {
              "text": "25 mg IM once",
              "orderSentence": "Promethazine IV/IM 25 mg IM once IV, IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "12.5-25 mg IV slow push (over 10-15 min to reduce phlebitis) or 25 mg deep IM; may repeat q4-6h; max 75 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation, respiratory depression (especially with opioids), tissue necrosis risk with IV extravasation"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation, respiratory status, IV site (severe vesicant)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "propofol": {
      "id": "propofol",
      "name": "Propofol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "sedation-during-ceeg": {
          "indication": "Sedation during cEEG",
          "doseOptions": [
            {
              "text": "5-50 mcg/kg",
              "orderSentence": "Propofol (sub-anesthetic) 5-50 mcg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-50 mcg/kg/min",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "sedation-during-ttm-additional-anti-seizure-properties-prefe": {
          "indication": "Sedation during TTM; additional anti-seizure properties; preferred for shorter-acting effect facilitating neurological assessment",
          "doseOptions": [
            {
              "text": "5-80 mcg/kg/min",
              "orderSentence": "Propofol 5-80 mcg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-50 mcg/kg/min; titrate to RASS -4 to -5 during active TTM; wean after rewarming",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "refractory-status-spasticus-not-responding-to-benzodiazepine": {
          "indication": "Refractory status spasticus not responding to benzodiazepines; ICU with mechanical ventilation",
          "doseOptions": [
            {
              "text": "20 mcg/kg/min",
              "orderSentence": "Propofol 20 mcg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.5-1 mg/kg IV bolus, then 20-50 mcg/kg/min infusion; titrate to spasm suppression; max 80 mcg/kg/min; avoid >48 hours at high doses",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Propofol allergy (egg/soy)",
          "Propofol infusion syndrome risk (monitor for metabolic acidosis, rhabdomyolysis, hypertriglyceridemia if >48h at high doses >70 mcg/kg/min)",
          "Same as anesthetic use",
          "egg/soy allergy",
          "hemodynamic instability",
          "propofol infusion syndrome risk >48h"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CK",
          "CK if prolonged use",
          "RASS",
          "Sedation scale",
          "Triglycerides q24h",
          "cEEG",
          "hemodynamics",
          "lactate",
          "metabolic panel",
          "propofol infusion syndrome (fever, rhabdo, metabolic acidosis, cardiac failure)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "status-epilepticus",
        "stiff-person-syndrome"
      ]
    },
    "propofol-infusion": {
      "id": "propofol-infusion",
      "name": "Propofol infusion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-status-epilepticus": {
          "indication": "Refractory status epilepticus",
          "doseOptions": [
            {
              "text": "1-2 mg/kg",
              "orderSentence": "Propofol infusion (refractory SE) 1-2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bolus: 1-2 mg/kg IV; Infusion: 20-80 mcg/kg/min (max 5 mg/kg/hr to avoid PRIS)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "severe-refractory-withdrawal-with-seizures-requiring-icu-lev": {
          "indication": "Severe refractory withdrawal with seizures requiring ICU-level sedation; GABA-A and NMDA activity",
          "doseOptions": [
            {
              "text": "1-2 mg/kg bolus, then 20-80 mcg/kg/min",
              "orderSentence": "Propofol infusion 1-2 mg/kg bolus, then 20-80 mcg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load 1-2 mg/kg IV bolus; infusion 20-80 mcg/kg/min; titrate to RASS -2 to -3; max 200 mcg/kg/min; limit duration <48h at high doses",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1-2 mg/kg",
              "orderSentence": "Propofol infusion 1-2 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 1-2 mg/kg IV bolus (may repeat x1); Infusion: start 20 mcg/kg/min, titrate by 10 mcg/kg/min q5min; max 200 mcg/kg/min; target burst suppression",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus",
            "autoimmune-encephalitis"
          ]
        },
        "refractory-ncse-rapid-onset-requires-intubation-icu": {
          "indication": "Refractory NCSE; rapid onset; requires intubation/ICU",
          "doseOptions": [
            {
              "text": "1 mg/kg",
              "orderSentence": "Propofol infusion 1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bolus: 1-2 mg/kg IV; Infusion: 20-80 mcg/kg/min; max 5 mg/kg/hr (higher doses increase PRIS risk); wean q24-48h",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Propofol infusion syndrome (PRIS) risk at high doses/prolonged use",
          "Propofol infusion syndrome risk",
          "Propofol infusion syndrome risk (limit to <48h at high dose), egg/soy allergy, pregnancy",
          "Propofol infusion syndrome risk (prolonged use >48h at high doses)",
          "egg/soy allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CPK",
          "Continuous EEG",
          "PRIS surveillance",
          "PRIS surveillance (metabolic acidosis + rhabdomyolysis + cardiac failure + lipemia)",
          "cEEG if concern for seizures",
          "cEEG, triglycerides q24-48h, CPK, metabolic acidosis, BP",
          "hemodynamics",
          "lactate",
          "metabolic acidosis panel",
          "triglycerides q24h",
          "triglycerides q48h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "autoimmune-encephalitis",
        "hashimotos-encephalopathy",
        "ncse",
        "status-epilepticus"
      ]
    },
    "propofol-sub-anesthetic-bolus": {
      "id": "propofol-sub-anesthetic-bolus",
      "name": "Propofol sub-anesthetic bolus",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "brief-burst-like-suppression-of-migraine-pain-via-gaba-modul": {
          "indication": "Brief burst-like suppression of migraine pain via GABA modulation; requires monitored setting",
          "doseOptions": [
            {
              "text": "20-30 mg IV once",
              "orderSentence": "Propofol sub-anesthetic bolus 20-30 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-30 mg IV bolus; may repeat q5min up to 100 mg total; must have respiratory monitoring",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Egg/soy allergy, hemodynamic instability, respiratory compromise without airway support"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "O2 sat, BP, respiratory status",
          "requires procedural sedation monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "propranolol": {
      "id": "propranolol",
      "name": "Propranolol",
      "genericName": "propranolol",
      "brandNames": [
        "Inderal",
        "Inderal LA",
        "InnoPran XL"
      ],
      "drugClass": "Non-selective Beta-Blocker",
      "mechanisms": [
        "Blocks beta-1 and beta-2 adrenergic receptors",
        "Reduces sympathetic nervous system activity"
      ],
      "routes": [
        "PO",
        "IV"
      ],
      "formulations": [
        "10 mg tablet",
        "20 mg tablet",
        "40 mg tablet",
        "60 mg tablet",
        "80 mg tablet",
        "60 mg LA capsule",
        "80 mg LA capsule",
        "120 mg LA capsule",
        "160 mg LA capsule",
        "1 mg/mL IV solution"
      ],
      "contexts": {
        "essential-tremor": {
          "indication": "Essential tremor (first-line)",
          "doseOptions": [
            {
              "text": "20 mg BID",
              "orderSentence": "Propranolol 20 mg PO BID"
            },
            {
              "text": "40 mg BID",
              "orderSentence": "Propranolol 40 mg PO BID"
            },
            {
              "text": "60 mg TID",
              "orderSentence": "Propranolol 60 mg PO TID"
            },
            {
              "text": "80 mg TID",
              "orderSentence": "Propranolol 80 mg PO TID"
            }
          ],
          "startingDose": "20-40 mg BID",
          "maxDose": "320 mg/day",
          "titration": "Increase every 1-2 weeks as tolerated",
          "notes": "First-line for essential tremor; 50-70% response rate"
        },
        "migraine-prophylaxis": {
          "indication": "Migraine prophylaxis",
          "doseOptions": [
            {
              "text": "40 mg BID",
              "orderSentence": "Propranolol 40 mg PO BID"
            },
            {
              "text": "60 mg BID",
              "orderSentence": "Propranolol 60 mg PO BID"
            },
            {
              "text": "80 mg BID",
              "orderSentence": "Propranolol 80 mg PO BID"
            },
            {
              "text": "80 mg LA daily",
              "orderSentence": "Propranolol LA 80 mg PO daily"
            },
            {
              "text": "160 mg LA daily",
              "orderSentence": "Propranolol LA 160 mg PO daily"
            }
          ],
          "startingDose": "40 mg BID or 80 mg LA daily",
          "maxDose": "240 mg/day",
          "titration": "Increase every 2-4 weeks",
          "notes": "First-line for migraine prophylaxis; Level A evidence"
        },
        "akathisia": {
          "indication": "Drug-induced akathisia",
          "doseOptions": [
            {
              "text": "10 mg TID",
              "orderSentence": "Propranolol 10 mg PO TID"
            },
            {
              "text": "20 mg TID",
              "orderSentence": "Propranolol 20 mg PO TID"
            },
            {
              "text": "40 mg TID",
              "orderSentence": "Propranolol 40 mg PO TID"
            }
          ],
          "startingDose": "10-20 mg TID",
          "maxDose": "120 mg/day",
          "titration": "Increase as needed for symptom control",
          "notes": "First-line for neuroleptic-induced akathisia"
        },
        "anxiety-with-somatic-symptoms-palpitations-tremor-comorbid-m": {
          "indication": "Anxiety with somatic symptoms (palpitations, tremor); comorbid migraine",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Propranolol 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg PO BID; titrate q1wk; max 80 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "functional-neurological-disorder"
          ]
        },
        "for-tardive-akathisia-component": {
          "indication": "For tardive akathisia component",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Propranolol 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg TID; titrate to 30-120 mg/day divided",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Propranolol 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 40 mg BID; titrate to 80-160 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache",
            "essential-tremor",
            "migraine"
          ]
        },
        "preventive-for-post-traumatic-headache": {
          "indication": "Preventive for post-traumatic headache",
          "doseOptions": [
            {
              "text": "20-40 mg",
              "orderSentence": "Propranolol 20-40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20-40 mg PO BID; target 80-240 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "empiric-symptomatic-relief-for-functionally-impairing-tremor": {
          "indication": "Empiric symptomatic relief for functionally impairing tremor while diagnostic workup in progress; effective for postural and action tremor",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Propranolol (empiric) 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20 mg BID; titrate by 20 mg q3-7d based on response and tolerability; target 60-320 mg/day in divided doses; use LA formulation once optimal dose determined",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "first-line-empiric-for-postural-action-tremor-pending-diagno": {
          "indication": "First-line empiric for postural/action tremor pending diagnosis; effective for essential tremor and enhanced physiologic tremor",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Propranolol (Inderal) 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20 mg BID; titrate by 20 mg q3-7d; target 60-320 mg/day divided BID-TID; Inderal LA 60-320 mg daily once stable dose determined",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "tremor": {
          "indication": "Tremor",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Propranolol 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20 mg BID; increase by 20-40 mg every 3-7 days; max 320 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "cerebellar-action-tremor-kinetic-intention-tremor-component-": {
          "indication": "Cerebellar action tremor (kinetic/intention tremor component); reduces tremor amplitude",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Propranolol 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20 mg BID; titrate by 20 mg/dose q1 week; max 320 mg/day; use LA formulation for once-daily dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "first-line-comorbid-anxiety-hypertension-or-essential-tremor": {
          "indication": "First-line; comorbid anxiety, hypertension, or essential tremor",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Propranolol 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 40 mg BID; increase every 1-2 weeks; target 80-240 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "first-line-prevention-comorbid-htn-anxiety-tremor": {
          "indication": "First-line prevention; comorbid HTN, anxiety, tremor",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Propranolol 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 40 mg BID or 80 mg LA daily; titrate q2wk; target 80-240 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        },
        "tremor-postural-action-component": {
          "indication": "Tremor (postural/action component)",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Propranolol 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20 mg BID; titrate to 120-240 mg/day; limited efficacy for wing-beating tremor",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [
          "Do not discontinue abruptly - risk of exacerbation of angina, MI, or arrhythmia"
        ],
        "contraindications": [
          "Cardiogenic shock",
          "Sinus bradycardia, heart block greater than first degree",
          "Bronchial asthma or severe COPD",
          "Decompensated heart failure"
        ],
        "precautions": [
          "May mask hypoglycemia symptoms in diabetics",
          "May worsen peripheral vascular disease",
          "Use with caution in hepatic impairment",
          "May worsen psoriasis",
          "Fatigue, exercise intolerance common",
          "May cause depression"
        ],
        "drugInteractions": [
          {
            "drug": "Calcium channel blockers (verapamil, diltiazem)",
            "severity": "high",
            "effect": "Risk of severe bradycardia and heart block"
          },
          {
            "drug": "Clonidine",
            "severity": "high",
            "effect": "Rebound hypertension if clonidine stopped first"
          },
          {
            "drug": "Antidiabetics",
            "severity": "moderate",
            "effect": "Masks hypoglycemia symptoms; prolongs hypoglycemia"
          },
          {
            "drug": "CYP2D6 inhibitors",
            "severity": "moderate",
            "effect": "Increased propranolol levels"
          },
          {
            "drug": "Epinephrine",
            "severity": "moderate",
            "effect": "Hypertensive response, bradycardia"
          }
        ],
        "pregnancyCategory": "C",
        "lactation": "Compatible with breastfeeding"
      },
      "renalAdjustment": {
        "required": false,
        "tiers": [
          {
            "gfr": "any",
            "adjustment": "No adjustment needed - hepatically metabolized"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": true,
        "notes": "Reduce dose by 50% in hepatic impairment; extensive first-pass metabolism"
      },
      "monitoring": {
        "baseline": [
          "Heart rate",
          "Blood pressure",
          "ECG if cardiac history"
        ],
        "ongoing": [
          "Heart rate",
          "Blood pressure",
          "Signs of heart failure"
        ],
        "frequency": "At each visit during titration"
      },
      "patientCounseling": [
        "Do not stop abruptly - taper over 1-2 weeks",
        "May cause fatigue, especially initially",
        "Take pulse - notify if <50 bpm",
        "Diabetics: may mask hypoglycemia symptoms",
        "May worsen asthma - use with extreme caution"
      ]
    },
    "propranolol-la": {
      "id": "propranolol-la",
      "name": "Propranolol LA",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "60-80 mg",
              "orderSentence": "Propranolol LA 60-80 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 60-80 mg daily; titrate to 160-320 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "essential-tremor"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "essential-tremor"
      ]
    },
    "propylthiouracil": {
      "id": "propylthiouracil",
      "name": "Propylthiouracil (PTU)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "hyperthyroid-tremor-use-in-first-trimester-pregnancy-or-when": {
          "indication": "Hyperthyroid tremor; use in first trimester pregnancy or when methimazole is contraindicated",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Propylthiouracil (PTU) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg TID; titrate per thyroid function; typical range 100-200 mg TID; tremor resolves with euthyroid state; endocrinology co-management",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hepatotoxicity (black box warning)",
          "prior agranulocytosis from antithyroid drugs"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC (agranulocytosis risk)",
          "LFTs q1-3 months (hepatotoxicity -- black box)",
          "Thyroid function tests q4-8 weeks initially",
          "instruct patient to report jaundice, dark urine, abdominal pain"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tremor-unspecified"
      ]
    },
    "protriptyline": {
      "id": "protriptyline",
      "name": "Protriptyline",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "anticataplectic-agent-with-stimulant-properties-less-sedatin": {
          "indication": "Anticataplectic agent with stimulant properties; less sedating TCA",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Protriptyline 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg in the morning; titrate by 5-10 mg every 1-2 weeks; max 60 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Recent MI",
          "cardiac conduction disease",
          "concurrent MAOIs",
          "narrow-angle glaucoma",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG if dose >20 mg/day or age >40",
          "anticholinergic effects",
          "dry mouth",
          "urinary retention"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "narcolepsy"
      ]
    },
    "pyrazinamide": {
      "id": "pyrazinamide",
      "name": "Pyrazinamide (PZA)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-anti-tb-therapy-excellent-cns-penetration-most-ef": {
          "indication": "First-line anti-TB therapy; excellent CNS penetration; most effective sterilizing agent in first 2 months; bactericidal at acidic pH (in caseous granulomas)",
          "doseOptions": [
            {
              "text": "25 mg/kg daily (max 2000 mg)",
              "orderSentence": "Pyrazinamide (PZA) 25 mg/kg daily (max 2000 mg) PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg/kg PO daily (max 2000 mg/day); round to nearest 250 mg; duration: 2 months (intensive phase only)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic disease",
          "acute gout (causes hyperuricemia)",
          "porphyria"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs at baseline, 2 weeks, monthly during PZA use",
          "joint pain assessment",
          "uric acid (expect elevation — treat only symptomatic gout)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tb-meningitis"
      ]
    },
    "pyridostigmine": {
      "id": "pyridostigmine",
      "name": "Pyridostigmine",
      "genericName": "pyridostigmine bromide",
      "brandNames": [
        "Mestinon",
        "Mestinon Timespan",
        "Regonol"
      ],
      "drugClass": "Acetylcholinesterase Inhibitor",
      "mechanisms": [
        "Inhibits acetylcholinesterase",
        "Increases acetylcholine at neuromuscular junction"
      ],
      "routes": [
        "PO",
        "IV",
        "IM"
      ],
      "formulations": [
        "60 mg tablet",
        "180 mg extended-release tablet",
        "60 mg/5mL syrup",
        "5 mg/mL injection"
      ],
      "contexts": {
        "myasthenia-gravis": {
          "indication": "Myasthenia gravis - symptomatic treatment",
          "doseOptions": [
            {
              "text": "30 mg TID",
              "orderSentence": "Pyridostigmine 30 mg PO TID"
            },
            {
              "text": "60 mg TID",
              "orderSentence": "Pyridostigmine 60 mg PO TID"
            },
            {
              "text": "60 mg QID",
              "orderSentence": "Pyridostigmine 60 mg PO QID"
            },
            {
              "text": "90 mg TID",
              "orderSentence": "Pyridostigmine 90 mg PO TID"
            },
            {
              "text": "120 mg TID",
              "orderSentence": "Pyridostigmine 120 mg PO TID"
            }
          ],
          "startingDose": "30-60 mg TID",
          "maxDose": "120 mg q3h (rarely >600-720 mg/day needed)",
          "titration": "Increase by 30-60 mg per dose every 3-7 days as needed",
          "notes": "Symptomatic only - does not modify disease; use lowest effective dose"
        },
        "myasthenia-gravis-severe": {
          "indication": "Myasthenia gravis - severe/crisis (NPO patients)",
          "doseOptions": [
            {
              "text": "2 mg IV q2-3h",
              "orderSentence": "Pyridostigmine 2 mg IV q2-3h"
            }
          ],
          "startingDose": "1-2 mg IV q2-3h",
          "maxDose": "Titrate to effect",
          "titration": "N/A - use for NPO patients only",
          "notes": "IV dose is 1/30 of oral dose; use only when oral not possible"
        },
        "orthostatic-hypotension": {
          "indication": "Neurogenic orthostatic hypotension",
          "doseOptions": [
            {
              "text": "30 mg TID",
              "orderSentence": "Pyridostigmine 30 mg PO TID"
            },
            {
              "text": "60 mg TID",
              "orderSentence": "Pyridostigmine 60 mg PO TID"
            }
          ],
          "startingDose": "30 mg TID",
          "maxDose": "60 mg TID",
          "titration": "Increase as tolerated",
          "notes": "Off-label; augments ganglionic transmission without supine hypertension"
        },
        "symptomatic-weakness-improvement": {
          "indication": "Symptomatic weakness improvement",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Pyridostigmine (when stable/recovering) 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Resume at 30 mg PO TID during recovery; titrate by 30 mg/dose q3-5 days to 60 mg PO q4-6h; max 120 mg q4h (rarely needed). Take 30-60 min before meals for dysphagia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "30-60 mg",
              "orderSentence": "Pyridostigmine 30-60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30-60 mg TID; augments ganglionic transmission",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "syncope"
          ]
        },
        "orthostatic-hypotension-enhances-ganglionic-transmission": {
          "indication": "Orthostatic hypotension; enhances ganglionic transmission",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Pyridostigmine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg TID; may increase to 60 mg TID; modest BP effect but no supine hypertension",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "first-line-symptomatic-treatment-for-all-mg-subtypes": {
          "indication": "First-line symptomatic treatment for all MG subtypes",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Pyridostigmine 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg TID; increase by 30 mg/dose every 3-5 days as tolerated; usual maintenance 60 mg q4-6h (max 120 mg q4h); take 30-60 min before meals for swallowing",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "orthostatic-hypotension-off-label": {
          "indication": "Orthostatic hypotension (off-label)",
          "doseOptions": [
            {
              "text": "30-60 mg",
              "orderSentence": "Pyridostigmine 30-60 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30-60 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "adjunctive-symptomatic-treatment-enhances-postsynaptic-acety": {
          "indication": "Adjunctive symptomatic treatment; enhances postsynaptic acetylcholine effect; less effective in LEMS than in MG but may provide modest additional benefit when combined with 3,4-DAP",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Pyridostigmine (Mestinon) 30 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg TID; increase by 30 mg per dose every 2-3 days; usual effective dose 60 mg q4-6h; max 120 mg per dose; less effective as monotherapy in LEMS than MG",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "neurogenic-oh-enhances-ganglionic-transmission-reduces-oh-wi": {
          "indication": "Neurogenic OH — enhances ganglionic transmission; reduces OH without supine hypertension",
          "doseOptions": [
            {
              "text": "30 mg TID",
              "orderSentence": "Pyridostigmine (Mestinon) 30 mg TID PO"
            },
            {
              "text": "60 mg TID",
              "orderSentence": "Pyridostigmine (Mestinon) 60 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 30 mg TID; increase to 60 mg TID if tolerated; modest effect on OH; advantage: does NOT worsen supine hypertension",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Mechanical GI or urinary obstruction",
          "Known hypersensitivity"
        ],
        "precautions": [
          "Cholinergic crisis with overdose (excessive secretions, bradycardia, weakness)",
          "Distinguish myasthenic crisis from cholinergic crisis",
          "Bronchospasm in asthmatics",
          "GI effects (cramping, diarrhea, nausea)",
          "Bradycardia",
          "Increased secretions"
        ],
        "drugInteractions": [
          {
            "drug": "Anticholinergics",
            "severity": "high",
            "effect": "Antagonize pyridostigmine effect"
          },
          {
            "drug": "Aminoglycosides",
            "severity": "moderate",
            "effect": "May worsen myasthenia"
          },
          {
            "drug": "Beta-blockers",
            "severity": "moderate",
            "effect": "Additive bradycardia"
          },
          {
            "drug": "Succinylcholine",
            "severity": "moderate",
            "effect": "Prolonged neuromuscular blockade"
          }
        ],
        "pregnancyCategory": "C",
        "lactation": "Compatible - poorly excreted in milk"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {
            "gfr": "≥30",
            "adjustment": "No adjustment typically needed"
          },
          {
            "gfr": "<30",
            "adjustment": "Reduce dose; renally excreted"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment needed"
      },
      "monitoring": {
        "baseline": [
          "Clinical assessment of MG symptoms"
        ],
        "ongoing": [
          "Symptom control",
          "Signs of cholinergic excess (SLUDGE)",
          "Heart rate"
        ],
        "frequency": "Frequent initially to optimize dosing"
      },
      "patientCounseling": [
        "Take 30-60 minutes before meals",
        "Dose before activities requiring strength",
        "Report excessive salivation, sweating, diarrhea, or worsening weakness",
        "Carry medical ID indicating myasthenia gravis",
        "Do not take more than prescribed - overdose can worsen weakness"
      ]
    },
    "pyridostigmine-sr": {
      "id": "pyridostigmine-sr",
      "name": "Pyridostigmine SR (Mestinon Timespan)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nocturnal-symptoms-morning-weakness-on-awakening": {
          "indication": "Nocturnal symptoms; morning weakness on awakening",
          "doseOptions": [
            {
              "text": "180 mg",
              "orderSentence": "Pyridostigmine SR (Mestinon Timespan) 180 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "180 mg at bedtime for nocturnal weakness; do NOT crush; erratic absorption limits daytime use; max 1 tablet daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Mechanical bowel/bladder obstruction",
          "known hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cholinergic symptoms (SLUDGE)",
          "bradycardia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "myasthenia-gravis"
      ]
    },
    "pyridoxine": {
      "id": "pyridoxine",
      "name": "Pyridoxine (empiric trial)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100-500 mg",
              "orderSentence": "Pyridoxine (empiric trial) 100-500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-500 mg IV; may try single dose empirically",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "prevention-of-isoniazid-induced-peripheral-neuropathy-always": {
          "indication": "Prevention of isoniazid-induced peripheral neuropathy; ALWAYS co-prescribe with INH",
          "doseOptions": [
            {
              "text": "25-50 mg daily",
              "orderSentence": "Pyridoxine (vitamin B6) 25-50 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg PO daily throughout INH therapy; use 50 mg daily if HIV co-infection, diabetes, alcoholism, malnutrition, or pre-existing neuropathy",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        },
        "neuropathy-prevention-throughout-inh-therapy": {
          "indication": "Neuropathy prevention throughout INH therapy",
          "doseOptions": [
            {
              "text": "25-50 mg daily",
              "orderSentence": "Pyridoxine (vitamin B6 — continuation) 25-50 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg PO daily for duration of INH therapy",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        },
        "required-supplement-with-d-penicillamine-therapy-penicillami": {
          "indication": "Required supplement with D-penicillamine therapy (penicillamine depletes B6)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Pyridoxine (Vitamin B6) 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25 mg PO daily; co-administer with penicillamine",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None",
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Clinical assessment",
          "Clinical neuropathy assessment",
          "Clinical neuropathy assessment at each visit",
          "Response to treatment",
          "peripheral neuropathy symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "status-epilepticus",
        "tb-meningitis",
        "wilsons-disease"
      ]
    },
    "pyrimethamine": {
      "id": "pyrimethamine",
      "name": "Pyrimethamine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "toxoplasma-brain-abscess-first-line-hiv-aids-with-cd4-100-an": {
          "indication": "Toxoplasma brain abscess (first-line); HIV/AIDS with CD4 <100 and ring-enhancing lesions; MUST co-administer with sulfadiazine and leucovorin",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Pyrimethamine 200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Pyrimethamine 200 mg PO load x1, then 50-75 mg PO daily; treat 6 weeks minimum then maintenance; always co-administer with sulfadiazine and leucovorin",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bone marrow suppression",
          "megaloblastic anemia",
          "must give leucovorin concurrently"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC twice weekly x 2 weeks then weekly",
          "LFTs",
          "leucovorin compliance essential",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-abscess"
      ]
    },
    "quetiapine": {
      "id": "quetiapine",
      "name": "Quetiapine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "severe-agitation-psychosis-when-non-pharmacologic-interventi": {
          "indication": "Severe agitation/psychosis when non-pharmacologic interventions fail",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Quetiapine (Seroquel) 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5-25 mg qHS; titrate slowly; keep dose as low as possible",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "psychosis-irritability-insomnia-less-eps-than-other-antipsyc": {
          "indication": "Psychosis; irritability; insomnia; less EPS than other antipsychotics",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Quetiapine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg qHS; titrate by 25-50 mg q3d; typical 150-400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "low-risk-antipsychotic-substitute-when-continued-antipsychot": {
          "indication": "Low-risk antipsychotic substitute when continued antipsychotic therapy required; low D2 receptor affinity",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Quetiapine (Seroquel) 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg QHS; titrate based on psychiatric response; usual range 150-800 mg/day; lowest effective dose to minimize EPS risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        },
        "psychosis-agitation-sleep-disruption": {
          "indication": "Psychosis, agitation, sleep disruption",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Quetiapine (psychosis/insomnia) 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg qHS; titrate to 200-400 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "psychotic-symptoms-general-paresis-with-psychosis-paranoid-d": {
          "indication": "Psychotic symptoms (general paresis with psychosis, paranoid delusions, grandiosity)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Quetiapine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg BID; titrate slowly to 50-100 mg BID; target 150-300 mg/day for psychosis",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "severe-psychosis-agitation-when-non-pharmacologic-fails": {
          "indication": "Severe psychosis/agitation when non-pharmacologic fails",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Quetiapine (if antipsychotic absolutely needed) 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg qHS; increase slowly by 12.5 mg q3-7d; max 50-100 mg; lowest effective dose for shortest time",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "agitation-psychosis-or-severe-behavioral-disturbance-in-had-": {
          "indication": "Agitation, psychosis, or severe behavioral disturbance in HAD; lowest effective dose; use non-pharmacologic interventions first",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Quetiapine 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5-25 mg QHS; titrate slowly to lowest effective dose; max 100-200 mg for behavioral symptoms in dementia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "agitation-psychosis-or-behavioral-disturbance-in-psp-safest-": {
          "indication": "Agitation, psychosis, or behavioral disturbance in PSP; safest antipsychotic in parkinsonian syndromes",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Quetiapine 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg QHS; titrate slowly to 25-100 mg QHS; lowest effective dose",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "agitation-psychosis-behavioral-disturbance-in-cjd-preferred-": {
          "indication": "Agitation, psychosis, behavioral disturbance in CJD -- preferred atypical antipsychotic due to lower EPS risk",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Quetiapine (agitation/psychosis) 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO qHS; increase by 25 mg/day every 2-3 days; max 200-400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "agitation-psychosis-behavioral-disturbance": {
          "indication": "Agitation, psychosis, behavioral disturbance",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Quetiapine 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg PO qHS; increase by 25 mg/day; max 200-400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        },
        "severe-agitation-psychosis-when-non-pharmacologic-and-first-": {
          "indication": "Severe agitation/psychosis when non-pharmacologic and first-line fail",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Quetiapine (Seroquel) 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5-25 mg qHS; titrate slowly (25 mg increments); keep dose as low as possible; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "severe-agitation-psychosis-when-non-pharmacologic-fails": {
          "indication": "Severe agitation/psychosis when non-pharmacologic fails",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Quetiapine (Seroquel) 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5-25 mg qHS; titrate slowly (25 mg increments); keep dose as low as possible",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Quetiapine (psychosis/insomnia) 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg qHS; titrate to 200-400 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        },
        "psychosis-alternative-if-pimavanserin-unavailable": {
          "indication": "Psychosis; alternative if pimavanserin unavailable",
          "doseOptions": [
            {
              "text": "12.5 mg qHS",
              "orderSentence": "Quetiapine 12.5 mg qHS PO"
            },
            {
              "text": "25 mg qHS",
              "orderSentence": "Quetiapine 25 mg qHS PO"
            },
            {
              "text": "50 mg qHS",
              "orderSentence": "Quetiapine 50 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5-25 mg qHS; titrate slowly by 12.5-25 mg q3-7d; typical max 150 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        },
        "psychosis-agitation-behavioral-disturbance": {
          "indication": "Psychosis, agitation, behavioral disturbance",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Quetiapine 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg QHS; titrate cautiously to 50-200 mg/day; avoid typical antipsychotics (worsen movement disorder)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Black box: increased mortality and stroke in dementia",
          "Black box: increased mortality in dementia",
          "Dementia with Lewy bodies (black box)",
          "Lewy body dementia (must distinguish from CJD -- DLB has worse antipsychotic sensitivity)",
          "Parkinson disease (avoid all antipsychotics in Lewy body)",
          "Parkinson's (less risk than other antipsychotics)",
          "Parkinson's (less risk than others)",
          "Parkinsonism",
          "QT prolongation",
          "QTc prolongation",
          "Uncontrolled diabetes",
          "avoid in FTD-parkinsonism",
          "avoid typical antipsychotics (D2 blockade worsens dystonia/parkinsonism)",
          "concurrent use of strong CYP3A4 inhibitors",
          "dementia-related psychosis (black box)",
          "metabolic syndrome",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "**Caution: metabolic effects compound ART metabolic toxicity**",
          "EPS",
          "EPS monitoring",
          "Glucose, lipids, QTc",
          "Metabolic effects",
          "Metabolic panel (glucose, lipids), weight, QTc, sedation, orthostatic BP",
          "Metabolic panel q3 months",
          "Monitor for worsening parkinsonism, sedation",
          "QTc",
          "QTc, fasting glucose, lipids, weight",
          "QTc, metabolic panel, sedation",
          "Sedation, metabolic effects, QTc",
          "fall risk",
          "falls",
          "fasting glucose",
          "glucose",
          "increased mortality risk (black box warning in dementia)",
          "lipids",
          "metabolic panel",
          "metabolic parameters",
          "orthostatic BP",
          "sedation",
          "tardive dyskinesia monitoring",
          "use ONLY atypical antipsychotics",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 15,
      "_sourcePlans": [
        "alzheimers-disease",
        "autoimmune-encephalitis",
        "creutzfeldt-jakob-disease",
        "drug-induced-parkinsonism",
        "frontotemporal-dementia",
        "hashimotos-encephalopathy",
        "hiv-associated-neurocognitive-disorder",
        "huntingtons-disease",
        "lewy-body-dementia",
        "neurosyphilis",
        "parkinsons-disease",
        "progressive-supranuclear-palsy",
        "rapidly-progressive-dementia",
        "vascular-dementia",
        "wilsons-disease"
      ]
    },
    "quinine-and-chloroquine": {
      "id": "quinine-and-chloroquine",
      "name": "Quinine and chloroquine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "cinchonism-tinnitus-hearing-loss-vertigo-usually-reversible": {
          "indication": "Cinchonism (tinnitus, hearing loss, vertigo); usually reversible",
          "doseOptions": [
            {
              "text": "-",
              "orderSentence": "**Quinine and chloroquine** - PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Reversible ototoxicity; reduce dose if tinnitus develops; hydroxychloroquine lower risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pre-existing tinnitus at therapeutic doses"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Monitor for tinnitus onset",
          "reduce dose if symptoms develop"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tinnitus-evaluation"
      ]
    },
    "quinine-sulfate": {
      "id": "quinine-sulfate",
      "name": "Quinine sulfate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "muscle-cramps-limited-use": {
          "indication": "Muscle cramps (limited use)",
          "doseOptions": [
            {
              "text": "200-300 mg",
              "orderSentence": "Quinine sulfate 200-300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200-300 mg PO at bedtime; FDA warns against off-label use for cramps",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "G6PD deficiency",
          "Thrombocytopenia",
          "myasthenia",
          "prolonged QT"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC, cardiac rhythm",
          "FDA black box warning for thrombocytopenia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "radiation-surgery-steroids": {
      "id": "radiation-surgery-steroids",
      "name": "Radiation + surgery + steroids",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Radiation + surgery + steroids 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Per oncology; dexamethasone 10 mg IV load → 4 mg IV q6h while radiation planned",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI prophylaxis",
          "Glucose"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "acute-myelopathy"
      ]
    },
    "radiation-therapy": {
      "id": "radiation-therapy",
      "name": "Radiation therapy (SCLC)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "EXT"
      ],
      "formulations": [],
      "contexts": {
        "limited-stage-sclc-with-or-without-concurrent-chemotherapy-p": {
          "indication": "Limited-stage SCLC with or without concurrent chemotherapy; palliative radiation for extensive-stage",
          "doseOptions": [
            {
              "text": "Per radiation oncology protocol",
              "orderSentence": "Radiation therapy (SCLC) Per radiation oncology protocol EXT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Concurrent chemoradiation for limited stage; palliative for extensive stage; prophylactic cranial irradiation per oncology",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per radiation oncology assessment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Neurological function",
          "esophagitis",
          "pneumonitis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "lambert-eaton-syndrome"
      ]
    },
    "radiologically-inserted-gastrostomy": {
      "id": "radiologically-inserted-gastrostomy",
      "name": "Radiologically-inserted gastrostomy (RIG)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "—"
      ],
      "formulations": [],
      "contexts": {
        "peg-contraindicated-fvc-50": {
          "indication": "PEG contraindicated; FVC <50%",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Radiologically-inserted gastrostomy (RIG) N/A —"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Alternative to PEG when FVC <50% or unable to tolerate endoscopy; fluoroscopic placement",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe ascites",
          "peritoneal adhesions"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Weight, tube site"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "ramelteon": {
      "id": "ramelteon",
      "name": "Ramelteon",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "sleep-onset-insomnia-melatonin-receptor-agonist": {
          "indication": "Sleep onset insomnia (melatonin receptor agonist)",
          "doseOptions": [
            {
              "text": "8 mg",
              "orderSentence": "Ramelteon 8 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8 mg PO QHS 30 minutes before bedtime",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment, concurrent fluvoxamine"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Well tolerated",
          "no abuse potential"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "post-concussion-syndrome"
      ]
    },
    "rasagiline": {
      "id": "rasagiline",
      "name": "Rasagiline",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "mao-b-inhibitor-once-daily-adjunct-or-monotherapy": {
          "indication": "MAO-B inhibitor; once daily; adjunct or monotherapy",
          "doseOptions": [
            {
              "text": "0.5 mg daily",
              "orderSentence": "Rasagiline 0.5 mg daily PO"
            },
            {
              "text": "1 mg daily",
              "orderSentence": "Rasagiline 1 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5-1 mg daily; max 1 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as selegiline"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Hypertensive crisis (rare)",
          "serotonin syndrome with other serotonergics"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease"
      ]
    },
    "ravulizumab": {
      "id": "ravulizumab",
      "name": "Ravulizumab (Ultomiris)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "achr-refractory-generalized-mg-longer-dosing-interval": {
          "indication": "AChR+ refractory generalized MG; longer dosing interval",
          "doseOptions": [
            {
              "text": "2700 mg",
              "orderSentence": "Ravulizumab (Ultomiris) 2700 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 40-60 kg: 2400 mg; 60-100 kg: 2700 mg; >100 kg: 3000 mg; Maintenance q8 weeks: 40-60 kg: 3000 mg; 60-100 kg: 3300 mg; >100 kg: 3600 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "fda-approved-for-aqp4-nmosd-long-acting-complement-c5-inhibi": {
          "indication": "FDA-approved for AQP4+ NMOSD; long-acting complement C5 inhibitor",
          "doseOptions": [
            {
              "text": "Weight-based loading then q8wk",
              "orderSentence": "**Ravulizumab (Ultomiris)** Weight-based loading then q8wk IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Loading dose: 2400-3000 mg IV (weight-based); maintenance: 3000-3600 mg IV every 8 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Ravulizumab (Ultomiris) N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Weight-based loading dose IV, then maintenance every 8 weeks; for AChR-positive generalized MG",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as eculizumab",
          "Unresolved Neisseria meningitidis infection",
          "not current with meningococcal vaccines"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Meningococcal infection risk (BLACK BOX)",
          "Same as eculizumab",
          "infusion reactions",
          "less frequent dosing advantage",
          "less frequent dosing improves adherence",
          "less frequent infusions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "myasthenia-gravis",
        "myasthenia-gravis-new-diagnosis",
        "nmosd"
      ]
    },
    "refractory-hypertension-fenoldopam-iv": {
      "id": "refractory-hypertension-fenoldopam-iv",
      "name": "Refractory hypertension: Fenoldopam IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-hypertensive-emergency-not-controlled-by-nicardip": {
          "indication": "Refractory hypertensive emergency not controlled by nicardipine/labetalol; selective dopamine-1 agonist that preserves renal perfusion",
          "doseOptions": [
            {
              "text": "0.1-0.3 mcg/kg/min",
              "orderSentence": "Refractory hypertension: Fenoldopam IV 0.1-0.3 mcg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.1 mcg/kg/min; titrate by 0.05-0.1 mcg/kg/min every 15 min; max 1.6 mcg/kg/min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Glaucoma (increases intraocular pressure)",
          "sulfite allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous BP",
          "heart rate",
          "intraocular pressure if glaucoma history",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "refractory-hypertension-nitroprusside-iv": {
      "id": "refractory-hypertension-nitroprusside-iv",
      "name": "Refractory hypertension: Nitroprusside IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "last-resort-iv-antihypertensive-for-severe-refractory-hypert": {
          "indication": "Last-resort IV antihypertensive for severe refractory hypertension; avoid if possible due to cerebral vasodilation and ICP elevation risk",
          "doseOptions": [
            {
              "text": "0.25-0.5 mcg/kg/min",
              "orderSentence": "Refractory hypertension: Nitroprusside IV 0.25-0.5 mcg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mcg/kg/min; titrate by 0.25 mcg/kg/min; max 10 mcg/kg/min; limit duration (<48h) due to cyanide toxicity",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Elevated ICP (relative -- may worsen)",
          "Leber optic atrophy",
          "hepatic failure",
          "vitamin B12 deficiency"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous arterial line BP",
          "ICP monitoring",
          "cyanide/thiocyanate levels if >48h or dose >3 mcg/kg/min",
          "methemoglobin"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "regular-insulin": {
      "id": "regular-insulin",
      "name": "Regular insulin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "hyperglycemia-180-mg-dl-target-140-180-mg-dl-avoid-hypoglyce": {
          "indication": "Hyperglycemia (>180 mg/dL); target 140-180 mg/dL; avoid hypoglycemia (<70 mg/dL) which worsens neurologic injury",
          "doseOptions": [
            {
              "text": "per protocol",
              "orderSentence": "Regular insulin per protocol IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Continuous insulin infusion titrated to BG 140-180; transition to sliding scale when hemodynamically stable and tolerating nutrition",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypoglycemia risk"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BG q1h while on drip",
          "potassium with each BG",
          "q4-6h on sliding scale"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "anoxic-brain-injury"
      ]
    },
    "repeat-epidural-blood-patch": {
      "id": "repeat-epidural-blood-patch",
      "name": "Repeat epidural blood patch",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Epidural"
      ],
      "formulations": [],
      "contexts": {
        "persistent-symptoms-after-initial-ebp-may-attempt-2-3-times-": {
          "indication": "Persistent symptoms after initial EBP; may attempt 2-3 times before escalating",
          "doseOptions": [
            {
              "text": "20-30 mL autologous blood",
              "orderSentence": "Repeat epidural blood patch 20-30 mL autologous blood Epidural"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Repeat EBP 5-7 days after first attempt if symptoms persist; may use larger volume (up to 30 mL); consider targeted approach if not done initially",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active systemic infection/bacteremia, local skin infection, coagulopathy (INR >1.5, platelets <50K), patient refusal"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Vital signs during and 1h post-procedure",
          "consider leak localization if second EBP fails",
          "neurologic exam"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "low-pressure-headache"
      ]
    },
    "repeat-iv-methylprednisolone": {
      "id": "repeat-iv-methylprednisolone",
      "name": "Repeat IV methylprednisolone (extended course)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "incomplete-response-to-initial-5-day-course-may-extend-to-7-": {
          "indication": "Incomplete response to initial 5-day course; may extend to 7-10 days in severe cases",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Repeat IV methylprednisolone (extended course) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV daily; extend course to 7-10 days total if partial response after initial 5 days",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "mogad"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active untreated infection",
          "steroid psychosis",
          "uncontrolled diabetes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Glucose q6h",
          "I/O",
          "bone protection",
          "infection surveillance",
          "mood"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "mogad"
      ]
    },
    "repeated-ivig-cycles": {
      "id": "repeated-ivig-cycles",
      "name": "Repeated IVIG cycles",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "maintenance-immunotherapy-for-partially-responsive-paraneopl": {
          "indication": "Maintenance immunotherapy for partially responsive paraneoplastic syndrome",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "Repeated IVIG cycles 0.4 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day x 5 days (repeat q4 weeks) or 1 g/kg x 2 days q4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "IgA deficiency",
          "thromboembolic history"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "IgG trough levels",
          "Renal function",
          "headache",
          "infusion reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "paraneoplastic-neurological-syndrome"
      ]
    },
    "repeated-ivig-or-plex-cycles": {
      "id": "repeated-ivig-or-plex-cycles",
      "name": "Repeated IVIG or PLEX cycles",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "Repeated IVIG or PLEX cycles 0.4 g/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "IVIG 0.4 g/kg/day x 5 days (repeat q4 weeks) or PLEX 5 exchanges (repeat as needed)",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as first-line"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same as first-line"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "autoimmune-encephalitis"
      ]
    },
    "repeated-plex-cycles": {
      "id": "repeated-plex-cycles",
      "name": "Repeated PLEX cycles",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "maintenance-plasmapheresis-for-partially-responsive-paraneop": {
          "indication": "Maintenance plasmapheresis for partially responsive paraneoplastic syndrome",
          "doseOptions": [
            {
              "text": "1-1.5 plasma volumes",
              "orderSentence": "Repeated PLEX cycles 1-1.5 plasma volumes IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 exchanges (repeat q4-6 weeks as needed); 1-1.5 plasma volumes per exchange; albumin replacement preferred",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hemodynamic instability",
          "coagulopathy",
          "sepsis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP during exchanges",
          "citrate reactions",
          "coagulation (fibrinogen)",
          "electrolytes (Ca, K, Mg)",
          "line site"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "paraneoplastic-neurological-syndrome"
      ]
    },
    "responsive-neurostimulation": {
      "id": "responsive-neurostimulation",
      "name": "Responsive neurostimulation (RNS)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Surgical implant"
      ],
      "formulations": [],
      "contexts": {
        "dre-with-1-2-identifiable-seizure-foci-closed-loop-stimulati": {
          "indication": "DRE with 1-2 identifiable seizure foci; closed-loop stimulation triggered by detected seizure activity; seizure reduction ~50-70% at 5 years",
          "doseOptions": [
            {
              "text": "N/A — device implantation",
              "orderSentence": "Responsive neurostimulation (RNS) N/A — device implantation Surgical"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Cranial neurostimulator + cortical/depth leads at seizure focus; device detects abnormal ECoG patterns and delivers stimulation",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "MRI after implant restricted",
          "Multifocal epilepsy >2 foci",
          "poor surgical candidacy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Remote device interrogation",
          "battery replacement ~8 years",
          "electrocorticography data review",
          "seizure diary correlation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "riboflavin": {
      "id": "riboflavin",
      "name": "Riboflavin (Vitamin B2)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Riboflavin (Vitamin B2) 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400 mg PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "adjunctive-preventive-level-b-evidence-nutraceutical": {
          "indication": "Adjunctive preventive; Level B evidence; nutraceutical",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Riboflavin (Vitamin B2) 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400 mg PO daily; may take 3 months for full effect",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "supplement-for-prevention-well-tolerated-may-reduce-aura": {
          "indication": "Supplement for prevention; well-tolerated; may reduce aura",
          "doseOptions": [
            {
              "text": "400 mg",
              "orderSentence": "Riboflavin (Vitamin B2) 400 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None",
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bright yellow urine (benign)",
          "Fluorescent yellow urine (reassure patient)",
          "None",
          "benign",
          "minimal side effects"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "migraine-with-aura"
      ]
    },
    "rifampin": {
      "id": "rifampin",
      "name": "Rifampin (adjunctive)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "**Rifampin (adjunctive)** 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "For staphylococcal osteomyelitis (vertebral involvement); enhances bone penetration; prevents biofilm; **ONLY as adjunctive therapy — never monotherapy (rapid resistance)**; Rifampin 300 mg PO BID added to primary anti-staphylococcal agent; check interactions (CYP3A4 inducer — reduces warfarin, HIV meds, oral contraceptives, etc.)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epidural-abscess"
          ]
        },
        "first-line-anti-tb-therapy-bactericidal-moderate-cns-penetra": {
          "indication": "First-line anti-TB therapy; bactericidal; moderate CNS penetration (10-20% of serum in inflamed meninges); critical for sterilizing activity",
          "doseOptions": [
            {
              "text": "10 mg/kg daily (max 600 mg)",
              "orderSentence": "Rifampin (RIF) 10 mg/kg daily (max 600 mg) PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg PO/IV daily (max 600 mg/day); some experts recommend 15 mg/kg (max 900 mg) for TBM due to lower CNS penetration; take on empty stomach; IV formulation available for patients unable to take PO",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        },
        "continuation-phase-anti-tb-therapy-months-3-12-of-treatment": {
          "indication": "Continuation phase anti-TB therapy; months 3-12 of treatment",
          "doseOptions": [
            {
              "text": "10 mg/kg daily (max 600 mg)",
              "orderSentence": "Rifampin (continuation phase) 10 mg/kg daily (max 600 mg) PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg/kg PO daily (max 600 mg/day); continue for total 12 months; drug interactions must be reviewed at each visit",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tb-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic disease",
          "concurrent protease inhibitors (major drug interactions)",
          "incompatible drug interactions",
          "porphyria"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC monthly (rare thrombocytopenia)",
          "CBC q3 months",
          "EXTENSIVE drug interactions (warfarin, OCPs, antiretrovirals, steroids)",
          "LFTs at baseline, 2 weeks, monthly",
          "LFTs monthly",
          "Rifampin improves outcomes in staphylococcal bone infections",
          "biofilm activity",
          "compliance assessment",
          "drug interaction review at each visit",
          "drug interactions are significant",
          "excellent bone penetration",
          "orange discoloration of bodily fluids (warn patient)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "epidural-abscess",
        "tb-meningitis"
      ]
    },
    "rifaximin": {
      "id": "rifaximin",
      "name": "Rifaximin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "hepatic-encephalopathy-adjunct-to-lactulose": {
          "indication": "Hepatic encephalopathy (adjunct to lactulose)",
          "doseOptions": [
            {
              "text": "550 mg",
              "orderSentence": "Rifaximin 550 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "550 mg PO BID; add if lactulose alone insufficient",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "C. difficile (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Mental status, hepatic function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wilsons-disease"
      ]
    },
    "riluzole": {
      "id": "riluzole",
      "name": "Riluzole",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "**Riluzole** 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg PO BID; modestly prolongs survival (~2-3 months); neuroprotective; continue unless intolerant",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuromuscular-respiratory-failure"
          ]
        },
        "slows-disease-progression-extends-survival-2-3-months": {
          "indication": "Slows disease progression; extends survival 2-3 months",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Riluzole (Rilutek) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg PO BID; take 1 hour before or 2 hours after meals for best absorption",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "investigational-in-psp-failed-to-show-benefit-in-clinical-tr": {
          "indication": "Investigational in PSP; failed to show benefit in clinical trial",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Riluzole N/A PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg BID trialed; NNIPPS trial showed no benefit in PSP; NOT recommended",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "some-spinocerebellar-ataxias-sca-neuroprotective-modest-evid": {
          "indication": "Some spinocerebellar ataxias (SCA); neuroprotective; modest evidence for ataxia improvement in selected patients",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Riluzole 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg PO BID; take on empty stomach (1 hour before or 2 hours after meals)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "ftd-with-als-overlap-may-modestly-slow-mnd-progression": {
          "indication": "FTD with ALS overlap; may modestly slow MND progression",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Riluzole 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg PO BID; take 1 hour before or 2 hours after meals",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ALT >5x ULN",
          "Hepatic impairment",
          "Hepatic impairment (ALT >5x ULN)",
          "hepatic impairment",
          "pregnancy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC if neutropenia suspected",
          "LFTs",
          "LFTs monthly x 3 months, then q3 months",
          "LFTs monthly x 3 months, then q3 months for first year, then periodically",
          "LFTs monthly x 3 months, then q3mo",
          "Only FDA-approved disease-modifying drug for ALS with survival benefit (though modest)",
          "continue through respiratory failure unless goals of care dictate otherwise",
          "nausea, asthenia",
          "neutropenia",
          "neutrophil count",
          "no proven benefit in PSP"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "als",
        "ataxia-evaluation",
        "frontotemporal-dementia",
        "neuromuscular-respiratory-failure",
        "progressive-supranuclear-palsy"
      ]
    },
    "rimabotulinumtoxinb-cervical-dystonia": {
      "id": "rimabotulinumtoxinb-cervical-dystonia",
      "name": "RimabotulinumtoxinB (Myobloc) - Cervical dystonia",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "type-a-toxin-non-responders-secondary-non-response": {
          "indication": "Type A toxin non-responders; secondary non-response",
          "doseOptions": [
            {
              "text": "2500 units",
              "orderSentence": "RimabotulinumtoxinB (Myobloc) - Cervical dystonia 2500 units IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2500-5000 units divided; max 10000 units; repeat q12wk; higher dry mouth rate",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ALS",
          "Infection at site",
          "myasthenia gravis",
          "type B protein allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dry mouth",
          "antibody formation",
          "dysphagia",
          "neck weakness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "dystonia"
      ]
    },
    "rimegepant": {
      "id": "rimegepant",
      "name": "Rimegepant",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Rimegepant 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75 mg PO once daily; ODT formulation",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "moderate-severe-migraine-dual-acute-preventive-use-lower-moh": {
          "indication": "Moderate-severe migraine; dual acute/preventive use; lower MOH risk",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Rimegepant (acute) 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75 mg PO ODT once daily PRN; do not exceed 1 dose/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "dual-purpose-acute-and-preventive-treatment-chronic-migraine": {
          "indication": "Dual-purpose: acute and preventive treatment; chronic migraine prevention",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Rimegepant (Nurtec ODT) 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75 mg PO ODT every other day for prevention; may also use PRN for acute attacks (75 mg, max once daily)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "cgrp-antagonist-can-use-for-acute-and-prevention": {
          "indication": "CGRP antagonist; can use for acute and prevention",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Rimegepant 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75 mg ODT at onset; max 75 mg/24hr for acute; also approved 75 mg every other day for prevention",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CYP3A4 inhibitors",
          "Strong CYP3A4 inhibitors",
          "Strong CYP3A4 inhibitors (ketoconazole, itraconazole)",
          "Strong CYP3A4 inhibitors/inducers",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs periodically",
          "LFTs q3-6 months",
          "None routine",
          "may have lower MOH risk",
          "monitor for dyspnea (rare)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "migraine-with-aura"
      ]
    },
    "risperidone": {
      "id": "risperidone",
      "name": "Risperidone (Risperdal)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "severe-aggression-psychosis-short-term-use-only": {
          "indication": "Severe aggression/psychosis (short-term use only)",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Risperidone (Risperdal) 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg BID; increase by 0.25 mg BID weekly; max 1 mg BID; limit to 6-12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "chorea-with-psychosis-antipsychotic-with-motor-benefit": {
          "indication": "Chorea with psychosis; antipsychotic with motor benefit",
          "doseOptions": [
            {
              "text": "0.5 mg",
              "orderSentence": "Risperidone 0.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.5 mg daily; titrate by 0.5 mg q1wk; max 6 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "second-line-evidence-from-rcts-for-tic-reduction": {
          "indication": "Second-line; evidence from RCTs for tic reduction",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Risperidone (Risperdal) 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg qHS; increase by 0.25-0.5 mg q1wk; target 1-3 mg/day; max 4 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        },
        "severe-aggression-psychosis-short-term-only": {
          "indication": "Severe aggression/psychosis (short-term only)",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Risperidone (Risperdal) 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg BID; increase by 0.25 mg BID weekly; max 1 mg BID; limit to 6-12 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Black box: increased mortality and CVA in dementia",
          "Hypersensitivity",
          "QTc prolongation",
          "caution in hepatic/renal impairment",
          "history of NMS"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "EPS",
          "EPS, metabolic effects, stroke risk, prolactin",
          "EPS, metabolic panel, prolactin",
          "QTc",
          "Weight, BMI q3mo",
          "fasting glucose, lipids q3-6mo",
          "prolactin (gynecomastia risk)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "alzheimers-disease",
        "huntingtons-disease",
        "tics-tourette-syndrome",
        "vascular-dementia"
      ]
    },
    "rituximab": {
      "id": "rituximab",
      "name": "Rituximab",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "375 mg/m2",
              "orderSentence": "Rituximab 375 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/m2 IV weekly x 4 weeks OR 1000 mg IV x 2 doses 2 weeks apart; especially effective in MuSK-positive MG",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "cidp",
            "status-epilepticus",
            "rapidly-progressive-dementia",
            "myasthenia-gravis-new-diagnosis",
            "acute-myelopathy",
            "autoimmune-encephalitis"
          ]
        },
        "refractory-nbd-failing-anti-tnf-therapy-case-reports-of-effi": {
          "indication": "Refractory NBD failing anti-TNF therapy; case reports of efficacy",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Rituximab (CPT 96365) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV x 2 doses (day 0 and day 14); re-dose based on CD19/CD20 repopulation or clinical relapse; premedicate with methylprednisolone 100 mg, acetaminophen, diphenhydramine; Pre-treatment: Hepatitis B serology, CBC, CMP, quantitative immunoglobulins, JCV antibody (PML risk), pregnancy test, vaccination update",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "refractory-dm-pm-not-responding-to-conventional-immunosuppre": {
          "indication": "Refractory DM/PM not responding to conventional immunosuppressants; anti-SRP IMNM; anti-synthetase syndrome refractory to first-line",
          "doseOptions": [
            {
              "text": "375 mg/m2 or 1000 mg",
              "orderSentence": "Rituximab (Rituxan) (CPT 96365) 375 mg/m2 or 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/m2 IV weekly x 4 weeks; OR 1000 mg IV x 2 doses 14 days apart; re-dose based on CD19/CD20 recovery and clinical response; onset 3-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "refractory-to-steroids-and-other-steroid-sparing-agents-mult": {
          "indication": "Refractory to steroids and other steroid-sparing agents; multiple relapses",
          "doseOptions": [
            {
              "text": "375 mg/m2",
              "orderSentence": "Rituximab (CPT 96365) 375 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/m2 IV weekly x 4 doses OR 1000 mg IV x 2 doses (day 0 and day 14); premedicate with methylprednisolone 100 mg, acetaminophen, diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "refractory-neurosarcoidosis-failing-anti-tnf-therapy-b-cell-": {
          "indication": "Refractory neurosarcoidosis failing anti-TNF therapy; B-cell-mediated disease component",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Rituximab 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/m2 IV weekly x 4 doses OR 1000 mg IV x 2 doses (day 0 and day 14); re-dose based on CD19/CD20 repopulation or clinical relapse; premedicate with methylprednisolone 100 mg, acetaminophen, diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "nmosd-aqp4-igg-positive": {
          "indication": "NMOSD (AQP4-IgG positive)",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Rituximab 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV days 1 and 15; maintenance 1000 mg q6 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "optic-neuritis"
          ]
        },
        "anti-cd20-monoclonal-antibody-combined-with-hd-mtx-in-r-mpv-": {
          "indication": "Anti-CD20 monoclonal antibody; combined with HD-MTX in R-MPV and MATRix regimens; PCNSL is CD20+ in >95% of cases; improves response rate when combined with MTX-based chemotherapy",
          "doseOptions": [
            {
              "text": "375 mg/m2",
              "orderSentence": "Rituximab 375 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/m2 IV; first infusion: start at 50 mg/h, increase by 50 mg/h q30min to max 400 mg/h; subsequent infusions: start at 100 mg/h, increase by 100 mg/h q30min to max 400 mg/h; administer per protocol schedule (typically Day 1 of each cycle); premedicate with acetaminophen 650 mg, diphenhydramine 50 mg, and methylprednisolone 100 mg IV",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "musk-positive-mg-often-first-line-after-steroids-refractory-": {
          "indication": "MuSK-positive MG (often first-line after steroids); refractory AChR+ MG",
          "doseOptions": [
            {
              "text": "375 mg/m2",
              "orderSentence": "Rituximab 375 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Either 375 mg/m2 IV weekly x 4 weeks OR 1000 mg IV x 2 doses (2 weeks apart); premedicate with methylprednisolone 100 mg, acetaminophen, diphenhydramine; repeat courses as needed",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "refractory-pacns-failing-cyclophosphamide-relapsing-disease-": {
          "indication": "Refractory PACNS failing cyclophosphamide; relapsing disease on maintenance therapy; steroid-dependent disease; cyclophosphamide contraindicated (fertility concerns, cumulative toxicity)",
          "doseOptions": [
            {
              "text": "375 mg/m2 weekly x 4 doses",
              "orderSentence": "Rituximab 375 mg/m2 weekly x 4 doses IV"
            },
            {
              "text": "1000 mg x 2 doses (day 0 and day 14)",
              "orderSentence": "Rituximab 1000 mg x 2 doses (day 0 and day 14) IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/m2 IV weekly x 4 doses OR 1000 mg IV x 2 doses (day 0, day 14); premedicate with methylprednisolone 100 mg IV, acetaminophen 650 mg PO, diphenhydramine 50 mg IV",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "second-line-maintenance-for-mogad-refractory-to-ivig-azathio": {
          "indication": "Second-line maintenance for MOGAD refractory to IVIG, azathioprine, or mycophenolate; less evidence than in AQP4-NMOSD; some MOGAD patients respond poorly to rituximab",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Rituximab (Rituxan) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/m2 IV weekly x 4 doses OR 1000 mg IV x 2 doses (day 0 and day 14); re-dose every 6 months or based on CD19/CD20 B-cell repopulation; premedicate with methylprednisolone 100 mg, acetaminophen, diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "aqp4-or-aqp4-nmosd-widely-used-before-fda-approved-agents": {
          "indication": "AQP4+ or AQP4- NMOSD; widely used before FDA-approved agents",
          "doseOptions": [
            {
              "text": "375 mg/m2",
              "orderSentence": "Rituximab (off-label) 375 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Induction: 375 mg/m2 IV weekly x 4 OR 1000 mg IV x 2 doses (2 weeks apart); maintenance: 1000 mg IV every 6 months or re-dose based on CD19/CD20 repopulation",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "anti-mag-neuropathy-vasculitic-neuropathy-refractory-cidp": {
          "indication": "Anti-MAG neuropathy, vasculitic neuropathy, refractory CIDP",
          "doseOptions": [
            {
              "text": "375 mg",
              "orderSentence": "Rituximab (CPT 96365) 375 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/mÃ‚Â² IV weekly Ãƒâ€” 4 weeks OR 1000 mg IV Ãƒâ€” 2 doses 14 days apart",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "refractory-a-lems-not-responding-to-conventional-immunosuppr": {
          "indication": "Refractory A-LEMS not responding to conventional immunosuppressants; may be used earlier in severe cases; less evidence than in MG but reported efficacy",
          "doseOptions": [
            {
              "text": "375 mg/m2",
              "orderSentence": "Rituximab (Rituxan) 375 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/m2 IV weekly x 4 weeks; OR 1000 mg IV x 2 doses 14 days apart; re-dose when CD19/CD20 recover or clinical worsening; onset 3-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "refractory-autoimmune-cerebellar-ataxia-anti-gad-other-antib": {
          "indication": "Refractory autoimmune cerebellar ataxia (anti-GAD, other antibody-mediated); gluten ataxia not responding to diet; MS cerebellar involvement",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Rituximab 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV on day 0 and day 14; repeat q6 months based on response or CD19/CD20 counts; premedicate with methylprednisolone, acetaminophen, diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "long-term-immunosuppression-for-autoimmune-cerebellar-ataxia": {
          "indication": "Long-term immunosuppression for autoimmune cerebellar ataxia (anti-GAD, CASPR2, other autoantibodies)",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Rituximab (maintenance) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV q6 months; adjust interval based on CD19/CD20 B cell counts and clinical response",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "second-line-immunotherapy-for-sps-b-cell-depletion-reduces-a": {
          "indication": "Second-line immunotherapy for SPS; B-cell depletion reduces anti-GAD production; used when IVIg insufficient or for IVIg-sparing",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Rituximab 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg IV x 2 doses (day 0 and day 14); repeat based on CD19/CD20 repopulation or clinical relapse (typically q6 months); premedicate with methylprednisolone 100 mg IV, acetaminophen 650 mg, diphenhydramine 50 mg",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "second-line-immunotherapy-for-refractory-paraneoplastic-synd": {
          "indication": "Second-line immunotherapy for refractory paraneoplastic syndrome; B-cell depletion; more effective for cell-surface antibody syndromes",
          "doseOptions": [
            {
              "text": "375 mg/m2",
              "orderSentence": "Rituximab 375 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/m2 IV weekly x 4 doses OR 1000 mg IV x 2 doses (day 0 and day 14); premedicate with methylprednisolone 100 mg, acetaminophen, diphenhydramine",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "long-term-immunosuppression-for-relapse-prevention-in-cell-s": {
          "indication": "Long-term immunosuppression for relapse prevention in cell-surface antibody paraneoplastic syndromes",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Rituximab (maintenance) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mg IV every 6 months; re-dose based on CD19/CD20 B-cell repopulation or clinical relapse",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "refractory-susac-syndrome-failing-ivig-steroids-maintenance-": {
          "indication": "Refractory Susac syndrome failing IVIG + steroids + maintenance immunosuppression; relapsing disease; B-cell mediated endotheliopathy component",
          "doseOptions": [
            {
              "text": "375 mg/m2 weekly x 4 doses",
              "orderSentence": "Rituximab (CPT 96365) 375 mg/m2 weekly x 4 doses IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "375 mg/m2 IV weekly x 4 doses OR 1000 mg IV x 2 doses (day 0, day 14); premedicate with methylprednisolone 100 mg IV, acetaminophen 650 mg PO, diphenhydramine 50 mg IV",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active HBV infection without antiviral prophylaxis (fatal reactivation risk)",
          "Active Hep B",
          "Active Hepatitis B",
          "Active hepatitis B",
          "Active hepatitis B (check HBsAg, anti-HBc before)",
          "Active infection, hepatitis B (reactivation risk — screen first)",
          "Active infection, hepatitis B (screen first)",
          "Active infection, hepatitis B (screen)",
          "PML history",
          "Per above",
          "active infection",
          "active severe infection",
          "known hypersensitivity",
          "live vaccines within 4 weeks",
          "pregnancy",
          "severe active infection",
          "severe cardiac disease (arrhythmia risk with infusion)",
          "severe heart failure",
          "severe hypersensitivity to murine proteins",
          "severe hypogammaglobulinemia",
          "severe hypogammaglobulinemia (IgG <300)",
          "severe immunodeficiency"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC q2-4 weeks",
          "CBC q2-4 weeks initially",
          "CBC q3 months",
          "CBC with differential q2-4 weeks",
          "CBC with differential q3 months",
          "CD19/20",
          "CD19/20 counts",
          "CD19/CD20 B-cell count q3-6 months",
          "CD19/CD20 B-cell counts",
          "CD19/CD20 B-cell counts q3 months",
          "CD19/CD20 counts before each infusion",
          "CD19/CD20 counts q3 months",
          "CD19/CD20 counts q3-6 months",
          "CD20 count, immunoglobulins q3 months",
          "HBV DNA if core antibody positive (q3 months)",
          "HBV serology before",
          "Hepatitis B serology (before first dose)",
          "Hepatitis B serology before first dose",
          "Hepatitis B serology, infusion reactions, infection monitoring",
          "Hepatitis B surveillance",
          "Infusion reaction monitoring (vitals q15min during first infusion, q30min subsequent)",
          "Infusion reactions",
          "Infusion reactions, infection, B-cell counts",
          "PML risk",
          "PML risk (rare)",
          "PML risk (very rare)",
          "PML screening (JCV risk very low with rituximab)",
          "PML surveillance",
          "Poor response to IVIG expected",
          "hepatitis B reactivation screening",
          "hepatitis B screening",
          "hepatitis B surveillance",
          "immunoglobulin levels q3 months",
          "immunoglobulin levels q3-6 months",
          "immunoglobulin levels q6 months",
          "immunoglobulins",
          "immunoglobulins annually",
          "immunoglobulins q6 months",
          "infection",
          "infection monitoring",
          "infection risk",
          "infections",
          "infusion reactions",
          "infusion reactions (premedicate with acetaminophen, diphenhydramine, methylprednisolone)",
          "infusion reactions (slow rate if reaction)",
          "premedicate with acetaminophen, diphenhydramine, methylprednisolone",
          "quantitative immunoglobulins q3 months",
          "rituximab preferred",
          "signs of progressive multifocal leukoencephalopathy (PML)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 27,
      "_sourcePlans": [
        "acute-myelopathy",
        "ataxia-evaluation",
        "autoimmune-encephalitis",
        "cidp",
        "cns-vasculitis",
        "hashimotos-encephalopathy",
        "inflammatory-myopathy",
        "lambert-eaton-syndrome",
        "mogad",
        "myasthenia-gravis",
        "myasthenia-gravis-crisis",
        "myasthenia-gravis-new-diagnosis",
        "neuro-behcets-disease",
        "neurosarcoidosis",
        "nmosd",
        "optic-neuritis",
        "paraneoplastic-neurological-syndrome",
        "peripheral-neuropathy",
        "primary-cns-lymphoma",
        "rapidly-progressive-dementia",
        "status-epilepticus",
        "stiff-person-syndrome",
        "susac-syndrome"
      ]
    },
    "rivaroxaban": {
      "id": "rivaroxaban",
      "name": "Rivaroxaban",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "af-related-vascular-dementia": {
          "indication": "AF-related vascular dementia",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Rivaroxaban 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg daily with dinner (15 mg if CrCl 15-50)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "alternative-doac-for-cvt-limited-data-but-increasingly-used": {
          "indication": "Alternative DOAC for CVT (limited data but increasingly used)",
          "doseOptions": [
            {
              "text": "20 mg daily",
              "orderSentence": "Rivaroxaban 20 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg PO daily with food; reduce to 15 mg daily if CrCl 15-50",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Rivaroxaban 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg PO daily with evening meal (15 mg daily if CrCl 15-50); start 4-14 days post-stroke for AF",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "anticoagulation-for-stroke-with-af-once-daily-dosing-advanta": {
          "indication": "Anticoagulation for stroke with AF; once-daily dosing advantage; ROCKET-AF data",
          "doseOptions": [
            {
              "text": "20 mg daily",
              "orderSentence": "Rivaroxaban 20 mg daily PO"
            },
            {
              "text": "15 mg daily",
              "orderSentence": "Rivaroxaban 15 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg PO daily with dinner (food enhances absorption); reduce to 15 mg daily if CrCl 15-50 mL/min; timing per infarct size",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "Active major bleeding",
          "CrCl <15",
          "Renal function q6-12 months",
          "active bleeding",
          "bleeding signs",
          "hepatic impairment (Child-Pugh B/C)",
          "mechanical valve",
          "severe hepatic impairment (Child-Pugh C)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC annually",
          "CrCl",
          "LFTs",
          "Renal function q6 months",
          "Renal function q6-12 months",
          "bleeding",
          "bleeding signs",
          "signs of bleeding"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "cerebral-venous-thrombosis",
        "post-stroke-management",
        "vascular-dementia"
      ]
    },
    "rivastigmine": {
      "id": "rivastigmine",
      "name": "Rivastigmine (Exelon)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO",
        "PO/Patch",
        "PO/TD"
      ],
      "formulations": [],
      "contexts": {
        "cognitive-impairment-alternative-to-donepezil": {
          "indication": "Cognitive impairment; alternative to donepezil",
          "doseOptions": [
            {
              "text": "1.5 mg",
              "orderSentence": "Rivastigmine 1.5 mg PO/Patch"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1.5 mg BID or 4.6 mg patch; titrate monthly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "4.6-13.3 mg",
              "orderSentence": "Rivastigmine (cognitive) 4.6-13.3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Patch 4.6-13.3 mg/24h; for PD dementia",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "avoid-may-worsen-behavioral-symptoms-in-ftd": {
          "indication": "AVOID - May worsen behavioral symptoms in FTD",
          "doseOptions": [
            {
              "text": "AVOID",
              "orderSentence": "Rivastigmine (Exelon) AVOID PO/TD"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Do NOT use; cholinesterase inhibitors not recommended in FTD; may cause paradoxical worsening",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "parkinson-s-disease-dementia": {
          "indication": "Parkinson's disease dementia",
          "doseOptions": [
            {
              "text": "1.5 mg BID",
              "orderSentence": "Rivastigmine (Exelon) 1.5 mg BID PO/Patch"
            },
            {
              "text": "3 mg BID",
              "orderSentence": "Rivastigmine (Exelon) 3 mg BID PO/Patch"
            },
            {
              "text": "4.5 mg BID",
              "orderSentence": "Rivastigmine (Exelon) 4.5 mg BID PO/Patch"
            },
            {
              "text": "6 mg BID",
              "orderSentence": "Rivastigmine (Exelon) 6 mg BID PO/Patch"
            },
            {
              "text": "9.5 mg/24hr patch",
              "orderSentence": "Rivastigmine (Exelon) 9.5 mg/24hr patch PO/Patch"
            },
            {
              "text": "13.3 mg/24hr patch",
              "orderSentence": "Rivastigmine (Exelon) 13.3 mg/24hr patch PO/Patch"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1.5 mg BID or 4.6 mg/24hr patch; titrate monthly; max 6 mg BID or 13.3 mg/24hr",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "FTD diagnosis",
          "GI bleeding, bradycardia",
          "Severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Nausea, bradycardia",
          "Nausea, weight loss",
          "Nausea, weight loss, tremor worsening",
          "Worsening behavior if inadvertently started"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "frontotemporal-dementia",
        "huntingtons-disease",
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "rivastigmine-oral": {
      "id": "rivastigmine-oral",
      "name": "Rivastigmine oral (Exelon)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "vascular-dementia-executive-dysfunction-may-help-mixed-ad-va": {
          "indication": "Vascular dementia; executive dysfunction; may help mixed AD/VaD",
          "doseOptions": [
            {
              "text": "1.5 mg",
              "orderSentence": "Rivastigmine oral (Exelon) 1.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1.5 mg BID with meals; increase by 1.5 mg BID every 2 weeks; target 6 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "cognitive-impairment-and-visual-hallucinations-fda-approved-": {
          "indication": "Cognitive impairment and visual hallucinations (FDA approved for PDD)",
          "doseOptions": [
            {
              "text": "1.5 mg",
              "orderSentence": "Rivastigmine oral 1.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1.5 mg BID with meals; increase by 1.5 mg BID q2-4wk; target 6 mg BID; may improve hallucinations",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1.5 mg",
              "orderSentence": "Rivastigmine oral 1.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1.5 mg BID with food; titrate to 6 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "mild-moderate-ad-may-be-better-for-attention-executive-sympt": {
          "indication": "Mild-moderate AD; may be better for attention/executive symptoms",
          "doseOptions": [
            {
              "text": "1.5 mg",
              "orderSentence": "Rivastigmine oral (Exelon) 1.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1.5 mg BID with meals; increase by 1.5 mg BID every 2 weeks; target 6 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI bleeding",
          "Same",
          "Sick sinus",
          "Sick sinus syndrome",
          "active GI bleeding",
          "second/third degree heart block",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI side effects more common than patch",
          "GI symptoms",
          "GI symptoms (most common)",
          "Nausea, weight loss, tremor worsening, bradycardia",
          "bradycardia",
          "weight loss"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "alzheimers-disease",
        "dementia-evaluation",
        "lewy-body-dementia",
        "vascular-dementia"
      ]
    },
    "rivastigmine-patch": {
      "id": "rivastigmine-patch",
      "name": "Rivastigmine patch (Exelon Patch)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO",
        "TD",
        "Transdermal"
      ],
      "formulations": [],
      "contexts": {
        "vascular-dementia-better-gi-tolerability-than-oral": {
          "indication": "Vascular dementia; better GI tolerability than oral",
          "doseOptions": [
            {
              "text": "4.6 mg/24hr",
              "orderSentence": "Rivastigmine patch (Exelon Patch) 4.6 mg/24hr TD"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4.6 mg/24hr patch; increase every 4 weeks; target 9.5-13.3 mg/24hr",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "alternative-to-donepezil-better-gi-tolerability-mci-with-pos": {
          "indication": "Alternative to donepezil; better GI tolerability; MCI with positive AD biomarkers",
          "doseOptions": [
            {
              "text": "4.6 mg/24hr",
              "orderSentence": "Rivastigmine patch 4.6 mg/24hr TD"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4.6 mg/24hr; increase q4wk to 9.5 mg/24hr; limited evidence in MCI",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "cognitive-impairment-better-gi-tolerability": {
          "indication": "Cognitive impairment; better GI tolerability",
          "doseOptions": [
            {
              "text": "4.6 mg/24hr",
              "orderSentence": "Rivastigmine patch 4.6 mg/24hr TD"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4.6 mg/24hr patch; increase q4wk; target 9.5-13.3 mg/24hr",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "cognitive-impairment-alternative-to-donepezil-may-help-atten": {
          "indication": "Cognitive impairment alternative to donepezil; may help attention and executive function",
          "doseOptions": [
            {
              "text": "4.6 mg/24h",
              "orderSentence": "Rivastigmine patch (Exelon) 4.6 mg/24h Transdermal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4.6 mg/24h patch; increase monthly to 9.5-13.3 mg/24h; patch preferred over oral (less GI side effects)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "4.6 mg",
              "orderSentence": "Rivastigmine patch (Exelon) 4.6 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4.6 mg/24h patch; increase monthly to 9.5-13.3 mg/24h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "mild-moderate-ad-better-gi-tolerability-than-oral": {
          "indication": "Mild-moderate AD; better GI tolerability than oral",
          "doseOptions": [
            {
              "text": "4.6 mg/24hr",
              "orderSentence": "Rivastigmine patch (Exelon Patch) 4.6 mg/24hr TD"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4.6 mg/24hr patch; increase every 4 weeks; target 9.5-13.3 mg/24hr; apply to clean, hairless skin",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bradycardia",
          "GI bleeding",
          "Same",
          "Same as oral",
          "Sick sinus syndrome",
          "active GI bleeding",
          "second/third degree heart block",
          "severe COPD",
          "severe hepatic impairment",
          "sick sinus syndrome",
          "skin reactions"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms less than oral",
          "Skin irritation",
          "Skin irritation (rotate sites)",
          "Skin irritation, GI effects, bradycardia",
          "Skin irritation, GI symptoms",
          "Skin irritation, GI, bradycardia",
          "Skin irritation, nausea",
          "heart rate",
          "rotate sites",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "alzheimers-disease",
        "dementia-evaluation",
        "lewy-body-dementia",
        "mild-cognitive-impairment",
        "progressive-supranuclear-palsy",
        "vascular-dementia"
      ]
    },
    "rizatriptan": {
      "id": "rizatriptan",
      "name": "Rizatriptan",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Rizatriptan 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO (ODT available); may repeat in 2h; max 30 mg/24h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "moderate-severe-migraine": {
          "indication": "Moderate-severe migraine",
          "doseOptions": [
            {
              "text": "5-10 mg",
              "orderSentence": "Rizatriptan 5-10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO (ODT available); may repeat in 2h; max 30 mg/24h; limit ≤9 days/month; use 5 mg if on propranolol",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "acute-typical-migraine-with-aura-fast-onset": {
          "indication": "Acute typical migraine with aura; fast onset",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Rizatriptan 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg PO (use 5 mg if on propranolol); may repeat after 2 hr; max 30 mg/24hr",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**HEMIPLEGIC MIGRAINE (motor aura)**",
          "5 mg if on propranolol",
          "CAD",
          "CAD, stroke/TIA, uncontrolled HTN, hemiplegic migraine, MAOIs, pregnancy",
          "MAOIs within 14 days",
          "Same",
          "ergots within 24 hr",
          "prior stroke/TIA",
          "reduce dose with propranolol",
          "uncontrolled HTN",
          "use 5 mg max if on propranolol"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Chest tightness, BP",
          "Same",
          "Triptan sensation",
          "medication days/month",
          "serotonin syndrome signs if on SNRI/SSRI"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "migraine-with-aura"
      ]
    },
    "rizatriptan-po": {
      "id": "rizatriptan-po",
      "name": "Rizatriptan PO (post-discharge rescue)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "outpatient-rescue-for-breakthrough-migraine-rapid-onset-oral": {
          "indication": "Outpatient rescue for breakthrough migraine; rapid-onset oral triptan option",
          "doseOptions": [
            {
              "text": "10 mg PO once",
              "orderSentence": "Rizatriptan PO (post-discharge rescue) 10 mg PO once PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg PO at onset (ODT available); may repeat in 2h; max 30 mg/24h; limit to ≤9 days/month; use 5 mg if on propranolol",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CAD, prior stroke/TIA, uncontrolled HTN (>140/90), hemiplegic or basilar migraine, pregnancy, concurrent ergot/DHE within 24h, concurrent MAOI"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Chest tightness, blood pressure, coronary symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "ropinirole": {
      "id": "ropinirole",
      "name": "Ropinirole (Requip)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.25 mg",
              "orderSentence": "Ropinirole (Requip) 0.25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg TID; titrate weekly to 3-8 mg TID; max 24 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis",
            "restless-legs-syndrome"
          ]
        },
        "adjunct-or-monotherapy-similar-to-pramipexole": {
          "indication": "Adjunct or monotherapy; similar to pramipexole",
          "doseOptions": [
            {
              "text": "0.25 mg TID",
              "orderSentence": "Ropinirole 0.25 mg TID PO"
            },
            {
              "text": "0.5 mg TID",
              "orderSentence": "Ropinirole 0.5 mg TID PO"
            },
            {
              "text": "1 mg TID",
              "orderSentence": "Ropinirole 1 mg TID PO"
            },
            {
              "text": "2 mg TID",
              "orderSentence": "Ropinirole 2 mg TID PO"
            },
            {
              "text": "3 mg TID",
              "orderSentence": "Ropinirole 3 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mg TID; titrate weekly; max 8 mg TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ICDs, hepatic impairment",
          "Same as pramipexole",
          "Severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "AUGMENTATION, ICDs, sleepiness",
          "Same as pramipexole"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis",
        "restless-legs-syndrome"
      ]
    },
    "ropinirole-xl": {
      "id": "ropinirole-xl",
      "name": "Ropinirole XL",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Ropinirole XL 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg daily; titrate weekly; max 24 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "extended-release-option-for-adherence": {
          "indication": "Extended-release option for adherence",
          "doseOptions": [
            {
              "text": "2 mg daily",
              "orderSentence": "Ropinirole XL 2 mg daily PO"
            },
            {
              "text": "4 mg daily",
              "orderSentence": "Ropinirole XL 4 mg daily PO"
            },
            {
              "text": "6 mg daily",
              "orderSentence": "Ropinirole XL 6 mg daily PO"
            },
            {
              "text": "8 mg daily",
              "orderSentence": "Ropinirole XL 8 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg daily; titrate by 2 mg q1-2wk; max 24 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same",
          "Same as IR"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same",
          "Same as IR"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "rosuvastatin": {
      "id": "rosuvastatin",
      "name": "Rosuvastatin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-high-intensity-statin-may-be-better-tolerated": {
          "indication": "Alternative high-intensity statin; may be better tolerated",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Rosuvastatin 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20 mg daily; max 40 mg; potent LDL lowering",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "hyperlipidemia-alternative-statin": {
          "indication": "Hyperlipidemia; alternative statin",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Rosuvastatin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5-10 mg daily; adjust to LDL goal",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20-40 mg",
              "orderSentence": "Rosuvastatin 20-40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mg PO daily (high-intensity alternative)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "high-intensity-statin-alternative-to-atorvastatin-may-be-mor": {
          "indication": "High-intensity statin alternative to atorvastatin; may be more potent for LDL lowering; non-CYP3A4 metabolism",
          "doseOptions": [
            {
              "text": "20 mg daily",
              "orderSentence": "Rosuvastatin 20 mg daily PO"
            },
            {
              "text": "40 mg daily",
              "orderSentence": "Rosuvastatin 40 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20 mg daily; may increase to 40 mg; max 40 mg; preferred if CYP3A4 drug interactions a concern",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "high-intensity-statin-alternative-to-atorvastatin-more-poten": {
          "indication": "High-intensity statin alternative to atorvastatin; more potent LDL lowering per mg; non-CYP3A4 metabolism avoids drug interactions",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Rosuvastatin 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 20 mg daily; increase to 40 mg if needed; max 40 mg; preferred if CYP3A4 drug interactions a concern; target LDL <70 mg/dL",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carotid-stenosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active liver disease",
          "Active liver disease, pregnancy, CrCl <30 for 40mg",
          "Asian dose adjustment (10 mg start)",
          "pregnancy",
          "severe renal impairment (dose adjust)",
          "severe renal impairment (max 10 mg if CrCl <30)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Asian patients: start 5-10 mg (increased levels)",
          "Asian patients: start 5-10 mg (increased rosuvastatin levels)",
          "CK if myalgia",
          "CK if symptomatic",
          "LFTs",
          "LFTs at baseline and 3 months",
          "LFTs, lipid panel",
          "Same as atorvastatin",
          "lipid panel q3-6 months",
          "myalgias"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "carotid-stenosis",
        "mild-cognitive-impairment",
        "post-stroke-management",
        "vascular-dementia"
      ]
    },
    "rotigotine-patch": {
      "id": "rotigotine-patch",
      "name": "Rotigotine patch (Neupro)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO",
        "TD"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Rotigotine patch (Neupro) 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg/24h; increase by 2 mg/week; max 8 mg/24h (early PD)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis",
            "restless-legs-syndrome"
          ]
        },
        "npo-patient-bridge-therapy": {
          "indication": "NPO patient; bridge therapy",
          "doseOptions": [
            {
              "text": "2 mg/24hr",
              "orderSentence": "Rotigotine patch 2 mg/24hr TD"
            },
            {
              "text": "4 mg/24hr",
              "orderSentence": "Rotigotine patch 4 mg/24hr TD"
            },
            {
              "text": "6 mg/24hr patch",
              "orderSentence": "Rotigotine patch 6 mg/24hr patch TD"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply patch equivalent to oral dopamine agonist dose; onset 2-3 hours",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Sulfite allergy",
          "Sulfite allergy (adhesive)",
          "Sulfite allergy, application site reactions"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "AUGMENTATION, ICDs, skin reactions",
          "Application site reactions",
          "ICDs, skin reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis",
        "restless-legs-syndrome"
      ]
    },
    "rozanolixizumab": {
      "id": "rozanolixizumab",
      "name": "Rozanolixizumab (Rystiggo)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "achr-generalized-mg-fcrn-inhibitor": {
          "indication": "AChR+ generalized MG; FcRn inhibitor",
          "doseOptions": [
            {
              "text": "420 mg",
              "orderSentence": "Rozanolixizumab (Rystiggo) 420 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "420 mg SC injection weekly x 6 weeks per treatment cycle; repeat cycles as needed",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Rozanolixizumab (Rystiggo) N/A SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Weight-based SC weekly × 6 weeks per cycle; for AChR-positive generalized MG",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "Active serious infection"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "IgG levels",
          "diarrhea",
          "headache",
          "headache common",
          "infection",
          "infection monitoring",
          "pyrexia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "myasthenia-gravis",
        "myasthenia-gravis-new-diagnosis"
      ]
    },
    "rufinamide": {
      "id": "rufinamide",
      "name": "Rufinamide (Banzel)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-due-to-lennox-gastaut-syndrome-adjunctive-therapy": {
          "indication": "DRE due to Lennox-Gastaut syndrome; adjunctive therapy",
          "doseOptions": [
            {
              "text": "200 mg BID",
              "orderSentence": "Rufinamide (Banzel) 200 mg BID PO"
            },
            {
              "text": "400 mg BID",
              "orderSentence": "Rufinamide (Banzel) 400 mg BID PO"
            },
            {
              "text": "800 mg BID",
              "orderSentence": "Rufinamide (Banzel) 800 mg BID PO"
            },
            {
              "text": "1600 mg BID",
              "orderSentence": "Rufinamide (Banzel) 1600 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 200-400 mg/day in 2 divided doses; increase by 200-400 mg every 2 days; target 1600-3200 mg/day; max 3200 mg/day; take with food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Familial short QT syndrome",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG (QT shortening)",
          "drowsiness",
          "multi-organ hypersensitivity",
          "vomiting"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "ruxolitinib": {
      "id": "ruxolitinib",
      "name": "Ruxolitinib (Jakafi)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "refractory-dm-skin-disease-refractory-anti-mda5-ild-emerging": {
          "indication": "Refractory DM skin disease; refractory anti-MDA5 ILD (emerging evidence)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Ruxolitinib (Jakafi) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO BID; may increase to 10 mg BID based on response and tolerability",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment",
          "concurrent strong CYP3A4 inhibitors (reduce dose)",
          "severe renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC weekly x 4 weeks then q2-4 weeks",
          "LFTs",
          "VTE risk",
          "infection",
          "lipids"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "inflammatory-myopathy"
      ]
    },
    "safinamide": {
      "id": "safinamide",
      "name": "Safinamide (Xadago)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Safinamide (Xadago) 50-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg daily; adjunct to levodopa",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "mao-b-inhibitor-with-additional-mechanisms-adjunct-in-fluctu": {
          "indication": "MAO-B inhibitor with additional mechanisms; adjunct in fluctuations",
          "doseOptions": [
            {
              "text": "50 mg daily",
              "orderSentence": "Safinamide 50 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Safinamide 100 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily; may increase to 100 mg daily after 2 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "MAOIs",
          "Same",
          "Severe hepatic impairment",
          "opioids",
          "severe hepatic impairment, retinal disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dyskinesia, falls",
          "Same as rasagiline",
          "may improve dyskinesia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "salt-supplementation": {
      "id": "salt-supplementation",
      "name": "Salt supplementation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "6-10 g/day",
              "orderSentence": "Salt supplementation 6-10 g/day PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "6-10 g/day if no HTN/HF",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "syncope"
          ]
        },
        "orthostatic-intolerance-if-no-htn": {
          "indication": "Orthostatic intolerance (if no HTN)",
          "doseOptions": [
            {
              "text": "1-2 g",
              "orderSentence": "Salt supplementation 1-2 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-2 g additional sodium daily via salt tablets or dietary increase",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "HTN, HF",
          "Hypertension, CHF, renal disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP, edema"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "post-concussion-syndrome",
        "syncope"
      ]
    },
    "satralizumab": {
      "id": "satralizumab",
      "name": "Satralizumab (Enspryng)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "fda-approved-for-aqp4-nmosd-il-6-receptor-inhibitor": {
          "indication": "FDA-approved for AQP4+ NMOSD; IL-6 receptor inhibitor",
          "doseOptions": [
            {
              "text": "120 mg",
              "orderSentence": "**Satralizumab (Enspryng)** 120 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Induction: 120 mg SC at weeks 0, 2, and 4; maintenance: 120 mg SC every 4 weeks; self-injectable",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "120 mg",
              "orderSentence": "Satralizumab 120 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "120 mg SC at weeks 0, 2, 4, then q4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active infection",
          "concurrent live vaccines",
          "hepatic impairment (ALT >5x ULN)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC, LFTs, lipid panel q4-8 weeks",
          "GI perforation risk",
          "LFTs",
          "elevated transaminases",
          "infection",
          "infection surveillance",
          "neutropenia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "acute-myelopathy",
        "nmosd"
      ]
    },
    "scig": {
      "id": "scig",
      "name": "SCIG (Subcutaneous Immunoglobulin)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "SCIG (Subcutaneous Immunoglobulin) N/A SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Convert from IVIG at equivalent weekly dose (total monthly IVIG dose ÷ 4); administer weekly",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cidp"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same (fewer systemic reactions)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Local site reactions"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cidp"
      ]
    },
    "scopolamine-patch": {
      "id": "scopolamine-patch",
      "name": "Scopolamine patch (Transderm Scop)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Transdermal"
      ],
      "formulations": [],
      "contexts": {
        "sialorrhea-transdermal-delivery-avoids-swallowing-difficulty": {
          "indication": "Sialorrhea; transdermal delivery avoids swallowing difficulty",
          "doseOptions": [
            {
              "text": "1.5 mg",
              "orderSentence": "Scopolamine patch (Transderm Scop) 1.5 mg Transdermal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1.5 mg patch q72 hours; apply behind ear; rotate sides",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Narrow-angle glaucoma",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Dry mouth, blurred vision, confusion (especially elderly)",
          "urinary retention"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "progressive-supranuclear-palsy"
      ]
    },
    "scopolamine-transdermal-patch": {
      "id": "scopolamine-transdermal-patch",
      "name": "Scopolamine transdermal patch",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "sialorrhea-continuous": {
          "indication": "Sialorrhea (continuous)",
          "doseOptions": [
            {
              "text": "1.5 mg",
              "orderSentence": "Scopolamine transdermal patch 1.5 mg TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply 1.5 mg patch behind ear; replace every 72 hours",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI obstruction",
          "Narrow-angle glaucoma",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Confusion (especially elderly), dry mouth, constipation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "second-course-ivig": {
      "id": "second-course-ivig",
      "name": "Second course IVIG",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dm-pm-with-incomplete-response-to-initial-ivig-course-relaps": {
          "indication": "DM/PM with incomplete response to initial IVIG course; relapse during taper",
          "doseOptions": [
            {
              "text": "2 g/kg",
              "orderSentence": "Second course IVIG 2 g/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 g/kg total divided over 2-5 days; repeat q4 weeks as maintenance",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.4 g/kg",
              "orderSentence": "Second course IVIG 0.4 g/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 g/kg/day x 5 days; consider if progressive deterioration after initial treatment or treatment-related fluctuation (TRF)",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "guillain-barre-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "IgA deficiency (use IgA-depleted product)",
          "Same as initial IVIG",
          "acute renal failure",
          "recent thrombotic event"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same as initial IVIG",
          "Vital signs q15min during infusion",
          "headache (aseptic meningitis)",
          "hemolysis (haptoglobin, LDH, direct Coombs)",
          "renal function (BUN, Cr)",
          "thrombotic events"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "guillain-barre-syndrome",
        "inflammatory-myopathy"
      ]
    },
    "sedation-minimization-protocol": {
      "id": "sedation-minimization-protocol",
      "name": "Sedation minimization protocol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "daily-sedation-interruption-and-light-sedation-targets-reduc": {
          "indication": "Daily sedation interruption and light sedation targets reduce ICUAW risk and facilitate early mobilization",
          "doseOptions": [
            {
              "text": "RASS target -1 to 0",
              "orderSentence": "Sedation minimization protocol RASS target -1 to 0 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Daily spontaneous awakening trial (SAT); target RASS -1 to 0; use analgesia-first approach (pain, delirium, then sedation); prefer dexmedetomidine or propofol over benzodiazepines (benzodiazepines increase delirium and ICUAW risk)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active seizures",
          "procedures requiring deep sedation",
          "severe agitation endangering patient safety (titrate to lowest necessary level)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CAM-ICU for delirium BID",
          "RASS q4h",
          "pain assessment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "critical-illness-myopathy-neuropathy"
      ]
    },
    "seizure-lacosamide-iv": {
      "id": "seizure-lacosamide-iv",
      "name": "Seizure: Lacosamide IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "second-line-asm-alternative-favorable-drug-interaction-profi": {
          "indication": "Second-line ASM alternative; favorable drug interaction profile in transplant patients on immunosuppressants",
          "doseOptions": [
            {
              "text": "200-400 mg IV load",
              "orderSentence": "Seizure: Lacosamide IV 200-400 mg IV load IV"
            },
            {
              "text": "100-200 mg IV q12h",
              "orderSentence": "Seizure: Lacosamide IV 100-200 mg IV q12h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200-400 mg IV loading dose over 15-30 min; then 100-200 mg IV or PO q12h; no renal adjustment needed",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "PR interval >200 ms",
          "Second/third-degree heart block",
          "severe cardiac conduction disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG (PR interval prolongation)",
          "cardiac rhythm",
          "dizziness/ataxia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "seizure-management": {
      "id": "seizure-management",
      "name": "Seizure management (acute)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.1 mg/kg",
              "orderSentence": "**Seizure management (acute)** 0.1 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Active seizure:** Lorazepam 0.1 mg/kg IV (max 4 mg), may repeat x1 in 5 min; **Then:** Levetiracetam 1000-1500 mg IV load (preferred - no drug interactions with chemotherapy) OR valproic acid 20-30 mg/kg IV load (avoid with hepatic metastases); Phenytoin/fosphenytoin only if above unavailable (interacts with many chemotherapies and targeted agents)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-metastases"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "AAN guidelines do NOT recommend prophylactic AEDs in brain tumor patients without seizures",
          "Levetiracetam preferred: no hepatic enzyme induction (does NOT reduce efficacy of steroids, chemotherapy, or targeted agents), renal elimination, broad spectrum"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-metastases"
      ]
    },
    "seizure-management-levetiracetam": {
      "id": "seizure-management-levetiracetam",
      "name": "Seizure management: Levetiracetam (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "first-line-asm-for-pres-associated-seizures-non-eclampsia-br": {
          "indication": "First-line ASM for PRES-associated seizures (non-eclampsia); broad-spectrum; no hepatic metabolism; no drug interactions with immunosuppressants",
          "doseOptions": [
            {
              "text": "1000-1500 mg IV load",
              "orderSentence": "Seizure management: Levetiracetam (CPT 96374) 1000-1500 mg IV load IV"
            },
            {
              "text": "500-1000 mg IV/PO BID",
              "orderSentence": "Seizure management: Levetiracetam (CPT 96374) 500-1000 mg IV/PO BID IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000-1500 mg IV loading dose over 15 min, then 500-1000 mg IV or PO BID; adjust for renal function (CrCl <50: reduce dose 50%)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe renal impairment (dose adjust, do not contraindicate)",
          "known hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Seizure monitoring",
          "behavioral side effects (agitation, psychosis in 1-2%)",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "seizure-management-lorazepam-iv": {
      "id": "seizure-management-lorazepam-iv",
      "name": "Seizure management: Lorazepam IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "rescue-benzodiazepine-for-acute-seizure-termination-use-whil": {
          "indication": "Rescue benzodiazepine for acute seizure termination; use while loading longer-acting ASM",
          "doseOptions": [
            {
              "text": "4 mg IV push",
              "orderSentence": "Seizure management: Lorazepam IV 4 mg IV push IV"
            },
            {
              "text": "may repeat x1",
              "orderSentence": "Seizure management: Lorazepam IV may repeat x1 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 mg IV push over 2 min; may repeat once in 5 min; max 8 mg; have airway equipment ready",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Acute narrow-angle glaucoma",
          "severe respiratory depression without ventilator support"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Respiratory rate",
          "blood pressure",
          "oxygen saturation",
          "sedation level"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "seizure-prophylaxis": {
      "id": "seizure-prophylaxis",
      "name": "Seizure prophylaxis (short-term)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Seizure prophylaxis (short-term) 1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Levetiracetam 1000 mg IV/PO load, then 500-1000 mg BID. AHA 2012: short-term (3-7 days) prophylaxis is reasonable. Avoid phenytoin (associated with worse cognitive outcomes in SAH — Naidech et al.)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment (dose adjust)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Seizure monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "subarachnoid-hemorrhage"
      ]
    },
    "seizure-prophylaxis-treatment": {
      "id": "seizure-prophylaxis-treatment",
      "name": "Seizure prophylaxis / treatment",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000-1500 mg",
              "orderSentence": "**Seizure prophylaxis / treatment** 1000-1500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Prophylaxis (TBI):** Levetiracetam 1000-1500 mg IV load → 500-1000 mg q12h x 7 days (BTF: early seizure prophylaxis x 7 days for severe TBI); **Active seizure:** Lorazepam 0.1 mg/kg (max 4 mg) → Levetiracetam 60 mg/kg load (max 4500 mg) OR fosphenytoin 20 mg PE/kg; **Status epilepticus:** Per SE protocol",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "elevated-icp-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Seizures dramatically increase CMRO2 and ICP",
          "early seizures occur in 10-15% of severe TBI",
          "levetiracetam preferred (no drug interactions, IV/PO equivalent)",
          "prophylaxis beyond 7 days NOT recommended (does not prevent late epilepsy)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "elevated-icp-management"
      ]
    },
    "seizure-valproic-acid-iv": {
      "id": "seizure-valproic-acid-iv",
      "name": "Seizure: Valproic acid IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "second-line-asm-if-levetiracetam-insufficient-for-seizure-co": {
          "indication": "Second-line ASM if levetiracetam insufficient for seizure control; broad-spectrum; avoid in pregnancy",
          "doseOptions": [
            {
              "text": "20-40 mg/kg IV load",
              "orderSentence": "Seizure: Valproic acid IV 20-40 mg/kg IV load IV"
            },
            {
              "text": "500 mg IV q12h",
              "orderSentence": "Seizure: Valproic acid IV 500 mg IV q12h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mg/kg IV loading dose (max 3000 mg) over 30-60 min; then 500 mg IV q12h; target level 50-100 mcg/mL",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "pres"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy (ABSOLUTE -- teratogenic)",
          "hepatic failure",
          "pancreatitis",
          "thrombocytopenia (<50,000)",
          "urea cycle disorder"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC with platelets",
          "LFTs",
          "Valproic acid level (target 50-100)",
          "ammonia if altered mental status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "pres"
      ]
    },
    "selegiline": {
      "id": "selegiline",
      "name": "Selegiline (Eldepryl)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Selegiline (Eldepryl) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg BID (breakfast and lunch); avoid evening dosing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "mao-b-inhibitor-adjunct-mild-neuroprotection-theory": {
          "indication": "MAO-B inhibitor; adjunct; mild neuroprotection theory",
          "doseOptions": [
            {
              "text": "5 mg BID",
              "orderSentence": "Selegiline 5 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg at breakfast and lunch (avoid evening due to insomnia); max 10 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "MAOIs",
          "Same as rasagiline",
          "TCAs (caution)",
          "meperidine"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Insomnia, hypertensive crisis with tyramine (rare at this dose)",
          "Insomnia, orthostatic hypotension"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis"
      ]
    },
    "senna": {
      "id": "senna",
      "name": "Senna",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "constipation-when-docusate-alone-is-insufficient": {
          "indication": "Constipation when docusate alone is insufficient",
          "doseOptions": [
            {
              "text": "8.6 mg",
              "orderSentence": "Senna 8.6 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8.6-17.2 mg PO qHS; may increase to BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "constipation": {
          "indication": "Constipation",
          "doseOptions": [
            {
              "text": "8.6-17.2 mg",
              "orderSentence": "Senna 8.6-17.2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8.6-17.2 mg qHS; max 34.4 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy",
            "ms-new-diagnosis",
            "guillain-barre-syndrome",
            "botulism"
          ]
        },
        "constipation-from-autonomic-dysfunction-adjunct-to-osmotic-l": {
          "indication": "Constipation from autonomic dysfunction; adjunct to osmotic laxative",
          "doseOptions": [
            {
              "text": "8.6 mg",
              "orderSentence": "Senna 8.6 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8.6-17.2 mg PO qHS; may increase to BID if needed; max 34.4 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "constipation-stimulant-laxative-adjunct-if-osmotic-alone-ins": {
          "indication": "Constipation — stimulant laxative adjunct if osmotic alone insufficient",
          "doseOptions": [
            {
              "text": "8.6 mg QHS",
              "orderSentence": "Senna (Senokot) 8.6 mg QHS PO"
            },
            {
              "text": "17.2 mg QHS",
              "orderSentence": "Senna (Senokot) 17.2 mg QHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8.6-17.2 mg at bedtime; may use daily or as needed; combine with PEG for refractory constipation",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "constipation-treatment-in-neurogenic-bowel-stimulant-laxativ": {
          "indication": "Constipation treatment in neurogenic bowel; stimulant laxative for bowel program",
          "doseOptions": [
            {
              "text": "8.6-17.2 mg",
              "orderSentence": "Senna 8.6-17.2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8.6-17.2 mg PO qHS; adjust based on bowel response",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bowel obstruction",
          "Bowel obstruction, acute abdominal conditions",
          "GI obstruction",
          "Intestinal obstruction",
          "acute abdomen",
          "acute abdominal pain"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bowel frequency",
          "Bowel frequency, cramping, electrolytes",
          "Bowel function",
          "Bowel habits",
          "Cramping",
          "avoid long-term use if possible",
          "dependency with chronic daily use",
          "electrolytes with chronic use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "botulism",
        "cervical-myelopathy",
        "critical-illness-myopathy-neuropathy",
        "guillain-barre-syndrome",
        "lambert-eaton-syndrome",
        "ms-new-diagnosis",
        "multiple-system-atrophy",
        "peripheral-neuropathy"
      ]
    },
    "senna-docusate": {
      "id": "senna-docusate",
      "name": "Senna + docusate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "constipation-stimulant": {
          "indication": "Constipation stimulant",
          "doseOptions": [
            {
              "text": "2 tablets",
              "orderSentence": "Senna + docusate 2 tablets PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 tablets qHS; may increase to 4 tablets",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia",
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bowel obstruction",
          "undiagnosed abdominal pain"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Electrolytes with chronic use"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "lewy-body-dementia",
        "parkinsons-disease"
      ]
    },
    "sepsis-resuscitation": {
      "id": "sepsis-resuscitation",
      "name": "Sepsis resuscitation (if septic)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "30 mL/kg",
              "orderSentence": "**Sepsis resuscitation (if septic)** 30 mL/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Surviving Sepsis guidelines: lactate measurement; blood cultures before antibiotics; IV crystalloid 30 mL/kg for hypotension or lactate ≥4 mmol/L; vasopressors (norepinephrine first-line) if MAP <65 despite fluids; reassess volume status; repeat lactate if initially elevated",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "epidural-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sepsis from SEA has high mortality",
          "early aggressive resuscitation improves outcomes"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epidural-abscess"
      ]
    },
    "serial-therapeutic-lp": {
      "id": "serial-therapeutic-lp",
      "name": "Serial therapeutic LP",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "LP"
      ],
      "formulations": [],
      "contexts": {
        "temporizing-measure-confirm-continued-benefit-bridge-to-surg": {
          "indication": "Temporizing measure; confirm continued benefit; bridge to surgery",
          "doseOptions": [
            {
              "text": "30-50 mL",
              "orderSentence": "Serial therapeutic LP 30-50 mL LP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Remove 30-50 mL every 1-4 weeks based on symptom recurrence",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "normal-pressure-hydrocephalus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Coagulopathy",
          "anticoagulation",
          "skin infection"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Post-LP symptoms",
          "duration of benefit"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "normal-pressure-hydrocephalus"
      ]
    },
    "sertraline": {
      "id": "sertraline",
      "name": "Sertraline",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "post-stroke-depression-evidence-based-flame-trial-first-line": {
          "indication": "Post-stroke depression (evidence-based; FLAME trial); first-line",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline (Zoloft) 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25 mg every 1-2 weeks; typical 50-100 mg daily; max 200 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "depression-anxiety-irritability": {
          "indication": "Depression; anxiety; irritability",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; titrate by 25-50 mg q1-2wk; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "depression-anxiety": {
          "indication": "Depression; anxiety",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO daily; increase by 25-50 mg q1-2 weeks; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als",
            "lewy-body-dementia",
            "alzheimers-disease"
          ]
        },
        "depression-anxiety-comorbidity-occurs-in-30-50-of-dre-patien": {
          "indication": "Depression/anxiety comorbidity (occurs in 30-50% of DRE patients); does NOT lower seizure threshold",
          "doseOptions": [
            {
              "text": "25 mg daily",
              "orderSentence": "Sertraline 25 mg daily PO"
            },
            {
              "text": "50 mg daily",
              "orderSentence": "Sertraline 50 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Sertraline 100 mg daily PO"
            },
            {
              "text": "200 mg daily",
              "orderSentence": "Sertraline 200 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25-50 mg q1-2wk; target 50-200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "tinnitus-with-comorbid-anxiety-depression": {
          "indication": "Tinnitus with comorbid anxiety/depression",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "**Sertraline** 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg daily, titrate to 100-200 mg; SSRI; treats comorbid anxiety and depression that amplify tinnitus distress",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tinnitus-evaluation"
          ]
        },
        "depression-anxiety-contributing-to-cognitive-complaints": {
          "indication": "Depression; anxiety contributing to cognitive complaints",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; titrate by 25 mg q1-2wk; typical 50-100 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "comorbid-depression-present-in-50-fnd-anxiety": {
          "indication": "Comorbid depression (present in ~50% FND); anxiety",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Sertraline 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily; titrate q2-4wk; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "functional-neurological-disorder"
          ]
        },
        "depression-common-with-general-paresis-and-chronic-neurosyph": {
          "indication": "Depression (common with general paresis and chronic neurosyphilis)",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Sertraline 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily; increase by 50 mg q2-4wk; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosyphilis"
          ]
        },
        "depression-and-anxiety-during-prolonged-icu-stay-and-recover": {
          "indication": "Depression and anxiety during prolonged ICU stay and recovery; common comorbidity in ICUAW",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg PO daily; titrate by 25-50 mg q1-2 weeks; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "comorbid-major-depression-present-in-50-85-of-pnes-patients-": {
          "indication": "Comorbid major depression (present in ~50-85% of PNES patients); comorbid anxiety; PTSD (first-line for all three)",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Sertraline 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily; titrate by 50 mg q2-4wk; max 200 mg/day; takes 4-6 weeks for full effect",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        },
        "depression-and-anxiety-commonly-associated-with-chronic-cns-": {
          "indication": "Depression and anxiety commonly associated with chronic CNS vasculitis and prolonged immunosuppression",
          "doseOptions": [
            {
              "text": "50 mg daily",
              "orderSentence": "Sertraline 50 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Sertraline 100 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg q2-4 weeks; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "depression-anxiety-irritability-post-tbi": {
          "indication": "Depression, anxiety, irritability post-TBI",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO daily; increase by 25 mg every 1-2 weeks; target 50-150 mg daily; max 200 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "depression-common-comorbidity-in-chronic-progressive-neuromu": {
          "indication": "Depression (common comorbidity in chronic progressive neuromuscular disease); also helps anxiety",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Sertraline 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO daily; increase to 50 mg after 1 week; may titrate by 25-50 mg q2-4 weeks; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "depression-comorbid-with-hand-prevalence-20-40-safe-in-hiv-m": {
          "indication": "Depression comorbid with HAND (prevalence 20-40%); safe in HIV; minimal drug interactions with ART",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25 mg q1-2 weeks; target 50-200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "depression-common-comorbidity": {
          "indication": "Depression (common comorbidity)",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Sertraline 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily; titrate q2-4wk; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "depression-common-in-psp-first-line-ssri": {
          "indication": "Depression common in PSP; first-line SSRI",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25 mg q1-2 weeks; target 50-100 mg daily; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "depression-and-emotional-lability-in-abi-survivors-common-po": {
          "indication": "Depression and emotional lability in ABI survivors; common post-anoxic complication",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO daily; increase by 25 mg q1-2 weeks; max 200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "ocd-comorbidity-alternative-ssri": {
          "indication": "OCD comorbidity; alternative SSRI",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline (Zoloft) 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25-50 mg q1-2wk; target 50-200 mg/day for OCD; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        },
        "depression": {
          "indication": "Depression",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Sertraline 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily; increase by 25-50 mg every 1-2 weeks; max 200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "depression-and-anxiety-commonly-comorbid-with-chronic-ataxia": {
          "indication": "Depression and anxiety commonly comorbid with chronic ataxia; does not worsen ataxia",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25 mg q1-2 weeks; target 50-150 mg daily; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "anxiety-and-depression-comorbidity-management-high-prevalenc": {
          "indication": "Anxiety and depression comorbidity management; high prevalence in SPS patients",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Sertraline 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 25-50 mg q1-2wk; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline (depression, anxiety) 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; target 50-100 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "depression-and-anxiety-associated-with-chronic-paraneoplasti": {
          "indication": "Depression and anxiety associated with chronic paraneoplastic neurological syndrome",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg daily; increase by 25-50 mg q1-2wk; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        },
        "depression-comorbidity-30-50-of-epilepsy-patients-does-not-l": {
          "indication": "Depression comorbidity (30-50% of epilepsy patients); does NOT lower seizure threshold; first-line antidepressant in epilepsy",
          "doseOptions": [
            {
              "text": "25 mg daily",
              "orderSentence": "Sertraline 25 mg daily PO"
            },
            {
              "text": "50 mg daily",
              "orderSentence": "Sertraline 50 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Sertraline 100 mg daily PO"
            },
            {
              "text": "200 mg daily",
              "orderSentence": "Sertraline 200 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25-50 mg q1-2wk; target 50-200 mg daily; max 200 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "depression-and-anxiety-commonly-associated-with-susac-syndro": {
          "indication": "Depression and anxiety commonly associated with Susac syndrome given multi-organ impairment (visual loss, hearing loss, cognitive decline)",
          "doseOptions": [
            {
              "text": "50 mg daily",
              "orderSentence": "Sertraline 50 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO daily; increase by 50 mg q2-4 weeks; target 100-200 mg/day; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "post-stroke-depression-affects-30-50-of-stroke-survivors-fla": {
          "indication": "Post-stroke depression (affects 30-50% of stroke survivors); FLAME trial showed improved motor recovery; first-line SSRI",
          "doseOptions": [
            {
              "text": "25 mg daily",
              "orderSentence": "Sertraline 25 mg daily PO"
            },
            {
              "text": "50 mg daily",
              "orderSentence": "Sertraline 50 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Sertraline 100 mg daily PO"
            },
            {
              "text": "200 mg daily",
              "orderSentence": "Sertraline 200 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25-50 mg q1-2wk; target 50-200 mg daily; FLAME trial used 20 mg fluoxetine — either SSRI effective",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "depression-apathy-anxiety-compulsive-behaviors-disinhibition": {
          "indication": "Depression; apathy; anxiety; compulsive behaviors; disinhibition",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline (Zoloft) 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25-50 mg every 1-2 weeks; typical 100-200 mg daily; max 200 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "depression-anxiety-ssri": {
          "indication": "Depression; anxiety — SSRI",
          "doseOptions": [
            {
              "text": "25 mg daily",
              "orderSentence": "Sertraline (Zoloft) 25 mg daily PO"
            },
            {
              "text": "50 mg daily",
              "orderSentence": "Sertraline (Zoloft) 50 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Sertraline (Zoloft) 100 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase to 50-100 mg after 1-2 weeks; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "depression-and-anxiety-common-comorbidities-in-chronic-progr": {
          "indication": "Depression and anxiety (common comorbidities in chronic progressive neuromuscular disease; adjustment disorder)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO daily; increase to 50 mg after 1 week; may titrate by 25-50 mg q2-4 weeks; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "depression-and-anxiety-associated-with-chronic-myelopathy-an": {
          "indication": "Depression and anxiety associated with chronic myelopathy and functional disability",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Sertraline 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg PO daily; titrate by 25-50 mg q2-4 weeks; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "depression-anxiety-chronic": {
          "indication": "Depression/anxiety (chronic)",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Sertraline 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg daily; increase by 25-50 mg q1-2 weeks; max 200 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        },
        "depression-in-pd": {
          "indication": "Depression in PD",
          "doseOptions": [
            {
              "text": "25 mg daily",
              "orderSentence": "Sertraline 25 mg daily PO"
            },
            {
              "text": "50 mg daily",
              "orderSentence": "Sertraline 50 mg daily PO"
            },
            {
              "text": "100 mg daily",
              "orderSentence": "Sertraline 100 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; titrate by 25 mg q1-2wk; typical 50-100 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        },
        "depression-anxiety-common-in-wd": {
          "indication": "Depression, anxiety (common in WD)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sertraline 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; titrate to 100-200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Bleeding risk, QT prolongation",
          "Concurrent MAO-I use",
          "Concurrent MAOI",
          "Concurrent MAOIs",
          "Concurrent MAOIs (14-day washout)",
          "Concurrent MAOIs, uncontrolled bipolar",
          "MAOI use",
          "MAOIs",
          "MAOIs (within 14 days)",
          "MAOIs within 14 days",
          "QT prolongation",
          "QT prolongation (rare)",
          "QT prolongation (relative)",
          "QT prolongation risk",
          "QTc prolongation",
          "QTc prolongation (high doses)",
          "QTc prolongation at high doses",
          "caution with QT-prolonging drugs",
          "caution with anticoagulants (increased bleeding risk with SSRIs)",
          "caution with bleeding risk",
          "caution with hepatic impairment (reduce dose)",
          "caution with ritonavir (increases sertraline levels)",
          "caution with serotonergic drugs",
          "concurrent QT-prolonging drugs (high doses)",
          "concurrent pimozide",
          "pimozide",
          "uncontrolled seizures (lowers threshold slightly)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI bleeding risk, hyponatremia, serotonin syndrome",
          "GI bleeding, hyponatremia",
          "GI effects",
          "GI side effects",
          "GI side effects initially",
          "GI symptoms",
          "GI symptoms initially",
          "GI upset",
          "GI upset initially",
          "Hepatic function (use lower doses in liver disease)",
          "Monitor mood",
          "Mood assessment",
          "Mood, suicidality, serotonin syndrome, hyponatremia (especially elderly)",
          "Na+ if elderly",
          "QTc",
          "QTc at high doses",
          "QTc if high dose",
          "QTc if risk factors",
          "Serotonin syndrome (caution with MAO-B inhibitors)",
          "Suicidality",
          "Suicidality (Black Box in children)",
          "Suicidality (especially first 4 weeks)",
          "Suicidality (first 8 weeks)",
          "Suicidality (first weeks), GI upset, sexual dysfunction",
          "Suicidality first 4 weeks",
          "Suicidality monitoring",
          "Suicidality monitoring (especially weeks 1-4)",
          "Suicidality monitoring (first 2-4 weeks)",
          "Suicidality monitoring (first 4 weeks)",
          "Suicidality monitoring (first 8 weeks)",
          "Suicidality monitoring (weeks 1-4)",
          "Suicidality monitoring first 4 weeks",
          "Suicidality monitoring weeks 1-4",
          "Suicidality, serotonin syndrome",
          "[Zoger et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16844885/): sertraline reduced tinnitus severity in patients with anxiety/depression",
          "activation",
          "apathy (rarely worsens)",
          "bleeding risk",
          "bleeding risk with anticoagulants",
          "fall risk",
          "hyponatremia",
          "hyponatremia (SIADH)",
          "hyponatremia (SIADH) in elderly",
          "hyponatremia (SIADH, especially elderly)",
          "hyponatremia (elderly)",
          "hyponatremia (especially elderly)",
          "may worsen OH",
          "reassess cognition after mood improves",
          "serotonin syndrome",
          "serotonin syndrome risk",
          "serotonin syndrome signs",
          "serotonin syndrome symptoms",
          "sexual dysfunction",
          "sexual side effects",
          "suicidality in young adults",
          "suicidality monitoring (first 4 weeks)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 35,
      "_sourcePlans": [
        "als",
        "alzheimers-disease",
        "anoxic-brain-injury",
        "ataxia-evaluation",
        "cervical-myelopathy",
        "cns-vasculitis",
        "critical-illness-myopathy-neuropathy",
        "dementia-evaluation",
        "drug-resistant-epilepsy",
        "epilepsy-chronic-management",
        "frontotemporal-dementia",
        "functional-neurological-disorder",
        "hiv-associated-neurocognitive-disorder",
        "huntingtons-disease",
        "inclusion-body-myositis",
        "lewy-body-dementia",
        "mild-cognitive-impairment",
        "ms-new-diagnosis",
        "multiple-system-atrophy",
        "myotonic-dystrophy",
        "neurosyphilis",
        "new-onset-seizure",
        "nmosd",
        "paraneoplastic-neurological-syndrome",
        "parkinsons-disease",
        "pnes",
        "post-concussion-syndrome",
        "post-stroke-management",
        "progressive-supranuclear-palsy",
        "stiff-person-syndrome",
        "susac-syndrome",
        "tics-tourette-syndrome",
        "tinnitus-evaluation",
        "vascular-dementia",
        "wilsons-disease"
      ]
    },
    "sildenafil": {
      "id": "sildenafil",
      "name": "Sildenafil",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "erectile-dysfunction-in-autonomic-sfn": {
          "indication": "Erectile dysfunction in autonomic SFN",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sildenafil 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg 1h before activity; max 100 mg; avoid with nitrates",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "erectile-dysfunction": {
          "indication": "Erectile dysfunction",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Sildenafil 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg 30-60 min before activity; may adjust 25-100 mg; max 100 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "erectile-dysfunction-from-autonomic-dysfunction-in-lems": {
          "indication": "Erectile dysfunction from autonomic dysfunction in LEMS",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Sildenafil 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO 1 hour before sexual activity; may increase to 50-100 mg; max 100 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lambert-eaton-syndrome"
          ]
        },
        "erectile-dysfunction-in-msa-pde5-inhibitor": {
          "indication": "Erectile dysfunction in MSA — PDE5 inhibitor",
          "doseOptions": [
            {
              "text": "25 mg PRN",
              "orderSentence": "Sildenafil (Viagra) 25 mg PRN PO"
            },
            {
              "text": "50 mg PRN",
              "orderSentence": "Sildenafil (Viagra) 50 mg PRN PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg (lower dose due to OH risk); take 30-60 min before activity; max 1 dose/day; CAUTION: may worsen orthostatic hypotension",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent nitrates",
          "Concurrent nitrates (CONTRAINDICATED)",
          "Nitrate use",
          "Nitrate use, severe OH (SBP <90 standing), severe cardiac disease",
          "recent MI/stroke",
          "recent stroke/MI within 6 months",
          "severe cardiovascular disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Blood pressure (standing) after first use",
          "Cardiovascular status",
          "Hypotension",
          "cardiac status",
          "priapism",
          "vision changes",
          "warn about OH risk"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "lambert-eaton-syndrome",
        "multiple-system-atrophy",
        "peripheral-neuropathy",
        "small-fiber-neuropathy"
      ]
    },
    "siponimod": {
      "id": "siponimod",
      "name": "Siponimod (Mayzent)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Siponimod (Mayzent) 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Titration pack, then 2 mg daily (1 mg if CYP2C9 *2/*3); approved for active SPMS",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CYP2C9 testing required",
          "Same as fingolimod",
          "Same plus CYP2C9 *3/*3 genotype (contraindicated)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CYP2C9 genotype",
          "Same",
          "Same as fingolimod",
          "genotype required before starting"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "sodium-correction": {
      "id": "sodium-correction",
      "name": "Sodium correction (hyponatremia -- LGI1)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100-150 mL",
              "orderSentence": "Sodium correction (hyponatremia -- LGI1) 100-150 mL IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If Na <125: 3% NaCl 100-150 mL IV over 10-20 min (repeat up to 3x); Target correction: 4-6 mEq/L in first 6h, max 8 mEq/L in 24h",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Avoid overcorrection (osmotic demyelination risk)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sodium q2-4h during correction",
          "neurologic status",
          "urine output"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "autoimmune-encephalitis"
      ]
    },
    "sodium-nitroprusside": {
      "id": "sodium-nitroprusside",
      "name": "Sodium nitroprusside",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "life-threatening-hypertensive-emergency-refractory-to-all-ot": {
          "indication": "Life-threatening hypertensive emergency refractory to all other agents; LAST RESORT in pregnancy due to cyanide risk to fetus",
          "doseOptions": [
            {
              "text": "0.25-0.5 mcg/kg/min",
              "orderSentence": "Sodium nitroprusside 0.25-0.5 mcg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.25 mcg/kg/min; titrate by 0.5 mcg/kg/min q5min; max 2 mcg/kg/min; use for shortest duration possible; **CYANIDE TOXICITY risk to fetus — LAST RESORT**",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Compensatory hypertension",
          "coarctation of aorta",
          "hepatic insufficiency"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "**FETAL MONITORING — cyanide crosses placenta**",
          "Arterial line mandatory",
          "thiocyanate levels if >24h"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy"
      ]
    },
    "sodium-oxybate": {
      "id": "sodium-oxybate",
      "name": "Sodium oxybate (Xyrem)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-for-cataplexy-also-improves-eds-and-disrupted-noc": {
          "indication": "First-line for cataplexy; also improves EDS and disrupted nocturnal sleep; REMS program (Xyrem REMS)",
          "doseOptions": [
            {
              "text": "2.25 g",
              "orderSentence": "Sodium oxybate (Xyrem) 2.25 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 4.5 g/night divided into 2 equal doses (2.25 g at bedtime + 2.25 g 2.5-4 hours later); titrate by 1.5 g/night every 1-2 weeks; effective range 6-9 g/night; max 9 g/night",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Succinic semialdehyde dehydrogenase deficiency",
          "concurrent opioids",
          "concurrent sedative-hypnotics or alcohol",
          "untreated sleep-disordered breathing"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CNS depression",
          "Respiratory depression",
          "abuse potential",
          "depression/suicidality",
          "sleepwalking",
          "sodium intake (high sodium content)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "narcolepsy"
      ]
    },
    "solifenacin": {
      "id": "solifenacin",
      "name": "Solifenacin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "bladder-urgency-better-tolerated-anticholinergic": {
          "indication": "Bladder urgency; better tolerated anticholinergic",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Solifenacin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; may increase to 10 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "bladder-urgency": {
          "indication": "Bladder urgency",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Solifenacin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; may increase to 10 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as oxybutynin",
          "Urinary retention",
          "gastric retention",
          "severe hepatic impairment",
          "uncontrolled narrow-angle glaucoma"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anticholinergic effects",
          "Dry mouth, constipation",
          "preferred over oxybutynin if cognitive concerns"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-new-diagnosis",
        "small-fiber-neuropathy"
      ]
    },
    "solriamfetol": {
      "id": "solriamfetol",
      "name": "Solriamfetol (Sunosi)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "eds-in-narcolepsy-dopamine-norepinephrine-reuptake-inhibitor": {
          "indication": "EDS in narcolepsy; dopamine/norepinephrine reuptake inhibitor",
          "doseOptions": [
            {
              "text": "75 mg",
              "orderSentence": "Solriamfetol (Sunosi) 75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 75 mg once daily upon awakening; may increase to 150 mg daily after ≥3 days; max 150 mg/day for narcolepsy",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAOIs",
          "end-stage renal disease",
          "severe renal impairment (eGFR <15)",
          "uncontrolled hypertension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood pressure",
          "heart rate",
          "psychiatric symptoms",
          "renal function",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "narcolepsy"
      ]
    },
    "somatostatin-analog": {
      "id": "somatostatin-analog",
      "name": "Somatostatin analog (Octreotide LAR)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "recurrent-meningioma-expressing-somatostatin-receptors-confi": {
          "indication": "Recurrent meningioma expressing somatostatin receptors (confirmed by octreotide scan or DOTATATE PET); limited evidence; some patients show disease stabilization",
          "doseOptions": [
            {
              "text": "30 mg",
              "orderSentence": "Somatostatin analog (Octreotide LAR) 30 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Octreotide LAR 30 mg IM every 4 weeks; may require dose adjustment based on response; continue if stable disease or objective response",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Gallbladder disease (relative)",
          "uncontrolled diabetes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GH/IGF-1 levels",
          "GI symptoms (diarrhea, abdominal pain)",
          "Gallbladder ultrasound q6 months",
          "glucose monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "meningioma"
      ]
    },
    "sphenopalatine-ganglion-block": {
      "id": "sphenopalatine-ganglion-block",
      "name": "Sphenopalatine ganglion (SPG) block",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IN"
      ],
      "formulations": [],
      "contexts": {
        "refractory-chronic-migraine-adjunctive-procedure": {
          "indication": "Refractory chronic migraine; adjunctive procedure",
          "doseOptions": [
            {
              "text": "0.3 mL",
              "orderSentence": "Sphenopalatine ganglion (SPG) block 0.3 mL IN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Lidocaine 4% or bupivacaine 0.5% via SPG applicator (e.g., SphenoCath, Tx360); bilateral",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Nasal pathology, anticoagulation, local anesthetic allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Throat numbness, transient epistaxis",
          "assess response",
          "series of treatments often needed"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "chronic-migraine"
      ]
    },
    "statin": {
      "id": "statin",
      "name": "Statin (controversial post-ICH)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "risk-benefit-discussion-sparcl-showed-small-increased-ich-ri": {
          "indication": "Risk-benefit discussion; SPARCL showed small increased ICH risk with atorvastatin but overall cardiovascular benefit. AHA 2022: statin not contraindicated after ICH",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Statin (controversial post-ICH) N/A PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Per cardiovascular risk; individualize",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Lipid panel"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "step-2-baseline-abg": {
      "id": "step-2-baseline-abg",
      "name": "Step 2: Baseline ABG",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Arterial"
      ],
      "formulations": [],
      "contexts": {
        "establish-paco2-baseline-must-be-35-45-mmhg-before-starting-": {
          "indication": "Establish PaCO2 baseline; must be 35-45 mmHg before starting apnea test",
          "doseOptions": [
            {
              "text": "ABG draw",
              "orderSentence": "**Step 2: Baseline ABG** ABG draw Arterial"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Draw ABG after pre-oxygenation; adjust ventilator to normalize PaCO2 if needed; if baseline PaCO2 chronically elevated (e.g., COPD), target must be ≥20 mmHg above chronic baseline AND ≥60 mmHg",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "If PaCO2 cannot be normalized to 35-45 (chronic hypercarbia), document chronic baseline and adjust targets accordingly"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "PaCO2 35-45 mmHg",
          "if chronically elevated CO2, document baseline",
          "pH 7.35-7.45"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-death-evaluation"
      ]
    },
    "step-3-disconnect-ventilator-and-apply-o2": {
      "id": "step-3-disconnect-ventilator-and-apply-o2",
      "name": "Step 3: Disconnect ventilator and apply O2",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Intratracheal"
      ],
      "formulations": [],
      "contexts": {
        "apnea-test-initiation-remove-external-respiratory-drive-obse": {
          "indication": "Apnea test initiation; remove external respiratory drive; observe for spontaneous respiratory effort",
          "doseOptions": [
            {
              "text": "6-10 L/min O2",
              "orderSentence": "**Step 3: Disconnect ventilator and apply O2** 6-10 L/min O2 Intratracheal"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Disconnect from ventilator; immediately place O2 cannula into trachea (or T-piece with CPAP at 5-10 cmH2O) delivering 6-10 L/min O2 at carina level; ensures oxygenation without ventilation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe ARDS with FiO2 >0.7 and PEEP >10 (may desaturate rapidly — consider ancillary test instead)",
          "hemodynamic instability (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "SpO2 continuous",
          "arterial line continuous",
          "direct observation for ANY respiratory movement (chest, abdomen)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-death-evaluation"
      ]
    },
    "step-5-post-apnea-abg": {
      "id": "step-5-post-apnea-abg",
      "name": "Step 5: Post-apnea ABG",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Arterial"
      ],
      "formulations": [],
      "contexts": {
        "confirm-paco2-rise-meets-threshold-for-valid-test": {
          "indication": "Confirm PaCO2 rise meets threshold for valid test",
          "doseOptions": [
            {
              "text": "ABG draw",
              "orderSentence": "**Step 5: Post-apnea ABG** ABG draw Arterial"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Draw ABG at 8-10 minutes of apnea (or sooner if SpO2 <85%); POSITIVE (absent respiratory drive): PaCO2 ≥60 mmHg AND rise ≥20 mmHg above baseline",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "If PaCO2 target not reached and test aborted for desaturation, test is INCONCLUSIVE — need ancillary test"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "PaCO2 ≥60 mmHg AND ≥20 above baseline = POSITIVE (brain death)",
          "if target not met → repeat or ancillary test"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-death-evaluation"
      ]
    },
    "stop-avoid-precipitating-medications": {
      "id": "stop-avoid-precipitating-medications",
      "name": "Stop/avoid precipitating medications",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "**Stop/avoid precipitating medications** N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**MG crisis precipitants (AVOID):** Aminoglycosides (gentamicin, tobramycin), fluoroquinolones (ciprofloxacin, levofloxacin — less risky but still caution), macrolides (azithromycin, erythromycin), beta-blockers, magnesium (IV), neuromuscular blockers, D-penicillamine, interferon-alpha, checkpoint inhibitors (nivolumab, pembrolizumab); **Full list in Appendix**",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "neuromuscular-respiratory-failure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Many medications can worsen neuromuscular transmission",
          "careful medication review essential",
          "see comprehensive list in appendix"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "neuromuscular-respiratory-failure"
      ]
    },
    "stress-ulcer-prophylaxis": {
      "id": "stress-ulcer-prophylaxis",
      "name": "Stress ulcer prophylaxis",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "**Stress ulcer prophylaxis** 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "PPI (omeprazole 20 mg daily or pantoprazole 40 mg daily) while on dexamethasone; continue throughout steroid course",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-metastases"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Combined corticosteroid + critical illness increases GI bleed risk"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-metastases"
      ]
    },
    "stress-ulcer-prophylaxis-famotidine": {
      "id": "stress-ulcer-prophylaxis-famotidine",
      "name": "Stress ulcer prophylaxis: Famotidine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "gi-prophylaxis-for-mechanically-ventilated-patients-with-icu": {
          "indication": "GI prophylaxis for mechanically ventilated patients with ICUAW",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Stress ulcer prophylaxis: Famotidine 20 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg IV q12h; transition to PO when tolerating enteral feeds",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe renal impairment (dose adjust)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "None significant"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "critical-illness-myopathy-neuropathy"
      ]
    },
    "stress-ulcer-prophylaxis-pantoprazole": {
      "id": "stress-ulcer-prophylaxis-pantoprazole",
      "name": "Stress ulcer prophylaxis: Pantoprazole",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "gi-prophylaxis-alternative-use-if-high-bleed-risk-coagulopat": {
          "indication": "GI prophylaxis alternative; use if high bleed risk (coagulopathy, prior GI bleed)",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Stress ulcer prophylaxis: Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV daily; transition to PO when tolerating enteral feeds",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Stress ulcer prophylaxis: Pantoprazole 40 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg IV/PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "subarachnoid-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "C. diff risk",
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "C. difficile risk with prolonged use",
          "GI symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "critical-illness-myopathy-neuropathy",
        "subarachnoid-hemorrhage"
      ]
    },
    "stroke-protocol": {
      "id": "stroke-protocol",
      "name": "Stroke protocol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "**Stroke protocol** N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "If central cause suspected or identified: acute stroke protocol; consider IV thrombolysis (tPA/tenecteplase) if within window; endovascular therapy for basilar artery occlusion; aspirin if not tPA candidate; admit to stroke unit",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vertigo-dizziness-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Posterior circulation stroke is life-threatening",
          "basilar artery occlusion has >80% mortality if untreated"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "vertigo-dizziness-evaluation"
      ]
    },
    "subcutaneous-immunoglobulin": {
      "id": "subcutaneous-immunoglobulin",
      "name": "Subcutaneous immunoglobulin (SCIg)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-ivig-for-maintenance-patient-self-administrat": {
          "indication": "Alternative to IVIG for maintenance; patient self-administration; fewer systemic side effects",
          "doseOptions": [
            {
              "text": "Weight-based",
              "orderSentence": "Subcutaneous immunoglobulin (SCIg) Weight-based SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Equivalent monthly dose to IVIG divided into weekly SC infusions; multiple sites simultaneously; onset immediate (conversion from IVIG)",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "alternative-to-ivig-for-dysphagia-management-patient-self-ad": {
          "indication": "Alternative to IVIG for dysphagia management; patient self-administration at home; fewer systemic side effects than IVIG",
          "doseOptions": [
            {
              "text": "Weight-based",
              "orderSentence": "Subcutaneous immunoglobulin (SCIg) Weight-based SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Equivalent monthly dose to IVIG divided into weekly SC infusions; multiple sites simultaneously; train patient/caregiver on self-administration",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "alternative-to-iv-maintenance-ivig-allows-home-self-administ": {
          "indication": "Alternative to IV maintenance IVIG; allows home self-administration; equivalent efficacy",
          "doseOptions": [
            {
              "text": "0.1-0.4 g/kg",
              "orderSentence": "Subcutaneous immunoglobulin (SCIg) 0.1-0.4 g/kg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Convert from IVIG: divide monthly dose by 4 for weekly dosing; typical 0.1-0.4 g/kg/week SC; adjust per response",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "IgA deficiency (anaphylaxis risk)",
          "IgA deficiency (use IgA-depleted product)",
          "acute renal failure",
          "inadequate SC tissue",
          "recent thromboembolic event",
          "recent thrombotic event",
          "skin infection at infusion site",
          "uncontrolled renal disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "IgG trough levels",
          "IgG trough levels q3 months",
          "Local infusion site reactions",
          "dysphagia response (MBSS q6 months)",
          "injection site reactions",
          "renal function",
          "thrombosis surveillance",
          "thrombotic events"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "inclusion-body-myositis",
        "inflammatory-myopathy",
        "mogad"
      ]
    },
    "sulfadiazine": {
      "id": "sulfadiazine",
      "name": "Sulfadiazine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "toxoplasma-brain-abscess-first-line-used-in-combination-with": {
          "indication": "Toxoplasma brain abscess (first-line); used in combination with pyrimethamine and leucovorin",
          "doseOptions": [
            {
              "text": "1-1.5 g",
              "orderSentence": "Sulfadiazine 1-1.5 g PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1-1.5 g PO q6h; treat 6 weeks minimum then maintenance; maintain adequate hydration to prevent crystalluria",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Sulfa allergy (use clindamycin as alternative)",
          "crystalluria risk",
          "severe renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "Renal function",
          "hydration status",
          "rash (Stevens-Johnson risk)",
          "urinalysis for crystalluria"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "brain-abscess"
      ]
    },
    "sumatriptan": {
      "id": "sumatriptan",
      "name": "Sumatriptan",
      "genericName": "sumatriptan",
      "brandNames": [
        "Imitrex",
        "Onzetra Xsail",
        "Tosymra",
        "Zembrace"
      ],
      "drugClass": "Triptan / 5-HT1B/1D Agonist",
      "mechanisms": [
        "Selective serotonin 5-HT1B/1D receptor agonist",
        "Causes cranial vasoconstriction",
        "Inhibits trigeminal nerve activation"
      ],
      "routes": [
        "PO",
        "SC",
        "Nasal"
      ],
      "formulations": [
        "25 mg tablet",
        "50 mg tablet",
        "100 mg tablet",
        "6 mg/0.5mL SC injection",
        "4 mg/0.5mL SC injection",
        "5 mg nasal spray",
        "10 mg nasal spray",
        "20 mg nasal spray"
      ],
      "contexts": {
        "migraine-acute": {
          "indication": "Acute migraine treatment",
          "doseOptions": [
            {
              "text": "25 mg PO PRN",
              "orderSentence": "Sumatriptan 25 mg PO PRN migraine"
            },
            {
              "text": "50 mg PO PRN",
              "orderSentence": "Sumatriptan 50 mg PO PRN migraine"
            },
            {
              "text": "100 mg PO PRN",
              "orderSentence": "Sumatriptan 100 mg PO PRN migraine"
            },
            {
              "text": "6 mg SC PRN",
              "orderSentence": "Sumatriptan 6 mg SC PRN migraine"
            },
            {
              "text": "20 mg nasal PRN",
              "orderSentence": "Sumatriptan 20 mg nasal spray PRN migraine"
            }
          ],
          "startingDose": "50 mg PO (or 6 mg SC for faster relief)",
          "maxDose": "200 mg PO/day; 12 mg SC/day; 40 mg nasal/day",
          "titration": "N/A - use lowest effective dose",
          "notes": "Take at onset of headache; may repeat in 2 hours if needed; SC fastest onset"
        },
        "cluster-headache-acute": {
          "indication": "Acute cluster headache treatment",
          "doseOptions": [
            {
              "text": "6 mg SC PRN",
              "orderSentence": "Sumatriptan 6 mg SC PRN cluster headache"
            },
            {
              "text": "20 mg nasal PRN",
              "orderSentence": "Sumatriptan 20 mg nasal spray PRN cluster headache"
            }
          ],
          "startingDose": "6 mg SC",
          "maxDose": "12 mg SC/day (two injections)",
          "titration": "N/A",
          "notes": "SC or nasal preferred over oral for cluster headache due to faster onset"
        },
        "suspected-migraine-with-uncertain-diagnosis-test-dose-is-dia": {
          "indication": "Suspected migraine with uncertain diagnosis; test dose is diagnostic and therapeutic",
          "doseOptions": [
            {
              "text": "6 mg",
              "orderSentence": "Sumatriptan (CPT 96372) 6 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "6 mg SC once; repeat in 2h if partial response; max 12 mg/24h",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "acute-migraine-type-post-traumatic-headache": {
          "indication": "Acute migraine-type post-traumatic headache",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Sumatriptan 50-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg PO once; may repeat in 2h; max 200 mg/24h; limit <9 days/month",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "6 mg",
              "orderSentence": "Sumatriptan (if refractory) 6 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "6 mg SC x1 (pregnancy registry data reassuring)",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "acute-migraine-with-typical-aura-visual-sensory-language-saf": {
          "indication": "Acute migraine with TYPICAL aura (visual, sensory, language) - SAFE",
          "doseOptions": [
            {
              "text": "6 mg",
              "orderSentence": "Sumatriptan 6 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "6 mg SC (may repeat after 1 hr, max 12 mg/24hr) OR 50-100 mg PO (may repeat after 2 hr, max 200 mg/24hr); take AFTER aura resolves or at headache onset",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "History of coronary artery disease, MI, Prinzmetal angina",
          "History of stroke or TIA",
          "Peripheral vascular disease",
          "Uncontrolled hypertension",
          "Hemiplegic or basilar migraine",
          "Use within 24 hours of another triptan or ergot",
          "Use within 2 weeks of MAOIs",
          "Severe hepatic impairment"
        ],
        "precautions": [
          "Chest tightness/pressure (triptan sensations - usually benign)",
          "Cardiovascular evaluation before use in patients with risk factors",
          "Serotonin syndrome with SSRIs/SNRIs (rare but possible)",
          "Medication overuse headache with frequent use (>10 days/month)"
        ],
        "drugInteractions": [
          {
            "drug": "Ergots",
            "severity": "contraindicated",
            "effect": "Additive vasospasm - separate by 24 hours"
          },
          {
            "drug": "Other triptans",
            "severity": "contraindicated",
            "effect": "Additive vasospasm - separate by 24 hours"
          },
          {
            "drug": "MAOIs",
            "severity": "contraindicated",
            "effect": "Increased sumatriptan levels - avoid within 2 weeks"
          },
          {
            "drug": "SSRIs/SNRIs",
            "severity": "moderate",
            "effect": "Risk of serotonin syndrome (rare)"
          }
        ],
        "pregnancyCategory": "C",
        "lactation": "Compatible - express and discard milk for 12 hours if concerned"
      },
      "renalAdjustment": {
        "required": false,
        "tiers": [
          {
            "gfr": "any",
            "adjustment": "No adjustment needed"
          }
        ]
      },
      "hepaticAdjustment": {
        "required": true,
        "notes": "Max 50 mg PO in mild-moderate impairment; contraindicated in severe impairment"
      },
      "monitoring": {
        "baseline": [
          "Cardiovascular risk assessment",
          "Blood pressure"
        ],
        "ongoing": [
          "Headache frequency (watch for MOH)",
          "Cardiovascular symptoms"
        ],
        "frequency": "At each visit; limit to <10 days/month to prevent MOH"
      },
      "patientCounseling": [
        "Take at first sign of migraine headache (not during aura)",
        "May repeat in 2 hours if needed; max 2 doses/day",
        "Do not use more than 10 days per month (medication overuse headache risk)",
        "Chest tightness is common and usually benign - but report if severe or persistent",
        "Do not use if you have heart disease or uncontrolled blood pressure",
        "Store injectable away from light"
      ]
    },
    "sumatriptan-nasal": {
      "id": "sumatriptan-nasal",
      "name": "Sumatriptan nasal",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IN",
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Sumatriptan nasal 20 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg intranasal; less effective than SC",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache",
            "migraine"
          ]
        },
        "alternative-triptan-route-when-sc-not-tolerated-or-for-moder": {
          "indication": "Alternative triptan route when SC not tolerated or for moderate attacks",
          "doseOptions": [
            {
              "text": "20 mg IN once",
              "orderSentence": "Sumatriptan nasal 20 mg IN once IN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg intranasal; may repeat in 2h; max 40 mg/24h",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CAD, prior stroke/TIA, uncontrolled hypertension (>140/90), hemiplegic or basilar migraine, pregnancy, use of ergotamine/DHE within 24h, concurrent MAOI",
          "Same as SC"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Chest tightness, blood pressure, coronary symptoms",
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "cluster-headache",
        "migraine",
        "status-migrainosus"
      ]
    },
    "sumatriptan-po": {
      "id": "sumatriptan-po",
      "name": "Sumatriptan PO",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "suspected-migraine-after-secondary-causes-excluded-milder-at": {
          "indication": "Suspected migraine after secondary causes excluded; milder attacks",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Sumatriptan PO 50-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg PO once; may repeat in 2h; max 200 mg/24h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Sumatriptan PO 50-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg PO once; may repeat in 2h; max 200 mg/24h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "moderate-severe-migraine": {
          "indication": "Moderate-severe migraine",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Sumatriptan PO 50-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg PO once; may repeat in 2h; max 200 mg/24h; limit ≤9 days/month",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "outpatient-rescue-for-breakthrough-migraine-after-discharge-": {
          "indication": "Outpatient rescue for breakthrough migraine after discharge from status migrainosus treatment",
          "doseOptions": [
            {
              "text": "100 mg PO once",
              "orderSentence": "Sumatriptan PO (post-discharge rescue) 100 mg PO once PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg PO at onset; may repeat in 2h; max 200 mg/24h; limit to ≤9 days/month",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CAD, prior stroke/TIA, uncontrolled HTN (>140/90), hemiplegic or basilar migraine, pregnancy, concurrent ergot/DHE within 24h",
          "CAD, stroke/TIA, uncontrolled HTN, hemiplegic migraine, MAOIs, pregnancy",
          "CAD, stroke/TIA, uncontrolled HTN, hemiplegic migraine, pregnancy, basilar migraine, within 24h of ergotamine",
          "Same as SC"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Chest tightness, BP",
          "Chest tightness, blood pressure, coronary symptoms",
          "Same",
          "medication days/month",
          "serotonin syndrome signs if on SNRI/SSRI"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "chronic-migraine",
        "headache-evaluation",
        "migraine",
        "status-migrainosus"
      ]
    },
    "sumatriptan-sc": {
      "id": "sumatriptan-sc",
      "name": "Sumatriptan SC",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "suspected-migraine-or-cluster-headache-with-moderate-severe-": {
          "indication": "Suspected migraine or cluster headache with moderate-severe pain (after secondary causes excluded)",
          "doseOptions": [
            {
              "text": "6 mg",
              "orderSentence": "Sumatriptan SC 6 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "6 mg SC once; may repeat in 2h; max 12 mg/24h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "6 mg",
              "orderSentence": "Sumatriptan SC 6 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "6 mg SC; may use up to 2 doses/24h (minimum 1h apart); max 12 mg/24h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache",
            "migraine"
          ]
        },
        "moderate-severe-migraine-rapid-relief-needed": {
          "indication": "Moderate-severe migraine; rapid relief needed",
          "doseOptions": [
            {
              "text": "6 mg",
              "orderSentence": "Sumatriptan SC 6 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "6 mg SC once; may repeat in 2h; max 12 mg/24h; limit ≤9 days/month",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "triptan-naive-or-triptan-responsive-patients-without-vascula": {
          "indication": "Triptan-naive or triptan-responsive patients without vascular contraindications; most effective when given early",
          "doseOptions": [
            {
              "text": "6 mg SC once",
              "orderSentence": "Sumatriptan SC 6 mg SC once SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "6 mg SC once; may repeat x1 in 2h; max 12 mg/24h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CAD, prior stroke/TIA, uncontrolled hypertension (>140/90), hemiplegic or basilar migraine, pregnancy, use of ergotamine/DHE within 24h, concurrent MAOI",
          "CAD, stroke/TIA, uncontrolled HTN, hemiplegic migraine, MAOIs, pregnancy",
          "CAD, stroke/TIA, uncontrolled HTN, hemiplegic migraine, pregnancy, basilar migraine, within 24h of ergotamine",
          "CAD, stroke/TIA, uncontrolled HTN, hemiplegic/basilar migraine, pregnancy",
          "CAD, uncontrolled HTN, recent stroke/TIA, hemiplegic migraine"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Chest tightness, BP",
          "Chest tightness, blood pressure, coronary symptoms",
          "medication days/month",
          "serotonin syndrome signs if on SNRI/SSRI"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "chronic-migraine",
        "cluster-headache",
        "headache-evaluation",
        "migraine",
        "status-migrainosus"
      ]
    },
    "sunitinib": {
      "id": "sunitinib",
      "name": "Sunitinib",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "recurrent-progressive-meningioma-refractory-to-standard-ther": {
          "indication": "Recurrent/progressive meningioma refractory to standard therapies; VEGFR/PDGFR tyrosine kinase inhibitor; Kaley et al. showed PFS-6 of 42% in atypical/anaplastic meningioma",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Sunitinib 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg PO daily for 28 days followed by 14-day rest (4/2 schedule); or 37.5 mg continuous daily schedule; dose reduce for toxicity",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "Uncontrolled hypertension",
          "bleeding risk",
          "hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP weekly initially",
          "CBC q2 weeks",
          "LFTs",
          "TSH q3 months",
          "cardiac function (LVEF)",
          "diarrhea",
          "hand-foot syndrome"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "meningioma"
      ]
    },
    "sunscreen-and-sun-protection": {
      "id": "sunscreen-and-sun-protection",
      "name": "Sunscreen and sun protection",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "dm-skin-disease-management-photosensitivity-is-hallmark-of-d": {
          "indication": "DM skin disease management; photosensitivity is hallmark of DM",
          "doseOptions": [
            {
              "text": "SPF 50+",
              "orderSentence": "Sunscreen and sun protection SPF 50+ TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply broad-spectrum SPF 50+ to all exposed areas daily; reapply q2h with sun exposure; photoprotective clothing",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Skin exam",
          "rash activity"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "inflammatory-myopathy"
      ]
    },
    "supplemental-oxygen": {
      "id": "supplemental-oxygen",
      "name": "Supplemental oxygen",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "INH"
      ],
      "formulations": [],
      "contexts": {
        "maintain-oxygenation-in-acute-stroke-from-dissection": {
          "indication": "Maintain oxygenation in acute stroke from dissection",
          "doseOptions": [
            {
              "text": "2-4 L/min",
              "orderSentence": "Supplemental oxygen 2-4 L/min INH"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Only if SpO2 <94%; nasal cannula or mask as needed; target SpO2 >=94%",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "maintain-oxygenation-during-and-after-seizure": {
          "indication": "Maintain oxygenation during and after seizure",
          "doseOptions": [
            {
              "text": "2-15 L",
              "orderSentence": "Supplemental oxygen 2-15 L INH"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2-4 L nasal cannula or non-rebreather as needed to maintain O2 sat >94%",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "15 L/min",
              "orderSentence": "Supplemental oxygen 15 L/min INH"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Non-rebreather 15 L/min or bag-valve-mask",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus",
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None",
          "Not applicable"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "O2 sat >94%",
          "O2 sat continuous",
          "SpO2 continuous monitoring",
          "avoid routine supplemental O2 if normoxic"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "cervical-artery-dissection",
        "new-onset-seizure",
        "status-epilepticus"
      ]
    },
    "supraorbital-nerve-block": {
      "id": "supraorbital-nerve-block",
      "name": "Supraorbital nerve block",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Local"
      ],
      "formulations": [],
      "contexts": {
        "additional-peripheral-nerve-block-targeting-frontal-headache": {
          "indication": "Additional peripheral nerve block targeting frontal headache distribution",
          "doseOptions": [
            {
              "text": "1-2 mL per side",
              "orderSentence": "Supraorbital nerve block 1-2 mL per side Local"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Bupivacaine 0.5% 1-2 mL per side at supraorbital notch",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local anesthetic allergy, infection at site"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Local reaction"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "status-migrainosus"
      ]
    },
    "suvorexant": {
      "id": "suvorexant",
      "name": "Suvorexant",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "insomnia-orexin-receptor-antagonist": {
          "indication": "Insomnia (orexin receptor antagonist)",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Suvorexant 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10 mg PO QHS; may increase to 20 mg; take within 30 min of bedtime",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Narcolepsy, severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Next-day somnolence",
          "sleep paralysis (rare)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "post-concussion-syndrome"
      ]
    },
    "switch-to-clozapine": {
      "id": "switch-to-clozapine",
      "name": "Switch to clozapine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "lowest-td-risk-for-patients-requiring-continued-antipsychoti": {
          "indication": "Lowest TD risk; for patients requiring continued antipsychotic",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Switch to clozapine 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5-25 mg/day; titrate by 25-50 mg q3-7d; target 200-450 mg/day; requires REMS",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Agranulocytosis history",
          "seizure disorder (relative)",
          "severe neutropenia"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ANC weekly x 6mo, q2wk x 6mo, then monthly",
          "myocarditis",
          "seizures"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tardive-dyskinesia"
      ]
    },
    "switch-to-quetiapine": {
      "id": "switch-to-quetiapine",
      "name": "Switch to quetiapine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "lower-td-risk-for-patients-requiring-continued-antipsychotic": {
          "indication": "Lower TD risk; for patients requiring continued antipsychotic",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Switch to quetiapine 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg BID; titrate by 50-100 mg/day q2-3d; target 300-800 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QT prolongation",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "QTc, sedation, metabolic parameters"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tardive-dyskinesia"
      ]
    },
    "symptomatic-relief": {
      "id": "symptomatic-relief",
      "name": "Symptomatic relief (vestibular suppressants)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "**Symptomatic relief (vestibular suppressants)** 25-50 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Acute severe vertigo:** Meclizine 25-50 mg PO q6-8h; OR Dimenhydrinate (Dramamine) 50 mg PO/IV q6h; OR Promethazine 25 mg PO/IM/IV q6h; OR Ondansetron 4-8 mg IV/PO q8h (for nausea); **IV fluids** for dehydration from vomiting; **Diazepam** 2-5 mg IV/PO for severe acute vertigo (benzodiazepines are potent vestibular suppressants)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "vertigo-dizziness-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Short-term use only (24-72h)",
          "avoid in suspected central cause until stroke ruled out",
          "vestibular suppressants interfere with central compensation if used chronically"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "vertigo-dizziness-evaluation"
      ]
    },
    "tacrolimus": {
      "id": "tacrolimus",
      "name": "Tacrolimus",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Tacrolimus 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "3 mg PO daily in 2 divided doses; target trough 5-10 ng/mL; onset 3-6 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-crisis",
            "myasthenia-gravis-new-diagnosis"
          ]
        },
        "steroid-sparing-agent-particularly-effective-for-anti-synthe": {
          "indication": "Steroid-sparing agent; particularly effective for anti-synthetase syndrome and ILD; faster onset than azathioprine/mycophenolate (2-3 months)",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Tacrolimus 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg PO BID; titrate to trough level 5-10 ng/mL; onset 2-3 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "steroid-sparing-faster-onset-than-azathioprine-3-6-months": {
          "indication": "Steroid-sparing; faster onset than azathioprine (3-6 months)",
          "doseOptions": [
            {
              "text": "3 mg",
              "orderSentence": "Tacrolimus 3 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 3 mg daily; adjust to trough level 5-10 ng/mL; usual dose 3 mg BID; faster onset than azathioprine",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal failure, uncontrolled hypertension",
          "Renal impairment",
          "Uncontrolled hypertension",
          "concurrent potassium-sparing diuretics",
          "concurrent strong CYP3A4 inhibitors",
          "renal impairment",
          "uncontrolled hypertension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Cr, K+, glucose, BP",
          "Tacrolimus trough level monthly",
          "Trough level q1 week initially, then monthly",
          "Trough levels",
          "Trough levels q1-2 weeks during titration then q1-3 months",
          "drug interactions (CYP3A4)",
          "electrolytes (K, Mg)",
          "glucose",
          "headache",
          "nephrotoxicity",
          "renal function",
          "renal function monthly",
          "renal function q2 weeks then monthly",
          "tremor"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "inflammatory-myopathy",
        "myasthenia-gravis",
        "myasthenia-gravis-crisis",
        "myasthenia-gravis-new-diagnosis"
      ]
    },
    "tadalafil": {
      "id": "tadalafil",
      "name": "Tadalafil",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "erectile-dysfunction": {
          "indication": "Erectile dysfunction",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Tadalafil 10 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg before activity (max once daily) OR 2.5-5 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as sildenafil"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "peripheral-neuropathy"
      ]
    },
    "tafamidis": {
      "id": "tafamidis",
      "name": "Tafamidis (Vyndamax/Vyndaqel)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "hereditary-and-wild-type-ttr-amyloidosis-with-polyneuropathy": {
          "indication": "Hereditary and wild-type TTR amyloidosis with polyneuropathy",
          "doseOptions": [
            {
              "text": "80 mg",
              "orderSentence": "Tafamidis (Vyndamax/Vyndaqel) 80 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "80 mg (Vyndamax) or 61 mg (Vyndaqel) PO daily; TTR stabilizer",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "hereditary-transthyretin-hattr-amyloidosis-with-polyneuropat": {
          "indication": "Hereditary transthyretin (hATTR) amyloidosis with polyneuropathy",
          "doseOptions": [
            {
              "text": "61 mg",
              "orderSentence": "Tafamidis (Vyndamax/Vyndaqel) 61 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "61 mg (Vyndamax) or 80 mg (Vyndaqel) daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None",
          "None absolute"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cardiac function",
          "LFTs",
          "clinical response",
          "neuropathy progression"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "peripheral-neuropathy",
        "small-fiber-neuropathy"
      ]
    },
    "tamsulosin": {
      "id": "tamsulosin",
      "name": "Tamsulosin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "urinary-retention-males-with-bph-component": {
          "indication": "Urinary retention (males with BPH component)",
          "doseOptions": [
            {
              "text": "0.4 mg",
              "orderSentence": "Tamsulosin 0.4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.4 mg daily; may increase to 0.8 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "normal-pressure-hydrocephalus"
          ]
        },
        "urinary-retention": {
          "indication": "Urinary retention",
          "doseOptions": [
            {
              "text": "0.4 mg",
              "orderSentence": "Tamsulosin 0.4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 mg once daily 30 min after meal",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia",
            "peripheral-neuropathy",
            "ms-new-diagnosis"
          ]
        },
        "urinary-retention-from-myelitis-related-neurogenic-bladder": {
          "indication": "Urinary retention from myelitis-related neurogenic bladder",
          "doseOptions": [
            {
              "text": "0.4 mg",
              "orderSentence": "Tamsulosin 0.4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 mg PO daily; take 30 min after same meal each day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "urinary-retention-from-myelitis": {
          "indication": "Urinary retention from myelitis",
          "doseOptions": [
            {
              "text": "0.4 mg daily",
              "orderSentence": "Tamsulosin 0.4 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 mg PO daily; may increase to 0.8 mg if needed",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "urinary-retention-with-elevated-post-void-residual-alpha-blo": {
          "indication": "Urinary retention with elevated post-void residual — alpha-blocker for bladder outlet relaxation",
          "doseOptions": [
            {
              "text": "0.4 mg daily",
              "orderSentence": "Tamsulosin (Flomax) 0.4 mg daily PO"
            },
            {
              "text": "0.8 mg daily",
              "orderSentence": "Tamsulosin (Flomax) 0.8 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 mg daily 30 min after same meal each day; may increase to 0.8 mg daily after 2-4 weeks; CAUTION: may worsen OH in MSA",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "multiple-system-atrophy"
          ]
        },
        "urinary-hesitancy-and-retention-from-neurogenic-bladder-faci": {
          "indication": "Urinary hesitancy and retention from neurogenic bladder; facilitates bladder emptying",
          "doseOptions": [
            {
              "text": "0.4 mg",
              "orderSentence": "Tamsulosin 0.4 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.4 mg PO daily 30 minutes after same meal; max 0.8 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent PDE5 inhibitors (orthostatic risk)",
          "Known hypersensitivity",
          "Orthostatic hypotension",
          "Severe orthostatic hypotension (may worsen OH), hypersensitivity",
          "Severe sulfonamide allergy",
          "Severe sulfonamide allergy (use caution)",
          "concurrent silodosin",
          "planned cataract surgery (IFIS)",
          "planned cataract surgery (intraoperative floppy iris)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "Orthostatic BP",
          "Orthostatic BP (may exacerbate OH — use cautiously in MSA), dizziness, retrograde ejaculation",
          "Orthostatic hypotension",
          "Orthostatic hypotension (caution if already orthostatic)",
          "Orthostatic hypotension (caution with existing OH)",
          "dizziness",
          "intraoperative floppy iris (inform ophthalmology)",
          "retrograde ejaculation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "cervical-myelopathy",
        "lewy-body-dementia",
        "mogad",
        "ms-new-diagnosis",
        "multiple-system-atrophy",
        "nmosd",
        "normal-pressure-hydrocephalus",
        "peripheral-neuropathy"
      ]
    },
    "tapentadol-er": {
      "id": "tapentadol-er",
      "name": "Tapentadol ER",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Tapentadol ER 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg BID; titrate by 50 mg q3 days; max 500 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "diabetic-neuropathy"
          ]
        },
        "refractory-pain-mu-opioid-agonist-with-norepinephrine-reupta": {
          "indication": "Refractory pain; mu-opioid agonist with norepinephrine reuptake inhibition",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Tapentadol ER 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg BID; titrate by 50 mg BID q3d; max 500 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "moderate-severe-neuropathic-pain": {
          "indication": "Moderate-severe neuropathic pain",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Tapentadol ER 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg BID; increase by 50 mg BID every 3 days; max 250 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "MAOIs",
          "Respiratory depression, severe hepatic impairment",
          "Same as tramadol",
          "Severe respiratory depression",
          "paralytic ileus"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI effects",
          "Respiratory",
          "Respiratory status, constipation, sedation",
          "Same",
          "Schedule II"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "diabetic-neuropathy",
        "peripheral-neuropathy",
        "small-fiber-neuropathy"
      ]
    },
    "targeted-iv-antibiotic-therapy": {
      "id": "targeted-iv-antibiotic-therapy",
      "name": "Targeted IV antibiotic therapy (based on culture results)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2g",
              "orderSentence": "**Targeted IV antibiotic therapy (based on culture results)** 2g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Tailor to organism and sensitivities; typical regimens:** — **MSSA:** Nafcillin 2g IV q4h OR cefazolin 2g IV q8h (preferred for tolerability); duration 6-8 weeks; — **MRSA:** Vancomycin 15-20 mg/kg IV q8-12h (trough 15-20) for 6-8 weeks; alternatives: daptomycin 6-8 mg/kg IV daily (avoid if pneumonia), linezolid 600 mg IV/PO q12h (monitor for toxicity if >2 weeks); — **Streptococci:** Penicillin G 4 million units IV q4h or ceftriaxone 2g IV q12h x 6 weeks; — **Enterococcus:** Ampicillin 2g IV q4h (if susceptible) ± gentamicin synergy; vancomycin if ampicillin-resistant; — **Gram-negatives:** Ceftriaxone 2g IV q12h or cefepime 2g IV q8h or ciprofloxacin 400 mg IV q8h x 6 weeks depending on sensitivities; — **Pseudomonas:** Cefepime 2g IV q8h or meropenem 2g IV q8h x 6 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "epidural-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "IV antibiotics are standard for SEA/osteomyelitis",
          "de-escalate from empiric coverage once cultures return",
          "oral transition data emerging (OVIVA trial) but traditionally 6-8 weeks IV"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "epidural-abscess"
      ]
    },
    "targeted-temperature-management-cooling-to-32-36c": {
      "id": "targeted-temperature-management-cooling-to-32-36c",
      "name": "Targeted Temperature Management (TTM) — cooling to 32-36C",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/External"
      ],
      "formulations": [],
      "contexts": {
        "all-comatose-cardiac-arrest-survivors-gcs-motor-6-after-rosc": {
          "indication": "ALL comatose cardiac arrest survivors (GCS motor <6 after ROSC). TTM2 trial: no difference between 33C vs 36C; both superior to fever. AHA/ILCOR 2020: target 32-36C for at least 24h",
          "doseOptions": [
            {
              "text": "32-36C",
              "orderSentence": "Targeted Temperature Management (TTM) — cooling to 32-36C 32-36C external/IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Initiate cooling ASAP post-ROSC; use surface (Arctic Sun) or intravascular (Thermogard) cooling; target temperature within 4h; maintain for at least 24h; rewarm at 0.25C/h (avoid >0.5C/h); prevent fever (<37.7C) for at least 72h after ROSC",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active hemorrhage (relative)",
          "refractory cardiogenic shock (relative)",
          "terminal illness (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Core temperature (esophageal or bladder probe) continuously",
          "coagulation q12h",
          "electrolytes (K, Mg, Ca, Phos) q4-6h during cooling",
          "shivering assessment (BSAS) q1h",
          "skin checks q4h for surface cooling"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "anoxic-brain-injury"
      ]
    },
    "temozolomide": {
      "id": "temozolomide",
      "name": "Temozolomide (relapsed PCNSL)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "relapsed-refractory-pcnsl-after-hd-mtx-failure-oral-alkylati": {
          "indication": "Relapsed/refractory PCNSL after HD-MTX failure; oral alkylating agent with CNS penetration",
          "doseOptions": [
            {
              "text": "150 mg/m2",
              "orderSentence": "Temozolomide (relapsed PCNSL) 150 mg/m2 PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150-200 mg/m2 PO days 1-5 of 28-day cycle; take on empty stomach 1h before bed; antiemetic pre-medication",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "recurrent-atypical-or-anaplastic-meningioma-who-grade-ii-iii": {
          "indication": "Recurrent atypical or anaplastic meningioma (WHO grade II/III) refractory to surgery and radiation; limited evidence; consider when no clinical trial available",
          "doseOptions": [
            {
              "text": "150 mg/m2",
              "orderSentence": "Temozolomide 150 mg/m2 PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150-200 mg/m2 PO days 1-5 of 28-day cycle; take on empty stomach 1h before bedtime; antiemetic pre-medication",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ANC <1500",
          "Severe myelosuppression",
          "hypersensitivity to dacarbazine",
          "platelets <100K",
          "pregnancy",
          "prior temozolomide intolerance",
          "severe hepatic/renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC Day 1 and Day 22 of each cycle",
          "LFTs monthly",
          "limited efficacy data in meningioma",
          "watch for lymphopenia and opportunistic infections"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "meningioma",
        "primary-cns-lymphoma"
      ]
    },
    "temozolomide-adjuvant": {
      "id": "temozolomide-adjuvant",
      "name": "Temozolomide - Adjuvant (Stupp Protocol Phase 2)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "standard-adjuvant-chemotherapy-following-concurrent-chemorad": {
          "indication": "Standard adjuvant chemotherapy following concurrent chemoradiation; 6 cycles of dose-dense temozolomide",
          "doseOptions": [
            {
              "text": "150 mg/m2",
              "orderSentence": "Temozolomide - Adjuvant (Stupp Protocol Phase 2) 150 mg/m2 PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Cycle 1: 150 mg/m2 PO days 1-5 of 28-day cycle; if tolerated (ANC >1500, platelets >100K), increase to 200 mg/m2 for cycles 2-6; take on empty stomach 1h before bedtime; antiemetic pre-medication; 6 cycles total",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ANC <1500",
          "platelets <100K on Day 1 of cycle",
          "same as concurrent phase"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC Day 1 and Day 22 of each cycle",
          "LFTs monthly",
          "MGMT methylation-positive patients have better response (median OS ~21 months vs. ~14 months)",
          "hold if ANC <1000 or platelets <50K until recovery",
          "reduce dose by 50 mg/m2 for Grade 3-4 toxicity"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "glioblastoma"
      ]
    },
    "temozolomide-alone": {
      "id": "temozolomide-alone",
      "name": "Temozolomide alone (elderly/poor KPS without RT)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "elderly-patients-70-or-poor-functional-status-kps-30-60-who-": {
          "indication": "Elderly patients (>70) or poor functional status (KPS 30-60) who cannot tolerate radiation; consider if MGMT methylated (better response); Wick et al. Lancet Oncol 2012 (NOA-08)",
          "doseOptions": [
            {
              "text": "150 mg/m2",
              "orderSentence": "Temozolomide alone (elderly/poor KPS without RT) 150 mg/m2 PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Standard 5/28 day dosing (as per adjuvant protocol); MGMT methylation status guides decision: methylated = temozolomide preferred; unmethylated = consider RT alone or best supportive care",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as concurrent/adjuvant temozolomide"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same as adjuvant temozolomide"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "glioblastoma"
      ]
    },
    "temozolomide-concurrent-with-rt": {
      "id": "temozolomide-concurrent-with-rt",
      "name": "Temozolomide - Concurrent with RT (Stupp Protocol Phase 1)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "standard-of-care-for-newly-diagnosed-gbm-concurrent-with-foc": {
          "indication": "Standard of care for newly diagnosed GBM; concurrent with focal radiation (60 Gy in 30 fractions); Stupp et al. NEJM 2005 demonstrated OS benefit (14.6 vs. 12.1 months)",
          "doseOptions": [
            {
              "text": "75 mg/m2",
              "orderSentence": "Temozolomide - Concurrent with RT (Stupp Protocol Phase 1) 75 mg/m2 PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "75 mg/m2 PO daily throughout radiation (42 consecutive days including weekends/holidays); take on empty stomach 1 hour before bedtime; antiemetic 30-60 min before (ondansetron 8 mg); PJP prophylaxis (TMP-SMX) mandatory",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ANC <1500",
          "known hypersensitivity to temozolomide or dacarbazine",
          "platelets <100K",
          "pregnancy/breastfeeding",
          "severe hepatic/renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC weekly during concurrent phase",
          "LFTs q2 weeks",
          "PJP prophylaxis",
          "if ANC <1000 or platelets <50K, hold temozolomide until recovery",
          "watch for severe lymphopenia (CD4 <200)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "glioblastoma"
      ]
    },
    "temozolomide-rechallenge": {
      "id": "temozolomide-rechallenge",
      "name": "Temozolomide rechallenge",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "recurrent-gbm-with-prior-temozolomide-response-dose-dense-or": {
          "indication": "Recurrent GBM with prior temozolomide response; dose-dense or metronomic schedule; consider if long interval since initial treatment",
          "doseOptions": [
            {
              "text": "75 mg/m2",
              "orderSentence": "Temozolomide rechallenge 75 mg/m2 PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Dose-dense: 75-150 mg/m2 PO daily x 21 days of 28-day cycle; metronomic: 50 mg/m2 PO daily continuous; take on empty stomach 1h before bed",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe myelosuppression",
          "hypersensitivity to dacarbazine",
          "prior temozolomide intolerance"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC weekly for first 2 cycles, then q2 weeks",
          "LFTs monthly",
          "watch for cumulative lymphopenia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "glioblastoma"
      ]
    },
    "temperature-management": {
      "id": "temperature-management",
      "name": "Temperature management (hyperthermia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1g",
              "orderSentence": "Temperature management (hyperthermia) 1g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Targeted temperature: 36-37C; cooling blankets; acetaminophen 1g IV/PO q6h PRN",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Avoid overcooling",
          "avoid shivering (increases metabolic demand)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Continuous temperature",
          "shivering assessment (BSAS)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "autoimmune-encephalitis"
      ]
    },
    "tenecteplase": {
      "id": "tenecteplase",
      "name": "Tenecteplase",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "alternative-thrombolytic-for-acute-posterior-circulation-str": {
          "indication": "Alternative thrombolytic for acute posterior circulation stroke; single bolus dosing",
          "doseOptions": [
            {
              "text": "0.25 mg/kg",
              "orderSentence": "Tenecteplase 0.25 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.25 mg/kg IV bolus (max 25 mg); single dose; emerging evidence for posterior circulation",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active hemorrhage",
          "BP >185/110",
          "INR >1.7",
          "platelets <100,000",
          "recent surgery",
          "see full stroke exclusion criteria"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q15min x 2h, then q30min x 6h, then q1h x 16h",
          "NIHSS",
          "neuro checks q15min during infusion",
          "signs of hemorrhage"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ataxia-evaluation"
      ]
    },
    "tenecteplase-iv": {
      "id": "tenecteplase-iv",
      "name": "Tenecteplase IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-ischemic-stroke-with-lvo-from-dissection-preferred-if-": {
          "indication": "Acute ischemic stroke with LVO from dissection; preferred if thrombectomy planned",
          "doseOptions": [
            {
              "text": "0.25 mg/kg",
              "orderSentence": "Tenecteplase IV 0.25 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.25 mg/kg IV single bolus (max 25 mg); preferred over alteplase if LVO planned for thrombectomy",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.25 mg/kg",
              "orderSentence": "Tenecteplase IV (CPT 96374) (if available) 0.25 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.25 mg/kg IV single bolus (max 25 mg); preferred if LVO planned for thrombectomy",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as alteplase"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same as alteplase"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "cervical-artery-dissection"
      ]
    },
    "tenofovir-alafenamide-emtricitabine": {
      "id": "tenofovir-alafenamide-emtricitabine",
      "name": "Tenofovir alafenamide (TAF) / Emtricitabine (Descovy)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nrti-backbone-taf-with-moderate-cpe-preferred-over-tdf-for-r": {
          "indication": "NRTI backbone; TAF with moderate CPE; preferred over TDF for renal/bone safety",
          "doseOptions": [
            {
              "text": "25/200 mg",
              "orderSentence": "Tenofovir alafenamide (TAF) / Emtricitabine (Descovy) 25/200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 tablet PO daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CrCl <30 (for combined formulation)",
          "concurrent use with other tenofovir products"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "HBV status (flare risk if discontinued)",
          "Renal function",
          "lipid panel"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "tenofovir-disoproxil-fumarate-emtricitabine": {
      "id": "tenofovir-disoproxil-fumarate-emtricitabine",
      "name": "Tenofovir disoproxil fumarate (TDF) / Emtricitabine (Truvada)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-nrti-backbone-tdf-has-slightly-higher-cpe-than-t": {
          "indication": "Alternative NRTI backbone; TDF has slightly higher CPE than TAF",
          "doseOptions": [
            {
              "text": "300/200 mg",
              "orderSentence": "Tenofovir disoproxil fumarate (TDF) / Emtricitabine (Truvada) 300/200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 tablet PO daily; dose adjust for CrCl <50",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CrCl <60 (relative)",
          "osteoporosis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "DEXA if >50 or risk factors",
          "Renal function q3-6 months",
          "phosphorus"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "teriflunomide": {
      "id": "teriflunomide",
      "name": "Teriflunomide (Aubagio)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "14 mg",
              "orderSentence": "Teriflunomide (Aubagio) 14 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "14 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy (Category X - teratogenic)",
          "Pregnancy (teratogenic), hepatic disease",
          "concurrent leflunomide",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "CBC",
          "LFTs monthly Ã— 6 months, then periodically",
          "LFTs monthly × 6mo",
          "accelerated elimination available",
          "hair thinning",
          "pregnancy test",
          "requires cholestyramine washout if pregnancy desired"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "testosterone-cypionate": {
      "id": "testosterone-cypionate",
      "name": "Testosterone cypionate (males)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "hypogonadotropic-hypogonadism-from-pituitary-sarcoidosis": {
          "indication": "Hypogonadotropic hypogonadism from pituitary sarcoidosis",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Testosterone cypionate (males) 200 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-200 mg IM every 2 weeks; titrate based on testosterone trough levels",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "symptomatic-hypogonadism-in-dm1-males-fatigue-reduced-libido": {
          "indication": "Symptomatic hypogonadism in DM1 males (fatigue, reduced libido, muscle wasting, osteoporosis); confirmed by low testosterone levels",
          "doseOptions": [
            {
              "text": "200 mg",
              "orderSentence": "Testosterone cypionate (males) 200 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Testosterone cypionate 200 mg IM q2 weeks; adjust dose based on trough levels; target total testosterone 400-700 ng/dL",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "OSA (untreated)",
          "Prostate cancer",
          "breast cancer",
          "desire for fertility",
          "polycythemia (Hct >54%)",
          "severe BPH",
          "untreated sleep apnea (caution -- OSA common in DM1)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "DRE annually",
          "Hct q3 months initially",
          "LFTs",
          "PSA",
          "PSA and DRE at baseline and annually",
          "Testosterone level",
          "bone density",
          "hematocrit q3-6 months (polycythemia risk)",
          "lipids",
          "sleep apnea symptoms",
          "testosterone trough levels"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "myotonic-dystrophy",
        "neurosarcoidosis"
      ]
    },
    "testosterone-gel-1": {
      "id": "testosterone-gel-1",
      "name": "Testosterone gel 1% (males)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "hypogonadotropic-hypogonadism-from-pituitary-sarcoidosis-alt": {
          "indication": "Hypogonadotropic hypogonadism from pituitary sarcoidosis; alternative to IM injection",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Testosterone gel 1% (males) 50 mg TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg (5g gel) applied to shoulders/upper arms daily; wash hands after application; avoid skin-to-skin transfer",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neurosarcoidosis"
          ]
        },
        "symptomatic-hypogonadism-in-dm1-males-fatigue-reduced-libido": {
          "indication": "Symptomatic hypogonadism in DM1 males (fatigue, reduced libido, muscle wasting, osteoporosis); alternative to IM injection; confirmed by low testosterone levels",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Testosterone gel 1% (males) 50 mg TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Testosterone gel 1% (50 mg) applied topically to shoulders/upper arms daily; avoid skin-to-skin transfer; adjust dose based on testosterone levels",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Prostate cancer",
          "breast cancer",
          "polycythemia (Hct >54%)",
          "severe BPH",
          "skin-to-skin transfer risk to women/children",
          "untreated sleep apnea (caution -- OSA common in DM1)",
          "women/children skin contact"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "DRE annually",
          "Hct q3 months initially",
          "LFTs",
          "PSA",
          "PSA and DRE at baseline and annually",
          "Testosterone level",
          "application site reactions",
          "bone density",
          "hematocrit q3-6 months (polycythemia risk)",
          "lipids",
          "sleep apnea symptoms",
          "testosterone levels"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "myotonic-dystrophy",
        "neurosarcoidosis"
      ]
    },
    "tetrabenazine": {
      "id": "tetrabenazine",
      "name": "Tetrabenazine (Xenazine)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "fda-approved-for-hd-chorea-first-line": {
          "indication": "FDA-approved for HD chorea; first-line",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Tetrabenazine (Xenazine) 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg daily; increase by 12.5 mg q1wk; max 100 mg/day (25 mg per dose); CYP2D6 testing recommended",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "hyperkinetic-movements-including-some-dystonias": {
          "indication": "Hyperkinetic movements including some dystonias",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Tetrabenazine 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg daily; increase by 12.5 mg q1wk; max 200 mg/day; CYP2D6 testing recommended",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "vmat2-inhibitor-older-agent-with-more-side-effects": {
          "indication": "VMAT2 inhibitor; older agent with more side effects",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Tetrabenazine (Xenazine) 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg daily; increase by 12.5 mg q1wk; max 50 mg/day (100 mg if CYP2D6 extensive metabolizer); require CYP2D6 genotyping >50 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        },
        "vmat2-inhibitor-third-line-for-moderate-severe-tics-refracto": {
          "indication": "VMAT2 inhibitor; third-line for moderate-severe tics refractory to first/second-line agents",
          "doseOptions": [
            {
              "text": "12.5 mg",
              "orderSentence": "Tetrabenazine (Xenazine) 12.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 12.5 mg daily; increase by 12.5 mg q1wk; target 25-75 mg/day divided BID-TID; max 200 mg/day; CYP2D6 genotyping required at doses >50 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active suicidality",
          "Depression",
          "Depression/suicidality",
          "Depression/suicidality (Black Box)",
          "MAO-I use",
          "Parkinsonism",
          "concurrent MAOIs",
          "hepatic impairment",
          "reserpine use within 20 days",
          "suicidality",
          "untreated depression",
          "untreated or inadequately treated depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Black Box: suicidality",
          "CYP2D6 genotyping",
          "Depression (PHQ-9 monthly), akathisia, parkinsonism, QTc",
          "Depression (PHQ-9)",
          "Depression screening (PHQ-9) at each visit",
          "Depression, sedation, parkinsonism, akathisia",
          "akathisia",
          "parkinsonism",
          "requires CYP2D6 genotyping",
          "sedation",
          "suicidality assessment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "dystonia",
        "huntingtons-disease",
        "tardive-dyskinesia",
        "tics-tourette-syndrome"
      ]
    },
    "tetrathiomolybdate": {
      "id": "tetrathiomolybdate",
      "name": "Tetrathiomolybdate (ammonium or bis-choline)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "investigational-chelator-neurologic-wd-may-have-less-neurolo": {
          "indication": "Investigational chelator; neurologic WD (may have less neurologic worsening than penicillamine)",
          "doseOptions": [
            {
              "text": "20 mg",
              "orderSentence": "Tetrathiomolybdate (ammonium or bis-choline) 20 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20 mg TID with meals + 20 mg TID between meals (total 120 mg/day); investigational — available through clinical trials or compassionate use",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic failure",
          "not yet widely approved"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC (bone marrow suppression), LFTs, copper levels, iron studies (iron deficiency from over-decoppering)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wilsons-disease"
      ]
    },
    "theophylline": {
      "id": "theophylline",
      "name": "Theophylline",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "adjunctive-treatment-for-sih-increases-csf-production-via-ad": {
          "indication": "Adjunctive treatment for SIH; increases CSF production via adenosine receptor antagonism",
          "doseOptions": [
            {
              "text": "200 mg BID",
              "orderSentence": "Theophylline 200 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 200 mg PO BID; titrate to 300 mg BID based on serum levels; target serum level 10-15 mcg/mL; may take 1-2 weeks for effect",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "low-pressure-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Seizure disorder, cardiac arrhythmia, active peptic ulcer, hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "GI symptoms",
          "Theophylline level q2-4 weeks initially",
          "drug interactions (CYP1A2)",
          "heart rate"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "low-pressure-headache"
      ]
    },
    "thiamine": {
      "id": "thiamine",
      "name": "Thiamine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "IV/PO"
      ],
      "formulations": [],
      "contexts": {
        "suspected-wernicke-s-alcoholism-malnutrition": {
          "indication": "Suspected Wernicke's; alcoholism; malnutrition",
          "doseOptions": [
            {
              "text": "500 mg IV TID x 3 days",
              "orderSentence": "Thiamine 500 mg IV TID x 3 days IV/PO"
            },
            {
              "text": "100 mg PO daily",
              "orderSentence": "Thiamine 100 mg PO daily IV/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV TID x 3 days if Wernicke suspected; then 100 mg PO daily maintenance",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia",
            "mild-cognitive-impairment",
            "alzheimers-disease"
          ]
        },
        "nutritional-deficiency-altered-mental-status": {
          "indication": "Nutritional deficiency; altered mental status",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Thiamine 100 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg IV daily x 3-5 days; then oral",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "prevent-wernicke-encephalopathy-alcohol-related-seizures": {
          "indication": "Prevent Wernicke encephalopathy; alcohol-related seizures",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Thiamine (before dextrose if malnourished/alcoholic) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV daily x 3 days; then 250 mg IV daily x 3 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "wernicke-encephalopathy-ataxia-ophthalmoplegia-confusion-emp": {
          "indication": "Wernicke encephalopathy (ataxia + ophthalmoplegia + confusion); empiric in alcoholism or malnutrition with acute ataxia",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Thiamine (vitamin B1) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV TID for 3 days, then 250 mg IV daily for 5 days; give BEFORE glucose; infuse over 30 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Thiamine (Wernicke-Korsakoff) (CPT 96374) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV TID × 3 days, then 250 mg IV daily × 5 days, then 100 mg PO daily",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        },
        "wernicke-encephalopathy-nystagmus-ataxia-confusion-triad-may": {
          "indication": "Wernicke encephalopathy (nystagmus + ataxia + confusion triad; may be incomplete)",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "**Thiamine (empiric if Wernicke suspected)** 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "**Thiamine 500 mg IV TID x 3-5 days, then 250 mg IV daily x 3-5 days, then 100 mg PO daily indefinitely**; give BEFORE glucose; [Galvin et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20642790/)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None",
          "None at therapeutic doses",
          "Rare anaphylaxis (IV formulation)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Allergic reaction during infusion",
          "Clinical improvement",
          "Clinical improvement in confusion",
          "Clinical response",
          "Monitor clinical improvement in nystagmus, ataxia, confusion",
          "None",
          "None routine",
          "anaphylaxis rare with IV thiamine",
          "clinical improvement (ophthalmoplegia resolves first, then confusion, then ataxia)",
          "improvement within hours to days supports diagnosis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "alzheimers-disease",
        "ataxia-evaluation",
        "dementia-evaluation",
        "huntingtons-disease",
        "mild-cognitive-impairment",
        "ncse",
        "nystagmus-evaluation",
        "vascular-dementia"
      ]
    },
    "thiamine-im": {
      "id": "thiamine-im",
      "name": "Thiamine IM (if IV not possible, unreliable oral)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Thiamine IM (if IV not possible, unreliable oral) 250 mg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250 mg IM daily × 3-5 days",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wernicke-encephalopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Coagulopathy (relative)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Clinical response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wernicke-encephalopathy"
      ]
    },
    "thiamine-iv": {
      "id": "thiamine-iv",
      "name": "Thiamine IV (if alcoholic or malnourished)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "wernicke-encephalopathy-prophylaxis-in-malnourished-patients": {
          "indication": "Wernicke encephalopathy prophylaxis in malnourished patients with neuropathic symptoms",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Thiamine IV (if alcoholic or malnourished) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV TID x 3 days, then 250 mg IV daily x 3-5 days, then oral",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "200-500 mg",
              "orderSentence": "Thiamine IV (prophylaxis - at-risk patients) (CPT 96374) 200-500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "200-500 mg IV TID × 3 days; then oral",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wernicke-encephalopathy",
            "status-epilepticus",
            "peripheral-neuropathy",
            "new-onset-seizure"
          ]
        },
        "wernicke-encephalopathy-prevention-and-treatment-must-give-b": {
          "indication": "Wernicke encephalopathy prevention and treatment; MUST give before or with glucose",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Thiamine IV (high-dose) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV TID for 3 days (diluted in 100 mL NS over 30 min), then 250 mg IV daily for 5 days; give BEFORE glucose",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "empiric-for-wernicke-encephalopathy-if-any-suspicion-alcohol": {
          "indication": "Empiric for Wernicke encephalopathy if ANY suspicion (alcohol, malnutrition, bariatric surgery); treat before glucose",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Thiamine (B1) IV (CPT 96374) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV TID x 3-5 days, then 250 mg IV daily x 3-5 days, then 100 mg PO daily ongoing",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None",
          "None significant",
          "Rare anaphylaxis (extremely uncommon)",
          "Same",
          "have epinephrine available"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anaphylaxis (rare)",
          "Clinical response (confusion, ataxia, ophthalmoplegia should improve)",
          "Infusion reaction (rare)",
          "None",
          "Same",
          "anaphylaxis extremely rare"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "new-onset-seizure",
        "paresthesia-numbness-tingling",
        "peripheral-neuropathy",
        "rapidly-progressive-dementia",
        "status-epilepticus",
        "wernicke-encephalopathy"
      ]
    },
    "thiamine-iv-empiric": {
      "id": "thiamine-iv-empiric",
      "name": "Thiamine (B1) IV -- empiric",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "empiric-for-wernicke-encephalopathy-while-rpd-workup-pending": {
          "indication": "Empiric for Wernicke encephalopathy while RPD workup pending; treat before glucose",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Thiamine (B1) IV -- empiric 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV TID x 3 days, then 250 mg IV daily x 3-5 days, then 100 mg PO daily",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Clinical response (confusion, ataxia, ophthalmoplegia)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "creutzfeldt-jakob-disease"
      ]
    },
    "thiamine-iv-suspected-confirmed-we": {
      "id": "thiamine-iv-suspected-confirmed-we",
      "name": "Thiamine IV (high-dose) - Suspected/Confirmed WE (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Thiamine IV (high-dose) - Suspected/Confirmed WE (CPT 96374) 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg IV TID × 3-5 days (in 100 mL NS over 30 min); then 250 mg IV daily × 3-5 days; then oral",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wernicke-encephalopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Rare anaphylaxis (give slowly)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anaphylaxis (rare)",
          "clinical response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wernicke-encephalopathy"
      ]
    },
    "thiamine-oral": {
      "id": "thiamine-oral",
      "name": "Thiamine oral (after IV course)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Thiamine oral (after IV course) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100 mg TID × weeks to months; indefinitely if ongoing risk",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wernicke-encephalopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Compliance",
          "symptoms"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wernicke-encephalopathy"
      ]
    },
    "thickened-liquids": {
      "id": "thickened-liquids",
      "name": "Thickened liquids",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dysphagia-with-thin-liquid-aspiration": {
          "indication": "Dysphagia with thin liquid aspiration",
          "doseOptions": [
            {
              "text": "Nectar to honey thick consistency",
              "orderSentence": "Thickened liquids Nectar to honey thick consistency PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Thicken all thin liquids per SLP recommendation; nectar, honey, or pudding thick consistency",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        },
        "dysphagia-with-thin-liquid-aspiration-on-swallow-study": {
          "indication": "Dysphagia with thin liquid aspiration on swallow study",
          "doseOptions": [
            {
              "text": "Per SLP recommendation",
              "orderSentence": "Thickened liquids Per SLP recommendation PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Nectar-thick, honey-thick, or pudding-thick per swallow study results; reassess as disease progresses",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None",
          "Patient refusal (goals of care discussion)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Hydration status, swallow function",
          "Weight, hydration status, aspiration events",
          "serial swallow evaluations"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "als",
        "progressive-supranuclear-palsy"
      ]
    },
    "thiotepa": {
      "id": "thiotepa",
      "name": "Thiotepa (MATRix regimen component or ASCT conditioning)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "component-of-matrix-regimen-cns-penetrating-alkylating-agent": {
          "indication": "Component of MATRix regimen; CNS-penetrating alkylating agent; also used in ASCT conditioning regimen",
          "doseOptions": [
            {
              "text": "30 mg/m2",
              "orderSentence": "Thiotepa (MATRix regimen component or ASCT conditioning) 30 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "30 mg/m2 IV over 15-30 min on Day 4 of each MATRix cycle; for ASCT conditioning: higher doses per transplant protocol",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CBC (profound myelosuppression expected)",
          "LFTs",
          "mucositis",
          "signs of VOD with high-dose conditioning",
          "skin toxicity (rash, hyperpigmentation)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "ticagrelor-aspirin": {
      "id": "ticagrelor-aspirin",
      "name": "Ticagrelor + Aspirin (DAPT — alternative)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-dapt-for-minor-stroke-tia-per-thales-trial-does-": {
          "indication": "Alternative DAPT for minor stroke/TIA per THALES trial; does NOT require CYP2C19 metabolism",
          "doseOptions": [
            {
              "text": "90 mg BID ticagrelor + 81 mg aspirin daily x 30 days",
              "orderSentence": "Ticagrelor + Aspirin (DAPT — alternative) 90 mg BID ticagrelor + 81 mg aspirin daily x 30 days PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Ticagrelor 180 mg load then 90 mg BID + aspirin 81 mg x 30 days; then switch to monotherapy; alternative when clopidogrel resistance suspected",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "concurrent strong CYP3A4 inhibitors",
          "history of ICH",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bleeding",
          "bradycardia",
          "dyspnea (common, usually benign)",
          "liver function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "post-stroke-management"
      ]
    },
    "tight-glycemic-control-protocol": {
      "id": "tight-glycemic-control-protocol",
      "name": "Tight glycemic control protocol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV/SC"
      ],
      "formulations": [],
      "contexts": {
        "target-glucose-140-180-mg-dl-to-reduce-icuaw-incidence-hyper": {
          "indication": "Target glucose 140-180 mg/dL to reduce ICUAW incidence; hyperglycemia independently increases CIM/CIP risk",
          "doseOptions": [
            {
              "text": "Insulin per protocol",
              "orderSentence": "Tight glycemic control protocol Insulin per protocol IV/SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "IV insulin infusion in ICU targeting 140-180 mg/dL; transition to basal-bolus SC insulin when tolerating nutrition; avoid tight control <110 (increased mortality per NICE-SUGAR)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Adrenal insufficiency (may require stress-dose steroids before aggressive glucose control)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Glucose q1-2h on infusion",
          "HbA1c at discharge",
          "q4-6h on SC insulin"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "critical-illness-myopathy-neuropathy"
      ]
    },
    "tizanidine": {
      "id": "tizanidine",
      "name": "Tizanidine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "spasticity-alternative-to-baclofen": {
          "indication": "Spasticity (alternative to baclofen)",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Tizanidine 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg qHS; may increase by 2-4 mg q6-8h; max 36 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als",
            "nmosd"
          ]
        },
        "spasticity-from-myelitis-alternative-to-baclofen": {
          "indication": "Spasticity from myelitis; alternative to baclofen",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Tizanidine 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg qHS; titrate by 2-4 mg q1-4d; max 36 mg/day divided TID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "axial-rigidity-spasticity-as-alternative-to-baclofen": {
          "indication": "Axial rigidity, spasticity as alternative to baclofen",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Tizanidine 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg at bedtime; titrate to 2-4 mg TID; max 36 mg/day; reduce dose in hepatic impairment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "spasticity-alternative-post-anoxic-hypertonia": {
          "indication": "Spasticity alternative; post-anoxic hypertonia",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Tizanidine 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg PO TID; titrate by 2 mg q3-7d; max 36 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "spasticity": {
          "indication": "Spasticity",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Tizanidine 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg qHS or TID; increase by 2-4 mg every 3-4 days; max 36 mg/day in 3 divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "adjunctive-therapy-for-rigidity-and-spasms-alpha-2-adrenergi": {
          "indication": "Adjunctive therapy for rigidity and spasms; alpha-2 adrenergic agonist muscle relaxant",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Tizanidine 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg PO TID; increase by 2-4 mg q3-7d; max 36 mg/day divided TID; take consistently with or without food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "stiff-person-syndrome"
          ]
        },
        "post-stroke-spasticity-alpha-2-agonist-alternative-or-adjunc": {
          "indication": "Post-stroke spasticity; alpha-2 agonist; alternative or adjunct to baclofen; less weakness but more sedation",
          "doseOptions": [
            {
              "text": "2 mg qHS",
              "orderSentence": "Tizanidine 2 mg qHS PO"
            },
            {
              "text": "4 mg TID",
              "orderSentence": "Tizanidine 4 mg TID PO"
            },
            {
              "text": "8 mg TID",
              "orderSentence": "Tizanidine 8 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg qHS; increase by 2 mg q3-7 days; target 4-8 mg TID; max 36 mg/day; sedating — use at bedtime initially",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        },
        "muscle-spasm-alternative-to-cyclobenzaprine": {
          "indication": "Muscle spasm (alternative to cyclobenzaprine)",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Tizanidine 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg TID; increase by 2-4 mg q6-8h; max 36 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "prevention-prominent-pericranial-muscle-tension": {
          "indication": "Prevention; prominent pericranial muscle tension",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Tizanidine 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg qHS; may increase by 2-4 mg every 3-7 days; max 36 mg/day in 3 divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "spasticity-alternative-to-baclofen-useful-when-baclofen-caus": {
          "indication": "Spasticity; alternative to baclofen; useful when baclofen causes excess sedation",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Tizanidine 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 2 mg PO qHS; increase by 2 mg q3-4 days; max 36 mg/day divided TID; take consistently with or without food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "spasticity-alternative": {
          "indication": "Spasticity (alternative)",
          "doseOptions": [
            {
              "text": "2 mg",
              "orderSentence": "Tizanidine 2 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2 mg PO TID; max 36 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent CYP1A2 inhibitors (ciprofloxacin, fluvoxamine)",
          "Concurrent ciprofloxacin or fluvoxamine (CYP1A2 inhibitors increase levels 10x)",
          "Concurrent ciprofloxacin or fluvoxamine (CYP1A2 inhibitors)",
          "Concurrent fluvoxamine or ciprofloxacin (CYP1A2 inhibitors)",
          "Hepatic impairment",
          "concurrent CYP1A2 inhibitors (cipro, fluvoxamine)",
          "concurrent CYP1A2 inhibitors (ciprofloxacin)",
          "concurrent CYP1A2 inhibitors (ciprofloxacin, fluvoxamine)",
          "concurrent CYP1A2 inhibitors (fluvoxamine, ciprofloxacin)",
          "concurrent ciprofloxacin or fluvoxamine (CYP1A2 inhibitors)",
          "concurrent fluvoxamine or ciprofloxacin (CYP1A2 inhibitors)",
          "hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP (hypotension)",
          "LFTs",
          "LFTs at baseline, 1 month, 3 months",
          "LFTs at baseline, 1 month, 3 months, then q6 months",
          "LFTs at baseline, 1, 3, 6 months",
          "LFTs at baseline, 1, 3, 6 months (hepatotoxicity)",
          "LFTs at baseline, 1, 3, 6 months, then periodically",
          "LFTs at baseline, 1mo, 3mo, 6mo",
          "LFTs monthly for first 6 months then periodically",
          "blood pressure (hypotension)",
          "dry mouth",
          "hypotension",
          "sedation",
          "sedation, dry mouth, hypotension",
          "sedation, hypotension, dry mouth"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 12,
      "_sourcePlans": [
        "acute-myelopathy",
        "als",
        "anoxic-brain-injury",
        "cervical-myelopathy",
        "mogad",
        "ms-new-diagnosis",
        "nmosd",
        "post-stroke-management",
        "progressive-supranuclear-palsy",
        "radiculopathy",
        "stiff-person-syndrome",
        "tension-headache"
      ]
    },
    "tmp-smx": {
      "id": "tmp-smx",
      "name": "TMP-SMX (PJP prophylaxis)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "pneumocystis-prophylaxis-during-concurrent-temozolomide-radi": {
          "indication": "Pneumocystis prophylaxis during concurrent temozolomide + radiation (Stupp protocol); lymphopenia risk",
          "doseOptions": [
            {
              "text": "1 DS tablet",
              "orderSentence": "TMP-SMX (PJP prophylaxis) 1 DS tablet PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "TMP-SMX 1 DS tablet 3x/week (Mon/Wed/Fri) during concurrent chemoradiation and for 1 month after; continue if CD4 <200 or ALC <500",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "prolonged-dexamethasone-20-mg-week-combined-with-chemotherap": {
          "indication": "Prolonged dexamethasone (>20 mg/week) combined with chemotherapy or immunosuppressive therapy",
          "doseOptions": [
            {
              "text": "1 DS tablet",
              "orderSentence": "**TMP-SMX (PJP prophylaxis)** 1 DS tablet PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "TMP-SMX 1 DS tablet PO Monday/Wednesday/Friday; alternative if sulfa allergic: atovaquone 1500 mg PO daily or dapsone 100 mg PO daily (check G6PD first)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        },
        "pneumocystis-prophylaxis-during-chemotherapy-induced-immunos": {
          "indication": "Pneumocystis prophylaxis during chemotherapy-induced immunosuppression; especially important given rituximab-induced B-cell depletion and chemotherapy-induced lymphopenia",
          "doseOptions": [
            {
              "text": "1 DS tablet",
              "orderSentence": "TMP-SMX (PJP prophylaxis) 1 DS tablet PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "TMP-SMX 1 DS tablet 3x/week (Mon/Wed/Fri) during chemotherapy and for 3-6 months after; continue if CD4 <200",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        },
        "pcp-prophylaxis-if-cd4-200-toxoplasmosis-prophylaxis-if-cd4-": {
          "indication": "PCP prophylaxis if CD4 <200; toxoplasmosis prophylaxis if CD4 <100 and Toxo IgG+; prevents OIs that worsen cognition",
          "doseOptions": [
            {
              "text": "1 DS tablet",
              "orderSentence": "TMP-SMX (Bactrim DS) 1 DS tablet PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 DS tablet (160/800 mg) PO daily; alternatives: dapsone, atovaquone if sulfa allergy",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "nocardia-brain-abscess-first-line-toxoplasma-alternative-ste": {
          "indication": "Nocardia brain abscess (first-line); Toxoplasma alternative; Stenotrophomonas",
          "doseOptions": [
            {
              "text": "5 mg/kg TMP",
              "orderSentence": "TMP-SMX (Trimethoprim-Sulfamethoxazole) 5 mg/kg TMP IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/kg IV q6-8h based on TMP component; transition to PO when stable; Nocardia: treat 6-12 months total",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "pneumocystis-jirovecii-pneumonia-prophylaxis-if-dexamethason": {
          "indication": "Pneumocystis jirovecii pneumonia prophylaxis if dexamethasone >20 mg/week AND concomitant temozolomide, bevacizumab, or other immunosuppression",
          "doseOptions": [
            {
              "text": "1 DS tab",
              "orderSentence": "TMP-SMX (PJP prophylaxis) 1 DS tab PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "TMP-SMX 1 DS tablet 3x/week (Mon/Wed/Fri); if sulfa allergic: atovaquone 1500 mg PO daily or dapsone 100 mg PO daily (check G6PD first)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "G6PD deficiency",
          "G6PD deficiency (for dapsone alternative)",
          "Sulfa allergy",
          "Sulfa allergy (use alternative)",
          "Sulfa allergy (use atovaquone 1500 mg daily or dapsone 100 mg daily as alternatives)",
          "Sulfonamide allergy",
          "folate deficiency (supplement)",
          "megaloblastic anemia from folate deficiency",
          "renal impairment",
          "renal impairment (dose adjust)",
          "severe renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "CBC (leukopenia from TMP-SMX)",
          "CBC q2-4 weeks",
          "CBC weekly (cytopenias)",
          "CMP",
          "GI symptoms",
          "LFTs",
          "Renal function",
          "folate supplementation",
          "hold during methotrexate infusion (interferes with MTX excretion)",
          "hyperkalemia",
          "potassium (hyperkalemia)",
          "rash",
          "rash (SJS rare)",
          "rash (Stevens-Johnson risk)",
          "renal function",
          "report fever/dyspnea"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "brain-abscess",
        "glioblastoma",
        "hiv-associated-neurocognitive-disorder",
        "leptomeningeal-carcinomatosis",
        "meningioma",
        "primary-cns-lymphoma"
      ]
    },
    "tocilizumab": {
      "id": "tocilizumab",
      "name": "Tocilizumab",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "refractory-nbd-failing-anti-tnf-therapy-alternative-biologic": {
          "indication": "Refractory NBD failing anti-TNF therapy; alternative biologic for severe parenchymal disease (targets IL-6 pathway -- critical in NBD pathogenesis)",
          "doseOptions": [
            {
              "text": "8 mg/kg",
              "orderSentence": "Tocilizumab (CPT 96365) 8 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8 mg/kg IV every 4 weeks (max 800 mg/dose); infuse over 1 hour; Pre-treatment: TB testing, Hepatitis B/C screening, CBC, LFTs, lipids, GI perforation risk assessment",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "refractory-pacns-failure-of-cyclophosphamide-and-rituximab-e": {
          "indication": "Refractory PACNS; failure of cyclophosphamide and rituximab; emerging evidence in CNS vasculitis",
          "doseOptions": [
            {
              "text": "8 mg/kg IV q4 weeks",
              "orderSentence": "Tocilizumab 8 mg/kg IV q4 weeks IV"
            },
            {
              "text": "162 mg SC weekly",
              "orderSentence": "Tocilizumab 162 mg SC weekly IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8 mg/kg IV every 4 weeks (max 800 mg/dose) OR 162 mg SC weekly",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "8 mg/kg",
              "orderSentence": "Tocilizumab 8 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8 mg/kg IV q4 weeks (emerging option)",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "status-epilepticus",
            "autoimmune-encephalitis"
          ]
        },
        "third-line-maintenance-for-mogad-refractory-to-ivig-and-stan": {
          "indication": "Third-line maintenance for MOGAD refractory to IVIG and standard immunosuppressants; emerging evidence",
          "doseOptions": [
            {
              "text": "8 mg/kg",
              "orderSentence": "Tocilizumab (Actemra) 8 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8 mg/kg IV every 4 weeks (max 800 mg) OR 162 mg SC every 2 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mogad"
          ]
        },
        "il-6-inhibition-refractory-nmosd": {
          "indication": "IL-6 inhibition; refractory NMOSD",
          "doseOptions": [
            {
              "text": "8 mg/kg",
              "orderSentence": "Tocilizumab (off-label) 8 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8 mg/kg IV every 4 weeks (max 800 mg) or 162 mg SC weekly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nmosd"
          ]
        },
        "fda-approved-steroid-sparing-agent-for-gca-giacta-trial-redu": {
          "indication": "FDA-approved steroid-sparing agent for GCA (GiACTA trial); reduces relapse rate and steroid exposure",
          "doseOptions": [
            {
              "text": "162 mg",
              "orderSentence": "**Tocilizumab (Actemra)** 162 mg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "162 mg SC weekly (preferred) or every 2 weeks; self-injectable; can also use 8 mg/kg IV q4wk",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "third-line-immunotherapy-for-refractory-cases-il-6-receptor-": {
          "indication": "Third-line immunotherapy for refractory cases; IL-6 receptor blockade",
          "doseOptions": [
            {
              "text": "8 mg/kg",
              "orderSentence": "Tocilizumab 8 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "8 mg/kg IV every 4 weeks (max 800 mg/dose)",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "EXT"
          },
          "_sourcePlans": [
            "paraneoplastic-neurological-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "ALT/AST >1.5x ULN",
          "ANC <2000",
          "Active infection",
          "Active infection, hepatic impairment",
          "CBC, LFTs, lipids q4-8 weeks",
          "GI perforation risk",
          "concurrent live vaccines",
          "diverticulitis",
          "diverticulitis (GI perforation risk)",
          "hepatic impairment (ALT >5x ULN)",
          "infection",
          "neutropenia",
          "platelets <100K"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC q4-8 weeks",
          "CBC, LFTs, lipids q4-8 weeks",
          "CRP may be unreliable (IL-6 blockade suppresses CRP)",
          "CRP suppressed (cannot use as infection marker)",
          "GI perforation risk",
          "GI perforation symptoms",
          "LFTs q4-8 weeks",
          "LFTs, lipids, infection",
          "NOTE: tocilizumab suppresses ESR/CRP -- cannot use these for disease monitoring (use IL-6 or clinical assessment instead)",
          "infection surveillance",
          "lipid panel q12 weeks",
          "lipid panel q3 months",
          "neutropenia",
          "watch for masking of infection (suppresses CRP/ESR)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 8,
      "_sourcePlans": [
        "autoimmune-encephalitis",
        "cns-vasculitis",
        "giant-cell-arteritis",
        "mogad",
        "neuro-behcets-disease",
        "nmosd",
        "paraneoplastic-neurological-syndrome",
        "status-epilepticus"
      ]
    },
    "tofacitinib": {
      "id": "tofacitinib",
      "name": "Tofacitinib (Xeljanz)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "refractory-dm-especially-skin-disease-anti-mda5-dm-with-ild-": {
          "indication": "Refractory DM (especially skin disease); anti-MDA5 DM with ILD (emerging evidence); refractory anti-synthetase syndrome",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Tofacitinib (Xeljanz) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg PO BID; may increase to 11 mg daily (XR formulation); onset 1-3 months",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active serious infection",
          "current or history of DVT/PE (FDA black box)",
          "lymphopenia <500",
          "malignancy history"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC q4-8 weeks",
          "LFTs",
          "TB screening",
          "VTE risk assessment",
          "infection screen",
          "lipids at 4-8 weeks",
          "renal function"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "inflammatory-myopathy"
      ]
    },
    "tofersen-for-sod1-mutations": {
      "id": "tofersen-for-sod1-mutations",
      "name": "Tofersen (Qalsody) - for SOD1 mutations",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IT"
      ],
      "formulations": [],
      "contexts": {
        "sod1-als-only-reduces-sod1-protein": {
          "indication": "SOD1-ALS only; reduces SOD1 protein",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Tofersen (Qalsody) - for SOD1 mutations 100 mg IT"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Loading: 100 mg IT on Days 1, 15, 29; Maintenance: 100 mg IT q28 days",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "als"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "No SOD1 mutation",
          "contraindication to IT injection"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CSF analysis",
          "Neurofilament levels",
          "myelopathy monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "als"
      ]
    },
    "topical-corticosteroid": {
      "id": "topical-corticosteroid",
      "name": "Topical corticosteroid (triamcinolone 0.1%)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "dm-skin-rash-gottron-papules-heliotrope-v-sign-shawl-sign": {
          "indication": "DM skin rash (Gottron papules, heliotrope, V-sign, shawl sign)",
          "doseOptions": [
            {
              "text": "Thin layer",
              "orderSentence": "Topical corticosteroid (triamcinolone 0.1%) Thin layer TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply thin layer to affected skin BID; avoid face for prolonged use (use hydrocortisone 1% or tacrolimus on face)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Skin infection at site",
          "skin atrophy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Skin atrophy",
          "infection",
          "telangiectasia"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "inflammatory-myopathy"
      ]
    },
    "topical-diclofenac": {
      "id": "topical-diclofenac",
      "name": "Topical diclofenac",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "localized-pain-inflammation": {
          "indication": "Localized pain/inflammation",
          "doseOptions": [
            {
              "text": "Apply gel",
              "orderSentence": "Topical diclofenac Apply gel TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply to wrist area TID-QID; max 4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Aspirin-sensitive asthma",
          "open wounds"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Local skin irritation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "carpal-tunnel-syndrome"
      ]
    },
    "topical-lidocaine-5-patch": {
      "id": "topical-lidocaine-5-patch",
      "name": "Topical lidocaine 5% patch",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "localized-neuropathic-pain-over-lateral-leg-dorsal-foot": {
          "indication": "Localized neuropathic pain over lateral leg/dorsal foot",
          "doseOptions": [
            {
              "text": "1 patch",
              "orderSentence": "Topical lidocaine 5% patch 1 patch TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply over painful area 12h on, 12h off; up to 3 patches simultaneously",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peroneal-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Broken skin",
          "severe hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Minimal systemic absorption",
          "local skin irritation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "peroneal-neuropathy"
      ]
    },
    "topical-tacrolimus-0-1": {
      "id": "topical-tacrolimus-0-1",
      "name": "Topical tacrolimus 0.1% (Protopic)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "dm-facial-rash-heliotrope-rash-steroid-sparing-for-facial-sk": {
          "indication": "DM facial rash (heliotrope rash); steroid-sparing for facial skin",
          "doseOptions": [
            {
              "text": "Thin layer",
              "orderSentence": "Topical tacrolimus 0.1% (Protopic) Thin layer TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Apply thin layer to affected facial skin BID; onset 2-4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Skin infection",
          "immunosuppression concern"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Burning sensation (transient)",
          "skin infection"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "inflammatory-myopathy"
      ]
    },
    "topiramate": {
      "id": "topiramate",
      "name": "Topiramate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Topiramate 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; titrate to 50-100 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "medication-overuse-headache",
            "cluster-headache",
            "status-epilepticus",
            "essential-tremor",
            "migraine"
          ]
        },
        "preventive-for-post-traumatic-headache-second-line": {
          "indication": "Preventive for post-traumatic headache (second-line)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Topiramate 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO QHS; increase by 25 mg/week; target 50-100 mg BID; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "second-line-for-tremor-evidence-for-essential-tremor": {
          "indication": "Second-line for tremor; evidence for essential tremor",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Topiramate (Topamax) 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; titrate by 25-50 mg/week; target 100-400 mg/day divided BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "adjunctive-therapy-reduces-tic-severity-also-treats-comorbid": {
          "indication": "Adjunctive therapy; reduces tic severity; also treats comorbid migraine",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Topiramate (Topamax) 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg qHS; increase by 25 mg q1-2wk; target 50-200 mg/day divided BID; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        },
        "tremor": {
          "indication": "Tremor",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Topiramate 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25 mg weekly; max 400 mg/day in divided doses",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "focal-and-generalized-epilepsy-migraine-prophylaxis-dual-ben": {
          "indication": "Focal and generalized epilepsy; migraine prophylaxis (dual benefit); weight loss effect",
          "doseOptions": [
            {
              "text": "25 mg BID",
              "orderSentence": "Topiramate (Topamax) 25 mg BID PO"
            },
            {
              "text": "50 mg BID",
              "orderSentence": "Topiramate (Topamax) 50 mg BID PO"
            },
            {
              "text": "100 mg BID",
              "orderSentence": "Topiramate (Topamax) 100 mg BID PO"
            },
            {
              "text": "200 mg BID",
              "orderSentence": "Topiramate (Topamax) 200 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg daily; increase by 25-50 mg q1-2wk; target 100-200 mg BID; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "first-line-oral-preventive-level-a-evidence-weight-neutral-l": {
          "indication": "First-line oral preventive; Level A evidence; weight-neutral/loss",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Topiramate 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg QHS; increase by 25 mg/week; target 50-100 mg BID; max 200 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "prevention-comorbid-migraine-or-obesity": {
          "indication": "Prevention; comorbid migraine or obesity",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Topiramate 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg qHS; increase by 25 mg/week; target 50-100 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "adjunctive-or-monotherapy": {
          "indication": "Adjunctive or monotherapy",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Topiramate 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg BID; increase by 50 mg/day weekly; target 200-400 mg/day in divided doses; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        },
        "first-line-oral-prevention-reduces-aura-frequency-weight-los": {
          "indication": "First-line oral prevention; reduces aura frequency; weight loss",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Topiramate 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg qHS; increase by 25 mg/wk; target 50-100 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**PREGNANCY (teratogenic)**",
          "**TERATOGENIC** (cleft lip/palate)",
          "Kidney stones",
          "Kidney stones, glaucoma, pregnancy",
          "Kidney stones, pregnancy (teratogenic), glaucoma",
          "Kidney stones, pregnancy, glaucoma",
          "Metabolic acidosis",
          "Metabolic acidosis, kidney stones",
          "Narrow-angle glaucoma",
          "Nephrolithiasis, pregnancy (teratogen - cleft palate), metabolic acidosis, glaucoma (acute angle-closure)",
          "acute myopia/angle-closure glaucoma",
          "acute narrow-angle glaucoma",
          "glaucoma",
          "kidney stones",
          "metabolic acidosis",
          "narrow-angle glaucoma",
          "pregnancy (teratogen)",
          "pregnancy (teratogenic)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bicarbonate",
          "Bicarbonate (metabolic acidosis)",
          "Bicarbonate level",
          "Bicarbonate q3-6mo, cognitive effects, paresthesias, weight, renal function",
          "Bicarbonate, cognitive effects",
          "Bicarbonate, renal function",
          "Cognitive effects",
          "Cognitive effects (word-finding difficulty, concentration)",
          "Cognitive effects (word-finding), paresthesias, weight loss, kidney stones, bicarbonate",
          "Cognitive effects, paresthesias",
          "Cognitive effects, paresthesias, metabolic acidosis",
          "Cognitive effects, paresthesias, weight loss",
          "Cognitive impairment (\"dopamax\")",
          "Cognitive slowing (\"dopamax\")",
          "cognitive effects (\"Dopamax\")",
          "cognitive effects (word-finding difficulty)",
          "cognitive side effects (may worsen PCS cognition)",
          "kidney stones",
          "metabolic acidosis",
          "paresthesias",
          "pregnancy test",
          "renal function",
          "serum bicarbonate",
          "weight",
          "weight loss",
          "word-finding difficulty"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 14,
      "_sourcePlans": [
        "chronic-migraine",
        "cluster-headache",
        "epilepsy-chronic-management",
        "essential-tremor",
        "medication-overuse-headache",
        "migraine",
        "migraine-with-aura",
        "ms-new-diagnosis",
        "new-onset-seizure",
        "post-concussion-syndrome",
        "status-epilepticus",
        "tension-headache",
        "tics-tourette-syndrome",
        "tremor-unspecified"
      ]
    },
    "topotecan": {
      "id": "topotecan",
      "name": "Topotecan",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "relapsed-refractory-pcnsl-topoisomerase-i-inhibitor-with-cns": {
          "indication": "Relapsed/refractory PCNSL; topoisomerase I inhibitor with CNS penetration",
          "doseOptions": [
            {
              "text": "1.5 mg/m2",
              "orderSentence": "Topotecan 1.5 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1.5 mg/m2 IV daily x 5 days every 21 days; dose reduce for renal impairment or myelosuppression",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe myelosuppression (ANC <1500, platelets <100K)",
          "severe renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC with differential before each cycle",
          "nadir at day 11",
          "renal function",
          "signs of infection during neutropenic period"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "tpa": {
      "id": "tpa",
      "name": "tPA (alteplase)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-hemisensory-deficit-with-confirmed-acute-ischemic-stro": {
          "indication": "Acute hemisensory deficit with confirmed acute ischemic stroke within treatment window",
          "doseOptions": [
            {
              "text": "0.9 mg/kg",
              "orderSentence": "tPA (alteplase) 0.9 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.9 mg/kg IV (max 90 mg); 10% bolus over 1 min, remainder over 60 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding, recent surgery, INR >1.7, platelets <100K",
          "see Acute Ischemic Stroke plan for full contraindications"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP q15min x 2h, then q30min x 6h, then q1h x 16h",
          "bleeding precautions",
          "neuro checks q15min"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "paresthesia-numbness-tingling"
      ]
    },
    "tramadol": {
      "id": "tramadol",
      "name": "Tramadol",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "moderate-neuropathic-pain-adjunct-short-term": {
          "indication": "Moderate neuropathic pain (adjunct, short-term)",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Tramadol 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg q6h PRN; ER option: 100 mg daily; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "moderate-neuropathic-pain-refractory-to-first-line-agents": {
          "indication": "Moderate neuropathic pain refractory to first-line agents",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Tramadol 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg q6h PRN; may increase to 100 mg q6h; max 400 mg/day; ER formulation 100-300 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Tramadol 50-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg q4-6h PRN; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "diabetic-neuropathy"
          ]
        },
        "moderate-pain-opioid-like-with-serotonergic-properties": {
          "indication": "Moderate pain; opioid-like with serotonergic properties",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Tramadol 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg q6h PRN; max 400 mg/day; reduce if renal/hepatic impairment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "moderate-neuropathic-pain-adjunct": {
          "indication": "Moderate neuropathic pain (adjunct)",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Tramadol 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg q6h PRN; may use ER 100 mg daily; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "moderate-radicular-pain-not-controlled-by-nsaids-gabapentino": {
          "indication": "Moderate radicular pain not controlled by NSAIDs/gabapentinoids",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Tramadol 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg q6h PRN; may use ER 100 mg daily; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "radiculopathy"
          ]
        },
        "moderate-neuropathic-and-musculoskeletal-pain-refractory-to-": {
          "indication": "Moderate neuropathic and musculoskeletal pain refractory to non-opioid agents",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Tramadol 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 50 mg PO q6h PRN; max 400 mg/day (200 mg/day if age >75); avoid extended-release initially",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "MAOIs",
          "SSRIs (serotonin syndrome)",
          "Seizure disorder",
          "Seizure disorder (lowers threshold)",
          "Seizure disorder, opioid dependence, MAOIs",
          "concurrent MAOIs",
          "concurrent MAOIs/SSRIs (serotonin syndrome risk)",
          "concurrent SSRIs (serotonin syndrome)",
          "concurrent SSRIs/SNRIs (serotonin syndrome risk)",
          "concurrent serotonergic agents",
          "severe hepatic or renal impairment",
          "severe renal/hepatic impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Seizure risk",
          "Seizures",
          "Seizures, serotonin syndrome, constipation",
          "Serotonin syndrome",
          "constipation",
          "dependence",
          "dependence (Schedule IV)",
          "respiratory depression",
          "sedation",
          "seizures",
          "serotonin syndrome"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 7,
      "_sourcePlans": [
        "b12-deficiency-neuropathy",
        "cervical-myelopathy",
        "diabetic-neuropathy",
        "paresthesia-numbness-tingling",
        "peripheral-neuropathy",
        "radiculopathy",
        "small-fiber-neuropathy"
      ]
    },
    "tranexamic-acid": {
      "id": "tranexamic-acid",
      "name": "Tranexamic acid (TXA)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1 g",
              "orderSentence": "Tranexamic acid (TXA) 1 g IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 g IV over 10 min then 1 g IV over 8h. TICH-2 trial: did NOT reduce mortality but reduced hematoma expansion. Not routine; consider if spot sign positive or early presentation with active expansion",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active DVT/PE",
          "hypercoagulable state"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Thrombotic events",
          "clinical hemostasis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "trazodone": {
      "id": "trazodone",
      "name": "Trazodone",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "insomnia-sundowning-mild-agitation": {
          "indication": "Insomnia; sundowning; mild agitation",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg qHS; titrate by 25-50 mg every 3-5 days; typical 50-150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia",
            "alzheimers-disease"
          ]
        },
        "insomnia-irritability-mild-sedation": {
          "indication": "Insomnia; irritability; mild sedation",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg qHS; titrate by 25-50 mg; max 200 mg for sleep",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "disrupted-nocturnal-sleep-comorbid-insomnia": {
          "indication": "Disrupted nocturnal sleep; comorbid insomnia",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg at bedtime; max 100 mg; avoid if nocturnal oxybate used",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        },
        "insomnia-in-mci-patients": {
          "indication": "Insomnia in MCI patients",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg qHS; titrate to effect; typical 50-100 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "insomnia-with-comorbid-depression": {
          "indication": "Insomnia with comorbid depression",
          "doseOptions": [
            {
              "text": "25-100 mg qHS",
              "orderSentence": "Trazodone 25-100 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-100 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "functional-neurological-disorder"
          ]
        },
        "persistent-insomnia": {
          "indication": "Persistent insomnia",
          "doseOptions": [
            {
              "text": "25-100 mg",
              "orderSentence": "Trazodone (insomnia) 25-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-100 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "sleep-disturbance-sundowning": {
          "indication": "Sleep disturbance; sundowning",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg qHS; titrate to 50-150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "normal-pressure-hydrocephalus"
          ]
        },
        "insomnia-sundowning": {
          "indication": "Insomnia; sundowning",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg qHS; titrate by 25 mg; typical 50-100 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "insomnia-during-icu-recovery-when-melatonin-insufficient": {
          "indication": "Insomnia during ICU recovery when melatonin insufficient",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg PO qHS; max 100 mg qHS for insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "critical-illness-myopathy-neuropathy"
          ]
        },
        "insomnia-common-pnes-comorbidity-adjunct-for-depression-avoi": {
          "indication": "Insomnia (common PNES comorbidity); adjunct for depression; avoids benzodiazepine hypnotics",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-100 mg PO qHS for insomnia; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        },
        "insomnia-non-habit-forming": {
          "indication": "Insomnia (non-habit forming)",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Trazodone 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg PO QHS; may increase to 100-150 mg; max 200 mg QHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "insomnia-common-in-chronic-disease-adjustment-disorder-pain-": {
          "indication": "Insomnia (common in chronic disease; adjustment disorder; pain-related)",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Trazodone 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg PO qHS; may increase to 100 mg qHS; max 200 mg for insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inclusion-body-myositis"
          ]
        },
        "insomnia-comorbid-with-hand-sleep-disruption-common-in-hiv-a": {
          "indication": "Insomnia comorbid with HAND; sleep disruption common in HIV; alternative to benzodiazepines (avoid in HAND)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg QHS; titrate to 50-100 mg QHS as needed; max 100 mg QHS for insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        },
        "insomnia-as-second-line-may-help-behavioral-symptoms": {
          "indication": "Insomnia as second-line; may help behavioral symptoms",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg QHS; max 100 mg QHS for sleep",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        },
        "insomnia-with-chronic-pain": {
          "indication": "Insomnia with chronic pain",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Trazodone 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg qHS; increase to 100-150 mg; max 200 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "steroid-induced-insomnia": {
          "indication": "Steroid-induced insomnia",
          "doseOptions": [
            {
              "text": "25-50 mg qHS",
              "orderSentence": "Trazodone 25-50 mg qHS PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg PO qHS; max 100 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-100 mg",
              "orderSentence": "Trazodone (sleep, agitation) 25-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-100 mg QHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation",
            "autoimmune-encephalitis"
          ]
        },
        "sleep-disruption-and-insomnia-common-in-cjd-preferred-over-b": {
          "indication": "Sleep disruption and insomnia -- common in CJD; preferred over benzodiazepine hypnotics to avoid excessive sedation",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone (insomnia) 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25 mg PO qHS; increase by 25 mg every 3-5 days; max 150 mg qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "insomnia-behavioral-disturbance": {
          "indication": "Insomnia, behavioral disturbance",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Trazodone 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 mg PO qHS; max 150 mg",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        },
        "agitation-irritability-disinhibition-insomnia-compulsive-beh": {
          "indication": "Agitation; irritability; disinhibition; insomnia; compulsive behaviors",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg BID; titrate by 25-50 mg q3-5d; typical 150-300 mg/day divided; max 400 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "insomnia-sleep-disruption-common-in-dm1-from-central-mechani": {
          "indication": "Insomnia (sleep disruption common in DM1 from central mechanisms, pain, and respiratory issues)",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "Trazodone 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg PO qHS; may increase to 100 mg qHS; max 200 mg for insomnia",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myotonic-dystrophy"
          ]
        },
        "insomnia-with-comorbid-pain-or-depression-avoids-benzodiazep": {
          "indication": "Insomnia with comorbid pain or depression; avoids benzodiazepine use in myelopathy patients at fall risk",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Trazodone 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 25-50 mg PO qHS; max 100 mg qHS for sleep; avoid in combination with serotonergic agents",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-myelopathy"
          ]
        },
        "insomnia": {
          "indication": "Insomnia",
          "doseOptions": [
            {
              "text": "25-100 mg",
              "orderSentence": "Trazodone 25-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-100 mg PO qHS",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAOIs",
          "MAOIs",
          "Orthostasis",
          "Orthostatic hypotension",
          "Orthostatic hypotension (caution in PSP with falls)",
          "Priapism (rare)",
          "QT prolongation",
          "QTc prolongation",
          "QTc prolongation (cardiac conduction disease in DM1)",
          "QTc prolongation (high dose)",
          "Severe hepatic impairment",
          "concurrent MAOIs",
          "may worsen daytime sedation",
          "orthostatic hypotension",
          "priapism history",
          "priapism risk",
          "significant QT prolongation"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Orthostatic hypotension",
          "Orthostatic hypotension (fall risk)",
          "Orthostatic hypotension, morning sedation",
          "Orthostatic hypotension, priapism",
          "Priapism (rare)",
          "QTc",
          "QTc monitoring",
          "Sedation",
          "Sedation, falls",
          "Sedation, orthostasis, priapism (rare)",
          "falls risk",
          "morning sedation",
          "next-day sedation",
          "orthostasis",
          "orthostatic hypotension",
          "orthostatic hypotension (fall risk in IBM)",
          "orthostatic hypotension (fall risk)",
          "priapism (rare -- counsel male patients)",
          "priapism (rare)",
          "sedation",
          "serotonin syndrome if combined with SSRIs",
          "swallowing safety"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 25,
      "_sourcePlans": [
        "alzheimers-disease",
        "autoimmune-encephalitis",
        "cervical-myelopathy",
        "creutzfeldt-jakob-disease",
        "critical-illness-myopathy-neuropathy",
        "dementia-evaluation",
        "frontotemporal-dementia",
        "functional-neurological-disorder",
        "giant-cell-arteritis",
        "hashimotos-encephalopathy",
        "hiv-associated-neurocognitive-disorder",
        "huntingtons-disease",
        "inclusion-body-myositis",
        "lewy-body-dementia",
        "mild-cognitive-impairment",
        "myotonic-dystrophy",
        "narcolepsy",
        "new-onset-seizure",
        "normal-pressure-hydrocephalus",
        "peripheral-neuropathy",
        "pnes",
        "post-concussion-syndrome",
        "progressive-supranuclear-palsy",
        "rapidly-progressive-dementia",
        "vascular-dementia"
      ]
    },
    "treat-delirium-triggers": {
      "id": "treat-delirium-triggers",
      "name": "Treat delirium triggers",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Various"
      ],
      "formulations": [],
      "contexts": {
        "infection-metabolic-medication-induced-delirium": {
          "indication": "Infection, metabolic, medication-induced delirium",
          "doseOptions": [
            {
              "text": "Per cause",
              "orderSentence": "Treat delirium triggers Per cause Various"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Treat UTI, correct electrolytes, remove offending drugs (especially anticholinergics)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Depends on intervention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Mental status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "lewy-body-dementia"
      ]
    },
    "treat-depression": {
      "id": "treat-depression",
      "name": "Treat depression (pseudodementia)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-50 mg",
              "orderSentence": "Treat depression (pseudodementia) 25-50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "SSRI (sertraline 25-50 mg, escitalopram 5-10 mg)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Per agent"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Mood, cognition"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "dementia-evaluation"
      ]
    },
    "treat-reversible-causes": {
      "id": "treat-reversible-causes",
      "name": "Treat reversible causes",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Various"
      ],
      "formulations": [],
      "contexts": {
        "identified-metabolic-or-infectious-etiology": {
          "indication": "Identified metabolic or infectious etiology",
          "doseOptions": [
            {
              "text": "Per specific cause",
              "orderSentence": "Treat reversible causes Per specific cause Various"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Correct hyponatremia slowly, treat UTI, replace B12, treat hypothyroidism",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia",
            "alzheimers-disease"
          ]
        },
        "identified-metabolic-nutritional-or-infectious-etiology": {
          "indication": "Identified metabolic, nutritional, or infectious etiology",
          "doseOptions": [
            {
              "text": "Per cause",
              "orderSentence": "Treat reversible causes Per cause Various"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Correct hypothyroidism, replace B12/folate, treat infections, adjust medications",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Depends on intervention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Cognitive reassessment 3-6 months after treatment",
          "Cognitive reassessment after treatment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "alzheimers-disease",
        "mild-cognitive-impairment",
        "vascular-dementia"
      ]
    },
    "triamcinolone-acetonide-injection": {
      "id": "triamcinolone-acetonide-injection",
      "name": "Triamcinolone acetonide injection",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Local injection"
      ],
      "formulations": [],
      "contexts": {
        "alternative-corticosteroid-for-injection": {
          "indication": "Alternative corticosteroid for injection",
          "doseOptions": [
            {
              "text": "20-40 mg",
              "orderSentence": "Triamcinolone acetonide injection 20-40 mg Local injection"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mg injected into carpal tunnel; ultrasound guidance recommended",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "carpal-tunnel-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local infection",
          "bleeding disorder",
          "uncontrolled diabetes"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood glucose (diabetics)",
          "skin depigmentation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "carpal-tunnel-syndrome"
      ]
    },
    "trientine": {
      "id": "trientine",
      "name": "Trientine (Syprine)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "wilson-s-disease-d-penicillamine-intolerant": {
          "indication": "Wilson's disease; D-penicillamine intolerant",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Trientine (Syprine) 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg TID; target 750-1250 mg/day divided TID; take 1hr before or 2hr after meals",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "wilson-disease-confirmed-use-when-d-penicillamine-is-not-tol": {
          "indication": "Wilson disease confirmed; use when D-penicillamine is not tolerated or contraindicated",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Trientine (Syprine) 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg TID; titrate to 750-1500 mg/day divided TID; take on empty stomach 1 hour before meals; separate from iron supplements by 2 hours",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tremor-unspecified"
          ]
        },
        "alternative-first-line-chelator-preferred-if-penicillamine-i": {
          "indication": "Alternative first-line chelator; preferred if penicillamine intolerant or neurologic presentation (lower risk of neurologic worsening); removes copper via renal excretion",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Trientine (Syprine, TETA) 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500-750 mg/day divided BID-TID; target 750-1500 mg/day; take on empty stomach (1h before or 2h after meals); available as trientine dihydrochloride or trientine tetrahydrochloride (Cuvrior — different dosing)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Caution with iron supplements (separate by 2hr)",
          "Iron supplementation within 2 hours (chelates iron)",
          "Pregnancy (teratogenic — switch to zinc)",
          "iron deficiency anemia (monitor closely)",
          "pregnancy (relative -- risk-benefit)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "24-hour urine copper q3-6 months",
          "24h urine copper q3-6 months (target 200-500 mcg/24h)",
          "CBC",
          "CBC monthly x6 months then q3 months",
          "CBC, LFTs, urinalysis monthly initially then q3mo",
          "LFTs monthly x6 months then q3 months",
          "fewer side effects than D-penicillamine",
          "hepatic function",
          "hepatologist co-management",
          "iron studies q6 months (sideropenia risk)",
          "watch for neurologic worsening (less common than penicillamine, ~10-15%)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "dystonia",
        "tremor-unspecified",
        "wilsons-disease"
      ]
    },
    "trigger-point-injection": {
      "id": "trigger-point-injection",
      "name": "Trigger point injection",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "pericranial-muscle-tenderness-refractory-to-oral-therapy": {
          "indication": "Pericranial muscle tenderness; refractory to oral therapy",
          "doseOptions": [
            {
              "text": "1-2 mL",
              "orderSentence": "Trigger point injection 1-2 mL IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Inject 1-2 mL 1% lidocaine into tender points in trapezius, temporalis, or cervical paraspinals; may repeat q2-4wk",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Local anesthetic allergy",
          "infection at site"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Local bruising",
          "vasovagal response"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tension-headache"
      ]
    },
    "trihexyphenidyl": {
      "id": "trihexyphenidyl",
      "name": "Trihexyphenidyl",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-oral-for-generalized-dystonia-young-patients-tole": {
          "indication": "First-line oral for generalized dystonia; young patients tolerate best",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Trihexyphenidyl 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg daily; increase by 1-2 mg q3-5d; typical target 6-30 mg/day divided TID; some patients require up to 60-80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "anticholinergic-for-dip-alternative-to-benztropine": {
          "indication": "Anticholinergic for DIP; alternative to benztropine",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Trihexyphenidyl (Artane) 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg daily; increase by 2 mg q3-5d; usual range 6-10 mg/day in divided doses; max 15 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-induced-parkinsonism"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Trihexyphenidyl (Artane) 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg daily; titrate to 2 mg TID; max 15 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease-new-diagnosis"
          ]
        },
        "tremor-dominant-pd-younger-patients": {
          "indication": "Tremor-dominant PD; younger patients",
          "doseOptions": [
            {
              "text": "1 mg TID",
              "orderSentence": "Trihexyphenidyl 1 mg TID PO"
            },
            {
              "text": "2 mg TID",
              "orderSentence": "Trihexyphenidyl 2 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg TID; titrate by 2 mg/day q3-5 days; max 15 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        },
        "dystonia-focal-or-generalized": {
          "indication": "Dystonia (focal or generalized)",
          "doseOptions": [
            {
              "text": "1 mg",
              "orderSentence": "Trihexyphenidyl 1 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 1 mg daily; increase by 1 mg every 3-5 days; target 6-15 mg/day divided TID; max 15 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI obstruction",
          "Glaucoma",
          "Glaucoma, urinary retention, cognitive impairment, age >65",
          "Glaucoma, urinary retention, dementia, age >65",
          "Narrow-angle glaucoma",
          "age >70",
          "dementia",
          "elderly (relative)",
          "urinary retention"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Anticholinergic effects (dry mouth, constipation, urinary retention, confusion)",
          "Anticholinergic effects (dry mouth, constipation, urinary retention, confusion), cognitive impairment, tachycardia",
          "Cognitive impairment, dry mouth, constipation, urinary retention",
          "Confusion, dry mouth, urinary retention, cognitive impairment",
          "Confusion, urinary retention, dry mouth",
          "cognitive effects in elderly"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "drug-induced-parkinsonism",
        "dystonia",
        "parkinsons-disease",
        "parkinsons-disease-new-diagnosis",
        "wilsons-disease"
      ]
    },
    "trimethobenzamide": {
      "id": "trimethobenzamide",
      "name": "Trimethobenzamide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM/PO"
      ],
      "formulations": [],
      "contexts": {
        "pretreat-before-apomorphine-to-prevent-nausea": {
          "indication": "Pretreat before apomorphine to prevent nausea",
          "doseOptions": [
            {
              "text": "300 mg IM/PO",
              "orderSentence": "Trimethobenzamide 300 mg IM/PO IM/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300 mg TID starting 3 days before apomorphine initiation",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Drowsiness"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "parkinsons-disease"
      ]
    },
    "trimethoprim-sulfamethoxazole": {
      "id": "trimethoprim-sulfamethoxazole",
      "name": "Trimethoprim-sulfamethoxazole (PJP prophylaxis)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "pcp-prevention-if-prednisone-20-mg-for-4-weeks-or-concurrent": {
          "indication": "PCP prevention if prednisone >=20 mg for >=4 weeks or concurrent immunosuppressants",
          "doseOptions": [
            {
              "text": "1 DS tablet (160/800 mg)",
              "orderSentence": "Trimethoprim-sulfamethoxazole (PCP prophylaxis) 1 DS tablet (160/800 mg) PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 DS tablet (160/800 mg) PO daily or 3 times per week",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "inflammatory-myopathy"
          ]
        },
        "pjp-prophylaxis-if-on-high-dose-steroids-other-immunosuppres": {
          "indication": "PJP prophylaxis if on high-dose steroids + other immunosuppression",
          "doseOptions": [
            {
              "text": "1 DS tablet",
              "orderSentence": "Trimethoprim-sulfamethoxazole 1 DS tablet PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 DS tablet (160/800 mg) PO Monday/Wednesday/Friday; or 1 SS tablet daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "pneumocystis-jirovecii-prophylaxis-during-combined-immunosup": {
          "indication": "Pneumocystis jirovecii prophylaxis during combined immunosuppression (steroids + cyclophosphamide)",
          "doseOptions": [
            {
              "text": "1 DS tablet 3x/week",
              "orderSentence": "Trimethoprim-sulfamethoxazole (PJP prophylaxis) 1 DS tablet 3x/week PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 double-strength tablet (160/800 mg) PO three times weekly; continue throughout immunosuppression",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        },
        "pjp-prophylaxis-if-on-20-mg-prednisone-for-4-weeks-with-addi": {
          "indication": "PJP prophylaxis if on ≥20 mg prednisone for >4 weeks with additional immunosuppression",
          "doseOptions": [
            {
              "text": "1 DS tablet",
              "orderSentence": "Trimethoprim-sulfamethoxazole (PJP prophylaxis) 1 DS tablet PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 DS tablet PO Monday/Wednesday/Friday",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "giant-cell-arteritis"
          ]
        },
        "pneumocystis-jirovecii-prophylaxis-during-combined-immunosup-2": {
          "indication": "Pneumocystis jirovecii prophylaxis during combined immunosuppression (steroids + immunosuppressant)",
          "doseOptions": [
            {
              "text": "1 DS tablet 3x/week",
              "orderSentence": "Trimethoprim-sulfamethoxazole (PJP prophylaxis) 1 DS tablet 3x/week PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 double-strength tablet (160/800 mg) PO three times weekly; continue throughout immunosuppression",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "susac-syndrome"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "800 mg",
              "orderSentence": "Trimethoprim-sulfamethoxazole (PCP prophylaxis) 800 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 DS tablet (160/800 mg) daily or 3 times per week if prednisone ≥20 mg for ≥4 weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "G6PD deficiency",
          "Sulfa allergy",
          "Sulfonamide allergy",
          "hyperkalemia",
          "megaloblastic anemia",
          "renal impairment",
          "severe renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "CBC periodically",
          "electrolytes",
          "potassium",
          "rash",
          "renal function",
          "use dapsone or atovaquone if allergic"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "cns-vasculitis",
        "giant-cell-arteritis",
        "inflammatory-myopathy",
        "myasthenia-gravis",
        "myasthenia-gravis-new-diagnosis",
        "susac-syndrome"
      ]
    },
    "tucatinib": {
      "id": "tucatinib",
      "name": "Tucatinib (HER2+ breast)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "her2-positive-breast-cancer-with-leptomeningeal-disease-smal": {
          "indication": "HER2-positive breast cancer with leptomeningeal disease; small molecule with CNS penetration",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "**Tucatinib (HER2+ breast)** 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Tucatinib 300 mg PO BID + trastuzumab (IV per schedule) + capecitabine 1000 mg/m2 PO BID days 1-14 q21d; per HER2CLIMB trial; trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV q3wk is alternative (DESTINY-Breast03 CNS data)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "leptomeningeal-carcinomatosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment",
          "capecitabine: DPD deficiency (fatal toxicity)",
          "severe renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC q3 weeks",
          "LFTs q2 weeks x 8 weeks then monthly",
          "cardiac function (LVEF q3 months)",
          "diarrhea assessment",
          "hand-foot syndrome monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "leptomeningeal-carcinomatosis"
      ]
    },
    "tumor-necrosis-factor-inhibitor": {
      "id": "tumor-necrosis-factor-inhibitor",
      "name": "Tumor necrosis factor inhibitor (infliximab)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-pacns-with-granulomatous-histology-case-reports-s": {
          "indication": "Refractory PACNS with granulomatous histology; case reports/small series suggest benefit",
          "doseOptions": [
            {
              "text": "5 mg/kg at weeks 0, 2, 6 then q8 weeks",
              "orderSentence": "Tumor necrosis factor inhibitor (infliximab) 5 mg/kg at weeks 0, 2, 6 then q8 weeks IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg/kg IV at weeks 0, 2, 6; then every 8 weeks; premedicate",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cns-vasculitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active TB",
          "active infection",
          "decompensated heart failure (NYHA III/IV)",
          "demyelinating disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "LFTs",
          "TB screening before and annually",
          "heart failure symptoms",
          "hepatitis B",
          "infection surveillance"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cns-vasculitis"
      ]
    },
    "tumor-treating-fields": {
      "id": "tumor-treating-fields",
      "name": "Tumor Treating Fields (TTFields / Optune)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "TOP"
      ],
      "formulations": [],
      "contexts": {
        "fda-approved-for-newly-diagnosed-gbm-as-adjuvant-with-temozo": {
          "indication": "FDA-approved for newly diagnosed GBM as adjuvant with temozolomide; alternating electric fields (200 kHz) disrupt mitosis; EF-14 trial: OS 20.9 vs. 16.0 months with temozolomide alone",
          "doseOptions": [
            {
              "text": "Continuous",
              "orderSentence": "Tumor Treating Fields (TTFields / Optune) Continuous TOP"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "4 transducer arrays applied to shaved scalp; continuous use >=18h/day for optimal benefit; worn during adjuvant temozolomide phase and beyond; continue until progression",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active implanted medical device in the brain (DBS, programmable shunt with metallic parts)",
          "pregnancy",
          "sensitivity to conductive hydrogel",
          "skull defect with no bone flap replacement"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "<75% compliance reduces benefit)",
          "Compliance monitoring (>=18h/day target",
          "quality of life assessment",
          "scalp skin assessment q2 weeks initially then monthly (contact dermatitis in ~16%)",
          "treat skin irritation with topical corticosteroids and array repositioning"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "glioblastoma"
      ]
    },
    "ublituximab": {
      "id": "ublituximab",
      "name": "Ublituximab (Briumvi)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "150 mg",
              "orderSentence": "Ublituximab (Briumvi) 150 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "150 mg IV day 1, 450 mg IV day 15, then 450 mg IV q6 months",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-chronic-management",
            "ms-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active Hepatitis B",
          "Same as ocrelizumab",
          "active infection"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "1-hour infusion (faster)",
          "Same",
          "Same as ocrelizumab"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "ms-chronic-management",
        "ms-new-diagnosis"
      ]
    },
    "ubrogepant": {
      "id": "ubrogepant",
      "name": "Ubrogepant",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Ubrogepant 50-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg PO; may repeat in 2h; max 200 mg/24h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "moderate-severe-migraine-cv-contraindications-to-triptans-lo": {
          "indication": "Moderate-severe migraine; CV contraindications to triptans; lower MOH risk",
          "doseOptions": [
            {
              "text": "50-100 mg",
              "orderSentence": "Ubrogepant 50-100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg PO once; may repeat in 2h; max 200 mg/24h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "cgrp-antagonist-use-if-triptan-contraindicated-or-cardiovasc": {
          "indication": "CGRP antagonist; use if triptan contraindicated or cardiovascular risk",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Ubrogepant 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50-100 mg PO; may repeat after 2 hr; max 200 mg/24hr",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "CYP3A4 inhibitors",
          "Strong CYP3A4 inhibitors",
          "no cardiovascular contraindications",
          "severe hepatic impairment",
          "severe hepatic/renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs periodically",
          "None routine",
          "may have lower MOH risk",
          "no cardiovascular contraindications"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "migraine-with-aura"
      ]
    },
    "unfractionated-heparin-iv": {
      "id": "unfractionated-heparin-iv",
      "name": "Unfractionated heparin (UFH) IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "acute-cvt-with-large-hemorrhagic-infarction-renal-failure-or": {
          "indication": "Acute CVT with large hemorrhagic infarction, renal failure, or anticipated procedures; preferred if endovascular intervention planned",
          "doseOptions": [
            {
              "text": "80 units/kg",
              "orderSentence": "Unfractionated heparin (UFH) IV 80 units/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "80 units/kg IV bolus (max 10,000 units), then 18 units/kg/hr infusion; target aPTT 1.5-2.5x control (60-80 sec)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active uncontrolled bleeding",
          "HIT",
          "severe thrombocytopenia (<50K)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "aPTT q6h until therapeutic x2, then q12-24h",
          "platelet count q2d (HIT screen)",
          "signs of bleeding"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cerebral-venous-thrombosis"
      ]
    },
    "vagus-nerve-stimulation": {
      "id": "vagus-nerve-stimulation",
      "name": "Vagus nerve stimulation (VNS)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "Surgical implant"
      ],
      "formulations": [],
      "contexts": {
        "palliative-neuromodulation-for-dre-when-surgery-not-feasible": {
          "indication": "Palliative neuromodulation for DRE when surgery not feasible; reduces seizure frequency by ~50% in ~50% of patients; efficacy improves over years",
          "doseOptions": [
            {
              "text": "N/A — device implantation",
              "orderSentence": "Vagus nerve stimulation (VNS) N/A — device implantation Surgical"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Generator implanted subcutaneously in left chest; lead wrapped around left vagus nerve; standard parameters: 30 sec on/5 min off; 0.25 mA titrated up over weeks",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Prior left vagotomy",
          "bradycardia/asystole during lead impedance testing",
          "caution with OSA"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "VNS interrogation q6 months",
          "battery life monitoring",
          "dyspnea",
          "magnet use training",
          "voice changes"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "valacyclovir": {
      "id": "valacyclovir",
      "name": "Valacyclovir (for HSV-2 Mollaret meningitis)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "suppressive-antiviral-therapy-for-recurrent-hsv-2-meningitis": {
          "indication": "Suppressive antiviral therapy for recurrent HSV-2 meningitis (Mollaret meningitis); reduces frequency and severity of recurrences",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Valacyclovir (for HSV-2 Mollaret meningitis) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg PO BID or 1000 mg PO daily for suppressive therapy; duration individualized (months to years); discuss risk/benefit with patient",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "oral-step-down-for-vzv-meningitis-in-immunocompetent-patient": {
          "indication": "Oral step-down for VZV meningitis in immunocompetent patients who are clinically improving; total treatment duration 10-14 days",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Valacyclovir (for VZV meningitis — oral step-down) 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO TID; complete total 10-14 day course (combined IV + PO)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "chronic-suppressive-therapy-for-recurrent-hsv-2-meningitis-m": {
          "indication": "Chronic suppressive therapy for recurrent HSV-2 meningitis (Mollaret meningitis); initiate after second or third recurrence; reduces frequency of episodes",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Valacyclovir (chronic suppression for Mollaret meningitis) 500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500 mg PO BID or 1000 mg PO daily; continue for 6-12 months then reassess; some patients require indefinite suppression",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000 mg",
              "orderSentence": "Valacyclovir (moderate-severe Bell's) 1000 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mg PO TID × 7 days; ALWAYS with steroids",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "bells-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment",
          "Renal impairment (dose adjust CrCl <30: 500 mg daily)",
          "Renal impairment (dose adjust)",
          "Renal impairment (reduce dose)",
          "TTP/HUS (rare, high-dose)",
          "thrombotic thrombocytopenic purpura (rare, high dose)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC annually",
          "CBC if prolonged use",
          "Renal function",
          "Renal function at baseline and periodically",
          "Renal function q3-6 months",
          "symptom recurrence diary"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "bells-palsy",
        "viral-meningitis"
      ]
    },
    "valbenazine": {
      "id": "valbenazine",
      "name": "Valbenazine (Ingrezza)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "off-label-for-hd-chorea-once-daily-dosing": {
          "indication": "Off-label for HD chorea; once daily dosing",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Valbenazine (Ingrezza) 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 40 mg daily; may increase to 80 mg after 1 week",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "fda-approved-first-line-for-td-vmat2-inhibitor": {
          "indication": "FDA-approved first-line for TD; VMAT2 inhibitor",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Valbenazine (Ingrezza) 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 40 mg once daily; increase to 80 mg daily after 1 week if tolerated; take with or without food",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        },
        "vmat2-inhibitor-once-daily-dosing-off-label-for-refractory-t": {
          "indication": "VMAT2 inhibitor; once-daily dosing; off-label for refractory tics",
          "doseOptions": [
            {
              "text": "40 mg",
              "orderSentence": "Valbenazine (Ingrezza) 40 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 40 mg once daily; increase to 80 mg daily after 1 week if tolerated; max 80 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Congenital long QT",
          "Severe hepatic impairment",
          "concurrent MAOIs",
          "congenital long QT",
          "severe hepatic impairment",
          "strong CYP2D6 inhibitors at higher dose"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Depression, akathisia, QTc prolongation",
          "QTc (baseline, after dose increase)",
          "QTc at baseline and after dose increase",
          "depression",
          "parkinsonism",
          "somnolence"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "huntingtons-disease",
        "tardive-dyskinesia",
        "tics-tourette-syndrome"
      ]
    },
    "valproate": {
      "id": "valproate",
      "name": "Valproate",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "250-500 mg",
              "orderSentence": "Valproate 250-500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250-500 mg BID; titrate to 500-1000 mg BID",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "medication-overuse-headache",
            "cluster-headache",
            "migraine"
          ]
        },
        "broad-spectrum-asm-first-line-for-generalized-epilepsy-jme-a": {
          "indication": "Broad-spectrum ASM; first-line for generalized epilepsy (JME, absence); effective for multiple seizure types",
          "doseOptions": [
            {
              "text": "250 mg BID",
              "orderSentence": "Valproate (Depakote) 250 mg BID PO"
            },
            {
              "text": "500 mg BID",
              "orderSentence": "Valproate (Depakote) 500 mg BID PO"
            },
            {
              "text": "750 mg BID",
              "orderSentence": "Valproate (Depakote) 750 mg BID PO"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Valproate (Depakote) 1000 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID (DR) or 500 mg ER daily; increase by 250-500 mg q1wk; target 500-1000 mg BID; max 60 mg/kg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**TERATOGENIC — CONTRAINDICATED IN PREGNANCY** (neural tube defects 1-2%, neurodevelopmental effects)",
          "Pregnancy, hepatic disease",
          "hepatic disease",
          "mitochondrial disease (POLG mutations)",
          "urea cycle disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs, CBC with platelets q3-6 months",
          "LFTs, ammonia",
          "LFTs, ammonia, weight",
          "PCOS screening in women",
          "ammonia if encephalopathy",
          "hair loss",
          "tremor",
          "weight"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 4,
      "_sourcePlans": [
        "cluster-headache",
        "epilepsy-chronic-management",
        "medication-overuse-headache",
        "migraine"
      ]
    },
    "valproate-divalproex": {
      "id": "valproate-divalproex",
      "name": "Valproate/Divalproex",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "first-line-level-a-evidence-may-benefit-comorbid-bipolar-dis": {
          "indication": "First-line; Level A evidence; may benefit comorbid bipolar disorder",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Valproate/Divalproex 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID or 500 mg ER QHS; increase to 500-1000 mg/day; max 1500 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "generalized-seizures": {
          "indication": "Generalized seizures",
          "doseOptions": [
            {
              "text": "10-15 mg/kg",
              "orderSentence": "Valproate/Divalproex 10-15 mg/kg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 10-15 mg/kg/day in divided doses; increase by 5-10 mg/kg/week; target 1000-2000 mg/day; max 60 mg/kg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        },
        "prevention-with-comorbid-bipolar-or-epilepsy": {
          "indication": "Prevention with comorbid bipolar or epilepsy",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Valproate/Divalproex 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID or 500 mg ER daily; titrate to 500-1000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**Pregnancy (teratogenic - neural tube defects)**",
          "Pregnancy (neural tube defects - ABSOLUTE), hepatic disease, mitochondrial disease, pancreatitis",
          "Pregnancy (teratogenic)",
          "hepatic disease",
          "mitochondrial disease",
          "pancreatitis history",
          "urea cycle disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "LFTs q6mo",
          "LFTs, ammonia, CBC, platelets at baseline, then q3-6mo",
          "LFTs, ammonia, CBC, weight q3-6mo",
          "hair loss",
          "mandatory contraception counseling in women",
          "tremor",
          "weight",
          "weight gain, hair loss, tremor"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine-with-aura",
        "new-onset-seizure"
      ]
    },
    "valproate-iv": {
      "id": "valproate-iv",
      "name": "Valproate IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "adjunctive-for-withdrawal-seizure-prevention-when-benzodiaze": {
          "indication": "Adjunctive for withdrawal seizure prevention when benzodiazepines insufficient; NOT a substitute for benzodiazepines",
          "doseOptions": [
            {
              "text": "20-40 mg/kg",
              "orderSentence": "Valproate IV 20-40 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mg/kg IV over 30 min; then 250-500 mg IV q8h; monitor ammonia",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "alcohol-withdrawal-seizure"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "40 mg/kg",
              "orderSentence": "Valproate IV 40 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg/kg IV (max 3000 mg) over 10 min",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "status-epilepticus"
          ]
        },
        "alternative-broad-spectrum": {
          "indication": "Alternative (broad-spectrum)",
          "doseOptions": [
            {
              "text": "40 mg/kg",
              "orderSentence": "Valproate IV 40 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg/kg IV over 10 min (max 3000 mg)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy (teratogenic - neural tube defects), hepatic disease, mitochondrial disease, urea cycle disorders",
          "Pregnancy (teratogenic)",
          "Pregnancy, hepatic disease, mitochondrial disease, urea cycle disorders, pancreatitis",
          "hepatic disease (common in this population)",
          "mitochondrial disease",
          "pancreatitis"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ammonia, LFTs",
          "LFTs, ammonia, platelets",
          "avoid in unknown pregnancy status",
          "hepatotoxicity risk higher in alcoholic liver disease",
          "pancreatitis risk"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "alcohol-withdrawal-seizure",
        "new-onset-seizure",
        "status-epilepticus"
      ]
    },
    "valproate-sodium": {
      "id": "valproate-sodium",
      "name": "Valproate sodium (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "refractory-headache-unresponsive-to-cocktail-broad-spectrum-": {
          "indication": "Refractory headache unresponsive to cocktail; broad-spectrum headache efficacy",
          "doseOptions": [
            {
              "text": "500-1000 mg",
              "orderSentence": "Valproate sodium (CPT 96365) 500-1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mg IV over 15-30 min",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "headache-unspecified"
          ]
        },
        "status-migrainosus-with-aura-refractory-to-first-line": {
          "indication": "Status migrainosus with aura; refractory to first-line",
          "doseOptions": [
            {
              "text": "500 mg",
              "orderSentence": "Valproate sodium 500 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mg IV over 5-10 min; may repeat 500 mg in 8 hr",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hepatic disease",
          "Pregnancy",
          "hepatic disease",
          "mitochondrial disease (POLG mutation)",
          "pancreatitis history",
          "pregnancy (teratogenic)",
          "urea cycle disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ammonia, LFTs",
          "LFTs",
          "ammonia if altered mental status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "headache-unspecified",
        "migraine-with-aura"
      ]
    },
    "valproate-sodium-iv": {
      "id": "valproate-sodium-iv",
      "name": "Valproate sodium IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "500-1000 mg",
              "orderSentence": "Valproate sodium IV 500-1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mg IV over 15-30 min",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "refractory-to-first-line-status-migrainosus": {
          "indication": "Refractory to first-line; status migrainosus",
          "doseOptions": [
            {
              "text": "500-1000 mg",
              "orderSentence": "Valproate sodium IV 500-1000 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mg IV over 15-30 min; may repeat in 8h",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "acute-migraine-treatment-for-patients-who-cannot-receive-tri": {
          "indication": "Acute migraine treatment for patients who cannot receive triptans/DHE or as adjunct; also anti-nausea properties",
          "doseOptions": [
            {
              "text": "500 mg IV once",
              "orderSentence": "Valproate sodium IV 500 mg IV once IV"
            },
            {
              "text": "1000 mg IV once",
              "orderSentence": "Valproate sodium IV 1000 mg IV once IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "500-1000 mg IV over 15-30 min; may repeat once in 8h",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "status-migrainosus"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy (teratogen), hepatic disease, mitochondrial disease, pancreatitis",
          "Pregnancy (teratogenic - neural tube defects), hepatic disease, mitochondrial disease (POLG mutation), urea cycle disorders, pancreatitis",
          "Pregnancy, hepatic disease, mitochondrial disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Ammonia, LFTs",
          "Ammonia, LFTs, platelet count",
          "Ammonia, LFTs, platelets"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine",
        "status-migrainosus"
      ]
    },
    "valproic-acid": {
      "id": "valproic-acid",
      "name": "Valproic acid",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "irritability-aggression-mood-stabilization": {
          "indication": "Irritability; aggression; mood stabilization",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Valproic acid 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID; titrate to level 50-100 mcg/mL",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "second-line-aed-some-preclinical-data-suggesting-synergy-wit": {
          "indication": "Second-line AED; some preclinical data suggesting synergy with temozolomide via HDAC inhibition (clinical significance uncertain)",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Valproic acid 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID; titrate by 250 mg q3-5 days to therapeutic level (50-100 mcg/mL); max 60 mg/kg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "glioblastoma"
          ]
        },
        "generalized-or-focal-seizures-dual-benefit-for-mood-stabiliz": {
          "indication": "Generalized or focal seizures; dual benefit for mood stabilization",
          "doseOptions": [
            {
              "text": "20-40 mg/kg",
              "orderSentence": "Valproic acid 20-40 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 20-40 mg/kg IV (max rate 6 mg/kg/min); Maintenance: 250-500 mg IV/PO q8h (target level 50-100 mcg/mL)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "mood-lability-agitation-dual-benefit-for-seizure-control-in-": {
          "indication": "Mood lability, agitation; dual benefit for seizure control in HE",
          "doseOptions": [
            {
              "text": "250-500 mg",
              "orderSentence": "Valproic acid (mood stabilization) 250-500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250-500 mg PO BID; titrate to level 50-100 mcg/mL",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "continue-after-loading-broad-spectrum": {
          "indication": "Continue after loading; broad-spectrum",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Valproic acid (maintenance) 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250-500 mg PO q8h (target level 50-100 mcg/mL)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        },
        "second-line-for-post-anoxic-seizures-add-if-seizures-refract": {
          "indication": "Second-line for post-anoxic seizures; add if seizures refractory to levetiracetam",
          "doseOptions": [
            {
              "text": "20-40 mg/kg",
              "orderSentence": "Valproic acid (Depakote) 20-40 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "20-40 mg/kg IV load over 15 min (max 3000 mg); then 500 mg IV q12h; target level 50-100 ug/mL",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "post-anoxic-myoclonus-adjunctive-or-alternative-to-clonazepa": {
          "indication": "Post-anoxic myoclonus (adjunctive or alternative to clonazepam)",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Valproic acid (myoclonus) 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg PO BID; titrate to 500-1000 mg TID; target level 50-100 ug/mL",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        },
        "myoclonus-and-seizure-control-add-to-or-substitute-for-clona": {
          "indication": "Myoclonus and seizure control -- add to or substitute for clonazepam if insufficient myoclonus control or excessive sedation from benzodiazepines",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Valproic acid (adjunctive for myoclonus) 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg PO BID; increase by 250 mg every 3-5 days; target level 50-100 mcg/mL; max 2000 mg/day",
          "settings": {
            "ED": "URGENT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "creutzfeldt-jakob-disease"
          ]
        },
        "myoclonus-adjunctive-seizures": {
          "indication": "Myoclonus (adjunctive); seizures",
          "doseOptions": [
            {
              "text": "250-500 mg",
              "orderSentence": "Valproic acid 250-500 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "250-500 mg PO BID; target level 50-100 µg/mL",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rapidly-progressive-dementia"
          ]
        },
        "impulsivity-aggression-mood-instability-off-label": {
          "indication": "Impulsivity; aggression; mood instability (off-label)",
          "doseOptions": [
            {
              "text": "125 mg",
              "orderSentence": "Valproic acid 125 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 125-250 mg BID; titrate to 500-1000 mg/day; monitor levels",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "frontotemporal-dementia"
          ]
        },
        "second-line-aed-for-meningioma-related-seizures-useful-when-": {
          "indication": "Second-line AED for meningioma-related seizures; useful when levetiracetam not tolerated",
          "doseOptions": [
            {
              "text": "250 mg",
              "orderSentence": "Valproic acid 250 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 250 mg BID; titrate by 250 mg q3-5 days to therapeutic level (50-100 mcg/mL); max 60 mg/kg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "ROUTINE"
          },
          "_sourcePlans": [
            "meningioma"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "20-40 mg/kg",
              "orderSentence": "Valproic acid 20-40 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 20-40 mg/kg IV (max rate 6 mg/kg/min); Maintenance: 250-500 mg IV/PO q8h (target level 50-100 mcg/mL)",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "autoimmune-encephalitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hepatic disease",
          "Hepatic failure",
          "Pregnancy",
          "Pregnancy (teratogenic -- Category X)",
          "hepatic disease",
          "liver disease",
          "mitochondrial disease",
          "mitochondrial disease (Alpers)",
          "mitochondrial disease (POLG)",
          "mitochondrial disorders",
          "mitochondrial disorders (Alpers syndrome)",
          "pancreatitis",
          "pancreatitis history",
          "pregnancy",
          "pregnancy (teratogenic)",
          "thrombocytopenia",
          "urea cycle disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC",
          "CBC (thrombocytopenia may limit chemotherapy)",
          "CBC (thrombocytopenia)",
          "LFTs",
          "LFTs at baseline and periodically",
          "LFTs, ammonia, level, weight",
          "VPA level",
          "Valproate level, LFTs, CBC, ammonia",
          "ammonia",
          "ammonia if AMS",
          "drug level",
          "drug level q1-2 weeks until stable",
          "pancreatitis",
          "pancreatitis symptoms",
          "thrombocytopenia",
          "tremor",
          "weight gain"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 13,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "autoimmune-encephalitis",
        "creutzfeldt-jakob-disease",
        "frontotemporal-dementia",
        "glioblastoma",
        "hashimotos-encephalopathy",
        "huntingtons-disease",
        "meningioma",
        "ncse",
        "rapidly-progressive-dementia"
      ]
    },
    "valproic-acid-iv": {
      "id": "valproic-acid-iv",
      "name": "Valproic acid IV",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "second-line-broad-spectrum-useful-if-seizure-type-unknown": {
          "indication": "Second-line; broad-spectrum; useful if seizure type unknown",
          "doseOptions": [
            {
              "text": "40 mg/kg",
              "orderSentence": "Valproic acid IV 40 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "40 mg/kg IV (max rate 10 mg/kg/min); then maintenance 250-500 mg IV q8h (target level 50-100 mcg/mL)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "ncse"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Pregnancy (Category X)",
          "hepatic disease",
          "mitochondrial disease (POLG)",
          "pancreatitis",
          "urea cycle disorders"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC (thrombocytopenia)",
          "LFTs",
          "VPA level",
          "ammonia",
          "do NOT use in suspected mitochondrial disease",
          "pancreatitis"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ncse"
      ]
    },
    "vancomycin": {
      "id": "vancomycin",
      "name": "Vancomycin (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "pending-csf-culture-results-covers-resistant-pneumococcus": {
          "indication": "Pending CSF culture results; covers resistant pneumococcus",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Vancomycin (empiric if bacterial meningitis not excluded) 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg IV q8-12h (actual body weight); target trough AUC/MIC 400-600",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "hashimotos-encephalopathy"
          ]
        },
        "shunt-infection-empiric": {
          "indication": "Shunt infection (empiric)",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Vancomycin 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg IV q8-12h; adjust for renal function; target trough 15-20 mcg/mL",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "normal-pressure-hydrocephalus"
          ]
        },
        "empiric-meningitis-coverage-for-resistant-organisms-give-wit": {
          "indication": "Empiric meningitis coverage for resistant organisms (give with ceftriaxone)",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Vancomycin (CPT 96365) 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg IV q8-12h (target trough 15-20 mcg/mL); max 2 g/dose",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "headache-evaluation"
          ]
        },
        "add-if-post-surgical-post-traumatic-abscess-mrsa-risk-penetr": {
          "indication": "ADD if: post-surgical/post-traumatic abscess, MRSA risk, penetrating trauma, or unknown source; covers MRSA and penicillin-resistant Streptococci",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Vancomycin (CPT 96365) 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg IV q8-12h; target trough 15-20 ug/mL or AUC/MIC 400-600; loading dose 25-30 mg/kg for severe cases",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        },
        "empiric-mrsa-and-resistant-pneumococcal-coverage-in-meningit": {
          "indication": "Empiric MRSA and resistant pneumococcal coverage in meningitis",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Vancomycin (if bacterial meningitis suspected) (CPT 96365) 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg IV q8-12h; target trough 15-20 mcg/mL. Administer with ceftriaxone for empiric coverage",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "thunderclap-headache-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Renal impairment (dose adjust)",
          "Vancomycin allergy",
          "Vancomycin allergy (use linezolid)",
          "red man syndrome (infuse over 1h minimum)",
          "red man syndrome (infuse over >1h)",
          "red man syndrome (infuse over >=1h)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Trough levels before 4th dose then q48-72h",
          "Trough levels, renal function, ototoxicity",
          "Vancomycin trough",
          "Vancomycin trough or AUC",
          "ototoxicity",
          "renal function",
          "renal function daily",
          "renal function daily initially then twice weekly"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 5,
      "_sourcePlans": [
        "brain-abscess",
        "hashimotos-encephalopathy",
        "headache-evaluation",
        "normal-pressure-hydrocephalus",
        "thunderclap-headache-evaluation"
      ]
    },
    "vancomycin-iv": {
      "id": "vancomycin-iv",
      "name": "Vancomycin IV (empiric — until bacterial meningitis excluded) (CPT 96365)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "covers-penicillin-resistant-s-pneumoniae-and-mrsa-essential-": {
          "indication": "Covers penicillin-resistant S. pneumoniae and MRSA; essential component of empiric bacterial meningitis coverage",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Vancomycin IV (empiric — until bacterial meningitis excluded) (CPT 96365) 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg IV q8-12h (target trough 15-20 ug/mL or AUC/MIC 400-600); loading dose 25-30 mg/kg if severe; discontinue when bacterial meningitis excluded",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "viral-meningitis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "15-20 mg/kg",
              "orderSentence": "Vancomycin IV (CPT 96365) 15-20 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "15-20 mg/kg IV q8-12h (target trough 15-20 µg/mL or AUC/MIC 400-600); loading dose 25-30 mg/kg if severe. Covers penicillin-resistant S. pneumoniae, MRSA",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Red man syndrome (infuse over 1h minimum)",
          "Red man syndrome (infuse over ≥1h)",
          "renal impairment (dose adjust)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Trough levels before 4th dose",
          "renal function daily",
          "watch for nephrotoxicity and ototoxicity",
          "watch nephrotoxicity and ototoxicity"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "bacterial-meningitis",
        "viral-meningitis"
      ]
    },
    "vasopressin": {
      "id": "vasopressin",
      "name": "Vasopressin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "adjunct-vasopressor-particularly-useful-in-brain-death-endog": {
          "indication": "Adjunct vasopressor; particularly useful in brain death (endogenous vasopressin deficiency from pituitary failure); hemodynamic support + DI treatment",
          "doseOptions": [
            {
              "text": "0.01-0.04 units/min",
              "orderSentence": "**Vasopressin** 0.01-0.04 units/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 0.01 units/min; titrate to MAP ≥60 mmHg; max 0.04 units/min for vasopressor effect; also treats DI at higher doses; AAN/HRSA donor management: 1 unit IV bolus then 0.5-2.4 units/hr",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        },
        "hemodynamic-support-and-di-treatment-first-line-vasopressor-": {
          "indication": "Hemodynamic support and DI treatment; first-line vasopressor for brain-dead donors per UNOS/HRSA protocol",
          "doseOptions": [
            {
              "text": "0.5-2.4 units/hr",
              "orderSentence": "**Vasopressin (donor management)** 0.5-2.4 units/hr IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "HRSA protocol: 1 unit IV bolus then 0.5-2.4 units/hr; titrate to MAP ≥60 mmHg; also treats DI; preferred over catecholamines (less myocardial oxygen demand)",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-death-evaluation"
          ]
        },
        "adjunctive-vasopressor-for-refractory-hypotension-when-norep": {
          "indication": "Adjunctive vasopressor for refractory hypotension when norepinephrine dose >0.3 mcg/kg/min",
          "doseOptions": [
            {
              "text": "0.01-0.04 units/min",
              "orderSentence": "Vasopressin 0.01-0.04 units/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.01-0.04 units/min; does not titrate above 0.04",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "anoxic-brain-injury"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Digital ischemia (relative)",
          "High-dose may cause mesenteric ischemia",
          "Mesenteric ischemia at high doses",
          "coronary vasoconstriction",
          "peripheral vascular disease"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CVP 4-12 mmHg",
          "MAP",
          "MAP continuous",
          "assess perfusion",
          "cardiac telemetry",
          "lactate",
          "lactate q6h",
          "peripheral perfusion",
          "serum Na",
          "serum sodium q2-4h",
          "target MAP 60-100 mmHg",
          "urine output",
          "urine output hourly"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "anoxic-brain-injury",
        "brain-death-evaluation"
      ]
    },
    "vasopressors-norepinephrine": {
      "id": "vasopressors-norepinephrine",
      "name": "Vasopressors: Norepinephrine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.1-0.5 µg/kg/min",
              "orderSentence": "Vasopressors: Norepinephrine 0.1-0.5 µg/kg/min IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.1-0.5 µg/kg/min IV; first-line for septic shock after fluid resuscitation",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "bacterial-meningitis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Only via central line"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "MAP target ≥65 mmHg",
          "continuous arterial monitoring"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "bacterial-meningitis"
      ]
    },
    "venlafaxine": {
      "id": "venlafaxine",
      "name": "Venlafaxine",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "anticataplectic-agent-also-treats-comorbid-depression-and-an": {
          "indication": "Anticataplectic agent; also treats comorbid depression and anxiety",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily; increase by 37.5-75 mg every 1-2 weeks; target 75-225 mg/day; max 225 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "narcolepsy"
          ]
        },
        "depression-with-comorbid-pain-syndromes-alternative-when-ssr": {
          "indication": "Depression with comorbid pain syndromes; alternative when SSRIs insufficient; does NOT significantly lower seizure threshold at therapeutic doses",
          "doseOptions": [
            {
              "text": "37.5 mg daily",
              "orderSentence": "Venlafaxine 37.5 mg daily PO"
            },
            {
              "text": "75 mg daily",
              "orderSentence": "Venlafaxine 75 mg daily PO"
            },
            {
              "text": "150 mg daily",
              "orderSentence": "Venlafaxine 150 mg daily PO"
            },
            {
              "text": "225 mg daily",
              "orderSentence": "Venlafaxine 225 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily (XR); increase by 75 mg q1wk; target 75-225 mg daily; max 225 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Concurrent MAOIs",
          "Uncontrolled hypertension",
          "abrupt discontinuation",
          "abrupt discontinuation risk",
          "concurrent MAOIs",
          "uncontrolled hypertension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Blood pressure",
          "discontinuation symptoms if stopped abruptly",
          "discontinuation syndrome (taper slowly)",
          "heart rate",
          "serotonin syndrome",
          "suicidality in young adults"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "epilepsy-chronic-management",
        "narcolepsy"
      ]
    },
    "venlafaxine-xr": {
      "id": "venlafaxine-xr",
      "name": "Venlafaxine XR",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "depression-with-fatigue-dual-mechanism": {
          "indication": "Depression with fatigue; dual mechanism",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily; titrate q1wk; max 225 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "huntingtons-disease"
          ]
        },
        "neuropathic-pain-snri-alternative": {
          "indication": "Neuropathic pain (SNRI alternative)",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5-75 mg daily; increase by 75 mg every 4-7 days; max 225 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "neuropathic-pain-second-line-snri": {
          "indication": "Neuropathic pain (second-line SNRI)",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily; increase by 75 mg every 4-7 days; target 150 mg daily; max 225 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "b12-deficiency-neuropathy"
          ]
        },
        "comorbid-depression-anxiety-chronic-pain": {
          "indication": "Comorbid depression + anxiety; chronic pain",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily x 1 week; titrate q1wk; max 225 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "functional-neurological-disorder"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "37.5-75 mg",
              "orderSentence": "Venlafaxine XR 37.5-75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "37.5-75 mg daily; titrate to 150-225 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "diabetic-neuropathy",
            "medication-overuse-headache",
            "migraine"
          ]
        },
        "snri-alternative-to-duloxetine": {
          "indication": "SNRI alternative to duloxetine",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily; increase by 37.5-75 mg q1wk; target 150-225 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "small-fiber-neuropathy"
          ]
        },
        "depression-anxiety": {
          "indication": "Depression; anxiety",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily; titrate q1-2wk; typical 75-150 mg",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "lewy-body-dementia"
          ]
        },
        "comorbid-depression-with-prominent-anxiety-chronic-pain-como": {
          "indication": "Comorbid depression with prominent anxiety; chronic pain comorbidity (dual SNRI benefit); alternative when SSRIs ineffective",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily x 1 week; titrate by 37.5-75 mg q1wk; max 225 mg/day; MUST taper to discontinue (severe discontinuation syndrome)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "pnes"
          ]
        },
        "dual-headache-prevention-and-mood-improvement": {
          "indication": "Dual headache prevention and mood improvement",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg PO daily; increase by 37.5 mg every 1-2 weeks; target 75-150 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-concussion-syndrome"
          ]
        },
        "neuropathic-pain": {
          "indication": "Neuropathic pain",
          "doseOptions": [
            {
              "text": "37.5-75 mg",
              "orderSentence": "Venlafaxine XR 37.5-75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5-75 mg daily; increase by 75 mg every 4-7 days; max 225 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        },
        "depression-pain": {
          "indication": "Depression/pain",
          "doseOptions": [
            {
              "text": "37.5-75 mg",
              "orderSentence": "Venlafaxine XR 37.5-75 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5-75 mg daily; increase by 75 mg every 4 days; max 225 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ms-new-diagnosis"
          ]
        },
        "first-line-comorbid-depression-anxiety-or-fibromyalgia": {
          "indication": "First-line; comorbid depression, anxiety, or fibromyalgia",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily x 1 week; increase to 75 mg daily; target 75-150 mg daily; max 225 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        },
        "prevention-comorbid-depression-or-anxiety-tca-intolerant": {
          "indication": "Prevention; comorbid depression or anxiety; TCA intolerant",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily; increase by 37.5-75 mg every 1 week; target 75-150 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tension-headache"
          ]
        },
        "depression-anxiety-in-pd": {
          "indication": "Depression; anxiety in PD",
          "doseOptions": [
            {
              "text": "37.5 mg daily",
              "orderSentence": "Venlafaxine XR 37.5 mg daily PO"
            },
            {
              "text": "75 mg daily",
              "orderSentence": "Venlafaxine XR 75 mg daily PO"
            },
            {
              "text": "150 mg daily",
              "orderSentence": "Venlafaxine XR 150 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily; titrate q1-2wk; typical 75-150 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "parkinsons-disease"
          ]
        },
        "prevention-with-comorbid-depression-anxiety": {
          "indication": "Prevention with comorbid depression, anxiety",
          "doseOptions": [
            {
              "text": "37.5 mg",
              "orderSentence": "Venlafaxine XR 37.5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 37.5 mg daily; increase by 37.5-75 mg q1wk; target 75-150 mg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "MAOIs",
          "MAOIs within 14 days",
          "MAOIs, uncontrolled HTN",
          "Same as sertraline",
          "Uncontrolled HTN",
          "Uncontrolled HTN, MAOI use",
          "Uncontrolled HTN, MAOI use, narrow-angle glaucoma",
          "Uncontrolled HTN, MAOIs",
          "Uncontrolled HTN, MAOIs, narrow-angle glaucoma",
          "Uncontrolled hypertension",
          "abrupt discontinuation (taper required)",
          "abrupt discontinuation risk",
          "concurrent MAOIs",
          "narrow-angle glaucoma",
          "serotonin syndrome risk with triptans (monitor closely)",
          "uncontrolled hypertension"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP (dose-dependent HTN), serotonin syndrome signs (agitation, hyperthermia, clonus), withdrawal if abrupt discontinuation",
          "BP (dose-dependent hypertension)",
          "BP at doses >150 mg",
          "BP at higher doses",
          "BP monitoring",
          "BP, serotonin syndrome",
          "Blood pressure at higher doses (>150 mg)",
          "HR",
          "discontinuation syndrome",
          "discontinuation syndrome (taper over 2+ weeks)",
          "discontinuation syndrome (taper slowly)",
          "discontinuation syndrome if stopped abruptly",
          "discontinuation syndrome risk (taper over 2-4 weeks)",
          "serotonin syndrome",
          "serotonin syndrome risk",
          "serotonin syndrome signs",
          "taper to discontinue"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 17,
      "_sourcePlans": [
        "b12-deficiency-neuropathy",
        "chronic-migraine",
        "diabetic-neuropathy",
        "functional-neurological-disorder",
        "huntingtons-disease",
        "lewy-body-dementia",
        "medication-overuse-headache",
        "migraine",
        "migraine-with-aura",
        "ms-new-diagnosis",
        "paresthesia-numbness-tingling",
        "parkinsons-disease",
        "peripheral-neuropathy",
        "pnes",
        "post-concussion-syndrome",
        "small-fiber-neuropathy",
        "tension-headache"
      ]
    },
    "verapamil": {
      "id": "verapamil",
      "name": "Verapamil",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV",
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "headache-prevention-in-moyamoya-calcium-channel-blocker-may-": {
          "indication": "Headache prevention in moyamoya (calcium channel blocker may improve collateral flow); migraine-like headache is common",
          "doseOptions": [
            {
              "text": "80 mg TID",
              "orderSentence": "Verapamil 80 mg TID PO"
            },
            {
              "text": "120 mg TID",
              "orderSentence": "Verapamil 120 mg TID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 80 mg TID; increase by 80 mg q1wk; target 120 mg TID; max 480 mg/day; extended-release preferred",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "moyamoya-disease"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "80 mg",
              "orderSentence": "Verapamil 80 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 80 mg TID; increase by 80 mg q1-2 weeks to 240-960 mg/day in divided doses (some patients need >480 mg/day)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache"
          ]
        },
        "calcium-channel-blocker-to-reduce-cerebral-vasoconstriction-": {
          "indication": "Calcium channel blocker to reduce cerebral vasoconstriction and prevent recurrent thunderclap headache",
          "doseOptions": [
            {
              "text": "80 mg",
              "orderSentence": "Verapamil (preferred first-line CCB) 80 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 80 mg PO TID; titrate to 120 mg TID (or 240 mg SR BID) over 3-5 days based on BP tolerance; max 480 mg/day; continue for 4-12 weeks until imaging resolution",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "refractory-vasoconstriction-with-progressive-neurologic-defi": {
          "indication": "Refractory vasoconstriction with progressive neurologic deficits despite oral CCB therapy",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Verapamil (IV loading — refractory cases) 5 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg IV over 2 min; may repeat q15min x3; max 20 mg; then transition to oral verapamil. Use with continuous cardiac monitoring",
          "settings": {
            "ED": "-",
            "HOSP": "URGENT",
            "OPD": "-",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "ongoing-ccb-therapy-during-recovery-phase-continue-until-ima": {
          "indication": "Ongoing CCB therapy during recovery phase; continue until imaging confirms resolution of vasoconstriction at 8-12 weeks",
          "doseOptions": [
            {
              "text": "240 mg",
              "orderSentence": "Verapamil (maintenance taper) 240 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Maintain effective dose (typically 240-480 mg/day as 80-120 mg TID or 240 mg SR BID) for 8-12 weeks; taper gradually over 2-4 weeks once follow-up CTA/MRA shows complete resolution",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "rcvs"
          ]
        },
        "hemiplegic-migraine-acute-if-severe-status-migrainosus": {
          "indication": "Hemiplegic migraine acute (if severe); status migrainosus",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Verapamil 5 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg IV over 2-3 min; may repeat in 30 min (max 20 mg)",
          "settings": {
            "ED": "-",
            "HOSP": "EXT",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine-with-aura"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Complete heart block",
          "Heart block",
          "Heart block (2nd/3rd degree AV block)",
          "Heart block (2nd/3rd degree)",
          "Heart block (2nd/3rd degree), sick sinus, severe LV dysfunction, WPW",
          "SBP <90",
          "Second/third-degree AV block",
          "concurrent IV beta-blocker",
          "concurrent beta-blocker",
          "concurrent beta-blocker use (risk of severe bradycardia/hypotension)",
          "hypotension",
          "severe LV dysfunction",
          "severe LV dysfunction (EF <30%)",
          "sick sinus syndrome"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "BP",
          "BP and HR q4-6h during titration",
          "BP at each visit",
          "BP q5min during infusion",
          "Continuous ECG",
          "Continuous telemetry",
          "ECG",
          "ECG at baseline and q2-4 weeks during taper",
          "ECG at baseline, after each dose increase",
          "ECG before starting and at 48-72h",
          "ECG for PR prolongation",
          "HR",
          "PR interval (hold if >280 ms)",
          "avoid in hypotension",
          "constipation",
          "continuous telemetry first 24h inpatient",
          "for hemiplegic migraine when triptans contraindicated",
          "repeat CTA/MRA at 8-12 weeks"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "cluster-headache",
        "migraine-with-aura",
        "moyamoya-disease",
        "rcvs"
      ]
    },
    "vestibular-suppressants": {
      "id": "vestibular-suppressants",
      "name": "Vestibular suppressants (short-term only)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25 mg",
              "orderSentence": "**Vestibular suppressants (short-term only)** 25 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Meclizine 25 mg q8h OR dimenhydrinate 50 mg q6h OR diazepam 5 mg BID x 1-3 days ONLY; taper off as soon as tolerated",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vertigo-dizziness-evaluation"
          ]
        },
        "delays-central-compensation-masks-underlying-pathology-sedat": {
          "indication": "Delays central compensation; masks underlying pathology; sedation; fall risk",
          "doseOptions": [
            {
              "text": "Avoid use beyond 72h",
              "orderSentence": "**Vestibular suppressants (prolonged use >72h)** Avoid use beyond 72h -"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Limit to 48-72h for acute peripheral vestibular nystagmus; NOT indicated for central nystagmus types",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "nystagmus-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Monitor duration of use",
          "STOP after 72 hours maximum — prolonged use delays compensation",
          "Short-term symptom relief",
          "initiate vestibular rehabilitation early"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "nystagmus-evaluation",
        "vertigo-dizziness-evaluation"
      ]
    },
    "vigabatrin": {
      "id": "vigabatrin",
      "name": "Vigabatrin (Sabril)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-refractory-to-other-therapies-infantile-spasms-first-lin": {
          "indication": "DRE refractory to other therapies; infantile spasms (first-line); tuberous sclerosis complex with epilepsy",
          "doseOptions": [
            {
              "text": "500 mg BID",
              "orderSentence": "Vigabatrin (Sabril) 500 mg BID PO"
            },
            {
              "text": "1000 mg BID",
              "orderSentence": "Vigabatrin (Sabril) 1000 mg BID PO"
            },
            {
              "text": "1500 mg BID",
              "orderSentence": "Vigabatrin (Sabril) 1500 mg BID PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 500 mg BID; increase by 500 mg/week; target 1000-1500 mg BID; max 3000 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "**IRREVERSIBLE VISUAL FIELD DEFECTS** (bilateral concentric constriction in 25-50%)",
          "retinal toxicity"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "**REMS PROGRAM REQUIRED**: Baseline ophthalmologic exam including perimetry",
          "OCT monitoring",
          "discontinue if no benefit by 3 months",
          "repeat q3 months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "drug-resistant-epilepsy"
      ]
    },
    "vincristine": {
      "id": "vincristine",
      "name": "Vincristine (R-MPV regimen component)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "component-of-r-mpv-regimen-vinca-alkaloid-contributes-to-mul": {
          "indication": "Component of R-MPV regimen; vinca alkaloid; contributes to multi-agent synergy",
          "doseOptions": [
            {
              "text": "1.4 mg/m2",
              "orderSentence": "Vincristine (R-MPV regimen component) 1.4 mg/m2 IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1.4 mg/m2 IV push (max 2 mg per dose) on Day 1 of each cycle; NEVER administer intrathecally (fatal); vesicant - administer through running IV",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "primary-cns-lymphoma"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Peripheral neuropathy assessment before each dose (grade and hold if Grade 3+)",
          "constipation (autonomic neuropathy)",
          "foot drop assessment",
          "ileus monitoring",
          "jaw pain"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "primary-cns-lymphoma"
      ]
    },
    "vitamin-b-complex-supplementation": {
      "id": "vitamin-b-complex-supplementation",
      "name": "Vitamin B complex supplementation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nutritional-support-for-nerve-recovery-adjunctive": {
          "indication": "Nutritional support for nerve recovery (adjunctive)",
          "doseOptions": [
            {
              "text": "B-complex",
              "orderSentence": "Vitamin B complex supplementation B-complex PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "One B-complex tablet daily; ensure adequate B1, B6, B12; not evidence-based as monotherapy for recovery",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "peroneal-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "B6 >200 mg/day causes neuropathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "None specific"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "peroneal-neuropathy"
      ]
    },
    "vitamin-b12": {
      "id": "vitamin-b12",
      "name": "Vitamin B12",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM",
        "IM/PO"
      ],
      "formulations": [],
      "contexts": {
        "b12-deficiency-300-pg-ml-or-elevated-mma": {
          "indication": "B12 deficiency (<300 pg/mL or elevated MMA)",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "Vitamin B12 1000 mcg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mcg IM daily x 7d, then weekly x 4wk, then monthly; or high-dose oral 1000-2000 mcg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "mild-cognitive-impairment"
          ]
        },
        "b12-deficiency-300-pg-ml": {
          "indication": "B12 deficiency (<300 pg/mL)",
          "doseOptions": [
            {
              "text": "1000 mcg IM daily x 7d",
              "orderSentence": "Vitamin B12 1000 mcg IM daily x 7d IM/PO"
            },
            {
              "text": "1000 mcg IM weekly x 4wk",
              "orderSentence": "Vitamin B12 1000 mcg IM weekly x 4wk IM/PO"
            },
            {
              "text": "1000 mcg IM monthly",
              "orderSentence": "Vitamin B12 1000 mcg IM monthly IM/PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mcg IM daily x 7d, then weekly x 4wk, then monthly; or high-dose oral 1000-2000 mcg daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "alzheimers-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 level at 2 months",
          "B12 level, MMA at 3 months",
          "cognitive improvement over months",
          "neurological improvement over months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "alzheimers-disease",
        "mild-cognitive-impairment"
      ]
    },
    "vitamin-b12-im": {
      "id": "vitamin-b12-im",
      "name": "Vitamin B12 IM (if deficient)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "documented-b12-deficiency-with-neurological-symptoms-do-not-": {
          "indication": "Documented B12 deficiency with neurological symptoms (do not wait for MMA result)",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "Vitamin B12 IM (if deficient) 1000 mcg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mcg IM daily x 7 days, then weekly x 4 weeks, then monthly indefinitely",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "paresthesia-numbness-tingling"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "Vitamin B12 IM (if deficient) 1000 mcg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mcg IM daily Ãƒâ€” 7 days, then weekly Ãƒâ€” 4 weeks, then monthly",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "URGENT"
          },
          "_sourcePlans": [
            "peripheral-neuropathy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Cobalt allergy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 level at 1-2 months",
          "Reticulocyte count at 1 week",
          "neurological exam"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "paresthesia-numbness-tingling",
        "peripheral-neuropathy"
      ]
    },
    "vitamin-b12-replacement": {
      "id": "vitamin-b12-replacement",
      "name": "Vitamin B12 replacement",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "Vitamin B12 replacement 1000 mcg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mcg IM daily × 7 days, then weekly × 4, then monthly; OR oral 1000-2000 mcg daily",
          "settings": {
            "ED": "URGENT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dementia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 levels"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "dementia-evaluation"
      ]
    },
    "vitamin-b12-supplementation": {
      "id": "vitamin-b12-supplementation",
      "name": "Vitamin B12 supplementation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM"
      ],
      "formulations": [],
      "contexts": {
        "b12-deficiency-causing-sensory-ataxia-subacute-combined-dege": {
          "indication": "B12 deficiency causing sensory ataxia (subacute combined degeneration); posterior column disease",
          "doseOptions": [
            {
              "text": "1000 mcg",
              "orderSentence": "Vitamin B12 supplementation 1000 mcg IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1000 mcg IM daily x 7 days, then weekly x 4 weeks, then monthly indefinitely; or high-dose oral 1000-2000 mcg daily if absorption adequate",
          "settings": {
            "ED": "URGENT",
            "HOSP": "URGENT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "None"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "B12 level at 2 months",
          "CBC (reticulocyte response)",
          "MMA for adequacy of replacement",
          "neurologic exam",
          "sensory exam improvement may take months"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ataxia-evaluation"
      ]
    },
    "vitamin-b6": {
      "id": "vitamin-b6",
      "name": "Vitamin B6 (pyridoxine)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "limited-evidence-some-trials-show-benefit": {
          "indication": "Limited evidence; some trials show benefit",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Vitamin B6 (pyridoxine) 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-400 mg daily; monitor for neuropathy at high doses",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Peripheral neuropathy"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Neuropathy with chronic high dose (>200 mg)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tardive-dyskinesia"
      ]
    },
    "vitamin-e": {
      "id": "vitamin-e",
      "name": "Vitamin E",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "limited-evidence-may-prevent-progression-minimal-therapeutic": {
          "indication": "Limited evidence; may prevent progression; minimal therapeutic effect",
          "doseOptions": [
            {
              "text": "400 IU",
              "orderSentence": "Vitamin E 400 IU PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "400-1600 IU daily; better evidence for prevention than treatment",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tardive-dyskinesia"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Coagulopathy",
          "vitamin K deficiency"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Bleeding risk at high doses"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tardive-dyskinesia"
      ]
    },
    "vitamin-e-supplementation": {
      "id": "vitamin-e-supplementation",
      "name": "Vitamin E supplementation",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "vitamin-e-deficiency-ataxia-abetalipoproteinemia-fat-malabso": {
          "indication": "Vitamin E deficiency ataxia (abetalipoproteinemia, fat malabsorption); treatable cause",
          "doseOptions": [
            {
              "text": "800 IU",
              "orderSentence": "Vitamin E supplementation 800 IU PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "800-1200 IU daily; higher doses may be needed in malabsorption syndromes; take with fatty meal",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "ataxia-evaluation"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Caution with anticoagulants (may increase bleeding risk at high doses)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "PT/INR if on anticoagulants",
          "Vitamin E levels q3 months initially",
          "clinical ataxia assessment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "ataxia-evaluation"
      ]
    },
    "vitamin-k": {
      "id": "vitamin-k",
      "name": "Vitamin K (neonatal)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IM",
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "all-neonates-born-to-mothers-on-enzyme-inducing-asms-hemorrh": {
          "indication": "All neonates born to mothers on enzyme-inducing ASMs; hemorrhagic disease of newborn prevention",
          "doseOptions": [
            {
              "text": "1 mg IM at birth",
              "orderSentence": "Vitamin K (neonatal) 1 mg IM at birth IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg vitamin K IM to neonate at delivery; standard of care but especially critical with enzyme-inducing maternal ASMs",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "eclampsia-seizure-pregnancy"
          ]
        },
        "neonates-born-to-mothers-on-enzyme-inducing-asms-at-increase": {
          "indication": "Neonates born to mothers on enzyme-inducing ASMs at increased risk of hemorrhagic disease of newborn",
          "doseOptions": [
            {
              "text": "1 mg IM at birth",
              "orderSentence": "Vitamin K (neonatal prophylaxis) 1 mg IM at birth IM"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "1 mg vitamin K IM to neonate at delivery; standard of care but especially critical with maternal enzyme-inducing ASMs",
          "settings": {
            "ED": "ROUTINE",
            "HOSP": "-",
            "OPD": "-",
            "ICU": "-"
          },
          "_sourcePlans": [
            "epilepsy-chronic-management"
          ]
        },
        "coagulopathy-hepatic-synthetic-failure": {
          "indication": "Coagulopathy; hepatic synthetic failure",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Vitamin K (phytonadione) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV daily x 3 days; limited efficacy in WD fulminant failure (hepatocyte loss)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Allergy",
          "None",
          "None needed beyond standard neonatal care"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "INR response",
          "Neonatal coagulation studies if clinically indicated"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "eclampsia-seizure-pregnancy",
        "epilepsy-chronic-management",
        "wilsons-disease"
      ]
    },
    "volume-repletion": {
      "id": "volume-repletion",
      "name": "Volume repletion",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "N/A",
              "orderSentence": "Volume repletion N/A IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "IV fluids acutely; oral fluids long-term (2-3 L/day)",
          "settings": {
            "ED": "STAT",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "syncope"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Heart failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Volume status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "syncope"
      ]
    },
    "voriconazole": {
      "id": "voriconazole",
      "name": "Voriconazole",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "aspergillus-meningitis-first-line-for-cns-aspergillosis-seco": {
          "indication": "Aspergillus meningitis (first-line for CNS aspergillosis); second-line for resistant Cryptococcus; good CNS penetration",
          "doseOptions": [
            {
              "text": "6 mg/kg IV q12h x2 doses (load)",
              "orderSentence": "Voriconazole 6 mg/kg IV q12h x2 doses (load) IV"
            },
            {
              "text": "4 mg/kg IV q12h",
              "orderSentence": "Voriconazole 4 mg/kg IV q12h IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Load: 6 mg/kg IV q12h for 2 doses; Maintenance: 4 mg/kg IV q12h (switch to PO 200-300 mg BID when stable); target trough 2-5.5 mcg/mL",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "fungal-meningitis"
          ]
        },
        "aspergillus-brain-abscess-first-line-other-mold-infections-i": {
          "indication": "Aspergillus brain abscess (first-line); other mold infections in immunocompromised",
          "doseOptions": [
            {
              "text": "6 mg/kg",
              "orderSentence": "Voriconazole 6 mg/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "6 mg/kg IV q12h x 2 loading doses, then 4 mg/kg IV q12h; transition to 200-300 mg PO BID when stable; duration 6-12 months minimum",
          "settings": {
            "ED": "-",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "brain-abscess"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hepatic impairment",
          "IV form contraindicated if CrCl <50 (cyclodextrin accumulation)",
          "IV formulation contains cyclodextrin — avoid in renal impairment (GFR <50)",
          "QT prolongation",
          "Severe hepatic impairment",
          "co-administration with sirolimus, rifampin, carbamazepine, phenobarbital",
          "concurrent strong CYP3A4 inducers (rifampin, carbamazepine)",
          "visual disturbances"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs weekly",
          "LFTs weekly initially then biweekly",
          "QTc",
          "Trough levels (target 2-5.5 mcg/mL)",
          "Voriconazole trough levels (target 2-5 ug/mL)",
          "dermatologic monitoring (photosensitivity, squamous cell carcinoma with prolonged use)",
          "drug interactions (CYP2C19 polymorphisms)",
          "drug interactions (CYP2C19, 2C9, 3A4)",
          "visual changes",
          "visual disturbance assessment"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "brain-abscess",
        "fungal-meningitis"
      ]
    },
    "warfarin": {
      "id": "warfarin",
      "name": "Warfarin",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "mechanical-valve-select-hypercoagulable-states-af-if-doacs-c": {
          "indication": "Mechanical valve; select hypercoagulable states; AF if DOACs contraindicated",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Warfarin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; adjust to INR 2-3",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "vascular-dementia"
          ]
        },
        "long-term-anticoagulation-for-cvt-in-non-parenchymal-nbd-tra": {
          "indication": "Long-term anticoagulation for CVT in non-parenchymal NBD (transition from heparin)",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Warfarin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily; adjust per INR; overlap with heparin minimum 5 days and until INR 2-3 for 24h; duration 3-12 months (indefinite in Behcet's with recurrent thrombosis)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "neuro-behcets-disease"
          ]
        },
        "dissection-with-high-embolic-risk-when-anticoagulation-chose": {
          "indication": "Dissection with high embolic risk when anticoagulation chosen over antiplatelet; CADISS trial showed equivalent outcomes",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Warfarin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily (2-3 mg if elderly, low weight, or drug interactions); target INR 2.0-3.0; overlap with heparin bridge until INR therapeutic x 2 consecutive days",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cervical-artery-dissection"
          ]
        },
        "long-term-anticoagulation-preferred-if-antiphospholipid-synd": {
          "indication": "Long-term anticoagulation; preferred if antiphospholipid syndrome confirmed",
          "doseOptions": [
            {
              "text": "5 mg daily",
              "orderSentence": "Warfarin 5 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg PO daily (lower if elderly, hepatic impairment, CYP2C9 variant); overlap with heparin until INR 2-3 x 2 consecutive days; target INR 2.0-3.0",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cerebral-venous-thrombosis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Warfarin 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg PO daily initial (2-3 mg if elderly, low weight, or interacting drugs); target INR 2.0-3.0 for AF; 2.5-3.5 for mechanical valve. Bridge with heparin",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "acute-ischemic-stroke"
          ]
        },
        "anticoagulation-for-mechanical-heart-valve-alternative-when-": {
          "indication": "Anticoagulation for mechanical heart valve; alternative when DOACs contraindicated; AF in severe renal failure",
          "doseOptions": [
            {
              "text": "Individualized per INR",
              "orderSentence": "Warfarin Individualized per INR PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily (2.5 mg if elderly, low weight, liver disease); adjust to INR 2-3 (2.5-3.5 for mechanical valve); check INR 2-3 days after start, then weekly until stable, then monthly",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "post-stroke-management"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active bleeding",
          "Active major bleeding",
          "INR daily until stable, then weekly, then monthly",
          "Pregnancy (teratogenic -- use LMWH instead)",
          "active bleeding",
          "diet counseling (vitamin K)",
          "frequent falls",
          "inability to monitor INR",
          "non-adherence (requires monitoring)",
          "poor adherence",
          "pregnancy",
          "pregnancy (teratogenic)",
          "severe hepatic disease",
          "severe hepatic failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "INR daily until stable, then weekly, then monthly",
          "INR q1-2 days initially",
          "INR q1-3 days initially",
          "INR q1-4 weeks (target 2-3)",
          "INR weekly then monthly",
          "bleeding signs",
          "bridge plan for procedures",
          "diet counseling (vitamin K consistency)",
          "dietary vitamin K counseling",
          "drug interactions",
          "drug/diet interactions",
          "target INR 2.0-3.0",
          "then monthly",
          "then q1-2 weeks",
          "weekly then monthly once stable"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 6,
      "_sourcePlans": [
        "acute-ischemic-stroke",
        "cerebral-venous-thrombosis",
        "cervical-artery-dissection",
        "neuro-behcets-disease",
        "post-stroke-management",
        "vascular-dementia"
      ]
    },
    "warfarin-reversal-4-factor-pcc": {
      "id": "warfarin-reversal-4-factor-pcc",
      "name": "Warfarin reversal: 4-factor PCC (Kcentra) (CPT 96374)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "25-50 units/kg",
              "orderSentence": "Warfarin reversal: 4-factor PCC (Kcentra) (CPT 96374) 25-50 units/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "25-50 units/kg IV (dose based on INR: INR 2-4: 25 u/kg; INR 4-6: 35 u/kg; INR >6: 50 u/kg); infuse over 10-15 min. Reverses INR within 15-30 min. PREFERRED over FFP (faster, smaller volume)",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Active DIC (relative)",
          "HIT (contains heparin traces)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "INR 15 min after infusion",
          "repeat if INR >1.4",
          "thrombotic risk"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "warfarin-reversal-ffp": {
      "id": "warfarin-reversal-ffp",
      "name": "Warfarin reversal: FFP (if PCC unavailable)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10-15 mL/kg",
              "orderSentence": "Warfarin reversal: FFP (if PCC unavailable) 10-15 mL/kg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10-15 mL/kg IV (typically 2-4 units). Slower than PCC; requires thawing and larger volume",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Volume overload",
          "transfusion reactions"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "INR",
          "volume status"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "warfarin-reversal-vitamin-k": {
      "id": "warfarin-reversal-vitamin-k",
      "name": "Warfarin reversal: Vitamin K (phytonadione)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IV"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Warfarin reversal: Vitamin K (phytonadione) 10 mg IV"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg IV slow push (over 10 min) to sustain INR correction (PCC is temporary). ALWAYS give WITH PCC",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "-",
            "ICU": "STAT"
          },
          "_sourcePlans": [
            "intracerebral-hemorrhage"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Known severe allergic reaction (rare)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "INR at 6h and 24h",
          "anaphylaxis risk (rare with slow IV)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "intracerebral-hemorrhage"
      ]
    },
    "zavegepant-nasal": {
      "id": "zavegepant-nasal",
      "name": "Zavegepant nasal",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IN"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Zavegepant nasal 10 mg IN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg intranasal once daily",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        },
        "moderate-severe-migraine-need-non-oral-route": {
          "indication": "Moderate-severe migraine; need non-oral route",
          "doseOptions": [
            {
              "text": "10 mg",
              "orderSentence": "Zavegepant nasal 10 mg IN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "10 mg intranasal once; do not repeat in 24h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "chronic-migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Hypersensitivity",
          "None significant"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LFTs periodically",
          "Local irritation",
          "Nasal irritation"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "chronic-migraine",
        "migraine"
      ]
    },
    "zidovudine": {
      "id": "zidovudine",
      "name": "Zidovudine (AZT, Retrovir)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "nrti-with-highest-cpe-score-cpe-4-use-in-cns-escape-despite-": {
          "indication": "NRTI with highest CPE score (CPE 4); use in CNS-escape despite toxicity; historical backbone of HAND treatment",
          "doseOptions": [
            {
              "text": "300 mg",
              "orderSentence": "Zidovudine (AZT, Retrovir) 300 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "300 mg PO BID; dose adjust for renal impairment",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "hiv-associated-neurocognitive-disorder"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe anemia (Hgb <7.5)",
          "myopathy",
          "neutropenia (ANC <750)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "CBC q2-4 weeks initially (anemia, neutropenia)",
          "CK if myopathy symptoms",
          "macrocytosis expected"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "hiv-associated-neurocognitive-disorder"
      ]
    },
    "zilucoplan": {
      "id": "zilucoplan",
      "name": "Zilucoplan (Zilbrysq)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "SC"
      ],
      "formulations": [],
      "contexts": {
        "achr-generalized-mg-c5-complement-inhibitor-daily-sc": {
          "indication": "AChR+ generalized MG; C5 complement inhibitor; daily SC",
          "doseOptions": [
            {
              "text": "0.3 mg/kg",
              "orderSentence": "Zilucoplan (Zilbrysq) 0.3 mg/kg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.3 mg/kg SC daily; self-administered; meningococcal vaccination required",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "0.3 mg/kg",
              "orderSentence": "Zilucoplan (Zilbrysq) 0.3 mg/kg SC"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "0.3 mg/kg SC daily (self-administered); for AChR-positive generalized MG",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "myasthenia-gravis-new-diagnosis"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as eculizumab",
          "Unresolved Neisseria infection"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "LDH",
          "Meningococcal infection risk",
          "Same meningococcal vaccination required",
          "URI",
          "diarrhea",
          "injection site reactions",
          "reticulocyte count"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "myasthenia-gravis",
        "myasthenia-gravis-new-diagnosis"
      ]
    },
    "zinc-acetate": {
      "id": "zinc-acetate",
      "name": "Zinc acetate (Galzin)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "wilson-s-disease-maintenance-presymptomatic-adjunct": {
          "indication": "Wilson's disease maintenance; presymptomatic; adjunct",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Zinc acetate (Galzin) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg TID (elemental zinc); take between meals; blocks intestinal copper absorption",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "dystonia"
          ]
        },
        "maintenance-therapy-after-initial-decoppering-with-chelator-": {
          "indication": "Maintenance therapy (after initial decoppering with chelator); mild/presymptomatic WD; pregnancy (safest option); family members with pre-clinical WD",
          "doseOptions": [
            {
              "text": "50 mg",
              "orderSentence": "Zinc acetate (Galzin) 50 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "50 mg elemental zinc TID (taken as zinc acetate 150 mg TID); take on empty stomach separated from meals by ≥1 hour; separate from chelator by ≥2 hours if used concurrently",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI intolerance common (nausea)",
          "GI upset",
          "None absolute",
          "do NOT use as sole therapy in symptomatic/severe WD (too slow onset)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "24h urine copper",
          "24h urine copper q3-6 months (target <75 mcg/24h on zinc monotherapy)",
          "24h urine zinc",
          "24h urine zinc (confirms compliance: >2 mg/24h)",
          "CBC q6 months (zinc-induced copper deficiency can cause neutropenia)",
          "LFTs q3-6 months",
          "serum zinc",
          "serum zinc level q3-6 months (target 125-150 mcg/dL)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 2,
      "_sourcePlans": [
        "dystonia",
        "wilsons-disease"
      ]
    },
    "zinc-sulfate": {
      "id": "zinc-sulfate",
      "name": "Zinc sulfate (alternative zinc formulation)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-to-zinc-acetate-for-maintenance-therapy-more-gi-": {
          "indication": "Alternative to zinc acetate for maintenance therapy; more GI side effects but less expensive",
          "doseOptions": [
            {
              "text": "220 mg",
              "orderSentence": "Zinc sulfate (alternative zinc formulation) 220 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "220 mg zinc sulfate TID (contains ~50 mg elemental zinc per 220 mg); take on empty stomach separated from meals by ≥1 hour; separate from chelator by ≥2 hours if used concurrently",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "wilsons-disease"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "GI intolerance common (nausea, gastric irritation)",
          "do NOT use as sole therapy in symptomatic/severe WD (too slow onset)"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "24h urine copper q3-6 months (target <75 mcg/24h on zinc monotherapy)",
          "24h urine zinc (confirms compliance: >2 mg/24h)",
          "CBC q6 months (zinc-induced copper deficiency can cause neutropenia)",
          "LFTs q3-6 months",
          "serum zinc level q3-6 months (target 125-150 mcg/dL)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "wilsons-disease"
      ]
    },
    "ziprasidone": {
      "id": "ziprasidone",
      "name": "Ziprasidone (Geodon)",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "alternative-atypical-antipsychotic-lower-weight-gain-but-qtc": {
          "indication": "Alternative atypical antipsychotic; lower weight gain but QTc risk",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Ziprasidone (Geodon) 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 5 mg daily; increase by 5-10 mg q1wk; target 5-40 mg/day; take with food (>500 kcal for absorption)",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "tics-tourette-syndrome"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "QTc prolongation",
          "concurrent QTc-prolonging drugs",
          "recent MI",
          "uncompensated heart failure"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "ECG at baseline",
          "EPS",
          "QTc monitoring",
          "weight, fasting glucose, lipids q3-6mo"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "tics-tourette-syndrome"
      ]
    },
    "zolmitriptan": {
      "id": "zolmitriptan",
      "name": "Zolmitriptan",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "2.5-5 mg",
              "orderSentence": "Zolmitriptan 2.5-5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "2.5-5 mg PO or nasal; may repeat in 2h; max 10 mg/24h",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "migraine"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "migraine"
      ]
    },
    "zolmitriptan-nasal": {
      "id": "zolmitriptan-nasal",
      "name": "Zolmitriptan nasal",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "IN"
      ],
      "formulations": [],
      "contexts": {
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Zolmitriptan nasal 5 mg IN"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5 mg intranasal; may repeat in 2h; max 10 mg/24h",
          "settings": {
            "ED": "STAT",
            "HOSP": "STAT",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "cluster-headache"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Same as sumatriptan"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Same"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "cluster-headache"
      ]
    },
    "zolpidem": {
      "id": "zolpidem",
      "name": "Zolpidem",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "oculomotor-dysfunction-limited-evidence-for-transient-improv": {
          "indication": "Oculomotor dysfunction; limited evidence for transient improvement in saccades and motor function",
          "doseOptions": [
            {
              "text": "5 mg",
              "orderSentence": "Zolpidem 5 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "5-10 mg once daily (trial dose); evidence is limited to case series; some patients show paradoxical improvement in motor and oculomotor function",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "progressive-supranuclear-palsy"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Severe hepatic impairment",
          "myasthenia gravis",
          "respiratory depression"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Sedation, falls (paradoxically may improve in some), confusion",
          "short trial recommended"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 1,
      "_sourcePlans": [
        "progressive-supranuclear-palsy"
      ]
    },
    "zonisamide": {
      "id": "zonisamide",
      "name": "Zonisamide",
      "genericName": "",
      "brandNames": [],
      "drugClass": "",
      "mechanisms": [],
      "routes": [
        "PO"
      ],
      "formulations": [],
      "contexts": {
        "dre-adjunctive-therapy-multiple-mechanisms-sodium-calcium-ch": {
          "indication": "DRE adjunctive therapy; multiple mechanisms (sodium/calcium channels, carbonic anhydrase); broad-spectrum",
          "doseOptions": [
            {
              "text": "100 mg daily",
              "orderSentence": "Zonisamide (Zonegran) 100 mg daily PO"
            },
            {
              "text": "200 mg daily",
              "orderSentence": "Zonisamide (Zonegran) 200 mg daily PO"
            },
            {
              "text": "300 mg daily",
              "orderSentence": "Zonisamide (Zonegran) 300 mg daily PO"
            },
            {
              "text": "400 mg daily",
              "orderSentence": "Zonisamide (Zonegran) 400 mg daily PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg daily; increase by 100 mg q2wk; target 200-400 mg daily; max 600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "ROUTINE",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "drug-resistant-epilepsy"
          ]
        },
        "general": {
          "indication": "-",
          "doseOptions": [
            {
              "text": "100-200 mg",
              "orderSentence": "Zonisamide 100-200 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "100-200 mg daily; off-label",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "EXT",
            "ICU": "-"
          },
          "_sourcePlans": [
            "essential-tremor"
          ]
        },
        "adjunctive-or-monotherapy": {
          "indication": "Adjunctive or monotherapy",
          "doseOptions": [
            {
              "text": "100 mg",
              "orderSentence": "Zonisamide 100 mg PO"
            }
          ],
          "startingDose": "",
          "maxDose": "",
          "titration": "",
          "notes": "Start 100 mg daily; increase by 100 mg every 2 weeks; target 300-400 mg daily; max 600 mg/day",
          "settings": {
            "ED": "-",
            "HOSP": "-",
            "OPD": "ROUTINE",
            "ICU": "-"
          },
          "_sourcePlans": [
            "new-onset-seizure"
          ]
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Sulfa allergy, kidney stones",
          "Sulfonamide allergy",
          "kidney stones",
          "severe hepatic/renal impairment"
        ],
        "precautions": [],
        "drugInteractions": [],
        "pregnancyCategory": "",
        "lactation": ""
      },
      "renalAdjustment": {
        "required": false,
        "tiers": []
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": ""
      },
      "monitoring": {
        "baseline": [],
        "ongoing": [
          "Kidney stones (carbonic anhydrase inhibitor)",
          "Kidney stones, cognitive",
          "Renal function",
          "bicarbonate (metabolic acidosis)",
          "heat intolerance (oligohidrosis)",
          "kidney stones",
          "metabolic acidosis",
          "oligohidrosis (pediatric)",
          "weight (often decreases)"
        ],
        "frequency": ""
      },
      "patientCounseling": [],
      "_harvested": true,
      "_sourceCount": 3,
      "_sourcePlans": [
        "drug-resistant-epilepsy",
        "essential-tremor",
        "new-onset-seizure"
      ]
    }
  }
}
